PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lipkin, SM; Wang, V; Jacoby, R; Banerjee-Basu, S; Baxevanis, AD; Lynch, HT; Elliott, RM; Collins, FS				Lipkin, SM; Wang, V; Jacoby, R; Banerjee-Basu, S; Baxevanis, AD; Lynch, HT; Elliott, RM; Collins, FS			MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-TUMOR SUSCEPTIBILITY; MICE DEFICIENT; MUTATION; MOUSE; PMS2; DATABASE; TISSUES; CELLS; MSH6	DNA mismatch repair is important because of its role in maintaining genomic integrity and its association with hereditary non-polyposis colon cancer (HNPCC). To identify new human mismatch repair proteins, we probed nuclear extracts with the conserved carboxy-terminal MLH1 interaction domain. Here we describe the cloning and complete genomic sequence of MLH3, which encodes a new DNA mismatch repair protein that interacts with MLH1. MLH3 is more similar to mismatch repair proteins from yeast, plants, worms and bacteria than to any known mammalian protein, suggesting that its conserved sequence may confer unique functions in mice and humans. Cells in culture stably expressing a dominant-negative MLH3 protein exhibit microsatellite instability. MIh3 is highly expressed in gastrointestinal epithelium and physically maps to the mouse complex trait locus colon cancer susceptibility I (Ccs1). Although we were unable to identify a mutation in the protein-coding region of MIh3 in the susceptible mouse strain, colon tumours from congenic Ccs1 mice exhibit microsatellite instability. Functional redundancy among MIh3, Pms1 and Pms2 may explain why neither Pms1 nor Pms2 mutant mice develop colon cancer, and why PMS1 and PMS2 mutations are only rarely found in HNPCC families.	NIH, Natl Ctr Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD 20892 USA; NIH, Natl Ctr Human Genome Res Inst, Genome Technol Branch, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Med, Div Gastroenterol, Madison, WI USA; New York State Dept Hlth, Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Wisconsin System; University of Wisconsin Madison; Roswell Park Cancer Institute; Creighton University	Collins, FS (corresponding author), NIH, Natl Ctr Human Genome Res Inst, Genet & Mol Biol Branch, Bethesda, MD 20892 USA.	fc23a@nih.gov	wang, vicky/AAO-6474-2020	Baxevanis, Andy/0000-0002-5370-0014	NATIONAL CANCER INSTITUTE [R01CA062225] Funding Source: NIH RePORTER; NCI NIH HHS [CA62225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; Dayhoff M., 1978, ATLAS PROTEIN SEQUEN; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; EDELMANN W, IN PRESS CANC RES; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; EVANS JT, 1977, CANCER RES, V37, P134; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Glaab WE, 1998, J BIOL CHEM, V273, P26662, DOI 10.1074/jbc.273.41.26662; HAWN MT, 1995, CANCER RES, V55, P3721; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649; Kolodner RD, 1999, CANCER RES, V59, P5068; Kondo E, 1999, J BIOCHEM-TOKYO, V125, P818; LANDER ES, 1989, GENETICS, V121, P185; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; LYNCH HT, 1994, ANTICANCER RES, V14, P1617; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; NAKAGAWA T, IN PRESS P NATL ACAD; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Risinger JI, 1998, CANCER RES, V58, P2978; RYAN J, 1987, JNCI-J NATL CANCER I, V79, P135; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	49	234	257	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					27	35		10.1038/71643	http://dx.doi.org/10.1038/71643			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615123				2022-12-25	WOS:000084609200011
J	McDonald, JW; Liu, XZ; Qu, Y; Liu, S; Mickey, SK; Turetsky, D; Gottlieb, DI; Choi, DW				McDonald, JW; Liu, XZ; Qu, Y; Liu, S; Mickey, SK; Turetsky, D; Gottlieb, DI; Choi, DW			Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord	NATURE MEDICINE			English	Article							ADULT-RAT; AXONAL REGENERATION; CNS NEURONS; IN-VITRO; GROWTH; GRAFTS; BRAIN	Transplantation approaches using cellular bridges(1-2), fetal central nervous system cells(3-5), fibroblasts expressing neurotrophin-3 (ref. 6), hybridoma cells expressing inhibitory protein-blocking antibodies: or olfactory nerves ensheathing glial cells(8) transplanted into the acutely injured spinal cord have produced axonal regrowth or functional benefits. Transplants of rat or cat fetal spinal cord tissue into the chronically injured cord survive and integrate with the host cord, and may be associated with some functional improvements(9). In addition, rats transplanted with fetal spinal cord cells have shown improvements in some gait parameters(10) and the delayed transplantation of fetal raphe cells can enhance reflexes(11). We transplanted neural differentiated mouse embryonic stem cells into a rat spinal cord 9 days after traumatic injury. Histological analysis 2-5 weeks later showed that transplant-derived cells survived and differentiated into astrocytes, oligodendrocytes and neurons, and migrated as far as 8 mm away from the lesion edge. Furthermore, gait analysis demonstrated that transplanted rats showed hindlimb weight support and partial hindlimb coordination not found in 'sham-operated' controls or control rats transplanted with adult mouse neocortical cells.	Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA; Washington Univ, Sch Med, Restorat Treatment & Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	McDonald, JW (corresponding author), Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037927, P01NS032636] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01931, NS37927, NS32636] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DK, 1991, RESTOR NEUROL NEUROS, V2, P309, DOI 10.3233/RNN-1991-245621; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BAUMRIND NL, 1992, DEV DYNAM, V194, P311, DOI 10.1002/aja.1001940407; BERNSTEIN JJ, 1987, EXP NEUROL, V98, P633, DOI 10.1016/0014-4886(87)90271-8; BREGMAN BS, 1993, EXP NEUROL, V123, P3, DOI 10.1006/exnr.1993.1136; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Grill R, 1997, J NEUROSCI, V17, P5560; HOWLAND DR, 1995, EXP NEUROL, V135, P123, DOI 10.1006/exnr.1995.1072; LAGENAUR C, 1981, J SUPRAMOL STR CELL, V15, P335, DOI 10.1002/jsscb.1981.380150404; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liu XZ, 1997, J NEUROSCI, V17, P5395; PRIVAT A, 1989, BRAIN RES BULL, V22, P123, DOI 10.1016/0361-9230(89)90136-6; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; STOKES BT, 1992, EXP NEUROL, V116, P1, DOI 10.1016/0014-4886(92)90171-L; WAXMAN SG, 1992, J NEUROTRAUM, V9, pS105; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113	20	941	1067	1	156	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1410	1412		10.1038/70986	http://dx.doi.org/10.1038/70986			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581084				2022-12-25	WOS:000084049700041
J	Puglielli, MT; Browning, JL; Brewer, AW; Schreiber, RD; Shieh, WJ; Altman, JD; Oldstone, MBA; Zaki, SR; Ahmed, R				Puglielli, MT; Browning, JL; Brewer, AW; Schreiber, RD; Shieh, WJ; Altman, JD; Oldstone, MBA; Zaki, SR; Ahmed, R			Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway	NATURE MEDICINE			English	Article							HANTAVIRUS PULMONARY SYNDROME; TUMOR-NECROSIS-FACTOR; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL RESPONSES; MONOCLONAL-ANTIBODIES; SURFACE LYMPHOTOXIN; VIRAL PERSISTENCE; KILLER-CELLS; BETA; RECEPTOR	At present, little is known about the pathogenesis of acute virus-induced shock and pulmonary failure. A chief impediment in understanding the underlying disease mechanisms and developing treatment strategies has been the lack of a suitable animal model. This study describes a mouse model of virus-induced systemic shock and respiratory distress, and shows that blockade of the lymphotoxin beta receptor pathway reverses the disease.	Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Biogen Inc, Cambridge, MA 02142 USA; Schering Plough Res Inst, Lafayette, NJ 07848 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Ctr Dis Control & Prevent, Infect Dis Pathol Act, Natl Ctr Infect Dis, Atlanta, GA 30322 USA; Scripps Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA	Emory University; Emory University; Biogen; Merck & Company; Schering-Plough Research Institute; Washington University (WUSTL); Centers for Disease Control & Prevention - USA; Scripps Research Institute	Ahmed, R (corresponding author), Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341; Browning, Jeffrey/0000-0001-9168-5233	NIAID NIH HHS [AI09866, AI30048] Funding Source: Medline; NINDS NIH HHS [NS21496] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030048, R37AI030048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021496] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABE Y, 1992, LYMPHOKINE CYTOK RES, V11, P115; AHMED R, 1988, J EXP MED, V167, P1719, DOI 10.1084/jem.167.5.1719; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FORCE WR, 1995, J IMMUNOL, V155, P5280; Hallin GW, 1996, CRIT CARE MED, V24, P252, DOI 10.1097/00003246-199602000-00012; HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324; Lacy M D, 1996, Adv Pediatr Infect Dis, V12, P21; Mackay F, 1997, J IMMUNOL, V159, P3299; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; MERTZ GJ, 1998, EMERGENCE CONTROL RO, V43, P43; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NOLTE KB, 1995, HUM PATHOL, V26, P110, DOI 10.1016/0046-8177(95)90123-X; Peters Clarence J., 1997, P779; SAYER WJ, 1955, ANN INTERN MED, V42, P839, DOI 10.7326/0003-4819-42-4-839; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; Sourdive DJD, 1998, J EXP MED, V188, P71, DOI 10.1084/jem.188.1.71; Talal N, 1974, Curr Top Microbiol Immunol, V64, P79; Toro J, 1998, EMERG INFECT DIS, V4, P687, DOI 10.3201/eid0404.980425; WARE CF, 1992, J IMMUNOL, V149, P3881; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zaki SR, 1996, ARCH PATHOL LAB MED, V120, P134; ZAKI SR, 1995, AM J PATHOL, V146, P552; 1998, MORBID MORTAL WEEKLY, V47, P449	34	55	58	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1370	1374						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581078				2022-12-25	WOS:000084049700035
J	Arikawa-Hirasawa, E; Watanabe, H; Takami, H; Hassell, JR; Yamada, Y				Arikawa-Hirasawa, E; Watanabe, H; Takami, H; Hassell, JR; Yamada, Y			Perlecan is essential for cartilage and cephalic development	NATURE GENETICS			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; FACTOR RECEPTOR 3; DYSPLASIA TYPE-I; THANATOPHORIC DYSPLASIA; EXPRESSION; ACTIVATION; MUTATIONS; SKELETAL; MEMBRANE		Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Shriners Hosp Crippled Children, Tampa, FL 33612 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, Y (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov						ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; Aszodi A, 1998, J MOL MED-JMM, V76, P238, DOI 10.1007/s001090050214; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Delezoide AL, 1997, HUM MOL GENET, V6, P1899, DOI 10.1093/hmg/6.11.1899; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; Harris MJ, 1997, TERATOLOGY, V56, P177, DOI 10.1002/(SICI)1096-9926(199709)56:3<177::AID-TERA1>3.0.CO;2-Z; HORTON WA, 1988, BONE, V9, P53, DOI 10.1016/8756-3282(88)90027-0; Horton William A., 1997, Current Opinion in Pediatrics, V9, P437, DOI 10.1097/00008480-199708000-00021; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; MORRISSKAY G, 1991, J CRAN GENET DEV BIO, V11, P181; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; ORNOY A, 1985, AM J MED GENET, V21, P613, DOI 10.1002/ajmg.1320210402; Peters PWJ, 1977, METHODS PRENATAL TOX, P153; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Weber M, 1998, J PEDIATR ORTHOP B, V7, P1, DOI 10.1097/01202412-199801000-00001; Wilcox WR, 1998, AM J MED GENET, V78, P274, DOI 10.1002/(SICI)1096-8628(19980707)78:3<274::AID-AJMG14>3.0.CO;2-C	30	395	409	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					354	358		10.1038/15537	http://dx.doi.org/10.1038/15537			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545953				2022-12-25	WOS:000083792200028
J	Bieri, C; Ernst, OP; Heyse, S; Hofmann, KP; Vogel, H				Bieri, C; Ernst, OP; Heyse, S; Hofmann, KP; Vogel, H			Micropatterned immobilization of a G protein-coupled receptor and direct detection of G protein activation	NATURE BIOTECHNOLOGY			English	Article						G protein-coupled receptors; chip-based functional real-time assays; micropatterning	SUPPORTED MEMBRANES; LIGHT-SCATTERING; ALPHA-SUBUNIT; RHODOPSIN; TRANSDUCIN; GOLD	G protein-coupled receptors (GPCRs) constitute an abundant family of membrane receptors of high pharmacological interest. Cell-based assays are the predominant means of assessing GPCR activation, but are limited by their inherent complexity. Functional molecular assays that directly and specifically report G protein activation by receptors could offer substantial advantages. We present an approach to immobilize receptors stably and with defined orientation to substrates. By surface plasmon resonance (SPR), we were able to follow ligand binding, G protein activation, and receptor deactivation of a representative GPCR, bovine rhodopsin. Microcontact printing was used to produce micrometer-sized patterns with high contrast in receptor activity. These patterns can be used for local referencing to enhance the sensitivity of chip-based assays. The immobilized receptor was stable both for hours and during several activation cycles. A ligand dose-response curve with the photoactivatable agonist 11-cis-retinal showed a half-maximal signal at 120 nM. Our findings may be useful to develop novel assay formats for GPCRs based on receptor immobilization to solid supports, particularly to sensor surfaces.	Swiss Fed Inst Technol, Inst Phys Chem, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, Berlin, Germany	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Vogel, H (corresponding author), Swiss Fed Inst Technol, Inst Phys Chem, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland.							ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Bain C. D., 1989, ANGEW CHEM, V101, P522; BRUCKERT F, 1988, EUR BIOPHYS J BIOPHY, V16, P207; Delamarche E, 1998, J PHYS CHEM B, V102, P3324, DOI 10.1021/jp980556x; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hermanson G.T., 1992, IMMOBILIZED AFFINITY; Heyse S, 1998, BIOCHEMISTRY-US, V37, P507, DOI 10.1021/bi971564r; Hovius R, 1999, J RECEPT SIGNAL TR R, V19, P533, DOI 10.3109/10799899909036670; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; O'SHANNESSY D J, 1985, Journal of Applied Biochemistry, V7, P347; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P240; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SPINKE J, 1993, J CHEM PHYS, V99, P7012, DOI 10.1063/1.465447; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	26	236	269	1	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1105	1108		10.1038/15090	http://dx.doi.org/10.1038/15090			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545918				2022-12-25	WOS:000083428000029
J	Goldberg, GS; Lampe, PD; Nicholson, BJ				Goldberg, GS; Lampe, PD; Nicholson, BJ			Selective transfer of endogenous metabolites through gap junctions composed of different connexins	NATURE CELL BIOLOGY			English	Article							C6 GLIOMA-CELLS; PERMEABILITY; PROTEIN; COMMUNICATION; CHANNELS		SUNY Buffalo, Buffalo, NY 14260 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Fred Hutchinson Cancer Center	Goldberg, GS (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 5-1-1 Tsukiji, Tokyo 104, Japan.			Nicholson, Bruce/0000-0003-1649-7173	NCI NIH HHS [CA480490] Funding Source: Medline; NIGMS NIH HHS [R01 GM055632, GM48773, R01 GM055437, GM55632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632, R01GM055437] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beblo DA, 1997, J GEN PHYSIOL, V109, P509, DOI 10.1085/jgp.109.4.509; BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; Cao FL, 1998, J CELL SCI, V111, P31; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; GOLDBERG GS, 1995, BIOTECHNIQUES, V18, P490; Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872; Goldberg GS, 1996, EXP CELL RES, V222, P48, DOI 10.1006/excr.1996.0006; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; PITTS JD, 1977, EXP CELL RES, V104, P153, DOI 10.1016/0014-4827(77)90078-7; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	14	249	256	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					457	459		10.1038/15693	http://dx.doi.org/10.1038/15693			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559992				2022-12-25	WOS:000083533100021
J	Mateo, V; Lagneaux, L; Bron, D; Biron, G; Armant, M; Delespesse, G; Sarfati, M				Mateo, V; Lagneaux, L; Bron, D; Biron, G; Armant, M; Delespesse, G; Sarfati, M			CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia	NATURE MEDICINE			English	Article							INTEGRIN-ASSOCIATED PROTEIN; MARROW STROMAL CELLS; B-CELL; INDUCED APOPTOSIS; T-LYMPHOCYTES; IN-VITRO; MONOCLONAL-ANTIBODIES; CROSS-LINKING; TUMOR-CELLS; BCL-2	Thrombospondin forms a 'molecular bridge' between phagocytic and apoptotic cells through interaction with alpha v beta 3/CD36. We report here that engagement of CD47, a newly described thrombospondin receptor, by immobilized monoclonal antibody against CD47 or by thrombospondin induced in all B-cell chronic lymphocytic leukemia clones the cytoplasmic features of apoptosis (cell shrinkage, decrease in mitochondrial transmembrane potential and phosphatidylserine externalization) without the nuclear features (chromatin condensation, appearance of single-stranded DNA, DNA fragmentation and cleavage of poly ADP-ribose polymerase). These cytoplasmic events of apoptosis were not prevented by the addition of caspase inhibitor z-VAD-fmk, or by the presence of survival factors (such as interleukin-4 and gamma interferon) or cell activation. Morphological studies confirmed the integrity of the nucleus and showed swelling of the mitochondria. This caspase-independent death pathway may be relevant to the development of alternate therapeutic strategies in chronic lymphocytic leukemia, which remains an incurable disease.	Univ Montreal, Hop Notre Dame, Ctr Hosp, Ctr Rech,Lab Allergie, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Hop Notre Dame, Ctr Hosp, Dept Hematol, Montreal, PQ H3C 3J7, Canada; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Universite de Montreal; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sarfati, M (corresponding author), Univ Montreal, Hop Notre Dame, Ctr Hosp, Ctr Rech,Lab Allergie, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	sarfatm@poste.umontreal.ca	Mateo, Véronique/AAD-1379-2019; Mateo, Véronique/O-9738-2017	Mateo, Véronique/0000-0002-9327-1277; Mateo, Véronique/0000-0002-9327-1277				Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bellosillo B, 1997, BLOOD, V89, P3378, DOI 10.1182/blood.V89.9.3378; Bellosillo B, 1998, BLOOD, V92, P1406, DOI 10.1182/blood.V92.4.1406.416k17_1406_1414; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; Cantwell MJ, 1996, BLOOD, V88, P4676, DOI 10.1182/blood.V88.12.4676.bloodjournal88124676; Chandra J, 1997, BLOOD, V90, P3673, DOI 10.1182/blood.V90.9.3673; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; Deas O, 1998, J IMMUNOL, V161, P3375; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Depraetere V, 1998, SCAND J IMMUNOL, V47, P523; Dighiero G, 1998, NEW ENGL J MED, V338, P1506, DOI 10.1056/NEJM199805213382104; Douglas RS, 1997, BLOOD, V89, P941, DOI 10.1182/blood.V89.3.941; FOURNIER S, 1992, J CLIN INVEST, V89, P1312, DOI 10.1172/JCI115717; FOURNIER S, 1995, BRIT J HAEMATOL, V89, P373, DOI 10.1111/j.1365-2141.1995.tb03314.x; FUENTE M, 1999, LEUKEMIA, V13, P266; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Ghetie MA, 1997, P NATL ACAD SCI USA, V94, P7509, DOI 10.1073/pnas.94.14.7509; Guo K, 1998, BIOL REPROD, V58, P739, DOI 10.1095/biolreprod58.3.739; HANADA M, 1993, BLOOD, V82, P1820; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Keating MJ, 1998, BLOOD, V92, P1165, DOI 10.1182/blood.V92.4.1165.416k03_1165_1171; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lesage S, 1997, J IMMUNOL, V159, P4762; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; MOWER DA, 1994, J IMMUNOL, V152, P4832; PANAYIOTIDIS P, 1993, BRIT J HAEMATOL, V85, P439; Panayiotidis P, 1996, BRIT J HAEMATOL, V92, P97, DOI 10.1046/j.1365-2141.1996.00305.x; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; ROBERTSON LE, 1993, BLOOD, V81, P143; Romano MF, 1998, BLOOD, V92, P990; Sarfati M, 1996, BLOOD, V88, P4259; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; Savill J, 1997, BRIT MED BULL, V53, P491; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thomas A, 1996, ONCOGENE, V12, P1055; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tinhofer I, 1998, BLOOD, V91, P4273, DOI 10.1182/blood.V91.11.4273.411k25_4273_4281; Truman JP, 1997, BLOOD, V89, P1996, DOI 10.1182/blood.V89.6.1996; Wang DK, 1997, BRIT J HAEMATOL, V97, P409, DOI 10.1046/j.1365-2141.1997.422688.x; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628	55	184	217	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1999	5	11					1277	1284		10.1038/15233	http://dx.doi.org/10.1038/15233			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545994				2022-12-25	WOS:000086550600038
J	Goedecke, W; Eijpe, M; Offenberg, HH; van Aalderen, M; Heyting, C				Goedecke, W; Eijpe, M; Offenberg, HH; van Aalderen, M; Heyting, C			Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis	NATURE GENETICS			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; SYNAPTONEMAL COMPLEXES; MEIOTIC RECOMBINATION; INITIATION SITE; BUDDING YEAST; DNA; REPAIR; IDENTIFICATION	Double-strand DNA breaks (DSBs) pose a major threat to living cells, and several mechanisms for repairing these lesions have evolved. Eukaryotes can process DSBs by homologous recombination (HR) or non-homologous end joining(1,2) (NHEJ). NHEJ connects DNA ends irrespective of their sequence, and it predominates in mitotic cells, particularly during G1 (ref. 3). HR requires interaction of the broken DNA molecule with an intact homologous copy, and allows restoration of the original DNA sequence. HR is active during G2 of the mitotic cycle(3) and predominates during meiosis, when the cell creates DSBs (ref. 4), which must be repaired by HR to ensure proper chromosome segregation. How the cell controls the choice between the two repair pathways is not understood. We demonstrate here a physical interaction between mammalian Ku70, which is essential for NHEJ (ref. 5), and Mre11, which functions both in NHEJ and meiotic HR (refs 2,6). Moreover, we show that irradiated cells deficient for Ku70 are incapable of targeting Mre11 to subnuclear foci that may represent DNA-repair complexes(7). Nevertheless, Ku70 and Mre11 were differentially expressed during meiosis. In the mouse testis, Mre11 and Ku70 co-localized in nuclei of somatic cells and in the XY bivalent. In early meiotic prophase, however, when meiotic recombination is most probably initiated(8), Mre11 was abundant, whereas Ku70 was not detectable. We propose that Ku70 acts as a switch between the two DSB repair pathways. When present, Ku70 destines DSBs for NHEJ by binding to DNA ends and attracting other factors for NHEJ, including Mre11; when absent, it allows participation of DNA ends and Mre11 in the meiotic HR pathway.	Agr Univ Wageningen, Genet Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Heyting, C (corresponding author), Agr Univ Wageningen, Genet Lab, Dreijenlaan 2, NL-6703 HA Wageningen, Netherlands.	Christa.Heyting@molcelgen.el.wau.nl						Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Golemis E A, 1997, Methods Mol Biol, V63, P197; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; OAKBERG EF, 1971, ANAT REC, V169, P515, DOI 10.1002/ar.1091690305; Offenberg HH, 1998, NUCLEIC ACIDS RES, V26, P2572, DOI 10.1093/nar/26.11.2572; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2	31	186	187	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					194	198		10.1038/13821	http://dx.doi.org/10.1038/13821			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508516				2022-12-25	WOS:000082827500019
J	Ronn, LCB; Olsen, M; Ostergaard, S; Kiselyov, V; Berezin, V; Mortensen, MT; Lerche, MH; Jensen, PH; Soroka, V; Saffells, JL; Doherty, P; Poulsen, FM; Bock, E; Holm, A				Ronn, LCB; Olsen, M; Ostergaard, S; Kiselyov, V; Berezin, V; Mortensen, MT; Lerche, MH; Jensen, PH; Soroka, V; Saffells, JL; Doherty, P; Poulsen, FM; Bock, E; Holm, A			Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides	NATURE BIOTECHNOLOGY			English	Article						cell adhesion; combinatorial chemistry; drug discovery; neural cell adhesion molecule; neurite outgrowth; nuclear magnetic resonance spectroscopy; surface plasmon resonance; synthetic peptide	LONG-TERM POTENTIATION; N-CAM; NEURITE OUTGROWTH; NCAM; BINDING; FGF; RECEPTOR; RAT; PROLIFERATION; SPECTROSCOPY	The neural cell adhesion molecule (NCAM) plays a key role in neural development, regeneration, and learning. In this study, we identified a synthetic peptide-ligand of the NCAM Ig1 module by combinatorial chemistry and showed it could modulate NCAM-mediated cell adhesion and signal transduction with high potency. In cultures of dissociated neurons, this peptide, termed C3, stimulated neurite outgrowth by activating a signaling pathway identical to that activated by homophilic NCAM binding. A similar effect was shown for the NCAM Ig2 module, the endogenous ligand of NCAM Ig1, By nuclear magnetic resonance spectroscopy, the C3 binding site in the NCAM Ig1 module was mapped and shown to be different from the binding site of the NCAM Ig2 module. The C3 peptide may prove useful as a lead in development of therapies for neurodegenerative disorders, and the C3 binding site of NCAM Ig1 may represent a target for discovery of nonpeptide drugs.	Univ Copenhagen, Panum Inst 6 2, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen N, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen, Denmark; Carlsberg Lab, Dept Chem, DK-2500 Valby, Denmark; Guys Hosp, GKT Sch Med, Dept Expt Pathol, London SE1 9RT, England	University of Copenhagen; University of Copenhagen; University of Copenhagen; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Ronn, LCB (corresponding author), Univ Copenhagen, Panum Inst 6 2, Inst Mol Pathol, Prot Lab, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Poulsen, Flemming M/E-6848-2010; Kiselyov, Vladislav/D-2273-2009; Doherty, Patrick/A-8752-2008; Ostergaard, Soren/B-8123-2019; Lerche, Mathilde Hauge/J-5487-2017	Ostergaard, Soren/0000-0002-9415-3352; Lerche, Mathilde Hauge/0000-0002-5899-2781				Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DOYLE E, 1992, J NEUROSCI RES, V31, P513, DOI 10.1002/jnr.490310315; EDVARDSEN K, 1994, INT J CANCER, V58, P116, DOI 10.1002/ijc.2910580119; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GEGELASHVILI G, 1996, TREATISE BIOMEMBRANE, V3, P33; Jensen PH, 1999, NAT STRUCT BIOL, V6, P486; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; KJAER M, 1994, METHODS ENZYMOL, V239, P288; Krushel LA, 1998, P NATL ACAD SCI USA, V95, P2592, DOI 10.1073/pnas.95.5.2592; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Maar TE, 1997, J NEUROSCI RES, V47, P163; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; OLSEN M, 1995, INT J DEV NEUROSCI, V13, P97, DOI 10.1016/0736-5748(95)00003-Y; OSTERGAARD S, 1995, FEBS LETT, V362, P306, DOI 10.1016/0014-5793(95)00262-8; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PROBSTMEIER R, 1989, J NEUROCHEM, V53, P1794, DOI 10.1111/j.1471-4159.1989.tb09245.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1994, J BIOL CHEM, V269, P27540; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; RONN LCB, 1995, BRAIN RES, V677, P145, DOI 10.1016/0006-8993(95)00147-I; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SPORNS O, 1995, P NATL ACAD SCI USA, V92, P542, DOI 10.1073/pnas.92.2.542; THIERY JP, 1977, J BIOL CHEM, V252, P6841; Thomsen NK, 1996, NAT STRUCT BIOL, V3, P581, DOI 10.1038/nsb0796-581; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; WILLIAMS EJ, 1995, J CELL SCI, V108, P3523; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	41	119	124	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1000	1005		10.1038/13697	http://dx.doi.org/10.1038/13697			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504702				2022-12-25	WOS:000083015700027
J	Schafer, K; Braun, T				Schafer, K; Braun, T			Early specification of limb muscle precursor cells by the homeobox gene Lbx1h	NATURE GENETICS			English	Article							CONNECTIVE-TISSUE; PROGENITOR CELLS; CHICK LIMB; EXPRESSION; PAX-3; MOUSE; MIGRATION; MUSCULATURE; EMBRYO	During vertebrate embryogenesis, myogenic precursor cells of limb muscles delaminate from the ventro-lateral edge of the semitic dermomyotome and migrate to the limb buds, where they congregate into dorsal and ventral muscle masses(1,2). It has been proposed that the surrounding connective tissue controls muscle pattern formation in limbs(3-5). Regulatory molecules such as receptor tyrosine kinases like c-Met (ref. 6) and those encoded by homeobox-containing genes, including c-Met (ref. 6), Tbx1 (ref. 7), Mox2 (ref. 8), Six1 and Six2 (ref. 9), Pitx2, Pax3 (refs 10,11) and Lbx1h (refs 12,13), are expressed in migrating limb precursor cells. The role of these genes in the patterning of limb muscles is unknown, although mutation of Pax3 or Met causes disruption of limb muscle development at an initial step, disturbing the epithelial-to-mesenchymal transition of the semitic epithelium(6,10,11). No limb muscle cells form in these mutants, and the early loss of myogenic precursor cells prevented an analysis of later functions of these genes during limb muscle development(14). Based on quail-chick chimaera studies(3,15), it was assumed that a cell-autonomous contribution of myogenic cells to the formation of individual limb muscles is negligible, and that an instructive role of limb mesenchyme is critical in this process. Here we show that Lbx1h determines migratory routes of muscle precursor cells in a cell-autonomous manner, thereby leading to the formation of distinct limb muscle patterns. Inactivation of Lbx1h, which is specifically expressed in migrating muscle precursor cells(12,13) , led to a lack of extensor muscles in forelimbs and an absence of muscles in hindlimbs. The defect was caused by the failure of all muscle precursor cells of hindlimbs and of precursor cells of extensor muscles of forelimbs to migrate to their corresponding muscle anlagen. Our results demonstrate that Lbx1h is a key regulator of muscle precursor cell migration and is required for the acquisition of dorsal identities of forelimb muscles.	Univ Halle Wittenberg, Inst Physiol Chem, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg	Braun, T (corresponding author), Univ Halle Wittenberg, Inst Physiol Chem, Hollystr 1, D-06097 Halle, Germany.	Thomas.Braun@medizin.uni-halle.de	Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804				Bancroft JD, 1990, THEORY PRACTICE HIST; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BrandSaberi B, 1996, INT J DEV BIOL, V40, P411; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUTLER J, 1988, DEVELOPMENT, V102, P763; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CHEVALLIER A, 1982, ROUX ARCH DEV BIOL, V191, P277, DOI 10.1007/BF00848416; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Daston G, 1996, DEVELOPMENT, V122, P1017; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; GOULDING M, 1994, DEVELOPMENT, V120, P957; Isaac A, 1998, DEVELOPMENT, V125, P1867; JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5; MARTIN P, 1990, International Journal of Developmental Biology, V34, P323; MAUGER A, 1983, J EMBRYOL EXP MORPH, V76, P199; Mennerich D, 1998, MECH DEVELOP, V73, P147, DOI 10.1016/S0925-4773(98)00046-X; OLIVER G, 1995, DEVELOPMENT, V121, P693; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; Zweigerdt R, 1997, DEV BIOL, V192, P172, DOI 10.1006/dbio.1997.8759	21	140	144	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					213	216		10.1038/13843	http://dx.doi.org/10.1038/13843			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508520				2022-12-25	WOS:000082827500023
J	Hendricks, KB; Wang, BQ; Schnieders, EA; Thorner, J				Hendricks, KB; Wang, BQ; Schnieders, EA; Thorner, J			Yeast homologue of neuronal frequenin is a regulator of phosphatidylinositol-4-OH kinase	NATURE CELL BIOLOGY			English	Article							CALCIUM-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; NEUROTRANSMITTER RELEASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; CALMODULIN GENE; SHUTTLE VECTORS; RNA-POLYMERASE; NERVOUS-SYSTEM; DNA	In metazoans, certain calmodulin-related calcium-binding proteins (recoverins, neurocalcins and frequenins) are found at highest levels in excitable cells, but their physiological roles are largely uncharacterized. Here we show that Saccharomyces cerevisiae contains a frequenin homologue, Frq1, and that its target is Pik1, a phosphatidylinositol-4-OH kinase. Frq1 binds to a conserved sequence motif in Pik1 outside Pik1's catalytic domain and stimulates its activity in vitro. N-myristoylated Frq1 may also assist in Pik1 localization.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Thorner, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	jeremy@socrates.berkeley.edu	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NCI NIH HHS [CA73380] Funding Source: Medline; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA073380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DAVIS TN, 1992, J CELL BIOL, V118, P607, DOI 10.1083/jcb.118.3.607; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Goda Y, 1997, CURR OPIN CELL BIOL, V9, P513, DOI 10.1016/S0955-0674(97)80027-0; Guthrie C, 1991, GUIDE YEAST GENETICS; HENDRICKS KB, 1999, THESIS U CALIFORNIA; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; OHYA Y, 1994, GENETICS, V138, P1041; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNIEDERS EA, 1996, THESIS U CALIFORNIA; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; Vignes M, 1996, NEUROCHEM INT, V28, P145, DOI 10.1016/0197-0186(95)00078-X; Wiedemann C, 1998, J NEUROSCI, V18, P5594; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	55	214	219	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					234	241		10.1038/12058	http://dx.doi.org/10.1038/12058			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559922				2022-12-25	WOS:000083102700019
J	Sotomayor, EM; Borrello, I; Tubb, E; Rattis, FM; Bien, H; Lu, ZB; Fein, S; Schoenberger, S; Levitsky, HI				Sotomayor, EM; Borrello, I; Tubb, E; Rattis, FM; Bien, H; Lu, ZB; Fein, S; Schoenberger, S; Levitsky, HI			Conversion of tumor-specific CD4(+) T-cell tolerance to T-cell priming through in vivo ligation of CD40	NATURE MEDICINE			English	Article							IN-VIVO; PERIPHERAL TOLERANCE; DENDRITIC CELLS; SELF-ANTIGENS; CROSS-PRESENTATION; INDUCTION; EXPRESSION; LYMPHOCYTES; LIGAND; ACTIVATION	Tumor antigen-specific T-cell tolerance limits the efficacy of therapeutic cancer vaccines. Antigen-presenting cells mediate the induction of T-cell tolerance to self-antigens. We therefore assessed the fate of tumor-specific CD4(+) T cells in tumor-bearing recipients after in vivo activation of antigen-presenting cells with antibodies against CD40. Such treatment not only preserved the responsiveness of this population, but resulted in their endogenous activation. Established tumors regressed in vaccinated mice treated with antibody against CD40 at a time when no response was achieved with vaccination alone. These results indicate that modulation of antigen-presenting cells may be a useful strategy for enhancing responsiveness to immunization.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; La Jolla Inst Allergy & Immunol, Div Immune Regulat, San Diego, CA 92121 USA	Johns Hopkins University; La Jolla Institute for Immunology	Levitsky, HI (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, 720 Rutland Ave,Ross Bldg,Room 347, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA078658, K08CA078656] Funding Source: NIH RePORTER; NCI NIH HHS [CA078656, R01 CA78658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler AJ, 1998, J EXP MED, V187, P1555, DOI 10.1084/jem.187.10.1555; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; BOWEN F, 1995, EUR J IMMUNOL, V25, P2830, DOI 10.1002/eji.1830251018; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; CONSTANT S, 1994, EUR J IMMUNOL, V24, P1073, DOI 10.1002/eji.1830240510; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Ferlin WG, 1998, EUR J IMMUNOL, V28, P525, DOI 10.1002/(SICI)1521-4141(199802)28:02&lt;525::AID-IMMU525&gt;3.0.CO;2-M; Fuchs E J, 1996, Semin Immunol, V8, P271, DOI 10.1006/smim.1996.0035; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; Heath WR, 1998, J EXP MED, V187, P1549, DOI 10.1084/jem.187.10.1549; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665; Jakobson E, 1998, INT J CANCER, V77, P849, DOI 10.1002/(SICI)1097-0215(19980911)77:6<849::AID-IJC9>3.0.CO;2-U; JANEWAY CA, 1993, SCI AM, V269, P72, DOI 10.1038/scientificamerican0993-72; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Kluth B, 1997, CANCER RES, V57, P891; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; Lane P, 1996, EUR J IMMUNOL, V26, P858, DOI 10.1002/eji.1830260420; Lanoue A, 1997, J EXP MED, V185, P405, DOI 10.1084/jem.185.3.405; Lanzavecchia A, 1998, NATURE, V393, P413, DOI 10.1038/30845; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Morgan DJ, 1998, J IMMUNOL, V160, P643; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; Pammer J, 1996, HISTOPATHOLOGY, V29, P517, DOI 10.1046/j.1365-2559.1996.d01-531.x; Pape KA, 1998, J IMMUNOL, V160, P4719; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Sotomayor EM, 1996, CRIT REV ONCOGENESIS, V7, P433, DOI 10.1615/CritRevOncog.v7.i5-6.30; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; TOPALIAN SL, 1994, CURR OPIN IMMUNOL, V6, P741, DOI 10.1016/0952-7915(94)90078-7; vandenOord JJ, 1996, AM J PATHOL, V149, P1953; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Viac J, 1997, ANTICANCER RES, V17, P569	48	351	399	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					780	787		10.1038/10503	http://dx.doi.org/10.1038/10503			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395323				2022-12-25	WOS:000081926600033
J	Ying, H; Zaks, TZ; Wang, RF; Irvine, KR; Kammula, US; Marincola, FM; Leitner, WW; Restifo, NP				Ying, H; Zaks, TZ; Wang, RF; Irvine, KR; Kammula, US; Marincola, FM; Leitner, WW; Restifo, NP			Cancer therapy using a self-replicating RNA vaccine	NATURE MEDICINE			English	Article							ESTABLISHED PULMONARY METASTASES; IMMUNE-RESPONSES; DNA IMMUNIZATION; VIRUS; ANTIGEN; MODEL; ENHANCEMENT; MELANOMA; CELLS	'Naked' nucleic acid Vaccines are potentially useful candidates for the treatment of patients with cancer(1-3), but their clinical efficacy has yet to be demonstrated. We sought to enhance the immunogenicity of a nucleic acid Vaccine by making it 'self-replicating'. We accomplished this by using a gene encoding an RNA replicase polyprotein derived from the Semliki forest virus, in combination with a model antigen. A single intramuscular injection of a self-replicating RNA immunogen elicited antigen-specific antibody and CD8(+) T-cell responses at doses as low as 0.1 mu g. Pre-immunization with a self-replicating RNA vector protected mice from tumor challenge, and therapeutic immunization prolonged the survival of mice with established tumors. The self-replicating RNA vectors did not mediate the production of substantially more model antigen than a conventional DNA vaccine did in vitro. However, the enhanced efficacy in vivo correlated with a caspase-dependent apoptotic death in transfected cells. This death facilitated the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity. Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines.	NCI, Surg Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Restifo, NP (corresponding author), NCI, Surg Branch, Bldg 10,Room 2B42,10 Ctr Dr, Bethesda, MD 20892 USA.		Leitner, Wolfgang W/F-5741-2011; Restifo, Nicholas Phillip/Z-1614-2019; Restifo, Nicholas P/A-5713-2008; Restifo, Nicholas Phillip/M-6549-2019	Leitner, Wolfgang W/0000-0003-3125-5922; Restifo, Nicholas P./0000-0003-4229-4580	Intramural NIH HHS [Z01 BC010763-01, Z99 CA999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Atkins GJ, 1996, MOL BIOTECHNOL, V5, P33, DOI 10.1007/BF02762410; Berglund P, 1998, NAT BIOTECHNOL, V16, P562, DOI 10.1038/nbt0698-562; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Chappell DB, 1999, CANCER RES, V59, P59; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Dubensky TW, 1998, NAT MED, V4, P1357, DOI 10.1038/3939; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Gurunathan S, 1998, J IMMUNOL, V161, P4563; Hariharan MJ, 1998, J VIROL, V72, P950, DOI 10.1128/JVI.72.2.950-958.1998; Irvine KR, 1996, J IMMUNOL, V156, P238; Liu MA, 1998, ADV EXP MED BIOL, V452, P187; Mandl CW, 1998, NAT MED, V4, P1438, DOI 10.1038/4031; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Rao JB, 1996, J IMMUNOL, V156, P3357; Restifo NP, 1996, CURR OPIN IMMUNOL, V8, P658, DOI 10.1016/S0952-7915(96)80082-3; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1998, J NATL CANCER I, V90, P1894, DOI 10.1093/jnci/90.24.1894; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; WANG M, 1995, J IMMUNOL, V154, P4685; Zaks TZ, 1999, J IMMUNOL, V162, P3273	23	249	318	1	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					823	827		10.1038/10548	http://dx.doi.org/10.1038/10548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395329	Green Accepted			2022-12-25	WOS:000081926600039
J	Deng, GM; Nilsson, IM; Verdrengh, M; Collins, LV; Tarkowski, A				Deng, GM; Nilsson, IM; Verdrengh, M; Collins, LV; Tarkowski, A			Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis	NATURE MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS; SEPTIC ARTHRITIS; INTERFERON-GAMMA; IMMUNE-SYSTEM; BINDING; MICE; INTERNALIZATION; ACTIVATION; EXPRESSION; RECEPTOR	Unmethylated CpG motifs are often found in bacterial DNA, and exert immunostimulatory effects on hematopoetic cells(1-3). Bacteria produce severe joint inflammation in septic and reactive arthritides; bacterial DNA may be involved in this process. We injected bacterial DNA originating from Escherichia coli and Staphylococcus aureus and oligonucleotides containing CpG directly into the knee joints of mice of different strains. Arthritis Nas seen by histopathology within 2 hours and lasted for at east 14 days. Unmethylated CpG motifs were responsible for this induction of arthritis, as oligonucleotides containing these motifs produced the arthritis. The arthritis was characterized by an influx of monocytic, Mac-1(+) cells and by a lack of T lymphocytes. Depletion of monocytes resulted in abrogation of the synovial inflammation. Tumor necrosis factor (TNF)-alpha, a cytokine produced by cells of the monocyte/macrophage lineage, is an important mediator of this disease, as expression of mRNA for TNF-alpha was evident in the inflamed joints, and the CpG-mediated inflammation was abrogated in mice genetically unable to produce this cytokine. These findings demonstrate that bacterial DNA containing unmethylated CpG motifs induces arthritis, and indicate an important pathogenic role for bacterial DNA in septic arthritis.	Gothenburg Univ, Dept Rheumatol, S-41346 Gothenburg, Sweden	University of Gothenburg	Deng, GM (corresponding author), Gothenburg Univ, Dept Rheumatol, Guldhedsgatan 10A, S-41346 Gothenburg, Sweden.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CALAME W, 1994, J INFECTION, V29, P53, DOI 10.1016/S0163-4453(94)95087-3; Geselowitz D A, 1992, Antisense Res Dev, V2, P17; Goldenberg DL, 1998, LANCET, V351, P197, DOI 10.1016/S0140-6736(97)09522-6; Hultgren O, 1998, J IMMUNOL, V161, P5937; JONSSON R, 1986, J IMMUNOL METHODS, V88, P109, DOI 10.1016/0022-1759(86)90058-X; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MAURITZ NJ, 1988, ARTHRITIS RHEUM, V31, P1297, DOI 10.1002/art.1780311012; Parks E, 1998, J IMMUNOL, V160, P4615; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Tarkowski A, 1998, MOL MED TODAY, V4, P15, DOI 10.1016/S1357-4310(97)80540-0; Verdrengh M, 1997, INFECT IMMUN, V65, P2517, DOI 10.1128/IAI.65.7.2517-2521.1997; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yi AK, 1998, J IMMUNOL, V160, P4755; Zhao YX, 1996, ARTHRITIS RHEUM-US, V39, P959, DOI 10.1002/art.1780390613; Zhao YX, 1998, IMMUNOLOGY, V93, P80	20	235	255	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					702	705		10.1038/9554	http://dx.doi.org/10.1038/9554			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371511				2022-12-25	WOS:000080823300041
J	Engelender, S; Kaminsky, Z; Guo, X; Sharp, AH; Amaravi, RK; Kleiderlein, JJ; Margolis, RL; Troncoso, JC; Lanahan, AA; Worley, PF; Dawson, VL; Dawson, TM; Ross, CA				Engelender, S; Kaminsky, Z; Guo, X; Sharp, AH; Amaravi, RK; Kleiderlein, JJ; Margolis, RL; Troncoso, JC; Lanahan, AA; Worley, PF; Dawson, VL; Dawson, TM; Ross, CA			Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions	NATURE GENETICS			English	Article							PARKINSONS-DISEASE; LEWY BODIES; ALZHEIMERS-DISEASE; PROTEIN; BRAIN; IDENTIFICATION; COMPONENT; PATHOLOGY; DEMENTIA; MUTATION	Parkinson disease (PD) is a neurodegenerative disease characterized by tremor, bradykinesia, rigidity and postural instability. Post-mortem examination shows loss of neurons and Lewy bodies, which are cytoplasmic eosinophilic inclusions, in the substantia nigra and other brain regions(1,2). A few families have PD caused by mutations (A53T or A30P) in the gene SNCA (encoding alpha-synuclein; refs 3-5). alpha-synuclein is present in Lewy bodies of patients with sporadic PD (refs 6,7), suggesting that alpha-synuclein may be involved in the pathogenesis of PD. It is unknown how alpha-synuclein contributes to the cellular and biochemical mechanisms of PD, and its normal functions and biochemical properties are poorly understood(8-10). To determine the protein-interaction partners of alpha-synuclein, we performed a yeast two-hybrid screen. We identified a novel interacting protein, which we term synphilin-1 (encoded by the gene SNCAIP). We found that alpha-synuclein interacts in vivo with synphilin-1 in neurons. Co-transfection of both proteins (but not control proteins) in HEK 293 cells yields cytoplasmic eosinophilic inclusions.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Program Cellular & Mol Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ross, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA.		Ross, Christopher A/H-8395-2013; Dawson, Valina/Y-9757-2019	Engelender, Simone/0000-0001-7401-6855; Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377, P50NS016375, P01NS016375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38377, NS16375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DAWSON VL, 1993, J NEUROSCI, V13, P2651; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Heintz N, 1997, NAT GENET, V16, P325, DOI 10.1038/ng0897-325; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; NAKAJO S, 1990, J NEUROCHEM, V55, P2031, DOI 10.1111/j.1471-4159.1990.tb05792.x; Nussbaum RL, 1997, HUM MOL GENET, V6, P1687, DOI 10.1093/hmg/6.10.1687; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6	30	403	425	2	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					110	114		10.1038/8820	http://dx.doi.org/10.1038/8820			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319874				2022-12-25	WOS:000080096300035
J	Marti, A; Wirbelauer, C; Scheffner, M; Krek, W				Marti, A; Wirbelauer, C; Scheffner, M; Krek, W			Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTION FACTOR E2F-1; F-BOX PROTEIN; S-PHASE ENTRY; CYCLIN-A; CELL-CYCLE; GENE-PRODUCT; HUMAN CUL-1; PROTEASOME PATHWAY; FIBROBLASTS LEADS; FAMILY PROTEINS	The transcription factor E2F-1 is important in the control of cell proliferation. Its activity must be tightly regulated in a cell-cycle-dependent manner to enable programs of gene expression to be coupled closely with cell-cycle position. Here we show that, following its accumulation in the late G1 phase of the cell cycle, E2F-1 is rapidly degraded in S/G2 phase. This event is linked to a specific interaction of E2F-1 with the F-box-containing protein p45(SKP2), which is the cell-cycle-regulated component of the ubiquitin-protein ligase SCFSKP2 that recognizes substrates for this ligase. Disruption of the interaction between E2F-1 and p45(SKP2) results in a reduction in ubiquitination of E2F-1 and the stabilization and accumulation of transcriptionally active E2F-1 protein. These results indicate that an SCFSKP2-dependent ubiquitination pathway may be involved in the downregulation of E2F-1 activity in the S/G2 phase of the cell cycle, and suggest a link between SCFSKP2 and cell-cycle-dependent gene control.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Deutsch Krebsforschungszentrum, D-69017 Heidelberg, Germany	Friedrich Miescher Institute for Biomedical Research; Helmholtz Association; German Cancer Research Center (DKFZ)	Krek, W (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	wilhelm.krek@fmi.ch	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V17, P61; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	45	297	305	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					14	19		10.1038/8984	http://dx.doi.org/10.1038/8984			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559858				2022-12-25	WOS:000083085300012
J	Shinkura, R; Kitada, K; Matsuda, F; Tashiro, K; Ikuta, K; Suzuki, M; Kogishi, K; Serikawa, T; Honjo, T				Shinkura, R; Kitada, K; Matsuda, F; Tashiro, K; Ikuta, K; Suzuki, M; Kogishi, K; Serikawa, T; Honjo, T			Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase	NATURE GENETICS			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; TUMOR-NECROSIS-FACTOR; PERIPHERAL LYMPHOID ORGANS; ALY MUTANT MICE; DEFICIENT MICE; CELL-DEATH; ALPHA; ORGANOGENESIS; ORGANIZATION; EXPRESSION	The alymphoplasia (aly) mutation of mouse is autosomal recessive and characterized by the systemic absence of lymph nodes (LN) and Peyer's patches (PP) and disorganized splenic and thymic structures with immunodeficiency(1-3). Although recent reports have shown that the interaction between lymphotoxin (LT) and the LT beta-receptor (Lt beta r, encoded by Ltbr) provides a critical signal for LN genesis in mice(4-10), the aly locus on chromosome 11 (ref, 11) is distinct from those for LT and its receptor. We found that the aly allele carries a point mutation causing an amino acid substitution in the carboxy-terminal interaction domain of Nf-kappa b-inducing kinase(12,13) (Nik, encoded by the gene Nik). Transgenic complementation with wild-type Nik restored the normal structures of LN, PP, spleen and thymus, and the normal immune response in aly/aly mice. In addition, the aly mutation in a kinase domain-truncated Nik abolished its dominant-negative effect on Nf-kappa b activation induced by an excess of Lt beta r. Our observations agree with previous reports that Lt beta r-deficient mice showed defects in LN genesis(4) and that Nik is a common mediator of Nf-kappa b activation by the tumour necrosis factor (TNF) receptor family(12,13). Nik is able to interact with members of the TRAF family (Traf1, 2, 3, 5 and 6; ref. 13), suggesting it acts downstream of TRAF-associating receptor signalling pathways, including Tnfr (ref. 12), Cd40 (refs 14,15), Cd30 (refs 16,17) and Lt beta r (refs 18-21). The phenotypes of aly/aly mice are more severe than those of Ltbr(-/-) mice, however, indicating involvement of Nik in signal transduction mediated by other receptors.	Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Inst Lab Anim, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068501, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8620976, Japan	Kyoto University; Kyoto University; Kyoto University; Kumamoto University	Honjo, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan.		Honjo, Tasuku/N-4470-2016; Matsuda, Fumihiko/B-9893-2009	Ikuta, Koichi/0000-0003-1319-1021				BANKS TA, 1995, J IMMUNOL, V155, P1685; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KOSCO MH, 1992, J IMMUNOL, V148, P2331; Krajewska M, 1998, AM J PATHOL, V152, P1549; KURAMOTO T, 1994, INT IMMUNOL, V6, P991, DOI 10.1093/intimm/6.7.991; KVIST S, 1983, EMBO J, V2, P245, DOI 10.1002/j.1460-2075.1983.tb01413.x; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; NAKAMURA T, 1995, GENOMICS, V30, P312, DOI 10.1006/geno.1995.9872; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shinkura R, 1996, INT IMMUNOL, V8, P1067, DOI 10.1093/intimm/8.7.1067; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460	28	380	388	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					74	77		10.1038/8780	http://dx.doi.org/10.1038/8780			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319865				2022-12-25	WOS:000080096300026
J	Kitagawa, R; Rose, AM				Kitagawa, R; Rose, AM			Components of the spindle-assembly checkpoint are essential in Caenorhabditis elegans	NATURE CELL BIOLOGY			English	Article							CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE CHECKPOINTS; XENOPUS EGG EXTRACTS; SACCHAROMYCES-CEREVISIAE; GERMLINE DEVELOPMENT; BUDDING YEAST; UNATTACHED KINETOCHORES; MICROTUBULE FUNCTION; OOCYTE DEVELOPMENT; PROTEIN MAD2	The spindle-assembly checkpoint ensures that, during mitosis and meiosis, chromosomes do not segregate until they are properly attached to the microtubules of the spindle. Here we show that mdf-l and mdf-2 are components of the spindle-assembly checkpoint in Caenorhabditis elegans, and are essential for the long-term survival and fertility of this organism. Loss of function of either of these genes leads to the accumulation of a variety of defects, including chromosome abnormalities, X-chromosome non-disjunction or loss, problems in gonad development, and embryonic lethality. Antibodies that recognize the MDF-2 protein localize to nuclei of the cleaving embryo in a cell-cycle-dependent manner. mdf-l, a gene encoding a product that interacts with MDF-2, is required for cell-cycle arrest and proper chromosome segregation in premeiotic germ cells treated with nocodoazole, a microtubule-depolymerizing agent. In the absence of mdf gene products, errors in chromosome segregation arise and accumulate, ultimately leading to genetic lethality.	Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Rose, AM (corresponding author), Univ British Columbia, Dept Med Genet, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Kitagawa, Risa/B-7264-2014; Kitagawa, Risa/E-3395-2011	Kitagawa, Risa/0000-0001-7999-5730; 				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Berry LW, 1997, DEVELOPMENT, V124, P925; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRANCIS R, 1995, GENETICS, V139, P579; FRANCIS R, 1995, GENETICS, V139, P607; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; GRAHAM PL, 1993, DEV GENET, V14, P471, DOI 10.1002/dvg.1020140608; GRAHAM PL, 1993, GENETICS, V133, P919; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HODGKIN J, 1979, GENETICS, V91, P67; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Iwasaki K, 1996, J CELL BIOL, V134, P699, DOI 10.1083/jcb.134.3.699; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kadyk LC, 1998, DEVELOPMENT, V125, P1803; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; O'Connell KF, 1998, GENETICS, V149, P1303; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; QIAO L, 1995, GENETICS, V141, P551; Rose KL, 1997, DEV BIOL, V192, P59, DOI 10.1006/dbio.1997.8728; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, GENETICS, V124, P251; TAAGEPERA S, 1995, EXP CELL RES, V221, P249, DOI 10.1006/excr.1995.1373; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181	48	110	113	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					514	521		10.1038/70309	http://dx.doi.org/10.1038/70309			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587648				2022-12-25	WOS:000084136100020
J	Michele, DE; Albayya, FP; Metzger, JM				Michele, DE; Albayya, FP; Metzger, JM			Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes	NATURE MEDICINE			English	Article							THIN FILAMENT; TROPONIN-T; MUTATIONS; GENE; SENSITIVITY; EXPRESSION	Familial hypertrophic cardiomyopathy is a clinically and genetically diverse autosomal dominant disorder characterized by ventricular hypertrophy and myocyte disarray in the absence of known hypertrophic stimuli(1,2). It has been linked to many cardiac contractile proteins, including four point mutations in alpha-tropomyosin(3,4,5) (Tm). Here we use adenoviral-mediated gene transfer into adult cardiac myocytes in vitro to show that all four hypertrophic cardiomyopathy alpha-Tm proteins can be expressed and incorporated into normal sarcomeric structures in cardiac myocytes at similar levels as normal alpha-Tm proteins after 5-6 days in culture. Isometric force recordings of single cardiac myocytes demonstrated inappropriate increased force output at submaximal calcium concentration with a specific mutant allele hierarchy. These data indicate that the severity of direct calcium-sensitizing effect of mutations in alpha-Tm may predict the clinical severity of mutant alpha-Tm-associated hypertrophic cardiomyopathy.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Metzger, JM (corresponding author), Univ Michigan, Dept Physiol, 7730 Med Sci 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.							Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Bottinelli R, 1998, CIRC RES, V82, P106; Coviello DA, 1997, J AM COLL CARDIOL, V29, P635, DOI 10.1016/S0735-1097(96)00538-4; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; Golitsina N, 1999, BIOCHEMISTRY-US, V38, P3850, DOI 10.1021/bi9950701; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTIN AF, 1981, J BIOL CHEM, V256, P964; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; Michele DE, 1999, J CELL BIOL, V145, P1483, DOI 10.1083/jcb.145.7.1483; Muthuchamy M, 1999, CIRC RES, V85, P47; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; Rust EM, 1998, MOL CELL BIOCHEM, V181, P143, DOI 10.1023/A:1006802719136; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6720; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; Westfall MV, 1997, METHOD CELL BIOL, V52, P307, DOI 10.1016/S0091-679X(08)60385-4; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; YamauchiTakihara K, 1996, HEART, V76, P63, DOI 10.1136/hrt.76.1.63	26	71	72	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1413	1417						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581085				2022-12-25	WOS:000084049700042
J	Young, JD; Lawrence, AJ; MacLean, AG; Leung, BP; McInnes, IB; Canas, B; Pappin, DJC; Stevenson, RD				Young, JD; Lawrence, AJ; MacLean, AG; Leung, BP; McInnes, IB; Canas, B; Pappin, DJC; Stevenson, RD			Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids	NATURE MEDICINE			English	Article							METHIONINE SULFOXIDE; HUMAN-NEUTROPHILS; OXIDATION; PROTEINS; RESIDUES; ACTIN; CELLS	The possibility that glucocorticoids upregulate the expression of anti-inflammatory mediators is an exciting prospect for therapy in inflammatory diseases, because these molecules could give the therapeutic benefits of steroids without toxic side effects(1,2). Supernatants from monocytes' and macrophages(4) cultured in the presence of glucocorticoids increase the dispersion of neutrophils from a cell pellet in the capillary tube migration assay. This supernatant factor, unlike other neutrophil agonists, promotes dispersive locomotion of neutrophils at uniform concentration, lowers their adhesion to endothelial cells, inhibits their chemotactic response to fMLP and induces distinctive morphological changes(5,6). Here we show that thymosin beta 4 sulfoxide is generated by monocytes in the presence of glucocorticoids and acts as a signal to inhibit an inflammatory response. In vitro, thymosin beta 4 sulfoxide inhibited neutrophil chemotaxis, and in vivo, the oxidized peptide, but not the native form, was a potent inhibitor of carrageenin-induced edema in the mouse paw. Thymosin beta 4 is unique, because oxidation attenuates its intracellular C-actin sequestering activity(7), but greatly enhances its extracellular signaling properties. This description of methionine oxidation conferring extracellular function on a cytosolic proteins may have far-reaching implications for future strategies of anti-inflammatory therapy.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Univ Glasgow, Inst Biomed & Life Sci, Dept Immunol, Glasgow G12 8QQ, Lanark, Scotland; Glasgow Royal Infirm, Dept Med, Ctr Rheumat Dis, Glasgow G31 2ES, Lanark, Scotland; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England; Glasgow Royal Infirm, Dept Resp Med, Glasgow G31 2ES, Lanark, Scotland	University of Glasgow; Harvard University; University of Glasgow; University of Glasgow; Cancer Research UK; University of Glasgow	Lawrence, AJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland.		CANAS, BENITO/O-9256-2019; Leung, Bernard/O-2409-2013; MacLean, Andrew/R-9906-2019	Leung, Bernard/0000-0002-1119-4934; Pappin, Darryl/0000-0002-8981-8401; McInnes, Iain/0000-0002-6462-4280; MacLean, Andrew/0000-0002-0356-0674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBINANTENISSEN JM, 1995, AM J PHYSIOL, V268, P601; BECKSPEIER I, 1988, FEBS LETT, V227, P1, DOI 10.1016/0014-5793(88)81401-7; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; CHETTIBI S, 1994, J CELL SCI, V107, P3173; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; FLISS H, 1983, P NATL ACAD SCI-BIOL, V80, P7160, DOI 10.1073/pnas.80.23.7160; HANNAPPEL E, 1987, J CHROMATOGR, V397, P279, DOI 10.1016/S0021-9673(01)85010-X; HEINTZ D, 1994, EUR J BIOCHEM, V223, P345, DOI 10.1111/j.1432-1033.1994.tb19000.x; IANARO A, 1994, IMMUNOLOGY, V82, P370; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MALINDA KM, 1997, FASEB J, V11, P472; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; SHERMAN NE, 1995, P 43 AMS C MASS SPEC; STEVENSON RD, 1977, LANCET, V1, P225; STEVENSON RD, 1976, CLIN EXP IMMUNOL, V24, P527; SWAIM MW, 1988, J LEUKOCYTE BIOL, V43, P365, DOI 10.1002/jlb.43.4.365; THURMAN GB, 1984, J BIOL RESP MODIF, V3, P160; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; VOGT W, 1992, MOL IMMUNOL, V29, P251, DOI 10.1016/0161-5890(92)90106-8; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; YOUNG JD, 1997, EXP BIOL ONLINE, V2, P7	25	167	181	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1424	1427						4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581087				2022-12-25	WOS:000084049700044
J	Harper, BK; Mabon, SA; Leffel, SM; Halfhill, MD; Richards, HA; Moyer, KA; Stewart, CN				Harper, BK; Mabon, SA; Leffel, SM; Halfhill, MD; Richards, HA; Moyer, KA; Stewart, CN			Green fluorescent protein as a marker for expression of a second gene in transgenic plants	NATURE BIOTECHNOLOGY			English	Article						green fluorescent protein; transgene presence/expression; transgenic plants; Bacillus thuringiensis cry1Ac	THURINGIENSIS CRYLAC GENE; IN-VIVO; CELLS; HYBRIDIZATION; TRANSFORMATION; TOBACCO; CROPS	The use of transgenic crops has generated concerns about transgene movement to unintended hosts and the associated ecological consequences. Moreover, the in-field monitoring of transgene expression is of practical concern (e.g., the underexpression of an herbicide tolerance gene in crop plants that are due to be sprayed with herbicide). A solution to these potential problems is to monitor the presence and expression of an agronomically important gene by linking it to a marker gene, such as GFP. Here we show that GFP fluorescence can indicate expression of the Bacillus thuringiensus cry1Ac gene when co-introduced into tobacco and oilseed rape, as demonstrated by insect bioassays and western blot analysis. Furthermore we conducted two seasons of field experiments to characterize the performance of three different GFP genes in transgenic tobacco. The best gene tested was mGFP5er, a mutagenized GFP gene that is targeted to the endoplasmic reticulum. We also demonstrated that host plants synthesizing GFP in the field suffered no fitness costs.	Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA	University of North Carolina; University of North Carolina Greensboro	Stewart, CN (corresponding author), Univ N Carolina, Dept Biol, Greensboro, NC 27402 USA.	nstewart@uncg.edu	Stewart, Neal/B-4709-2009	Stewart, Neal/0000-0003-3026-9193				Allen GC, 1996, PLANT CELL, V8, P899, DOI 10.1105/tpc.8.5.899; AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; Chevre AM, 1997, NATURE, V389, P924, DOI 10.1038/40054; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Grebenok RJ, 1997, PLANT J, V11, P573, DOI 10.1046/j.1365-313X.1997.11030573.x; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HELM R, 1996, CURR BIOL, V8, P178; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JORGENSEN RB, 1994, AM J BOT, V81, P1620, DOI 10.2307/2445340; Kohler RH, 1997, PLANT J, V11, P613, DOI 10.1046/j.1365-313X.1997.11030613.x; Leffel SM, 1997, BIOTECHNIQUES, V23, P912, DOI 10.2144/97235bi01; Mikkelsen TR, 1996, NATURE, V380, P31, DOI 10.1038/380031a0; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RAYBOULD AF, 1993, J APPL ECOL, V30, P199, DOI 10.2307/2404623; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; ROGERS HJ, 1995, J EXP BOT, V46, P467, DOI 10.1093/jxb/46.5.467; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SOKAL RR, 1981, BIOMETRY, V2, P372; Stewart CN, 1996, PLANT PHYSIOL, V112, P115, DOI 10.1104/pp.112.1.121; Stewart CN, 1997, MOL ECOL, V6, P773, DOI 10.1046/j.1365-294X.1997.00239.x; Stewart CN, 1996, PLANT PHYSIOL, V112, P121, DOI 10.1104/pp.112.1.121; Stewart CN, 1996, NAT BIOTECHNOL, V14, P682, DOI 10.1038/nbt0696-682; Whitton J, 1997, THEOR APPL GENET, V95, P33, DOI 10.1007/s001220050529; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	26	93	98	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1125	1129		10.1038/15114	http://dx.doi.org/10.1038/15114			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545923	Bronze			2022-12-25	WOS:000083428000034
J	Lutgens, E; Gorelik, L; Daemen, MJAP; de Muinck, E; Grewal, IS; Koteliansky, VE; Flavell, RA				Lutgens, E; Gorelik, L; Daemen, MJAP; de Muinck, E; Grewal, IS; Koteliansky, VE; Flavell, RA			Requirement for CD154 in the progression of atherosclerosis	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; CD40 LIGAND; ENDOTHELIAL-CELLS; T-CELLS; MICE; MACROPHAGES; CHEMOKINES; LESIONS	Atherosclerosis is a systemic disease of the large arteries, and activation of inflammatory pathways is important in its pathogenesis(1). Increasing evidence supports the importance of CD40-CD154 interactions in atherosclerosis(2,3), interactions originally known to be essential in major immune reactions(4) and autoimmune diseases(5). CD40 is present on atheroma-derived cells in vitro and in human atheromata in situ(6). Ligation of CD40 on atheroma-associated cells in vitro activates the production of chemokines(6), cytokines(6), matrix metalloproteinases(7,8), adhesion molecules(9,10) and tissue factor: substances responsible for lesion progression and plaque destabilization(1). Administration of antibody against CD154 to low-density lipoprotein receptor-deficient mice has been shown to reduce atherosclerosis and decrease T-lymphocyte and macrophage content; however, only initial lesions were studied(3). Here, we determined the effect of genetic disruption of CD154 in ApoE(-/-) mice in both initial and advanced atherosclerotic lesions. Plaque area was reduced 550%. In contrast to previous reports, initial lesion development was not affected. Advanced plaques in CD154(-/-)ApoE(-/-) mice had a less-lipid-containing, collagen-rich, stable plaque phenotype, with a reduced T-lymphocyte/macrophage content. These data indicate that CD40-CD154 signaling is important in late atherosclerotic changes, such as lipid core formation and plaque destabilization.	Biogen, Cambridge, MA 02142 USA; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Pathol, NL-6202 AZ Maastricht, Netherlands; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Cardiol, NL-6202 AZ Maastricht, Netherlands; Yale Univ, Sch Med, Howard Hughes Inst, Dept Immunobiol, New Haven, CT 06520 USA	Biogen; Maastricht University; Maastricht University; Howard Hughes Medical Institute; Yale University	Daemen, MJAP (corresponding author), Biogen, 14 Cambridge Ctr, Cambridge, MA 02142 USA.		Lutgens, Esther/E-2919-2010	Lutgens, Esther/0000-0002-2609-5744; Grewal, Iqbal S/0000-0002-4775-055X				ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Kornbluth RS, 1998, P NATL ACAD SCI USA, V95, P5205, DOI 10.1073/pnas.95.9.5205; Lutgens E, 1999, CARDIOVASC RES, V41, P473, DOI 10.1016/S0008-6363(98)00311-3; Lutgens E, 1999, CIRCULATION, V99, P276, DOI 10.1161/01.CIR.99.2.276; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, CIRCULATION, V96, P396; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Mach F, 1998, ATHEROSCLEROSIS, V137, pS89, DOI 10.1016/S0021-9150(97)00309-2; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schonbeck U, 1997, CIRC RES, V81, P448, DOI 10.1161/01.RES.81.3.448; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	20	372	395	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1313	1316		10.1038/15271	http://dx.doi.org/10.1038/15271			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10546000				2022-12-25	WOS:000086550600044
J	McElroy, D				McElroy, D			Moving agbiotech downstream - Companies must turn to effective process develpment as a competitive weapon in agricultural biotechnology	NATURE BIOTECHNOLOGY			English	News Item							GENE INTROGRESSION; BREEDING PROGRAMS; PLANTS; PRODUCTS		Maxygen, Agr Business Operat, Redwood City, CA 94063 USA		McElroy, D (corresponding author), Maxygen, Agr Business Operat, 515 Galveston Dr, Redwood City, CA 94063 USA.							COOK ML, 1994, FOOD AGR MARKETS QUI; Diehn S H, 1996, Genet Eng (N Y), V18, P83; Duke S. O., 1996, HERBICIDE RESISTANT; Gebhardt C, 1997, TRENDS PLANT SCI, V2, P243, DOI 10.1016/S1360-1385(97)86340-6; Herbers K, 1996, TRENDS BIOTECHNOL, V14, P198, DOI 10.1016/0167-7799(96)10027-5; HILL WG, 1993, J HERED, V84, P212, DOI 10.1093/oxfordjournals.jhered.a111319; HILLEL J, 1990, GENETICS, V124, P783; HORNER HT, 1995, CROP SCI, V35, P1527, DOI 10.2135/cropsci1995.0011183X003500060002x; HOSPITAL F, 1992, GENETICS, V132, P1199; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; MAZUR BJ, 1995, TRENDS BIOTECHNOL, V13, P319, DOI 10.1016/S0167-7799(00)88975-1; MONSANTO AA, 1997, SEED CROP DIGEST, V6, P23; OHLROGGE JB, 1994, PLANT PHYSIOL, V104, P821, DOI 10.1104/pp.104.3.821; PISANO GP, 1997, DEV FACTORY; Register JC, 1997, TRENDS BIOTECHNOL, V15, P141, DOI 10.1016/S0167-7799(97)01008-1	15	20	23	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1071	1074		10.1038/15054	http://dx.doi.org/10.1038/15054			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545911				2022-12-25	WOS:000083428000022
J	Meyer, DE; Chilkoti, A				Meyer, DE; Chilkoti, A			Purification of recombinant proteins by fusion with thermally-responsive polypeptides	NATURE BIOTECHNOLOGY			English	Article						elastin-like polypeptide; inverse phase transition; environmentally responsive; fusion protein; protein purification	INVERSE TEMPERATURE TRANSITION; ESCHERICHIA-COLI EXPRESSION; FREE-ENERGY TRANSDUCTION; MONOCLONAL-ANTIBODY; LOCAL HYPERTHERMIA; SYSTEM; THIOREDOXIN; SEPARATION; POLYMER; PEPTIDE	Elastin-like polypeptides (ELPs) undergo a reversible, inverse phase transition. Below their transition temperature (T-t), ELPs are soluble in water, but when the temperature is raised above ft, phase transition occurs, leading to aggregation of the polypeptide. We demonstrate a method for purification of soluble fusion proteins incorporating an ELF tag. Advantages of this method, termed "inverse transition cycling," include technical simplicity, low cost, ease of scale-up, and capacity for multiplexing. More broadly, the ability to environmentally modulate the physicochemical properties of recombinant proteins by fusion with ELPs will allow diverse applications in bioseparation, immunoassays, biocatalysis, and drug delivery.	Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA	Duke University	Chilkoti, A (corresponding author), Duke Univ, Dept Biomed Engn, Box 90281, Durham, NC 27708 USA.			Meyer, Dan/0000-0002-1574-1704	NIGMS NIH HHS [1R21-GM-057373-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057373] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN JP, 1990, BIOMATERIALS, V11, P631, DOI 10.1016/0142-9612(90)90020-Q; CHILKOTI A, 1994, BIOCONJUGATE CHEM, V5, P504, DOI 10.1021/bc00030a004; COLLGAN JE, 1995, CURRENT PROTOCOLS PR; COPE DA, 1990, CANCER RES, V50, P1803; DEWHIRST MW, 1988, CURRENT CONCEPTS HYP; Diamandis E.P., 1996, IMMUNOASSAY; Hartmeier W., 1988, IMMOBILIZED BIOCATAL; Hauck ML, 1997, CLIN CANCER RES, V3, P63; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; KIM JS, 1993, PROTEIN SCI, V2, P348; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; McPherson DT, 1996, PROTEIN EXPRES PURIF, V7, P51, DOI 10.1006/prep.1996.0008; Moore DD, 1995, GLOB MOB SURV; NILSSON B, 1992, CURR OPIN STRUC BIOL, V2, P569; NISSON J, 1997, PROTEIN EXPRES PURIF, V11, P1; ONG E, 1989, TRENDS BIOTECHNOL, V7, P239, DOI 10.1016/0167-7799(89)90014-0; PORATH J, 1992, PROT EXPR PURIF, V3, P262; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Smith PA, 1998, NUCLEIC ACIDS RES, V26, P1414, DOI 10.1093/nar/26.6.1414; SU XZ, 1992, BIOTECHNIQUES, V13, P756; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; URRY DW, 1992, PROG BIOPHYS MOL BIO, V57, P23, DOI 10.1016/0079-6107(92)90003-O; URRY DW, 1991, J AM CHEM SOC, V113, P4346, DOI 10.1021/ja00011a057; URRY DW, 1985, BIOPOLYMERS, V24, P2345, DOI 10.1002/bip.360241212; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; Urry DW, 1997, J PHYS CHEM B, V101, P11007, DOI 10.1021/jp972167t; VERTESY L, 1984, EUR J BIOCHEM, V141, P505, DOI 10.1111/j.1432-1033.1984.tb08221.x	31	662	718	8	225	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1112	1115		10.1038/15100	http://dx.doi.org/10.1038/15100			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545920				2022-12-25	WOS:000083428000031
J	Hollander, MC; Sheikh, MS; Bulavin, DV; Lundgren, K; Augeri-Henmueller, L; Shehee, R; Molinaro, TA; Kim, KE; Tolosa, E; Ashwell, JD; Rosenberg, MP; Zhan, QM; Fernandez-Salguero, PM; Morgan, WF; Deng, CX; Fornace, AJ				Hollander, MC; Sheikh, MS; Bulavin, DV; Lundgren, K; Augeri-Henmueller, L; Shehee, R; Molinaro, TA; Kim, KE; Tolosa, E; Ashwell, JD; Rosenberg, MP; Zhan, QM; Fernandez-Salguero, PM; Morgan, WF; Deng, CX; Fornace, AJ			Genomic instability in Gadd45a-deficient mice	NATURE GENETICS			English	Article							CELL-CYCLE ARREST; P53-DEFICIENT MICE; P53; GADD45; DEFICIENT; PROTEIN; P21	Gadd45a-null mice generated by gene targeting exhibited several of the phenotypes characteristic of p53-deficient mice, including genomic instability, increased radiation carcinogenesis and a low frequency of exencephaly. Genomic instability was exemplified by aneuploidy, chromosome aberrations, gene amplification and centrosome amplification, and was accompanied by abnormalities in mitosis, cytokinesis and growth control. Unequal segregation of chromosomes due to multiple spindle poles during mitosis occurred in several Gadd45a(-/-) cell lineages and may contribute to the aneuploidy. Our results indicate that Gadd45a is one component of the p53 pathway that contributes to the maintenance of genomic stability.	NCI, Gene Response Sect, DBS, Bethesda, MD 20892 USA; Glaxo Wellcome Res & Dev Inc, Res Triangle Pk, NC 27709 USA; NCI, Lab Immune Cell Biol, DBS, Bethesda, MD 20892 USA; NCI, Lab Metab, DBS, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; NIDDKD, Genet Dev & Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Fornace, AJ (corresponding author), NCI, Gene Response Sect, DBS, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016; Tolosa, Eva/S-3454-2016; Fernandez-Salguero, Pedro M./J-8437-2014; Fornace, Albert/A-7407-2008	Fernandez-Salguero, Pedro M./0000-0003-2839-5027; Fornace, Albert/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrier F, 1999, MOL CELL BIOL, V19, P1673; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Kamien R, 1997, MUSIC THEOR SPECTRUM, V19, P1, DOI 10.1525/mts.1997.19.1.02a00010; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NELSONREES WA, 1980, CYTOGENET CELL GENET, V27, P216, DOI 10.1159/000131490; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takeshi K, 1998, JPN QUART, V45, P4; WANG X, IN PRESS J BIOL CHEM; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	30	425	440	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					176	184		10.1038/13802	http://dx.doi.org/10.1038/13802			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508513				2022-12-25	WOS:000082827500016
J	Kim, BS; Nikolovski, J; Bonadio, J; Mooney, DJ				Kim, BS; Nikolovski, J; Bonadio, J; Mooney, DJ			Cyclic mechanical strain regulates the development of engineered smooth muscle tissue	NATURE BIOTECHNOLOGY			English	Article						smooth muscle; tissue engineering; elastin; collagen; mechanical stimulation	VASCULAR CELLS; BLOOD-VESSEL; GROWTH; COLLAGEN; INVITRO; RAT; STRETCH; ARTERY; PROLIFERATION; COMPONENTS	We show that the appropriate combinations of mechanical stimuli and polymeric scaffolds can enhance the mechanical properties of engineered tissues. The mechanical properties of tissues engineered from cells and polymer scaffolds are significantly lower than the native tissues they replace. We hypothesized that application of mechanical stimuli to engineered tissues would alter their mechanical properties. Smooth muscle tissue was engineered on two different polymeric scaffolds and subjected to cyclic mechanical strain. Short-term application of strain increased proliferation of smooth muscle cells (SMCs) and expression of collagen and elastin, but only when SMCs were adherent to specific scaffolds. Long-term application of cyclic strain upregulated elastin and collagen gene expression and led to increased organization in tissues. This resulted in more than an order of magnitude increase in the mechanical properties of the tissues.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Select Genet, San Diego, CA 92121 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.		; Byung-Soo, Kim/O-2352-2013	Mooney, David/0000-0001-6299-1194; Byung-Soo, Kim/0000-0001-5210-7430	NICHD NIH HHS [5T32 HD07505-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BIRUKOV KG, 1995, MOL CELL BIOCHEM, V144, P131, DOI 10.1007/BF00944392; BUCK RC, 1983, ATHEROSCLEROSIS, V46, P217, DOI 10.1016/0021-9150(83)90112-0; Choi RS, 1998, J PEDIATR SURG, V33, P991, DOI 10.1016/S0022-3468(98)90520-6; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COSTA KA, 1991, FASEB J, V5, pA1609; Fung YC, 1990, BIOMECHANICS MOTION; Hirai J, 1996, CELL TRANSPLANT, V5, P93, DOI 10.1016/0963-6897(95)02002-0; HUME WR, 1980, HYPERTENSION, V2, P738, DOI 10.1161/01.HYP.2.6.738; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KANDA K, 1993, CELL TRANSPLANT, V2, P475, DOI 10.1177/096368979300200606; KANDA K, 1994, CELL TRANSPLANT, V3, P481, DOI 10.1177/096368979400300605; Kim BS, 1998, J BIOMED MATER RES, V41, P322, DOI 10.1002/(SICI)1097-4636(199808)41:2<322::AID-JBM18>3.0.CO;2-M; Kim BS, 1998, BIOTECHNOL BIOENG, V57, P46; KOLPAKOV V, 1995, CIRC RES, V77, P823, DOI 10.1161/01.RES.77.4.823; KULIK TJ, 1993, J CELL PHYSIOL, V157, P615, DOI 10.1002/jcp.1041570322; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LEUNG DYM, 1976, SCIENCE, V191, P475; LEUNG DYM, 1977, EXP CELL RES, V109, P285, DOI 10.1016/0014-4827(77)90008-8; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; MILLS I, 1993, HEMODYNAMIC FORCES V, P66; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149, DOI 10.1038/6146; PARK J B, 1992, BIOMATERIALS INTRO, V2; PREDEL HG, 1992, LANCET, V340, P878; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; STANISLAWSKI L, 1995, J BIOMED MATER RES, V29, P315, DOI 10.1002/jbm.820290306; SUMPIO BE, 1988, J SURG RES, V44, P696, DOI 10.1016/0022-4804(88)90103-5; Tranquillo RT, 1996, BIOMATERIALS, V17, P349, DOI 10.1016/0142-9612(96)85573-6; VANDERLEI B, 1987, SURGERY, V101, P459; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	35	356	367	5	72	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					979	983		10.1038/13671	http://dx.doi.org/10.1038/13671			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504698				2022-12-25	WOS:000083015700023
J	Nordhoff, E; Krogsdam, AM; Jorgensen, HF; Kallipolitis, BH; Clark, BFC; Roepstorff, P; Kristiansen, K				Nordhoff, E; Krogsdam, AM; Jorgensen, HF; Kallipolitis, BH; Clark, BFC; Roepstorff, P; Kristiansen, K			Rapid identification of DNA-binding proteins by mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						protein-DNA interactions; matrix-assisted laser desorption/ionization time-of-flight mass spectrometry	POLY(ADP-RIBOSE) POLYMERASE; ESCHERICHIA-COLI; RECEPTOR PROTEIN; RETINOIC ACID; TRANSCRIPTION; SPECIFICITIES; PROMOTER; SYSTEM; YEAST; GELS	We report a protocol for the rapid identification of DNA-binding proteins. Immobilized DNA probes harboring a specific sequence motif are incubated with cell or nuclear extract. Proteins are analyzed directly off the solid support by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The determined molecular masses are often sufficient for identification. If not, the proteins are subjected to mass spectrometric peptide mapping followed by database searches. Apart from protein identification, the protocol also yields information on posttranslational modifications. The protocol was validated by the identification of known prokaryotic and eukaryotic DNA-binding proteins, and its use provided evidence that poly(ADP-ribose) polymerase exhibits DNA sequence-specific binding to DNA.	Univ Aarhus, Inst Mol & Struct Biol, Dept Biostruct Biol, Aarhus, Denmark; Odense Univ, Dept Mol Biol, DK-5230 Odense, Denmark	Aarhus University; University of Southern Denmark	Nordhoff, E (corresponding author), Max Planck Inst Mol Genet, Berlin, Germany.		Kristiansen, Karsten/J-5148-2014; Krogsdam, Anne/AAM-7278-2020	Kristiansen, Karsten/0000-0002-6024-0917; Kallipolitis, Birgitte H./0000-0003-1233-9776; Jorgensen, Helle/0000-0002-7909-2977; Krogsdam, Anne/0000-0002-5478-0511				ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; Dent C, 1993, TRANSCRIPTION FACTOR; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Gobom J, 1997, INT J MASS SPECTROM, V169, P153, DOI 10.1016/S0168-1176(97)00216-4; HENRY K, 1995, TOXICOL APPL PHARM, V132, P317, DOI 10.1006/taap.1995.1113; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lechler A, 1998, J MOL BIOL, V278, P897, DOI 10.1006/jmbi.1998.1744; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; VALENTINHANSEN P, 1978, MOL GEN GENET, V159, P191, DOI 10.1007/BF00270893; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929	23	56	58	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					884	888		10.1038/12873	http://dx.doi.org/10.1038/12873			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471930				2022-12-25	WOS:000082365800030
J	Koivunen, E; Arap, W; Valtanen, H; Rainisalo, A; Medina, OP; Heikkila, P; Kantor, C; Gahmberg, CG; Salo, T; Konttinen, YT; Sorsa, T; Ruoslahti, E; Pasqualini, R				Koivunen, E; Arap, W; Valtanen, H; Rainisalo, A; Medina, OP; Heikkila, P; Kantor, C; Gahmberg, CG; Salo, T; Konttinen, YT; Sorsa, T; Ruoslahti, E; Pasqualini, R			Tumor targeting with a selective gelatinase inhibitor	NATURE BIOTECHNOLOGY			English	Article						phage display; matrix metalloproteinase; tumor targeting; angiogenesis; cancer therapy	MATRIX METALLOPROTEINASE INHIBITOR; EXTRACELLULAR-MATRIX; CYCLIC-PEPTIDES; IV COLLAGENASE; PHAGE DISPLAY; STROMAL CELLS; CANCER; ANGIOGENESIS; METASTASIS; CARCINOMA	Several lines of evidence suggest that tumor growth, angiogenesis, and metastasis are dependent on matrix metalloproteinase (MMP) activity, However, the lack of inhibitors specific for the type IV collagenase/gelatinase family of MMPs has thus far prevented the selective targeting of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) for therapeutic intervention in cancer, Here, we describe the isolation of specific gelatinase inhibitors from phage display peptide libraries. We show that cyclic peptides containing the sequence HWGF are potent and selective inhibitors of MMP-2 and MMP-9 but not of several other MMP family members, Our prototype synthetic peptide, CTTHWGFTLC, inhibits the migration of human endothelial cells and tumor cells, Moreover, it prevents tumor growth and invasion in animal models and improves survival of mice bearing human tumors. Finally, we show that CTTHWGFTLC-displaying phage specifically target angiogenic blood vessels in vivo. Selective gelatinase inhibitors may prove useful in tumor targeting and anticancer therapies.	Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Burnham Inst, La Jolla, CA 92037 USA; Univ Helsinki, Dept Periodontol, FIN-00014 Helsinki, Finland; Univ Oulu, Dept Diagnost & Oral Med, FIN-90401 Oulu, Finland; Univ Helsinki, Dept Anat, FIN-00014 Helsinki, Finland	University of Helsinki; Sanford Burnham Prebys Medical Discovery Institute; University of Helsinki; University of Oulu; University of Helsinki	Koivunen, E (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikinkaari 5, FIN-00014 Helsinki, Finland.	erkki.koivunen@helsinki.fi; pasqualini@burnham-inst.org	Gahmberg, Carl/AAE-1876-2019; , tuula/ABG-2051-2021; Penate-Medina, oula/ABB-8198-2021; medina, oula penate/G-5136-2012	Penate-Medina, oula/0000-0001-9878-5309; medina, oula penate/0000-0001-9878-5309; Salo, Tuula/0000-0001-6039-0088; Koivunen, Erkki/0000-0002-6443-9595; Gahmberg, Carl/0000-0001-9892-9296; Heikkila, Pia/0000-0002-5925-1993	NCI NIH HHS [CA30199, CA74238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074238, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson IC, 1996, CANCER RES, V56, P715; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Beckett RP, 1996, DRUG DISCOV TODAY, V1, P16, DOI 10.1016/1359-6446(96)89115-X; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; DAVIES B, 1993, CANCER RES, V53, P2087; DOMINGO GJ, 1995, INT J PEPT PROT RES, V46, P79; Eccles SA, 1996, CANCER RES, V56, P2815; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferry G, 1997, MOL DIVERS, V2, P135, DOI 10.1007/BF01682201; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heppner KJ, 1996, AM J PATHOL, V149, P273; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; Itoh T, 1998, CANCER RES, V58, P1048; Karakiulakis George, 1997, Invasion and Metastasis, V17, P158; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; Krook M, 1998, MOL DIVERS, V3, P149; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; PASQUALINI R, 1999, IN RPESS PHAGE DISPL; PASQUALINI R, 1997, NAT BIOTECHNOL, V245, P346; Pulli T, 1997, J BIOL CHEM, V272, P21176, DOI 10.1074/jbc.272.34.21176; PYKE C, 1993, AM J PATHOL, V142, P359; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; RUI F, 1996, BIOCHEM BIOPH RES CO, V220, P53; Santos O, 1997, CLIN EXP METASTAS, V15, P499, DOI 10.1023/A:1018418725453; Seftor REB, 1998, CLIN EXP METASTAS, V16, P217, DOI 10.1023/A:1006588708131; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; Sugiura Y, 1998, CANCER RES, V58, P2209; Talbot DC, 1996, EUR J CANCER, V32A, P2528; TARABOLETTI G, 1995, J NATL CANCER I, V87, P293, DOI 10.1093/jnci/87.4.293; Teronen O, 1997, J DENT RES, V76, P1529, DOI 10.1177/00220345970760090401; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Wojtowicz-Praga S, 1998, J CLIN ONCOL, V16, P2150, DOI 10.1200/JCO.1998.16.6.2150	52	490	556	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					768	774		10.1038/11703	http://dx.doi.org/10.1038/11703			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429241				2022-12-25	WOS:000081751400025
J	Larkin, J; Clayton, M; Sun, B; Perchonock, CE; Morgan, JL; Siracusa, LD; Michaels, FH; Feitelson, MA				Larkin, J; Clayton, M; Sun, B; Perchonock, CE; Morgan, JL; Siracusa, LD; Michaels, FH; Feitelson, MA			Hepatitis B virus transgenic mouse model of chronic liver disease	NATURE MEDICINE			English	Article							HEPATOCELLULAR-CARCINOMA; AUTOANTIBODY PRODUCTION; CARRIER PATIENTS; MICE; REPLICATION; INFECTION; PATHOGENESIS; EXPRESSION; GENOME; STATE	A model for hepatitis B virus-associated chronic liver disease has been made using cloned hepatitis B virus DNA as a transgene in a severe combined immunodeficient host. These mice consistently support virus gene expression and replication. After adoptive transfer of unprimed, syngeneic splenocytes, these mice cleared virus from liver and serum, and developed chronic liver disease. This model will permit identification of the host and virus contributions to chronic liver disease in the absence of tolerance.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Feitelson, MA (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 222 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.			Larkin, Jonathan/0000-0002-1202-9287	NATIONAL CANCER INSTITUTE [R01CA048656, R29CA048656, R01CA066971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186] Funding Source: NIH RePORTER; NCI NIH HHS [CA66971, CA48656] Funding Source: Medline; NIAAA NIH HHS [AA07186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BLUM HE, 1984, VIROLOGY, V139, P87, DOI 10.1016/0042-6822(84)90332-5; Blumberg BS, 1997, RES VIROLOGY, V148, P91, DOI 10.1016/S0923-2516(97)89890-1; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; Dienstag JL, 1984, VIRAL HEPATITIS LIVE, P135; FARZA H, 1988, J VIROL, V62, P4144, DOI 10.1128/JVI.62.11.4144-4152.1988; FEITELSON M, 1994, HEPATOLOGY, V19, P558, DOI 10.1002/hep.1840190304; FEITELSON MA, 1989, MOL BIOL MED, V6, P367; FEITELSON MA, 1988, J VIROL, V62, P1408, DOI 10.1128/JVI.62.4.1408-1415.1988; FEITELSON MA, 1990, GASTROENTEROLOGY, V99, P500, DOI 10.1016/0016-5085(90)91033-3; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; HOGAN B, 1994, MANIPULATION MOUSE E; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Hoofnagle J. H., 1984, VIRAL HEPATITIS LIVE, P97; Hoofnagle JH, 1997, J VIRAL HEPATITIS, V4, P41, DOI 10.1111/j.1365-2893.1997.tb00159.x; HOOFNAGLE JH, 1986, SEMIN LIVER DIS, V6, P1, DOI 10.1055/s-2008-1040787; Korba BA, 1996, HEPATOLOGY, V23, P958; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; Lohrengel B, 1998, IMMUNOGENETICS, V47, P332, DOI 10.1007/s002510050366; MASON WS, 1994, HEPATOLOGY, V19, P398; MILICH DR, 1991, P NATL ACAD SCI USA, V88, P4348, DOI 10.1073/pnas.88.10.4348; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; OMATA M, 1990, HEPATOLOGY, V12, P364, DOI 10.1002/hep.1840120226; PUGH JC, 1990, BRIT MED BULL, V46, P329, DOI 10.1093/oxfordjournals.bmb.a072402; RAY MB, 1979, HEPATITIS B VIRUS AN; ROBINSON WS, 1982, VIRAL HEPATITIS, P57; RUIZOPAZO N, 1982, J CELL BIOCHEM, V19, P281, DOI 10.1002/jcb.240190310; Sambrook J., 2002, MOL CLONING LAB MANU; Saracco G, 1997, DRUGS, V53, P74, DOI 10.2165/00003495-199753010-00005; SCHAEFFER DO, 1994, LAB ANIM SCI, V44, P189; Shanmuganathan S, 1997, J MED VIROL, V52, P128, DOI 10.1002/(SICI)1096-9071(199706)52:2<128::AID-JMV2>3.0.CO;2-5; SUMMERS J, 1981, HEPATOLOGY, V1, P179, DOI 10.1002/hep.1840010215; THOMAS HC, 1990, J HEPATOL, V11, P583; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; Waynforth H.B, 1992, EXPT SURG TECHNIQUES; WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0; WIRTH S, 1995, J IMMUNOL, V154, P2504	42	54	66	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					907	912		10.1038/11347	http://dx.doi.org/10.1038/11347			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426314				2022-12-25	WOS:000081684000034
J	Marchington, DR; Barlow, D; Poulton, J				Marchington, DR; Barlow, D; Poulton, J			Transmitochondrial mice carrying resistance to chloramphenicol on mitochondrial DNA: Developing the first mouse model of mitochondrial DNA disease	NATURE MEDICINE			English	Article							RIBOSOMAL-RNA MUTATION; NON-SYNDROMIC DEAFNESS; MTDNA; SEGREGATION; PHENOTYPE; MYOPATHY; FEMALE		John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England; Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford, England	University of Oxford; University of Oxford	Poulton, J (corresponding author), John Radcliffe Hosp, Dept Paediat, Level 4, Oxford OX3 9DU, England.		Poulton, Joanna/AAB-4828-2021	Poulton, Joanna/0000-0002-2460-5587	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		FERRIS SD, 1982, NATURE, V295, P163, DOI 10.1038/295163a0; FISCHELGHODSIAN N, 1993, AM J OTOLARYNG, V14, P399, DOI 10.1016/0196-0709(93)90113-L; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963; HOWELL N, 1988, SOMAT CELL MOLEC GEN, V14, P185, DOI 10.1007/BF01534403; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; KEARSEY SE, 1981, NATURE, V290, P607, DOI 10.1038/290607a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Laipis P J, 1996, Methods Enzymol, V264, P345, DOI 10.1016/S0076-6879(96)64033-6; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Meirelles FV, 1997, GENETICS, V145, P445; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; WHITE S, 1999, THESIS U MELBOURNE	17	51	53	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					957	960		10.1038/11403	http://dx.doi.org/10.1038/11403			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426324				2022-12-25	WOS:000081684000044
J	Zhang, HL; He, C; Yan, XX; Mirshahi, T; Logothetis, DE				Zhang, HL; He, C; Yan, XX; Mirshahi, T; Logothetis, DE			Activation of inwardly rectifying K+ channels by distinct PtdIns(4,5)P-2 interactions	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEINS; POTASSIUM CHANNELS; ATP CHANNELS; ACH CHANNEL; BETA-GAMMA; SUBUNIT; PIP2; GIRK1	Direct interactions of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) with inwardly rectifying potassium channels are stronger with channels rendered constitutively active by binding to PtdIns(4,5)P-2, such as IRK1, than with G-protein-gated channels (GIRKs), As a result, PtdIns(4,5)P-2 alone can activate IRK1 but not GIRKs, which require extra gating molecules such as the py subunits of G proteins or sodium ions. Here we identify two conserved residues near the inner-membrane interface of these channels that are critical in interactions with PtdIns(4,5)P-2. Between these two arginines, a conservative change of isoleucine residue 229 in GIRK4 to the corresponding leucine found in IRK1 strengthens GIRK4-PtdIns(4,5)P-2 interactions, eliminating the need for extra gating molecules. A negatively charged GIRK4 residue, two positions away from the most strongly interacting arginine, mediates stimulation of channel activity by sodium by strengthening channel-PtdIns(4,5)P-2 interactions. Our results provide a mechanistic framework for understanding how distinct gating mechanisms of inwardly rectifying potassium channels allow these channels to subserve their physiological roles.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Howard Hughes Med Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Logothetis, DE (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218, New York, NY 10029 USA.				NHLBI NIH HHS [HL59949, HL07824] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hilgemann Donald W., 1995, P307; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILLE B, 1992, IONIC CHANNELS EXCIT, V2, P115; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553	22	243	250	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					183	188		10.1038/11103	http://dx.doi.org/10.1038/11103			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559906				2022-12-25	WOS:000083102500018
J	Sethi, T; Rintoul, RC; Moore, SM; MacKinnon, AC; Salter, D; Choo, C; Chilvers, ER; Dransfield, I; Donnelly, SC; Strieter, R; Haslett, C				Sethi, T; Rintoul, RC; Moore, SM; MacKinnon, AC; Salter, D; Choo, C; Chilvers, ER; Dransfield, I; Donnelly, SC; Strieter, R; Haslett, C			Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo	NATURE MEDICINE			English	Article							MULTIPLE NEUROPEPTIDES; SURVIVAL FACTOR; FIBRONECTIN; INHIBITION; EXPRESSION; CARCINOMA; INTEGRIN; RECEPTOR; TENASCIN; ADHESION	Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer (SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) at both primary and metastatic sites. Adhesion of SCLC cells to ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of pi integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis. SCLC may create a specialized microenvironment, and the survival of cells bound to ECM could explain the partial responses and local recurrence of SCLC often seen clinically after chemotherapy. Strategies based on blocking pi integrin-mediated survival signals may represent a new therapeutic approach to improve the response to chemotherapy in SCLC.	Univ Edinburgh, Sch Med, Rayne Lab, Resp Med Unit, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA	University of Edinburgh; University of Edinburgh; University of Michigan System; University of Michigan	Sethi, T (corresponding author), Univ Edinburgh, Sch Med, Rayne Lab, Resp Med Unit, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.		Rintoul, Robert Campbell/Q-1727-2015; Haslett, Christopher/ABF-7689-2020	Rintoul, Robert Campbell/0000-0003-3875-3780; Donnelly, Seamas/0000-0001-7145-1843; Dransfield, Ian/0000-0001-5848-7059; Chilvers, Edwin/0000-0002-4230-9677				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BEPLER G, 1988, J CANCER RES CLIN, V114, P235, DOI 10.1007/BF00405828; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CARNEY DN, 1980, CANCER RES, V40, P1820; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DUKE RC, 1992, CURRENT PROTOCOLS IM; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIACCONE G, 1994, ANTICANCER RES, V14, P269; HEDIN U, 1991, AM J PATHOL, V139, P649; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IHDE D, 1993, CANC PRINCIPLES PRAC, P591; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LAI SL, 1989, J NATL CANCER I, V81, P1144, DOI 10.1093/jnci/81.15.1144; LANGDON SP, 1994, CANCER TOPICS, V9, P10; MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SMITH PJ, 1994, BRIT J CANCER, V70, P914, DOI 10.1038/bjc.1994.420; SMYTH JF, 1986, Q J MED, V61, P969; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Suzuki J, 1998, FEBS LETT, V437, P112, DOI 10.1016/S0014-5793(98)01213-7; Tallett A, 1996, CANCER RES, V56, P4255; VOGEL BE, 1990, J BIOL CHEM, V265, P5934	40	620	644	0	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1999	5	6					662	668		10.1038/9511	http://dx.doi.org/10.1038/9511			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371505				2022-12-25	WOS:000080823300035
J	Sturniolo, T; Bono, E; Ding, JY; Raddrizzani, L; Tuereci, O; Sahin, U; Braxenthaler, M; Gallazzi, F; Protti, MP; Sinigaglia, F; Hammer, J				Sturniolo, T; Bono, E; Ding, JY; Raddrizzani, L; Tuereci, O; Sahin, U; Braxenthaler, M; Gallazzi, F; Protti, MP; Sinigaglia, F; Hammer, J			Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices	NATURE BIOTECHNOLOGY			English	Article						HLA matrix; epitope prediction; DNA microarrays; tumor immunology; genomics	MHC CLASS-II; PEPTIDE BINDING-SPECIFICITY; HUMAN-GENOME-PROJECT; CD4(+) T-CELLS; CRYSTAL-STRUCTURE; TUMOR-ANTIGENS; IDENTIFICATION; PREDICTION; PROTEIN; HLA-DR1	Most pockets in the human leukocyte antigen-group DR (HLA-DR) groove are shaped by clusters of polymorphic residues and, thus, have distinct chemical and size characteristics in different HLA-DR alleles, Each HLA-DR pocket can be characterized by "pocket profiles," a quantitative representation of the interaction of all natural amino acid residues with a given pocket. In this report we demonstrate that pocket profiles are nearly independent of the remaining HLA-DR cleft. A small database of profiles was sufficient to generate a large number of HLA-DR matrices, representing the majority of human HLA-DR peptide-binding specificity. These virtual matrices were incorporated in software (TEPITOPE) capable of predicting promiscuous HLA class II ligands, This software, in combination with DNA microarray technology, has provided a new tool for the generation of comprehensive databases of candidate promiscuous T-cell epitopes in human disease tissues. First, DNA microarrays are used to reveal genes that are specifically expressed or upregulated in disease tissues. Second, the prediction software enables the scanning of these genes for promiscuous HLA-DR binding sites. In an example, we demonstrate that starting from nearly 20,000 genes, a database of candidate colon cancer-specific and promiscuous T-cell epitopes could be fully populated within a matter of days. Our approach has implications for the development of epitope-based vaccines.	Roche Milano Ric, I-20132 Milan, Italy; Hoffmann La Roche Inc, Dept Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Saarlandes, Dept Internal Med, D-66421 Homburg, Germany; San Raffaele Sci Inst, Lab Tumor Immunol, I-20132 Milan, Italy	Roche Holding; Roche Holding; Saarland University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Hammer, J (corresponding author), Roche Milano Ric, I-20132 Milan, Italy.		Protti, Maria Pia/J-7899-2016; Sahin, Ugur/L-4818-2017	Protti, Maria Pia/0000-0001-9079-2336; Sahin, Ugur/0000-0003-0363-1564				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BENMAHREZ K, 1988, BRIT J CANCER, V57, P529, DOI 10.1038/bjc.1988.123; Blackwell JM, 1997, T ROY SOC TROP MED H, V91, P107, DOI 10.1016/S0035-9203(97)90187-5; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brusic V, 1998, BIOINFORMATICS, V14, P121, DOI 10.1093/bioinformatics/14.2.121; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Degrave W, 1997, MEM I OSWALDO CRUZ, V92, P859, DOI 10.1590/S0074-02761997000600023; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Hammer J, 1997, ADV IMMUNOL, V66, P67, DOI 10.1016/S0065-2776(08)60596-9; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; HAMMER J, 1995, CURR OPIN IMMUNOL, V7, P263, DOI 10.1016/0952-7915(95)80013-1; HAMMER J, 1998, MHC, V2, P197; Harwood CR, 1996, FEBS LETT, V389, P84, DOI 10.1016/0014-5793(96)00524-8; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Manici S, 1999, J EXP MED, V189, P871, DOI 10.1084/jem.189.5.871; Marsh SGE, 1998, TISSUE ANTIGENS, V51, P582, DOI 10.1111/j.1399-0039.1998.tb02998.x; MARSHALL KW, 1995, J IMMUNOL, V154, P5927; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Raddrizzani L, 1997, J IMMUNOL, V159, P703; RAMMENSEE HG, 1998, SYFPEITHI INTERNET D; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SINIGAGLIA F, 1994, CURR OPIN IMMUNOL, V6, P52, DOI 10.1016/0952-7915(94)90033-7; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; TOPALIAN SL, 1994, CURR OPIN IMMUNOL, V6, P741, DOI 10.1016/0952-7915(94)90078-7; Tsuji K, 1992, P 11 INT HIST WORKSH; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	36	581	701	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					555	561		10.1038/9858	http://dx.doi.org/10.1038/9858			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385319				2022-12-25	WOS:000080716500026
J	Al-Mehdi, AB; Tozawa, K; Fisher, AB; Shientag, L; Lee, A; Muschel, RJ				Al-Mehdi, AB; Tozawa, K; Fisher, AB; Shientag, L; Lee, A; Muschel, RJ			Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis	NATURE MEDICINE			English	Article							MATRIX; EXPRESSION; MELANOMA; EXTRAVASATION; APOPTOSIS; SURVIVAL; ARREST; GROWTH; LUNGS; LINES	Metastasis is a frequent complication of cancer, yet the process through which circulating tumor cells form distant colonies is poorly understood. We have been able to observe the steps in early hematogenous metastasis by epifluorescence microscopy of tumor cells expressing green fluorescent protein in subpleural microvessels in intact, perfused mouse and rat lungs. Metastatic tumor cells attached to the endothelia of pulmonary pre-capillary arterioles and capillaries. Extravasation of tumor cells was rare, and it seemed that the transmigrated cells were cleared quickly by the lung, leaving only the endothelium-attached cells as the seeds of secondary tumors. Early colonies were entirely within the blood vessels. Although most models of metastasis include an extravasation step early in the process(1), here we show that in the lung, metastasis is initiated by attachment of tumor cells to the vascular endothelium and that hematogenous metastasis originates from the proliferation of attached intravascular tumor cells rather than from extravasated ones. Intravascular metastasis formation would make early colonies especially vulnerable to intravascular drugs, and this possibility has potential for the prevention of tumor cell attachment to the endothelium.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Muschel, RJ (corresponding author), Univ Penn, Dept Pathol & Lab Med, 269A John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.		Al-Mehdi, Abu-Bakr/A-8636-2009		NATIONAL CANCER INSTITUTE [R01CA046830] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA46830-09] Funding Source: Medline; NHLBI NIH HHS [P50-HL60290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CRISSMAN JD, 1985, LAB INVEST, V53, P470; DINGEMANS KP, 1973, JNCI-J NATL CANCER I, V51, P1883, DOI 10.1093/jnci/51.6.1883; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1990, ONCOGENE, V5, P75; Hangan D, 1996, CANCER RES, V56, P3142; Hauser PJ, 1998, ONCOGENE, V17, P3083, DOI 10.1038/sj.onc.1202235; Hua J, 1996, CANCER RES, V56, P5279; LAPIS K, 1988, CLIN EXP METASTAS, V6, P73, DOI 10.1007/BF01580408; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Nikiforov MA, 1996, ONCOGENE, V13, P1709; ROOS E, 1979, BIOCHIM BIOPHYS ACTA, V560, P135, DOI 10.1016/0304-419X(79)90005-2; Scherbarth S, 1997, CANCER RES, V57, P4105; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034	20	524	542	2	49	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					100	102		10.1038/71429	http://dx.doi.org/10.1038/71429			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613833				2022-12-25	WOS:000084583300044
J	Chang, P; Stearns, T				Chang, P; Stearns, T			delta-Tubulin and epsilon-tubulin: two new human centrosomal tubulins reveal new aspects of centrosome structure and function	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; HAMSTER OVARY CELLS; GAMMA-TUBULIN; SACCHAROMYCES-CEREVISIAE; BETA-TUBULIN; COMPONENT; COMPLEX; CHLAMYDOMONAS; ORGANIZATION; DUPLICATION	The centrosome organizes microtubules, which are made up of alpha-tubulin and beta-tubulin, and contains centrosome-bound gamma-tubulin, which is involved in microtubule nucleation. Here we identify two new human tubulins and show that they are associated with the centrosome. One is a homologue of the Chlamydomonas delta-tubulin Uni3, and the other is a new tubulin, which we have named epsilon-tubulin. Localization of delta-tubulin and epsilon-tubulin to the centrosome is independent of microtubules, and the patterns of localization are distinct from each other and from that of gamma-tubulin. delta-Tubulin is found in association with the centrioles, whereas epsilon-tubulin localizes to the pericentriolar material. epsilon-Tubulin exhibits a cell-cycle-specific pattern of localization, first associating with only the older of the centrosomes in a newly duplicated pair and later associating with both centrosomes. epsilon-Tubulin thus distinguishes the old centrosome from the new at the level of the pericentriolar material, indicating that there may be a centrosomal maturation event that is marked by the recruitment of epsilon-tubulin.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Chang, P (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Stearns, Tim/0000-0002-0671-6582	NIGMS NIH HHS [GM52032] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052032] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRECHTBUEHLER G, 1980, EXP CELL RES, V126, P427, DOI 10.1016/0014-4827(80)90282-7; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BURNS RG, 1995, CELL MOTIL CYTOSKEL, V31, P255, DOI 10.1002/cm.970310402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Detraves C, 1997, CELL MOTIL CYTOSKEL, V36, P179, DOI 10.1002/(SICI)1097-0169(1997)36:2<179::AID-CM7>3.0.CO;2-4; Dutcher SK, 1998, MOL BIOL CELL, V9, P1293, DOI 10.1091/mbc.9.6.1293; Frankel S, 1996, CURR OPIN CELL BIOL, V8, P30, DOI 10.1016/S0955-0674(96)80045-7; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; Harlow E, 1998, ANTIBODIES LAB MANUA; JULIAN M, 1993, J CELL SCI, V105, P145; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LAJOIEMAZENC I, 1994, J CELL SCI, V107, P2825; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; MARIANI BD, 1981, P NATL ACAD SCI-BIOL, V78, P4985, DOI 10.1073/pnas.78.8.4985; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; RIEDER CL, 1982, BIOL CELL, V44, P117; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Vogel JM, 1997, J CELL BIOL, V137, P193, DOI 10.1083/jcb.137.1.193; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	36	123	134	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					30	35		10.1038/71350	http://dx.doi.org/10.1038/71350			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620804				2022-12-25	WOS:000084843600016
J	Hsieh-Li, HM; Chang, JG; Jong, YJ; Wu, MH; Wang, NM; Tsai, CH; Li, H				Hsieh-Li, HM; Chang, JG; Jong, YJ; Wu, MH; Wang, NM; Tsai, CH; Li, H			A mouse model for spinal muscular atrophy	NATURE GENETICS			English	Article							SURVIVAL MOTOR-NEURON; SMN PROTEIN; DETERMINING GENE; IDENTIFICATION; DISEASE; CELLS; TISSUES	The survival motor neuron gene is present in humans in a telomeric copy, SMN1, and several centromeric copies, SMN2. Homozygous mutation of SMN1 is associated with proximal spinal muscular atrophy (SMA), a severe motor neuron disease characterized by early childhood onset of progressive muscle weakness(1-5). To understand the functional role of SMN1 in SMA, we produced mouse lines deficient for mouse Smn and transgenic mouse lines that expressed human SMN2. Smn(-/-) mice died during the peri-implantation stage. In contrast, transgenic mice harbouring SMN2 in the Smn(-/-) background showed pathological changes in the spinal cord and skeletal muscles similar tho those of SMA patients. The severity of the pathological changes in these mice correlated with the amount of SMN protein that contained the region encoded by exon 7. Our results demonstrate that SMN2 can partially compensate for lack of SMN1, The variable phenotypes of Smn(-/-)SMN2 mice reflect those seen in SMA patients, providing a mouse model for this disease.	Acad Sinica, Inst Mol Biol, Taipei, Taiwan; China Med Coll Hosp, Dept Med Res, Taichung, Taiwan; Kaohsiung Med Univ, Dept Pediat, Kaohsiung, Taiwan; Kaohsiung Med Univ, Dept Clin Lab, Kaohsiung, Taiwan	Academia Sinica - Taiwan; China Medical University Taiwan; Kaohsiung Medical University; Kaohsiung Medical University	Li, H (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.		Jong, Yuh-Jyh/B-8782-2009; Chang, Jan-Gowth/C-9544-2009					Bergin A, 1997, GENE, V204, P47, DOI 10.1016/S0378-1119(97)00510-6; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Burlet P, 1998, HUM MOL GENET, V7, P1927, DOI 10.1093/hmg/7.12.1927; Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886; Chang JG, 1997, HUM GENET, V100, P577, DOI 10.1007/s004390050555; CHOU SM, 1978, ACTA NEUROPATHOL, V41, P45, DOI 10.1007/BF00689556; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DIMITAR K, 1998, NAT GENET, V20, P230; DUBOWLTZ V, 1995, MUSCLE DISORDERS CHI; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HENDREY J, 1995, DEV BIOL, V172, P253, DOI 10.1006/dbio.1995.0020; Hogan B, 1994, MANIPULATING MOUSE E; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; La Bella V, 1998, EUR J NEUROSCI, V10, P2913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li H, 1996, EMBO J, V15, P714, DOI 10.1002/j.1460-2075.1996.tb00407.x; Melki J, 1997, CURR OPIN NEUROL, V10, P381, DOI 10.1097/00019052-199710000-00005; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Parsons DW, 1998, AM J HUM GENET, V63, P1712, DOI 10.1086/302160; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; vanderSteege G, 1996, AM J HUM GENET, V59, P834; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	30	548	572	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					66	70		10.1038/71709	http://dx.doi.org/10.1038/71709			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615130				2022-12-25	WOS:000084609200018
J	O'Donnell, RA; Saul, A; Cowman, AF; Crabb, BS				O'Donnell, RA; Saul, A; Cowman, AF; Crabb, BS			Functional conservation of the malaria vaccine antigen MSP-1(19) across distantly related Plasmodium species	NATURE MEDICINE			English	Article							MEROZOITE SURFACE PROTEIN-1; TERMINAL FRAGMENT; SERUM ANTIBODIES; FALCIPARUM; INVASION; EPITOPES; INHIBIT; REGION; CELL	The C-terminal region of Plasmodium falciparum merozoite surface protein 1 (MSP-1(19)) is at present a leading malaria vaccine candidate. Antibodies against the epidermal growth factor-like domains of MSP-1(19) are associated with immunity to P. falciparum(1-4) and active immunization with recombinant forms of the molecule protect against malaria challenge in various experimental systems(5-8), These findings, with the knowledge that epidermal growth factor-like domains in other molecules have essential binding functions, indicate the importance of this protein in merozoite invasion of red blood cells. Despite extensive molecular epidemiological investigations, only limited sequence polymorphism has been identified in P. falciparum MSP-1(19) (refs, 9-11). This indicates its sequence is functionally constrained, and is used in support of the use of MSP-1(19) as a vaccine. Here, we have successfully complemented the function of most of P. falciparum MSP-1(19) with the corresponding but highly divergent sequence from the rodent parasite P. chabaudi. The results indicate that the role of MSP-1(19) in red blood cell invasion is conserved across distantly related Plasmodium species and show that the sequence of P. falciparum MSP-1(19) is not constrained by function.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia; Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Brisbane, Qld 4029, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	University of Melbourne; QIMR Berghofer Medical Research Institute; University of Queensland; Walter & Eliza Hall Institute	Crabb, BS (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.		Cowman, Alan F/C-7642-2013; Saul, Allan J/I-6968-2013; Saul, Allan/ABH-2091-2020; Crabb, Brendan/F-5287-2013	Cowman, Alan F/0000-0001-5145-9004; Saul, Allan J/0000-0003-0665-4091; Saul, Allan/0000-0003-0665-4091; 				BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; CHANG SP, 1994, J IMMUNOL, V152, P3483; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; COOPER JA, 1992, MOL BIOCHEM PARASIT, V51, P301, DOI 10.1016/0166-6851(92)90080-4; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993; Egan A, 1997, INFECT IMMUN, V65, P3024, DOI 10.1128/IAI.65.8.3024-3031.1997; EGAN AF, 1995, INFECT IMMUN, V63, P456, DOI 10.1128/IAI.63.2.456-466.1995; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Egan AF, 1999, PARASITE IMMUNOL, V21, P133, DOI 10.1046/j.1365-3024.1999.00209.x; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; KANG Y, 1995, MOL BIOCHEM PARASIT, V73, P103, DOI 10.1016/0166-6851(95)00102-7; LING IT, 1994, PARASITE IMMUNOL, V16, P63, DOI 10.1111/j.1365-3024.1994.tb00324.x; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Perera KLRL, 1998, INFECT IMMUN, V66, P1500, DOI 10.1128/IAI.66.4.1500-1506.1998; Qari SH, 1998, MOL BIOCHEM PARASIT, V92, P241, DOI 10.1016/S0166-6851(98)00010-3; Rotman HL, 1999, EXP PARASITOL, V91, P78, DOI 10.1006/expr.1999.4357	20	149	154	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					91	95		10.1038/71595	http://dx.doi.org/10.1038/71595			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613831				2022-12-25	WOS:000084583300042
J	Annas, GJ; Caplan, A; Elias, S				Annas, GJ; Caplan, A; Elias, S			Stem cell politics, ethics and medical progress	NATURE MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA; Univ Penn, Med Ctr, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Illinois, Dept Obstet & Gynecol, Chicago, IL 60612 USA	Boston University; University of Pennsylvania; Pennsylvania Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V334, P1329, DOI 10.1056/NEJM199605163342012; ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; CAPLAN A, 1992, NEW ENGL J MED, V322, P1592; Feiler CL, 1998, FORDHAM LAW REV, V66, P2435; *GER ETH ADV BOARD, 1998, RES HUM EMBR STEM CE, P1; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; *NAT BIOETH ADV CO, 1999, ETH ISS STEM CELL RE; *OFF DIR, 1999, FACT SHEET STEM CELL; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	10	29	30	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1339	1341		10.1038/70900	http://dx.doi.org/10.1038/70900			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581063	Green Published			2022-12-25	WOS:000084049700018
J	Walch-Solimena, C; Novick, P				Walch-Solimena, C; Novick, P			The yeast phosphatidylinositol-4-OH kinase Pik1 regulates secretion at the Golgi	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; 4-KINASE; PROTEIN; ENCODES; PATHWAY; MUTANTS; ACTIN; GENE		Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA	Yale University	Novick, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06510 USA.							DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAMA H, IN PRESS J BIOL CHEM; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Martini L, 1998, SUPERCOND SCI TECH, V11, P231, DOI 10.1088/0953-2048/11/2/011; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	20	262	267	2	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					523	525		10.1038/70319	http://dx.doi.org/10.1038/70319			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587649				2022-12-25	WOS:000084136100021
J	Zozulya, S; Lioubin, M; Hill, RJ; Abram, C; Gishizky, ML				Zozulya, S; Lioubin, M; Hill, RJ; Abram, C; Gishizky, ML			Mapping signal transduction pathways by phage display	NATURE BIOTECHNOLOGY			English	Article						signal transduction; tyrosine phosphorylation; protein interaction screening; phage display	EPIDERMAL GROWTH-FACTOR; PHOSPHOTYROSINE INTERACTION DOMAIN; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; BACTERIOPHAGE-LAMBDA; ADAPTER MOLECULE; CAPSID PROTEIN; EGF-RECEPTOR; SH3 DOMAIN; RAS	Rapid identification of proteins that interact with a novel gene product is an important element of functional genomics. Here we describe a phage display-based technique for interaction screening of complex cDNA libraries using proteins or synthetic peptides as baits. Starting with the epidermal growth factor receptor (EGFR) cytoplasmic tail, we identified known protein interactions that link EGFR to the Ras/MAP kinase signal transduction cascade and several novel interactions. This approach can be used as a rapid and efficient tool for elucidating protein networks and mapping intracellular signal transduction pathways.	Sugen Inc, S San Francisco, CA USA	Pfizer	Zozulya, S (corresponding author), Sugen Inc, 230 E Grand Ave, S San Francisco, CA USA.		Zozulya, Sergey A/F-2986-2015	Zozulya, Sergey A/0000-0002-1179-2993				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERNARD DJ, 1992, BRIT J CANCER, V66, P88, DOI 10.1038/bjc.1992.222; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DUNN IS, 1995, J MOL BIOL, V248, P497, DOI 10.1006/jmbi.1995.0237; EFIMOV VP, 1995, VIRUS GENES, V10, P172; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Kay B. K, 1996, PHAGE DISPLAY PEPTID; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin JW, 1998, J NEUROSCI, V18, P2017; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; MARUYAMA IN, 1994, P NATL ACAD SCI USA, V91, P8273, DOI 10.1073/pnas.91.17.8273; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; *NOV, 1999, T7 SEL SYST MAN TB17; Nutt JE, 1996, EUR J CANCER, V32A, P2127, DOI 10.1016/S0959-8049(96)00261-4; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Ren ZJ, 1996, PROTEIN SCI, V5, P1833, DOI 10.1002/pro.5560050909; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Rosenbrock H, 1996, J PROCESS CONTR, V6, P1, DOI 10.1016/0959-1524(96)81787-2; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; Santini C, 1998, J MOL BIOL, V282, P125, DOI 10.1006/jmbi.1998.1986; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SOLER C, 1994, CELL GROWTH DIFFER, V5, P519; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; TODA M, 1993, BIOCHEM BIOPH RES CO, V196, P468, DOI 10.1006/bbrc.1993.2273; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	52	66	82	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1193	1198		10.1038/70736	http://dx.doi.org/10.1038/70736			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585717				2022-12-25	WOS:000084170700027
J	Bleazard, W; McCaffery, JM; King, EJ; Bale, S; Mozdy, A; Tieu, Q; Nunnari, J; Shaw, JM				Bleazard, W; McCaffery, JM; King, EJ; Bale, S; Mozdy, A; Tieu, Q; Nunnari, J; Shaw, JM			The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast	NATURE CELL BIOLOGY			English	Article							OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; LIVING CELLS; PROTEIN; FUSION; INHERITANCE; ORGANIZATION; MORPHOLOGY; REQUIRES	The dynamin-related GTPase Dnm1 controls mitochondrial morphology in yeast. Here we show that dnm1 mutations convert the mitochondrial compartment into a planar 'net' of interconnected tubules. We propose that this net morphology results from a defect in mitochondrial fission. Immunogold labelling localizes Dnm1 to the cytoplasmic face of constricted mitochondrial tubules that appear to be dividing and to the ends of mitochondrial tubules that appear to have recently completed division. The activity of Dnm1 is epistatic to that of Fzo1, a GTPase in the outer mitochondrial membrane that regulates mitochondrial fusion. dnm1 mutations prevent mitochondrial fragmentation in fzo1 mutant strains. These findings indicate that Dnm1 regulates mitochondrial fission, assembling on the cytoplasmic face of mitochondrial tubules at sites at which division will occur.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Johns Hopkins Univ, Dept Biol, Integrated Imaging Ctr, Baltimore, MD 21218 USA; Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA	Utah System of Higher Education; University of Utah; Johns Hopkins University; University of California System; University of California Davis	Shaw, JM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053466] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Berger KH, 1997, J CELL BIOL, V136, P545, DOI 10.1083/jcb.136.3.545; Boldogh I, 1998, J CELL BIOL, V141, P1371, DOI 10.1083/jcb.141.6.1371; BURGESS SM, 1994, J CELL BIOL, V126, P1375, DOI 10.1083/jcb.126.6.1375; Fuller Margaret T., 1993, P71; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hermann GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hermann GJ, 1998, ANNU REV CELL DEV BI, V14, P265, DOI 10.1146/annurev.cellbio.14.1.265; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SHERMAN F, 1986, METHODS YEAST GENETI, P1; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; TOURTE M, 1981, DEV GROWTH DIFFER, V23, P9; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Williamson DH, 1976, GENETICS BIOGENESIS, P99; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	24	568	579	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					298	304		10.1038/13014	http://dx.doi.org/10.1038/13014			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559943	Green Accepted			2022-12-25	WOS:000083169600019
J	Harrison, KA; Thaler, J; Pfaff, SL; Gu, H; Kehrl, JH				Harrison, KA; Thaler, J; Pfaff, SL; Gu, H; Kehrl, JH			Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice	NATURE GENETICS			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; HOMEOBOX GENE; BETA-CELLS; DIFFERENTIATION; REVEALS; REQUIREMENT; MESENCHYME; INTESTINE; NOTOCHORD; PDX-1	In most mammals the pancreas develops from the foregut endoderm as ventral and dorsal buds. These buds fuse and develop into a complex organ composed of endocrine, exocrine and ductal components(1,2). This developmental process depends upon an integrated network of transcription factors. Gene targeting experiments have revealed critical roles for Pdx1, lsl1, Pax4, Pax6 and Nkx2-2 (refs 3-10). The homeobox gene HLXB9 (encoding HB9) is prominently expressed in adult human pancreas(11), although its role in pancreas development and function is unknown. To facilitate its study, we isolated the mouse HLXB9 orthologue, Hlxb9. During mouse development, the dorsal and ventral pancreatic buds and mature beta-cells in the islets of Langerhans express Hlxb9. In mice homologous for a null mutation of Hlxb9, the dorsal lobe of the pancreas fails to develop. The remnant Hlxb9(-/-) pancreas has small islets of Langerhans with reduced numbers of insulin-producing p-cells. Hlxb9(-/-) beta-cells express low levels of the glucose transporter Glut2 and homeodomain factor Nkx 6-1. Thus, Hlxb9 is key to normal pancreas development and function.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Salk Institute	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	jkehrl@niaid.nih.gov	Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000737, Z01AI000719] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; BAUBONIS W, 1993, NUCLEIC ACIDS RES, V21, P2025, DOI 10.1093/nar/21.9.2025; Githens Sherwood, 1993, P21; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kim SK, 1997, DEVELOPMENT, V124, P4243; Offield MF, 1996, DEVELOPMENT, V122, P983; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Ross AJ, 1998, NAT GENET, V20, P358, DOI 10.1038/3828; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; THALER J, IN PRESS NEURON; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	26	275	294	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					71	75		10.1038/12674	http://dx.doi.org/10.1038/12674			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471502				2022-12-25	WOS:000082337300019
J	Knoblauch, M; Hibberd, JM; Gray, JC; van Bel, AJE				Knoblauch, M; Hibberd, JM; Gray, JC; van Bel, AJE			A galinstan expansion femtosyringe for microinjection of eukaryotic organelles and prokaryotes	NATURE BIOTECHNOLOGY			English	Article						microinjection; galinstan expansion femtosyringe; green fluorescent protein; chloroplast; cyanobacteria; transformation	GREEN-FLUORESCENT PROTEIN; PLASTID TRANSFORMATION; NICOTIANA-TABACUM; PLANTS; DNA; PROTOPLASTS; CONNECTIONS; EXPRESSION; TRANSIENT; COMPLEX	A galinstan expansion femtosyringe enables femtoliter to attoliter samples to be introduced into prokaryotes and subcellular compartments of eukaryotes. The method uses heat-induced expansion of galinstan (a liquid metal alloy of gallium, indium, and tin) within a glass syringe to expel samples through a tip diameter of about 0.1 mu m. The narrow tip inflicts less damage than conventional capillaries, and the heat-induced expansion of the galinstan allows fine control over the rate of injection. We demonstrate injection of Lucifer Yellow and Lucifer Yellow-dextran conjugates into cyanobacteria, and into nuclei and chloroplasts of higher organisms. Injection of a plasmid containing the bla gene into the cyanobacterium Phormidium laminosum resulted in transformed ampiciltin-resistant cultures. Green fluorescent protein was expressed in attached leaves of tobacco and Vicia faba following injection of DNA cantaining its gene into individual chloroplasts.	Univ Giessen, Inst Gen Bot & Plant Physiol, D-35390 Giessen, Germany; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	Justus Liebig University Giessen; University of Cambridge	Knoblauch, M (corresponding author), Univ Giessen, Inst Gen Bot & Plant Physiol, Senckenbergstr 17, D-35390 Giessen, Germany.			Knoblauch, Michael/0000-0003-0391-9891				DANIELL H, 1991, PLANT CELL REP, V9, P615, DOI 10.1007/BF00231800; DANIELL H, 1990, P NATL ACAD SCI USA, V87, P88, DOI 10.1073/pnas.87.1.88; GOLDS T, 1993, BIO-TECHNOL, V11, P95, DOI 10.1038/nbt0193-95; Grebenok RJ, 1997, PLANT J, V11, P573, DOI 10.1046/j.1365-313X.1997.11030573.x; HANDLER JS, 1981, AM J PHYSIOL, V240, P103; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hibberd JM, 1998, PLANT J, V16, P627, DOI 10.1046/j.1365-313x.1998.00328.x; HONER B, 1988, J CELL BIOL, V107, P2181, DOI 10.1083/jcb.107.6.2181; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kempers R, 1997, PLANTA, V201, P195, DOI 10.1007/BF01007704; KHAN MS, 1999, NAT BIOTECHNOL, V17; Knoblauch M, 1998, PLANT CELL, V10, P35, DOI 10.1105/tpc.10.1.35; Kohler R, 1997, TRENDS CELL BIOL, V7, P392; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; KOST B, 1995, J EXP BOT, V46, P1157, DOI 10.1093/jxb/46.9.1157; MALIGA P, 1993, TRENDS BIOTECHNOL, V11, P101, DOI 10.1016/0167-7799(93)90059-I; Nguyen L, 1996, P NATL ACAD SCI USA, V93, P12643, DOI 10.1073/pnas.93.22.12643; OKA MT, 1990, CELL STRUCT FUNCT, V15, P373, DOI 10.1247/csf.15.373; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; TAKESHIMA Y, 1996, DNA RES, V1, P181; VANDERSCHOOT C, 1989, THESIS U UTRECHT; WALTON PA, 1992, J CELL BIOL, V118, P499, DOI 10.1083/jcb.118.3.499	26	122	145	1	49	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					906	909		10.1038/12902	http://dx.doi.org/10.1038/12902			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471935				2022-12-25	WOS:000082365800035
J	Strausbaugh, HJ; Green, PG; Lo, E; Tangemann, K; Reichling, DB; Rosen, SD; Levine, JD				Strausbaugh, HJ; Green, PG; Lo, E; Tangemann, K; Reichling, DB; Rosen, SD; Levine, JD			Painful stimulation suppresses joint inflammation by inducing shedding of L-selectin from neutrophils	NATURE MEDICINE			English	Article							CHEMOTACTIC FACTORS; ENDOTHELIAL-CELLS; SHEAR-FLOW; IN-VITRO; ADHESION; LEUKOCYTES; INVIVO; MAC-1; EXPRESSION; INJURY	Although the inflammatory response is essential for protecting tissues from injury and infection(1), unrestrained inflammation can cause chronic inflammatory diseases such as arthritis, colitis and asthma. Physiological mechanisms that downregulate inflammation are poorly understood. Potent control might be achieved by regulating early stages in the inflammatory response, such as accumulation of neutrophils at the site of injury, where these cells release chemical mediators that promote inflammatory processes including plasma extravasation(2), bacteriocide and proteolysis. To access an inflammatory site, neutrophils must first adhere to the vascular endothelium in a process mediated in part by the leukocyte adhesion molecule L-selectin(3). This adhesion is prevented when L-selectin is shed from the neutrophil membrane(4,5) Although shedding of L-selectin is recognized as a potentially important mechanism for regulating neutrophilse(4,7), its physiological function has not been demonstrated. Shedding of L-selectin may mediate endogenous downregulation of inflammation by limiting neutrophil accumulation at inflammatory sites. Here we show that activation of nociceptive neurons induces shedding of L-selectin from circulating neutrophils in vivo and that this shedding suppresses an ongoing inflammatory response by inhibiting neutrophil accumulation. These findings indicate a previously unknown mechanism for endogenous feedback control of inflammation. failure of this mechanism could contribute to the etiology of chronic inflammatory disease.	Univ Calif San Francisco, NIH, Pain Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Strausbaugh, HJ (corresponding author), Univ Calif San Francisco, NIH, Pain Ctr, 521 Parnassus Ave, San Francisco, CA 94143 USA.		Green, Paul/C-5943-2011	Green, Paul/0000-0001-7648-6826; Rosen, Steven/0000-0002-6245-701X	NIADDK NIH HHS [AM32624] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Anders R.F., 1985, Parasitology Today, V1, P152, DOI 10.1016/0169-4758(85)90171-1; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; BURTON JL, 1995, J LEUKOCYTE BIOL, V57, P317, DOI 10.1002/jlb.57.2.317; Carlson SL, 1996, BRAIN BEHAV IMMUN, V10, P55, DOI 10.1006/brbi.1996.0005; DIAZGONZALEZ F, 1995, J CLIN INVEST, V95, P1756, DOI 10.1172/JCI117853; DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5; Gautam N, 1998, BRIT J PHARMACOL, V125, P1109, DOI 10.1038/sj.bjp.0702186; GREEN PG, 1995, J NEUROSCI, V15, P4678; Green PG, 1998, J NEUROPHYSIOL, V80, P3120, DOI 10.1152/jn.1998.80.6.3120; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Mills PJ, 1997, BRAIN BEHAV IMMUN, V11, P333, DOI 10.1006/brbi.1997.0500; MULLIGAN MS, 1995, J IMMUNOL, V154, P1350; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SternerKock A, 1996, AM J RESP CRIT CARE, V153, P436, DOI 10.1164/ajrccm.153.1.8542155; TABORSKY GJ, 1982, AM J PHYSIOL, V242, pE317, DOI 10.1152/ajpendo.1982.242.5.E317; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0	25	36	38	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1057	1061		10.1038/12497	http://dx.doi.org/10.1038/12497			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470085				2022-12-25	WOS:000082337200042
J	Carrano, AC; Eytan, E; Hershko, A; Pagano, M				Carrano, AC; Eytan, E; Hershko, A; Pagano, M			SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE REGULATION; HUMAN CUL-1; S-PHASE; DEPENDENT DEGRADATION; FISSION YEAST; KINASE; PROTEIN; COMPLEX; PATHWAY; CANCER	Degradation of the mammalian cyclin-dependent kinase (CDK) inhibitor p27 is required for the cellular transition from quiescence to the proliferative state. The ubiquitination and subsequent degradation of p27 depend on its phosphorylation by cyclin-CDK complexes. However, the ubiquitin-protein ligase necessary for p27 ubiquitination has not been identified. Here we show that the F-box protein SKP2 specifically recognizes p27 in a phosphorylation-dependent manner that is characteristic of an F-box-protein-substrate interaction. Furthermore, both in vivo and in vitro, SKP2 is a rate-limiting component of the machinery that ubiquitinates and degrades phosphorylated p27, Thus, p27 degradation is subject to dual control by the accumulation of both SKP2 and cyclins following mitogenic stimulation.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; New York University	Pagano, M (corresponding author), NYU, Med Ctr, Dept Pathol, MSB 548,550 1st Ave, New York, NY 10016 USA.		高, 雨莉/HGU-8187-2022	pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76584] Funding Source: Medline; NIGMS NIH HHS [R01 GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boratynskogo E. A., 1998, LETOPIS ZHIZNI TVORC; BUDEL L, IN PRESS BLOOD; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Esposito V, 1997, CANCER RES, V57, P3381; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HARLOW E, 1998, USING ANTIBODIES LAB, P187; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maekawa H, 1998, CURR GENET, V33, P29, DOI 10.1007/s002940050305; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mayor S, 1997, BRIT MED J, V314, P323, DOI 10.1136/bmj.314.7077.323a; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; OCONNOR PM, 1995, CELL CYCLE MAT METHO, P63; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PAGANO M, 1992, EMBO J, V11, P761; PAGANO M, 1995, CELL CYCLE MAT METHO, P271; PIVA R, IN PRESS J NEUROPATH; Sheaff R J, 1998, Results Probl Cell Differ, V22, P1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Steeg PS, 1997, NAT MED, V3, P152, DOI 10.1038/nm0297-152; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	48	1286	1344	2	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					193	199		10.1038/12013	http://dx.doi.org/10.1038/12013			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559916				2022-12-25	WOS:000083102700013
J	Felsenfeld, DP; Schwartzberg, PL; Venegas, A; Tse, R; Sheetz, MP				Felsenfeld, DP; Schwartzberg, PL; Venegas, A; Tse, R; Sheetz, MP			Selective regulation of integrin-cytoskeleton interactions by the tyrosine kinase Src	NATURE CELL BIOLOGY			English	Article							EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; CELL-MIGRATION; C-SRC; FIBRONECTIN; BINDING; ALPHA(V)BETA(3); ASSOCIATION; FIBROBLASTS; PP125(FAK)	Cell motility on extracellular-matrix (ECM) substrates depends on the regulated generation of force against the substrate through adhesion receptors known as integrins, Here we show that integrin-mediated traction forces can be selectively modulated by the tyrosine kinase Src, In Src-deficient fibroblasts, cell spreading on the ECM component vitronectin is inhibited, while the strengthening of linkages between integrin vitronectin receptors and the force-generating cytoskeleton in response to substrate rigidity is dramatically increased. In contrast, Src deficiency has no detectable effects on fibronectin-receptor function. Finally, truncated Src (lacking the kinase domain) co-localizes to focal-adhesion sites with alpha(v) but not with beta(1) integrins, These data are consistent with a selective, functional interaction between Src and the vitronectin receptor that acts at the integrin-cytoskeleton interface to regulate cell spreading and migration.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Sheetz, MP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	m.sheetz@cellbio.duke.edu						BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FATH KR, 1989, J CELL SCI, V92, P67; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; Galbraith CG, 1997, P NATL ACAD SCI USA, V94, P9114, DOI 10.1073/pnas.94.17.9114; Galbraith CG, 1998, CELL MOTIL CYTOSKEL, V40, P317, DOI 10.1002/(SICI)1097-0169(1998)40:4<317::AID-CM1>3.0.CO;2-8; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; ROBERTS K, 1991, J EXP MED, V173, P231, DOI 10.1084/jem.173.1.231; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yee KO, 1998, CIRC RES, V83, P241, DOI 10.1161/01.RES.83.3.241	36	224	227	0	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					200	206		10.1038/12021	http://dx.doi.org/10.1038/12021			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559917				2022-12-25	WOS:000083102700014
J	Delpire, E; Lu, JM; England, R; Dull, C; Thorne, T				Delpire, E; Lu, JM; England, R; Dull, C; Thorne, T			Deafness and imbalance associated with inactivation of the secretory Ma-K-2Cl co-transporter	NATURE GENETICS			English	Article							K-CL COTRANSPORTER; INNER-EAR; NA-K-2CL COTRANSPORTER; MOLECULAR-CLONING; LOOP DIURETICS; LOCALIZATION; CELLS; GENE; EXPRESSION; MUTATION	Deaf ness can result from a variety of gene defects'. Some genes involved in the physiology of hearing encode membrane transporters that regulate the ionic composition of the fluid bathing the inner ear. The endolymph is an extracellular fluid with an atypical composition that resembles the intracellular milieu, high in K+ and low in Na+. Recent studies have emphasized the prominent role of K+ channels in endolymph secretion(2-4) and mechanical transduction(5). Coupled electroneutral transport of Na+, K+ and Cl- is: mediated by two isoforms of the. Na-K-2Cl cotransporter:the absorptive isoform BSC1 (also called NKCC2, encoded by SIc12a1 in mouse) that is exclusively expressed in kidney;- and BSC2/NKCC1 (encoded by SIc12a2 in mouse).: the secretory isoform which has a wider pattern of expression including epithelia, muscle cells; neurons, and red blood cells(6,7). These Eo-transporters: share 57% homology at the amino acid level(8-11) and are pharmacologically inhibited by loop diuretics. There is functional(12-14) and histochemical(15-17) evidence for the presence of the secretory isoform of the Na-K-2Cl co-transporter in gerbil. rat and rabbit inner ear. We disrupted mouse SIc12a2 and report here that SIc12a2(-/-) mice are deaf and exhibit classic shaker/waltzer behaviour, indicative of inner-ear defects. We localized the co-transporter to key secreting epithelia of the mouse inner ear and-show that absence of functional co-transporter leads to structural damages in the inner ear consistent with a decrease in endolymph secretion.	Vanderbilt Univ, Med Ctr, Anesthesiol Res Div, Labs Cellular & Mol Physiol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Delpire, E (corresponding author), Vanderbilt Univ, Med Ctr, Anesthesiol Res Div, Labs Cellular & Mol Physiol, Nashville, TN 37232 USA.							Alvarez-Leefmans F.J., 1998, PRESYNAPTIC INHIBITI, P50; Belal A Jr, 1980, Am J Otolaryngol, V1, P275, DOI 10.1016/S0196-0709(80)80030-5; COOPERMAN LB, 1973, AM HEART J, V85, P831, DOI 10.1016/0002-8703(73)90434-1; Crouch JJ, 1997, J HISTOCHEM CYTOCHEM, V45, P773, DOI 10.1177/002215549704500601; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Deol M S, 1968, J Med Genet, V5, P137, DOI 10.1136/jmg.5.2.137; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Goto S, 1997, BRAIN RES, V765, P324, DOI 10.1016/S0006-8993(97)00679-3; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Ikeda K, 1997, HEARING RES, V107, P1, DOI 10.1016/S0378-5955(97)00009-9; Kalatzis V, 1998, HUM MOL GENET, V7, P1589, DOI 10.1093/hmg/7.10.1589; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; MARCUS DC, 1987, HEARING RES, V30, P55, DOI 10.1016/0378-5955(87)90183-3; MARCUS NY, 1987, AM J PHYSIOL, V253, pF613, DOI 10.1152/ajprenal.1987.253.4.F613; Mizuta K, 1997, HEARING RES, V106, P154, DOI 10.1016/S0378-5955(97)00010-5; Mount DB, 1998, J EXP BIOL, V201, P2091; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173, DOI 10.1152/ajpcell.1997.272.1.C173; Randall J, 1997, AM J PHYSIOL-CELL PH, V273, pC1267, DOI 10.1152/ajpcell.1997.273.4.C1267; ROSE BD, 1991, KIDNEY INT, V39, P336, DOI 10.1038/ki.1991.43; RYBAK LP, 1993, OTOLARYNG CLIN N AM, V26, P829; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; SHIGA N, 1995, BBA-BIOMEMBRANES, V1240, P48, DOI 10.1016/0005-2736(95)00175-1; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANGEMANN P, 1995, HEARING RES, V84, P19, DOI 10.1016/0378-5955(95)00009-S	30	307	328	1	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					192	195		10.1038/9713	http://dx.doi.org/10.1038/9713			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369265				2022-12-25	WOS:000080680900028
J	Ilyin, SE; Plata-Salaman, CR				Ilyin, SE; Plata-Salaman, CR			Probe generation by PCR coupled with ligation - An approach for the efficient production of RNA probes.	NATURE BIOTECHNOLOGY			English	Article									Univ Delaware, Newark, DE 19716 USA	University of Delaware	Ilyin, SE (corresponding author), RW Johnson Pharmaceut Res Inst, Welsh & McKean Rd, Spring House, PA 19477 USA.							Ilyin SE, 1998, MOL CHEM NEUROPATHOL, V33, P125, DOI 10.1007/BF02870186; Ilyin SE, 1998, J NEUROSCI METH, V84, P139, DOI 10.1016/S0165-0270(98)00108-3; Plata-Salaman CR, 1998, INT J MOL MED, V1, P387; URRUTIA R, 1993, J BIOCHEM BIOPH METH, V26, P113, DOI 10.1016/0165-022X(93)90041-L; YANG HH, 1995, METH NEUROSCI, V26, P227	5	2	3	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					608	609		10.1038/9928	http://dx.doi.org/10.1038/9928			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385329				2022-12-25	WOS:000080716500036
J	Kaltschmidt, JA; Davidson, CM; Brown, NH; Brand, AH				Kaltschmidt, JA; Davidson, CM; Brown, NH; Brand, AH			Rotation and asymmetry of the mitotic spindle direct asymmetric cell division in the developing central nervous system	NATURE CELL BIOLOGY			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; PROSPERO GENE; ANIMAL-CELLS; PROTEIN; CENTROSOME; EMBRYOS; LOCALIZATION; ENCODES; FATES	The asymmetric segregation of cell-fate determinants and the generation of daughter cells of different sizes rely on the correct orientation and position of the mitotic spindle. In the Drosophila embryo, the determinant Prospero is localized basally and is segregated equally to daughters of similar cell size during epidermal cell division. In contrast, during neuroblast division Prospero is segregated asymmetrically to the smaller daughter cell. This simple switch between symmetric and asymmetric segregation is achieved by changing the orientation of cell division: neural cells divide in a plane perpendicular to that of epidermoblast division. Here, by labelling mitotic spindles in living Drosophila embryos, we show that neuroblast spindles are initially formed in the same axis as epidermal cells, but rotate before cell division. We find that daughter cells of different sizes arise because the spindle itself becomes asymmetric at anaphase: apical microtubules elongate, basal microtubules shorten, and the midbody moves basally until it is positioned asymmetrically between the two spindle poles. This observation contradicts the widely held hypothesis that the cleavage furrow is always placed midway between the two centrosomes.	Univ Cambridge, Wellcome CRC, Inst Genet, Cambridge CB2 1QR, England; Univ Cambridge, Wellcome CRC, Dept Genet, Cambridge CB2 1QR, England; Univ Cambridge, Wellcome CRC, Inst Anat, Cambridge CB2 1QR, England; Univ Cambridge, Wellcome CRC, Dept Anat, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Kaltschmidt, JA (corresponding author), Univ Cambridge, Wellcome CRC, Inst Genet, Tennis Court Rd, Cambridge CB2 1QR, England.	ahb@mole.bio.cam.ac.uk	Brand, Andrea H/F-8220-2014	Brand, Andrea H/0000-0002-2089-6954; Brown, Nicholas/0000-0002-8958-7017				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; Brand A, 1999, METHOD CELL BIOL, V58, P165; BRAND A, 1995, TRENDS GENET, V11, P324, DOI 10.1016/S0168-9525(00)89091-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; CALLAINI G, 1988, EXP CELL RES, V178, P415, DOI 10.1016/0014-4827(88)90410-7; Conklin EG, 1917, J EXP ZOOL, V22, P311, DOI 10.1002/jez.1400220205; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Doe CQ, 1996, CELL, V86, P695, DOI 10.1016/S0092-8674(00)80142-7; Dormand EL, 1998, DEVELOPMENT, V125, P1659; FIRC A, 1998, NATURE, V391, P806; Hacker U, 1997, DEVELOPMENT, V124, P3565; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; Keating HH, 1998, J CELL SCI, V111, P3027; KELLOGG DR, 1995, MOL BIOL CELL, V6, P1673, DOI 10.1091/mbc.6.12.1673; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Oegema K, 1997, P NATL ACAD SCI USA, V94, P4817, DOI 10.1073/pnas.94.10.4817; OEGEMA K, 1995, J CELL BIOL, V131, P1261, DOI 10.1083/jcb.131.5.1261; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; RAPPAPORT R, 1990, ANN NY ACAD SCI, V582, P15; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; Rappaport R., 1996, CYTOKINESIS ANIMAL C; ROBERTSON HM, 1988, GENETICS, V118, P461; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shaw SL, 1997, J CELL BIOL, V139, P985, DOI 10.1083/jcb.139.4.985; Skop AR, 1998, CURR BIOL, V8, P1110, DOI 10.1016/S0960-9822(98)70465-8; SPANA EP, 1995, DEVELOPMENT, V121, P3187; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Tio M, 1999, J CELL SCI, V112, P1541; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; VALLEN EA, 1992, CELL, V69, P505, DOI 10.1016/0092-8674(92)90451-H; WADDLE JA, 1994, DEVELOPMENT, V120, P2317; WHITFIELD WGF, 1995, J CELL SCI, V108, P3377; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	47	239	243	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					7	12		10.1038/71323	http://dx.doi.org/10.1038/71323			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620800				2022-12-25	WOS:000084843600012
J	Eisenmann, KM; McCarthy, JB; Simpson, MA; Keely, PJ; Guan, JL; Tachibana, K; Lim, L; Manser, E; Furcht, LT; Iida, J				Eisenmann, KM; McCarthy, JB; Simpson, MA; Keely, PJ; Guan, JL; Tachibana, K; Lim, L; Manser, E; Furcht, LT; Iida, J			Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130(cas)	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION KINASE; ACTIN STRESS FIBERS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; ALPHA-4-BETA-1 INTEGRIN; METASTATIC PROPERTIES; EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCAN; VASCULAR ENDOTHELIUM; SURFACE	Melanoma chondroitin sulphate proteoglycan (MCSP) is a cell-surface antigen that has been implicated in the growth and invasion of melanoma tumours, Although this antigen is expressed early in melanoma progression, its biological function is unknown. MCSP can stimulate the integrin-alpha(4)beta(1)-mediated adhesion and spreading of melanoma cells. Here we show that stimulated MCSP recruits tyrosine-phosphorylated p130(cas), an adaptor protein important in tumour cell motility and invasion. MCSP stimulation also results in a pronounced activation and recruitment of the Rho-family GTPase Cdc42. MCSP-induced spreading of melanoma cells is dependent upon active Cdc42, a Cdc42-associated tyrosine kinase (Ack-1) and tyrosine phosphorylation of p130(cas). Furthermore, vectors inhibiting Ack-1 or Cdc42 expression and/or function abrogate MCSP-induced tyrosine phosphorylation and recruitment of p130(cas). Our findings indicate that MCSP may modify tumour growth or invasion by a unique signal-transduction pathway that links Cdc42 activation to downstream tyrosine phosphorylation and subsequent cytoskeletal reorganization.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Biomed Engn, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Neurol Inst, London WC1N 1PJ, England; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 119076, Singapore	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Wisconsin System; University of Wisconsin Madison; Cornell University; Harvard University; Harvard Medical School; University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	McCarthy, JB (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.		Manser, Edward/ABD-2301-2020	Eisenmann, Kathryn/0000-0002-5337-5928	NCI NIH HHS [CA21463] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021463, R01CA021463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BUMOL TF, 1983, P NATL ACAD SCI-BIOL, V80, P529, DOI 10.1073/pnas.80.2.529; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; FIDLER IJ, 1986, CANCER METAST REV, V5, P29, DOI 10.1007/BF00049529; GAROFALO A, 1995, CANCER RES, V55, P414; GARRIGUES HJ, 1986, J CELL BIOL, V103, P1699, DOI 10.1083/jcb.103.5.1699; GEHLSEN KR, 1992, CLIN EXP METASTAS, V10, P111, DOI 10.1007/BF00114587; HARPER JR, 1983, J NATL CANCER I, V71, P259; HARPER JR, 1984, J IMMUNOL, V132, P2096; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HYNES RO, 1992, CELL, V69, P443; IIDA J, 1995, CANCER RES, V55, P2177; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; IIDA J, 1994, TRENDS GLYCOSCI GLYC, V6, P1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LaFlamme SE, 1996, SEMIN CANCER BIOL, V7, P111, DOI 10.1006/scbi.1996.0016; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; QUI RG, 1997, MOL CELL BIOL, V17, P3449; REISFELD RA, 1987, ADV IMMUNOL, V40, P323, DOI 10.1016/S0065-2776(08)60242-4; RICE GE, 1988, AM J PATHOL, V133, P204; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SATYAMOORTHY K, 1997, MELANOMA RES S2, V7, P35; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524	47	166	174	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					507	513		10.1038/70302	http://dx.doi.org/10.1038/70302			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587647	Green Published			2022-12-25	WOS:000084136100019
J	Coers, J; Monahan, C; Roy, CR				Coers, J; Monahan, C; Roy, CR			Modulation of phagosome biogenesis by Legionella pneumophila creates an organelle permissive for intracellular growth	NATURE CELL BIOLOGY			English	Article							HUMAN-MONOCYTES; MUTANTS; PROTEIN; GENES		Yale Univ, Sch Med, Sect Microbial Pathogenesis, Boyer Ctr Mol Med, New Haven, CT 06511 USA	Yale University	Roy, CR (corresponding author), Yale Univ, Sch Med, Sect Microbial Pathogenesis, Boyer Ctr Mol Med, Room 354,295 Congress Ave, New Haven, CT 06511 USA.			Roy, Craig/0000-0003-4490-440X; Coers, Jorn/0000-0001-8707-4608	NIAID NIH HHS [AI41699] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041699, R01AI041699] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu Kwaik Y, 1998, APPL ENVIRON MICROB, V64, P3127; Andrews HL, 1998, INFECT IMMUN, V66, P950, DOI 10.1128/IAI.66.3.950-958.1998; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; MINTZ CS, 1988, INFECT IMMUN, V56, P1449, DOI 10.1128/IAI.56.6.1449-1455.1988; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Roy CR, 1998, MOL MICROBIOL, V28, P663, DOI 10.1046/j.1365-2958.1998.00841.x; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Wiater LA, 1998, INFECT IMMUN, V66, P4450; Zuckman DM, 1999, MOL MICROBIOL, V32, P990, DOI 10.1046/j.1365-2958.1999.01410.x	15	120	122	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					451	453		10.1038/15687	http://dx.doi.org/10.1038/15687			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559990				2022-12-25	WOS:000083533100019
J	Hakumaki, JM; Poptani, H; Sandmair, AM; Yla-Herttuala, S; Kauppinen, RA				Hakumaki, JM; Poptani, H; Sandmair, AM; Yla-Herttuala, S; Kauppinen, RA			H-1 MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TUMOR-NECROSIS-FACTOR; IN-VIVO; THYMIDINE KINASE; LIPID DROPLETS; BRAIN-TUMORS; CELL-DEATH; ACTIVATION; PROLIFERATION; GANCICLOVIR		AI Virtanen Inst Mol Sci, NMR Res Grp, FIN-70211 Kuopio, Finland; AI Virtanen Inst Mol Sci, Mol Med Grp, FIN-70211 Kuopio, Finland		Hakumaki, JM (corresponding author), AI Virtanen Inst Mol Sci, NMR Res Grp, FIN-70211 Kuopio, Finland.	jhakumak@messi.uku.fi; kauppine@messi.uku.fi	Hakumäki, Juhana/AAH-1058-2021; Kauppinen, Risto A/F-3274-2011	Hakumaki, Juhana/0000-0001-7341-5440; Yla-Herttuala, Seppo/0000-0001-7593-2708; Poptani, Harish/0000-0002-0593-3235				AGREN JJ, 1992, J LIPID RES, V33, P1871; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786; CALLIES R, 1993, MAGNET RESON MED, V29, P546, DOI 10.1002/mrm.1910290418; CHIOCCA EA, 1998, GENE THERAPY NEUROLO; De Valck D, 1998, J CELL BIOCHEM, V71, P392, DOI 10.1002/(SICI)1097-4644(19981201)71:3<392::AID-JCB8>3.0.CO;2-N; Finstad HS, 1998, BIOCHEM J, V336, P451, DOI 10.1042/bj3360451; FREEMAN SM, 1993, CANCER RES, V53, P5274; Hakumaki J. M., 1997, CURR TOP NEUROCHEM, V1, P59; Hakumaki JM, 1998, CANCER RES, V58, P3791; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUESEL AC, 1994, NMR BIOMED, V7, P149, DOI 10.1002/nbm.1940070308; MOUNTFORD CE, 1982, CANCER RES, V42, P2270; Negendank W, 1996, ANTICANCER RES, V16, P1533; Poptani H, 1998, CANCER GENE THER, V5, P101; Remy C, 1997, CANCER RES, V57, P407; SMITH TAD, 1991, BRIT J CANCER, V64, P821, DOI 10.1038/bjc.1991.407; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; USENIUS JPR, 1994, J COMPUT ASSIST TOMO, V18, P705, DOI 10.1097/00004728-199409000-00005; Veale MF, 1997, BIOCHEM BIOPH RES CO, V239, P868, DOI 10.1006/bbrc.1997.7566; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; WELLER PF, 1991, J CELL BIOL, V113, P137, DOI 10.1083/jcb.113.1.137; WHATLEY RE, 1994, J CLIN INVEST, V94, P1889, DOI 10.1172/JCI117539; Williamson MS, 1998, GRADIVA, V6, P40; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; YLAHERTTUALA S, 1985, ATHEROSCLEROSIS, V56, P1, DOI 10.1016/0021-9150(85)90079-6	28	220	224	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1999	5	11					1323	1327		10.1038/15279	http://dx.doi.org/10.1038/15279			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10546002				2022-12-25	WOS:000086550600046
J	Hille, B; Armstrong, CM; MacKinnon, R				Hille, B; Armstrong, CM; MacKinnon, R			Ion channels: From idea to reality	NATURE MEDICINE			English	Editorial Material							POTASSIUM CHANNEL; MYELINATED NERVE; SODIUM CHANNEL; SQUID AXONS; K+ CHANNEL; INACTIVATION; CONDUCTANCE; PERMEABILITY; CATIONS; PORES		Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Penn, Philadelphia, PA 19104 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	University of Washington; University of Washington Seattle; University of Pennsylvania; Marine Biological Laboratory - Woods Hole; Rockefeller University; Howard Hughes Medical Institute	Hille, B (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.							ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P645; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1971, J GEN PHYSIOL, V58, P599, DOI 10.1085/jgp.58.6.599; Hille B., 1970, Progr. Biophys. molec. Biol., V21, P1, DOI 10.1016/0079-6107(70)90022-2; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hodking A. L., 1955, J PHYSIOL-LONDON, V128, P61; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471	25	98	105	2	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1105	1109		10.1038/13415	http://dx.doi.org/10.1038/13415			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502800				2022-12-25	WOS:000082933200021
J	Enjyoji, K; Sevigny, J; Lin, Y; Frenette, PS; Christie, PD; Esch, JSA; Imai, M; Edelberg, JM; Rayburn, H; Lech, M; Beeler, DL; Csizmadia, E; Wagner, DD; Robson, SC; Rosenberg, RD				Enjyoji, K; Sevigny, J; Lin, Y; Frenette, PS; Christie, PD; Esch, JSA; Imai, M; Edelberg, JM; Rayburn, H; Lech, M; Beeler, DL; Csizmadia, E; Wagner, DD; Robson, SC; Rosenberg, RD			Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation	NATURE MEDICINE			English	Article							ATP-DIPHOSPHOHYDROLASE; PLATELET ACTIVATION; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; EXTRACELLULAR ATP; ADP; RECEPTORS; NUCLEOTIDES; EXPRESSION; THROMBOSIS	CD39, or vascular adenosine triphosphate diphosphohydrolase, has been considered an important inhibitor of platelet activation. Unexpectedly, cd39-deficient mice had prolonged bleeding times with minimally perturbed coagulation parameters. Platelet interactions with injured mesenteric vasculature were considerably reduced in vivo and purified mutant platelets failed to aggregate to standard agonists in vitro. This platelet hypofunction was reversible and associated with purinergic type P2Y1 receptor desensitization. In keeping with deficient vascular protective mechanisms, fibrin deposition was found at multiple organ sites in cd39-deficient mice and in transplanted cardiac grafts. Our data indicate a dual role for adenosine triphosphate diphosphohydrolase in modulating hemostasis and thrombotic reactions.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	rdrrosen@mit.edu	Frenette, Paul S/J-8272-2012; Robson, Simon C./AAA-8537-2021; Sévigny, Jean/AGH-9323-2022; Sevigny, Jean/E-8039-2012; Esch, Jan Schulte am/AAL-9904-2021	Frenette, Paul S/0000-0003-0862-9922; Sévigny, Jean/0000-0003-2922-1600; Sevigny, Jean/0000-0003-2922-1600; Esch, Jan Schulte am/0000-0002-2101-5012	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057307, R01HL041002, R37HL041002] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41002, HL57307] Funding Source: Medline; PHS HHS [P01-41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BAKKER WW, 1989, J LAB CLIN MED, V114, P531; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Berger G, 1998, BLOOD, V92, P4446, DOI 10.1182/blood.V92.11.4446; BEURLINGHARBURY C, 1990, THROMB HAEMOSTASIS, V63, P286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Candinas D, 1996, THROMB HAEMOSTASIS, V76, P807; Chadwick A, 1998, J SMALL ANIM PRACT, V39, P357, DOI 10.1111/j.1748-5827.1998.tb03729.x; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Deguchi H, 1998, THROMB RES, V91, P57, DOI 10.1016/S0049-3848(98)00045-0; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Edelberg JM, 1998, J CLIN INVEST, V102, P837, DOI 10.1172/JCI3058; FIJNHEER R, 1992, THROMB HAEMOSTASIS, V68, P595; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; HEYNS ADP, 1977, THROMB HAEMOSTASIS, V37, P429; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Johnson EN, 1998, P NATL ACAD SCI USA, V95, P3100, DOI 10.1073/pnas.95.6.3100; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Koyamada N, 1998, TRANSPLANTATION, V65, P1210, DOI 10.1097/00007890-199805150-00012; Koyamada N, 1996, TRANSPLANTATION, V62, P1739, DOI 10.1097/00007890-199612270-00008; Liu MA, 1995, ANN NY ACAD SCI, V772, P15, DOI 10.1111/j.1749-6632.1995.tb44727.x; LUNDIN A, 1976, ANAL BIOCHEM, V75, P611, DOI 10.1016/0003-2697(76)90116-0; LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P558, DOI 10.1007/BF01719786; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; MARCUS AJ, 1993, FASEB J, V7, P516, DOI 10.1096/fasebj.7.6.8472890; MOTTE S, 1995, INT J BIOCHEM CELL B, V27, P1, DOI 10.1016/1357-2725(94)00059-X; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Saito H, 1999, AM J RESP CRIT CARE, V159, P1014, DOI 10.1164/ajrccm.159.3.9803100; Schafer AI, 1997, J CLIN INVEST, V99, P1143, DOI 10.1172/JCI119266; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; SHEN J, 1993, BIOPHYS J, V64, P1323, DOI 10.1016/S0006-3495(93)81498-X; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Sun B, 1998, J BIOL CHEM, V273, P11544, DOI 10.1074/jbc.273.19.11544; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von Albertini M, 1998, BIOCHEM BIOPH RES CO, V248, P822, DOI 10.1006/bbrc.1998.9055; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; Weisman GA, 1998, DRUG DEVELOP RES, V45, P222, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<222::AID-DDR20>3.0.CO;2-8; YANG ZH, 1991, LANCET, V337, P939, DOI 10.1016/0140-6736(91)91571-B; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	45	451	460	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1010	1017		10.1038/12447	http://dx.doi.org/10.1038/12447			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470077				2022-12-25	WOS:000082337200034
J	Gedeon, AK; Colley, A; Jamieson, R; Thompson, EM; Rogers, J; Sillence, D; Tiller, GE; Mulley, JC; Gecz, J				Gedeon, AK; Colley, A; Jamieson, R; Thompson, EM; Rogers, J; Sillence, D; Tiller, GE; Mulley, JC; Gecz, J			Identification of the gene (SEDL) causing X-linked spondyloepiphyseal dysplasia tarda	NATURE GENETICS			English	Article							PROTEIN; LINKAGE; CHROMOSOME; CLONING; ENCODES; DXS16; XP22; MAP	Spondyloepiphyseal dysplasia tarda (SEDL; MIM 313400) is an X-linked recessive osteochondrodysplasia that occurs in approximately two of every one million people(1). This progressive skeletal disorder which manifests in childhood is characterized by disproportionate short stature with short neck and trunk, barrel chest and absence of systemic complications(2-4). Distinctive radiological signs are platyspondyly with hump-shaped central and posterior portions, narrow disc spaces, and mild to moderate epiphyseal dysplasia. The latter usually leads to premature secondary osteoarthritis often requiring hip arthroplasty(3-5), Obligate female carriers are generally clinically and radiographically indistinguishable from the general population(4,5), although some cases have phenotypic changes consistent with expression of the gene defect(2,4,6,7). The SEDL gene has been localized to Xp22 (refs 8,9) in the approximately 2-Mb interval between DXS16 and DXS987 (ref, 10). Here we confirm and refine this localization to an interval of less than 170 kb by critical recombination events at DXS16 and AFMa124wc1 in two families. In one candidate gene we detected three dinucleotide deletions in three Australian families which effect frameshifts causing premature stop codons. The gene designated SEDL is transcribed as a 2.8-kb transcript in many tissues including fetal cartilage. SEDL encodes a 140 amino acid protein with a putative role in endoplasmic reticulum (ER)-to-Golgi vesicular transport.	Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia; Liverpool Hlth Serv, Dept Clin Genet, Liverpool, NSW 2170, Australia; New Childrens Hosp, Dept Clin Genet, Sydney, NSW, Australia; Womens & Childrens Hosp, Ctr Med Genet, S Australian Clin Genet Serv, Adelaide, SA 5006, Australia; Victorian Clin Genet Serv, Melbourne, Vic, Australia; Vanderbilt Univ, Sch Med, Dept Pediat, Div Med Genet, Nashville, TN 37232 USA; Univ Adelaide, Dept Paediat, Adelaide, SA, Australia	Womens & Childrens Hospital Australia; University of Sydney; Womens & Childrens Hospital Australia; Vanderbilt University; University of Adelaide	Gecz, J (corresponding author), Womens & Childrens Hosp, Ctr Med Genet, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia.	jgecz@mad.adelaide.edu.au	Gedeon, Agi/G-7890-2011; Gecz, Jozef/X-3469-2019; Jamieson, Robyn/M-5161-2019	Gecz, Jozef/0000-0002-7884-6861; Jamieson, Robyn/0000-0002-7285-0253	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR045477] Funding Source: NIH RePORTER; NIAMS NIH HHS [R55 AR45477] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BANNERMAN RM, 1971, J MED GENET, V8, P291, DOI 10.1136/jmg.8.3.291; CHANG YPC, 1994, HUM MOL GENET, V3, P1029, DOI 10.1093/hmg/3.6.1029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies JP, 1997, GENOMICS, V41, P131, DOI 10.1006/geno.1997.4644; de Conciliis L, 1998, GENOMICS, V51, P243, DOI 10.1006/geno.1998.5348; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FERRERO GB, 1995, HUM MOL GENET, V4, P1821, DOI 10.1093/hmg/4.10.1821; GOTTESMAN GS, 1996, J BONE MINER RES  S1, V11, pS252; HARPER PS, 1973, BRIT J RADIOL, V46, P676, DOI 10.1259/0007-1285-46-549-676; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEUERTZ S, 1993, GENOMICS, V18, P100, DOI 10.1006/geno.1993.1431; HEUERTZ S, 1995, HUM GENET, V96, P407, DOI 10.1007/BF00191797; ICETON JA, 1986, J BONE JOINT SURG BR, V68, P616, DOI 10.1302/0301-620X.68B4.3733841; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MacKenzie JJ, 1996, J MED GENET, V33, P823, DOI 10.1136/jmg.33.10.823; Narayanan V, 1998, AM J MED GENET, V78, P165, DOI 10.1002/(SICI)1096-8628(19980630)78:2<165::AID-AJMG13>3.0.CO;2-L; ROSSI G, 1995, MOL BIOL CELL, V6, P1769, DOI 10.1091/mbc.6.12.1769; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; SZPIROTAPIA S, 1988, HUM GENET, V81, P61, DOI 10.1007/BF00283731; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Whyte MP, 1999, MEDICINE, V78, P9, DOI 10.1097/00005792-199901000-00002; WYNNEDAVIES R, 1985, J BONE JOINT SURG BR, V67, P133, DOI 10.1302/0301-620X.67B1.3155744	23	142	167	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					400	404		10.1038/11976	http://dx.doi.org/10.1038/11976			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431248				2022-12-25	WOS:000081772500026
J	Latham, PW				Latham, PW			Therapeutic peptides revisited	NATURE BIOTECHNOLOGY			English	Article								After a roller coaster ride of successes and failures, new discovery technologies and advances in manufacturing promise a brighter future for peptides in human therapy.	New Venture Advisors, Boston, MA 02130 USA		Latham, PW (corresponding author), New Venture Advisors, Boston, MA 02130 USA.		Minkiewicz, Piotr/G-6765-2011; Iwaniak, Anna/N-3589-2018	Minkiewicz, Piotr/0000-0003-0481-1196; Iwaniak, Anna/0000-0001-5068-0428				Kelley WS, 1996, BIO-TECHNOL, V14, P28, DOI 10.1038/nbt0196-28	1	165	179	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					755	757		10.1038/11686	http://dx.doi.org/10.1038/11686			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429238				2022-12-25	WOS:000081751400022
J	Derry, JMJ; Gormally, E; Means, GD; Zhao, W; Meindl, A; Kelley, RI; Boyd, Y; Herman, GE				Derry, JMJ; Gormally, E; Means, GD; Zhao, W; Meindl, A; Kelley, RI; Boyd, Y; Herman, GE			Mutations in a Delta(8)-Delta(7) sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata	NATURE GENETICS			English	Article							PEROXISOMAL ENZYME DEFICIENCY; LEMLI-OPITZ-SYNDROME; CHOLESTEROL-BIOSYNTHESIS; BINDING-PROTEIN; VITAMIN-D; INHIBITION	Tattered (Td) is an X-linked, semi-dominant mouse mutation associated with prenatal male lethality(1). Heterozygous females are small and at 4-5 days of age develop patches of hyperkeratotic skin where no hair grows, resulting in a striping of the coat in adults(2). Craniofacial anomalies and twisted toes have also been observed in some affected females(3,4). A potential second allele of Td has also been described(5). The phenotype of Td is similar to that seen in heterozygous females with human X-linked dominant chondrodysplasia punctata (CDPX2, alternatively known as X-linked dominant Conradi-Hunermann-Happle syndrome) as well as another X-linked, semi-dominant mouse mutation, bare patches (Bpa). The Bpa gene has recently been identified(6) and encodes a protein with homology to 3 beta-hydroxysteroid dehydrogenases that functions in one of the later steps of cholesterol biosynthesis. CDPX2 patients display skin defects including linear or whorled atrophic and pigmentary lesions, striated hyperkeratosis, coarse lusterless hair and alopecia, cataracts and skeletal abnormalities including short stature, rhizomelic shortening of the limbs, epiphyseal stippling and craniofacial defects (MIM 302960). We have now identified the defect in Td mice as a single amino acid substitution in the Delta(8)-Delta(7) sterol isomerase emopamil binding protein (Ebp; encoded by Ebp in mouse) and identified alterations in human EBP in seven unrelated CDPX2 patients.	Immunex Res & Dev Corp, Seattle, WA 98101 USA; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; Ohio State Univ, Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; LMU, Kinderpolklin, Abt Med Genet, Munich, Germany; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Ohio State University; Research Institute at Nationwide Children's Hospital; Ohio State University; University of Munich; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University	Derry, JMJ (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.				NINDS NIH HHS [R01 NS34953] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034953] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLAIR HJ, 1994, MOUSE GENOME, V92, P511; CATTANACH BM, 1982, MOUSE NEWS LETT, V66, P61; Cho SY, 1998, MOL CELLS, V8, P233; CLAYTON PT, 1989, J INHERIT METAB DIS, V12, P358, DOI 10.1007/BF03335422; DERRY JMJ, 1995, HUM MOL GENET, V4, P2307, DOI 10.1093/hmg/4.12.2307; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HOLMES RD, 1987, NEW ENGL J MED, V316, P1608; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kelley RI, 1998, AM J HUM GENET, V63, P322, DOI 10.1086/301987; Kelley RI, 1999, AM J MED GENET, V83, P213, DOI 10.1002/(SICI)1096-8628(19990319)83:3<213::AID-AJMG15>3.0.CO;2-C; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; Labit-Le Bouteiller C, 1998, EUR J BIOCHEM, V256, P342, DOI 10.1046/j.1432-1327.1998.2560342.x; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; MERRELL K, 1995, MAMM GENOME, V6, P291, DOI 10.1007/BF00352419; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RASBERRY C, 1995, MOUSE GENOME, V93, P1028; Seo KW, 1997, MAMM GENOME, V8, P578, DOI 10.1007/s003359900507; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; TRAUPE H, 1992, HUM GENET, V89, P659, DOI 10.1007/BF00221958; Uwechue IC, 1996, GENOMICS, V37, P238, DOI 10.1006/geno.1996.0549; UWECHUE IC, 1997, THESIS U OXFORD; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	24	180	187	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					286	290		10.1038/10350	http://dx.doi.org/10.1038/10350			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391218				2022-12-25	WOS:000081125900023
J	Kanzaki, M; Zhang, YQ; Mashima, H; Li, L; Shibata, H; Kojima, I				Kanzaki, M; Zhang, YQ; Mashima, H; Li, L; Shibata, H; Kojima, I			Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE PROGRESSION; BALB/C 3T3 CELLS; GLUCOSE-TRANSPORT; B-LYMPHOCYTES; CD20; ACTIVATION; RECEPTOR; 3-KINASE; EXPRESSION; MOLECULE	Calcium plays a critical part in the regulation of cell growth, and growth factors stimulate calcium entry into cells through calcium-permeable channels. However, the molecular nature and regulation of calcium-permeable channels are still unclear at present. Here we report the molecular characterization of a calcium-permeable cation channel that is regulated by insulin-like growth factor-I (IGF-I). This channel, which we name growth-factor-regulated channel (GRC), belongs to the TRP-channel family and localizes mainly to intracellular poets under basal conditions. Upon stimulation of cells by IGF-I, GRC translocates to the plasma membrane. Thus, IGF-I augments calcium entry through GRC by regulating trafficking of the channel.	Gunma Univ, Inst Mol & Cell Regulat, Dept Cell Biol, Maebashi, Gumma 3718512, Japan	Gunma University	Kojima, I (corresponding author), Gunma Univ, Inst Mol & Cell Regulat, Dept Cell Biol, Maebashi, Gumma 3718512, Japan.	ikojima@akagi.sb.gunma-u.ac.jp	Kanzaki, Makoto/H-6680-2017; Mashima, Hirosato/ABE-6412-2020	Kanzaki, Makoto/0000-0002-6884-2955; 				BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KOIIMA I, 1988, J BIOL CHEM, V263, P16561; KOIIMA I, 1993, J BIOL CHEM, V268, P1003; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lovisolo D, 1997, NEWS PHYSIOL SCI, V12, P279; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATSUMOTO B, 1993, METHOD CELL BIOL, V38, P20; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; OKADA T, 1994, J BIOL CHEM, V269, P3563; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	25	378	404	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					165	170		10.1038/11086	http://dx.doi.org/10.1038/11086			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559903				2022-12-25	WOS:000083102500015
J	Hodson-de-Jaramillo, E; Aramendis, RH				Hodson-de-Jaramillo, E; Aramendis, RH			New confrontations	NATURE BIOTECHNOLOGY			English	Editorial Material									COLCIENCIAS, Inst Colombiano Desarrollo Ciencia & Tecnol Franc, Programa Nacl Biotecnol, Bogota, Colombia		Hodson-de-Jaramillo, E (corresponding author), COLCIENCIAS, Inst Colombiano Desarrollo Ciencia & Tecnol Franc, Programa Nacl Biotecnol, Transversal 9A 133-28, Bogota, Colombia.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					512	513		10.1038/9773	http://dx.doi.org/10.1038/9773			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385297				2022-12-25	WOS:000080716500003
J	Kobayashi, K; Sinasac, DS; Iijima, M; Boright, AP; Begum, L; Lee, JR; Yasuda, T; Ikeda, S; Hirano, R; Terazono, H; Crackower, MA; Kondo, I; Tsui, LC; Scherer, SW; Saheki, T				Kobayashi, K; Sinasac, DS; Iijima, M; Boright, AP; Begum, L; Lee, JR; Yasuda, T; Ikeda, S; Hirano, R; Terazono, H; Crackower, MA; Kondo, I; Tsui, LC; Scherer, SW; Saheki, T			The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein	NATURE GENETICS			English	Article							ORTHOTOPIC LIVER-TRANSPLANTATION; SECRETORY TRYPSIN-INHIBITOR; ARGININOSUCCINATE SYNTHETASE; CLASSICAL CITRULLINEMIA; MESSENGER-RNA; UREA CYCLE; MUTATIONS; CLONING; CALCIUM; DNA	Citrullinaemia (CTLN) is an autosomal recessive disease caused by deficiency of argininosuccinate synthetase (ASS). Adultonset type II citrullinaemia (CTLN2) is characterized by a liverspecific ASS deficiency with no abnormalities in hepatic ASS mRNA or the gene ASS (refs 1-17). CTLN2 patients (1/100.000 in Japan(13)) suffer from a disturbance of consciousness and coma, and most die with cerebral edema within a few years of onset. CTLN2 differs from classical citrullinaemia (CTLN1, OMIM 215700) in that CTLN1 is neonatal or infantile in onset, with ASS enzyme defects (in all tissues) arising due to mutations in ASS on chromosome 9q34 (refs 18-21). We collected 118 CTLN2 families, and localized the CTLN2 locus to chromosome 7q21.3 by homozygosity mapping analysis of individuals from 18 consanguineous unions. Using positional cloning we identified a novel gene, SLC5A13, and found five different DNA sequence alterations that account for mutations in all consanguineous patients examined. SLC25A13 encodes a 3.4-kb transcript expressed most abundantly in liver. The protein encoded by SLC25A13, named citrin, is bipartite in structure, containing a mitochondrial carrier motif and four EF-hand domains, suggesting it is a calcium-dependent mitochondrial solute transporter with a role in urea cycle function.	Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 890820, Japan; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Yagi Clin, Aira 8995400, Japan; Ehime Univ, Sch Med, Dept Hyg, Shigenobu, Ehime 7910295, Japan	Kagoshima University; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ehime University	Kobayashi, K (corresponding author), Kagoshima Univ, Fac Med, Dept Biochem, 8-35-1 Sakuragaoka, Kagoshima 890820, Japan.		Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; Sinasac, David/0000-0002-3749-5989				Crackower MA, 1999, GENOMICS, V55, P257, DOI 10.1006/geno.1998.5665; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Hegele RA, 1997, J CLIN ENDOCR METAB, V82, P3373, DOI 10.1210/jc.82.10.3373; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; IMAMURA Y, 1987, CLIN CHIM ACTA, V164, P201, DOI 10.1016/0009-8981(87)90071-4; Kakinoki H, 1997, HUM MUTAT, V9, P250, DOI 10.1002/(SICI)1098-1004(1997)9:3<250::AID-HUMU6>3.3.CO;2-K; Kawamoto S, 1997, CLIN TRANSPLANT, V11, P453; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KOBAYASHI K, 1986, AM J HUM GENET, V38, P667; KOBAYASHI K, 1995, FEBS LETT, V372, P69, DOI 10.1016/0014-5793(95)00948-9; KOBAYASHI K, 1994, AM J HUM GENET, V55, P1103; KOBAYASHI K, 1995, HUM GENET, V96, P454; Kobayashi K, 1997, HEPATOLOGY, V25, P1160, DOI 10.1002/hep.510250519; KOBAYASHI K, 1993, AM J HUM GENET, V53, P1024; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; SAHEKI T, 1982, CLIN CHIM ACTA, V118, P93; SAHEKI T, 1987, CLIN CHIM ACTA, V170, P297, DOI 10.1016/0009-8981(87)90140-9; SAHEKI T, 1987, REV PHYSIOL BIOCH P, V108, P21, DOI 10.1007/BFb0034071; SAHEKI T, 1981, CLIN CHIM ACTA, V109, P325, DOI 10.1016/0009-8981(81)90318-1; Saheki T, 1983, ADV EXP MED BIOL, V153, P63; SAHEKI T, 1985, GUANIDINES, P149; Sameshima Y., 1986, J CLIN BIOCHEM NUTR, V1, P129; SASE M, 1985, HUM GENET, V69, P130, DOI 10.1007/BF00293282; TODO S, 1992, HEPATOLOGY, V15, P419, DOI 10.1002/hep.1840150311; YAGI Y, 1988, AM J CLIN PATHOL, V89, P735, DOI 10.1093/ajcp/89.6.735; Yazaki M, 1996, TRANSPLANTATION, V62, P1679, DOI 10.1097/00007890-199612150-00027	30	310	356	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					159	163		10.1038/9667	http://dx.doi.org/10.1038/9667			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369257				2022-12-25	WOS:000080680900020
J	Meraldi, P; Lukas, J; Fry, AM; Bartek, J; Nigg, EA				Meraldi, P; Lukas, J; Fry, AM; Bartek, J; Nigg, EA			Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A	NATURE CELL BIOLOGY			English	Article							HAMSTER OVARY CELLS; XENOPUS EGG EXTRACTS; PROTEIN-KINASE; DNA-SYNTHESIS; CYCLIN-E; S-PHASE; RETINOBLASTOMA-PROTEIN; CENTRIOLE CYCLE; ORGANIZATION; REPRODUCTION	Centrosome duplication is a key requirement for bipolar spindle formation and correct segregation of chromosomes during cell division. In a manner highly reminiscent of DNA replication, the centrosome must be duplicated once, and only once, in each cell cycle. How centrosome duplication is regulated and coordinated with other cell-cycle functions remains poorly understood. Here, we have established a centrosome duplication assay using mammalian somatic cells. We show that centrosome duplication requires the activation of E2F transcription factors and Cdk2-cyclin A activity.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Geneva; Danish Cancer Society; University of Leicester	Nigg, EA (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Bartek, Jiri/G-5870-2014; Meraldi, Patrick/D-6190-2013	nigg, erich/0000-0003-4835-5719; Lukas, Jiri/0000-0001-9087-506X; Meraldi, Patrick/0000-0001-9742-8756				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Chretien D, 1997, J STRUCT BIOL, V120, P117, DOI 10.1006/jsbi.1997.3928; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALAZZO RE, 1992, SCIENCE, V256, P219, DOI 10.1126/science.1566068; Paoletti A, 1997, Prog Cell Cycle Res, V3, P285; PHILLIPS SG, 1976, J CELL BIOL, V70, P9, DOI 10.1083/jcb.70.1.9; Pihan GA, 1998, CANCER RES, V58, P3974; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; Stearns T, 1997, CELL, V91, P303, DOI 10.1016/S0092-8674(00)80414-6; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Strausfeld UP, 1996, J CELL SCI, V109, P1555; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOROBJEV IA, 1982, J CELL BIOL, V93, P938, DOI 10.1083/jcb.93.3.938; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WINEY M, 1993, TRENDS GENET, V9, P300, DOI 10.1016/0168-9525(93)90247-F; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	49	409	417	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					88	93		10.1038/10054	http://dx.doi.org/10.1038/10054			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559879				2022-12-25	WOS:000083102200015
J	Higashitsuji, H; Itoh, K; Nagao, T; Dawson, S; Nonoguchi, K; Kido, T; Mayer, RJ; Arii, S; Fujita, J				Higashitsuji, H; Itoh, K; Nagao, T; Dawson, S; Nonoguchi, K; Kido, T; Mayer, RJ; Arii, S; Fujita, J			Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas	NATURE MEDICINE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE CONTROL; P53 GENE; DEGRADATION; SUBUNIT	Hepatocellular carcinoma (HCC) is one of the most common cancers in Asia and Africa, where hepatitis virus infection and exposure to specific liver carcinogens are prevalent(1,2). Although inactivation of some tumor suppressor genes such as p53 and p16(INK4A) has been identified(3), no known oncogene is commonly activated in hepatocellular carcinomas. Here we have isolated genes overexpressed in hepatocellular carcinomas by cDNA subtractive hybridization(4), and identified an oncoprotein consisting of six ankyrin repeats (gankyrin). The expression of gankyrin was increased in all 34 hepatocellular carcinomas studied. Gankyrin induced anchorage-independent growth and tumorigenicity in NIH/3T3 cells. Gankyrin bound to the product of the retinoblastoma gene (RB1), increasing its phosphorylation and releasing the activity of the transcription factor E2F-1. Gankyrin accelerated the degradation of RB1 in vitro and in vivo, and was identical to or interacted with a subunit of the 265 proteasome(5,6). These results demonstrate the importance of ubiquitin-proteasome pathway in the regulation of cell growth and oncogenic transformation, and indicate that gankyrin overexpression contributes to hepatocarcinogenesis by destabilizing RB1.	Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England; Kyoto Univ, Fac Med, Dept Surg 1, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; University of Nottingham; Kyoto University	Fujita, J (corresponding author), Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.							Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Dawson S, 1997, MOL BIOL REP, V24, P39, DOI 10.1023/A:1006800522814; HIGUCHI T, 1995, ENDOCRINOLOGY, V136, P4973, DOI 10.1210/en.136.11.4973; Hori T, 1998, GENE, V216, P113, DOI 10.1016/S0378-1119(98)00309-6; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Israel A, 1997, NATURE, V388, P519, DOI 10.1038/41433; Johnson BE, 1998, MATH MECH SOLIDS, V3, P447, DOI 10.1177/108128659800300405; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; LIEW, 1999, ONCOGENE, V18, P789; Mahaffey D, 1999, FEBS LETT, V450, P123, DOI 10.1016/S0014-5793(99)00456-1; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258	20	258	278	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					96	99		10.1038/71600	http://dx.doi.org/10.1038/71600			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613832				2022-12-25	WOS:000084583300043
J	Komatsu, K; Miyashita, T; Hang, HY; Hopkins, KM; Zheng, W; Cuddeback, S; Yamada, M; Lieberman, HB; Wang, HG				Komatsu, K; Miyashita, T; Hang, HY; Hopkins, KM; Zheng, W; Cuddeback, S; Yamada, M; Lieberman, HB; Wang, HG			Human homologue of S-pombe Rad9 interacts with BCL-2/BCL-x(L) and promotes apoptosis	NATURE CELL BIOLOGY			English	Article							CYCLE CHECKPOINT CONTROL; BCL-2 PROTEIN FAMILY; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DNA-REPAIR; CELL-DEATH; ATAXIA-TELANGIECTASIA; KINASE RAF-1; BH3 DOMAIN; GENE	DNA damage induces apoptosis through a signalling pathway that can be suppressed by the BCL-2 protein, but the mechanism by which DNA damage does this is unknown, Here, using yeast two-hybrid and co-immunoprecipitation studies, we show that RADS, a human protein involved in the control of a cell-cycle checkpoint, interacts with the anti-apoptotic Bel-2-family proteins BCL-2 and BCL-x(L), but not with the pro-apoptotic BAX and BAD. When overexpressed in mammalian cells, RADS induces apoptosis that can be blocked by BCL-2 or BCL-x(L), Conversely, antisense RADS RNA suppresses cell death induced by methyl methanesulphonate, These findings indicate that RADS may have a new role in regulating apoptosis after DNA damage, in addition to its previously described checkpoint-control and other radioresistance-promoting functions.	Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, H Lee Moffit Canc Ctr & Res Inst,Drug Discovery P, Tampa, FL 33612 USA; Natl Childrens Med Res Ctr, Dept Genet, Tokyo 154, Japan; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	State University System of Florida; University of South Florida; National Center for Child Health & Development - Japan; Columbia University	Komatsu, K (corresponding author), Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, H Lee Moffit Canc Ctr & Res Inst,Drug Discovery P, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA082197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NCI NIH HHS [CA82197-01] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Diaz JL, 1997, J BIOL CHEM, V272, P11350; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LIEBERMAN HB, 1995, GENETICS, V141, P107; LIEBERMAN HB, 1992, MOL GEN GENET, V232, P367, DOI 10.1007/BF00266239; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Takagi M, 1998, CANCER RES, V58, P4923; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	36	118	122	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					1	6		10.1038/71316	http://dx.doi.org/10.1038/71316			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620799				2022-12-25	WOS:000084843600011
J	Gaensler, KML; Tu, GH; Bruch, S; Liggitt, D; Lipshutz, GS; Metkus, A; Harrison, M; Heath, TD; Debs, RJ				Gaensler, KML; Tu, GH; Bruch, S; Liggitt, D; Lipshutz, GS; Metkus, A; Harrison, M; Heath, TD; Debs, RJ			Fetal gene transfer by transuterine injection of cationic liposome-DNA complexes	NATURE BIOTECHNOLOGY			English	Article						gene therapy; gene transfer; cationic liposomes; fetus; in utero	HEMATOPOIETIC STEM-CELLS; IN-VIVO; TRANSGENIC MICE; HUMAN ALPHA-1-ANTITRYPSIN; ADENOVIRAL VECTOR; IMMUNE-RESPONSE; ADULT MICE; EXPRESSION; THERAPY; DELIVERY	In utero injection of cationic liposome-DNA complexes (CLDCs) containing chloramphenicol acetyltransferase, beta-galactosidase (beta-gal), or human granulocyte colony-stimulating factor (hG-CSF) expression plasmids produced high-level gene expression in fetal rats. Tissues adjacent to the injection site exhibited the highest levels of gene expression. Chloramphenicol acetyltransferase expression persisted for at least 14 days and was reexpressed following postnatal reinjection of CLDCs. Intraperitoneal administration of the hG-CSF gene produced high serum hG-CSF levels. X-gal staining demonstrated widespread beta-gal expression in multiple fetal tissues and cell types. No toxic or inflammatory responses were observed, nor was there evidence of fetal-maternal or maternal-fetal gene transfer, suggesting that CLDCs may provide a useful alternative to viral vectors for in utero gene transfer.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Inst Res, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison	Gaensler, KML (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.			Lipshutz, Gerald/0000-0001-7876-6776	NHLBI NIH HHS [HL53762] Funding Source: Medline; NIDDK NIH HHS [DK49550, DK45917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049550, R01DK045917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BARTKE A, 1994, P SOC EXP BIOL MED, V206, P345, DOI 10.3181/00379727-206-43771; BOUT A, 1993, EXP LUNG RES, V19, P193, DOI 10.3109/01902149309031719; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CLAPP DW, 1991, BLOOD, V78, P1132, DOI 10.1182/blood.V78.4.1132.bloodjournal7841132; Cooper MJ, 1997, P NATL ACAD SCI USA, V94, P6450, DOI 10.1073/pnas.94.12.6450; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; Halbert CL, 1997, J VIROL, V71, P5932, DOI 10.1128/JVI.71.8.5932-5941.1997; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HATZOGLOU M, 1995, SOMAT CELL MOLEC GEN, V21, P265, DOI 10.1007/BF02255781; HOITZMAN DM, 1996, ANN NEUROL, V39, P114; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ICHIKAWA T, 1995, EXP HEMATOL, V23, P192; Iwamoto HS, 1999, GENE THER, V6, P98, DOI 10.1038/sj.gt.3300804; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; KAWAKAMI M, 1990, BLOOD, V76, P1962; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Ketteler M, 1994, Curr Opin Nephrol Hypertens, V3, P446, DOI 10.1097/00041552-199407000-00011; Kurth R, 1995, ANN NY ACAD SCI, V772, P140, DOI 10.1111/j.1749-6632.1995.tb44739.x; Larson JE, 1997, LANCET, V349, P619, DOI 10.1016/S0140-6736(05)61567-X; LEDLEY FD, 1993, OBSTET GYN CLIN N AM, V3, P611; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; LOW JA, 1993, CLIN OBSTET GYNECOL, V36, P82, DOI 10.1097/00003081-199303000-00011; Mason CAE, 1999, NAT MED, V5, P176, DOI 10.1038/5538; MCCRAY PB, 1995, J CLIN INVEST, V95, P2620, DOI 10.1172/JCI117964; Mounkes LC, 1997, J LIPOS RES, V7, P161, DOI 10.3109/08982109709035493; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; PANETH N, 1983, AM J OBSTET GYNECOL, V147, P960, DOI 10.1016/0002-9378(83)90254-5; PHILIP R, 1993, J BIOL CHEM, V268, P16087; PITT BR, 1995, GENE THER, V2, P344; Sambrook J., MOL CLONING LAB MANU; SEKHON HS, 1995, NAT MED, V1, P1201, DOI 10.1038/nm1195-1201; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SORSCHER EJ, 1994, HUM GENE THER, V5, P1259, DOI 10.1089/hum.1994.5.10-1259; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; VINCENT MC, 1995, HUM GENE THER, V6, P1019, DOI 10.1089/hum.1995.6.8-1019; Walter J, 1996, P NATL ACAD SCI USA, V93, P3056, DOI 10.1073/pnas.93.7.3056; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	50	30	30	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1188	1192		10.1038/70729	http://dx.doi.org/10.1038/70729			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585716				2022-12-25	WOS:000084170700026
J	Liberatore, GT; Jackson-Lewis, V; Vukosavic, S; Mandir, AS; Vila, M; McAuliffe, WG; Dawson, VL; Dawson, TM; Przedborski, S				Liberatore, GT; Jackson-Lewis, V; Vukosavic, S; Mandir, AS; Vila, M; McAuliffe, WG; Dawson, VL; Dawson, TM; Przedborski, S			Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease	NATURE MEDICINE			English	Article							TYROSINE-HYDROXYLASE; NADPH-DIAPHORASE; MESSENGER-RNA; GLIAL-CELLS; BRAIN; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; NEUROTOXICITY; MICE; PEROXYNITRITE; MACROPHAGES	MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine damages dopaminergic neurons as seen in Parkinson disease. Here we show that after administration of MPTP to mice, there was a robust gliosis in the substantia nigra pars compacta associated with significant upregulation of inducible nitric oxide synthase (iNOS). These changes preceded or paralleled MPTP-induced dopaminergic neurodegeneration. We also show that mutant mice lacking the iNOS gene were significantly more resistant to MPTP than their wild-type littermates. This study demonstrates that iNOS is important in the MPTP neurotoxic process and indicates that inhibitors of iNOS may provide protective benefit in the treatment of Parkinson disease.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Neurosci & Physiol, Baltimore, MD 21287 USA; Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Columbia University; Columbia University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Przedborski, S (corresponding author), Columbia Univ, Dept Neurol, New York, NY 10032 USA.	SP30@Columbia.edu	Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970; Vila, Miquel/0000-0002-1352-989X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037345, P50NS038370, R01NS038586] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS38370, R29 NS37345, R01 NS38586] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams MH, 1996, ANIM BIOTECHNOL, V7, P1, DOI 10.1080/10495399609525844; Almer G, 1999, J NEUROCHEM, V72, P2415, DOI 10.1046/j.1471-4159.1999.0722415.x; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; ASMUS SE, 1994, J NEUROBIOL, V25, P156, DOI 10.1002/neu.480250207; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DAWSON TM, 1994, J NEUROSCI, V14, P5147; Dawson TM, 1996, ANNU REV MED, V47, P219, DOI 10.1146/annurev.med.47.1.219; DAWSON TM, 1996, NITRIC OXIDE SOURCES, P349; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Dugas N, 1998, CYTOKINE, V10, P680, DOI 10.1006/cyto.1998.0352; FAHN S, 1988, CECILS TXB MED, V18, P2143; FORNO LS, 1992, PROG BRAIN RES, V94, P429; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Garcion E, 1998, GLIA, V22, P282, DOI 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HALLIWELL B, 1991, FREE RADICAL BIOL ME; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Hara H, 1996, NEUROSCIENCE, V75, P881, DOI 10.1016/0306-4522(96)00313-2; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hornykiewicz O, 1987, Adv Neurol, V45, P19; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; Keilhoff G, 1996, NEUROSCIENCE, V75, P1193, DOI 10.1016/0306-4522(96)00330-2; KOSTIC V, 1991, NEUROLOGY, V41, P202, DOI 10.1212/WNL.41.2_Part_1.202; LANGSTON JW, 1986, CLIN NEUROPHARMACOL, V9, P485, DOI 10.1097/00002826-198612000-00001; LEONARD CS, 1995, J COMP NEUROL, V362, P411, DOI 10.1002/cne.903620309; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Matthews RT, 1997, EXP NEUROL, V143, P282, DOI 10.1006/exnr.1996.6406; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1977, J EXP MED, V146, P1648, DOI 10.1084/jem.146.6.1648; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1998, CURR OPIN NEUROL, V11, P335, DOI 10.1097/00019052-199808000-00009; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; WALLACE MN, 1992, NEUROREPORT, V3, P953, DOI 10.1097/00001756-199211000-00001; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; YE YZ, 1996, NITRIC OXIDE PHYSL P, P201	51	888	920	4	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1999	5	12					1403	1409						7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581083				2022-12-25	WOS:000084049700040
J	Marth, GT; Korf, I; Yandell, MD; Yeh, RT; Gu, ZJ; Zakeri, H; Stitziel, NO; Hillier, L; Kwok, PY; Gish, WR				Marth, GT; Korf, I; Yandell, MD; Yeh, RT; Gu, ZJ; Zakeri, H; Stitziel, NO; Hillier, L; Kwok, PY; Gish, WR			A general approach to single-nucleotide polymorphism discovery	NATURE GENETICS			English	Article							EXPRESSED SEQUENCE TAGS; HUMAN-GENOME	Single-nucleotide polymorphisms (SNPs) are the most abundant form of human genetic variation and a resource for mapping complex genetic traits'. The large volume of data produced by high-throughput sequencing projects is a rich and largely untapped source of SNPs (refs 2-5). We present here a unified approach to the discovery of variations in genetic sequence data of arbitrary DNA sources. We propose to use the rapidly emerging genomic: sequence(6,7) as a template on which to layer often unmapped, fragmentary sequence data(8-11) and to use base quality values(12) to discern true allelic variations from sequencing errors. By taking advantage of the genomic sequence we are able to use simpler yet more accurate methods for sequence organization: fragment clustering, paralogue identification and multiple alignment. We analyse these sequences with a novel, Bayesian inference engine, POLYBAYES, to calculate the probability that a given site is polymorphic. Rigorous treatment of base quality permits completely automated evaluation of the full length of all sequences, without limitations on alignment depth. We demonstrate this approach by accurate SNP predictions in human ESTs aligned to finished and working-draft quality genomic sequences, a data set representative of the typical challenges of sequence-based SNP discovery.	Washington Univ, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Genome Sequencing Ctr, St Louis, MO 63110 USA; Washington Univ, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Marth, GT (corresponding author), Washington Univ, Dept Genet, St Louis, MO 63110 USA.		Kwok, Pui-Yan/F-7725-2014; Stitziel, Nathan/AAL-8413-2021; Gish, Warren/C-8123-2012	Kwok, Pui-Yan/0000-0002-5087-3059; Stitziel, Nathan/0000-0002-4963-8211; 	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001720, P50HG001458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284] Funding Source: NIH RePORTER; NHGRI NIH HHS [P50HG01458, R01HG1720] Funding Source: Medline; NIAMS NIH HHS [T32AR07284] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aaronson JS, 1996, GENOME RES, V6, P829, DOI 10.1101/gr.6.9.829; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; Bayes T., 1764, PHILOS T ROY SOC LON, V53, P370, DOI [10.1098/rstl.1763.0053, DOI 10.1098/RSTL.1763.0053]; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Durbin R, 1998, GENOME RES, V8, P161, DOI 10.1101/gr.8.3.161; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KWOK PY, 1994, GENOMICS, V23, P138, DOI 10.1006/geno.1994.1469; Marra M, 1996, GENOME RES, V6, P1118, DOI 10.1101/gr.6.11.1118; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Picoult-Newberg L, 1999, GENOME RES, V9, P167; *SANG CTR WASH U G, 1998, GENOME RES, V8, P1097; Taillon-Miller P, 1998, GENOME RES, V8, P748, DOI 10.1101/gr.8.7.748; TaillonMiller P, 1997, GENOMICS, V46, P307, DOI 10.1006/geno.1997.5042; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	23	370	436	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					452	456		10.1038/70570	http://dx.doi.org/10.1038/70570			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581034				2022-12-25	WOS:000084023900023
J	Slusher, BS; Vornov, JJ; Thomas, AG; Hurn, PD; Harukuni, I; Bhardwaj, A; Traystman, RJ; Robinson, MB; Britton, P; Lu, XCM; Tortella, FC; Wozniak, KM; Yudkoff, M; Potter, BM; Jackson, PF				Slusher, BS; Vornov, JJ; Thomas, AG; Hurn, PD; Harukuni, I; Bhardwaj, A; Traystman, RJ; Robinson, MB; Britton, P; Lu, XCM; Tortella, FC; Wozniak, KM; Yudkoff, M; Potter, BM; Jackson, PF			Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury	NATURE MEDICINE			English	Article							LINKED ACIDIC DIPEPTIDASE; CEREBRAL-ARTERY OCCLUSION; N-ACETYLASPARTYLGLUTAMATE; RAT-BRAIN; FOCAL ISCHEMIA; NERVOUS-SYSTEM; TISSUE-CULTURE; AMINO-ACIDS; RECEPTOR; TRANSIENT	We describe here a new strategy for the treatment of stroke, through the inhibition of NAALADase (N-acetylated-alpha-linked-acidic dipeptidase), an enzyme responsible for the hydrolysis of the neuropeptide NAAG (N-acetyl-aspartyl-glutamate) to N-acetyl-aspartate and glutamate. We demonstrate that the newly described NAALADase inhibitor 2-PMPA (2-(phosphonomethyl)pentanedioic acid) robustly protects against ischemic injury in a neuronal culture model of stroke and in rats after transient middle cerebral artery occlusion. Consistent with inhibition of NAALADase, we show that 2-PMPA increases NAAG and attenuates the ischemia-induced rise in glutamate. Both effects could contribute to neuroprotection. These data indicate that NAALADase inhibition may have use in neurological disorders in which excessive excitatory amino acid transmission is pathogenic.	Guilford Pharmaceut, Dept Res, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Walter Reed Army Med Ctr, Div Neurosci, Washington, DC 20307 USA	Johns Hopkins University; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Slusher, BS (corresponding author), Guilford Pharmaceut, Dept Res, Baltimore, MD 21224 USA.		Vornov, James/F-6794-2013	Vornov, James/0000-0003-1965-5456				BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Britton P, 1997, LIFE SCI, V60, P1729, DOI 10.1016/S0024-3205(97)00132-X; Britton P, 1996, J NEUROCHEM, V67, P324; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHEN J, 1995, BRAIN RES, V699, P121, DOI 10.1016/0006-8993(95)00868-Q; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; COYLE JT, 1991, EXCITATORY AMINO ACI, P69; FAGG GE, 1986, TRENDS PHARMACOL SCI, V7, P357, DOI 10.1016/0165-6147(86)90386-X; Fix AS, 1996, TOXICOL PATHOL, V24, P291, DOI 10.1177/019262339602400305; FUHRMAN S, 1994, J NEUROCHEM, V62, P275; Goda H, 1998, EUR J PHARMACOL, V357, P149, DOI 10.1016/S0014-2999(98)00559-7; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; JOHANSEN PA, 1995, MOL PHARMACOL, V48, P140; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MEYERHOFF JL, 1992, BRAIN RES, V593, P140, DOI 10.1016/0006-8993(92)91276-K; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; PUTTFARCKEN PS, 1993, J PHARMACOL EXP THER, V266, P796; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SEKIGUCHI M, 1989, BRAIN RES, V482, P87, DOI 10.1016/0006-8993(89)90545-3; SERVAL V, 1990, J NEUROCHEM, V55, P39, DOI 10.1111/j.1471-4159.1990.tb08818.x; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; Small DL, 1997, INT REV NEUROBIOL, V40, P137; STAUCH BL, 1989, NEUROSCI LETT, V100, P295, DOI 10.1016/0304-3940(89)90702-7; Takahashi H, 1996, STROKE, V27, P2120, DOI 10.1161/01.STR.27.11.2120; THOMSEN C, 1994, EUR J PHARM-MOLEC PH, V267, P77, DOI 10.1016/0922-4106(94)90227-5; TSAI G, 1990, BRAIN RES, V518, P313, DOI 10.1016/0006-8993(90)90989-O; VALLIVULLAH HM, 1994, J NEUROCHEM, V63, P1714; VORNOV JJ, 1995, J NEUROCHEM, V65, P1681; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; WAHLGREN NG, 1997, INT REV NEUROBIOL, P337; Wozniak DF, 1996, BRAIN RES, V707, P165, DOI 10.1016/0006-8993(95)01230-3; Wroblewska B, 1997, J NEUROCHEM, V69, P174; ZOLLINGER M, 1990, J CHROMATOGR, V32, P27	38	252	263	1	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1396	1402		10.1038/70971	http://dx.doi.org/10.1038/70971			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581082				2022-12-25	WOS:000084049700039
J	Verdu, J; Buratovich, MA; Wilder, EL; Birnbaum, MJ				Verdu, J; Buratovich, MA; Wilder, EL; Birnbaum, MJ			Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB	NATURE CELL BIOLOGY			English	Article							B C-AKT; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; SIGNALING PATHWAY; GENETIC MOSAICS; DIVISION CYCLE; SIZE CONTROL; EXPRESSION; MELANOGASTER	Organismal size is determined by a tightly regulated mechanism that coordinates cell growth, cell proliferation and cell death. The Drosophila insulin receptor/Chico/Dp110 pathway regulates cell and organismal size. Here we show that genetic manipulation of the phosphoinositide-3-OH-kinase-dependent serine/threonine protein kinase Akt (protein kinase B) during development of the Drosophila imaginal disc affects cell and organ size in an autonomous manner. Ectopic expression of Akt does not affect cell-fate determination, apoptosis or proliferation rates in imaginal discs. Thus, Akt appears to stimulate intracellular pathways that specifically regulate cell and compartment size independently of cell proliferation in vivo.	Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Howard Hughes Med Inst, 415 Curie Blvd,Clin Res Bldg, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680	NIGMS NIH HHS [GM55162] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ANDJELKOVIC M, 1995, J BIOL CHEM, V270, P4066, DOI 10.1074/jbc.270.8.4066; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FERNANDEZALMONACID R, 1987, MOL CELL BIOL, V7, P2718, DOI 10.1128/MCB.7.8.2718; Flick K, 1998, MOL CELL BIOL, V18, P2492, DOI 10.1128/MCB.18.5.2492; FRANKE TF, 1994, ONCOGENE, V9, P141; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pimentel B, 1996, BIOCHEM BIOPH RES CO, V226, P855, DOI 10.1006/bbrc.1996.1440; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANTAMARIA P, 1983, DEV BIOL, V96, P285, DOI 10.1016/0012-1606(83)90165-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; WOLFF T, 1991, DEVELOPMENT, V113, P825; XU T, 1993, DEVELOPMENT, V117, P1223; Zaffran S, 1998, DEVELOPMENT, V125, P3571	48	303	318	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					500	506		10.1038/70293	http://dx.doi.org/10.1038/70293			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587646				2022-12-25	WOS:000084136100018
J	Warrick, JM; Chan, HYE; Gray-Board, GL; Chai, YH; Paulson, HL; Bonini, NM				Warrick, JM; Chan, HYE; Gray-Board, GL; Chai, YH; Paulson, HL; Bonini, NM			Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70	NATURE GENETICS			English	Article							MACHADO-JOSEPH DISEASE; NEURONAL INTRANUCLEAR INCLUSIONS; EXPANDED POLYGLUTAMINE; SPINOCEREBELLAR ATAXIA; PROTEIN; AGGREGATION; HUNTINGTIN; LOCALIZATION; DEGENERATION; EXPRESSION	At least eight inherited human neurodegenerative diseases are caused by expansion of a polyglutamine domain within the respective proteins(1,2). This confers dominant toxicity on the proteins, leading to dysfunction and loss of neurons. Expanded polyglutamine proteins form aggregates, including nuclear inclusions (NI), within neurons, possibly due to misfolding of the proteins(3-5). MI are ubiquitinated and sequester molecular chaperone proteins and proteasome components(6-9), suggesting that disease pathogenesis includes activation of cellular stress pathways to help refold, disaggregate or degrade the mutant disease proteins. Overexpression of specific chaperone proteins reduces polyglutamine aggregation in transfected cells(7-9), but whether this alters toxicity is unknown. Using a Drosophila melanogaster model of polyglutamine disease(10), we show that directed expression of the molecular chaperone HSP70 suppresses polyglutamine-induced neurodegeneration in vivo. Suppression by HSP70 occurred without a visible effect on NI formation, indicating that polyglutamine toxicity can be dissociated from formation of large aggregates. Our studies indicate that HSP70 or related molecular chaperones may provide a means of treating these and other neurodegenerative diseases associated with abnormal protein conformation and toxicity.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Iowa, Coll Med, Iowa City, IA USA	University of Pennsylvania; University of Iowa	Bonini, NM (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.		Chan, Edwin/A-9478-2011	Chan, Edwin/0000-0003-4307-474X				BRAND AH, 1993, DEVELOPMENT, V118, P401; CAHI Y, IN PRESS J NEUROSCI; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Durr A, 1996, ANN NEUROL, V39, P490, DOI 10.1002/ana.410390411; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; LANDSBURU P, 1997, NEURON, V19, P1151; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; RANUM LPW, 1995, AM J HUM GENET, V57, P603; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wolff Tanya, 1993, P1277	29	665	693	0	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					425	428		10.1038/70532	http://dx.doi.org/10.1038/70532			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581028				2022-12-25	WOS:000084023900017
J	Adebanjo, OA; Anandatheerthavarada, HK; Koval, AP; Moonga, BS; Biswas, G; Sun, L; Sodam, BR; Bevis, PJR; Huang, CLH; Epstein, S; Lai, FA; Avadhani, NG; Zaidi, M				Adebanjo, OA; Anandatheerthavarada, HK; Koval, AP; Moonga, BS; Biswas, G; Sun, L; Sodam, BR; Bevis, PJR; Huang, CLH; Epstein, S; Lai, FA; Avadhani, NG; Zaidi, M			A new function for CD38/ADP-ribosyl cyclase in nuclear Ca2+ homeostasis	NATURE CELL BIOLOGY			English	Article							RAT-LIVER NUCLEI; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; EXTRACELLULAR CA2+; PHOSPHOLIPASE-C; CALCIUM; RELEASE; PROTEIN; KINASE	Nucleoplasmic calcium ions (Ca2+) influence nuclear functions as critical as gene transcription, apoptosis, DNA repair, topoisomerase activation and polymerase unfolding. Although both inositol trisphosphate receptors and ryanodine receptors, types of Ca2+ channel, are present in the nuclear membrane, their role in the homeostasis of nuclear Ca2+ remains unclear. Here we report the existence in the inner nuclear membrane of a functionally active CD38/ADP-ribosyl cyclase that has its catalytic site within the nucleoplasm. We propose that the enzyme catalyses the intranuclear cyclization of nicotinamide adenine dinucleotide to cyclic adenosine diphosphate ribose. The latter activates ryanodine receptors of the inner nuclear membrane to trigger nucleoplasmic Ca2+ release.	CUNY Mt Sinai Sch Med, Div Endocrinol, New York, NY 10029 USA; Med Coll Penn & Hahnemann Univ, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Cambridge, Physiol Lab, Cardiff CB2 3EG, S Glam, Wales; Univ Wales, Coll Med, Cardiff CF14 4XN, S Glam, Wales	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Drexel University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Cambridge; Cardiff University	Zaidi, M (corresponding author), CUNY Mt Sinai Sch Med, Div Endocrinol, Mailbox 1055,1 Gustave Levy Pl, New York, NY 10029 USA.		Huang, Christopher LH/A-6248-2008	Lai, Tony/0000-0003-2852-8547	NATIONAL CANCER INSTITUTE [R37CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014917] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA22762] Funding Source: Medline; NIA NIH HHS [R01-AG14917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; ASANO M, 1994, J BIOL CHEM, V269, P12360; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Fox JL, 1997, BIOCHEM J, V326, P491, DOI 10.1042/bj3260491; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HARDINGHAM GE, 1996, NATURE, V285, P260; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; LAREA LS, 1993, NEURON, V10, P31; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; Matter N, 1996, FEBS LETT, V387, P85, DOI 10.1016/0014-5793(96)00464-4; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PerezTerzic C, 1997, CELL CALCIUM, V21, P275, DOI 10.1016/S0143-4160(97)90115-9; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; SANTELLA L, 1997, CELL CALCIUM, V22, P1; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197	27	132	136	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					409	414		10.1038/15640	http://dx.doi.org/10.1038/15640			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559984				2022-12-25	WOS:000083533100013
J	Debrauwere, H; Buard, J; Tessier, J; Aubert, D; Vergnaud, G; Nicolas, A				Debrauwere, H; Buard, J; Tessier, J; Aubert, D; Vergnaud, G; Nicolas, A			Meiotic instability of human minisatellite CEB1 in yeast requires DNA double-strand breaks	NATURE GENETICS			English	Article							COMPLEX RECOMBINATION EVENTS; SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; MISMATCH REPAIR; INITIATION SITE; MUTATION; MEIOSIS; SEQUENCE; SIZE		Inst Curie, CNRS, UMR 144, Sect Rech, F-75231 Paris, France; Inst Biol, Nantes, France; Univ Paris Sud, Inst Genet & Microbiol, Orsay, France; Ctr Etud Bouchet, F-91710 Vert Le Petit, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay	Nicolas, A (corresponding author), Inst Curie, CNRS, UMR 144, Sect Rech, F-75231 Paris, France.		Vergnaud, Gilles/P-1304-2015; Vergnaud, Gilles/AAC-1162-2020	Vergnaud, Gilles/0000-0003-0913-194X; Vergnaud, Gilles/0000-0003-0913-194X				ALANI E, 1994, GENETICS, V137, P19; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Appelgren H, 1997, MOL GEN GENET, V256, P7, DOI 10.1007/s004380050540; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bois P, 1997, HUM MOL GENET, V6, P1565, DOI 10.1093/hmg/6.9.1565; Borde V, 1999, MOL CELL BIOL, V19, P4832; Buard J, 1998, EMBO J, V17, P3495, DOI 10.1093/emboj/17.12.3495; BUARD J, 1994, EMBO J, V13, P3203, DOI 10.1002/j.1460-2075.1994.tb06619.x; DEMASSY B, 1993, EMBO J, V12, P1459, DOI 10.1002/j.1460-2075.1993.tb05789.x; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KEENEY S, IN PRESS GENOMICS; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KLAPHOLZ S, 1980, GENETICS, V96, P567; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROCCO V, 1992, P NATL ACAD SCI USA, V89, P12068, DOI 10.1073/pnas.89.24.12068; ROMANIENKO PJ, IN PRESS GENOMICS; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tamaki K, 1999, HUM MOL GENET, V8, P879, DOI 10.1093/hmg/8.5.879; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297	30	53	54	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					367	371		10.1038/15557	http://dx.doi.org/10.1038/15557			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545956				2022-12-25	WOS:000083792200031
J	Edwards, RJ; Bentley, NJ; Carr, AM				Edwards, RJ; Bentley, NJ; Carr, AM			A Rad3-Rad26 complex responds to DNA damage independently of other checkpoint proteins	NATURE CELL BIOLOGY			English	Article							ATAXIA-TELANGIECTASIA GENE; CELL-CYCLE CHECKPOINTS; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; REPLICATION CHECKPOINT; BUDDING YEAST; KINASE; HOMOLOG; REPAIR	The conserved PIK-related kinase Rad3 is required for all DNA-integrity-checkpoint responses in fission yeast. Here we report a stable association between Rad3 and Rad26 in soluble protein extracts. Rad26 shows Rad3-dependent phosphorylation after DNA damage. Unlike phosphorylation of Hus1, Crb2/Rhp9, Cds1 and Chk1, phosphorylation of Rad26 does not require other known checkpoint proteins. Rad26 phosphorylation is the first biochemical marker of Rad3 function, indicating that Rad3-related checkpoint kinases may have a direct role in DNA-damage recognition.	Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England	University of Sussex	Carr, AM (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.	a.m.carr@sussex.ac.uk		Carr, Antony Michael/0000-0002-2028-2389				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; Crits-Christoph P., 1981, CLIN PSYCHOL REV, V1, P19; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Griffiths DJF, 1998, CONT CANC RES, P449; Gutz H., 1974, HDB GENETICS, V1, P395; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	34	169	171	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					393	398		10.1038/15623	http://dx.doi.org/10.1038/15623			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559981				2022-12-25	WOS:000083533100010
J	Evans, DT; O'Connor, DH; Jing, PC; Dzuris, JL; Sidney, J; da Silva, J; Allen, TM; Horton, H; Venham, JE; Rudersdorf, RA; Vogel, T; Pauza, CD; Bontrop, RE; DeMars, R; Sette, A; Hughes, AL; Watkins, DI				Evans, DT; O'Connor, DH; Jing, PC; Dzuris, JL; Sidney, J; da Silva, J; Allen, TM; Horton, H; Venham, JE; Rudersdorf, RA; Vogel, T; Pauza, CD; Bontrop, RE; DeMars, R; Sette, A; Hughes, AL; Watkins, DI			Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef	NATURE MEDICINE			English	Article							INFECTED RHESUS-MONKEYS; HIV-1 INFECTION; IN-VIVO; ESCAPE; VARIANTS; CTL; IMMUNODOMINANT; PROGRESSION; DISEASE; PATHOGENESIS	Cytotoxic T-lymphocyte (CTL) responses to human immunodeficiency virus arise early after infection, but ultimately fail to prevent progression to AIDS. Human immunodeficiency virus may evade the CTL response by accumulating amino-acid replacements within CTL epitopes. We studied 10 CTL epitopes during the course of simian immunodeficiency virus disease progression in three related macaques. All 10 of these CTL epitopes accumulated amino-acid replacements and showed evidence of positive selection by the time the macaques died. Many of the amino-acid replacements in these epitopes reduced or eliminated major histocompatibility complex class I binding and/or CTL recognition. These findings strongly support the CTL 'escape' hypothesis.	Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Epimmune, San Diego, CA 92121 USA; Penn State Univ, Inst Mol Evolut Genet, University Pk, PA 16802 USA; Univ Wisconsin, Genet Lab, Madison, WI 53715 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53715 USA; TNO, Biomed Primate Res Ctr, NL-2280 HV Rijswijk, Netherlands	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Netherlands Organization Applied Science Research	Watkins, DI (corresponding author), Univ Wisconsin, Wisconsin Reg Primate Res Ctr, 1220 Capitol Court, Madison, WI 53715 USA.		Bontrop, Ronald E./D-4844-2011; Sette, Alessandro/AFO-8916-2022; Bontrop, Ronald E/J-3628-2012; da Silva, Jack/H-1266-2014; Allen, Todd/F-5473-2011	Bontrop, Ronald E/0000-0003-0874-6467; da Silva, Jack/0000-0001-5631-5421; Allen, Todd/0000-0002-6609-1318; Dzuris, John/0000-0002-0046-8426; o'connor, david/0000-0003-2139-470X	NIAID NIH HHS [AI42641, AI32426, AI41913] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032426, R01AI041913, R21AI042641] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen TM, 1998, J IMMUNOL, V160, P6062; Balter M, 1998, SCIENCE, V280, P1860, DOI 10.1126/science.280.5371.1860; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DAI L C, 1992, Journal of Virology, V66, P3151; DELGUERCIO MF, 1995, J IMMUNOL, V154, P685; Dykhuizen M, 1998, J GEN VIROL, V79, P2461, DOI 10.1099/0022-1317-79-10-2461; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Haas G, 1996, J IMMUNOL, V157, P4212; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McMichael A, 1998, CELL, V93, P673, DOI 10.1016/S0092-8674(00)81428-2; McMichael AJ, 1997, ANNU REV IMMUNOL, V15, P271, DOI 10.1146/annurev.immunol.15.1.271; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; NEI M, 1986, MOL BIOL EVOL, V3, P418; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; TRIVEDI P, 1994, J VIROL, V68, P7649, DOI 10.1128/JVI.68.11.7649-7653.1994; VANBAALEN CA, 1993, AIDS, V7, P781, DOI 10.1097/00002030-199306000-00004; VOSS G, 1995, VIROLOGY, V208, P770, DOI 10.1006/viro.1995.1209; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	37	339	351	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1270	1276		10.1038/15224	http://dx.doi.org/10.1038/15224			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545993				2022-12-25	WOS:000086550600037
J	Gallucci, S; Lolkema, M; Matzinger, P				Gallucci, S; Lolkema, M; Matzinger, P			Natural adjuvants: Endogenous activators of dendritic cells	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; MHC CLASS-II; APOPTOTIC CELLS; T-CELLS; EFFICIENT PRESENTATION; ADHESION MOLECULE-1; HOST-DEFENSE; IN-VITRO; ANTIGEN	Dendritic cells, the most potent antigen-presenting cells, need to be activated before they can function to initiate an immune response. We report here that, in the absence of any foreign substances, dendritic cells can be activated by endogenous signals received from cells that are stressed, virally infected or killed necrotically, but not by healthy cells or those dying apoptotically. Injected in vivo with an antigen, the endogenous activating substances can function as natural adjuvants to stimulate a primary immune response, and they may represent the natural initiators of transplant rejection, spontaneous tumor rejection, and some forms of autoimmunity.	NIAID, Ghost Lab, T Cell Tolerance & Memory Sect, Lab Cellular & Mol Immunol,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gallucci, S (corresponding author), NIAID, Ghost Lab, T Cell Tolerance & Memory Sect, Lab Cellular & Mol Immunol,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Lolkema, M.P./AAE-2906-2019	Lolkema, M.P./0000-0003-0466-2928				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARTOCCIONI E, 1994, CLIN EXP IMMUNOL, V95, P166; Bradley J A, 1996, Int Rev Immunol, V13, P245, DOI 10.3109/08830189609061751; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chakrabarti D, 1996, J IMMUNOL, V157, P522; Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x; COLE WH, 1981, J SURG ONCOL, V17, P201, DOI 10.1002/jso.2930170302; COLEY W, 1898, JAMA-J AM MED ASSOC, V20, P389; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRESSER I, 1976, J EXP MED, V144, P1305, DOI 10.1084/jem.144.5.1305; HARDING C, 1984, EUR J CELL BIOL, V35, P256; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; LAND W, 1994, TRANSPLANTATION, V57; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Luft T, 1998, J IMMUNOL, V161, P1947; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Ronchetti A, 1999, J IMMUNOL, V163, P130; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SEN GC, 1992, J BIOL CHEM, V267, P5017; Slupsky JR, 1998, THROMB HAEMOSTASIS, V80, P1008; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWENSSON H, 1996, SCAND J IMMUNOL, V44, P164; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	49	1311	1377	3	53	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1249	1255		10.1038/15200	http://dx.doi.org/10.1038/15200			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545990				2022-12-25	WOS:000086550600034
J	Girod, A; Storrie, B; Simpson, JC; Johannes, L; Goud, B; Roberts, LM; Lord, JM; Nilsson, T; Pepperkok, R				Girod, A; Storrie, B; Simpson, JC; Johannes, L; Goud, B; Roberts, LM; Lord, JM; Nilsson, T; Pepperkok, R			Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum	NATURE CELL BIOLOGY			English	Article							STOMATITIS-VIRUS GLYCOPROTEIN; RETROGRADE TRANSPORT; SHIGA TOXIN; MEMBRANE-PROTEIN; B-FRAGMENT; TRANSMEMBRANE PROTEINS; COATOMER BINDING; KDEL RECEPTOR; CELL-SURFACE; ER PROTEINS	The cytosolic coat-protein complex COP-I interacts with cytoplasmic 'retrieval' signals present in membrane proteins that cycle between the endoplasmic reticulum (ER) and the Golgi complex, and is required for both anterograde and retrograde transport in the secretory pathway, Here we study the role of COP-I in Golgi-to-ER transport of several distinct marker molecules. Microinjection of anti-COP-I antibodies inhibits retrieval of the lectin-like molecule ERGIC-53 and of the KDEL receptor from the Golgi to the ER, Transport to the ER of protein toxins, which contain a sequence that is recognized by the KDEL receptor, is also inhibited, In contrast, microinjection of anti-COP-I antibodies or expression of a GTP-restricted Arf-l mutant does not interfere with Golgi-to-ER transport of Shiga toxin/Shiga-like toxin-1 or with the apparent recycling to the ER of Golgi-resident glycosylation enzymes. Overexpression of a GDP-restricted mutant of Rab6 blocks transport to the ER of Shiga toxin/Shiga-like toxin-1 and glycosylation enzymes, but not of ERGIC-53, the KDEL receptor or KDEL-containing toxins. These data indicate the existence of at least two distinct pathways for Golgi-to-ER transport, one COP-I dependent and the other COP-I independent. The COP-I-independent pathway is specifically regulated by Rab6 and is used by Golgi glycosylation enzymes and Shiga toxin/Shiga-like toxin-1.	European Mol Biol Lab, Cell Biol & Biophys Programme, D-69117 Heidelberg, Germany; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	European Molecular Biology Laboratory (EMBL); Virginia Polytechnic Institute & State University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; University of Warwick	Nilsson, T (corresponding author), European Mol Biol Lab, Cell Biol & Biophys Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Nilsson@EMBL-Heidelberg.de; Pepperko@EMBL-Heidelberg.de	Johannes, Ludger/W-8593-2019; Goud, Bruno/GWC-4807-2022; Johannes, Ludger/M-9778-2017	Johannes, Ludger/0000-0002-2168-0004; Johannes, Ludger/0000-0002-2168-0004; Pepperkok, Rainer/0000-0002-9762-3583; Simpson, Jeremy/0000-0002-7956-7805				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Jackson ME, 1999, J CELL SCI, V112, P467; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Johannes L, 1997, J BIOL CHEM, V272, P19554, DOI 10.1074/jbc.272.31.19554; JOHNSTON PA, 1994, J CELL SCI, V107, P529; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lippincott-Schwartz J, 1993, Subcell Biochem, V21, P95; Lord JM, 1998, J CELL BIOL, V140, P733; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; Pepperkok R, 1998, J CELL SCI, V111, P1877; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; Rottger S, 1998, J CELL SCI, V111, P45; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; Sandvig K, 1999, FEBS LETT, V452, P67, DOI 10.1016/S0014-5793(99)00529-3; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; Sata M, 1999, P NATL ACAD SCI USA, V96, P2752, DOI 10.1073/pnas.96.6.2752; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TEAL SB, 1994, J BIOL CHEM, V269, P3135; WHITE J, IN PRESS J CELL BIOL	51	289	295	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					423	430		10.1038/15658	http://dx.doi.org/10.1038/15658			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559986				2022-12-25	WOS:000083533100015
J	Huang, LP; Kuo, YM; Gitschier, J				Huang, LP; Kuo, YM; Gitschier, J			The pallid gene encodes a novel, syntaxin 13-interacting protein involved in platelet storage pool deficiency	NATURE GENETICS			English	Article							HERMANSKY-PUDLAK-SYNDROME; CHEDIAK-HIGASHI-SYNDROME; PALE EAR EP; MUTATION ANALYSIS; MOUSE; COMPLEX; DISTINCT; AP-3; IDENTIFICATION; EXPRESSION		Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gitschier, J (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.							Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Gwynn B, 1997, GENOMICS, V42, P532, DOI 10.1006/geno.1997.4764; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; James P, 1996, GENETICS, V144, P1425; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; LYON MF, 1989, GENETIC VARIANTS STR, P274; MARTORANA PA, 1993, LAB INVEST, V68, P233; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; NOVAK EK, 1984, BLOOD, V63, P536; NOVAK EK, 1979, GENETICS, V92, P189; O'Donohue MF, 1998, BIOTECHNIQUES, V24, P910, DOI 10.2144/98246bm01; Oh J, 1998, AM J HUM GENET, V62, P593, DOI 10.1086/301757; Ooi CE, 1997, EMBO J, V16, P4508; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Roberts E, 1931, SCIENCE, V74, P569, DOI 10.1126/science.74.1927.569; ROBINSON PJ, 1981, IMMUNOGENETICS, V14, P449, DOI 10.1007/BF00373326; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; THERIAULT LL, 1970, DEV BIOL, V23, P261, DOI 10.1016/0012-1606(70)90098-9; White R. A., 1997, Mouse Genome, V95, P492; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; Zuberi AR, 1996, GENOMICS, V33, P75, DOI 10.1006/geno.1996.0161	28	144	147	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					329	332		10.1038/15507	http://dx.doi.org/10.1038/15507			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610180				2022-12-25	WOS:000083792200023
J	Persidis, A				Persidis, A			Antibacterial and antifungal drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material									RHeoGene, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), RHeoGene, 706 Forest St, Charlottesville, VA 22903 USA.							Fleming A, 1929, BRIT J EXP PATHOL, V10, P226; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Kirjavainen PV, 1999, ANN MED, V31, P288, DOI 10.3109/07853899908995892; Ma ZK, 1999, J MED CHEM, V42, P4202, DOI 10.1021/jm990191k; Moore PA, 1999, J AM DENT ASSOC, V130, P1341, DOI 10.14219/jada.archive.1999.0404; MOVAHED PV, 1999, J S C MED ASS, V95, P303; Ouellette AJ, 1999, AM J PHYSIOL-GASTR L, V277, pG257, DOI 10.1152/ajpgi.1999.277.2.G257; Sreenan C, 1999, ARCH PEDIAT ADOL MED, V153, P984, DOI 10.1001/archpedi.153.9.984	10	14	16	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1141	1142		10.1038/15141	http://dx.doi.org/10.1038/15141			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545930				2022-12-25	WOS:000083428000038
J	Grossman, Z; Polis, M; Feinberg, MB; Grossman, Z; Levi, I; Jankelevich, S; Yarchoan, R; Boon, J; de Wolf, F; Lange, JMA; Goudsmit, J; Dimitrov, DS; Paul, WE				Grossman, Z; Polis, M; Feinberg, MB; Grossman, Z; Levi, I; Jankelevich, S; Yarchoan, R; Boon, J; de Wolf, F; Lange, JMA; Goudsmit, J; Dimitrov, DS; Paul, WE			Ongoing HIV dissemination during HAART	NATURE MEDICINE			English	Editorial Material							T-CELL HOMEOSTASIS; ANTIRETROVIRAL THERAPY; INDUCTION THERAPY; DRUG-THERAPY; IN-VIVO; INFECTION; LYMPHOCYTES; REPLICATION; DYNAMICS; RNA		NIH, Off AIDS Res, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Emory Univ, Ctr AIDS Res, Atlanta, GA 30322 USA; Chaim Sheba Med Ctr, Inst Virol, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Infect Dis, IL-52621 Tel Hashomer, Israel; NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Expt & Computat Biol, Frederick Canc Res Ctr, NIH, Frederick, MD 21701 USA; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1012 WX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University; Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Grossman, Z (corresponding author), NIH, Off AIDS Res, Bldg 10, Bethesda, MD 20892 USA.	grossman@helix.nih.gov	Grossman, Zvi/A-9643-2008	Polis, Michael/0000-0002-9151-2268	DIVISION OF BASIC SCIENCES - NCI [Z01BC010042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000493, ZIAAI000493, ZIAAI000390, Z01AI000390] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Bucy RP, 1999, AIDS RES HUM RETROV, V15, P223, DOI 10.1089/088922299311394; Cavert W, 1997, SCIENCE, V276, P1321; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Grossman Z, 1998, IMMUNOL TODAY, V19, P528, DOI 10.1016/S0167-5699(98)01353-X; Grossman Z, 1997, NAT MED, V3, P486, DOI 10.1038/nm0597-486; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Igarashi T, 1999, NAT MED, V5, P211, DOI 10.1038/5576; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; Mueller BU, 1998, AIDS, V12, pF191, DOI 10.1097/00002030-199815000-00004; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Zhang LQ, 1999, J VIROL, V73, P855, DOI 10.1128/JVI.73.1.855-860.1999; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	26	129	132	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1099	1104		10.1038/13410	http://dx.doi.org/10.1038/13410			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502799				2022-12-25	WOS:000082933200020
J	Kalman, D; Weiner, OD; Goosney, DL; Sedat, JW; Finlay, BB; Abo, A; Bishop, JW				Kalman, D; Weiner, OD; Goosney, DL; Sedat, JW; Finlay, BB; Abo, A; Bishop, JW			Enteropathogenic E-coli acts through WASP and Arp2/3 complex to form actin pedestals	NATURE CELL BIOLOGY			English	Article							WISKOTT-ALDRICH-SYNDROME; GTPASE CDC42HS; PROTEIN		Univ Calif San Francisco, GW Hooper Fdn Labs, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Onyx Pharmaceut, Richmond, CA 94806 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia; University of British Columbia	Kalman, D (corresponding author), Univ Calif San Francisco, GW Hooper Fdn Labs, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	kalman@cgl.ucsf.edu	Weiner, Orion D/F-2576-2011	Weiner, Orion D/0000-0002-1778-6543	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM027800-27] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abo A, 1998, CELL MOL LIFE SCI, V54, P1145, DOI 10.1007/s000180050242; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Ben-Ami G, 1998, INFECT IMMUN, V66, P1755, DOI 10.1128/IAI.66.4.1755-1758.1998; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Goosney DL, 1999, TRENDS CELL BIOL, V9, P11, DOI 10.1016/S0962-8924(98)01418-4; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042	10	169	172	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					389	391		10.1038/14087	http://dx.doi.org/10.1038/14087			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559969	Green Accepted			2022-12-25	WOS:000083169800025
J	Sawa, A; Wiegand, GW; Cooper, J; Margolis, RL; Sharp, AH; Lawler, JF; Greenamyre, JT; Snyder, SH; Ross, CA				Sawa, A; Wiegand, GW; Cooper, J; Margolis, RL; Sharp, AH; Lawler, JF; Greenamyre, JT; Snyder, SH; Ross, CA			Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; PERMEABILITY TRANSITION; CELL-DEATH; LOCALIZATION; DYSFUNCTION; AGGREGATION; EXPRESSION; MEMBRANE; NECROSIS; NUCLEUS	Huntington disease (HD) is a genetically dominant condition caused by expanded CAG repeats coding for glutamine in the HD gene product huntingtin(1). Although HD symptoms reflect preferential neuronal death in specific brain regions, huntingtin is expressed in almost all tissues(2), so abnormalities outside the brain might be expected. Although involvement of nuclei(3-7) and mitochondria(8-14) in HD pathophysiology has been suggested, specific intracellular defects that might elicit cell death have been unclear. Mitochondria dysfunction is reported in HD brains(10-13); mitochondria are organelles that regulates apoptotic cell death(15,16). We now report that lymphoblasts derived from HD patients showed increased stress-induced apoptotic cell death associated with caspase-3 activation. When subjected to stress, HD lymphoblasts also manifested a considerable increase in mitochondrial depolarization correlated with increased glutamine repeats.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21205 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emory University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Greenamyre, J. Timothy/B-4049-2011; Ross, Christopher A/H-8395-2013	Greenamyre, J. Timothy/0000-0003-3468-7878				ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321; BEAL MF, 1993, J NEUROSCI, V13, P4181; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Koroshetz WJ, 1997, ANN NEUROL, V41, P160, DOI 10.1002/ana.410410206; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Penno M. B., 1993, Journal of Tissue Culture Methods, V15, P43, DOI 10.1007/BF02387289; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sawa A, 1997, MOL BRAIN RES, V48, P53, DOI 10.1016/S0169-328X(97)00078-8; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Schapira AHV, 1997, ANN NEUROL, V41, P141, DOI 10.1002/ana.410410203; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	33	305	309	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1194	1198		10.1038/13518	http://dx.doi.org/10.1038/13518			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502825				2022-12-25	WOS:000082933200048
J	Halford, WP				Halford, WP			The essential prerequisites for quantitative RT-PCR	NATURE BIOTECHNOLOGY			English	Editorial Material							POLYMERASE CHAIN-REACTION; MESSENGER-RNA; EXPRESSION		Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Halford, WP (corresponding author), Univ Penn, Dept Microbiol, 221 Johnson Pavil, Philadelphia, PA 19104 USA.							Chandler DP, 1998, J IND MICROBIOL BIOT, V21, P128, DOI 10.1038/sj.jim.2900546; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GREEMAN WM, 1999, BIOTECHNIQUES, V26, P112; Haberhausen G, 1998, J CLIN MICROBIOL, V36, P628, DOI 10.1128/JCM.36.3.628-633.1998; Halford WP, 1999, ANAL BIOCHEM, V266, P181, DOI 10.1006/abio.1998.2913; Halford WP, 1997, VIROLOGY, V238, P53, DOI 10.1006/viro.1997.8806; Hill JM, 1996, ANAL BIOCHEM, V235, P44, DOI 10.1006/abio.1996.0089; Martell M, 1999, J CLIN MICROBIOL, V37, P327, DOI 10.1128/JCM.37.2.327-332.1999; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; VANDEVYVER C, 1995, CELL MOL BIOL, V41, P683; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WIESNER RJ, 1993, NATURE, V366, P416, DOI 10.1038/366416b0; Zhang CF, 1996, BIOCHEM BIOPH RES CO, V223, P450, DOI 10.1006/bbrc.1996.0914	14	49	53	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					835	835		10.1038/12783	http://dx.doi.org/10.1038/12783			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471906				2022-12-25	WOS:000082365800006
J	Schuetz, JD; Connelly, MC; Sun, DX; Paibir, SG; Flynn, PM; Srinivas, RV; Kumar, A; Fridland, A				Schuetz, JD; Connelly, MC; Sun, DX; Paibir, SG; Flynn, PM; Srinivas, RV; Kumar, A; Fridland, A			MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRACELLULAR METABOLISM; HIV-INFECTION; CELLS; 3'-AZIDO-3'-DEOXYTHYMIDINE; PHOSPHORYLATION; REPLICATION	Dideoxynucleosides, which are potent inhibitors of HIV reverse transcriptase and other viral DNA polymerases, are a common component of highly active anti-retroviral therapy (HAART) (ref. 1). Six reverse transcriptase inhibitors have been approved for human use: azidothymidine; 2'3'-dideoxycytidine; 2'3'-dideoxyinosine; 2',3'-didehydro-3'deoxythymidine; 2',3'-dideoxy-3'-thiacytidine; and 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol. Although drug-resistant HIV strains resulting from genetic mutation have emerged in patients treated with HAART (ref. 1), some patients show signs of drug resistance in the absence of drug-resistant viruses(2,3). In our study of alternative or additional mechanisms of resistance operating during antiviral therapy, overexpression and amplification of the MRP4 gene correlated with ATP-dependent efflux of PMEA (9-(2-phosphonylmethoxyethyl)adenine) and azidothymidine monophosphate from cells and, thus, with resistance to these drugs. Overexpression of MRP4 mRNA and MRP4 protein severely impaired the antiviral efficacy of PMEA, azidothymidine and other nucleoside analogs. Increased resistance to PMEA and amplification of the MRP4 gene correlated with enhanced drug efflux; transfer of chromosome 13 containing the amplified MRP4 gene conferred resistance to PMEA. MRP4 is the first transporter, to our knowledge, directly linked to the efflux of nucleoside monophosphate analogs from mammalian cells.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Schuetz, JD (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.schuetz@stjude.org	Flynn, Patricia M/N-8146-2018; Schuetz, John D/N-2692-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027652, R21AI027652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005851, R29ES005851] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27652] Funding Source: Medline; NIEHS NIH HHS [ES/GM 8568, ES/GM 5851] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; Balzarini J, 1998, NAT MED, V4, P132, DOI 10.1038/nm0298-132a; Berger EA, 1998, P NATL ACAD SCI USA, V95, P11511, DOI 10.1073/pnas.95.20.11511; BOER R, 1994, EUR J CANCER, V30A, P1117, DOI 10.1016/0959-8049(94)90469-3; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; Groschel B, 1997, INTERVIROLOGY, V40, P400, DOI 10.1159/000150572; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; KARMATA P, 1998, P AM ASSOC CANC RES, V39, P3198; Kepler TB, 1998, P NATL ACAD SCI USA, V95, P11514, DOI 10.1073/pnas.95.20.11514; Kool M, 1997, CANCER RES, V57, P3537; Lavie A, 1997, NAT MED, V3, P922, DOI 10.1038/nm0897-922; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEVY JA, 1989, ANN NY ACAD SCI, V567, P58; MEDINA DJ, 1995, J VIROL, V69, P1606, DOI 10.1128/JVI.69.3.1606-1611.1995; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; Robbins BL, 1996, ANTIMICROB AGENTS CH, V40, P2651, DOI 10.1128/AAC.40.11.2651; ROBBINS BL, 1995, MOL PHARMACOL, V47, P391; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SCHUETZ JD, 1989, ARCH BIOCHEM BIOPHYS, V274, P355, DOI 10.1016/0003-9861(89)90449-9; Srinivas RV, 1997, ANTIVIR RES, V35, P23, DOI 10.1016/S0166-3542(97)01035-8; WOLVERTON JS, 1989, CANCER RES, V49, P2422	22	467	485	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1048	1051		10.1038/12487	http://dx.doi.org/10.1038/12487			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470083				2022-12-25	WOS:000082337200040
J	Bach, I; Rodriguez-Esteban, C; Carriere, C; Bhushan, A; Krones, A; Rose, DW; Glass, CK; Andersen, B; Belmonte, JCI; Rosenfeld, MG				Bach, I; Rodriguez-Esteban, C; Carriere, C; Bhushan, A; Krones, A; Rose, DW; Glass, CK; Andersen, B; Belmonte, JCI; Rosenfeld, MG			RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex	NATURE GENETICS			English	Article							VERTEBRATE LIMB; SONIC HEDGEHOG; RING FINGER; ZINC-FINGER; N-COR; PROTEIN; DOMAIN; REPRESSION; INITIATION; INDUCTION	LIM domains(1) are required for both inhibitory effects on LIM homeodomain transcription factors and synergistic transcriptional activation events(1-4). The inhibitory actions of the LIM domain can often be overcome by the LIM co-regulator known as CLIM2, LDB1 and NLI (referred to hereafter as CLIM2; refs 2-4). The association of the CLIM cofactors with LIM domains does not, however, improve the DNA-binding ability of LIM homeodomain proteins(4,5). suggesting the action of a LIM-associated inhibitor factor. Here we present evidence that LIM domains are capable of binding a novel RING-H2 zinc-finger protein, Rlim (for RING finger LIM domain-binding protein), which acts as a negative co-regulator via the recruitment of the Sin3A/histone deacetylase corepressor complex. A corepressor function of RLIM is also suggested by in vivo studies of chick wing development. Overexpression of the gene Rnf12, encoding Rlim, results in phenotypes similar to those observed after inhibition of the LIM homeodomain factor LHX2, which is required for the formation of distal structures along the proximodistal axis, or by overexpression of dominant-negative CLIM1. We conclude that Rlim is a novel corepressor that recruits histone deacetylase-containing complexes to the LIM domain.	Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Eukaryot Regulatory Biol Program, La Jolla, CA 92093 USA; Salk Inst Biol Sci, Gene Express Lab, San Diego, CA 92186 USA; Salk Inst Biol Sci, Clayton Fdn, San Diego, CA 92186 USA; Univ Calif San Diego, Whittier Diabet Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Hamburg, Ctr Mol Neurobiol, D-20246 Hamburg, Germany	Howard Hughes Medical Institute; University of California System; University of California San Diego; Salk Institute; Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Hamburg	Bach, I (corresponding author), Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, Eukaryot Regulatory Biol Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ingolf.bach@zmnh.uni-hamburg.de; belmonte@salk.edu; mrosenfeld@ucsd.edu	Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002080, R01AR044882] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02080, AR044882] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Rodriguez-Esteban C, 1998, DEVELOPMENT, V125, P3925; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Toyama R, 1998, MECH DEVELOP, V71, P197, DOI 10.1016/S0925-4773(97)00202-5; Tranque P, 1996, P NATL ACAD SCI USA, V93, P3105, DOI 10.1073/pnas.93.7.3105; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0	28	120	124	1	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					394	399		10.1038/11970	http://dx.doi.org/10.1038/11970			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431247				2022-12-25	WOS:000081772500025
J	Brooks-Wilson, A; Marcil, M; Clee, SM; Zhang, LH; Roomp, K; van Dam, M; Yu, L; Brewer, C; Collins, JA; Molhuizen, HOF; Loubser, O; Ouelette, BFF; Fichter, K; Ashbourne-Excoffon, KJD; Sensen, CW; Scherer, S; Mott, S; Denis, M; Martindale, D; Frohlich, J; Morgan, K; Koop, B; Pimstone, S; Kastelein, JJP; Genest, J; Hayden, MR				Brooks-Wilson, A; Marcil, M; Clee, SM; Zhang, LH; Roomp, K; van Dam, M; Yu, L; Brewer, C; Collins, JA; Molhuizen, HOF; Loubser, O; Ouelette, BFF; Fichter, K; Ashbourne-Excoffon, KJD; Sensen, CW; Scherer, S; Mott, S; Denis, M; Martindale, D; Frohlich, J; Morgan, K; Koop, B; Pimstone, S; Kastelein, JJP; Genest, J; Hayden, MR			Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency	NATURE GENETICS			English	Article							CORONARY HEART-DISEASE; MULTILOCUS LINKAGE ANALYSIS; HDL CHOLESTEROL LEVELS; GENE ABCR; PHOSPHOLIPASE-C; ARTERY DISEASE; FIBROBLASTS; EFFLUX; COMPUTATIONS; TRANSPORTERS	Genes have a major role in the control of high-density lipoprotein (HDL) cholesterol (HDL-C) levels. Here we have identified two Tangier disease (TD) families, confirmed 9q31 linkage and refined the disease locus to a limited genomic region containing the gene encoding the ATP-binding cassette transporter (ABC1). Familiar HDL deficiency (FHA) is a more frequent cause of low HDL levels. On the basis of independent linkage and meiotic recombinants, we localized the FHA locus to the same genomic region as the TD locus, Mutations in ABC1 were detected in both TD and FHA, indicating that TD and FHA are allelic. This indicates that the protein encoded by ABC1 is a key gatekeeper influencing intracellular cholesterol transport, hence we have named it cholesterol efflux regulatory protein (CERP).	Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Xenon Biores Inc, NRC Innovat Ctr, Vancouver, BC V6T 1W5, Canada; Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Clin Res Inst Montreal, Cardiovasc Genet Lab, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada; Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Victoria, Ctr Environm Hlth, Dept Biol, Victoria, BC V8W 3N5, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; National Research Council Canada; University of Amsterdam; Academic Medical Center Amsterdam; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; McGill University; International Business Machines (IBM); National Research Council Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Victoria; University of British Columbia	Hayden, MR (corresponding author), Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Ouellette, Francis/G-1684-2010; Koop, Ben F./A-8151-2008; van Dam, Marjel/AFT-3071-2022; Clee, Susanne/AAC-4278-2020; Hayden, Michael R/D-8581-2011; Sensen, Christoph W./C-1798-2013; Scherer, Stephen W./B-3785-2013; Brooks-Wilson, Angela/E-9399-2012; Kastelein, John/AAF-7950-2020; Excoffon, Katherine/ABC-5037-2021; Collins, Jennifer/AAE-1895-2020; Clee, Susanne/F-7312-2010	Koop, Ben F./0000-0003-0045-5200; Hayden, Michael R/0000-0001-5159-1419; Sensen, Christoph W./0000-0001-9604-8962; Scherer, Stephen W./0000-0002-8326-1999; Brooks-Wilson, Angela/0000-0003-1009-6408; Excoffon, Katherine/0000-0003-3945-0298; Clee, Susanne/0000-0001-7946-688X; van Dam, Marjel/0000-0001-9802-7516; Ouellette, B. F. Francis/0000-0003-4676-675X				Allikmets R, 1998, GENE, V215, P111, DOI 10.1016/S0378-1119(98)00269-8; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; Baxevanis AD, 1998, METHOD BIOCHEM ANAL, V39, P98; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; DROBNIK W, 1995, ARTERIOSCL THROM VAS, V15, P1369, DOI 10.1161/01.ATV.15.9.1369; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FREDRICKSON D, 1961, ANN INTERN MED, V55, P1016, DOI 10.7326/0003-4819-55-6-1016; FROHLICH J, 1987, CLIN INVEST MED, V10, P377; GARTNER J, 1992, NAT GENET, V1, P23; Genest J, 1999, J INVEST MED, V47, P31; GENEST J, 1993, ARTERIOSCLER THROMB, V13, P1728, DOI 10.1161/01.ATV.13.12.1728; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; KANNEL WB, 1983, AM J CARDIOL, V52, pB9, DOI 10.1016/0002-9149(83)90649-5; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATHROP GM, 1986, GENET EPIDEMIOL, V3, P39, DOI 10.1002/gepi.1370030105; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MARCIL M, 1995, ARTERIOSCL THROM VAS, V15, P1015, DOI 10.1161/01.ATV.15.8.1015; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROWEN L, 1994, AUTOMATED DNA SEQUEN; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Schuler GD, 1998, METHOD BIOCHEM ANAL, V39, P145; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; TALMUD P, 1982, GENET EPIDEMIOL, V45, P161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	50	1437	1496	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					336	345		10.1038/11905	http://dx.doi.org/10.1038/11905			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431236				2022-12-25	WOS:000081772500014
J	Segre, JA; Bauer, C; Fuchs, E				Segre, JA; Bauer, C; Fuchs, E			Klf4 is a transcription factor required for establishing the barrier function of the skin	NATURE GENETICS			English	Article							ZINC-FINGER PROTEIN; KRUPPEL-LIKE FACTOR; EPIDERMAL-KERATINOCYTES; STRATUM-CORNEUM; ACID RECEPTOR; MICE LACKING; GENE; DIFFERENTIATION; EXPRESSION; ENVELOPES	Located at the interface between body and environment, the epidermis must protect the body against toxic agents and dehydration, and protect itself against physical and mechanical stresses(1-4). Acquired just before birth and at the last stage of epidermal differentiation, the skin's proteinaceous/lipid barrier creates a surface seal essential for protecting animals against microbial infections and dehydration. We show here that Kruppel-like factor 4 (Klf4, encoded by the gene Klf4), highly expressed in the differentiating layers of epidermis, is both vital to and selective for barrier acquisition. Klf4(-/-) mice die shortly after birth due to loss of skin barrier function, as measured by penetration of external dyes and rapid loss of body fluids. The defect was not corrected by grafting of Klf4(-/-) skin onto nude mice. Loss of the barrier occurs without morphological and biochemical alterations to the well-known structural features of epidermis that are essential for mechanical integrity. Instead, late-stage differentiation structures are selectively perturbed, including the cornified envelope, a likely scaffold for lipid organization. Using suppressive subtractive hybridization, we identified three transcripts encoding cornified envelope proteins with altered expression in the absence of Klf4. Sprr2a is one, and is the only epidermal gene whose promoter is known to possess a functional Klf4 binding site. Our studies provide new insights into transcriptional governance of barrier function, and pave the way for unravelling the molecular events that orchestrate this essential process.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Fuchs, E (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Fuchs, Elaine/G-1565-2016		NIAMS NIH HHS [AR31737] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; DOWNING DT, 1992, J LIPID RES, V33, P301; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; IMAKADO S, 1995, GENE DEV, V9, P317, DOI 10.1101/gad.9.3.317; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MICHEL S, 1988, J INVEST DERMATOL, V91, P11, DOI 10.1111/1523-1747.ep12463281; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; STEVEN AC, 1994, J CELL SCI, V107, P693; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; WICKETT RR, 1995, SKIN PHARMACOL, V8, P179; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026	30	611	634	2	55	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					356	360		10.1038/11926	http://dx.doi.org/10.1038/11926			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431239				2022-12-25	WOS:000081772500017
J	Van Etten, WJ; Steen, RG; Nguyen, H; Castle, AB; Slonim, DK; Ge, B; Nusbaum, C; Schuler, GD; Lander, ES; Hudson, TJ				Van Etten, WJ; Steen, RG; Nguyen, H; Castle, AB; Slonim, DK; Ge, B; Nusbaum, C; Schuler, GD; Lander, ES; Hudson, TJ			Radiation hybrid map of the mouse genome	NATURE GENETICS			English	Article								Radiation hybrid (RH) maps are a useful tool for genome analysis, providing a direct method for localizing genes and anchoring physical maps and genomic sequence along chromosomes, The construction of a comprehensive RH map for the human genome(1) has resulted in gene maps reflecting the location of more than 30,000 human genes(2,3). Here we report the first comprehensive RH map of the mouse genome. The map contains 2,486 loci screened against an RH panel of 93 cell lines(4). Most loci (93%) are simple sequence length polymorphisms (SSLPs) taken from the mouse genetic map, thereby providing direct integration between these two key maps, We performed RH mapping by a new and efficient approach in which we replaced traditional gel- or hybridization-based assays by a homogeneous 5'-nuclease assay(5) involving a single common probe for all genetic markers. The map provides essentially complete connectivity and coverage across the genome, and good resolution for ordering loci, with 1 centiRay (cR) corresponding to an average of approximately 100 kb, The RH map, together with an accompanying World-Wide Web server, makes it possible for any investigator to rapidly localize sequences in the mouse genome. Together with the previously constructed genetic map(6) and a YAC-based physical map reported in a companion paper(7), the fundamental maps required for mouse genomics are now available.	MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02142 USA; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge, MA 02142 USA.			Slonim, Donna/0000-0003-3357-437X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001806] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01806] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Slonim D, 1997, J COMPUT BIOL, V4, P487, DOI 10.1089/cmb.1997.4.487	10	93	100	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					384	387		10.1038/11962	http://dx.doi.org/10.1038/11962			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431245				2022-12-25	WOS:000081772500023
J	Yang, XW; Wynder, C; Doughty, ML; Heintz, N				Yang, XW; Wynder, C; Doughty, ML; Heintz, N			BAC-mediated gene-dosage analysis reveals a role for Zipro1 (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin	NATURE GENETICS			English	Article							HOMOLOGOUS RECOMBINATION; MOUSE CEREBELLUM; FINGER PROTEINS; FOLIAL PATTERN; ZINC FINGERS; DROSOPHILA; MICE; IDENTIFICATION; EXPRESSION; MUTATIONS	Geneticanalysis in mice has most commonly employed two general strategies: phenotypic screens for spontaneous or induced mutations and genotypic analysis using homologous recombination or gene trapping to produce deletion or insertion mutants. Here we use bacterial artificial chromosome (BAC)-mediated gene-dosage analysis in transgenic mice to reveal novel genetic functions that are not evident from conventional loss-of-function mutations. We demonstrate a role for the zinc-finger transcription factor Zipro1 (formerly Ru49 and Zfp38) in the proliferation of granule cell precursors in the developing cerebellum, and document the contribution of this process to the final stages of cerebellar morphogenesis. We also show that Zipro I is expressed in skin, and increased Zipro1 dosage results in a hair-loss phenotype associated with increased epithelial cell proliferation and abnormal hair follicle development.	Howard Hughes Med Inst, Mol Biol Lab, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Heintz, N (corresponding author), Howard Hughes Med Inst, Mol Biol Lab, 1230 York Ave,Box 260, New York, NY 10021 USA.	heintz@rockvax.rockefeller.edu	Pillay, Nischalan/F-9536-2012		NIGMS NIH HHS [GM07739] Funding Source: Medline; DS NIH HHS [NINDS 30532] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); DS NIH HHS		Alder J, 1996, NEURON, V17, P389, DOI 10.1016/S0896-6273(00)80172-5; ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOWDHURY K, 1992, MECH DEVELOP, V39, P129, DOI 10.1016/0925-4773(92)90040-Q; Clarke ND, 1998, SCIENCE, V282, P2018, DOI 10.1126/science.282.5396.2018; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; FUJITA S, 1966, J COMP NEUROL, V128, P191, DOI 10.1002/cne.901280206; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; Helms AW, 1998, DEVELOPMENT, V125, P919; INOUYE M, 1980, J COMP NEUROL, V190, P357, DOI 10.1002/cne.901900209; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; LAUDER JM, 1974, BRAIN RES, V76, P33, DOI 10.1016/0006-8993(74)90511-3; Levine K, 1995, Prog Cell Cycle Res, V1, P101; MARES V, 1970, BRAIN RES, V23, P343, DOI 10.1016/0006-8993(70)90061-2; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; NEUMANN PE, 1990, BRAIN RES, V524, P85, DOI 10.1016/0006-8993(90)90495-W; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Perrimon N, 1998, P NATL ACAD SCI USA, V95, P9716, DOI 10.1073/pnas.95.17.9716; ROBERTS PA, 1982, GENETICS, V102, P75; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; SOUTHERN PJ, 1982, J MOL APPL GENET, V4, P321; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; Sundberg JP, 1996, J INVEST DERMATOL, V106, P368, DOI 10.1111/1523-1747.ep12343152; Thompson CC, 1996, J NEUROSCI, V16, P7832; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang XW, 1996, DEVELOPMENT, V122, P555	50	99	102	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					327	335		10.1038/11896	http://dx.doi.org/10.1038/11896			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431235				2022-12-25	WOS:000081772500013
J	Agris, CH				Agris, CH			Patenting plants: What to claim	NATURE BIOTECHNOLOGY			English	Editorial Material									Baker & Botts LLP, Houston, TX 77002 USA		Agris, CH (corresponding author), Baker & Botts LLP, Houston, TX 77002 USA.							Agris CH, 1999, NAT BIOTECHNOL, V17, P197, DOI 10.1038/6205; BAGGOT B, 1999, GEN ENG NEWS, V2, P1; HOLZMAN D, 1999, GEN ENG NEWS, V2, P8; Moffat AS, 1998, SCIENCE, V282, P2176, DOI 10.1126/science.282.5397.2176; *OJEPO, 1995, T35693 OJEPO, P345; SEIDE RK, 1998, 8 ANN PAT PROS WORKS, P337; 5900525; 5639947; 5066830; 5783394; 5843782; 5436395; 5844118	13	6	6	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					717	718		10.1038/10938	http://dx.doi.org/10.1038/10938			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409355				2022-12-25	WOS:000081296900035
J	Bonadio, J; Smiley, E; Patil, P; Goldstein, S				Bonadio, J; Smiley, E; Patil, P; Goldstein, S			Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration	NATURE MEDICINE			English	Article							NATIONAL-OSTEOPOROSIS-FOUNDATION; PARATHYROID-HORMONE; BONE-FORMATION; FRACTURES; RECEPTOR; GROWTH; RATS; MICE; DNA	The inability to deliver growth factors locally in a transient but sustained manner is a substantial barrier to tissue regeneration. Systems capable of localized plasmid gene delivery for prolonged times may offer lower toxicity and should be well-suited for growth factor therapeutics. We investigated the potency of plasmid gene delivery from genes physically entrapped in a polymer matrix (gene activated matrix) using bone regeneration as the endpoint in vivo. implantation of gene activated matrices at sites of bone injury was associated with retention and expression of plasmid DNA for at least 6 weeks, and with the induction of centimeters of normal new bone in a stable, reproducible, dose- and time-dependent manner.	Univ Michigan, Sch Med, Orthopaed Res Labs, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bonadio, J (corresponding author), Select Genet, 11035 Roselle St, San Diego, CA 92121 USA.							Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; Bartus RT, 1998, SCIENCE, V281, P1161, DOI 10.1126/science.281.5380.1161; Bonadio J, 1998, ADV DRUG DELIVER REV, V33, P53, DOI 10.1016/S0169-409X(98)00020-9; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; Cosman F, 1998, CALCIFIED TISSUE INT, V62, P475, DOI 10.1007/s002239900464; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753; FELDMAN AM, 1998, NAT MED, V4, P7839; Giannobile WV, 1996, BONE, V19, pS23, DOI 10.1016/S8756-3282(96)00127-5; GUNNESSHEY M, 1989, BONE, V10, P447, DOI 10.1016/8756-3282(89)90077-X; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; Kay MA, 1997, P NATL ACAD SCI USA, V94, P12744, DOI 10.1073/pnas.94.24.12744; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer R, 1998, NATURE, V392, P5; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEW D, 1995, HUM GENE THER, V6, P553, DOI 10.1089/hum.1995.6.5-553; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Melton LJ, 1997, J BONE MINER RES, V12, P16, DOI 10.1359/jbmr.1997.12.1.16; PARKER SE, 1995, HUM GENE THER, V6, P575, DOI 10.1089/hum.1995.6.5-575; PARSONS JA, 1974, NATURE, V250, P254, DOI 10.1038/250254a0; PARSONS JA, 1981, OSTEOPOROSIS RECENT, P457; PODBESEK R, 1983, ENDOCRINOLOGY, V112, P1000, DOI 10.1210/endo-112-3-1000; PODBESEK R, 1980, HORMONAL CONTROL CAL, P118; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHLEEF M, 1999, BIOTECHNOLOGY, P443; Segre Gino V., 1996, P377; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; SINGH RH, 1966, INDIAN J MED RES, V54, P872; TERRELL TG, 1993, INT REV EXP PATHOL, V34, P43; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; VOLPON JB, 1994, ARCH ORTHOP TRAUM SU, V113, P312, DOI 10.1007/BF00426178; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7	36	526	579	0	38	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					753	759		10.1038/10473	http://dx.doi.org/10.1038/10473			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395319				2022-12-25	WOS:000081926600029
J	Botchkarev, VA; Botchkareva, NV; Roth, W; Nakamura, M; Chen, LH; Herzog, W; Lindner, G; McMahon, JA; Peters, C; Lauster, R; McMahon, AP; Paus, R				Botchkarev, VA; Botchkareva, NV; Roth, W; Nakamura, M; Chen, LH; Herzog, W; Lindner, G; McMahon, JA; Peters, C; Lauster, R; McMahon, AP; Paus, R			Noggin is a mesenchymally derived stimulator of hair-follicle induction	NATURE CELL BIOLOGY			English	Article							BONE MORPHOGENETIC PROTEIN-4; ADHESION MOLECULES; NEURAL INDUCTION; BETA-CATENIN; EXPRESSION; MOUSE; APOPTOSIS; GROWTH; TOOTH; SKIN	The induction of developmental structures derived from the ectoderm, such as the neural tube or tooth, occurs through neutralization of the inhibitory activity of members of the bone-morphogenetic protein (BMP) family by BMP antagonists. Here we show that, during hair-follicle development, the neural inducer and BMP-neutralizing protein Noggin is expressed in the follicular mesenchyme, that noggin-knockout mice show significant retardation of hair-follicle induction, and that Noggin neutralizes the inhibitory action of BMP-4 and stimulates hair-follicle induction in embryonic skin organ culture. As a crucial mesenchymal signal that stimulates hair-follicle induction, Noggin operates through antagonistic interactions with BMP-4, which result in upregulation of the transcription factor Lef-1 and the cell-adhesion molecule NCAM, as well as through BMP4-independent downregulation of the 75 kD neurotrophin receptor in the developing hair follicle.	Humboldt Univ, Dept Dermatol, D-13344 Berlin, Germany; Univ Freiburg, Dept Internal Med, D-79106 Freiburg, Germany; Deutsch Rheumaforsch Zentrum, D-10117 Berlin, Germany; Kyoto Univ, Dept Dermatol, Kyoto 6068507, Japan; Harvard Univ, Cambridge, MA 02138 USA; Univ Hamburg, Univ Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany	Humboldt University of Berlin; University of Freiburg; Deutsches Rheuma-Forschungszentrum (DRFZ); Kyoto University; Harvard University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Botchkarev, VA (corresponding author), Humboldt Univ, Dept Dermatol, D-13344 Berlin, Germany.	vladbotc@bu.edu; paus@uke.uni-hamburg.de	McMahon, Andrew P/ABE-7520-2020; Paus, Ralf/F-6243-2011	Herzog, Wiebke/0000-0002-9843-3458; Botchkarev, Vladimir/0000-0002-5212-5353; Lindner, Gerd/0000-0003-2336-2058				BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; Brunn H, 1998, ECO EFFICIEN IND, V1, P155; Buckland RA, 1998, MECH DEVELOP, V71, P143, DOI 10.1016/S0925-4773(98)00008-2; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Cerletti N., 1991, European Patent Application, Patent No. 0433225; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Dassule HR, 1998, DEV BIOL, V202, P215, DOI 10.1006/dbio.1998.8992; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Hardy MH, 1996, ACTA ANAT, V157, P169; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; HOLBROOK KA, 1991, ANN NY ACAD SCI, V642, P167; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; JIANG TX, 1992, DEV BIOL, V150, P82, DOI 10.1016/0012-1606(92)90009-6; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; Kim J, 1998, BIOCHEM BIOPH RES CO, V250, P516, DOI 10.1006/bbrc.1998.9280; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; LYONS KM, 1990, DEVELOPMENT, V109, P833; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Muller-Rover S, 1998, J HISTOCHEM CYTOCHEM, V46, P1401; Muller-Rover S, 1998, MOL BASIS EPITHELIAL, P283; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Ohsugi M, 1996, DEV DYNAM, V206, P391, DOI 10.1002/(SICI)1097-0177(199608)206:4<391::AID-AJA5>3.0.CO;2-D; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Schmidt C, 1998, DEV BIOL, V202, P253, DOI 10.1006/dbio.1998.9011; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Tucker AS, 1998, SCIENCE, V282, P1136, DOI 10.1126/science.282.5391.1136; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Yamada N, 1996, BRIT J CANCER, V73, P624, DOI 10.1038/bjc.1996.108; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	51	312	335	0	32	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					158	164		10.1038/11078	http://dx.doi.org/10.1038/11078			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559902				2022-12-25	WOS:000083102500014
J	Braverman, N; Lin, P; Moebius, FF; Obie, C; Moser, A; Glossmann, H; Wilcox, WR; Rimoin, DL; Smith, M; Kratz, L; Kelley, RI; Valle, D				Braverman, N; Lin, P; Moebius, FF; Obie, C; Moser, A; Glossmann, H; Wilcox, WR; Rimoin, DL; Smith, M; Kratz, L; Kelley, RI; Valle, D			Mutations in the gene encoding 3 beta-hydroxysteroid-Delta(8),Delta(7)-isomerase cause X-linked dominant Conradi-Hunermann syndrome	NATURE GENETICS			English	Article							LEMLI-OPITZ-SYNDROME; ANTAGONIST BINDING-PROTEIN; CHONDRODYSPLASIA PUNCTATA; DISRUPTION; REDUCTASE; RECEPTOR; YEAST; LIVER	X-linked dominant Conradi-Hunermann syndrome (CDPX2; MIM 302960) is one of a group of disorders with aberrant punctate calcification in cartilage, or chondrodysplasia punctata (CDP). This is most prominent around the vertebral column, pelvis and long bones in CPDX2. Additionally, CDPX2 patients may have asymmetric rhizomesomelia, sectorial cataracts, patchy alopecia, ichthyosis and atrophoderma(1). The phenotype in CDPX2 females ranges from stillborn to mildly affected individuals identified in adulthood. CDPX2 is presumed lethal in males, although a few affected males have been reported(2,3). We found increased 8(9)-cholestenol and 8-dehydrocholesterol in tissue samples from seven female probands with CDPX2 (ref. 4). This pattern of accumulated cholesterol intermediates suggested a deficiency of 3 beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (sterol-Delta(8)-isomerase), which catalyses an intermediate step in the conversion of lanosterol to cholesterol(4). A candidate gene encoding a sterol-Delta(8)-isomerase (EBP) has been identified and mapped to Xp11.22-p11.23 (refs 5,6). Using SSCP analysis and sequencing of genomic DNA, we found EBP mutations in all probands. We confirmed the functional significance of two missense alleles by expressing them in a sterol-Delta(8)-isomerase-deficient yeast strain. Our results indicate that defects in sterol-Delta(8)-isomerase cause CDPX2 and suggest a role for sterols in bone development.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Inst Biochem Pharmacol, Innsbruck, Austria; Univ Calif Los Angeles, Burns & Allen Cedars Sinai Res Inst, Dept Pediat, Sch Med, Los Angeles, CA 90048 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Irvine	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.		Glossmann, Hartmut/AAL-9790-2020	glossmann, hartmut h./0000-0002-7392-3266; Braverman, Nancy/0000-0003-1621-5164	NCRR NIH HHS [RR00052, RR00722] Funding Source: Medline; NICHD NIH HHS [P01HD10981] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; BJORKHEM I, 1987, J LIPID RES, V28, P1137; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BRODY LC, 1992, J BIOL CHEM, V267, P3302; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Derry JMJ, 1999, NAT GENET, V22, P286, DOI 10.1038/10350; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.0.CO;2-S; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HAPPLE R, 1995, AM J MED GENET, V57, P493, DOI 10.1002/ajmg.1320570327; HAPPLE R, 1979, HUM GENET, V53, P65, DOI 10.1007/BF00289453; HERMAN GE, 1990, GENOMICS, V7, P307, DOI 10.1016/0888-7543(90)90162-N; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kelley RI, 1999, AM J MED GENET, V83, P213, DOI 10.1002/(SICI)1096-8628(19990319)83:3<213::AID-AJMG15>3.0.CO;2-C; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Liu XY, 1999, NAT GENET, V22, P182, DOI 10.1038/9700; MOEBIUS FF, 1994, J BIOL CHEM, V269, P29314; Moebius FF, 1999, BIOCHEMISTRY-US, V38, P1119, DOI 10.1021/bi981804i; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Schindelhauer D, 1996, GENOME RES, V6, P1056, DOI 10.1101/gr.6.11.1056; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; SUTPHEN R, 1995, AM J MED GENET, V57, P489, DOI 10.1002/ajmg.1320570326; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205	25	200	205	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					291	294		10.1038/10357	http://dx.doi.org/10.1038/10357			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391219				2022-12-25	WOS:000081125900024
J	Greiner, S; Rausch, T; Sonnewald, U; Herbers, K				Greiner, S; Rausch, T; Sonnewald, U; Herbers, K			Ectopic expression of a tobacco invertase inhibitor homolog prevents cold-induced sweetening of potato tubers	NATURE BIOTECHNOLOGY			English	Article						potato; cold sweetening; vacuolar invertase; invertase inhibitor	CELL-WALL INVERTASE; SOLANUM-TUBEROSUM; STARCH; PROTEIN	We have transformed potato with Nt-inhh cDNA, encoding a putative vacuolar homolog of a tobacco cell wall invertase inhibitor, under the control of the CaMV 35S promoter. In transgenic tubers, cold-induced hexose accumulation was reduced by up to 75%, without any effect on potato tuber yield. Processing quality of tubers was greatly improved without changing starch quantity or quality, an important prerequisite for the biotechnological use of Nt-inhh for potato transformation.	Inst Bot, D-69120 Heidelberg, Germany; IPK Gatersleben, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Rausch, T (corresponding author), Inst Bot, INF 360, D-69120 Heidelberg, Germany.	trausch@botanik1.bot.uni-heidelberg.de	Greiner, Steffen/D-3423-2014; Sonnewald, Uwe/J-7875-2012	Sonnewald, Uwe/0000-0003-1835-5339				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Burton W.G., 1989, POTATO, V3rd ed.; Greiner S, 1998, PLANT PHYSIOL, V116, P733, DOI 10.1104/pp.116.2.733; GREINER S, 1995, PLANT PHYSIOL, V108, P825, DOI 10.1104/pp.108.2.825; GREINER S, Y12806 EMBL NUCL SEQ; HERBERS K, 1994, PLANTA, V194, P230, DOI 10.1007/BF01101682; HOFGEN R, 1990, PLANT SCI, V66, P221, DOI 10.1016/0168-9452(90)90207-5; ISHERWOO.FA, 1973, PHYTOCHEMISTRY, V12, P2579, DOI 10.1016/0031-9422(73)85060-5; Krausgrill S, 1998, PLANT J, V13, P275, DOI 10.1046/j.1365-313X.1998.00026.x; Lorberth R, 1998, NAT BIOTECHNOL, V16, P473, DOI 10.1038/nbt0598-473; Muller-Thurgau H., 1882, LANDW JB, V11, P751; POLLOCK CJ, 1975, PHYTOCHEMISTRY, V14, P613, DOI 10.1016/0031-9422(75)83003-2; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; Stark DM, 1996, ANN NY ACAD SCI, V792, P26, DOI 10.1111/j.1749-6632.1996.tb32487.x; STITT M, 1989, METHOD ENZYMOL, V174, P518; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIL M, 1990, PLANT PHYSIOL, V94, P1575, DOI 10.1104/pp.94.4.1575; Zrenner R, 1996, PLANTA, V198, P246, DOI 10.1007/BF00206250; ZRENNER R, 1993, THESIS FREIE U BERLI	20	146	175	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					708	711		10.1038/10924	http://dx.doi.org/10.1038/10924			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404166				2022-12-25	WOS:000081296900033
J	Persidis, A				Persidis, A			Arthritis drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material									Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.							Bernacka K, 1969, Reumatologia, V7, P207; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BRANEMARK PI, 1969, ACTA ORTHOP SCAND, V40, P153, DOI 10.3109/17453676908989496; BRANEMARK PI, 1969, ACTA ORTHOP SCAND, V40, P279, DOI 10.3109/17453676908989508; BUCHHOLZ HW, 1969, LANGENBECKS ARCH CHI, V325, P77; Evans CH, 1999, INTERNAL MED, V38, P233, DOI 10.2169/internalmedicine.38.233; Fernandez-Herlihy L, 1970, Lahey Clin Found Bull, V19, P124; GASTON JSH, 1986, ANN RHEUM DIS, V45, P932, DOI 10.1136/ard.45.11.932; Geis GS, 1999, J RHEUMATOL, V26, P31; Golden BD, 1999, RHEUM DIS CLIN N AM, V25, P359, DOI 10.1016/S0889-857X(05)70073-9; Gross DM, 1998, SCIENCE, V281, P703, DOI 10.1126/science.281.5377.703; Kirwan JR, 1999, RHEUMATOLOGY, V38, P100, DOI 10.1093/rheumatology/38.2.100; Laan RFJM, 1999, RHEUMATOLOGY, V38, P6, DOI 10.1093/rheumatology/38.1.6; Lotz M, 1999, RHEUM DIS CLIN N AM, V25, P269, DOI 10.1016/S0889-857X(05)70067-3; Mandell BF, 1999, CLEV CLIN J MED, V66, P285; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; NILAS L, 1986, CLIN ENDOCRINOL, V25, P711, DOI 10.1111/j.1365-2265.1986.tb03627.x; PALOSUO T, 1978, CLIN IMMUNOL IMMUNOP, V10, P355, DOI 10.1016/0090-1229(78)90193-9; Persidis A, 1998, NAT BIOTECHNOL, V16, P882, DOI 10.1038/nbt0998-882; Shin H, 1999, ANN RHEUM DIS, V58, P55, DOI 10.1136/ard.58.1.55; Ushiyama T, 1999, ANN RHEUM DIS, V58, P7, DOI 10.1136/ard.58.1.7; Verhoef CM, 1999, ANN RHEUM DIS, V58, P49, DOI 10.1136/ard.58.1.49; WEDUM BG, 1970, ANN RHEUM DIS, V29, P516, DOI 10.1136/ard.29.5.516; Wendling D, 1999, REV RHUM, V66, P187	24	4	4	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					726	728		10.1038/10954	http://dx.doi.org/10.1038/10954			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409361				2022-12-25	WOS:000081296900037
J	Vlodavsky, I; Friedmann, Y; Elkin, M; Aingorn, H; Atzmon, R; Ishai-Michaeli, R; Bitan, M; Pappo, O; Peretz, T; Michal, I; Spector, L; Pecker, I				Vlodavsky, I; Friedmann, Y; Elkin, M; Aingorn, H; Atzmon, R; Ishai-Michaeli, R; Bitan, M; Pappo, O; Peretz, T; Michal, I; Spector, L; Pecker, I			Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis	NATURE MEDICINE			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; FIBROBLAST GROWTH-FACTOR; HUMAN-PLATELET HEPARITINASE; SULFATED POLYSACCHARIDES; MEDIATED DEGRADATION; LYMPHOMA-CELLS; PROTEOGLYCANS; INVASION; BINDING; MOUSE	Heparan sulfate proteoglycans interact with many extracellular matrix constituents, growth factors and enzymes. Degradation of heparan sulfate by endoglycosidic heparanase cleavage affects a variety of biological processes. We have purified a 50-kDa heparanase from human hepatoma and placenta, and now report cloning of the cDNA and gene encoding this enzyme. Expression of the cloned cDNA in insect and mammalian cells yielded 65-kDa and 50-kDa recombinant heparanase proteins. The 50-kDa enzyme represents an N-terminally processed enzyme, at least 100-fold more active than the 65-kDa form. The heparanase mRNA and protein are preferentially expressed in metastatic cell lines and specimens of human breast, colon and liver carcinomas. Low metastatic murine T-lymphoma and melanoma cells transfected with the heparanase cDNA acquired a highly metastatic phenotype in vivo, reflected by a massive liver and lung colonization. This represents the first cloned mammalian heparanase, to our knowledge, and provides direct evidence for its role in tumor metastasis. Cloning of the heparanase gene enables the development of specific molecular probes for early detection and treatment of cancer metastasis and autoimmune disorders.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Insight, IL-76121 Rehovot, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel.							Bame KJ, 1997, J BIOL CHEM, V272, P2245; BARNER M, 1985, INT J CANCER, V35, P483, DOI 10.1002/ijc.2910350411; BARNER M, 1987, BLOOD, V70, P551; BASHKIN P, 1990, BLOOD, V75, P2204; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DEVOUGE MW, 1994, INT J CANCER, V56, P286, DOI 10.1002/ijc.2910560224; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; GONZALO V, 1999, BIOCHIM BIOPHYS ACTA, V1429, P431; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Graham LD, 1996, BIOCHEM MOL BIOL INT, V39, P563; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JIN L, 1990, INT J CANCER, V45, P1088, DOI 10.1002/ijc.2910450618; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LARIZZA L, 1984, J EXP MED, V160, P1579, DOI 10.1084/jem.160.5.1579; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; NAKAGAWA H, 1988, J NEURO-ONCOL, V6, P157, DOI 10.1007/BF02327392; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; PERETZ T, 1990, INT J CANCER, V45, P1054, DOI 10.1002/ijc.2910450613; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; SOULE HD, 1990, CANCER RES, V50, P6075; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; Vlodavsky I, 1997, TUMOUR ANGIOGENESIS, P125; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Vlodavsky I, 1998, ANTLANGIOGENIC AGENT, P93; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YAHALOM J, 1984, J CLIN INVEST, V74, P1842, DOI 10.1172/JCI111603; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	689	817	1	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					793	802		10.1038/10518	http://dx.doi.org/10.1038/10518			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395325				2022-12-25	WOS:000081926600035
J	Waldo, GS; Standish, BM; Berendzen, J; Terwilliger, TC				Waldo, GS; Standish, BM; Berendzen, J; Terwilliger, TC			Rapid protein-folding assay using green fluorescent protein	NATURE BIOTECHNOLOGY			English	Article						protein folding; solubility; reporter; aggregation directed evolution; green fluorescent protein; inclusion body	MOLECULAR EVOLUTION; DIRECTED EVOLUTION; ESCHERICHIA-COLI; IN-VITRO; EXPRESSION; IDENTIFICATION; CHROMOPHORE; MUTATIONS; FERRITIN; MUTANTS	Formation of the chromophore of green fluorescent protein (GFP) depends on the correct folding of the protein. We constructed a "folding reporter" vector, in which a test protein is expressed as an N-terminal fusion with GFP. Using a test panel of 20 proteins, we demonstrated that the fluorescence of Escherichia coli cells expressing such GFP fusions is related to the productive folding of the upstream protein domains expressed alone. We used this fluorescent indicator of protein folding to evolve proteins that are normally prone to aggregation during expression in E. coli into closely related proteins that ford robustly and are fully soluble and functional. This approach to improving protein folding does not require functional assays for the protein of interest and provides a simple route to improving protein folding and expression by directed evolution.	Univ Calif Los Alamos Natl Lab, Struct Biol Grp, Los Alamos, NM 87545 USA; Univ Calif Los Alamos Natl Lab, Biophys Grp, Los Alamos, NM 87545 USA; Univ New Mexico, Albuquerque, NM 87131 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of New Mexico	Waldo, GS (corresponding author), Univ Calif Los Alamos Natl Lab, Struct Biol Grp, MS-M888, Los Alamos, NM 87545 USA.		Wood, David W/B-2992-2012; Terwilliger, Thomas/AEF-4827-2022; Terwilliger, Thomas/AAM-4079-2020; Terwilliger, Thomas C/K-4109-2012	Terwilliger, Thomas/0000-0001-6384-0320; Terwilliger, Thomas C/0000-0001-6384-0320; Berendzen, Joel/0000-0002-9454-9074				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Arnold FH, 1996, CHEM ENG SCI, V51, P5091, DOI 10.1016/S0009-2509(96)00288-6; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; JAPPELLI R, 1992, J MOL BIOL, V227, P532, DOI 10.1016/0022-2836(92)90905-Y; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; MOOS T, 1993, HISTOCHEMISTRY, V99, P471; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; TERWILLIGER TC, 1994, J MOL BIOL, V236, P556, DOI 10.1006/jmbi.1994.1165; Terwilliger TC, 1998, PROTEIN SCI, V7, P1851, DOI 10.1002/pro.5560070901; WALDO GS, 1996, FERRITIN IRON BIOMIN, P65; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; WILKINSON DL, 1991, BIO-TECHNOL, V9, P443, DOI 10.1038/nbt0591-443; Zhang Y, 1998, PROTEIN EXPRES PURIF, V12, P159, DOI 10.1006/prep.1997.0834; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	31	691	736	7	143	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					691	695		10.1038/10904	http://dx.doi.org/10.1038/10904			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404163				2022-12-25	WOS:000081296900030
J	Yu, X; Waltzer, L; Bienz, M				Yu, X; Waltzer, L; Bienz, M			A new Drosophila APC homologue associated with adhesive zones of epithelial cells	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; SIGNALING ACTIVITY; ZONULA ADHERENS; E-CADHERIN; ARMADILLO; WINGLESS; GENE; EXPRESSION; EMBRYOS	Adenomatous polyposis coil protein (APC) is an important tumour suppressor in the human colon epithelium. In a complex with glycogen synthase kinase-3 (GSK-3), APC binds to and destabilizes cytoplasmic ('free') beta-catenin. Here, using a yeast two-hybrid screen for proteins that bind to the Drosophila beta-catenin homologue, Armadillo, we identify a new Drosophila APC homologue, E-APC. E-APC also binds to Shaggy, the Drosophila GSK-3 homologue. Interference with E-APC function produces embryonic phenotypes like those of shaggy mutants. Interestingly, E-APC is concentrated in apicolateral adhesive zones of epithelial cells, along with Armadillo and E-cadherin, which are both integral components of the adherens junctions in these zones. Various mutant conditions that cause dissociation of E-APC from these zones also obliterate the segmental modulation of free Armadillo levels that is normally induced by Wingless signalling. We propose that the Armadillo-destabilizing protein complex, consisting of E-APC, Shaggy, and a third protein, Axin, is anchored in adhesive zones, and that Wingless signalling may inhibit the activity of this complex by causing dissociation of E-APC from these zones.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Waltzer, Lucas/0000-0002-5361-727X				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; Foe Victoria E., 1993, P149; Grawe F, 1996, DEVELOPMENT, V122, P951; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUST E, 1994, TRENDS GENET, V10, P275, DOI 10.1016/0168-9525(90)90010-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakagawa H, 1998, CANCER RES, V58, P5176; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pai LM, 1997, DEVELOPMENT, V124, P2255; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P681; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yu X, 1996, DEVELOPMENT, V122, P849; YU X, IN PRESS MECH DEV	55	102	104	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					144	151		10.1038/11064	http://dx.doi.org/10.1038/11064			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559900				2022-12-25	WOS:000083102500012
J	Siegfried, Z; Eden, S; Mendelsohn, M; Feng, X; Tsuberi, BZ; Cedar, H				Siegfried, Z; Eden, S; Mendelsohn, M; Feng, X; Tsuberi, BZ; Cedar, H			DNA methylation represses transcription in vivo	NATURE GENETICS			English	Article							CELL-SPECIFIC DEMETHYLATION; GLOBIN GENE-EXPRESSION; CYTOSINE METHYLATION; CPG ISLAND; ACTIVATION; BINDING; SITES	DNA in somatic tissue is characterized by a bimodal pattern of methylation, which is established in the animal through a series of developmental events'. In the mouse blastula, most DNA is unmethylated, but after implantation a wave of de novo methylation modifies most of the genome, excluding the majority of Cpt islands, which are mainly associated with housekeeping genes. This genomic methylation pattern is broadly maintained during the life of the organism by maintenance methylation, and generally correlates with gene expression. Experiments both in vitro(3-5) and in vivo(6-9) indicate that methylation inhibits transcription, It has not yet been possible, however, to determine the role of DNA methylation on specific. sequences during normal development Cis-acting regulatory elements and trans-acting factors appear to be involved in both stage- and tissue-specific demethylation processes(10,11). Spl-like elements have a key role in protecting the CpG island of Aprt (encoding adenine phosphoribosyl transferase) from de novo methylation, and when these elements are specifically mutated, the Aprf CpG island becomes methylated genome, in transgenic mice(12,13) . We have now characterized an embryo-specific element,ment from the CpG island sequence upstream of Aprt that can protect itself from de novo methylation in transgenic mice as well as reduce methylation of flanking sequences. We placed this element on a removable cassette adjacent to a human HBB (encoding P-globin) reporter and generated a transgene whose methylation pattern can be switched in vivo. Analysis of globin transcription in this system showed that methylation in cis inhibits gt,ne expression in a variety of tissues, indicating that DNA modification may serve as a global genomic repressor.	Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Columbia Univ, Sch Med, Ctr Neurobiol & Behav, New York, NY 10032 USA	Hebrew University of Jerusalem; Columbia University	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem, IL-91120 Jerusalem, Israel.	cedar@md2.huji.ac.il						BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HOGAN B, 1986, MANIPULATING MOUSE E, P92; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	28	273	280	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					203	206		10.1038/9727	http://dx.doi.org/10.1038/9727			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369268				2022-12-25	WOS:000080680900031
J	Yamamoto, H; Simon, A; Eriksson, U; Harris, E; Berson, EL; Dryja, TP				Yamamoto, H; Simon, A; Eriksson, U; Harris, E; Berson, EL; Dryja, TP			Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus	NATURE GENETICS			English	Article								The:metabolic pathways that produce Il-cis retinal are important for vision because this retinoid is the chromophore residing in rhodopsin and the tone opsins. The all-trans retinal that is generated after cone and rod photopigments absorb photons of light is recycled back to 11-cis retinal by the retinal pigment epithelium and Muller cells: of the retina. Several of the enzymes involved have:recently been purified and molecularly cloned (1-3);:here we focus on Il-cis retinol dehydrogenase (encoded by the gene RDH5; chromosome 12q13-14; ref. 4), the first cloned enzyme in this pathway. This microsomal enzyme is abundant in the retinal pigment epithelium(5), where it has been proposed to catalyse the conversion of Il-cis retinol to Il-cis retinal. We evaluated patients with hereditary retinal diseases featuring subretinal spots (retinitis punctata albescens and fundus albipunctatus) and patients with typical dominant or recessive retinitis pigmentosa for mutations in RDH5. Mutations were found only in two unrelated patients, both with fundus albipunctatus; they segregated with disease in the respective families. Recombinant mutant Il-cis retinol dehydrogenases had reduced activity compared with recombinant enzyme with wild-type sequence. Our results suggest that mutant alleles in RDH5 are a cause of fundus albipunctatus, a rare form of stationary night blindness characterized by a delay in the regeneration of cone and rod photopigments.	Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenat, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ocular Mol Genet Inst, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA; Ludwig Inst Canc Res, S-10401 Stockholm, Sweden	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Ludwig Institute for Cancer Research	Dryja, TP (corresponding author), Harvard Univ, Sch Med, Berman Gund Lab Study Retinal Degenat, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.	dryja@helix.mgh.harvard.edu		Simon, Andras/0000-0002-1018-1891	NEI NIH HHS [EY00169, EY08683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000169, R01EY008683, R37EY000169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERSON EL, 1968, ARCH OPHTHALMOL-CHIC, V80, P58; BERSON EL, 1976, T AM ACAD OPHTHALMOL, V81, pO659; Carr RE, 1974, DOC OPHTHALMOL P SER, V9, P193; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARMOR MF, 1976, DOC OPHTHAL P SERIES, V13, P227; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; RIPPS H, 1982, INVEST OPHTH VIS SCI, V23, P588; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; Simon A, 1999, J CELL SCI, V112, P549; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023	16	210	226	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					188	191		10.1038/9707	http://dx.doi.org/10.1038/9707			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369264				2022-12-25	WOS:000080680900027
J	Galvez, AF; de Lumen, BO				Galvez, AF; de Lumen, BO			A soybean cDNA encoding a chromatin-binding peptide inhibits mitosis of mammalian cells	NATURE BIOTECHNOLOGY			English	Article						antimitosis; chromatin-binding; soybean peptide; DNA endoreduplication	HUMAN CENTROMERE; CENP-B; PROTEINS; HOMOLOG; SEED; DNA; IDENTIFICATION; KINETOCHORE; EXPRESSION; METAPHASE	A soybean cDNA encoding the small subunit peptide of a cotyledon-specific 2S albumin (Gm2S-1) is thought to play a role in arresting mitosis during the DNA endoreduplication and cell expansion phase of seed development. The peptide (termed lunasin) contains the cell adhesion motif Arg-Gly-Asp (RGD) followed by eight aspartic acid residues at its C-terminal end. A chimeric gene encoding the lunasin peptide tagged with green fluorescent protein (GFP) arrested cell division, caused abnormal spindle fiber elongation, chromosomal fragmentation, and cell lysis when transiently transfected into murine embryo fibroblast, murine hepatoma, and human breast cancer cells. Deletion of the polyaspartyl end abolished the antimitotic effect. Subcellular localization of lunasin and immunobinding assay using synthetic peptides revealed the preferential adherence of lunasin to chromatin. Immunofluorescence showed that kinetochore proteins were displaced from the centromere in lunasin-transfected cells. These observations suggest that lunasin binds to the chromatin, leading to disruption of kinetochore formation and inhibition of mitosis.	Univ Calif Berkeley, Div Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	de Lumen, BO (corresponding author), Univ Calif Berkeley, Div Nutr Sci & Toxicol, Berkeley, CA 94720 USA.							AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; CALVEZ AF, 1997, PLANT PHYSIOL, V114, P1567; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CONCEICAO AD, 1994, PLANT J, V5, P493, DOI 10.1046/j.1365-313X.1994.05040493.x; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; GOODWIN GH, 1978, CELL NUCLEUS, V6, P181; HAUXWELL AJ, 1990, DEVELOPMENT, V110, P283; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Higgins T. J. V., 1981, COMMENTARIES PLANT S, V2, P175; KENNEDY AR, 1995, J NUTR, V125, pS733, DOI 10.1093/jn/125.3_Suppl.733S; Lee JK, 1997, P NATL ACAD SCI USA, V94, P8427, DOI 10.1073/pnas.94.16.8427; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANIATIS T, 1982, MOL CLONING LABORATO, P368; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; ODANI S, 1987, J BIOL CHEM, V262, P10502; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SCHWEIZER L, 1995, P NATL ACAD SCI USA, V92, P7070, DOI 10.1073/pnas.92.15.7070; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; Wilson Leslie, 1994, V13, P59; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	30	108	119	1	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					495	500		10.1038/8676	http://dx.doi.org/10.1038/8676			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331812				2022-12-25	WOS:000080074500037
J	Waterman-Storer, CM; Worthylake, RA; Liu, BP; Burridge, K; Salmon, ED				Waterman-Storer, CM; Worthylake, RA; Liu, BP; Burridge, K; Salmon, ED			Microtubule growth activates Rac1 to promote lamellipodial profusion in fibroblasts	NATURE CELL BIOLOGY			English	Article							ACTIN STRESS FIBERS; CELL LOCOMOTION; PSEUDOPODIAL ACTIVITY; FOCAL ADHESIONS; RHO; MEMBRANE; GTPASES; FLOW; DEPOLYMERIZATION; POLYMERIZATION	Microtubules are involved in actin-based protrusion at the leading-edge lamellipodia of migrating fibroblasts. Here we show that the growth of microtubules induced in fibroblasts by removal of the microtubule destabilizer nocodazole activates Rad GTPase, leading to the polymerization of actin in lamellipodial protrusions. Lamellipodial protrusions are also activated by the rapid growth of a disorganized array of very short microtubules induced by the microtubule-stabilizing drug taxol. Thus, neither microtubule shortening nor long-range microtubule-based intracellular transport is required for activating protrusion. We suggest that the growth phase of microtubule dynamic instability at leading-edge lamellipodia locally activates Rad to drive actin polymerization and lamellipodial protrusion required for cell migration.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell Biol Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Waterman-Storer, CM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.			Waterman, Clare/0000-0001-6142-6775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024364] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BERSHADSKY AD, 1991, CELL MOTIL CYTOSKEL, V19, P152, DOI 10.1002/cm.970190303; Best A, 1996, J BIOL CHEM, V271, P3756; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Fernandez JA, 1999, J BIOL CHEM, V274, P1401, DOI 10.1074/jbc.274.3.1401; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; LIAO GJ, 1995, J CELL SCI, V108, P3473; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Salmon ED, 1998, METHOD CELL BIOL, V56, P185, DOI 10.1016/S0091-679X(08)60427-6; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; VASILIEV JM, 1991, J CELL SCI, V98, P1; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415	36	389	393	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					45	50		10.1038/9018	http://dx.doi.org/10.1038/9018			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559863				2022-12-25	WOS:000083085300017
J	Hu, ZL; Bonifas, JM; Beech, J; Bench, G; Shigihara, T; Ogawa, H; Ikeda, S; Mauro, T; Epstein, EH				Hu, ZL; Bonifas, JM; Beech, J; Bench, G; Shigihara, T; Ogawa, H; Ikeda, S; Mauro, T; Epstein, EH			Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease	NATURE GENETICS			English	Article							YEAST SECRETORY PATHWAY; IDENTIFICATION; GENE; CHROMOSOME; RETICULUM; GOLGI; PMR1; DIFFERENTIATION; TRANSPORT; PEMPHIGUS	Hailey-Hailey disease (HHD, MIM 16960) is inherited in an autosomal dominant manner and characterized by persistent blisters and erosions of the skin(1). Impaired intercellular adhesion and epidermal blistering also occur in individuals with pemphigus (which is due to autoantibodies directed against desmosomal proteins) and in patients with Darier disease (DD, MIM 124200), which is caused by mutations in a gene encoding a sarco/endoplasmic reticulum (ER)-Golgi calcium pump(2). We report here the identification of mutations in ATP2C1, encoding the human homologue of an ATP-powered pump that sequesters calcium into the Golgi in yeast, in 21 HHD kindreds. Regulation of cytoplasmic calcium is impaired in cultured keratinocytes from HHD patients, and the normal epidermal calcium gradient is attenuated in vivo in HHD patients. Our findings not only provide an understanding of the molecular basis of HHD, but also underscore the importance of calcium control to the functioning of stratified squamous epithelia.	San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Dermatol, VA Med Ctr, San Francisco, CA 94143 USA; Univ Calif Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94550 USA; Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 113, Japan	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Juntendo University	Epstein, EH (corresponding author), San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA.			Bench, Graham/0000-0002-1969-6867; hu, zhilan/0000-0003-2925-5595	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043119, R29AR044341] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43119, AR44341] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amagai M, 1996, J INVEST DERMATOL, V107, P539, DOI 10.1111/1523-1747.ep12582796; Amar LS, 1999, CELL ADHES COMMUN, V7, P125, DOI 10.3109/15419069909034396; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; BERTELLI A, 1994, DRUG EXP CLIN RES, V20, P7; BUNSE T, 1991, ACTA DERM-VENEREOL, V71, P287; BURGE SM, 1992, BRIT J DERMATOL, V126, P275, DOI 10.1111/j.1365-2133.1992.tb00658.x; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; Christiano AM, 1997, HUM MUTAT, V10, P408, DOI 10.1002/(SICI)1098-1004(1997)10:5<408::AID-HUMU12>3.3.CO;2-B; Elias PM, 1998, J INVEST DERMATOL, V110, P399, DOI 10.1046/j.1523-1747.1998.00151.x; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; IKEDA S, 1994, HUM MOL GENET, V3, P1147, DOI 10.1093/hmg/3.7.1147; IKEDA S, 1991, J INVEST DERMATOL, V97, P644, DOI 10.1111/1523-1747.ep12483596; KAUFMAN RJ, 1994, BIOCHEMISTRY-US, V33, P9813, DOI 10.1021/bi00199a001; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; Mauro T, 1998, J INVEST DERMATOL, V111, P1198, DOI 10.1046/j.1523-1747.1998.00421.x; Mauro T, 1997, J INVEST DERMATOL, V108, P864, DOI 10.1111/1523-1747.ep12292585; ODA K, 1992, J BIOL CHEM, V267, P17465; PELUSO AM, 1995, GENOMICS, V30, P77; RESING KA, 1993, J BIOL CHEM, V268, P25139; Richards L, 1995, STUDIES QUALITATIVE, V5, P105; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sorin A, 1997, J BIOL CHEM, V272, P9895; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453	27	393	427	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					61	65		10.1038/71701	http://dx.doi.org/10.1038/71701			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615129				2022-12-25	WOS:000084609200017
J	Li, J; Post, M; Volk, R; Gao, Y; Li, M; Metais, C; Sato, K; Tsai, J; Aird, W; Rosenberg, RD; Hampton, TG; Li, JY; Sellke, F; Carmeliet, P; Simons, M				Li, J; Post, M; Volk, R; Gao, Y; Li, M; Metais, C; Sato, K; Tsai, J; Aird, W; Rosenberg, RD; Hampton, TG; Li, JY; Sellke, F; Carmeliet, P; Simons, M			PR39, a peptide regulator of angiogenesis	NATURE MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; ANTIMICROBIAL PEPTIDE; ISCHEMIC-HEART; IN-VITRO; EXPRESSION; HYPOXIA; PR-39; GENE; THERMOTOLERANCE	Although tissue injury and inflammation are considered essential for the induction of angiogenesis, the molecular controls of this cascade are mostly unknown. Here we show that a macrophage-derived peptide, PR39, inhibited the ubiquitin-proteasome-dependent degradation of hypoxia-inducible factor-1 alpha protein, resulting in accelerated formation of vascular structures in vitro and increased myocardial vasculature in mice. For the latter, coronary flow studies demonstrated that PR39-induced angiogenesis resulted in the production of functional blood vessels. These findings show that PR39 and related compounds can be used as potent inductors of angiogenesis, and that selective inhibition of hypoxia-inducible factor-la degradation may underlie the mechanism of inflammation-induced angiogenesis.	Beth Israel Deaconess Med Ctr, Dept Surg, Angiogenesis Res Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Div Hematol & Mol Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Catholic Univ Louvain, B-3000 Louvain, Belgium	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Universite Catholique Louvain	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, Angiogenesis Res Ctr, Boston, MA 02215 USA.	msimons@caregroup.harvard.edu	Carmeliet, Peter/AAQ-5140-2020; Simons, Michael/G-8553-2014	Carmeliet, Peter/0000-0001-7961-1821; Simons, Michael/0000-0003-0348-7734	NHLBI NIH HHS [HL 46716, R01 HL53793, P50 HL 56993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, R01HL053793, R01HL046716, R29HL046716] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Arras M, 1998, BASIC RES CARDIOL, V93, P97, DOI 10.1007/s003950050069; Bein K, 1997, J CELL PHYSIOL, V173, P319, DOI 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q; Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4; Bush KT, 1997, J BIOL CHEM, V272, P9086; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1998, NATURE, V395, P525, DOI 10.1038/26791; Chan YR, 1998, J BIOL CHEM, V273, P28978, DOI 10.1074/jbc.273.44.28978; Dhanabal M, 1999, CANCER RES, V59, P189; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; GUDMUNDSSON GH, 1995, P NATL ACAD SCI USA, V92, P7085, DOI 10.1073/pnas.92.15.7085; Guillot PV, 1999, J CLIN INVEST, V103, P799, DOI 10.1172/JCI6017; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Li J, 1997, J CLIN INVEST, V100, P18, DOI 10.1172/JCI119510; Li JA, 1997, CIRC RES, V81, P785; Martin C, 1998, AM J OBSTET GYNECOL, V178, P527, DOI 10.1016/S0002-9378(98)70433-8; MAULIK N, 1995, CARDIOVASC RES, V30, P593, DOI 10.1016/0008-6363(95)00093-3; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; PASSANITI A, 1992, LAB INVEST, V67, P519; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sellke FW, 1996, SURGERY, V120, P182, DOI 10.1016/S0039-6060(96)80286-8; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; SUNDERKOTTER C, 1991, PHARMACOL THERAPEUT, V51, P195, DOI 10.1016/0163-7258(91)90077-Y; Ware JA, 1997, NAT MED, V3, P158, DOI 10.1038/nm0297-158	35	315	368	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					49	55		10.1038/71527	http://dx.doi.org/10.1038/71527			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613823				2022-12-25	WOS:000084583300034
J	Dyck, MK; Gagne, D; Ouellet, M; Senechal, JF; Belanger, E; Lacroix, D; Sirard, MA; Pothier, F				Dyck, MK; Gagne, D; Ouellet, M; Senechal, JF; Belanger, E; Lacroix, D; Sirard, MA; Pothier, F			Seminal vesicle production and secretion of growth hormone into seminal fluid	NATURE BIOTECHNOLOGY			English	Article						transgenic mice; agriculture; genetic engineering; bioreactor	BINDING-PROTEINS; TRANSGENE EXPRESSION; REGULATED EXPRESSION; PROTEASE INHIBITOR; ACROSIN INHIBITOR; BOAR SPERMATOZOA; HEPARIN-BINDING; MAMMARY-GLAND; PLASMA; PROMOTER	Production of foreign proteins in the tissues of transgenic animals represents an efficient and economical method of producing therapeutic and pharmaceutical proteins. In this study, we demonstrate that the mouse P12 gene promoter specific to the male accessory sex gland can be used to generate transgenic mice that express human growth hormone (hGH) in their seminal vesicle epithelium. The hGH is secreted into the ejaculated seminal fluids with the seminal vesicle lumen contents containing concentrations of up to 0.5 mg/ml. As semen is a body fluid that can be collected easily on a continuous basis, the production of transgenic animals expressing pharmaceutical proteins into their seminal fluid could prove to be a viable alternative to use of the mammary gland as a bioreactor.	Univ Laval, Ctr Rech Biol Reprod, Dept Anim Sci, St Foy, PQ G1K 7P4, Canada	Laval University	Pothier, F (corresponding author), Univ Laval, Ctr Rech Biol Reprod, Dept Anim Sci, Pavillon Paul Comtois, St Foy, PQ G1K 7P4, Canada.		Sirard, Marc/A-9112-2011	Sirard, Marc Andre/0000-0001-8667-6682				Anderson L. L., 1993, P343; BREM G, 1989, MOL BIOL MED, V6, P531; Calvete JJ, 1997, FEBS LETT, V407, P201, DOI 10.1016/S0014-5793(97)00344-X; CECHOVA D, 1981, METHOD ENZYMOL, V80, P729; CECIM M, 1995, BIOL REPROD, V52, P1144, DOI 10.1095/biolreprod52.5.1144; Cerdan MG, 1998, MOL REPROD DEV, V49, P236, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;236::AID-MRD3&gt;3.0.CO;2-P; Chen LL, 1998, BIOL REPROD, V59, P1498, DOI 10.1095/biolreprod59.6.1498; EVANGELLSTA DJ, 1997, J CHROMATOGR B, V699, P383; Eyestone WH, 1999, TRANSGENIC ANIMALS IN AGRICULTURE, P177; Fink E, 1976, Methods Enzymol, V45, P825; Fritz H, 1976, Methods Enzymol, V45, P834; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; Hogan B, 1994, MANIPULATING MOUSE E; Houdebine LM, 1995, REPROD NUTR DEV, V35, P609, DOI 10.1051/rnd:19950601; HUHTALA ML, 1984, H-S Z PHYSIOL CHEM, V365, P819, DOI 10.1515/bchm2.1984.365.2.819; JANNE J, 1994, INT J BIOCHEM, V26, P859, DOI 10.1016/0020-711X(94)90078-7; Kerr DE, 1998, NAT BIOTECHNOL, V16, P75, DOI 10.1038/nbt0198-75; MELOUN B, 1983, H-S Z PHYSIOL CHEM, V364, P1665, DOI 10.1515/bchm2.1983.364.2.1665; MILLS JS, 1987, NUCLEIC ACIDS RES, V15, P7709, DOI 10.1093/nar/15.19.7709; MILLS JS, 1987, EMBO J, V6, P3711, DOI 10.1002/j.1460-2075.1987.tb02705.x; MOOS J, 1992, MOL REPROD DEV, V33, P165, DOI 10.1002/mrd.1080330208; NEEDHAM M, 1988, NUCLEIC ACIDS RES, V16, P6229, DOI 10.1093/nar/16.13.6229; PARRY RV, 1992, MOL REPROD DEV, V33, P108, DOI 10.1002/mrd.1080330115; Pursel V G, 1990, J Reprod Fertil Suppl, V40, P235; Rosen Jeffrey M., 1996, American Journal of Clinical Nutrition, V63, p627S; SANZ L, 1993, MOL REPROD DEV, V35, P37, DOI 10.1002/mrd.1080350107; Setchell B.P., 1988, P753; SWANSON ME, 1992, BIO-TECHNOL, V10, P557, DOI 10.1038/nbt0592-557; TSCHESCHE H, 1982, EUR J BIOCHEM, V126, P99, DOI 10.1111/j.1432-1033.1982.tb06752.x; Wall RJ, 1997, J DAIRY SCI, V80, P2213, DOI 10.3168/jds.S0022-0302(97)76170-8; WILKINSON HA, 1992, CLIN J PAIN, V8, P49, DOI 10.1097/00002508-199203000-00010; 1999, SPERMNOTES MINITUBE, V3, P1	33	25	29	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1087	1090		10.1038/15067	http://dx.doi.org/10.1038/15067			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545914				2022-12-25	WOS:000083428000025
J	Miller, HI				Miller, HI			Substantial equivalence: Its uses and abuses	NATURE BIOTECHNOLOGY			English	Editorial Material																		[Anonymous], 1992, Nature, V356, P1; [Anonymous], 1992, FED REG, V57, p[22, 984, 988, 991]; [Anonymous], 1993, SAFETY EVALUATION FO; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MACKENZIE D, 1999, NEWS SCI        0417; Masood E, 1999, NATURE, V398, P98, DOI 10.1038/18086; Millstone E, 1999, NATURE, V401, P525, DOI 10.1038/44006; 1986, RECOMBINANT DNA SAFE; 1989, FIELD TESTING GENETI; 1998, OECD WORKSH TOX NUTR	10	24	26	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1042	1043		10.1038/14987	http://dx.doi.org/10.1038/14987			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545866				2022-12-25	WOS:000083428000003
J	Rangel-Aldao, R				Rangel-Aldao, R			International agbio consortium takes shape in Beijing	NATURE BIOTECHNOLOGY			English	Editorial Material									Empresas Polar, Ctr Tecnol Polar, Caracas, Venezuela		Rangel-Aldao, R (corresponding author), Empresas Polar, Ctr Tecnol Polar, Caracas, Venezuela.								0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1044	1044		10.1038/14988	http://dx.doi.org/10.1038/14988			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545867	Bronze			2022-12-25	WOS:000083428000004
J	Rodriguez, A; Regnault, A; Kleijmeer, M; Ricciardi-Castagnoli, P; Amigorena, S				Rodriguez, A; Regnault, A; Kleijmeer, M; Ricciardi-Castagnoli, P; Amigorena, S			Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells	NATURE CELL BIOLOGY			English	Article							EXOGENOUS SOLUBLE-ANTIGEN; MOLECULES; COMPLEX; MACROPHAGES; MACROPINOCYTOSIS; PHAGOCYTOSIS; EXPRESSION; PROTEINS; IMMUNITY; RECEPTOR	In order for cytotoxic T cells to initiate immune responses, peptides derived from internalized antigens must be presented to the cytotoxic T cells on major histocompatibility complex (MHC) class I molecules. Here we show that dendritic cells, the only antigen-presenting cells that initiate immune responses efficiently, have developed a unique membrane transport pathway linking the lumen of endocytic compartments and the cytosol, Endosome-to-cytosol transport is restricted to dendritic cells, specific to internalized antigens and selective for the size of the transported molecules. Thus, in dendritic cells, internalized antigens gain access to the cytosolic antigen-processing machinery and to the conventional MHC class I antigen-presentation pathway.	Inst Curie, INSERM, U520, Sect Rech, F-75005 Paris, France; Biomembrane Inst, UMC, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Milano Bicocca, Dept Biosci & Biotechnol, I-20126 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Milano-Bicocca	Amigorena, S (corresponding author), Inst Curie, INSERM, U520, Sect Rech, F-75005 Paris, France.		Castagnoli, Paola/E-8288-2010; REGNAULT, Armelle/G-4142-2011	REGNAULT, Armelle/0000-0001-7286-9491; Amigorena, Sebastian/0000-0001-8583-8416; Rodriguez, Ana/0000-0002-0060-3405				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Bachmann MF, 1996, EUR J IMMUNOL, V26, P2595, DOI 10.1002/eji.1830261109; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; DRAKE JR, 1989, J IMMUNOL, V143, P1768; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Germain RN, 1996, IMMUNOL REV, V151, P5, DOI 10.1111/j.1600-065X.1996.tb00701.x; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; Huang AYC, 1996, IMMUNITY, V4, P349, DOI 10.1016/S1074-7613(00)80248-4; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Mitchell DA, 1998, EUR J IMMUNOL, V28, P1923, DOI 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Oh YK, 1997, VACCINE, V15, P511, DOI 10.1016/S0264-410X(97)00221-1; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Prina E, 1996, J IMMUNOL, V156, P4318; RAPOSO G, 1997, WEIRS HDB EXPT IMMUN, P1; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rescigno M, 1998, P NATL ACAD SCI USA, V95, P5229, DOI 10.1073/pnas.95.9.5229; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; SHASTRI N, 1993, J IMMUNOL, V150, P2724; Shen ZH, 1997, J IMMUNOL, V158, P2723; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; SOUSA CRE, 1995, J EXP MED, V182, P841, DOI 10.1084/jem.182.3.841; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; YEWDELL J, IN PRESS ADV IMMUNOL	33	452	465	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					362	368		10.1038/14058	http://dx.doi.org/10.1038/14058			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559964				2022-12-25	WOS:000083169800020
J	Sidow, A; Bulotsky, MS; Kerrebrock, AW; Birren, BW; Altshuler, D; Jaenisch, R; Johnson, KR; Lander, ES				Sidow, A; Bulotsky, MS; Kerrebrock, AW; Birren, BW; Altshuler, D; Jaenisch, R; Johnson, KR; Lander, ES			A novel member of the F-box/WD40 gene family, encoding dactylin, is disrupted in the mouse dactylaplasia mutant	NATURE GENETICS			English	Article							APICAL ECTODERMAL RIDGE; F-BOX; UBIQUITIN-LIGASE; LIMB; PROTEOLYSIS; MUTATION; COMPLEX; LOCUS; RNA	Early outgrowth of the vertebrate embryonic limb requires signalling by the apical ectodermal ridge (AER) to the progress zone (PZ), which in response proliferates and lays down the pattern of the presumptive limb in a proximal to distal progression(1). Signals from the PZ maintain the AER until the anlagen for the distal phalanges have been formed(2). The semidominant mouse mutant dactylaplasia (Dac) disrupts the maintenance of the AER, leading to truncation of distal structures of the developing footplate, or autopod(3-5). Adult Dac homozygotes thus lack hands and feet except for malformed single digits, whereas heterozygotes lack phalanges of the three middle digits. Dac resembles the human autosomal dominant split hand/foot malformation (SHFM) diseases. One of these, SHFM3, maps to chromosome 10q24 (refs 6,7), which is syntenic to the Dac region on chromosome 19, and may disrupt the orthologue of Dac. We report here the positional cloning of Dac and show that it belongs to the F-box/WD40 gene family, which encodes adapters that target specific proteins for destruction by presenting them to the ubiquitination machinery(8). In conjuction with recent biochemical studies(9-12), this report demonstrates the importance of this gene family in vertebrate embryonic development.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Jackson Laboratory	Sidow, A (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, R248B, Stanford, CA 94305 USA.		Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107				Altabef M, 1997, DEVELOPMENT, V124, P4547; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CHAI CK, 1981, J HERED, V72, P234, DOI 10.1093/oxfordjournals.jhered.a109486; Crackower M, 1998, DEV BIOL, V201, P78, DOI 10.1006/dbio.1998.8938; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; Ji W, 1994, PCR Methods Appl, V4, P109; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Loomis CA, 1998, DEVELOPMENT, V125, P1137; LYONS KM, 1990, DEVELOPMENT, V109, P833; McKusick V.A., 1998, MENDELIAN INHERITANC; Michaud JL, 1997, DEVELOPMENT, V124, P1453; NUNES ME, 1995, HUM MOL GENET, V4, P2165, DOI 10.1093/hmg/4.11.2165; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAUNDERS JW, 1963, DEV BIOL, V7, P64, DOI 10.1016/0012-1606(63)90107-6; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; WOLF DA, IN PRESS CURR BIOL; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	80	83	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					104	107		10.1038/12709	http://dx.doi.org/10.1038/12709			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471509				2022-12-25	WOS:000082337300026
J	Syvanen, M				Syvanen, M			In search of horizontal gene transfer	NATURE BIOTECHNOLOGY			English	Editorial Material							DNA; TRANSFORMATION; MICE		Univ Calif Davis, Sch Med, Dept Microbiol & Immunol, Davis, CA 95616 USA	University of California System; University of California Davis	Syvanen, M (corresponding author), Univ Calif Davis, Sch Med, Dept Microbiol & Immunol, Davis, CA 95616 USA.							de Vries J, 1998, MOL GEN GENET, V257, P606, DOI 10.1007/s004380050688; Gebhard F, 1998, APPL ENVIRON MICROB, V64, P1550; SCHLUTER K, 1995, BIO-TECHNOL, V13, P1094, DOI 10.1038/nbt1095-1094; Schubbert R, 1998, MOL GEN GENET, V259, P569, DOI 10.1007/s004380050850; Schubbert R, 1997, P NATL ACAD SCI USA, V94, P961, DOI 10.1073/pnas.94.3.961; *US FOOD DRUG ADM, 1995, FDAS POL FOODS DEV B	6	18	19	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					833	833		10.1038/12781	http://dx.doi.org/10.1038/12781			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471904				2022-12-25	WOS:000082365800004
J	Bowles, J; Cooper, L; Berkman, J; Koopman, P				Bowles, J; Cooper, L; Berkman, J; Koopman, P			Sry requires a CAG repeat domain for male sex determination in Mus musculus	NATURE GENETICS			English	Article							DETERMINING REGION; DETERMINING GENE; DNA; MOUSE; MICE; REVERSAL; PROTEINS; EXPRESSION; EVOLUTION; LOCUS	SRY, the mammalian Y-chromosomal sex-determining gene(1-3) encodes a protein characterized by a DNA-binding and -bending domain referred to as the HMG box(4,5). Despite the pivotal role of this gene, only the HMG box region has been conserved through evolution(6,7), suggesting that SRY function depends solely on the HMG box and therefore acts as an architectural transcription factors. In mice (genus Mus) Sry also includes a large CAG trinucleotide repeat region encoding a carboxy-terminal glutamine-rich domain that acts as a transcriptional trans-activator in vitro(9). The absence of this or any other potential trans-activating domain in other mammals(1,9), however, has raised doubts as to its biological relevance. To test directly whether the glutamine-rich region is required for Sry function in vivo, we created truncation mutations of the Mus musculus musculus Sry gene and tested their ability to induce testis formation in XX embryos using a transgenic mouse assay. Sry constructs that encode proteins lacking the glutamine-rich region were unable to effect male sex determination, in contrast to their wild-type counterparts. We conclude that the glutamine-rich repeat domain of the mouse Sry protein has an essential role in sex determination in vivo, and that Sry may act via a fundamentally different biochemical mechanism in mice compared with other mammals.	Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia	University of Queensland	Koopman, P (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia.	p.koopman@cmcb.uq.edu.au	Koopman, Peter A/C-9416-2009; Bowles, Josephine/AAG-4903-2020; Bowles, Josephine/B-6583-2013	Koopman, Peter A/0000-0001-6939-0914; Bowles, Josephine/0000-0003-2867-7438; Bowles, Josephine/0000-0003-2867-7438				Albrecht KH, 1997, GENETICS, V147, P1267; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Eicher EM, 1995, PHILOS T R SOC B, V350, P263, DOI 10.1098/rstb.1995.0160; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; LATCHMAN DS, 1998, EUKARYOTIC TRANSCRIP; Lau YFC, 1998, CYTOGENET CELL GENET, V80, P128, DOI 10.1159/000014968; MANN JR, 1993, METHOD ENZYMOL, V225, P771; MILLER KE, 1995, MAMM GENOME, V6, P206, DOI 10.1007/BF00293015; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	30	105	108	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					405	408		10.1038/11981	http://dx.doi.org/10.1038/11981			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431249				2022-12-25	WOS:000081772500027
J	Chaerle, L; Van Caeneghem, W; Messens, E; Lambers, H; Van Montagu, M; Van Der Straeten, D				Chaerle, L; Van Caeneghem, W; Messens, E; Lambers, H; Van Montagu, M; Van Der Straeten, D			Presymptomatic visualization of plant-virus interactions by thermography	NATURE BIOTECHNOLOGY			English	Article						infrared thermography; plant-pathogen interaction; respiration; salicylic acid; TMV tobacco; transpiration	TOBACCO MOSAIC-VIRUS; SYSTEMIC ACQUIRED-RESISTANCE; SALICYLIC-ACID; INFECTED TOBACCO; GENE-EXPRESSION; INDUCTION; SIGNAL; HYDROXYLASE; TEMPERATURE; RESPIRATION	Salicylic acid (SA), produced by plants as a signal in defense against pathogens, induces metabolic heating mediated by alternative respiration in flowers of thermogenic plants, and, when exogenously applied, increases leaf temperature in nonthermogenic plants. We have postulated that the latter phenomenon would be detectable when SA is synthesized locally in plant leaves. Here, resistance to tobacco mosaic virus (TMV) was monitored thermographically before any disease symptoms became visible on tobacco leaves. Spots of elevated temperature that were confined to the place of infection increased in intensity from 8 h before the onset of visible cell death, and remained detectable as a halo around the ongoing necrosis. Salicylic acid accumulates during the prenecrotic phase in TMV-infected tobacco and is known to induce stomatal closure in certain species. We show that the time course of SA accumulation correlates with the evolution of both localized thermal effect and stomatal closure. Since the contribution of leaf respiration is marginal, we concluded that the thermal effect results predominantly from localized, SA-induced stomatal closure. The presymptomatic temperature increase could be of general significance in incompatible plant-pathogen interactions.	State Univ Ghent VIB, Dept Plantengenet, Genet Lab, B-9000 Ghent, Belgium; Univ Western Australia, Fac Agr, Nedlands, WA 6907, Australia; Univ Utrecht, Dept Plant Ecol & Evolutionary Biol, NL-3584 CA Utrecht, Netherlands	Flanders Institute for Biotechnology (VIB); Ghent University; University of Western Australia; Utrecht University	Van Der Straeten, D (corresponding author), State Univ Ghent VIB, Dept Plantengenet, Genet Lab, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	dostr@gengenp.rug.ac.be	Lambers, Hans/A-1544-2008; Van Der Straeten, Dominique/E-7385-2016	Lambers, Hans/0000-0002-4118-2272; Van Der Straeten, Dominique/0000-0002-7755-1420				Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; Breidenbach RW, 1997, PLANT PHYSIOL, V114, P1137, DOI 10.1104/pp.114.4.1137; Chivasa S, 1997, PLANT CELL, V9, P547, DOI 10.1105/tpc.9.4.547; Chivasa S, 1998, PLANT CELL, V10, P1489, DOI 10.1105/tpc.10.9.1489; Day DA, 1996, PLANT PHYSIOL, V110, P1, DOI 10.1104/pp.110.1.1; DECAROLIS C, 1975, P 10 INT S REM SENS, P659; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Friedrich L, 1995, PLANT MOL BIOL, V29, P959, DOI 10.1007/BF00014969; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; LARQUESAAVEDRA A, 1979, Z PFLANZENPHYSIOL, V93, P371, DOI 10.1016/S0044-328X(79)80271-8; Lennon AM, 1997, PLANT PHYSIOL, V115, P783, DOI 10.1104/pp.115.2.783; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; LIANG P, 1997, METHODS MOL BIOL, V85; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MANTHE B, 1992, J CHEM ECOL, V18, P1525, DOI 10.1007/BF00993226; MCNULTY AK, 1987, PLANT CELL ENVIRON, V10, P319, DOI 10.1111/j.1365-3040.1987.tb01612.x; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Mur LAJ, 1997, PLANT J, V12, P1113, DOI 10.1046/j.1365-313X.1997.12051113.x; NILLSSON HE, 1995, ANNU REV PHYTOPATHOL, V15, P489; RASKIN I, 1989, P NATL ACAD SCI USA, V86, P2214, DOI 10.1073/pnas.86.7.2214; RASKIN I, 1988, PLANTA, V173, P73, DOI 10.1007/BF00394490; *SAS I INC, 1992, P229 SAS I INC; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; Van Der Straeten D, 1995, PLANTA, V196, P412, DOI 10.1007/BF00203637; Weyers J. D. B., 1990, METHODS STOMATAL RES; WHENHAM RJ, 1981, PHYSIOL PLANT PATHOL, V18, P267; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	29	116	127	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					813	816		10.1038/11765	http://dx.doi.org/10.1038/11765			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429250				2022-12-25	WOS:000081751400034
J	Waisfisz, Q; Morgan, NV; Savino, M; de Winter, JP; van Berkel, CGM; Hoatlin, ME; Ianzano, L; Gibson, RA; Arwert, F; Savoia, A; Mathew, CG; Pronk, JC; Joenje, H				Waisfisz, Q; Morgan, NV; Savino, M; de Winter, JP; van Berkel, CGM; Hoatlin, ME; Ianzano, L; Gibson, RA; Arwert, F; Savoia, A; Mathew, CG; Pronk, JC; Joenje, H			Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism	NATURE GENETICS			English	Article							GROUP-A; SALMONELLA-TYPHIMURIUM; ALKYLATING-AGENTS; GENETIC-DEFECT; ANEMIA; MUTATIONS; HISD3052; LOCUS; CELLS	Somatic mosaicism due to reversion of a pathogenic allele to wild type has been described in several autosomal recessive disorders(1-6), The best known mechanism involves intragenic mitotic recombination or gene conversion in compound heterozygous patients, whereby one allele serves to restore the wild-type sequence in the other. Here we document for the first time functional correction of a pathogenic microdeletion, microinsertion and missense mutation in homozygous Fanconi anaemia(7) (FA) patients resulting from compensatory secondary sequence alterations in cis, The frameshift mutation 1615delG in FANCA was compensated by two additional single base-pair deletions (1637delA and 1641delT); another FANCA frameshift mutation, 3559insG, was compensated by 3580insCGCTG; and a missense mutation in FANCC (1749T-->G, Leu496Arg) was altered by 1748C-->T, creating a cysteine codon. Although in all three cases the predicted proteins were different from wild type, their cDNAs complemented the characteristic hypersensitivity of FA cells to crosslinking agents, thus establishing a functional correction to wild type.	Free Univ Amsterdam, Dept Clin Genet & Human Genet, NL-1081 BT Amsterdam, Netherlands; UMDS, Guys Hosp, Kings & St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England; Osped CSS, IRCCS, Serv Genet Med, I-71013 San Giovanni Rotondo, Italy; Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA	Vrije Universiteit Amsterdam; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; IRCCS Casa Sollievo Della Sofferenza; Oregon Health & Science University	Joenje, H (corresponding author), Free Univ Amsterdam, Dept Clin Genet & Human Genet, Vander Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Mathew, Christopher G/G-3434-2015; Savoia, Anna/B-6463-2014; Morgan, Neil V/A-5475-2009; Savoia, Anna/AIC-4560-2022	Mathew, Christopher G/0000-0003-4178-1838; Savoia, Anna/0000-0002-2407-2696; Morgan, Neil V/0000-0001-6433-5692; Savoia, Anna/0000-0002-2407-2696; Gibson, Rachel/0000-0002-1338-1290; Waisfisz, Quinten/0000-0002-7384-9182	NHLBI NIH HHS [HL56045] Funding Source: Medline; Telethon [E.0688] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056045, R01HL056045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ariga T, 1998, BLOOD, V92, P699, DOI 10.1182/blood.V92.2.699; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; DeMarini DM, 1998, GENETICS, V149, P17; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; Gibson RA, 1996, HUM MUTAT, V8, P140, DOI 10.1002/(SICI)1098-1004(1996)8:2<140::AID-HUMU6>3.0.CO;2-F; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; HOATLIN ME, 1987, J VIROL, V61, P144; ISHIDA R, 1982, CANCER RES, V42, P4000; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Jonkman MF, 1997, CELL, V88, P543, DOI 10.1016/S0092-8674(00)81894-2; Kruyt FAE, 1997, BLOOD, V90, P3288, DOI 10.1182/blood.V90.9.3288; Kruyt FAE, 1996, BLOOD, V87, P938, DOI 10.1182/blood.V87.3.938.bloodjournal873938; KVITTINGEN EA, 1994, J CLIN INVEST, V94, P1657, DOI 10.1172/JCI117509; KWEE ML, 1983, HUM GENET, V64, P384, DOI 10.1007/BF00292372; Lo Ten Foe J R, 1997, EUR J HUM GENET, V5, P137; OHARA SM, 1991, MUTAT RES, V247, P45, DOI 10.1016/0027-5107(91)90032-J; Savino M, 1997, AM J HUM GENET, V61, P1246, DOI 10.1086/301632; Savoia A, 1996, HUM GENET, V97, P599; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; von Borstel RC, 1998, GENETICS, V148, P1647; Wijker M, 1999, EUR J HUM GENET, V7, P52, DOI 10.1038/sj.ejhg.5200248; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	24	156	159	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					379	383		10.1038/11956	http://dx.doi.org/10.1038/11956			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431244				2022-12-25	WOS:000081772500022
J	Chowdhury, PS; Pastan, I				Chowdhury, PS; Pastan, I			Improving antibody affinity by mimicking somatic hypermutation in vitro	NATURE BIOTECHNOLOGY			English	Article						phage display; single-chain antibody; hot spots; affinity improvement	SINGLE-CHAIN FV; PHAGE DISPLAY; RECOMBINANT IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; ANTITUMOR-ACTIVITY; BREAST-CANCER; MATURATION; SELECTION; MUTATION; MUTAGENESIS	In vivo affinity maturation of antibodies involves mutation of hot spots in the DNA encoding the variable regions. We have used this information to develop a strategy to improve antibody affinity in vitro using phage display technology. In our experiment with the antimesothelin scFv, SS(scFv), we identified DNA sequences in the variable regions that are naturally prone to hypermutations, selected a few hot spots encoding nonconserved amino acids, and introduced random mutations to make libraries with a size requirement between 10(3) and 10(4) independent clones. Fanning of the hot spot libraries yielded several mutants with a 15- to 55-fold increase in affinity compared with a single clone with a fourfold increased affinity from a library in which mutagenesis was done outside the hot spots. The strategy should be generally applicable for the rapid isolation of higher-affinity mutants of Fvs, Fabs, and other recombinant antibodies from antibody phage libraries that are small in size.	NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Div Basic Sci, NIH, Bldg 37,Room 4E16, Bethesda, MD 20892 USA.	pasta@helix.nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				Adams GP, 1998, CANCER RES, V58, P485; ADAMS GP, 1993, CANCER RES, V53, P4026; BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203; Baselga J, 1998, CANCER RES, V58, P2825; BRINKMANN U, 1991, P NATL ACAD SCI USA, V88, P8616, DOI 10.1073/pnas.88.19.8616; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; Chowdhury PS, 1998, J MOL BIOL, V281, P917, DOI 10.1006/jmbi.1998.1980; Chowdhury PS, 1998, P NATL ACAD SCI USA, V95, P669, DOI 10.1073/pnas.95.2.669; CLAUSS MA, 1990, CANCER RES, V50, P3487; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; Goldhirsch A, 1998, ANN ONCOL, V9, P973, DOI 10.1023/A:1008436810268; GOLDING GB, 1987, GENETICS, V115, P169; GONZALEZFERNANDEZ A, 1994, P NATL ACAD SCI USA, V91, P12614, DOI 10.1073/pnas.91.26.12614; Goyenechea B, 1996, P NATL ACAD SCI USA, V93, P13979, DOI 10.1073/pnas.93.24.13979; GRAM H, 1992, P NATL ACAD SCI USA, V89, P3576, DOI 10.1073/pnas.89.8.3576; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; INSEL RA, 1994, INT IMMUNOL, V6, P1437, DOI 10.1093/intimm/6.9.1437; JAIN RK, 1990, CANCER RES, V50, pS814; JOHNSON G, 1996, WEIRS HDB EXPT IMMUN, V1, pCH6; Jolly C J, 1996, Semin Immunol, V8, P159, DOI 10.1006/smim.1996.0020; KOLCHANOV NA, 1987, FEBS LETT, V214, P87, DOI 10.1016/0014-5793(87)80018-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Maloney DG, 1997, BLOOD, V90, P2188; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; ROGOZIN IB, 1991, BIOCHIM BIOPHYS ACTA, V1089, P175, DOI 10.1016/0167-4781(91)90005-7; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; YELTON DE, 1995, J IMMUNOL, V155, P1994; YOKOTA T, 1992, CANCER RES, V52, P3402	38	201	287	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					568	572		10.1038/9872	http://dx.doi.org/10.1038/9872			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385321				2022-12-25	WOS:000080716500028
J	Gerber, HP; Vu, TH; Ryan, AM; Kowalski, J; Werb, Z; Ferrara, N				Gerber, HP; Vu, TH; Ryan, AM; Kowalski, J; Werb, Z; Ferrara, N			VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; VASCULAR ENDOTHELIUM; PLATE CARTILAGE; RECEPTOR FLT-1; EXON STRUCTURE; EXPRESSION; CELLS; GENE; CHONDROCYTES	Hypertrophic chondrocytes in the epiphyseal growth plate express the angiogenic protein vascular endothelial growth factor (VEGF). To determine the role of VECF in endochondral bone formation, we inactivated this factor through the systemic administration of a soluble receptor chimeric protein (Flt-(1-3)-IgG) to 24-day-old mice. Blood vessel invasion was almost completely suppressed, concomitant with impaired trabecular bone formation and expansion of hypertrophic chondrocyte zone. Recruitment and/or differentiation of chondroclasts, which express gelatinase B/matrix metalloproteinase-9, and resorption of terminal chondrocytes decreased. Although proliferation, differentiation and maturation of chondrocytes were apparently normal, resorption was inhibited. Cessation of the anti-VEGF treatment was followed by capillary invasion, restoration of bone growth, resorption of the hypertrophic cartilage and normalization of the growth plate architecture. These findings indicate that VEGF-mediated capillary invasion is an essential signal that regulates growth plate morphogenesis and triggers cartilage remodeling. Thus, VECF is an essential coordinator of chandrocyte death, chondroclast function, extracellular matrix remodeling, angiogenesis and bone formation in the growth plate.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Med Ctr, Dept Anat, San Francisco, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.				NHLBI NIH HHS [HL03880] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; Albrecht U, 1997, MOL CELLULAR METHODS, P23; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Barleon B, 1997, CANCER RES, V57, P5421; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BARNESS LA, 1997, POTTERS PATHOLOGY FE, P561; BARON J, 1994, ENDOCRINOLOGY, V135, P2790, DOI 10.1210/en.135.6.2790; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; Enholm B, 1998, TRENDS CARDIOVAS MED, V8, P292, DOI 10.1016/S1050-1738(98)00026-7; FARNUM CE, 1989, AM J ANAT, V186, P346, DOI 10.1002/aja.1001860404; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jee W., 1988, CELL TISSUE BIOL TXB, P213; JINGUSHI S, 1995, J ORTHOPAED RES, V13, P761, DOI 10.1002/jor.1100130516; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; LEWINSON D, 1992, ANAT REC, V233, P504, DOI 10.1002/ar.1092330403; MAROTEAUX P, 1984, AM J MED GENET, V19, P171, DOI 10.1002/ajmg.1320190117; METSARANTA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P241, DOI 10.1016/0167-4781(91)90014-D; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEHAN DC, 1980, THEORY PRACTICE HIST; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; SIMIONESCU N, 1992, ENDOTHELIAL CELL DYS; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WALTNEBERGER J, 1994, J BIOL CHEM, V268, P26988; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	44	1540	1663	3	124	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					623	628		10.1038/9467	http://dx.doi.org/10.1038/9467			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371499				2022-12-25	WOS:000080823300029
J	Reddy, TR; Xu, WD; Mau, JKL; Goodwin, CD; Suhasini, M; Tang, HL; Frimpong, K; Rose, DW; Wong-Staal, F				Reddy, TR; Xu, WD; Mau, JKL; Goodwin, CD; Suhasini, M; Tang, HL; Frimpong, K; Rose, DW; Wong-Staal, F			Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev	NATURE MEDICINE			English	Article							VIRUS TYPE-1 REV; RNA-BINDING PROTEIN; HUMAN T-CELLS; NUCLEAR EXPORT; REGULATORY PROTEINS; ACTIVATION DOMAIN; PROTECTIVE GENE; EXPRESSION; RECEPTOR; MITOSIS	The HIV-1 Rev protein facilitates the nuclear export of mRNA containing the Rev response element (RRE) through binding to the export receptor CRM-1. Here we show that a cellular nuclear protein, Sam68 (Src-associated protein in mitosis), specifically interacts with RRE and can partially substitute for as well as synergize with Rev in RRE-mediated gene expression and virus replication. Differential sensitivity to leptomycin B, an inhibitor of CRM-1, indicates that the export pathways mediated by Rev and Sam68 are distinct. C-terminally deleted mutants of Sam68 inhibited the transactivation of RRE-mediated expression by both wild-type Sam68 and Rev. They were retained in the cytoplasm and impeded the nuclear localization of Rev in coexpressed cells. These mutants also inhibited wild-type HIV-1 replication to the same extent as the RevM 10 mutant, and may be useful as anti-viral agents in the treatment of AIDS.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Diabetes Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Vet Med Res Fdn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Veterans Medical Research Foundation	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.		Tang, Hengli/F-2085-2014; Williamson, James R/B-2891-2009	Williamson, James R/0000-0002-8772-468X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056089] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04050] Funding Source: Medline; NIAID NIH HHS [P30AI 36214-06] Funding Source: Medline; NIGMS NIH HHS [GM056089] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Chen TR, 1997, IEEE PHOTONIC TECH L, V9, P17, DOI 10.1109/68.554156; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES DR, 1995, PHYSIOL ZOOL, V68, P9, DOI 10.1086/physzool.68.4.30166356; Junker U, 1998, HUM GENE THER, V9, P333, DOI 10.1089/hum.1998.9.3-333; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MYER BE, 1994, GENE DEV, V8, P1538; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Powell DM, 1997, P NATL ACAD SCI USA, V94, P973, DOI 10.1073/pnas.94.3.973; Ranga U, 1998, P NATL ACAD SCI USA, V95, P1201, DOI 10.1073/pnas.95.3.1201; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; Woffendin C, 1996, P NATL ACAD SCI USA, V93, P2889, DOI 10.1073/pnas.93.7.2889; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xu Yuan, 1996, Journal of Biomedical Science, V3, P82, DOI 10.1007/BF02255535; YU M, 1994, GENE THER, V1, P13	39	131	139	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					635	642		10.1038/9479	http://dx.doi.org/10.1038/9479			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371501				2022-12-25	WOS:000080823300031
J	Miettinen, PJ; Chin, JR; Shum, L; Slavkin, HC; Shuler, CF; Derynck, R; Werb, Z				Miettinen, PJ; Chin, JR; Shum, L; Slavkin, HC; Shuler, CF; Derynck, R; Werb, Z			Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure	NATURE GENETICS			English	Article							FACTOR-ALPHA-GENE; CLEFT-PALATE; EGF RECEPTOR; MICE LACKING; ORGAN-CULTURE; MOUSE; LIP; ASSOCIATION; DEFECTS; MORPHOGENESIS	Craniofacial malformations are among the most frequent congenital birth defects in humans; cleft palate, that is inadequate fusion of the palatal shelves, occurs with an annual incidence of 1 in 700 to 1 in 1,000 live births among individuals of European descent(1). The secondary palate arises as bilateral outgrowths from the maxillary processes(2), and its formation depends on the coordinated development of craniofacial structures including the Meckel's cartilage and the mandible(3). Cleft lip and palate syndromes in humans are associated with polymorphisms in the gene (TGFA) encoding transforming growth factor-alpha (TGF-alpha), an epidermal growth factor receptor (EGFR) ligand made by most epithelia(1,4). Here we have characterized craniofacial develop ment in Egfr-deficient (Egfr(-/-)) mice. Newborn Egfr(-/-) mice have facial mediolateral defects including narrow, elongated snouts, underdeveloped lower jaw and a high incidence of cleft palate. Palatal shelf explants from Egfr(-/-) mice fused, but frequently had residual epithelium in the midline. In addition, morphogenesis of Meckel's cartilage was deficient in cultured mandibular processes from Egfr(-/-) embryos. The secretion of matrix metalloproteinases (MMPs) was diminished in Egfr(-/-) explants, consistent with the ability of EGF to increase MMP secretion and with the decreased MMP expression caused by inhibition of Egfr sig nailing in wild-type explants. Accordingly, inactivation of MMPs in wild-type explants phenocopied the defective morphology of Meckel's cartilage seen in Egfr(-/-) explants. Our results indicate that EGFR signalling is necessary for normal craniofacial development and that its role is mediated in part by its downstream targets, the MMPs, and may explain the genetic correlation of human cleft palate with polymorphisms in TGFA.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; NIAMSD, Craniofacial Dev Sect, NIH, Bethesda, MD 20892 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90025 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Southern California	Miettinen, PJ (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland.	paivi.miettinen@helsinki.fi			NCI NIH HHS [CA54826] Funding Source: Medline; NIAMS NIH HHS [AR41114] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041114, Z01AR041114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBOTT BD, 1987, J CRAN GENET DEV BIO, V7, P219; Abbott BD, 1995, TOXICOLOGY, V105, P365, DOI 10.1016/0300-483X(95)03234-7; ARDINGER HH, 1989, AM J HUM GENET, V45, P348; CHENEVIXTRENCH G, 1992, AM J HUM GENET, V51, P1377; Chin JR, 1997, DEVELOPMENT, V124, P1519; CHRISTENSEN K, 1995, NEW ENGL J MED, V333, P161, DOI 10.1056/NEJM199507203330305; CHUNG CS, 1968, AM J HUM GENET, V20, P44; Diehl SR, 1997, P NATL ACAD SCI USA, V94, P5231, DOI 10.1073/pnas.94.10.5231; DIXON MJ, 1992, ARCH ORAL BIOL, V37, P395, DOI 10.1016/0003-9969(92)90024-3; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; Iamaroon A, 1996, J DENT RES, V75, P1534, DOI 10.1177/00220345960750080301; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mitchell LE, 1997, GENET EPIDEMIOL, V14, P231; NEEL JV, 1958, AM J HUM GENET, V10, P398; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SEEGMILLER RE, 1977, J EMBRYOL EXP MORPH, V38, P227; Sheehan D.C., 1980, THEORY PRACTICE HIST; SHIANG R, 1993, AM J HUM GENET, V53, P836; SHULER C F, 1991, International Journal of Developmental Biology, V35, P463; SHULER CF, 1995, CRIT REV ORAL BIOL M, V6, P202, DOI 10.1177/10454411950060030301; SHUM L, 1993, DEVELOPMENT, V118, P903; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; van der Zee E, 1998, J PERIODONTAL RES, V33, P65; WILSON JB, 1993, CELL GROWTH DIFFER, V4, P67	28	204	218	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					69	73		10.1038/8773	http://dx.doi.org/10.1038/8773			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319864				2022-12-25	WOS:000080096300025
J	Driver, SE; Robinson, GS; Flanagan, J; Shen, W; Smith, LEH; Thomas, DW; Roberts, PC				Driver, SE; Robinson, GS; Flanagan, J; Shen, W; Smith, LEH; Thomas, DW; Roberts, PC			Oligonucleotide-based inhibition of embryonic gene expression	NATURE BIOTECHNOLOGY			English	Article						gene function; knockout; antisense; oligonucleotide; angiogenesis; development	ENDOTHELIAL GROWTH-FACTOR; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; TARGETED MUTATIONS; VEGF; TRANSCRIPTION; INJECTION; LETHALITY; RECEPTORS; MOLECULE; BINDING	We describe a technique to define gene function using antisense oligonucleotide (AS-ODN) inhibition of gene expression in mice. A single intravenous injection of an AS-ODN targeting vascular endothelial growth factor (VEGF) into pregnant mice between E7.5-8.5 resulted in a lack of primary angiogenesis. This enabled us to define the critical window required to inhibit VEGF expression and recapitulate the primary loss of function phenotype observed in VEGF (-/-) embryos. This phenotype was sequence-specific and time- and dose-dependent. Injection of an AS-ODN targeting a second gene, E-cadherin, into pregnant mice at E10 confirmed a hypothesized secondary phenotype. This is the first report of AS-ODN inhibition of gene expression in utero and provides a new strategy for target validation in functional genomics.	QIK Technol Inc, Boston, MA USA; Ontogeny Inc, Cambridge, MA USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Tanox Biosyst Inc, Houston, TX 77025 USA; Genzyme Corp, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation	Driver, SE (corresponding author), QIK Technol Inc, Boston, MA USA.							Aiello LP, 1994, NEW ENGL J MED, V331, P480; ANDERSON H, 1990, EXPERIENTIA, V46, P2, DOI 10.1007/BF01955407; Baumgartner I, 1998, VASA-J VASCULAR DIS, V27, P201; BOURQUE AJ, 1994, J CHROMATOGR B, V662, P343, DOI 10.1016/0378-4347(94)00207-X; Bramlage B, 1998, TRENDS BIOTECHNOL, V16, P434, DOI 10.1016/S0167-7799(98)01236-0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN BY, 1995, BIOL REPROD, V53, P1229, DOI 10.1095/biolreprod53.5.1229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christoffersen RE, 1997, NAT BIOTECHNOL, V15, P483, DOI 10.1038/nbt0697-483; Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Gaudette M F, 1993, Antisense Res Dev, V3, P391; Grunstein J, 1999, CANCER RES, V59, P1592; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; Jones DA, 1999, CURR OPIN CHEM BIOL, V3, P71, DOI 10.1016/S1367-5931(99)80013-1; Juliano RL, 1999, PHARM RES-DORDR, V16, P494, DOI 10.1023/A:1011958726518; Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416; Lai LW, 1999, EXP NEPHROL, V7, P11; Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3; Nyce JW, 1999, TRENDS PHARMACOL SCI, V20, P79, DOI 10.1016/S0165-6147(99)01305-X; Osterrieder N, 1998, REV SCI TECH OIE, V17, P351, DOI 10.20506/rst.17.1.1100; PACIFICI GM, 1995, CLIN PHARMACOKINET, V28, P235, DOI 10.2165/00003088-199528030-00005; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; Rockwell P, 1997, P NATL ACAD SCI USA, V94, P6523, DOI 10.1073/pnas.94.12.6523; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Smyth AP, 1997, J INVEST DERMATOL, V108, P523, DOI 10.1111/1523-1747.ep12289740; Takeichi M, 1997, COLD SPRING HARB SYM, V62, P505; Tatton WG, 1997, J NEURAL TRANSM-SUPP, P245; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yu D, 1996, BIOORGAN MED CHEM, V4, P1685, DOI 10.1016/0968-0896(96)00160-5; Zhao QY, 1998, ANTISENSE NUCLEIC A, V8, P451, DOI 10.1089/oli.1.1998.8.451	35	23	27	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1184	1187		10.1038/70724	http://dx.doi.org/10.1038/70724			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585715				2022-12-25	WOS:000084170700025
J	Grossel, MJ; Wang, HM; Gadea, B; Yeung, W; Hinds, PW				Grossel, MJ; Wang, HM; Gadea, B; Yeung, W; Hinds, PW			A yeast two-hybrid system for discerning differential interactions using multiple baits	NATURE BIOTECHNOLOGY			English	Article							PROTEIN-PROTEIN INTERACTIONS; REVERSE 2-HYBRID; PHOSPHATASE; ACTIVATOR; INHIBITOR		Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hinds, PW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM55684] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Inouye C, 1997, GENETICS, V147, P479; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Xu CW, 1997, P NATL ACAD SCI USA, V94, P12473, DOI 10.1073/pnas.94.23.12473	12	11	14	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1232	1233		10.1038/70792	http://dx.doi.org/10.1038/70792			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585727				2022-12-25	WOS:000084170700037
J	Kim, SH; Kaminker, P; Campisi, J				Kim, SH; Kaminker, P; Campisi, J			TIN2, a new regulator of telomere length in human cells	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; REPLICATIVE SENESCENCE; CHROMOSOME STABILITY; RETROVIRAL VECTORS; HUMAN FIBROBLASTS; GENE-TRANSFER; RAP1 PROTEIN; LIFE-SPAN; IN-VITRO; YEAST	Telomeres are DNA-protein structures that cap linear chromosomes and are essential for maintaining genomic stability and cell phenotype. We identified a novel human telomere-associated protein, TIN2, by interaction cloning using the telomeric DNA-binding-protein TRF1 as a bait. TIN2 interacted with TRF1 in vitro and in cells, and colocalized with TRF1 in nuclei and metaphase chromosomes. A mutant TIN2 that lacks amino-terminal sequences effects elongated human telomeres in a telomerase-dependent manner. Our findings suggest that TRF1 is insufficient for control of telomere length in human cells, and that TIN2 is an essential mediator of TRF1 function.	Lawrence Berkeley Natl Lab, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Campisi, J (corresponding author), Lawrence Berkeley Natl Lab, Dept Cell & Mol Biol, Berkeley, CA 94720 USA.	jcampisi@lbl.gov			NATIONAL INSTITUTE ON AGING [R01AG009909, T32AG000266, R37AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG009909, T32 AG000266, AG00266, AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi Judith, 1996, P121; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; FINER MH, 1994, BLOOD, V83, P43; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; James P, 1996, GENETICS, V144, P1425; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Sambrook J, 1989, MOL CLONING; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	47	407	432	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					405	412		10.1038/70508	http://dx.doi.org/10.1038/70508			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581025	Green Published, Green Accepted			2022-12-25	WOS:000084023900014
J	Ranta, S; Zhang, YH; Ross, B; Lonka, L; Takkunen, E; Messer, A; Sharp, J; Wheeler, R; Kusumi, K; Mole, S; Liu, WC; Soares, MB; Bonaldo, MD; Hirvasniemi, A; de la Chapelle, A; Gilliam, TC; Lehesjoki, AE				Ranta, S; Zhang, YH; Ross, B; Lonka, L; Takkunen, E; Messer, A; Sharp, J; Wheeler, R; Kusumi, K; Mole, S; Liu, WC; Soares, MB; Bonaldo, MD; Hirvasniemi, A; de la Chapelle, A; Gilliam, TC; Lehesjoki, AE			The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8	NATURE GENETICS			English	Article							NORTHERN EPILEPSY SYNDROME; PROTEIN; MOUSE; DEGENERATION; CHILDHOOD; DISEASE; MODEL	The neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of progressive neurodegenerative disorders characterized by the accumulation of autofluorescent lipopigment in various tissues(1). Progressive epilepsy with mental retardation (EPMR, MIM 600143) was recently recognized as a new NCL subtype(2) (CLN8), It is an autosomal recessive disorder characterized by onset of generalized seizures between 5 and 10 years, and subsequent progressive mental retardation(3). Here we report the positional cloning of a novel gene, CLN8, which is mutated in EPMR. It encodes a putative transmembrane protein. EPMR patients were homozygous for a missense mutation (70C-->G, R24G) that was not found in homozygosity in 433 controls. We also cloned the mouse Cln8 sequence. It displays 82% nucleotide identity with CLN8, conservation of the codon harbouring the human mutation and is localized to the same region as the motor neuron degeneration mouse, mnd, a naturally occurring mouse NCL (ref. 4). In mnd/mnd mice, we identified a homozygous 1-bp insertion (267-268insC, codon 90) predicting a frameshift and a truncated protein. Our data demonstrate that mutations in these orthologous genes underlie NCL phenotypes in human and mouse, and represent the first description of the molecular basis of a naturally occurring animal model for NCL.	Folkhalsan Inst Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Columbia Univ, Dept Psychiat, New York, NY USA; Columbia Univ, Dept Genet & Dev, New York, NY USA; Columbia Univ, Columbia Genome Ctr, New York, NY USA; New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY USA; UCL, Dept Paediat, Royal Free & Univ Coll Med Sch, London, England; Cambridge Ctr Mol Recognit, Whitehead Inst Biomed Res, Cambridge, MA USA; Univ Iowa, Iowa City, IA USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; Columbia University; Columbia University; Columbia University; State University of New York (SUNY) System; Wadsworth Center; University of London; University College London; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Iowa; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ranta, S (corresponding author), Folkhalsan Inst Genet, Helsinki, Finland.	susanna.ranta@helsinki.fi	Ranta, Susanna/C-6149-2016; Kusumi, Kenro/J-2626-2012; Mole, Sara/C-2024-2008	Kusumi, Kenro/0000-0002-1458-4540; Mole, Sara/0000-0003-4385-4957; Jaaskelainen, Elina/0000-0002-2880-3206	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029110] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29110] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BONALDO MD, 1994, HUM MOL GENET, V3, P1663; BRONSON RT, 1993, ANN NEUROL, V33, P381, DOI 10.1002/ana.410330408; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Haltia M, 1999, BIOM HLTH R, V33, P117; Hellsten E, 1996, EMBO J, V15, P5240, DOI 10.1002/j.1460-2075.1996.tb00909.x; HIRVASNIEMI A, 1995, EPILEPSIA, V36, P792, DOI 10.1111/j.1528-1157.1995.tb01616.x; HIRVASNIEMI A, 1994, J MED GENET, V31, P177, DOI 10.1136/jmg.31.3.177; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MESSER A, 1993, NEUROMUSCULAR DISORD, V3, P129, DOI 10.1016/0960-8966(93)90004-4; MESSER A, 1987, J NEUROGENET, V4, P201, DOI 10.3109/01677068709102341; MESSER A, 1993, EXP EYE RES, V57, P637, DOI 10.1006/exer.1993.1169; MESSER A, 1986, J NEUROGENET, V3, P345, DOI 10.3109/01677068609106858; MESSER A, 1995, AM J MED GENET, V57, P361, DOI 10.1002/ajmg.1320570251; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PARDO CA, 1994, AM J PATHOL, V144, P829; Porter JC, 1997, MOL CELL NEUROSCI, V9, P185, DOI 10.1006/mcne.1997.0617; Ranta S, 1997, GENOME RES, V7, P887, DOI 10.1101/gr.7.9.887; ROST B, 1995, PROTEIN SCI, V4, P521; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802	25	221	226	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					233	236		10.1038/13868	http://dx.doi.org/10.1038/13868			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508524				2022-12-25	WOS:000082827500027
J	Lamlum, H; Ilyas, M; Rowan, A; Clark, S; Johnson, V; Bell, J; Frayling, I; Efstathiou, J; Pack, K; Payne, S; Roylance, R; Gorman, P; Sheer, D; Neale, K; Phillips, R; Talbot, I; Bodmer, W; Tomlinson, I				Lamlum, H; Ilyas, M; Rowan, A; Clark, S; Johnson, V; Bell, J; Frayling, I; Efstathiou, J; Pack, K; Payne, S; Roylance, R; Gorman, P; Sheer, D; Neale, K; Phillips, R; Talbot, I; Bodmer, W; Tomlinson, I			The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis	NATURE MEDICINE			English	Article							COLORECTAL TUMORS; DESMOID TUMORS; GENE; COMPLEX; PROTEIN; ALLELES; FAP	APC is often cited as a prime example of a tumor suppressor gene. Truncating germline and somatic mutations (or, infrequently, allelic loss) occur in tumors in FAP (familial adenomatous polyposis). Most sporadic colorectal cancers also have two APC mutations'. Clues from attenuated polyposis(2-4), missense germline variants with mild disease(5,6) and the somatic mutation cluster region (codons 1,250-1,450)(1,7,8) indicate, however, that APC mutations might not result in simple loss of protein function. We have found that FAP patients with germline APC mutations within a small region (codons 1,194-1,392 at most) mainly show allelic loss in their colorectal adenomas, in contrast to other FAP patients, whose 'second hits' tend to occur by truncating mutations in the mutation cluster region. Our results indicate that different APC mutations provide cells with different selective advantages, with mutations close to codon 1,300 providing the greatest advantage. Allelic loss is selected strongly in cells with one mutation near codon 1,300. A different germline-somatic APC mutation association exists in FAP desmoids. APC is not, therefore, a classical tumor suppressor. Our findings also indicate a new mechanism for disease severity: if a broader spectrum of mutations is selected in tumors, the somatic mutation rate is effectively higher and more tumors grow.	Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Human Cytogenet Lab, London WC2A 3PX, England; John Radcliffe Hosp, Canc Immunol & Genet Lab, Imperial Canc Res Fund, Inst Mol Med, Oxford OX3 9DZ, England; St Marks & Northwick Pk Hosp NHS Trust, Imperial Canc Res Fund, Colorectal Unit, Harrow HA1 3UJ, Middx, England; St Marks & Northwick Pk Hosp NHS Trust, Kennedy Galton Ctr, Dept Clin Genet, Harrow HA1 3UJ, Middx, England; St Marks & Northwick Pk Hosp NHS Trust, Polyposis Registry, Harrow HA1 3UJ, Middx, England; St Marks & Northwick Pk Hosp NHS Trust, Acad Dept Histopathol, Harrow HA1 3UJ, Middx, England	Cancer Research UK; Cancer Research UK; University of Oxford	Tomlinson, I (corresponding author), Imperial Canc Res Fund, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Sheer, Denise/C-6705-2011; Clark, Susan/J-8103-2012	Sheer, Denise/0000-0001-9067-1796; Clark, Susan/0000-0002-6929-8082; Frayling, Ian/0000-0002-3420-0794; Bodmer, Walter/0000-0001-6244-9792	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Berx G, 1998, CELL ADHES COMMUN, V6, P171, DOI 10.3109/15419069809004474; Biggs PJ, 1996, ONCOGENE, V12, P1375; CASPARI R, 1995, HUM MOL GENET, V4, P337, DOI 10.1093/hmg/4.3.337; Frayling Ian M., 1996, P63; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; Friedl W, 1996, HUM GENET, V97, P579; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; HODGSON GS, 1993, ST COMP COM, V5, P369; ICHII S, 1993, ONCOGENE, V8, P2399; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LUONGO C, 1994, CANCER RES, V54, P5947; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1993, CANCER RES, V53, P5079; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; Spirio LN, 1998, NAT GENET, V20, P385, DOI 10.1038/3865; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; Wells D, 1999, NUCLEIC ACIDS RES, V27, P1214, DOI 10.1093/nar/27.4.1214; Won YJ, 1999, J HUM GENET, V44, P103, DOI 10.1007/s100380050118	25	276	295	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1071	1075		10.1038/12511	http://dx.doi.org/10.1038/12511			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470088				2022-12-25	WOS:000082337200045
J	Raab, A; Han, WH; Badt, D; Smith-Gill, SJ; Lindsay, SM; Schindler, H; Hinterdorfer, P				Raab, A; Han, WH; Badt, D; Smith-Gill, SJ; Lindsay, SM; Schindler, H; Hinterdorfer, P			Antibody recognition imaging by force microscopy	NATURE BIOTECHNOLOGY			English	Article						force microscopy; molecular recognition; antibody-antigen; receptor-ligand; lysozyme	DNA; RESOLUTION; BIOLOGY; EVENTS	We have developed a method that combines dynamic force microscopy with the simultaneous molecular recognition of an antigen by an antibody, during imaging. A magnetically oscillated atomic force microscopy tip carrying a tethered antibody was scanned over a surface to which lysozyme was bound. By oscillating the probe at an amplitude of only a few nanometers, the antibody was kept in close proximity to the surface, allowing fast and efficient antigen recognition and gentle interaction between tip and sample. Antigenic sites were evident from reduction of the oscillation amplitude, as a result of antibody-antigen recognition during the lateral scan. Lysozyme molecules bound to the surface were recognized by the antibody on the scanning tip with a few nanometers lateral resolution. In principle, any ligand can be tethered to the tip; thus, this technique could potentially be used for nanometer-scale epitope mapping of biomolecules and localizing receptor sites during biological processes.	Univ Linz, Inst Biophys, A-4040 Linz, Austria; Mol Imaging Corp, Phoenix, AZ USA; NCI, Basic Res Lab, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA	Johannes Kepler University Linz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Arizona State University; Arizona State University-Tempe	Hinterdorfer, P (corresponding author), Univ Linz, Inst Biophys, A-4040 Linz, Austria.	peter.hinterdorfer@jk.uni-linz.ac.at	Hinterdorfer, Peter/C-4235-2013	Hinterdorfer, Peter/0000-0003-2583-1305	DIVISION OF BASIC SCIENCES - NCI [Z01BC008950] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen S, 1997, BIOCHEMISTRY-US, V36, P7457, DOI 10.1021/bi962531z; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOLAND T, 1995, P NATL ACAD SCI USA, V92, P5297, DOI 10.1073/pnas.92.12.5297; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRISBIE CD, 1994, SCIENCE, V265, P2071, DOI 10.1126/science.265.5181.2071; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; HAN W, 1996, APPL PHYS LETT, V69, P1; Han WH, 1997, P NATL ACAD SCI USA, V94, P10565, DOI 10.1073/pnas.94.20.10565; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; HASELGRUBLER T, 1995, BIOCONJUGATE CHEM, V6, P242, DOI 10.1021/bc00033a002; Hinterdorfer P, 1996, P NATL ACAD SCI USA, V93, P3477, DOI 10.1073/pnas.93.8.3477; HINTERDORFER P, 1998, NANOBIOLOGY, V4, P39; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; Ludwig M, 1997, BIOPHYS J, V72, P445, DOI 10.1016/S0006-3495(97)78685-5; MULLER DJ, 1995, BIOPHYS J, V68, P1681, DOI 10.1016/S0006-3495(95)80345-0; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; Ros R, 1998, P NATL ACAD SCI USA, V95, P7402, DOI 10.1073/pnas.95.13.7402; SHAO ZF, 1995, Q REV BIOPHYS, V28, P195, DOI 10.1017/S0033583500003061; Willemsen OH, 1998, BIOPHYS J, V75, P2220, DOI 10.1016/S0006-3495(98)77666-0; Wong SS, 1998, NATURE, V394, P52, DOI 10.1038/27873	24	199	208	3	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					902	905		10.1038/12898	http://dx.doi.org/10.1038/12898			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471934				2022-12-25	WOS:000082365800034
J	Adlakha-Hutcheon, G; Bally, MB; Shew, CR; Madden, TD				Adlakha-Hutcheon, G; Bally, MB; Shew, CR; Madden, TD			Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity	NATURE BIOTECHNOLOGY			English	Article						mitoxantrone; programmable fusogenic vesicles; cationic liposomes; polyethylene glycol; antitumor efficacy	STERICALLY STABILIZED LIPOSOMES; PH-SENSITIVE IMMUNOLIPOSOMES; INTERBILAYER TRANSFER; PHARMACOKINETICS; BIODISTRIBUTION; STEALTH; TUMORS; MICE	Programmable fusogenic vesicles (PFVs) are lipid-based drug-delivery systems that exhibit time-dependent destabilization. The rate at which this destabilization occurs is determined by the exchange rate of a bilayer-stabilizing component, polyethylene glycol-phosphatidylethanolamine (PEG-PE) from the vesicle surface. This exchange rate is controlled, in turn, by the acyl chain composition of the PEG-PE. We describe in vitro and in vivo studies using PFVs as delivery vehicles far the anticancer drug mitoxantrone. We demonstrate that the PEG-PE acyl composition determined the rate at which PFVs are eliminated from plasma after intravenous administration, and the rate of mitoxantrone leakage from PFV, The nature of the PEG-PE component also determined the antitumor efficacy of mitoxantrone-loaded PFV in murine and human in murine and human xenograft tumor models. Increased circulation time and improved activity were obtained for PN containing PEG-PE with an 18-carbon acyl chain length, as a result of slower vesicle destabilization.	Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada; British Columbia Canc Agcy, Div Med Oncol Adv Therapeut, Vancouver, BC V5Z 4E6, Canada	University of British Columbia; British Columbia Cancer Agency	Madden, TD (corresponding author), Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z3, Canada.							ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P133, DOI 10.1016/0005-2736(91)90201-I; Allen TM, 1997, DRUGS, V54, P8, DOI 10.2165/00003495-199700544-00004; BALLY MB, 1994, CANCER CHEMOTH PHARM, V34, P137, DOI 10.1007/BF00685931; Chang CW, 1997, BRIT J CANCER, V75, P169, DOI 10.1038/bjc.1997.28; CONNOR J, 1985, J CELL BIOL, V101, P582, DOI 10.1083/jcb.101.2.582; CONNOR J, 1986, BIOCHIM BIOPHYS ACTA, V884, P474, DOI 10.1016/0304-4165(86)90197-2; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Gaber MH, 1996, INT J RADIAT ONCOL, V36, P1177, DOI 10.1016/S0360-3016(96)00389-6; GABIZON AA, 1992, CANCER RES, V52, P891; Holland JW, 1996, BIOCHEMISTRY-US, V35, P2618, DOI 10.1021/bi952000v; Holland JW, 1996, BIOCHEMISTRY-US, V35, P2610, DOI 10.1021/bi951999j; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V852, P123; Lim HJ, 1997, J PHARMACOL EXP THER, V281, P566; OGIHARA I, 1986, J NUCL MED, V27, P1300; OSTRO MJ, 1989, AM J HOSP PHARM, V46, P1576, DOI 10.1093/ajhp/46.8.1576; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PRESANT C A, 1986, Proceedings of the American Association for Cancer Research Annual Meeting, V27, P158; PROFFITT RT, 1983, SCIENCE, V220, P502, DOI 10.1126/science.6836294; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P13318, DOI 10.1021/bi00211a045; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WEINSTEIN JN, 1980, CANCER RES, V40, P1388; WU NZ, 1993, CANCER RES, V53, P3765; YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025	25	99	105	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					775	779		10.1038/11710	http://dx.doi.org/10.1038/11710			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429242				2022-12-25	WOS:000081751400026
J	Hu, WJ; Harding, SA; Lung, J; Popko, JL; Ralph, J; Stokke, DD; Tsai, CJ; Chiang, VL				Hu, WJ; Harding, SA; Lung, J; Popko, JL; Ralph, J; Stokke, DD; Tsai, CJ; Chiang, VL			Repression of lignin biosynthesis promotes cellulose accumulation and growth in transgenic trees	NATURE BIOTECHNOLOGY			English	Article						plant generic engineering; lignin biosynthesis; 4CL; transgenic; Populus tremuloides	CINNAMYL ALCOHOL-DEHYDROGENASE; PHENYLALANINE AMMONIA-LYASE; ASPEN POPULUS-TREMULOIDES; O-METHYLTRANSFERASE GENE; DOWN-REGULATION; TOBACCO PLANTS; 4-COUMARATE-COENZYME-A LIGASE; CORRELATION SPECTROSCOPY; AUXIN TRANSPORT; EXPRESSION	Because lignin limits the use of wood for fiber, chemical, and energy production, strategies for its downregulation are of considerable interest, We have produced transgenic aspen (Populus tremuloides Michx,) trees in which expression of a lignin biosynthetic pathway gene Pt4CL1 encoding 4-coumarate:coenzyme A ligase (4CL) has been downregulated by antisense inhibition. Trees with suppressed Pt4CL1 expression exhibited up to a 45% reduction of lignin, but this was compensated for by a 15% increase in cellulose. As a result, the total lignin-cellulose mass remained essentially unchanged, Leaf, root, and stem growth were substantially enhanced, and structural integrity was maintained both at the cellular and whole-plant levels in the transgenic lines. Our results indicate that lignin and cellulose deposition could be regulated in a compensatory fashion, which may contribute to metabolic flexibility and a growth advantage to sustain the long-term structural integrity of woody perennials.	Michigan Technol Univ, Sch Forestry & Wood Prod, Plant Biotechnol Res Ctr, Houghton, MI 49931 USA; Univ Wisconsin, USDA ARS, US Dairy Forage Res Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Forestry, Madison, WI 53706 USA; Iowa State Univ, Dept Forestry, Ames, IA 50011 USA	Michigan Technological University; United States Department of Agriculture (USDA); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Iowa State University	Chiang, VL (corresponding author), Michigan Technol Univ, Sch Forestry & Wood Prod, Plant Biotechnol Res Ctr, Houghton, MI 49931 USA.		Ralph, John/C-3161-2009; Tsai, CJ/C-2450-2009	Ralph, John/0000-0002-6093-4521; Tsai, CJ/0000-0002-9282-7704				Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; BATE NJ, 1994, P NATL ACAD SCI USA, V91, P7608, DOI 10.1073/pnas.91.16.7608; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUGOS RC, 1995, BIOTECHNIQUES, V19, P734; CHIANG VL, 1983, WOOD SCI TECHNOL, V17, P217, DOI 10.1007/BF00372320; CHIANG VL, 1990, HOLZFORSCHUNG, V44, P147, DOI 10.1515/hfsg.1990.44.2.147; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Creelman RA, 1997, PLANT CELL, V9, P1211, DOI 10.1105/tpc.9.7.1211; DATLA RSS, 1993, PLANT SCI, V94, P139, DOI 10.1016/0168-9452(93)90015-R; Davis MW, 1998, J WOOD CHEM TECHNOL, V18, P235, DOI 10.1080/02773819809349579; DWIVEDI UN, 1994, PLANT MOL BIOL, V26, P61, DOI 10.1007/BF00039520; ELKIND Y, 1990, P NATL ACAD SCI USA, V87, P9057, DOI 10.1073/pnas.87.22.9057; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; HARTLEY RD, 1971, J CHROMATOGR, V54, P335, DOI 10.1016/S0021-9673(01)80289-2; HIBINO T, 1995, BIOSCI BIOTECH BIOCH, V59, P929, DOI 10.1271/bbb.59.929; Hu WJ, 1998, P NATL ACAD SCI USA, V95, P5407, DOI 10.1073/pnas.95.9.5407; JACOBS M, 1988, SCIENCE, V241, P346, DOI 10.1126/science.241.4863.346; Kajita S, 1996, PLANT CELL PHYSIOL, V37, P957, DOI 10.1093/oxfordjournals.pcp.a029045; Kajita S, 1997, PLANT PHYSIOL, V114, P871, DOI 10.1104/pp.114.3.871; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; LEE TT, 1965, PHYSIOL PLANTARUM, V18, P386, DOI 10.1111/j.1399-3054.1965.tb06902.x; Logemann E, 1995, PLANT J, V8, P865, DOI 10.1046/j.1365-313X.1995.8060865.x; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; NITSCH J. P., 1962, ANN PHYSIOL VEG [PARIS], V4, P211; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; Piquemal J, 1998, PLANT J, V13, P71, DOI 10.1046/j.1365-313X.1998.00014.x; RALPH J, 1994, J AM CHEM SOC, V116, P9448, DOI 10.1021/ja00100a006; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Ruegger M, 1997, PLANT CELL, V9, P745, DOI 10.1105/tpc.9.5.745; RUIZCABELLO J, 1992, J MAGN RESON, V100, P282, DOI 10.1016/0022-2364(92)90262-6; Sewalt VJH, 1997, PLANT PHYSIOL, V115, P41, DOI 10.1104/pp.115.1.41; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/1360-1385(96)10040-6; TAN KS, 1992, J PLANT PHYSIOL, V140, P460, DOI 10.1016/S0176-1617(11)80825-4; Timell T. E, 1986, COMPRESSION WOOD GYM; TSAI CJ, 1994, PLANT CELL REP, V14, P94, DOI 10.1007/BF00233768; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; VanDoorsselaere J, 1995, PLANT J, V8, P855, DOI 10.1046/j.1365-313X.1995.8060855.x; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; ZENK MH, 1963, NATURE, V200, P761, DOI 10.1038/200761a0	46	555	658	1	127	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					808	812		10.1038/11758	http://dx.doi.org/10.1038/11758			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429249	Green Published			2022-12-25	WOS:000081751400033
J	Levkau, B; Scatena, M; Giachelli, CM; Ross, R; Raines, EW				Levkau, B; Scatena, M; Giachelli, CM; Ross, R; Raines, EW			Apoptosis overrides survival signals through a caspase-mediated dominant negative NF-kappa B loop	NATURE CELL BIOLOGY			English	Article							CELL-DEATH; TRANSCRIPTION FACTOR; PRECURSOR PROTEIN; ACTIVATION; ALPHA; BCL-2; CLEAVAGE; P65; PHOSPHORYLATION; SUPPRESSION	The transcription factor NF-kappa B is an important regulator of gene expression during immune and inflammatory responses, and can also protect against apoptosis, Here we show that endothelial cells undergo apoptosis when deprived of growth factors. Surviving viable cells exhibit increased activity of NF-kappa B, whereas apoptotic cells show caspase-mediated cleavage of the NF-kappa B p65/RelA subunit. This cleavage leads to loss of carboxy-terminal transactivation domains and a transcriptionally inactive p65 molecule. The truncated p65 acts as a dominant-negative inhibitor of NF-kappa B, promoting apoptosis, whereas an uncleavable, caspase-resistant p65 protects the cells from apoptosis, The generation of a dominant-negative fragment of p65 during apoptosis may be an efficient pro-apoptotic feedback mechanism between caspase activation and NF-kappa B inactivation.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany	University of Washington; University of Washington Seattle; University of Munster	Raines, EW (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.		Levkau, Bodo/N-9144-2017		NHLBI NIH HHS [HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Ravi R, 1998, CANCER RES, V58, P882; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	39	168	175	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					227	233		10.1038/12050	http://dx.doi.org/10.1038/12050			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559921				2022-12-25	WOS:000083102700018
J	Squirrell, JM; Wokosin, DL; White, JG; Bavister, BD				Squirrell, JM; Wokosin, DL; White, JG; Bavister, BD			Long-term two-photon fluorescence imaging of mammalian embryos without compromising viability	NATURE BIOTECHNOLOGY			English	Article						two-photon microscopy; laser scanning confocal microscopy; live cell fluorescence imaging; embryo; mitochondrial dynamics; mammal; hamster	VISIBLE-LIGHT; PROBE 2',7'-DICHLOROFLUORESCIN; PREIMPLANTATION EMBRYOS; ACTIVE MITOCHONDRIA; HYDROGEN-PEROXIDE; HAMSTER EMBRYOS; MOUSE EMBRYOS; CELLS; MICROSCOPY; CULTURE	A major challenge for fluorescence imaging of living mammalian cells is maintaining viability following prolonged exposure to excitation illumination. We have monitored the dynamics of mitochondrial distribution in hamster embryos at frequent intervals over 24 h using two-photon microscopy (1,047 nm) while maintaining blastocyst, and even fetal, developmental competence. In contrast, confocal imaging for only 8 h inhibits development, even without fluorophore excitation, Photo-induced production of H2O2 may account, in part, for this inhibition, Thus, two-photon microscopy, but not confocal microscopy, has permitted long-term fluorescence observations of the dynamics of three-dimensional cytoarchitecture in highly photosensitive specimens such as mammalian embryos.	Univ Wisconsin, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Squirrell, JM (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	jsquirre@students.wisc.edu			NCRR NIH HHS [RR00570, P41 RR000570] Funding Source: Medline; NICHD NIH HHS [HD22023] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD022023] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000570] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325; Barnett DK, 1996, DEV DYNAM, V205, P64, DOI 10.1002/(SICI)1097-0177(199601)205:1<64::AID-AJA6>3.0.CO;2-3; Barnett DK, 1997, MOL REPROD DEV, V48, P227, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;227::AID-MRD10&gt;3.0.CO;2-V; BATTEN BE, 1987, AM J ANAT, V178, P204, DOI 10.1002/aja.1001780212; Bavister BD, 1995, HUM REPROD UPDATE, V1, P91, DOI 10.1093/humupd/1.2.91; BAVISTER BD, 1988, IN VITRO CELL DEV B, V24, P759; CAPCO DG, 1993, CELL MOTIL CYTOSKEL, V24, P85, DOI 10.1002/cm.970240202; CATHCART R, 1984, METHOD ENZYMOL, V105, P352; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DANIEL JC, 1964, NATURE, V201, P316, DOI 10.1038/201316a0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; HAUGLAND RP, 1995, BIOTECH HISTOCHEM, V70, P243, DOI 10.3109/10520299509108201; HEGELEHARTUNG C, 1991, ANAT EMBRYOL, V183, P559; HILLMAN N, 1969, AM J ANAT, V126, P151, DOI 10.1002/aja.1001260203; HIRAO Y, 1978, J EXP ZOOL, V206, P365, DOI 10.1002/jez.1402060308; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hockberger PE, 1996, P SOC PHOTO-OPT INS, V2678, P129, DOI 10.1117/12.239502; HOLY J, 1991, J ELECTRON MICR TECH, V17, P384, DOI 10.1002/jemt.1060170403; Konig K, 1996, CELL MOL BIOL, V42, P1181; Konig K, 1997, OPT LETT, V22, P135, DOI 10.1364/OL.22.000135; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Ludwig TE, 1998, BIOL REPROD, V58, P167; McKiernan SH, 1998, THERIOGENOLOGY, V49, P209, DOI 10.1016/S0093-691X(98)90562-3; MOHLER W, IN PRESS IMAGING NEU; NAKAYAMA T, 1994, THERIOGENOLOGY, V41, P499, DOI 10.1016/0093-691X(94)90086-X; NASRESFAHANI MH, 1990, DEVELOPMENT, V109, P501; NASRESFAHANI MM, 1991, DEVELOPMENT, V113, P551; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Terasaki M., 1995, P327; WANG RJ, 1978, IN VITRO CELL DEV B, V14, P715; WILLEKENS P, 1994, DSP APPL, V3, P8; Wokosin DL, 1996, IEEE J SEL TOP QUANT, V2, P1051, DOI 10.1109/2944.577337; WOKOSIN DL, 1997, 3 DIMENSIONAL MICROS, P24; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118; [No title captured]	38	463	482	3	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					763	767		10.1038/11698	http://dx.doi.org/10.1038/11698			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429240	Green Accepted			2022-12-25	WOS:000081751400024
J	van Leeuwen, FN; van Delft, S; Kain, HE; van der Kammen, RA; Collard, JG				van Leeuwen, FN; van Delft, S; Kain, HE; van der Kammen, RA; Collard, JG			Rac regulates phosphorylation of the myosin-II heavy chain, actinomyosin disassembly and cell spreading	NATURE CELL BIOLOGY			English	Article							KINASE RHO-KINASE; FOCAL ADHESIONS; STRESS FIBERS; ACTIN; ACTIVATION; GTPASES; FAMILY; PAK; CONTRACTILITY; FIBROBLASTS	GTPases of the Rho family regulate actinomyosin-based contraction in non-muscle cells. Activation of Rho increases contractility, leading to cell rounding and neurite retraction in neuronal cell lines. Activation of Rac promotes cell spreading and interferes with Rho-mediated cell rounding. Here we show that activation of Rac may antagonize Rho by regulating phosphorylation of the myosin-ll heavy chain. Stimulation of PC12 cells or N1E-115 neuroblastoma cells with bradykinin induces phosphorylation of threonine residues in the myosin-ll heavy chain; this phosphorylation is Ca2+ dependent and regulated by Rac, Both bradykinin-mediated and constitutive activation of Rac promote cell spreading, accompanied by a loss of cortical myosin II. Our results identify the myosin-ll heavy chain as a new target of Rac-regulated kinase pathways, and implicate Rac as a Rho antagonist during myosin-II-dependent cell-shape changes.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FESOLATO C, 1988, J BIOL CHEM, V263, P17350; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lee WPA, 1996, HAND CLIN, V12, P271; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Ramos E, 1997, RECEPT SIGNAL TRANS, V7, P99; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SPUDICH A, 1994, CELL MOTIL CYTOSKEL, V29, P345, DOI 10.1002/cm.970290407; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wilson JR, 1998, J BIOL CHEM, V273, P22729, DOI 10.1074/jbc.273.35.22729; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	41	181	182	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					242	248		10.1038/12068	http://dx.doi.org/10.1038/12068			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559923				2022-12-25	WOS:000083102700020
J	Czermak, BJ; Sarma, V; Pierson, CL; Warner, RL; Huber-Lang, M; Bless, NM; Schmal, H; Friedl, HP; Ward, PA				Czermak, BJ; Sarma, V; Pierson, CL; Warner, RL; Huber-Lang, M; Bless, NM; Schmal, H; Friedl, HP; Ward, PA			Protective effects of C5a blockade in sepsis	NATURE MEDICINE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; INFLAMMATORY RESPONSE SYNDROME; RECEPTOR; COMPLEMENT; ENDOTOXIN; INFECTION; SHOCK; INTERNALIZATION; PHOSPHORYLATION; ANTIBODIES	Sepsis in humans is a difficult condition to treat and is often associated with a high mortality rate. In this study, we induced sepsis in rats using cecal ligation and puncture (CLP). In rats depleted of the complement factor C3, CLP led to very short survival times (about 4 days). Of the rats that underwent CLP ('CLP rats') that were C3-intact and treated with preimmune Igc, most (92%) were dead by 7 days. Blood neutrophils from these rats contained on their surfaces the powerful complement activation product C5a. This group had high levels of bacteremia, and their blood neutrophils when stimulated in vitro had greatly reduced production of H2O2 which is known to be essential for the bactericidal function of neutrophils. In contrast, when companion CLP rats were treated with IgG antibody against C5a, survival rates were significantly improved, levels of bacteremia were considerably reduced, and the H2O2 response of blood neutrophils was preserved. Bacterial colony-forming units in spleen and liver were very high in CLP rats treated with preimmune IgG and very low in CLP rats treated with IgG antibody against C5a, similar to values obtained in rats that underwent 'sham' operations (without CLP). These data indicate that sepsis causes an excessive production of C5a, which compromises the bactericidal function of neutrophils. Thus, C5a may be a useful target for the treatment of sepsis.	Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA; Univ Freiburg, Sch Med, Dept Trauma Surg, D-79106 Freiburg, Germany	University of Michigan System; University of Michigan; University of Freiburg	Ward, PA (corresponding author), Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA.		Huber-Lang, Markus/AAJ-2209-2020; Schmal, Hagen/B-2684-2016	Schmal, Hagen/0000-0002-8801-2385				ALEXANDER JW, 1979, SURGER, V86, P84; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BORDER JR, 1987, ANN SURG, V206, P427, DOI 10.1097/00000658-198710000-00004; Czermak BJ, 1999, AM J PATHOL, V154, P1057, DOI 10.1016/S0002-9440(10)65358-8; Deitch EA, 1997, SHOCK, V9, P1; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; ELSBACH P, 1985, IMMUNOL LETT, V11, P159, DOI 10.1016/0165-2478(85)90163-4; Fischer MB, 1997, J IMMUNOL, V159, P976; GIANNINI E, 1995, J IMMUNOL, V154, P4055; HILL JH, 1971, J EXP MED, V133, P885, DOI 10.1084/jem.133.4.885; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; JOHNSON KJ, 1971, J IMMUNOL, V106, P1125; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KOEHL J, 1993, ANAPHYLOTOXINS COMPL, P299; KUBENS BS, 1988, COMPLEMENT SYSTEM, P469; MAY JE, 1972, J IMMUNOL, V109, P893; Mohr M, 1998, EUR J CLIN INVEST, V28, P227; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; Naik N, 1997, J CELL SCI, V110, P2381; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; NICHOLS RL, 1984, NEW ENGL J MED, V311, P1065, DOI 10.1056/NEJM198410253111701; OLSON LM, 1985, ANN SURG, V202, P771, DOI 10.1097/00000658-198512000-00018; QUEZADO ZMN, 1994, J EXP MED, V179, P569, DOI 10.1084/jem.179.2.569; Rothermel E, 1997, BBA-GENE STRUCT EXPR, V1351, P9, DOI 10.1016/S0167-4781(97)00006-7; SCHUMACHER WA, 1991, AGENTS ACTIONS, V34, P345, DOI 10.1007/BF01988727; SOLOMKIN JS, 1981, SURGERY, V90, P319; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; VANEPPS DE, 1993, J IMMUNOL, V150, P246; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WARD PA, 1968, J EXP MED, V127, P693, DOI 10.1084/jem.127.4.693; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2	33	303	333	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					788	792		10.1038/10512	http://dx.doi.org/10.1038/10512			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395324				2022-12-25	WOS:000081926600034
J	May, A; Ashburner, J; Buchel, C; McGonigle, DJ; Friston, KJ; Frackowiak, RSJ; Goadsby, PJ				May, A; Ashburner, J; Buchel, C; McGonigle, DJ; Friston, KJ; Frackowiak, RSJ; Goadsby, PJ			Correlation between structural and functional changes in brain in an idiopathic headache syndrome	NATURE MEDICINE			English	Article							CLUSTER HEADACHE	Fundamental to the concept of idiopathic or primary headache, including migraine, tension-type headache and cluster headache, is the currently accepted view that these conditions are due to abnormal brain function with completely normal brain structure(1). Cluster headache is one such idiopathic headache with many similarities to migraine, including normal brain structure on magnetic resonance imaging and abnormal function in the hypothalamic grey matter by positron emission tomography(2). Given the consistency of the positron emission tomography findings with the clinical presentation, we sought to assess whether the brains of such patients were structurally normal. We used voxel-based morphometry, an objective and automated method of analyzing changes in brain structure, to study the structure of the brains of patients with cluster headache. We found a co-localization of structural changes and changes in local brain activity with positron emission tomography in the same area of the brain in the same patients. The results indicate that the current view of the neurobiology of cluster headache requires complete revision and that this periodic headache is associated with a hitherto unrecognized brain abnormality in the hypothalamic region. We believe that voxel-based morphometry has the potential to change in the most fundamental way our concept of primary headache disorders, requiring a radical reappraisal of the tenet of structural normality.	UCL Natl Hosp Neurol & Neurosurg, Univ Dept Clin Neurol, Neurol Inst, London, England; UCL Natl Hosp Neurol & Neurosurg, Wellcome Dept Cognit Neurol, Neurol Inst, London, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Goadsby, PJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Univ Dept Clin Neurol, Neurol Inst, Queen Sq, London, England.	peterg@ion.ucl.ac.uk	McGonigle, David/Q-2166-2019; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; Friston, Karl/D-9230-2011; Goadsby, Peter J/B-2267-2009; Ashburner, John/I-3757-2013; Goadsby, Peter J/Z-1970-2019; McGonigle, David/A-2760-2009	McGonigle, David/0000-0001-9595-6352; Frackowiak, Richard/0000-0002-3151-822X; Friston, Karl/0000-0001-7984-8909; Ashburner, John/0000-0001-7605-2518; Goadsby, Peter J/0000-0003-3260-5904; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Ashburner J, 1997, NEUROIMAGE, V6, P344, DOI 10.1006/nimg.1997.0299; ASHBURNER J, IN PRESS NEUROIMAGE; EVANS AC, 1994, NATO ADV SCI INST SE, V264, P263; Friston K. J., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; ISLER H, 1993, CEPHALALGIA, V13, P172, DOI 10.1046/j.1468-2982.1993.1303172.x; Lance JW, 1998, MECH MANAGEMENT HEAD; LEONE M, 1990, CEPHALALGIA, V10, P235, DOI 10.1046/j.1468-2982.1990.1005235.x; May A, 1998, LANCET, V352, P275, DOI 10.1016/S0140-6736(98)02470-2; May A, 1998, CURR OPIN NEUROL, V11, P199, DOI 10.1097/00019052-199806000-00002; Sjaastad O., 1992, CLUSTER HEADACHE SYN; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TFELTHANSEN P, 1982, CEPHALALGIA, V2, P25, DOI 10.1046/j.1468-2982.1982.0201025.x; Wright IC, 1995, NEUROIMAGE, V2, P244, DOI 10.1006/nimg.1995.1032	14	395	399	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					836	838		10.1038/10561	http://dx.doi.org/10.1038/10561			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395332				2022-12-25	WOS:000081926600042
J	Pelletier, JN; Arndt, KM; Pluckthun, A; Michnick, SW				Pelletier, JN; Arndt, KM; Pluckthun, A; Michnick, SW			An in vivo library-versus-library selection of optimized protein-protein interactions	NATURE BIOTECHNOLOGY			English	Article						library screening; library-versus-library; protein-fragment complementation assay; selection strategy; protein-protein interaction; leucine zipper; coiled coil; dihydrofolate reductase; trinucleotide	GCN4 LEUCINE-ZIPPER; HETERODIMERIC COILED-COIL; ELECTROSTATIC INTERACTIONS; DIHYDROFOLATE-REDUCTASE; DOMAIN; SYSTEM; PHAGE; STABILITY; SEQUENCE; PARALLEL	We describe a rapid and efficient in vivo library-versus-library screening strategy for identifying optimally interacting pairs of heterodimerizing polypeptides. Two leucine zipper libraries, semi-randomized at the positions adjacent to the hydrophobic core, were genetically fused to either one of two designed fragments of the enzyme murine dihydrofolate reductase (mDHFR), and cotransformed into Escherichia coli. Interaction between the library polypeptides reconstituted enzymatic activity of mDHFR, allowing bacterial growth. Analysis of the resulting colonies revealed important biases in the zipper sequences relative to the original libraries, which are consistent with selection for stable, heterodimerizing pairs. Using more weakly associating mDHFR fragments, we increased the stringency of selection. We enriched the best-performing leucine zipper pairs by multiple passaging of the pooled, selected colonies in liquid culture, as the best pairs allowed for better bacterial propagation. This competitive growth allowed small differences among the pairs to be amplified, and different sequence positions were enriched at different rates. We applied these selection processes to a library-versus-library sample of 2.0 x 10(6) combinations and selected a novel leucine zipper pair that may be appropriate for use in further in vivo heterodimerization strategies.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	Universite de Montreal; University of Zurich	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, 2900 Edouard Montpetit, Montreal, PQ H3C 3J7, Canada.		Plückthun, Andreas/C-2746-2009; Wood, David W/B-2992-2012	Plückthun, Andreas/0000-0003-4191-5306; Arndt, Katja/0000-0001-9220-0920				Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Jelesarov I, 1996, J MOL BIOL, V263, P344, DOI 10.1006/jmbi.1996.0579; JOHN M, 1994, J BIOL CHEM, V269, P16247; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Muller KM, 1998, FEBS LETT, V422, P259, DOI 10.1016/S0014-5793(98)00021-0; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; PELLETIER JN, J BIOMOL TECHNIQUES; Remy I, 1999, P NATL ACAD SCI USA, V96, P5394, DOI 10.1073/pnas.96.10.5394; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rudert F, 1998, FEBS LETT, V440, P135, DOI 10.1016/S0014-5793(98)01413-6; SENGUPTA DJ, 1996, P NATL ACAD SCI USA, V93, P8495; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Spada S, 1997, NAT MED, V3, P694, DOI 10.1038/nm0697-694; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zeng XG, 1997, PROTEIN SCI, V6, P2218; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	29	162	208	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					683	690		10.1038/10897	http://dx.doi.org/10.1038/10897			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404162				2022-12-25	WOS:000081296900029
J	Roy, S; Luetterforst, R; Harding, A; Apolloni, A; Etheridge, M; Stang, E; Rolls, B; Hancock, JF; Parton, RG				Roy, S; Luetterforst, R; Harding, A; Apolloni, A; Etheridge, M; Stang, E; Rolls, B; Hancock, JF; Parton, RG			Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains	NATURE CELL BIOLOGY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; N-RAS; IN-VIVO; EARLY ENDOSOME; K-RAS; PROTEIN; KINASE; DISTINCT; GROWTH; SIGNAL	The plasma membrane pits known as caveolae have been implicated both in cholesterol homeostasis and in signal transduction. Cav(DGV) and Cav(KSY), two dominant-negative amino-terminal truncation mutants of caveolin, the major structural protein of caveolae, significantly inhibited caveola-mediated SV40 infection, and were assayed for effects on Ras function. We find that Cav(DGV) completely blocked Raf activation mediated by H-Ras, but not that mediated by K-Ras. Strikingly, the inhibitory effect of Cav(DGV) on H-Ras signalling was completely reversed by replenishing cell membranes with cholesterol and was mimicked by cyclodextrin treatment, which depletes membrane cholesterol. These results provide a crucial link between the cholesterol-trafficking role of caveolin and its postulated role in signal transduction through cholesterol-rich surface domains. They also provide direct evidence that H-Ras and K-Ras, which are targeted to the plasma membrane by different carboxyterminal anchors, operate in functionally distinct microdomains of the plasma membrane.	Univ Queensland, Sch Med, Queensland Canc Fund Lab Expt Oncol, Dept Pathol, Brisbane, Qld 4006, Australia; Univ Queensland, Dept Physiol & Pharmacol, Ctr Microscopy & Microanal, Ctr Mol & Cellular Biol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Queensland Canc Fund Lab Expt Oncol, Dept Pathol, Herston Rd, Brisbane, Qld 4006, Australia.	j.hancock@mailbox.uq.edu.au	Eckhardt, Erik/G-1567-2010; Rolls, Barbara J/AAE-3899-2019; Harding, Angus/B-4120-2012; Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; Hancock, John/0000-0003-0542-4710				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BOS JL, 1989, CANCER RES, V49, P4682; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown RE, 1998, J CELL SCI, V111, P1; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding CJ, 1997, J LIPID RES, V38, P1503; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garver VS, 1997, BBA-MOL BASIS DIS, V1361, P272, DOI 10.1016/S0925-4439(97)00047-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Hailstones D, 1998, J LIPID RES, V39, P369; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; LUETTERFORST R, IN PRESS J CELL BIOL; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Porpaczy Z, 1997, EXP CELL RES, V234, P217, DOI 10.1006/excr.1997.3612; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wilson JM, 1997, J CELL BIOL, V136, P319, DOI 10.1083/jcb.136.2.319; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	50	399	404	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					98	105		10.1038/10067	http://dx.doi.org/10.1038/10067			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559881				2022-12-25	WOS:000083102200017
J	Jensen, J; Pedersen, EE; Galante, P; Hald, J; Heller, RS; Ishibashi, M; Kageyama, R; Guillemot, F; Serup, P; Madsen, OD				Jensen, J; Pedersen, EE; Galante, P; Hald, J; Heller, RS; Ishibashi, M; Kageyama, R; Guillemot, F; Serup, P; Madsen, OD			Control sf endodermal endocrine development by Hes-1	NATURE GENETICS			English	Article							HELIX TRANSCRIPTION FACTOR; EPITHELIAL-MESENCHYMAL INTERACTIONS; ACHAETE-SCUTE HOMOLOG-1; SEX DETERMINATION; NERVOUS-SYSTEM; BETA-CELLS; DIFFERENTIATION; DROSOPHILA; GENE; PANCREAS	Development of endocrine cells in the endoderm involves Atonal and Achaete/Scute-related basic helix-loop-helix (bHLH) proteins. These proteins also serve as neuronal determination and differentiation factors, and are antagonized by the Notch pathway partly acting through Hairy and Enhancer-of-split (HES)-type proteins. Here we show that mice deficient in Hes1 (encoding Hes-1) display severe pancreatic hypoplasia caused by depletion of pancreatic epithelial precursors due to accelerated differentiation of post-mitotic endocrine cells expressing glucagon. Moreover, upregulation of several bHLH components is associated with precocious and excessive differentiation of multiple endocrine cell types in the developing stomach and gut, showing that Hes-1 operates as a general negative regulator of endodermal endocrine differentiation.	Hagedorn Res Lab, Dept Dev Biol, Gentofte, Denmark; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, Strasbourg, France	Novo Nordisk; Hagedorn Research Institute; Kyoto University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Madsen, OD (corresponding author), Hagedorn Res Lab, Dept Dev Biol, Gentofte, Denmark.	ODM@Novo.dk	Serup, Palle/A-7407-2011; Madsen, Ole D./A-7415-2011; Guillemot, Francois/AAV-1482-2021; Heller, R.Scott/A-7279-2008	Serup, Palle/0000-0002-0858-590X; Madsen, Ole D./0000-0002-2753-5203; Jensen, Jan/0000-0003-0657-4032	NIDDK NIH HHS [DK-55284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BARBASH DA, 1995, GENETICS, V141, P1451; Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Cau E, 1997, DEVELOPMENT, V124, P1611; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DESHPANDE G, 1995, MOL CELL BIOL, V15, P4430; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HOGAN B, 1994, MANIPULATING MOUSE E, P303; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JENSEN J, IN PRESS DIABETES; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Larsson LI, 1998, MECH DEVELOP, V79, P153, DOI 10.1016/S0925-4773(98)00182-8; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Offield MF, 1996, DEVELOPMENT, V122, P983; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; Pabst O, 1997, DEV DYNAM, V209, P29; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; Robb L, 1998, DEV DYNAM, V213, P105, DOI 10.1002/(SICI)1097-0177(199809)213:1<105::AID-AJA10>3.0.CO;2-1; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Valsecchi V, 1997, MECH DEVELOP, V69, P203, DOI 10.1016/S0925-4773(97)00146-9; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5	48	866	898	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					36	44		10.1038/71657	http://dx.doi.org/10.1038/71657			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615124				2022-12-25	WOS:000084609200012
J	Scheffold, A; Assenmacher, M; Reiners-Schramm, L; Lauster, R; Radbruch, A				Scheffold, A; Assenmacher, M; Reiners-Schramm, L; Lauster, R; Radbruch, A			High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines gamma interferon and interleukin-10 on the surface of cytokine-secreting cells	NATURE MEDICINE			English	Article							COLLAGEN PRODUCTION; DERMAL FIBROBLASTS; TUMOR-GROWTH; T-CELLS; EXPRESSION; INHIBITION; RECEPTOR; CONTACT; MOUSE		Deutsch Rheuma Forschungszentrum Berlin, D-10115 Berlin, Germany; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); Miltenyi Biotec	Scheffold, A (corresponding author), Deutsch Rheuma Forschungszentrum Berlin, Hannoversche Str 27, D-10115 Berlin, Germany.		Scheffold, Alexander/S-2090-2016	Scheffold, Alexander/0000-0002-0626-343X; Radbruch, Andreas/0000-0001-5753-0000				Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; BROTHERICK I, 1994, CYTOMETRY, V16, P262, DOI 10.1002/cyto.990160311; Bruno L, 1999, CURR BIOL, V9, P559, DOI 10.1016/S0960-9822(99)80259-0; Chizzolini C, 1998, ARTHRITIS RHEUM-US, V41, P2039; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOLLINI PL, 1993, INT J CANCER, V55, P320, DOI 10.1002/ijc.2910550224; Rezzonico R, 1998, J BIOL CHEM, V273, P18720, DOI 10.1074/jbc.273.30.18720; RICHTER G, 1993, CANCER RES, V53, P4134; SCHEFFOLD A, 1995, IMMUNOTECHNOLOGY, V1, P127, DOI 10.1016/1380-2933(95)00014-3; Shapiro H. M., 1988, PRACTICAL FLOW CYTOM; Zola H, 1994, IMMUNOLOGIST, V2, P47	14	65	70	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					107	110		10.1038/71441	http://dx.doi.org/10.1038/71441			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613835				2022-12-25	WOS:000084583300046
J	Draghia-Akli, R; Fiorotto, ML; Hill, LA; Malone, PB; Deaver, DR; Schwartz, RJ				Draghia-Akli, R; Fiorotto, ML; Hill, LA; Malone, PB; Deaver, DR; Schwartz, RJ			Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs	NATURE BIOTECHNOLOGY			English	Article						growth hormone-releasing hormone; gene therapy; muscle-specific promoter; electroporation	GENE-TRANSFER; PORCINE PLASMA; GH SECRETION; GRF ANALOGS; IN-VIVO; CHILDREN; BOVINE; ELECTROPORATION; DEGRADATION; STABILITY	Ectopic expression of a new serum protease-resistant porcine growth hormone-releasing hormone, directed by an injectable muscle-specific synthetic promoter plasmid vector (pSP-HV-GHRH), elicits growth in pigs. A single 10 mg intramuscular injection of pSP-HV-GHRH DNA followed by electroporation in three week-old piglets elevated serum GHRH levels by twofold to fourfold, enhanced growth hormone secretion, and increased serum insulin-like growth factor-I by threefold to sixfold over control pigs. After 65 days the average body weight of the pigs injected with pSP-HV-GHRH was similar to 37% greater than the placebo-injected controls and resulted in a significant reduction in serum urea concentration, indicating a decrease in amino acid catabolism. Evaluation of body composition indicated a uniform increase in mass, with no organomegaly or associated pathology.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Penn State Univ, University Pk, PA 16802 USA; Appl Vet Syst, Houston, TX 77030 USA; Natl Space Biol Res Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Draghia-Akli, R (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Draghia-Akli, Ruxandra/0000-0001-6372-4039				Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Albanese A, 1997, HORM RES, V48, P173, DOI 10.1159/000185509; Benfield MR, 1997, J PEDIATR-US, V131, pS28, DOI 10.1016/S0022-3476(97)70007-6; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; CAMPBELL RM, 1991, PEPTIDES, V12, P569, DOI 10.1016/0196-9781(91)90103-V; CORPAS E, 1993, J CLIN ENDOCR METAB, V76, P134, DOI 10.1210/jc.76.1.134; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; Draghia-Akli R, 1997, NAT BIOTECHNOL, V15, P1285, DOI 10.1038/nbt1197-1285; ELLIS KJ, 1993, BASIC LIFE SCI, P153; ETHERTON TD, 1986, J ANIM SCI, V63, P1389, DOI 10.2527/jas1986.6351389x; Etherton TD, 1998, PHYSIOL REV, V78, P745, DOI 10.1152/physrev.1998.78.3.745; FROHMAN LA, 1992, FRONT NEUROENDOCRIN, V13, P344; FROHMAN LA, 1984, J CLIN INVEST, V73, P1304, DOI 10.1172/JCI111333; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GESUNDHEIT N, 1995, ENDOCRINE THERAPY RE, P491; Heptulla RA, 1997, J CLIN ENDOCR METAB, V82, P3234, DOI 10.1210/jc.82.10.3234; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; KUBIAK TM, 1989, DRUG METAB DISPOS, V17, P393; LAPIERRE H, 1991, J ANIM SCI, V69, P587; Li XY, 1999, NAT BIOTECHNOL, V17, P241, DOI 10.1038/6981; MARTIN RA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P252, DOI 10.1016/0167-4838(93)90256-Q; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Muramatsu T, 1998, INT J MOL MED, V1, P55; PARK JS, 1995, GROWTH HORMONE DEFIC, P473; Savage MO, 1999, ACTA PAEDIATR, V88, P89, DOI 10.1111/j.1651-2227.1999.tb14360.x; SU CM, 1991, HORM METAB RES, V23, P15, DOI 10.1055/s-2007-1003601; Tanaka H, 1998, EUR J ENDOCRINOL, V138, P275, DOI 10.1530/eje.0.1380275; TANNER JW, 1990, J ENDOCRINOL, V125, P109, DOI 10.1677/joe.0.1250109; Thorner MO, 1997, RECENT PROG HORM RES, V52, P215; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Veldhuis JD, 1997, ENDOCRINE, V7, P41, DOI 10.1007/BF02778061; Watkins SL, 1996, KIDNEY INT, V49, pS126	33	87	112	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1179	1183		10.1038/70718	http://dx.doi.org/10.1038/70718			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585714				2022-12-25	WOS:000084170700024
J	Fisher, S; Halpern, ME				Fisher, S; Halpern, ME			Patterning the zebrafish axial skeleton requires early chordin function	NATURE GENETICS			English	Article							BONE MORPHOGENETIC PROTEINS; SONIC HEDGEHOG; EMBRYO; GENE; ORGANIZER; MICE; MSX2; EXPRESSION; INDUCTION; DOMAINS	Members of the bone morphogenetic protein (BMP) family actively promote ventral cell fates, such as epidermis and blood, in the vertebrate gastrula. More dorsally, the organizer region counteracts BMP signalling through secretion of BMP-binding antagonists chordin and noggin, allowing dorsally derived tissues such as neurectoderm and semitic muscle to develop(1). BMPs also function in skeletal development and regeneration of bone following injury(2). Noggin antagonism is thought to prevent osteogenesis at sites of joint formation(3), whereas chordin has not yet been implicated in skeletogenesis. Analyses of zebrafish mutants have confirmed the action of chordin (chd) in opposing ventralizing signals at gastrulation(4-6). Some ventralized mutants recover and develop into fertile adults, thereby revealing a requirement for chd function for the later processes of fin and caudal skeletal patterning. We observe in mutants the misexpression of genes encoding BMPs and putative downstream genes, and ectopic sclerotomal cells. Through injections of chd mRNA into the early embryo, we restored wild-type gene expression patterns, and the resultant fish, although genotypically mutant, developed normal axial skeletons and fins. Our results demonstrate that chordin function during gastrulation is important for the correct morphogenesis of the adult zebrafish skeleton.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Fisher, S (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001851] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01851-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; Ashe HL, 1999, NATURE, V398, P427, DOI 10.1038/18892; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Connors SA, 1999, DEVELOPMENT, V126, P3119; Fisher S, 1997, DEVELOPMENT, V124, P1301; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JOLY JS, 1993, DEVELOPMENT, V119, P1261; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Maeda R, 1997, DEVELOPMENT, V124, P2553; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Miller-Bertaglio V, 1999, DEV BIOL, V214, P72, DOI 10.1006/dbio.1999.9384; Miller-Bertoglio VE, 1997, DEV BIOL, V192, P537, DOI 10.1006/dbio.1997.8788; MonsoroBurq AH, 1996, DEVELOPMENT, V122, P3607; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Teillet MA, 1998, DEVELOPMENT, V125, P2019; Thomsen GH, 1997, TRENDS GENET, V13, P209, DOI 10.1016/S0168-9525(97)01117-7; Westerfield M, 1995, ZEBRAFISH BOOK; Winograd J, 1997, HUM MOL GENET, V6, P369, DOI 10.1093/hmg/6.3.369	30	82	82	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					442	446		10.1038/70557	http://dx.doi.org/10.1038/70557			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581032				2022-12-25	WOS:000084023900021
J	Nothacker, HP; Wang, ZW; McNeil, AM; Saito, Y; Merten, S; O'Dowd, B; Duckles, SP; Civelli, O				Nothacker, HP; Wang, ZW; McNeil, AM; Saito, Y; Merten, S; O'Dowd, B; Duckles, SP; Civelli, O			Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction	NATURE CELL BIOLOGY			English	Article							UROTENSIN-II; NEUROPEPTIDE; PEPTIDE; FAMILY		Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Toronto, Dept Pharmacol & Med, Toronto, ON M5S 2S1, Canada; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of Toronto; University of California System; University of California Irvine	Civelli, O (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	ocivelli@uci.edu	Civelli, Olivier/A-8392-2012					Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; GIBSON A, 1988, J PHARM PHARMACOL, V40, P893, DOI 10.1111/j.2042-7158.1988.tb06298.x; GIBSON A, 1986, GEN COMP ENDOCR, V64, P435, DOI 10.1016/0016-6480(86)90080-8; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; ITOH H, 1988, EUR J PHARMACOL, V149, P61, DOI 10.1016/0014-2999(88)90042-8; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PEARSON D, 1980, P NATL ACAD SCI-BIOL, V77, P5021, DOI 10.1073/pnas.77.8.5021; PERKINS TDJ, 1990, BIOCHEM SOC T, V18, P918, DOI 10.1042/bst0180918; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; TAL M, 1995, BIOCHEM BIOPH RES CO, V209, P752, DOI 10.1006/bbrc.1995.1563; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489	17	218	228	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					383	385		10.1038/14081	http://dx.doi.org/10.1038/14081			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559967				2022-12-25	WOS:000083169800023
J	Ashcroft, GS; Yang, X; Glick, AB; Weinstein, M; Letterio, JJ; Mizel, DE; Anzano, M; Greenwell-Wild, T; Wahl, SM; Deng, CX; Roberts, AB				Ashcroft, GS; Yang, X; Glick, AB; Weinstein, M; Letterio, JJ; Mizel, DE; Anzano, M; Greenwell-Wild, T; Wahl, SM; Deng, CX; Roberts, AB			Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; HUMAN-MONOCYTES; EXPRESSION; KERATINOCYTES; TGF-BETA-1; MACROPHAGE; INDUCTION; REPAIR; CELLS	The generation of animals lacking SMAD proteins, which transduce signals from transforming growth factor-beta (TGF-beta), has made it possible to explore the contribution of the SMAD proteins to TGF-beta activity in vivo. Here we report that, in contrast to predictions made on the basis of the ability of exogenous TGF-beta to improve wound healing, Smad3-null (Smad3(ex8/ex8)) mice paradoxically show accelerated cutaneous wound healing compared with wild-type mice, characterized by an increased rate of re-epithelialization and significantly reduced local infiltration of monocytes. Smad3(ex8/ex8) keratinocytes show altered patterns of growth and migration, and Smad3(ex8/ex8) monocytes exhibit a selectively blunted chemotactic response to TGF-beta. These data are, to our knowledge, the first to implicate Smad3 in specific pathways of tissue repair and in the modulation of keratinocyte and monocyte function in vivo.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NIDCR, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bldg 41,Room C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.	Robertsa@dce41.nci.nih.gov	XIAO, YANG/GPW-5529-2022; deng, chuxia/N-6713-2016	Yang, Xiao/0000-0002-0298-9831	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashcroft GS, 1997, NAT MED, V3, P1209, DOI 10.1038/nm1197-1209; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; GROSS J, 1995, P NATL ACAD SCI USA, V92, P5982, DOI 10.1073/pnas.92.13.5982; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; MUSTOE TA, 1991, J CLIN INVEST, V87, P694, DOI 10.1172/JCI115048; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229, DOI 10.1073/pnas.86.7.2229; Roberts Anita B., 1995, Wound Repair and Regeneration, V3, P408, DOI 10.1046/j.1524-475X.1995.30405.x; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; WAHL SM, 1993, P NATL ACAD SCI USA, V90, P4577, DOI 10.1073/pnas.90.10.4577; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	33	732	787	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					260	266		10.1038/12971	http://dx.doi.org/10.1038/12971			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559937				2022-12-25	WOS:000083169600013
J	Hurvitz, JR; Suwairi, WM; Van Hul, W; El-Shanti, H; Superti-Furga, A; Roudier, J; Holderbaum, D; Pauli, RM; Herd, JK; Van Hul, E; Rezai-Delui, H; Legius, E; Le Merrer, M; Al-Alami, J; Bahabri, SA; Warman, ML				Hurvitz, JR; Suwairi, WM; Van Hul, W; El-Shanti, H; Superti-Furga, A; Roudier, J; Holderbaum, D; Pauli, RM; Herd, JK; Van Hul, E; Rezai-Delui, H; Legius, E; Le Merrer, M; Al-Alami, J; Bahabri, SA; Warman, ML			Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia	NATURE GENETICS			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; CHILDHOOD PPAC; CYR61; EXPRESSION; PRODUCT; CELLS; MOUSE; DISORDER; IDENTIFICATION	Members of the CCN (for CTGF; cyr61/cef10, nov) gene family encode cysteine-rich secreted proteins with roles in cell growth and differentiation(1). Cell-specific and tissue-specific differences in the expression and function of different CCN family members suggest they have non-redundant roles. Using a positional-candidate approach, we found that mutations in the CCN family member WISP3 are associated with the autosomal recessive skeletal disorder progressive pseudorheumatoid dysplasia (PPD; MIM 208230). PPD is an autosomal recessive disorder that may be initially misdiagnosed as juvenile rheumatoid arthritis(2-5). Its population incidence has been estimated at 1 per million in the United Kingdom(4), but it is likely to be higher in the Middle East and Gulf States(6). Affected individuals are asymptomatic in early childhood(2, 3). Signs and symptoms of disease typically develop between three and eight years of age. Clinically and radiographically, patients experience continued cartilage loss and destructive bone changes as they age(2-7), in several instances necessitating joint replacement surgery by the third decade of life. Extraskeletal manifestations have not been reported in PPD. Cartilage appears to he the primary affected tissue, and in one patient, a biopsy of the iliac crest revealed abnormal nests of chondrocytes and loss of normal cell columnar organization in growth zones(5). We have identified nine different WISP3 mutations in unrelated, affected individuals, indicating that the gene is essential for normal post-natal skeletal growth and cartilage homeostasis.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Div Rheumatol, Cleveland, OH 44106 USA; Royal Mil Hosp, Dept Pediat, Riyadh, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia; Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Jordan Univ Sci & Technol, Dept Pediat, Irbid, Jordan; Jordan Univ Sci & Technol, Dept Med Lab Sci, Irbid, Jordan; Jordan Univ Sci & Technol, Dept Biochem, Irbid, Jordan; Univ Zurich, Dept Pediat, Div Mol Pediat, Zurich, Switzerland; Univ Mediterranee, INSERM E9940, Marseille, France; Univ Wisconsin, Childrens Hosp, Div Genet, Madison, WI 53706 USA; E Tennessee State Univ, James H Quillen Coll Med, Dept Pediat, Johnson City, TN 37614 USA; Mashad Univ, Ghaen Hosp, Dept Radiol, Mashad, Iran; Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; Hop Necker Enfants Malad, Dept Genet, Paris, France; Hop Necker Enfants Malad, INSERM U393, Paris, France	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Prince Sultan Military Medical City; King Faisal Specialist Hospital & Research Center; University of Antwerp; Jordan University of Science & Technology; Jordan University of Science & Technology; Jordan University of Science & Technology; University of Zurich; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Children's Hospital of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; East Tennessee State University; Universite Catholique Louvain; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Warman, ML (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.		superti-furga, andrea/E-9162-2015; Legius, Eric/H-1735-2011; roudier, jean/A-8654-2011; El-Shanti, Hatem/O-5990-2014; EL-SHANTI, HATEM/Q-4932-2016	superti-furga, andrea/0000-0002-3543-7531; roudier, jean/0000-0001-5435-8567; El-Shanti, Hatem/0000-0001-6230-8316; EL-SHANTI, HATEM/0000-0001-6230-8316; Van Hul, Wim/0000-0002-5065-7858	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043827] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43827] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Carrel L, 1996, HUM MOL GENET, V5, P391, DOI 10.1093/hmg/5.3.391; Dale TC, 1998, BIOCHEM J, V329, P209; El-Shanti H, 1998, EUR J HUM GENET, V6, P251, DOI 10.1038/sj.ejhg.5200187; ElShanti HE, 1997, J MED GENET, V34, P559, DOI 10.1136/jmg.34.7.559; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fischer J, 1998, HUM GENET, V103, P60, DOI 10.1007/s004390050784; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; KOZLOWSKI K, 1986, Australasian Radiology, V30, P244, DOI 10.1111/j.1440-1673.1986.tb01748.x; LEGIUS E, 1993, CLIN GENET, V44, P152; Martinerie C, 1996, ONCOGENE, V12, P1479; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Parr BA, 1998, DEV BIOL, V202, P228, DOI 10.1006/dbio.1998.9007; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; REZAIDELUI H, 1994, SKELETAL RADIOL, V23, P411; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Schutze N, 1998, ENDOCRINOLOGY, V139, P1761, DOI 10.1210/en.139.4.1761; SPRANGER J, 1983, EUR J PEDIATR, V140, P34, DOI 10.1007/BF00661902; TEEBI AS, 1986, J MED GENET, V23, P189, DOI 10.1136/jmg.23.2.189-a; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; WYNNEDAVIES R, 1982, J BONE JOINT SURG BR, V64, P442, DOI 10.1302/0301-620X.64B4.6807993; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623-199812000-00004; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	33	200	219	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					94	98		10.1038/12699	http://dx.doi.org/10.1038/12699			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471507				2022-12-25	WOS:000082337300024
J	Jones, CR; Campbell, SS; Zone, SE; Cooper, F; DeSano, A; Murphy, PJ; Jones, B; Czajkowski, L; Ptacek, LJ				Jones, CR; Campbell, SS; Zone, SE; Cooper, F; DeSano, A; Murphy, PJ; Jones, B; Czajkowski, L; Ptacek, LJ			Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans	NATURE MEDICINE			English	Article							CLOCK	Biological circadian clocks oscillate with an approximately 24-hour period, are ubiquitous, and presumably confer a selective advantage by anticipating the transitions between day and night. The circadian rhythms of sleep, melatonin secretion and body core temperature are thought to be generated by the suprachiasmatic nucleus of the hypothalamus, the anatomic locus of the mammalian circadian clock(1,2). Autosomal semi-dominant mutations in rodents with fast or slow biological clocks (that is, short or long endogenous period lengths; tau) are associated with phase-advanced or delayed sleep-wake rhythms, respectively. These models predict the existence of familial human circadian rhythm variants(3,4) but none of the human circadian rhythm disorders are known to have a familial tendency(5). Although a slight 'morning lark' tendency is common, individuals with a large and disabling sleep phase-advance are rare. This disorder, advanced sleep-phase syndrome, is characterized by very early sleep onset and offset; only two cases are reported in young adults(6,7). Here we describe three kindreds with a profound phase advance of the sleep-wake, melatonin and temperature rhythms associated with a very short tau. The trait segregates as an autosomal dominant with high penetrance. These kindreds represent a well-characterized familial circadian rhythm variant in humans and provide a unique opportunity for genetic analysis of human circadian physiology.	Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA; Univ Hosp, Sleep Disorders Ctr, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Management, Salt Lake City, UT 84112 USA; Univ Utah, David Eccles Sch Business, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Program Neurosci, Salt Lake City, UT 84112 USA; Cornell Univ, Weill Med Coll, Dept Psychiat, White Plains, NY 10605 USA	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Cornell University	Ptacek, LJ (corresponding author), Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA.			Jones, Bryan/0000-0001-5527-6643	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059596] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [HL/HD 59596] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS, P133; Beck A.T, 1978, BECK DEPRESSION INVE; Billiard M, 1993, SLEEP RES, V22, P109; CAMPBELL SS, 1989, SLEEP, V12, P529; CAMPBELL SS, 1993, SLEEP, V16, P638; CARSKADON MA, 1975, ELECTROEN CLIN NEURO, V39, P145, DOI 10.1016/0013-4694(75)90004-8; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Drennan M. D., 1992, Society for Neuroscience Abstracts, V18, P196; Duffy J. F, 1999, SLEEP, V22, pS92; GREENWOOD KM, 1994, ERGONOMICS, V37, P377, DOI 10.1080/00140139408963653; Haimov I, 1997, SLEEP, V20, P294, DOI 10.1093/sleep/20.4.294; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; KEENAN SA, 1994, SLEEP DISORDERS MED, P79; Klerman EB, 1996, AM J PHYSIOL-REG I, V270, pR271, DOI 10.1152/ajpregu.1996.270.1.R271; LAVIE P, 1986, ELECTROEN CLIN NEURO, V63, P414, DOI 10.1016/0013-4694(86)90123-9; LEWY AJ, 1989, CHRONOBIOL INT, V6, P93, DOI 10.3109/07420528909059144; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED, P1; SHANAHAN TL, 1991, J CLIN ENDOCR METAB, V73, P27; Singer CM, 1989, SLEEP RES, V18, P445; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	24	359	372	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1062	1065		10.1038/12502	http://dx.doi.org/10.1038/12502			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470086				2022-12-25	WOS:000082337200043
J	Saxena, M; Williams, S; Tasken, K; Mustelin, T				Saxena, M; Williams, S; Tasken, K; Mustelin, T			Crosstalk between cAMP-dependent kinase and MAP kinase through a protein tyrosine phosphatase	NATURE CELL BIOLOGY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; SURFACE MOLECULES; RESPONSE ELEMENT; NUCLEAR-PROTEIN; T-LYMPHOCYTES; ACTIVATION	The haematopoietic protein tyrosine phosphatase (HePTP) is a negative regulator of the MAP kinases Erk1, Erk2 and p38. HePTP binds to these kinases through a kinase-interaction motif (KIM) in its non-catalytic amino terminus and inactivates them by dephosphorylating the critical phosphorylated tyrosine residue in their activation loop. Here we show that cyclic-AMP-dependent protein kinase (PKA) phosphorylates serine residue 23 in the KIM of HePTP in vitro and in intact cells. This modification reduces binding of MAP kinases to the KIM, an effect that is prevented by mutation of serine 23 to alanine. The PKA-mediated release of MAP kinase from HePTP is sufficient to activate the kinase and to induce transcription from the c-fos promoter. Expression of a HePTP serine-23-to-alanine mutant inhibits MAP-kinase dissociation and activation and induction of transcription from the c-fos promoter. We conclude that HePTP not only controls the activity of MAP kinases, but also mediates crosstalk between the cAMP system and the MAP-kinase cascade.	Sidney Kimmel Canc Ctr, Lab Signal Transduct, San Diego, CA 92121 USA; Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway	University of Oslo	Mustelin, T (corresponding author), Sidney Kimmel Canc Ctr, Lab Signal Transduct, 10835 Altman Row, San Diego, CA 92121 USA.			Mustelin, Tomas/0000-0001-5912-8840; Tasken, Kjetil/0000-0003-2841-4697	NIAID NIH HHS [AI40552, AI35603, AI41481] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040552, R01AI040552, R01AI141481, R01AI035603, R01AI041481] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chen TS, 1999, CANCER RES, V59, P213; Choudhry MA, 1998, J IMMUNOL, V160, P929; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KAMMER GM, 1994, J CLIN INVEST, V94, P422, DOI 10.1172/JCI117340; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; Levy FO, 1996, EUR J IMMUNOL, V26, P1290, DOI 10.1002/eji.1830260617; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; LUO K, 1990, ONCOGENE, V5, P921; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Muda M, 1996, J BIOL CHEM, V271, P4319; Mustelin T., 1998, Frontiers in Bioscience, V3, pD1060; MUSTELIN T, IN PRESS CELL SIGNAL; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; SHIOZUKA K, 1995, GENE, V162, P279, DOI 10.1016/0378-1119(95)00306-Q; Skalhegg Bjorn S., 1997, Frontiers in Bioscience (online), V2, pD331; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SWEITER M, 1995, J BIOL CHEM, V270, P21902; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WHISLER RL, 1992, CELL IMMUNOL, V142, P398, DOI 10.1016/0008-8749(92)90300-E; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	48	182	184	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					305	311		10.1038/13024	http://dx.doi.org/10.1038/13024			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559944				2022-12-25	WOS:000083169600020
J	Braun, BC; Glickman, M; Kraft, R; Dahlmann, B; Kloetzel, PM; Finley, D; Schmidt, M				Braun, BC; Glickman, M; Kraft, R; Dahlmann, B; Kloetzel, PM; Finley, D; Schmidt, M			The base of the proteasome regulatory particle exhibits chaperone-like activity	NATURE CELL BIOLOGY			English	Article							CITRATE SYNTHASE; 20S PROTEASOME; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; BINDING; DEGRADATION; RESOLUTION	Protein substrates of the proteasome must apparently be unfolded and translocated through a narrow channel to gain access to the proteolytic active sites of the enzyme. Protein folding in vivo is mediated by molecular chaperones. Here, to test for chaperone activity of the proteasome, we assay the reactivation of denatured citrate synthase, Both human and yeast proteasomes stimulate the recovery of the native structure of citrate synthase, We map this chaperone-like activity to the base of the regulatory particle of the proteasome, that is, to the ATPase-containing assembly located at the substrate-entry ports of the channel. Denatured but not native citrate synthase is bound by the base complex. Ubiquitination of citrate synthase is not required for its binding or refolding by the base complex of the proteasome, These data suggest a model in which ubiquitin-protein conjugates are initially tethered to the proteasome by specific recognition of their ubiquitin chains; this step is followed by a nonspecific interaction between the base and the target protein, which promotes substrate unfolding and translocation.	Humboldt Univ, Inst Biochem, Fak Med, D-10117 Berlin, Germany; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Diabet Forschungsinst, D-40225 Dusseldorf, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Humboldt University of Berlin; Technion Israel Institute of Technology; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Harvard University; Harvard Medical School	Schmidt, M (corresponding author), Humboldt Univ, Inst Biochem, Fak Med, Monbijoustr 2, D-10117 Berlin, Germany.	marion_schmidt@hms.harvard.edu	Braun, Beate C/J-8641-2016	Glickman, Michael/0000-0002-1222-8104	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043601, R01GM043601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43601] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama Y, 1998, MOL MICROBIOL, V28, P803, DOI 10.1046/j.1365-2958.1998.00843.x; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Henke W, 1999, MOL BIOL REP, V26, P29, DOI 10.1023/A:1006991419464; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021	29	370	378	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					221	226		10.1038/12043	http://dx.doi.org/10.1038/12043			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559920				2022-12-25	WOS:000083102700017
J	Nef, S; Parada, LF				Nef, S; Parada, LF			Cryptorchidism in mice mutant for Insl3	NATURE GENETICS			English	Article							TESTICULAR DESCENT; HORMONAL-CONTROL; CELLS; GUBERNACULUM; EXPRESSION; RECEPTOR; NEURONS; TESTES; MOUSE; GENE	Impaired testicular descent (cryptorchidism) is one of the most frequent congenital abnormalities in humans, involving 2% of male births'. Cryptorchidism can result in infertility and increases risk for development of germ-cell tumours. Testicular descent from abdomen to scrotum occurs in two distinct phases: the trans-abdominal phase and the inguino-scrotal phase(1-3). Currently, little is known about the factors that regulate the trans-abdominal phase of testicular descent. Leydig insulin-like hormone (Insl3) is a member of the insulin hormone superfamily(4) expressed in the developing testis(5). We show here that mice mutant for Insl(3) are viable, but exhibit bilateral cryptorchidism due to developmental abnormalities of the gubernaculum, resulting in abnormal spermatogenesis and infertility. Female homozygotes have impaired fertility associated with deregulation of the oestrus cycle. These findings reveal roles for lnsl(3) in the development of the urogenital tract and in female fertility. lnsl(3) may act as a hormone to regulate the growth and differentiation of the gubernaculum, thereby mediating intra-abdominal testicular descent.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Nef, Serge/AAV-6445-2020; Parada, luis F/B-9400-2014	Nef, Serge/0000-0001-5462-0676; 				ADHAM IM, 1993, J BIOL CHEM, V268, P26668; BERKOWITZ GS, 1993, PEDIATRICS, V92, P44; GRIFFITHS AL, 1993, INT J ANDROL, V16, P380, DOI 10.1111/j.1365-2605.1993.tb01365.x; HUSMANN DA, 1995, UROLOGY, V46, P267, DOI 10.1016/S0090-4295(99)80207-6; HUTSON JM, 1994, REPROD FERT DEVELOP, V6, P151, DOI 10.1071/RD9940151; HUTSON JM, 1985, LANCET, V2, P419; Liebl DJ, 1997, J NEUROSCI, V17, P9113; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nef S, 1997, P NATL ACAD SCI USA, V94, P4766, DOI 10.1073/pnas.94.9.4766; NISHIMUNE Y, 1978, FERTIL STERIL, V29, P95; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; RESKO JA, 1973, ENDOCRINOLOGY, V93, P156, DOI 10.1210/endo-93-1-156; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; Shono T, 1996, INT J ANDROL, V19, P263, DOI 10.1111/j.1365-2605.1996.tb00474.x; Thomson AA, 1997, DEVELOPMENT, V124, P2431; Tsuji M, 1998, J STEROID BIOCHEM, V67, P113, DOI 10.1016/S0960-0760(98)00079-X; VISSER JH, 1995, J UROLOGY, V153, P516, DOI 10.1097/00005392-199502000-00074; VONFENTENER VJM, 1988, ENDOCRINOLOGY, V123, P2868; WENSING CJG, 1988, HORM RES, V30, P144, DOI 10.1159/000181051; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; WILSON JD, 1983, AUST J BIOL SCI, V36, P101; Zarrow MX, 1964, EXPT ENDOCRINOLOGY S; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmermann S, 1997, MOL REPROD DEV, V47, P30, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;30::AID-MRD5&gt;3.0.CO;2-R; Zimmermann S, 1999, MOL ENDOCRINOL, V13, P681, DOI 10.1210/me.13.5.681	26	547	572	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					295	299		10.1038/10364	http://dx.doi.org/10.1038/10364			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391220				2022-12-25	WOS:000081125900025
J	Pawliuk, R; Bachelot, T; Wise, RJ; Mathews-Roth, MM; Leboulch, P				Pawliuk, R; Bachelot, T; Wise, RJ; Mathews-Roth, MM; Leboulch, P			Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy	NATURE MEDICINE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; BETA-GLOBIN GENE; RETROVIRAL VECTORS; HOST-DEFENSE; HOUSE MOUSE; STEM-CELLS; IN-VIVO; FERROCHELATASE; SELECTION; EXPRESSION	Definitive cure of an animal model of a human disease by gene transfer into hematopoietic stem cells has not yet been accomplished in the absence of spontaneous in vivo selection for transduced cells. Erythropoietic protoporphyria is a genetic disease in which ferrochelatase is defective. Protoporphyrin accumulates in erythrocytes, leaks into the plasma and results in severe skin photosensitivity. Using a mouse model of erythropoietic protoporphyria, we demonstrate here that ex vivo preselection of hematopoietic stem cells transduced with a polycistronic retrovirus expressing both human ferrochelatase and green fluorescent protein results in complete and long-term correction of skin photosensitivity in all transplanted mice.	Harvard Univ, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA; Genetix Pharmaceut, Cambridge, MA 02139 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT)	Mathews-Roth, MM (corresponding author), Harvard Univ, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL55435] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjorgvinsdottir H, 1997, BLOOD, V89, P41, DOI 10.1182/blood.V89.1.41.41_41_48; BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Cheng LZ, 1998, BLOOD, V92, P83, DOI 10.1182/blood.V92.1.83.413k09_83_92; Conneally E, 1998, BLOOD, V91, P3487, DOI 10.1182/blood.V91.9.3487.3487_3487_3493; DESNICK R, 1994, HARRISONS PRINCIPLES, V1, P2073; deTorres I, 1996, TRANSPLANTATION, V61, P1412, DOI 10.1097/00007890-199605150-00024; HAWLEY RG, 1994, GENE THER, V1, P136; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; LEBOULCH P, 1994, EMBO J, V13, P3065, DOI 10.1002/j.1460-2075.1994.tb06605.x; Mardiney M, 1997, BLOOD, V89, P2268, DOI 10.1182/blood.V89.7.2268; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MATHEWSROTH MM, 1977, ARCH DERMATOL, V113, P1229, DOI 10.1001/archderm.113.9.1229; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; PAWLIUK R, 1994, BLOOD, V84, P2868, DOI 10.1182/blood.V84.9.2868.bloodjournal8492868; Pawliuk R, 1997, HUM GENE THER, V8, P1595, DOI 10.1089/hum.1997.8.13-1595; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perez-Tamayo R, 1979, Pathol Annu, V14 Pt 2, P183; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; PIOMELLI S, 1977, CLIN CHEM, V23, P264; Raftopoulos H, 1997, BLOOD, V90, P3414, DOI 10.1182/blood.V90.9.3414; SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414; TUTOIS S, 1991, J CLIN INVEST, V88, P1730, DOI 10.1172/JCI115491; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Youssoufian H, 1996, NAT GENET, V13, P255, DOI 10.1038/ng0796-255; Zimmermann A, 1997, SCHWEIZ MED WSCHR, V127, P812	27	70	71	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	1999	5	7					768	773		10.1038/10488	http://dx.doi.org/10.1038/10488			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395321				2022-12-25	WOS:000081926600031
J	Atkinson, MA; Leiter, EH				Atkinson, MA; Leiter, EH			The NOD mouse model of type 1 diabetes: As good as it gets?	NATURE MEDICINE			English	Editorial Material									Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Jackson Lab, Bar Harbor, ME 04609 USA	State University System of Florida; University of Florida; Jackson Laboratory	Atkinson, MA (corresponding author), Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA.							Delovitch TL, 1997, IMMUNITY, V7, P727, DOI 10.1016/S1074-7613(00)80392-1; Ellerman KE, 1996, DIABETES, V45, P557, DOI 10.2337/diabetes.45.5.557; Komeda K, 1998, ENDOCR J, V45, P737, DOI 10.1507/endocrj.45.737; LEITER EH, 1998, MED INTELLIGENCE UNI; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V; Takahashi K, 1998, J IMMUNOL, V161, P2629	6	469	508	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1999	5	6					601	604		10.1038/9442	http://dx.doi.org/10.1038/9442			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371488				2022-12-25	WOS:000080823300018
J	Falcioni, F; Ito, K; Vidovic, D; Belunis, C; Campbell, R; Berthel, SJ; Bolin, DR; Gillespie, PB; Huby, N; Olson, GL; Sarabu, R; Guenot, J; Madison, V; Hammer, J; Sinigaglia, F; Steinmetz, M; Nagy, ZA				Falcioni, F; Ito, K; Vidovic, D; Belunis, C; Campbell, R; Berthel, SJ; Bolin, DR; Gillespie, PB; Huby, N; Olson, GL; Sarabu, R; Guenot, J; Madison, V; Hammer, J; Sinigaglia, F; Steinmetz, M; Nagy, ZA			Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules	NATURE BIOTECHNOLOGY			English	Article						peptidomimetics; antigen presentation; autoimmune disease	MHC CLASS-II; RHEUMATOID-ARTHRITIS; CRYSTAL-STRUCTURE; BINDING PEPTIDES; SELF-PEPTIDES; T-CELLS; COMPLEX; HLA; SUSCEPTIBILITY; HLA-DR1	We have identified a heptapeptide with high affinity to rheumatoid arthritis-associated class II major histocompatibility (MHC) molecules. Using a model of its interaction with the class II binding site, a variety of mimetic substitutions were introduced into the peptide. Several unnatural amino acids and dipeptide mimetics were found to be appropriate substituents and could be combined into compounds with binding affinities comparable to that of the original peptide. Compounds were designed that were several hundred-fold to more than a thousand-fold more potent than the original peptide in inhibiting T-cell responses to processed protein antigens presented by the target MHC molecules. Peptidomimetic compounds of this type could find therapeutic use as MHC-selective antagonists of antigen presentation in the treatment of autoimmune diseases.	Hoffmann La Roche Inc, Dept Inflammat & Autoimmune Dis, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Dept Phys Chem, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Dept Preclin Res, Nutley, NJ 07110 USA; Hoffmann La Roche Inc, Dept Immunol, Nutley, NJ 07110 USA; Roche Milano Ric, I-20132 Milan, Italy	Roche Holding; Roche Holding; Roche Holding; Roche Holding; Roche Holding	Nagy, ZA (corresponding author), Genome Pharmaceut Corp, D-82152 Martinsried, Germany.		Berthel, Steven/AAQ-7526-2020	Berthel, Steven/0000-0003-1250-0208				ADORINI L, 1988, NATURE, V334, P623, DOI 10.1038/334623a0; ATTWOOD MR, 1986, J CHEM SOC P1, V1, P1011, DOI DOI 10.1039/P19860001011; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHO JH, 1987, J ORG CHEM, V52, P4517, DOI 10.1021/jo00229a016; CHUNG JYL, 1990, J ORG CHEM, V55, P270, DOI 10.1021/jo00288a045; DELOMBAERT S, 1994, TETRAHEDRON LETT, V35, P7513, DOI 10.1016/S0040-4039(00)78331-6; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; DORROW RL, 1995, J ORG CHEM, V60, P4986; EVANS DA, 1989, J AM CHEM SOC, V111, P1063, DOI 10.1021/ja00185a042; Falcioni F, 1996, HUM IMMUNOL, V50, P79, DOI 10.1016/0198-8859(96)00121-8; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GORDON T, 1993, BIOORG MED CHEM LETT, V3, P915, DOI 10.1016/S0960-894X(00)80692-7; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; HURTENBACH U, 1993, J EXP MED, V177, P1499, DOI 10.1084/jem.177.5.1499; ISHIOKA GY, 1994, J IMMUNOL, V152, P4310; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; LANCHBURY JSS, 1991, HUM IMMUNOL, V32, P56, DOI 10.1016/0198-8859(91)90117-R; LAPATSANIS L, 1983, SYNTHESIS-STUTTGART, P671, DOI 10.1055/s-1983-30468; MCMICHAEL AJ, 1977, ARTHRITIS RHEUM, V20, P1037, DOI 10.1002/art.1780200501; NEPOM BS, 1993, CLIN IMMUNOL IMMUNOP, V67, pS50, DOI 10.1006/clin.1993.1084; NEPOM GT, 1989, ARTHRITIS RHEUM, V32, P15, DOI 10.1002/anr.1780320104; OHTA N, 1982, HUM IMMUNOL, V5, P123, DOI 10.1016/0198-8859(82)90057-X; SAKAI K, 1989, P NATL ACAD SCI USA, V86, P9470, DOI 10.1073/pnas.86.23.9470; SCHIFF B, 1982, ANN RHEUM DIS, V41, P403, DOI 10.1136/ard.41.4.403; Siklodi B, 1998, HUM IMMUNOL, V59, P463, DOI 10.1016/S0198-8859(98)00038-X; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STORK G, 1976, J ORG CHEM, V41, P3491, DOI 10.1021/jo00883a044; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; WEISS GA, 1995, CHEM BIOL, V2, P401, DOI 10.1016/1074-5521(95)90221-X; WORDSWORTH P, 1992, AM J HUM GENET, V51, P585; Woulfe SL, 1997, J PHARMACOL EXP THER, V281, P663; WUCHERPFENNIG KW, 1995, P NATL ACAD SCI USA, V92, P11935, DOI 10.1073/pnas.92.25.11935	40	50	60	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					562	567		10.1038/9865	http://dx.doi.org/10.1038/9865			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385320				2022-12-25	WOS:000080716500027
J	Houten, SM; Kuis, W; Duran, M; de Koning, TJ; van Royen-Kerkhof, A; Romeijn, GJ; Frenkel, J; Dorland, L; de Barse, MMJ; Huijbers, WAR; Rijkers, GT; Waterham, HR; Wanders, RJA; Poll-The, BT				Houten, SM; Kuis, W; Duran, M; de Koning, TJ; van Royen-Kerkhof, A; Romeijn, GJ; Frenkel, J; Dorland, L; de Barse, MMJ; Huijbers, WAR; Rijkers, GT; Waterham, HR; Wanders, RJA; Poll-The, BT			Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome	NATURE GENETICS			English	Article							ACIDURIA; IDENTIFICATION; CHOLESTEROL; DEFICIENCY	Hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM 260920) is an autosomal recessive disorder characterized by recurrent episodes of fever associated with lymphadenopathy, arthralgia, gastrointestinal dismay and skin rash(1,) (2). Diagnostic hallmark of HIDS is a constitutively elevated level of serum immunoglobulin D (IgD), although patients have been reported with normal IgD levels'. To determine the underlying defect in HIDS, we analysed urine of several patients and discovered increased concentrations of mevalonic acid during severe episodes of fever, but not between crises. Subsequent analysis of cells from four unrelated HIDS patients revealed reduced activities of mevalonate kinase (MK; encoded by the gene MVK), a key enzyme of isoprenoid biosynthesis. Sequence analysis of MVK cDNA from the patients identified three different mutations, one of which was common to all patients. Expression of the mutant cDNAs in Escherichia coli showed that all three mutations affect the activity of the encoded proteins. Moreover, immunoblot analysis demonstrated a deficiency of MK protein in patient fibroblasts, indicating a protein-destabilizing effect of the mutations.	Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Metab Disorders, Utrecht, Netherlands; Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Immunol, Utrecht, Netherlands; Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Gen Pediat, Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat, NL-1105 AZ Amsterdam, Netherlands; Beatrix Hosp, Gorinchem, Netherlands	Utrecht University; Utrecht University; Utrecht University; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Waterham, HR (corresponding author), Univ Utrecht, Childrens Hosp Het Wilhelmina Kinderziekenhuis, Dept Metab Disorders, Utrecht, Netherlands.	h.r.waterham@amc.uva.nl; b.pollthe@wkz.azu.nl	Rijkers, Ger/R-7236-2019; Houten, Sander/Y-3599-2019; De Koning, Tom J/AAE-1323-2020; Rijkers, Ger/AAW-6143-2020	Rijkers, Ger/0000-0001-6948-6123; Houten, Sander/0000-0002-6167-9147; De Koning, Tom J/0000-0001-5609-1309; Poll-The, Bwee Tien/0000-0002-8118-5419				BIARDI L, 1994, J BIOL CHEM, V269, P1197; Centola M, 1998, HUM MOL GENET, V7, P1581, DOI 10.1093/hmg/7.10.1581; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hinson DD, 1997, J BIOL CHEM, V272, P26756, DOI 10.1074/jbc.272.42.26756; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; HOFFMANN GF, 1992, J INHERIT METAB DIS, V15, P738, DOI 10.1007/BF01800016; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7; Lindenthal B, 1996, J LIPID RES, V37, P2193; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; VANDERMEER JWM, 1984, LANCET, V1, P1087	13	367	377	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	1999	22	2					175	177		10.1038/9691	http://dx.doi.org/10.1038/9691			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369261				2022-12-25	WOS:000080680900024
J	Pitt, D; Werner, P; Raine, CS				Pitt, D; Werner, P; Raine, CS			Glutamate excitotoxicity in a model of multiple sclerosis	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NMDA RECEPTOR; INVITRO; BRAIN; MICE	Glutamate excitotoxicity mediated by the AMPA/kainate type of glutamate receptors damages not only neurons but also the myelin-producing cell of the central nervous system, the oligodendrocyte(1). In multiple sclerosis, myelin, oligodendrocytes and some axons are lost as a result of an inflammatory attack on the central nervous system(2). Because glutamate is released in large quantities by activated immune cells(3), we expected that during inflammation in MS, glutamate excitotoxicity might contribute to the lesion. We addressed this by using the AMPA/kainate antagonist NBQX to treat mice sensitized for experimental autoimmune encephalomyelitis, a demyelinating model that mimics many of the clinical and pathologic features of multiple sclerosis. Treatment resulted in substantial amelioration of disease, increased oligodendrocyte survival and reduced dephosphorylation of neurofilament H, an indicator of axonal damage(4). Despite the clinical differences, treatment with NBQX had no effect on lesion size and did not reduce the degree of central nervous system inflammation. In addition, NBQX did not alter the proliferative activity of antigen-primed T cells in vitro, further indicating a lack of effect on the immune system. Thus, glutamate excitotoxicity seems to be an important mechanism in autoimmune demyelination, and its prevention with AMPA/kainate antagonists may prove to be an effective therapy for multiple sclerosis.	Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Beth Israel Med Ctr, Dept Neurol, New York, NY 10003 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Beth Israel Deaconess Medical Center	Werner, P (corresponding author), Albert Einstein Coll Med, Dept Neurol, F-121N,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011920, P50NS011920] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 11920, NS 07098, NS 08952] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RD, 1952, AM J MED, V12, P510, DOI 10.1016/0002-9343(52)90234-9; BURYAKOVA AV, 1975, ARCH NEUROL-CHICAGO, V32, P28, DOI 10.1001/archneur.1975.00490430050007; Cannella B, 1998, P NATL ACAD SCI USA, V95, P10100, DOI 10.1073/pnas.95.17.10100; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; Ding MZ, 1998, J IMMUNOL, V160, P2560; Espey MG, 1998, J NEUROCHEM, V71, P2079; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; HardinPouzet H, 1997, GLIA, V20, P79, DOI 10.1002/(SICI)1098-1136(199705)20:1<79::AID-GLIA8>3.0.CO;2-0; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; O'Neill MJ, 1998, NEUROPHARMACOLOGY, V37, P1211, DOI 10.1016/S0028-3908(98)00134-8; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Prineas J. W., 1997, GREENFIELDS NEUROPAT, P813; Raine C.S., 1997, MULTIPLE SCLEROSIS C, P243; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Rosenberg LJ, 1999, J NEUROSCI, V19, P464, DOI 10.1523/JNEUROSCI.19-01-00464.1999; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; SZARO BG, 1990, J COMP NEUROL, V302, P220, DOI 10.1002/cne.903020204; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Yoshioka A, 1996, J NEUROSCI RES, V46, P427	22	662	696	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					67	70		10.1038/71555	http://dx.doi.org/10.1038/71555			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613826				2022-12-25	WOS:000084583300037
J	Su, H; Wang, XH; Bradley, A				Su, H; Wang, XH; Bradley, A			Nested chromosomal deletions induced with retroviral vectors in mice	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; GENETIC-MAP; MOUSE; SCREEN	Chromosomal deletions, especially nested deletions, are major genetic tools in diploid organisms that facilitate the functional analysis of large chromosomal regions and allow the rapid localization of mutations to specific genetic intervals. In mice, well-characterized overlapping deletions are only available at a few chromosomal loci(1,2), partly due to drawbacks of existing methods. Here we exploit the random integration of a retrovirus to generate high-resolution sets of nested deletions around defined loci in embryonic stem (ES) cells, with sizes extending from a few kilobases to several megabases. This approach expands the application of Cre-loxP-based chromosome engineering(3) because it not only allows the construction of hundreds of overlapping deletions, but also provides molecular entry points to regions based on the retroviral tags. Our approach can be extended to any region of the mouse genome.	Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Bradley, A (corresponding author), Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839				Abuin A, 1996, MOL CELL BIOL, V16, P1851; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Bridges CB, 1917, GENETICS, V2, P445; Cai WW, 1998, GENOMICS, V54, P387, DOI 10.1006/geno.1998.5620; CATTANACH BM, 1993, NAT GENET, V3, P56, DOI 10.1038/ng0193-56; DALBY B, 1995, GENETICS, V139, P757; DIETRICH W, 1992, GENETICS, V131, P423; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; Kushi A, 1998, MAMM GENOME, V9, P269, DOI 10.1007/s003359900747; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; Liu PT, 1998, GENETICS, V150, P1155; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; OCHMAN H, 1988, GENETICS, V120, P621; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Rinchik E.M., 1990, GENOME ANAL, P121; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; Thomas JW, 1998, P NATL ACAD SCI USA, V95, P1114, DOI 10.1073/pnas.95.3.1114; You Y, 1997, NAT GENET, V15, P285, DOI 10.1038/ng0397-285; ZHANG HB, 1994, MOL CELL BIOL, V14, P2404, DOI 10.1128/MCB.14.4.2404; ZHENG B, IN PRESS MOL CELL BI	24	45	51	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					92	95		10.1038/71756	http://dx.doi.org/10.1038/71756			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615136				2022-12-25	WOS:000084609200024
J	Wiles, MV; Vauti, F; Otte, J; Fuchtbauer, EM; Ruiz, P; Fuchtbauer, A; Arnold, HH; Lehrach, H; Metz, T; von Melchner, H; Wurstz, W				Wiles, MV; Vauti, F; Otte, J; Fuchtbauer, EM; Ruiz, P; Fuchtbauer, A; Arnold, HH; Lehrach, H; Metz, T; von Melchner, H; Wurstz, W			Establishment of a gene-trap sequence tag library to generate mutant mice from embryonic stem cells	NATURE GENETICS			English	Letter							DEVELOPMENTALLY-REGULATED GENES; DISRUPTION; REPORTER; VECTORS; SCREEN		GSF, Nat Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany; Max Planck Inst Mol Genet, Berlin, Germany; Goethe Univ Frankfurt, Sch Med, Lap Mol Hematol, Frankfurt, Germany; Max Planck Inst Immunobiol, Dept Dev Biol, D-7800 Freiburg, Germany; Univ Aarhus, Inst Mol & Struct Biol, Aarhus, Denmark; TU Braunschweig, Dept Cell & Mol Biol, Inst Biochem & Biotechnol, Braunschweig, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Goethe University Frankfurt; Max Planck Society; Aarhus University; Braunschweig University of Technology; Max Planck Society	Wurstz, W (corresponding author), GSF, Nat Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany.	wurst@mpipsykl.mpg.de	Noppinger, Patricia Ruiz/AAH-1753-2019; Ruiz Noppinger, Patricia/D-6418-2014	Noppinger, Patricia Ruiz/0000-0001-5617-8965; Ruiz Noppinger, Patricia/0000-0001-5617-8965; wiles, michael/0000-0002-3620-8386; Vauti, Franz/0000-0003-0275-1433; Wurst, Wolfgang/0000-0003-4422-7410				Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; HILL DP, 1993, METHOD ENZYMOL, V225, P664; NIWA H, 1993, J BIOCHEM-TOKYO, V113, P343, DOI 10.1093/oxfordjournals.jbchem.a124049; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; Salminen M, 1998, DEV DYNAM, V212, P326, DOI 10.1002/(SICI)1097-0177(199806)212:2<326::AID-AJA17>3.0.CO;2-1; Scherer CA, 1996, CELL GROWTH DIFFER, V7, P1393; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; WURST W, 1995, GENETICS, V139, P889; YOSHIDA M, 1995, TRANSGENIC RES, V4, P277, DOI 10.1007/BF01969122; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	14	111	122	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					13	14		10.1038/71622	http://dx.doi.org/10.1038/71622			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615117				2022-12-25	WOS:000084609200006
J	Horwitz, M; Benson, KF; Person, RE; Aprikyan, AG; Dale, DC				Horwitz, M; Benson, KF; Person, RE; Aprikyan, AG; Dale, DC			Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis	NATURE GENETICS			English	Article							CELLS; SPECIFICITY; THROMBIN; COMPLEX; GENE	Human cyclic haematopoiesis (cyclic neutropenia, MIM 162800) is an autosomal dominant disease in which blood-cell production from the bone marrow oscillates with 21-day periodicity(1,2). Circulating neutrophils vary between almost normal numbers and zero. During intervals of neutropenia, affected individuals are at risk for opportunistic infection(3). Monocytes, platelets, lymphocytes and reticulocytes also cycle with the same frequency. Here we use a genome-wide screen and positional cloning to map the locus to chromosome 19p13.3. We identified 7 different single-base substitutions in the gene (ELA2) encoding neutrophil elastase (EC 3.4.21.37, also known as leukocyte elastase, elastase 2 and medullasin), a serine protease of neutrophil and monocyte granules, on unique haplotypes in 13 of 13 families as well as a new mutation in a sporadic case. Neutrophil elastase (a 240-aa mature protein predominantly found in neutrophil granules(4)) is the target for protease inhibition by alpha(1)-antitrypsin, and its unopposed release destroys tissue at sites of inflammation. We hypothesize that a perturbed interaction between neutrophil elastase and serpins or other substrates may regulate mechanisms governing the clock-like timing of haematopoiesis.	Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Horwitz, M (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA.			Horwitz, Marshall/0000-0002-1683-1680	NIDDK NIH HHS [DK18951] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018951] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Berger SP, 1996, J AM SOC NEPHROL, V7, P694; BIETH JG, 1998, HDB PROTEOLYTIC ENZY, P54; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Cregge RJ, 1998, J MED CHEM, V41, P2461, DOI 10.1021/jm970812e; DALE DC, 1988, BLOOD REV, V2, P178, DOI 10.1016/0268-960X(88)90023-9; Fasman KH, 1997, NUCLEIC ACIDS RES, V25, P72, DOI 10.1093/nar/25.1.72; Haurie C, 1998, BLOOD, V92, P2629, DOI 10.1182/blood.V92.8.2629.420a35_2629_2640; Hung SH, 1998, PROTEIN ENG, V11, P669, DOI 10.1093/protein/11.8.669; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; Palmer SE, 1996, AM J MED GENET, V66, P413, DOI 10.1002/(SICI)1096-8628(19961230)66:4<413::AID-AJMG5>3.0.CO;2-L; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; SINHA S, 1987, P NATL ACAD SCI USA, V84, P2228, DOI 10.1073/pnas.84.8.2228; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A	23	317	327	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					433	436		10.1038/70544	http://dx.doi.org/10.1038/70544			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581030				2022-12-25	WOS:000084023900019
J	Madsen, LS; Andersson, EC; Jansson, L; Krogsgaard, M; Andersen, CB; Engberg, J; Strominger, JL; Svejgaard, A; Hjorth, JP; Holmdahl, R; Wucherpfennig, KW; Fugger, L				Madsen, LS; Andersson, EC; Jansson, L; Krogsgaard, M; Andersen, CB; Engberg, J; Strominger, JL; Svejgaard, A; Hjorth, JP; Holmdahl, R; Wucherpfennig, KW; Fugger, L			A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor	NATURE GENETICS			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BASIC-PROTEIN PEPTIDE; TRANSGENIC MICE; MYELIN; SUSCEPTIBILITY; EXPRESSION; COMPLEX; SCREEN; LOCI; CD4		Aarhus Univ Hosp, Skejby Sygehus, Dept Clin Immunol, DK-8000 Aarhus, Denmark; Rigshosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Aarhus Univ, Inst Mol & Struct Biol, Aarhus, Denmark; Univ Lund, Sect Med Inflammat Res, Lund, Sweden; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Aarhus University; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Royal Danish School of Pharmacy; Harvard University; Aarhus University; Lund University; Harvard University; Dana-Farber Cancer Institute	Fugger, L (corresponding author), Aarhus Univ Hosp, Skejby Sygehus, Dept Clin Immunol, DK-8000 Aarhus, Denmark.		Holmdahl, Rikard/AAI-7682-2020					Coraddu F, 1998, NEUROGENETICS, V2, P24, DOI 10.1007/s100480050048; Ebers GC, 1998, SEMIN NEUROL, V18, P295, DOI 10.1055/s-2008-1040880; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; FOGDELL A, 1995, TISSUE ANTIGENS, V46, P333, DOI 10.1111/j.1399-0039.1995.tb02503.x; Fugger L, 1996, EUR J IMMUNOL, V26, P928, DOI 10.1002/eji.1830260431; FUGGER L, 1994, P NATL ACAD SCI USA, V91, P6151, DOI 10.1073/pnas.91.13.6151; Goverman J, 1999, IMMUNOL REV, V169, P147, DOI 10.1111/j.1600-065X.1999.tb01313.x; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; Haines JL, 1998, HUM MOL GENET, V7, P1229, DOI 10.1093/hmg/7.8.1229; JANSSON L, 1991, EUR J IMMUNOL, V21, P693, DOI 10.1002/eji.1830210323; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOUSKOFF V, 1993, J IMMUNOL METHODS, V166, P287, DOI 10.1016/0022-1759(93)90370-M; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; Noseworthy JH, 1999, NATURE, V399, pA40, DOI 10.1038/399a040; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Pearson CI, 1997, J EXP MED, V185, P583, DOI 10.1084/jem.185.4.583; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; Sawcer S, 1998, CURR OPIN IMMUNOL, V10, P697, DOI 10.1016/S0952-7915(98)80091-5; Smith A, 1998, PHARM SCI TECHNOL TO, V1, P188, DOI 10.1016/S1461-5347(98)00057-1; Spurkland A, 1997, TISSUE ANTIGENS, V50, P15, DOI 10.1111/j.1399-0039.1997.tb02828.x; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; SUNDVALL M, 1995, NAT GENET, V10, P313, DOI 10.1038/ng0795-313; Van de Keere F, 1998, J EXP MED, V188, P1875, DOI 10.1084/jem.188.10.1875; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	30	252	273	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					343	347		10.1038/15525	http://dx.doi.org/10.1038/15525			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610182				2022-12-25	WOS:000083792200026
J	Morgan, HD; Sutherland, HGE; Martin, DIK; Whitelaw, E				Morgan, HD; Sutherland, HGE; Martin, DIK; Whitelaw, E			Epigenetic inheritance at the agouti locus in the mouse	NATURE GENETICS			English	Article							GENE-EXPRESSION; MOLECULAR-BASIS; METHYLATION; MICE; PHENOTYPE; MUTATIONS; MITOSIS; MEIOSIS; ALLELE		Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Sydney; University of Edinburgh; Fred Hutchinson Cancer Center	Whitelaw, E (corresponding author), Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia.			Sutherland, Heidi/0000-0002-8512-1498				ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; Argeson AC, 1996, GENETICS, V142, P557; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; BELAYEV DK, 1981, J HERED, V72, P267; BRINK RA, 1956, GENETICS, V41, P872; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Chen YR, 1996, GENETICS, V144, P265; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; FEDEROFF NV, 1988, GENETICS, V120, P559; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HOLLICK JB, 1995, GENETICS, V141, P709; JABLONKA E, 1992, J THEOR BIOL, V158, P245, DOI 10.1016/S0022-5193(05)80722-2; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; MARTINEZ AR, 1994, GYNECOL ENDOCRINOL, V8, P1, DOI 10.3109/09513599409028450; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MONK M, 1995, DEV GENET, V17, P188, DOI 10.1002/dvg.1020170303; PERRY WL, 1994, BIOESSAYS, V16, P705, DOI 10.1002/bies.950161002; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; WOLFF GL, 1978, GENETICS, V88, P529; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949	25	991	1027	2	167	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					314	318		10.1038/15490	http://dx.doi.org/10.1038/15490			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545949				2022-12-25	WOS:000083792200020
J	Hahn, WC; Stewart, SA; Brooks, MW; York, SG; Eaton, E; Kurachi, A; Beijersbergen, RL; Knoll, JHM; Meyerson, M; Weinberg, RA				Hahn, WC; Stewart, SA; Brooks, MW; York, SG; Eaton, E; Kurachi, A; Beijersbergen, RL; Knoll, JHM; Meyerson, M; Weinberg, RA			Inhibition of telomerase limits the growth of human cancer cells	NATURE MEDICINE			English	Article							CATALYTIC SUBUNIT GENE; HUMAN FIBROBLASTS; IMMORTAL CELLS; RNA COMPONENT; FISSION YEAST; LIFE-SPAN; IN-VITRO; P53; SENESCENCE; APOPTOSIS	Telomerase is a ribonucleoprotein enzyme that maintains the protective structures at the ends of eukaryotic chromosomes, called telomeres. In most human somatic cells, telomerase expression is repressed, and telomeres shorten progressively with each cell division. In contrast, most human tumors express telomerase, resulting in stabilized telomere length. These observations indicate that telomere maintenance is essential to the proliferation of tumor cells. We show here that expression of a mutant catalytic subunit of human telomerase results in complete inhibition of telomerase activity, reduction in telomere length and death of tumor cells. Moreover, expression of this mutant telomerase eliminated tumorigenicity in vivo. These observations demonstrate that disruption of telomere maintenance limits cellular lifespan in human cancer cells, thus validating human telomerase reverse transcriptase as an important target for the development of anti-neoplastic therapies.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol,Cytogenet Serv, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Weinberg, RA (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Meyerson, Matthew L/E-7123-2012; Stewart, Sheila A/C-5213-2012	Knoll, Joan/0000-0001-6691-1710; Beijersbergen, Roderick/0000-0003-0116-4130				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Goi K, 1997, CANCER RES, V57, P1895; GREIDER CW, 1995, TELOMERES, P35; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; LANDSDORP PM, 1996, HUM MOL GENET, V5, P685; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Ramakrishnan S, 1998, CANCER RES, V58, P622; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SEABRIGH.M, 1971, LANCET, V2, P971; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Strahl C, 1996, MOL CELL BIOL, V16, P53; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	57	885	943	4	107	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1164	1170		10.1038/13495	http://dx.doi.org/10.1038/13495			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502820				2022-12-25	WOS:000082933200043
J	Lahn, M; Kanehio, A; Takeda, K; Joetham, A; Schwarze, J; Kohler, G; O'Brien, R; Gelfand, EW; Born, W				Lahn, M; Kanehio, A; Takeda, K; Joetham, A; Schwarze, J; Kohler, G; O'Brien, R; Gelfand, EW; Born, W			Negative regulation of airway responsiveness that is dependent on gamma delta T cells and independent of alpha beta T cells	NATURE MEDICINE			English	Article							MURINE MODEL; MICE; HYPERRESPONSIVENESS; LYMPHOCYTES; HYPERREACTIVITY; RECEPTOR; ANTIGEN; SENSITIZATION; INFLAMMATION; REQUIREMENT	The mechanisms regulating airway function are complex and still poorly understood. In diseases such as asthma, involvement of immune-dependent mechanisms has been suggested in causing changes in airway responsiveness to bronchoconstrictors. We now demonstrate that gamma delta T cells can regulate airway function in an alpha beta T cell-independent manner, identifying them as important cells in pulmonary homeostasis. This function of gamma delta T cells differs from previously described immune-dependent mechanisms and may reflect their interaction with innate systems of host defense.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Basic Immunol, Denver, CO 80206 USA; Univ Freiburg, Inst Pathol, D-79104 Freiburg, Germany	National Jewish Health; National Jewish Health; University of Freiburg	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Schwarze, Jürgen/F-7396-2011	Schwarze, Jurgen/0000-0002-6899-748X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001291, R01AI040611] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-01291, AI-40611] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BALA V, 1995, IEEE T PARALL DISTR, V6, P154, DOI 10.1109/71.342126; Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289; Boismenu R, 1996, J IMMUNOL, V157, P985; Born W, 1999, Adv Immunol, V71, P77; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; DiTirro J, 1998, INFECT IMMUN, V66, P2284, DOI 10.1128/IAI.66.5.2284-2289.1998; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; Geba GP, 1997, J CLIN INVEST, V100, P629, DOI 10.1172/JCI119574; Gelfand EW, 1997, NAT MED, V3, P382, DOI 10.1038/nm0497-382; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; King DP, 1999, J IMMUNOL, V162, P5033; Lahn M, 1998, J IMMUNOL, V160, P5221; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318, DOI 10.1152/jappl.1988.64.6.2318; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Penido C, 1997, J IMMUNOL, V159, P853; Schramm CM, 1999, AM J RESP CRIT CARE, V159, pA255; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Strickland D, 1996, IMMUNOLOGY, V87, P250, DOI 10.1046/j.1365-2567.1996.459542.x; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TAKEDA K, 1998, AM J RESP CRIT CARE, V157, pA599; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; WOOLCOCK AJ, 1994, TXB RESP MED, V2, P1288; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	32	152	158	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1150	1156		10.1038/13476	http://dx.doi.org/10.1038/13476			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502818				2022-12-25	WOS:000082933200041
J	Persons, DA; Paulson, RF; Loyd, MR; Herley, MT; Bodner, SM; Bernstein, A; Correll, PH; Ney, PA				Persons, DA; Paulson, RF; Loyd, MR; Herley, MT; Bodner, SM; Bernstein, A; Correll, PH; Ney, PA			Fv2 encodes a truncated form of the Stk receptor tyrosine kinase	NATURE GENETICS			English	Article							FRIEND-LEUKEMIA VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; FV-2 GENE-ACTION; PROGENITOR CELLS; CELLULAR SITE; ERYTHROLEUKEMIA; GLYCOPROTEIN; GP55; MICE; ONCOGENE	The Friend virus susceptibility 2 (Fv2) locus encodes a dominant host factor that confers susceptibility to Friend virus-induced erythroleukaemia in mice. We mapped Fv2 to a 1.0-Mb interval that also contained the gene (Ron) encoding the stem cell kinase receptor (Stk). A truncated form of Stk (Sf-stk), which was the most abundant form of Stk in Fv2-sensitive (Fv2(ss)) erythroid cells, was not expressed in Fv2 resistant (Fv2(rr)) cells. Enforced expression of Sf-stk conferred susceptibility to Friend disease, whereas targeted disruption of Ron caused resistance. We conclude that the Fv2 locus encodes Ron, and that a naturally expressed, truncated form of Stk confers susceptibility to Friend virus-induced erythroleukaemia.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Hematol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Ney, PA (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	paul.ney@stjude.org			NATIONAL CANCER INSTITUTE [R01CA084214, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084214-02, R01 CA084214, R01 CA084214-03, R01 CA084214-01, R01 CA084214-04, P30 CA21765, R01 CA084214-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AMANUMA H, 1983, P NATL ACAD SCI-BIOL, V80, P3913, DOI 10.1073/pnas.80.13.3913; AXELRAD A, 1969, CAN CANC C, V8, P313; AXELRAD AA, 1964, VIROLOGY, V24, P513, DOI 10.1016/0042-6822(64)90199-0; BEHRINGER RR, 1989, EXP HEMATOL, V17, P330; BEHRINGER RR, 1985, CELL, V40, P441, DOI 10.1016/0092-8674(85)90158-8; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENNETT M, 1968, SCIENCE, V162, P564, DOI 10.1126/science.162.3853.564; BERGER SA, 1985, P NATL ACAD SCI USA, V82, P6913, DOI 10.1073/pnas.82.20.6913; Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; Blake JA, 1998, NUCLEIC ACIDS RES, V26, P130, DOI 10.1093/nar/26.1.130; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHESEBRO B, 1978, J IMMUNOL, V120, P1081; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; Correll Pamela H., 1997, Genes and Function, V1, P69; DIETRICH W, 1992, GENETICS, V131, P423; ELIOTT RW, 1978, ELECTROPHORESIS, P261; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GEIB RW, 1987, VIRUS RES, V8, P327, DOI 10.1016/0168-1702(87)90005-0; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOATLIN ME, 1995, J VIROL, V69, P856, DOI 10.1128/JVI.69.2.856-863.1995; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KAI K, 1986, VIROLOGY, V150, P509, DOI 10.1016/0042-6822(86)90315-6; KOZAK CA, 1985, J VIROL, V55, P281, DOI 10.1128/JVI.55.2.281-285.1985; KUMAR V, 1978, J NATL CANCER I, V61, P1117; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LILLY F, 1970, J NATL CANCER I, V45, P163; MAGER D, 1981, MOL CELL BIOL, V1, P721, DOI 10.1128/MCB.1.8.721; Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766; METCALF D, 1959, CANCER RES, V19, P52; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Paulson RF, 1998, MAMM GENOME, V9, P381, DOI 10.1007/s003359900774; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Riberdy JM, 1999, J VIROL, V73, P1453, DOI 10.1128/JVI.73.2.1453-1459.1999; Santoro MM, 1997, MOL CELL BIOL, V17, P1758; SHIBUYA T, 1982, NATURE, V296, P577, DOI 10.1038/296577a0; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STEEVES RA, 1975, J NATL CANCER I, V54, P289, DOI 10.1093/jnci/54.2.289; STEEVES RA, 1968, NATURE, V218, P372, DOI 10.1038/218372a0; SUZUKI S, 1980, CELL, V19, P225, DOI 10.1016/0092-8674(80)90404-3; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; VANDERGAAG HC, 1990, VIROLOGY, V177, P837, DOI 10.1016/0042-6822(90)90561-5; Waltz SE, 1998, ONCOGENE, V16, P27, DOI 10.1038/sj.onc.1201508; Wei MH, 1996, CANCER RES, V56, P1487; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034	50	124	128	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					159	165		10.1038/13787	http://dx.doi.org/10.1038/13787			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508511				2022-12-25	WOS:000082827500014
J	Ellerby, HM; Arap, W; Ellerby, LM; Kain, R; Andrusiak, R; Del Rio, G; Krajewski, S; Lombardo, CR; Rao, R; Ruoslahti, E; Bredesen, DE; Pasqualini, R				Ellerby, HM; Arap, W; Ellerby, LM; Kain, R; Andrusiak, R; Del Rio, G; Krajewski, S; Lombardo, CR; Rao, R; Ruoslahti, E; Bredesen, DE; Pasqualini, R			Anti-cancer activity of targeted pro-apoptotic peptides	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ANTIMICROBIAL PEPTIDES; OUTER-MEMBRANE; RAT-LIVER; MITOCHONDRIAL; ANGIOGENESIS; CARDIOLIPIN; RECEPTOR; RESIDUES; MODEL	We have designed short peptides composed of two functional domains, one a tumor blood vessel 'homing' motif and the other a programmed cell death-inducing sequence, and synthesized them by simple peptide chemistry. The 'homing' domain was designed to guide the peptide to targeted cells and allow its internalization. The pro-apoptotic domain was designed to be nontoxic outside cells, but toxic when internalized into targeted cells by the disruption of mitochondrial membranes. Although our prototypes contain only 21 and 26 residues, they were selectively toxic to angiogenic endothelial cells and showed anti-cancer activity in mice. This approach may yield new therapeutic agents.	Burnham Inst, Program Aging & Canc, La Jolla, CA 92037 USA; Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Program Aging & Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kain, Renate/ACR-4709-2022	Kain, Renate/0000-0002-2428-543X	NATIONAL CANCER INSTITUTE [P01CA028896, R01CA074238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033376] Funding Source: NIH RePORTER; NCI NIH HHS [CA28896, CA74238] Funding Source: Medline; NINDS NIH HHS [NS33376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/bj3020535; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; BAITCHEFFSKY H, 1981, MITOCHONDRIA MICROSO; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; Bicknell R, 1997, TUMOUR ANGIOGENESIS, P19; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V882, P1; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Epand RM, 1993, AMPHIPATHIC HELIX; Folkman Judah, 1997, P3075; GOTO F, 1993, LAB INVEST, V69, P508; HART SL, 1994, J BIOL CHEM, V269, P12468; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Mancheno JM, 1998, J PEPT RES, V51, P142; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PASQUALINI R, IN PRESS PHAGE DISPL; PASQUALINI R, 1996, NATURE, V380, P36; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samaniego F, 1998, AM J PATHOL, V152, P1433; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	31	785	888	5	152	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1032	1038		10.1038/12469	http://dx.doi.org/10.1038/12469			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470080				2022-12-25	WOS:000082337200037
J	Fan, HR; Lin, Q; Morrissey, GR; Khavari, PA				Fan, HR; Lin, Q; Morrissey, GR; Khavari, PA			Immunization via hair follicles by topical application of naked DNA to normal skin	NATURE BIOTECHNOLOGY			English	Article						gene transfer; DNA vaccine; skin; immunization; hair follicle	DRUG-DELIVERY; GENE-TRANSFER; VACCINATION; VACCINES; IMMUNITY; ANTIGEN; HUMANS	In order to test the immune response generated to small amounts of foreign protein in skin, we applied naked DNA in aqueous solution to untreated normal skin. Topical application of plasmid expression vectors for lacZ and the hepatitis B surface antigen (HBsAg) to intact skin induced antigen-specific immune responses that displayed T-H2 features. For HBsAg, specific antibody and cellular responses were induced to the same order of magnitude as those produced by intramuscular injection of the commercially available recombinant HBsAS polypeptide vaccine. Finally, topical gene transfer was dependent on the presence of normal hair follicles.	Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, Palo Alto, CA 94305 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Khavari, PA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Sch Med, Stanford, CA 94305 USA.							ALEXANDER MY, 1995, HUM MOL GENET, V4, P2279, DOI 10.1093/hmg/4.12.2279; Barry MA, 1997, VACCINE, V15, P788, DOI 10.1016/S0264-410X(96)00265-4; Beard CW, 1998, NAT BIOTECHNOL, V16, P1325, DOI 10.1038/4298; BERTI JJ, 1995, MAYO CLIN PROC, V70, P581, DOI 10.4065/70.6.581; BERTI JJ, 1999, MAYO CLIN P, V112, P370; Davis HL, 1998, J IMMUNOL, V160, P870; Domashenko A, 1999, J INVEST DERMATOL, V112, P552; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Janda JM, 1997, EUR J CLIN MICROBIOL, V16, P189, DOI 10.1007/BF01709581; LAUER AC, 1995, PHARM RES-DORDR, V12, P179, DOI 10.1023/A:1016250422596; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Livingston BD, 1997, J IMMUNOL, V159, P1383; Lu B, 1997, J INVEST DERMATOL, V108, P803, DOI 10.1111/1523-1747.ep12292254; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Tang DC, 1997, NATURE, V388, P729, DOI 10.1038/41917; Tuting T, 1998, J INVEST DERMATOL, V111, P183, DOI 10.1046/j.1523-1747.1998.00261.x; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; WYU WH, 1999, J INVEST DERMATOL, V112, P370; Zierhut M, 1996, IMMUNOL TODAY, V17, P448, DOI 10.1016/0167-5699(96)30056-X	19	147	156	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					870	872		10.1038/12856	http://dx.doi.org/10.1038/12856			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471927				2022-12-25	WOS:000082365800027
J	Godi, A; Pertile, P; Meyers, R; Marra, P; Di Tullio, G; Iurisci, C; Luini, A; Corda, D; De Matteis, MA				Godi, A; Pertile, P; Meyers, R; Marra, P; Di Tullio, G; Iurisci, C; Luini, A; Corda, D; De Matteis, MA			ARF mediates recruitment of PtdIns-4-OH kinase-beta and stimulates synthesis of PtdIns(4,5)P-2 on the Golgi complex	NATURE CELL BIOLOGY			English	Article							PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ADP-RIBOSYLATION FACTOR; LYSOSOME-LIKE VACUOLE; PHOSPHOLIPASE-D; PROTEIN-KINASE; TRANSPORT VESICLES; GUANINE-NUCLEOTIDE; PHOSPHATIDIC-ACID; 4-KINASE; 3-KINASE	The small GTPase ADP-ribosylation factor (ARF) regulates the structure and function of the Golgi complex through mechanisms that are understood only in part, and which include an ability to control the assembly of coat complexes and phospholipase D (PLD), Here we describe a new property of ARF, the ability to recruit phosphatidylinositol-4-OH kinase-beta and a still unidentified phosphatidylinositol-4-phosphate-5-OH kinase to the Golgi complex, resulting in a potent stimulation of synthesis of phosphatidylinositol-4-phosphate and phosphatidylinositol-4,5-bisphosphate; this ability is independent of its activities on coat proteins and PLD, Phosphatidylinositol-4-OH kinase-beta is required for the structural integrity of the Golgi complex: transfection of a dominant-negative mutant of the kinase markedly alters the organization of the organelle.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Ch, Italy; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Harvard University; Beth Israel Deaconess Medical Center	De Matteis, MA (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Ch, Italy.	demattei@cmns.mnegri.it	Luini, Alberto/L-1372-2013; Corda, Daniela/K-6385-2016	Luini, Alberto/0000-0002-8729-2549; Corda, Daniela/0000-0002-3614-751X; De Matteis, Maria Antonietta/0000-0003-0053-3061	Telethon [E.0732] Funding Source: Medline	Telethon(Fondazione Telethon)		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chen H, 1998, INT J MATH, V9, P653, DOI 10.1142/S0129167X98000294; Choi JH, 1998, MOL BIOL CELL, V9, p120A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; FULLEKRUG J, 1994, J CELL SCI, V107, P2719; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JERGIL B, 1983, J BIOL CHEM, V258, P7968; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; LEE FJS, 1994, J BIOL CHEM, V269, P21555; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MOSS J, 1991, METHOD ENZYMOL, V195, P243; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	43	439	451	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					280	287		10.1038/12993	http://dx.doi.org/10.1038/12993			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559940				2022-12-25	WOS:000083169600016
J	Kunkel, T; Niu, QW; Chan, YS; Chua, NH				Kunkel, T; Niu, QW; Chan, YS; Chua, NH			Inducible isopentenyl transferase as a high-efficiency marker for plant transformation	NATURE BIOTECHNOLOGY			English	Article						inducible ipt expression; selective regeneration; plant transformation marker	TRANSGENIC TOBACCO; LEAF SENESCENCE; CYTOKININ; GENE; EXPRESSION; RESISTANCE; PROMOTER; MUTANT	Overexpression of the isopentenyltransferase gene (ipt) from the Ti-plasmid of Agrobacterium tumefaciens increases cytokinin levels, leading to generation of shoots from transformed plant cells. When combined with a dexamethasone-inducible system for controlling expression, ipt expression can be used to select for transgenic regenerants without using an antibiotic-resistance marker. The combined system allows efficient cointroduction of multiple genes (in addition to ipt) and produces transgenic plants without morphological or developmental defects.	Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore	Rockefeller University; National University of Singapore	Chua, NH (corresponding author), Rockefeller Univ, Plant Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	chua@rockefeller.rockvax.edu						AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; BARRY GF, 1984, P NATL ACAD SCI-BIOL, V81, P4776, DOI 10.1073/pnas.81.15.4776; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BEVAN MW, 1982, ANNU REV GENET, V16, P357, DOI 10.1146/annurev.ge.16.120182.002041; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; CLINE MG, 1994, PHYSIOL PLANTARUM, V90, P230, DOI 10.1034/j.1399-3054.1994.900133.x; Coenen C, 1997, TRENDS PLANT SCI, V2, P351, DOI 10.1016/S1360-1385(97)84623-7; CURTIS IS, 1994, J EXP BOT, V45, P1441, DOI 10.1093/jxb/45.10.1441; Davies P.J., 1995, PLANT HORMONES THEIR; Ebinuma H, 1997, P NATL ACAD SCI USA, V94, P2117, DOI 10.1073/pnas.94.6.2117; Faiss M, 1997, PLANT J, V12, P401, DOI 10.1046/j.1365-313X.1997.12020401.x; FRALEY RT, 1986, CRC CR REV PLANT SCI, V4, P1, DOI 10.1080/07352688609382217; GAN SS, 1995, SCIENCE, V270, P1986, DOI 10.1126/science.270.5244.1986; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; Goliber T, 1999, CURR TOP DEV BIOL, V43, P259; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Ishige F, 1999, PLANT J, V18, P443, DOI 10.1046/j.1365-313X.1999.00456.x; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; KLEE H, 1987, ANNU REV PLANT PHYS, V38, P467, DOI 10.1146/annurev.pp.38.060187.002343; Kuraishi F., 1956, BOT MAG TOKYO, P300; Lotan T, 1998, CELL, V93, P1195, DOI 10.1016/S0092-8674(00)81463-4; McKenzie MJ, 1998, PLANT PHYSIOL, V116, P969, DOI 10.1104/pp.116.3.969; MEDFORD JI, 1989, PLANT CELL, V1, P403, DOI 10.1105/tpc.1.4.403; Michelet B, 1996, PLANT MOL BIOL REP, V14, P320, DOI 10.1007/BF02673364; MIklashevichs E, 1997, PHYSIOL PLANTARUM, V100, P528, DOI 10.1034/j.1399-3054.1997.1000314.x; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; MOK DWS, 1994, CYTOKININS CHEM ACTI, P155; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; Redig P, 1996, PLANT PHYSIOL, V112, P141, DOI 10.1104/pp.112.1.141; SACHS T, 1967, AM J BOT, V54, P136, DOI 10.2307/2440896; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; SMIGOCKI AC, 1988, P NATL ACAD SCI USA, V85, P5131, DOI 10.1073/pnas.85.14.5131; VAN KMTT, 1981, ANNU REV PLANT PHYS, V32, P291, DOI 10.1146/annurev.pp.32.060181.001451; WALDRON C, 1985, PLANT MOL BIOL, V5, P103, DOI 10.1007/BF00020092; Wingler A, 1998, PLANT PHYSIOL, V116, P329, DOI 10.1104/pp.116.1.329	36	103	121	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					916	919		10.1038/12914	http://dx.doi.org/10.1038/12914			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471937				2022-12-25	WOS:000082365800037
J	Liu, PT; Wakamiya, M; Shea, MJ; Albrecht, U; Behringer, RR; Bradley, A				Liu, PT; Wakamiya, M; Shea, MJ; Albrecht, U; Behringer, RR; Bradley, A			Requirement for Wnt3 in vertebrate axis formation	NATURE GENETICS			English	Article							ANTERIOR PRIMITIVE ENDODERM; EMBRYONIC AXIS; MOUSE EMBRYO; EXPRESSION; XENOPUS; GENES; NEUROECTODERM	Several studies have implicated Wnt signalling in primary axis formation during vertebrate embryogenesis, yet no Wnt protein has been shown to be essential for this process(1-3), In the mouse, primitive streak formation is the first overt morphological sign of the anterior-posterior axis, Here we show that Wnt3 is expressed before gastrulation in the proximal epiblast of the egg cylinder, then is restricted to the posterior proximal epiblast and its associated visceral endoderm and subsequently to the primitive streak and mesoderm, Wnt3(-/-) mice develop a normal egg cylinder but do not form a primitive streak, mesoderm or The epiblast continues to proliferate in an undifferentiated state that lacks anterior-posterior neural patterning, but anterior visceral endoderm markers are expressed and correctly positioned. Our results suggest that regional patterning of the visceral endoderm is independent of primitive streak formation, but the subsequent establishment of anterior-posterior neural pattern in the ectoderm is dependent on derivatives of the primitive streak. These studies provide genetic proof for the requirement of Wnt3 in primary axis formation in the mouse.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Albrecht, Urs/A-9831-2011	Albrecht, Urs/0000-0002-0663-8676; Bradley, Allan/0000-0002-2349-8839				ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; KRAUSS S, 1992, DEVELOPMENT, V116, P249; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Liu PT, 1998, GENETICS, V150, P1155; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; PARR BA, 1993, DEVELOPMENT, V119, P247; Popperl H, 1997, DEVELOPMENT, V124, P2997; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; TAM PPL, IN PRESS CURR TOPICS; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949; ZHENG Z, 1997, CELL, V90, P181	27	651	678	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					361	365		10.1038/11932	http://dx.doi.org/10.1038/11932			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431240				2022-12-25	WOS:000081772500018
J	Mir, KU; Southern, EM				Mir, KU; Southern, EM			Determining the influence of structure on hybridization using oligonucleotide arrays	NATURE BIOTECHNOLOGY			English	Article						antisense; DNA chips; microarray; spatially addressable array; combinatorial library; RNA secondary structure	TRANSFER-RNA; COMPLEMENTARY OLIGONUCLEOTIDES; DUPLEX STABILITY; HYBRID DUPLEXES; ANTICODON LOOP; ANTISENSE RNA; DNA PROBES; BINDING; EXPRESSION; SEQUENCE	We have studied the effects of structure on nucleic acid heteroduplex formation by analyzing hybridization of tRNA(phe) to a complete set of complementary oligonucleotides, ranging from single nucleotides to dodecanucleotides. The analysis points to features in tRNA that determine heteroduplex yield. All heteroduplexes that give high yield include both double-stranded stems as well as single-stranded regions. Bases in the single-stranded regions are stacked onto the stems, and heteroduplexes terminate at potential interfaces for coaxial stacking. Heteroduplex formation is disfavored by sharp turns or a lack of helical order in single-stranded regions, competition from bases displaced from a stem, and stable tertiary interactions. The study is relevant to duplex formation on oligonucleotide microarrays and to antisense technologies.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Mir, KU (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	kalim@bioch.ox.ac.uk						[Anonymous], 1994, PRINCIPLES NUCL ACID; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P1303; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; DOTY P., 1959, PROC NATL ACAD SCI, V45, P482, DOI 10.1073/pnas.45.4.482; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; EISINGER J, 1973, J MOL BIOL, V73, P131, DOI 10.1016/0022-2836(73)90165-4; ENGLAND IE, 1977, METHOD ENZYMOL, V65, P65; Fountain MA, 1996, BIOCHEMISTRY-US, V35, P6539, DOI 10.1021/bi952697k; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FREIER SM, 1975, BIOCHEMISTRY-US, V14, P3310, DOI 10.1021/bi00686a004; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; KALLENBACH NR, 1968, J MOL BIOL, V37, P445, DOI 10.1016/0022-2836(68)90114-9; KIELECZAWA J, 1992, SCIENCE, V258, P1787, DOI 10.1126/science.1465615; KUMAZAWA Y, 1992, NUCLEIC ACIDS RES, V20, P2223, DOI 10.1093/nar/20.9.2223; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LEROY JL, 1977, EUR J BIOCHEM, V74, P567, DOI 10.1111/j.1432-1033.1977.tb11426.x; LEWIS JB, 1970, NATURE, V225, P510, DOI 10.1038/225510a0; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; MASKOS U, 1993, NUCLEIC ACIDS RES, V21, P2267, DOI 10.1093/nar/21.9.2267; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1675, DOI 10.1093/nar/20.7.1675; Matveeva O, 1997, NUCLEIC ACIDS RES, V25, P5010, DOI 10.1093/nar/25.24.5010; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; MIR KU, 1995, THESIS U OXFORD; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PONGS O, 1973, EUR J BIOCHEM, V32, P117, DOI 10.1111/j.1432-1033.1973.tb02586.x; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SMITH M, 1983, METHODS DNA RNA SEQU, P23; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; STUDIER FW, 1969, J MOL BIOL, V41, P199, DOI 10.1016/0022-2836(69)90385-4; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; SUDDATH FL, 1974, SCIENCE, V185, P435; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; UHLENBEC.OC, 1970, NATURE, V225, P508, DOI 10.1038/225508a0; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069; WILLIAMS JC, 1994, NUCLEIC ACIDS RES, V22, P1365, DOI 10.1093/nar/22.8.1365; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WREDE P, 1978, J MOL BIOL, V120, P83, DOI 10.1016/0022-2836(78)90296-6; WU R, 1972, NATURE-NEW BIOL, V236, P198, DOI 10.1038/newbio236198a0	56	151	165	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					788	792		10.1038/11732	http://dx.doi.org/10.1038/11732			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429245				2022-12-25	WOS:000081751400029
J	Clute, P; Pines, J				Clute, P; Pines, J			Temporal and spatial control of cyclin B1 destruction in metaphase	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; VERTEBRATE SOMATIC-CELLS; MAMMALIAN-CELLS; NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; SPINDLE CHECKPOINT; REGULATED BINDING; MITOTIC ARREST; FISSION YEAST; PROTEIN	The proteolysis of key regulatory proteins is thought to control progress through mitosis. Here we analyse cyclin B1 degradation in real time and Sind that it begins as soon as the last chromosome aligns on the metaphase plate, just after the spindle-assembly checkpoint is inactivated. At this point, cyclin B1 staining disappears from the spindle poles and from the chromosomes. Cyclin B1 destruction can subsequently be inactivated throughout metaphase if the spindle checkpoint is reimposed, and this correlates with the reappearance of cyclin B1 on the spindle poles and the chromosomes. These results provide a temporal and spatial link between the spindle-assembly checkpoint and ubiquitin-mediated proteolysis.	Wellcome CRC Inst, Cambridge CB2 1QR, England		Clute, P (corresponding author), Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	j.pines@welc.cam.ac.uk		Pines, Jonathon/0000-0002-5227-6004	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GIRARD F, 1995, J CELL SCI, V108, P2599; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jorgensen PM, 1998, MOL CELL BIOL, V18, P468; Karlsson C, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P246; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 1997, P NATL ACAD SCI USA, V94, P5107, DOI 10.1073/pnas.94.10.5107; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Shaw SL, 1997, CURR BIOL, V7, P701, DOI 10.1016/S0960-9822(06)00299-5; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	42	551	558	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					82	87		10.1038/10049	http://dx.doi.org/10.1038/10049			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559878				2022-12-25	WOS:000083102200014
J	Coffee, B; Zhang, FP; Warren, ST; Reines, D				Coffee, B; Zhang, FP; Warren, ST; Reines, D			Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells	NATURE GENETICS			English	Article							REPRESS TRANSCRIPTION; DNA METHYLATION; GENE; REGION; DEACETYLASE; EXPRESSION; PROMOTER; YEAST; REACTIVATION; NUCLEOSOME	Mutation of FMR1 results in fragile X mental retardation(1). The most common FMR1 mutation is expansion of a CGG repeat tract at the 5' end of FMR1 (refs 2-4), which leads to cytosine methylation and transcriptional silencing(5,6). Both DNA methylation and histone deacetylation have been associated with transcriptional inactivity(7-9). The finding that the methyl cytosine-binding protein MeCP2 binds to histone deacetylases and represses transcription in vivo(10,11) supports a model in which MeCP2 recruits histone deacetylases to methylated DNA, resulting in histone deacetylation, chromatin condensation and transcriptional silencing(12). Here we demonstrate that the 5' end of FMR1 is associated with acetylated histones H3 and H4 in cells from normal individuals, but acetylation is reduced in cells from fragile X patients. Treatment of fragile X cells with 5-aza-2'-deoxycytidine (5-aza-dC) resulted in reassociation of acetylated histones H3 and H4 with FMR1 and transcriptional reactivation, whereas treatment with trichostatin A (TSA) led to almost complete acetylated histone H4 and little acetylated histone H3 reassociation with FMR1, as well as no detectable transcription. Our results represent the first description of loss of histone acetylation at a specific locus in human disease, and advance understanding of the mechanism of FMR1 transcriptional silencing.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA	Emory University; Emory University; Howard Hughes Medical Institute; Emory University; Emory University	Reines, D (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.		excellency, Your/R-2357-2019; Warren, Stephen T/A-2498-2012	excellency, Your/0000-0003-0832-6243; 	NICHD NIH HHS [HD35576] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD035576] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Ammerpohl O, 1998, NUCLEIC ACIDS RES, V26, P5256, DOI 10.1093/nar/26.23.5256; ARTS J, 1995, BIOCHEM J, V310, P171, DOI 10.1042/bj3100171; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; Drouin R, 1997, HUM MOL GENET, V6, P2051, DOI 10.1093/hmg/6.12.2051; Eberhart DE, 1996, SOMAT CELL MOLEC GEN, V22, P435, DOI 10.1007/BF02369435; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; Schwemmle S, 1997, AM J HUM GENET, V60, P1354, DOI 10.1086/515456; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	30	254	258	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					98	101		10.1038/8807	http://dx.doi.org/10.1038/8807			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319871				2022-12-25	WOS:000080096300032
J	Merrifield, CJ; Moss, SE; Ballestrem, C; Imhof, BA; Giese, G; Wunderlich, I; Almers, W				Merrifield, CJ; Moss, SE; Ballestrem, C; Imhof, BA; Giese, G; Wunderlich, I; Almers, W			Endocytic vesicles move at the tips of actin tails in cultured mast cells	NATURE CELL BIOLOGY			English	Article							LISTERIA-MONOCYTOGENES; MOTILITY; DYNAMICS; MACROPINOCYTOSIS; INTERNALIZATION; PROFILIN; SURFACE		UCL, Dept Physiol, London WC1E 6BT, England; Ctr Med Univ Geneva, Dept Pathol, CH-1211 Geneva, Switzerland; Max Planck Inst Med Res, D-69120 Heidelberg, Germany	University of London; University College London; University of Geneva; Max Planck Society	Almers, W (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, 3181 Sam Jackson Pk Rd, Portland, OR 97201 USA.	almersw@ohsu.edu		Ballestrem, Christoph/0000-0002-5375-7985				Ballestrem C, 1998, J CELL SCI, V111, P1649; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; GOLDBERG MB, 1995, P NATL ACAD SCI USA, V92, P6572, DOI 10.1073/pnas.92.14.6572; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HEUSER JE, 1992, MOL BIOL CELL ABSTR, V3, P172; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAMAZE C, 1997, J BIOL CHEM, V272, P20333; NANAVATI D, 1994, CELL MOTIL CYTOSKEL, V28, P346, DOI 10.1002/cm.970280408; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; SWANSON JA, 1989, J CELL SCI, V94, P135; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Zeile WL, 1996, J CELL BIOL, V133, P49, DOI 10.1083/jcb.133.1.49	18	275	280	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					72	74		10.1038/9048	http://dx.doi.org/10.1038/9048			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559868				2022-12-25	WOS:000083085300022
J	Taylor, JK; Zhang, QQ; Wyatt, JR; Dean, NM				Taylor, JK; Zhang, QQ; Wyatt, JR; Dean, NM			Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						Bcl-x; antisense oligonucleotide; apoptosis; alternative splicing	MESSENGER-RNA; CELL-DEATH; APOPTOSIS; EXPRESSION; BCL-X(S); INHIBITION; DIFFERENTIATION; IDENTIFICATION; ACTIVATION; SURVIVAL	Resistance to apoptosis, which plays an important role in tumors that are refractory to chemotherapy, is regulated by the ratio of antiapoptotic to proapoptotic proteins. By manipulating levels of these proteins, cells can become sensitized to undergo apoptosis in response to chemotherapeutic agents. Alternative splicing of the bcl-x gene gives rise to two proteins with antagonistic functions: Bcl-xL, a well-characterized antiapoptotic protein, and Bcl-xS, a proapoptotic protein. We show here that altering the ratio of Bcl-xL to Bcl-xS in the cell using an antisense oligonucleotide permitted cells to be sensitized to undergo apoptosis in response to ultraviolet B radiation and chemotherapeutic drug treatment. These results demonstrate the ability of a chemically modified oligonucleotide to alter splice site selection in an endogenous gene and illustrate a powerful tool to regulate cell survival.	ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA; ISIS Pharmaceut, Dept Biol Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc	Dean, NM (corresponding author), ISIS Pharmaceut, Dept Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.							Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Ealovega MW, 1996, CANCER RES, V56, P1965; Fridman JS, 1998, ONCOGENE, V17, P2981, DOI 10.1038/sj.onc.1202224; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; HARRIS AL, 1992, ACTA ONCOL, V31, P205, DOI 10.3109/02841869209088904; HODGE D, 1995, MOL PHARMACOL, V48, P905; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kole R, 1997, ACTA BIOCHIM POL, V44, P231; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MONIA BP, 1992, J BIOL CHEM, V267, P19954; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Tao WK, 1998, J BIOL CHEM, V273, P23704, DOI 10.1074/jbc.273.37.23704; Taylor J K, 1999, Curr Opin Drug Discov Devel, V2, P147; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yu K, 1997, CELL DEATH DIFFER, V4, P745, DOI 10.1038/sj.cdd.4400295	32	167	187	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1097	1100		10.1038/15079	http://dx.doi.org/10.1038/15079			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545916				2022-12-25	WOS:000083428000027
J	Nowak, KJ; Wattanasirichaigoon, D; Goebel, HH; Wilce, M; Pelin, K; Donner, K; Jacob, RL; Hubner, C; Oexle, K; Anderson, JR; Verity, CM; North, KN; Iannaccone, ST; Muller, CR; Nurnberg, P; Muntoni, F; Sewry, C; Hughes, I; Sutphen, R; Lacson, AG; Swoboda, KJ; Vigneron, J; Wallgren-Pettersson, C; Beggs, AH; Laing, NG				Nowak, KJ; Wattanasirichaigoon, D; Goebel, HH; Wilce, M; Pelin, K; Donner, K; Jacob, RL; Hubner, C; Oexle, K; Anderson, JR; Verity, CM; North, KN; Iannaccone, ST; Muller, CR; Nurnberg, P; Muntoni, F; Sewry, C; Hughes, I; Sutphen, R; Lacson, AG; Swoboda, KJ; Vigneron, J; Wallgren-Pettersson, C; Beggs, AH; Laing, NG			Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy	NATURE GENETICS			English	Article							MISSENSE MUTATIONS; DNASE-I; CARDIOMYOPATHY; SEQUENCE; COMPLEX	Muscle contraction results from the force generated between the thin filament protein actin and the thick filament protein myosin, which causes the thick and thin muscle filaments to slide past each other(1). There are skeletal muscle, cardiac muscle, smooth muscle and non-muscle isoforms of both actin and myosin(2). Inherited diseases in humans have been associated with defects in cardiac actin (dilated cardiomyopathy(3) and hypertrophic cardiomyopathy(4)), cardiac myosin (hypertrophic cardiomyopathy(5)) and non-muscle myosin (deafness(6)). Here we report that mutations in the human skeletal muscle cr-actin gene(2) (ACTA1) are associated with two different muscle diseases, 'congenital myopathy with excess of thin myofilaments' (actin myopathy(7)) and nemaline myopathy(8). Both diseases are characterized by structural abnormalities of the muscle fibres and variable degrees of muscle weakness. We have identified 15 different missense mutations resulting in 14 different amino acid changes. The missense mutations in ACTA1 are distributed throughout all six coding exons(2), and some involve known functional domains of actin(9). Approximately half of the patients died within their first year, but two female patients have survived into their thirties and have children. We identified dominant mutations in all but 1 of 14 families, with the missense mutations being single and heterozygous. The only family showing dominant inheritance comprised a 33-year-old affected mother and her two affected and two unaffected children. In another family, the clinically unaffected father is a somatic mosaic for the mutation seen in both of his affected children. We identified recessive mutations in one family in which the two affected siblings had heterozygous mutations in two different exons, one paternally and the other maternally inherited. We also identified de novo mutations in seven sporadic probands for which it was possible to analyse parental DNA.	Univ Western Australia, Queen Elizabeth II Med Ctr, Australian Neuromuscular Res Inst, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; Murdoch Univ, Dept Vet & Biomed Sci, Murdoch, WA 6150, Australia; Harvard Univ, Childrens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA; Univ Mainz, Dept Neuropathol, D-6500 Mainz, Germany; Univ Western Australia, Crystallog Ctr, Perth, WA 6009, Australia; Univ Western Australia, Dept Pharmacol, Perth, WA 6009, Australia; Univ Helsinki, Folkhalsan Inst Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Royal Perth Hosp, Dept Neuropathol, Perth, WA, Australia; Humboldt Univ, Dept Neuropaediat, Berlin, Germany; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Child Dev Ctr, Cambridge, England; Royal Alexandra Hosp Children, Neurogenet Res Unit, Sydney, NSW, Australia; Univ Texas, SW Med Ctr, Texas Scottish Rite Hosp Children, Dallas, TX USA; Univ Wurzburg, Dept Human Genet, D-8700 Wurzburg, Germany; Humboldt Univ, Inst Med Genet, Charite Med Sch, Berlin, Germany; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Paediat & Neonatal Med, London, England; Royal Manchester Childrens Hosp, Dept Paediat Neurol, Manchester M27 1HA, Lancs, England; Univ S Florida, Sch Med, All Childrens Hosp, Tampa, FL 33620 USA; Univ S Florida, Sch Med, Dept Pediat, Tampa, FL 33620 USA; Univ S Florida, Sch Med, Dept Pathol, Tampa, FL 33620 USA; Serv Matern Reg A Pinard, Nancy, France; Univ Helsinki, Folkhalsan Dept Med Genet, Helsinki, Finland	University of Western Australia; Murdoch University; Harvard University; Boston Children's Hospital; Harvard Medical School; Johannes Gutenberg University of Mainz; University of Western Australia; University of Western Australia; University of Helsinki; University of Helsinki; Royal Perth Hospital; University of Western Australia; Humboldt University of Berlin; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Texas Scottish Rite Hospital for Children; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Wurzburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Imperial College London; Royal Manchester Children's Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Helsinki	Laing, NG (corresponding author), Univ Western Australia, Queen Elizabeth II Med Ctr, Australian Neuromuscular Res Inst, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia.		; North, Kathryn/K-6476-2012	Donner, Kati/0000-0001-9190-4336; Pelin, Katarina/0000-0002-7040-7266; Swoboda, Kathryn/0000-0002-4593-6342; Beggs, Alan/0000-0001-8818-0568; Oexle, Konrad/0000-0001-7447-2252; North, Kathryn/0000-0003-0841-8009; Laing, Nigel/0000-0001-5111-3732				AKKARI PA, 1994, CYTOGENET CELL GENET, V65, P265, DOI 10.1159/000133644; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Craig R, 1994, MYOLOGY, P134; DIETZEN CJ, 1993, MUSCLE NERVE, V16, P328; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; DRUMMOND DR, 1992, EUR J BIOCHEM, V209, P171, DOI 10.1111/j.1432-1033.1992.tb17274.x; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; Goebel HH, 1997, NEUROMUSCULAR DISORD, V7, P160, DOI 10.1016/S0960-8966(97)00441-0; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAING NG, 1995, CURR OPIN NEUROL, V8, P391, DOI 10.1097/00019052-199510000-00012; LAING NG, 1995, NAT GENET, V9, P75, DOI 10.1038/ng0195-75; Lammens M, 1997, NEUROPEDIATRICS, V28, P116, DOI 10.1055/s-2007-973683; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; North KN, 1997, J MED GENET, V34, P705, DOI 10.1136/jmg.34.9.705; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pelin K, 1999, P NATL ACAD SCI USA, V96, P2305, DOI 10.1073/pnas.96.5.2305; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; SAKAI Y, 1990, J BIOCHEM-TOKYO, V107, P499, DOI 10.1093/oxfordjournals.jbchem.a123074; SHETERLINE P, 1999, ACTIN, P1; TAN P, 1997, NEUROMUSCULAR DISORD, V7, P427; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; WALLGRENPETTERS.C, 1998, INHERITED NEUROMUSCU, P247; WALLGRENPETTERSSON C, 1989, J NEUROL SCI, V89, P1, DOI 10.1016/0022-510X(89)90002-6; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WERTMAN KF, 1992, GENETICS, V132, P337	30	292	299	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					208	212		10.1038/13837	http://dx.doi.org/10.1038/13837			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508519				2022-12-25	WOS:000082827500022
J	Feliubadalo, L; Font, M; Purroy, J; Rousaud, F; Estivill, X; Nunes, V; Golomb, E; Centola, M; Aksentijevich, I; Kreiss, Y; Goldman, B; Pras, M; Kastner, DL; Pras, E; Gasparini, P; Bisceglia, L; Beccia, E; Gallucci, M; de Sanctis, L; Ponzone, A; Rizzoni, GF; Zelante, L; Bassi, MT; George, AL; Manzoni, M; De Grandi, A; Riboni, M; Endsley, JK; Ballabio, A; Borsani, G; Reig, N; Fernandez, E; Estevez, R; Pineda, M; Torrents, D; Camps, M; Lloberas, J; Zorzano, A; Palacin, M				Feliubadalo, L; Font, M; Purroy, J; Rousaud, F; Estivill, X; Nunes, V; Golomb, E; Centola, M; Aksentijevich, I; Kreiss, Y; Goldman, B; Pras, M; Kastner, DL; Pras, E; Gasparini, P; Bisceglia, L; Beccia, E; Gallucci, M; de Sanctis, L; Ponzone, A; Rizzoni, GF; Zelante, L; Bassi, MT; George, AL; Manzoni, M; De Grandi, A; Riboni, M; Endsley, JK; Ballabio, A; Borsani, G; Reig, N; Fernandez, E; Estevez, R; Pineda, M; Torrents, D; Camps, M; Lloberas, J; Zorzano, A; Palacin, M		Int Cystinuria Consortium	Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b(o,+)AT) of rBAT	NATURE GENETICS			English	Article							AMINO-ACID-TRANSPORT; EXPRESSION CLONING; SLC3A1 GENE; IDENTIFICATION; LOCALIZATION; KIDNEY; SYSTEM	Cystinuria (MIM 220100) is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids. Mutations in SLC3A1, encoding rBAT, cause cystinuria type I (ref. 1), but not other types of cystinuria (ref. 2). A gene whose mutation causes non-type I cystinuria has been mapped by linkage analysis to 19q12-13.1 (refs 3,4). We have identified a new transcript, encoding a protein (b(o,+)AT, for b(o,+) amino acid transporter) belonging to a family of light subunits of amino acid transporters, expressed in kidney, liver, small intestine and placenta, and localized its gene (SLC7A9) to the non-type I cystinuria 19q locus. Co-transfection of b(o,+)AT and rBAT brings the latter to the plasma membrane, and results in the uptake of L-arginine in COS cells. We have found SLC7A9 mutations in Libyan-Jews, North American, Italian and Spanish non-type I cystinuria patients. The Libyan Jewish patients are homozygous for a founder missense mutation (V170M) that abolishes b(o,+)AT amino-acid uptake activity when co-transfected with rBAT in COS cells. We identified four missense mutations (G105R, A182T, G195R and C295R) and two frameshift (520insT and 596delTG) mutations in other patients. Our data establish that mutations in SLC7A9 cause non-type I cystinuria, and suggest that b(o,+)AT is the light subunit of rBAT.	Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, E-08028 Barcelona, Spain; Hosp Duran & Reynals, Ctr Genet Med & Mol IRO, E-08907 Barcelona, Spain; Fdn Puigvert, Serv Nefrol IUNA, E-08025 Barcelona, Spain; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; NIAMSD, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Inst Human Genet, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med F, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Heller Inst Med Sci, IL-52621 Tel Hashomer, Israel; IRCCS, Med Genet Serv, Hosp CSS, San Giovanni Rotondo, Italy; IRCCS, Div Urol, Hosp CSS, San Giovanni Rotondo, Italy; Hosp Cristo Re, Div Urol, Rome, Italy; Univ Turin, Dept Pediat, I-10124 Turin, Italy; Hosp Bambino Gesu, Div Pediat Nephrol, Rome, Italy; Telethon Inst Genet & Med, I-20132 Milan, Italy; Vanderbilt Univ, Dept Med, Div Med Genet, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Div Nephrol, Nashville, TN 37232 USA; Univ Barcelona, Dept Fisiol Biol Macrophage, Fac Biol, E-08028 Barcelona, Spain	University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Fundacio Puigvert; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo Della Sofferenza; University of Turin; IRCCS Bambino Gesu; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Vanderbilt University; Vanderbilt University; University of Barcelona	Palacin, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Fac Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Estivill, Xavier/E-2957-2012; Palacín, Manuel/G-9786-2015; Bisceglia, Luigi/B-8720-2017; Feliubadalo, Lidia/G-4577-2016; Riu, Marta Pineda/I-1497-2015; Lloberas, Jorge/D-4303-2014; De Sanctis, Luisa/AAC-6902-2022; Borsani, Giuseppe/B-1709-2010; Wilson, Matthew H/K-3193-2013; Aksentijevich, Ivona/AAF-1335-2019; Estivill, Xavier/A-3125-2013; Zorzano, Antonio/R-5479-2018; Bassi, Maria Teresa T/A-3517-2014; Nunes, Virginia/AAD-1014-2019; Nunes, Virginia/D-4356-2014; Gasparini, Paolo/B-6173-2014; Camps Camprubi, Marta/F-6557-2016; Torrents, David/G-5785-2015; Gallucci, Michele/K-9600-2016; Estevez, Raul/D-8610-2015	Bisceglia, Luigi/0000-0001-5367-8518; Feliubadalo, Lidia/0000-0002-1736-0112; Riu, Marta Pineda/0000-0002-5403-5845; Lloberas, Jorge/0000-0001-7075-4201; Borsani, Giuseppe/0000-0003-0110-1148; Estivill, Xavier/0000-0002-0723-2256; Bassi, Maria Teresa T/0000-0002-8236-1197; Nunes, Virginia/0000-0002-5747-9310; Nunes, Virginia/0000-0002-5747-9310; Camps Camprubi, Marta/0000-0001-5392-1792; Gasparini, Paolo/0000-0002-0859-0856; Torrents, David/0000-0002-6086-9037; Gallucci, Michele/0000-0002-3637-6531; DE SANCTIS, Luisa/0000-0003-2113-6196; Estevez, Raul/0000-0003-1579-650X; BALLABIO, Andrea/0000-0003-1381-4604; Palacin, Manuel/0000-0002-8670-293X	Telethon [E.0556, TGM97000, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; Bisceglia L, 1997, AM J HUM GENET, V60, P611; BISCEGLIA L, 1994, HUM MUTAT, V4, P136, DOI 10.1002/humu.1380040208; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; FELIUBADALO L, IN PRESS GENOMICS; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GOODYER PR, 1993, J PEDIATR-US, V122, P568, DOI 10.1016/S0022-3476(05)83537-1; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Pras E, 1998, AM J MED GENET, V80, P173, DOI 10.1002/(SICI)1096-8628(19981102)80:2<173::AID-AJMG16>3.0.CO;2-S; PRAS E, IN PRESS GENOMICS; Sambrook J., 2002, MOL CLONING LAB MANU; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Wartenfeld R, 1997, AM J HUM GENET, V60, P617	29	254	259	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					52	57		10.1038/12652	http://dx.doi.org/10.1038/12652			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471498				2022-12-25	WOS:000082337300015
J	Friedman, DS; Vale, RD				Friedman, DS; Vale, RD			Single-molecule analysis of kinesin motility reveals regulation by the cargo-binding tail domain	NATURE CELL BIOLOGY			English	Article							BOVINE BRAIN KINESIN; MICROTUBULE-BASED MOTILITY; HEAVY-CHAIN; LIGHT-CHAIN; TERMINAL DOMAIN; ATPASE ACTIVITY; MOTOR-ACTIVITY; NECK REGION; PHOSPHORYLATION; CLONING	Conventional kinesin transports membranes along microtubules in vivo, but the majority of cellular kinesin is unattached to cargo. The motility of non-cargo-bound, soluble kinesin may be repressed by an interaction between the amino-terminal motor and carboxy-terminal cargo-binding tail domains, but neither bead nor microtubule-gliding assays have shown such inhibition. Here we use a single-molecule assay that measures the motility of kinesin unattached to a surface. We show that full-length kinesin binds microtubules and moves about ten times less frequently and exhibits discontinuous motion compared with a truncated kinesin lacking a tail. Mutation of either the stalk hinge or neck coiled-coil domain activates motility of full-length kinesin, indicating that these regions are important for tail-mediated repression. Our results suggest that the motility of soluble kinesin in the cell is inhibited and that the motor becomes activated by cargo binding.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Friedman, DS (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.				NIGMS NIH HHS [T32 GM08120] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; COHN SA, 1989, J BIOL CHEM, V264, P4290; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; GIBBONS IR, 1979, J BIOL CHEM, V254, P187; Grummt M, 1998, EMBO J, V17, P5536, DOI 10.1093/emboj/17.19.5536; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; JIANG MY, 1995, BIOPHYS J S, V68, P283; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCLLVAIN JM, 1994, J BIOL CHEM, V269, P19176; MORAGA DE, 1997, MOL BIOL CELL ABSTR, V8, P258; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Pierce DW, 1998, METHOD ENZYMOL, V298, P154, DOI 10.1016/S0076-6879(98)98016-8; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Tripet B, 1997, J BIOL CHEM, V272, P8946; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; VALE RD, 1999, GUIDEBOOK CYTOSKELET, P398; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WAGNER MC, 1989, CELL MOTIL CYTOSKEL, V12, P195, DOI 10.1002/cm.970120403; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	48	195	197	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					293	297		10.1038/13008	http://dx.doi.org/10.1038/13008			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559942				2022-12-25	WOS:000083169600018
J	Ng, HH; Zhang, Y; Hendrich, B; Johnson, CA; Turner, BM; Erdjument-Bromage, H; Tempst, P; Reinberg, D; Bird, A				Ng, HH; Zhang, Y; Hendrich, B; Johnson, CA; Turner, BM; Erdjument-Bromage, H; Tempst, P; Reinberg, D; Bird, A			MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex	NATURE GENETICS			English	Article							CPG BINDING-PROTEIN; DNA METHYLATION; CHROMOSOMAL PROTEIN; TRICHOSTATIN-A; IDENTIFICATION; LOCALIZATION; ACETYLATION; COMPONENT	Mammalian DNA is methylated at many CpG dinucleotides. The biological consequences of methylation are mediated by a family of methyl-CpG binding proteins(1-4). The best characterized family member is MeCP2, a transcriptional repressor that recruits histone deacetylases(5-7). Our report concerns MBD2, which can bind methylated DNA in vivo and in vitro(4) and has been reported to actively demethylate DNA (ref. 8). As DNA methylation causes gene silencing, the MBD2 demethylase is a candidate transcriptional activator. Using specific antibodies, however, we find here that MBD2 in Hela cells is associated with histone deacetylase (HDAC) in the MeCP1 repressor complex(1,9). An affinity-purified HDAC1 corepressor complex(10,11) also contains MBD2, suggesting that MeCP1 corresponds to a fraction of this complex. Exogenous MBD2 represses transcription in a transient assay, and repression can he relieved by the deacetylase inhibitor trichostatin A (TSA; ref. 12). in our hands, MBDZ does not demethylate DNA. Our data suggest that Hela cells, which lack the known methylation-dependent repressor MeCP2, use an alternative pathway involving MBD2 to silence methylated genes.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Edinburgh; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Birmingham; Memorial Sloan Kettering Cancer Center	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.		Ng, Huck Hui/A-1135-2009; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Johnson, Colin/0000-0002-2979-8234; Bird, Adrian/0000-0002-8600-0372; Zhang, Yi/0000-0002-2789-0811; Reinberg, Danny/0000-0003-4288-2016	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; WHITE DA, IN PRESS METHODS; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang BG, 1997, DYN CONTIN DISCRET I, V3, P89; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	24	708	742	1	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					58	61		10.1038/12659	http://dx.doi.org/10.1038/12659			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471499	Green Published			2022-12-25	WOS:000082337300016
J	Xu, X; Toselli, PA; Russell, LD; Seldin, DC				Xu, X; Toselli, PA; Russell, LD; Seldin, DC			Globozoospermia in mice lacking the casein kinase II alpha ' catalytic subunit	NATURE GENETICS			English	Article							HEADED HUMAN SPERMATOZOA; DEFICIENT MICE; SPERMATOGENESIS; SPERMIOGENESIS; MANCHETTE; NUCLEAR; CELLS; GENE	Protein kinase casein kinase II (Ck2) is a cyclic-AMP and calcium-independent serine-threonine kinase that is composed of two catalytic subunits (alpha and alpha') and two regulatory beta-subunits. Ck2 is not a casein kinase in vivo, but over 100 substrates are known(1). The highly conserved amino acid sequences of its subunits(2, 3) and their broad expression suggest that Ck2 may have a fundamental role in cell function. Ck2 has been implicated in DNA replication, regulation of basal and inducible transcription, translation and control of metabolism. The Ck2 alpha and Ck2 alpha' isoforms (products of the genes Csnk2a1 and Csnk2a2, respectively) are highly homologous, but the reason for their redundancy and evolutionary conservation is unknown. We find here that Csnk2a2 is preferentially expressed in late stages of spermatogenesis, and male mice in which Csnk2a2 has been disrupted are infertile, with oligospermia and globozoospermia ('round-headed' spermatozoa). This is the first demonstration of a unique role for a Ck2 isoform in development. The primary spermatogenic defect in Csnk2a2(-/-) testis is a specific abnormality of anterior head shaping of elongating spermatids; this is the first defined gene that regulates sperm head morphogenesis. As the germ cells differentiate, they are capable of undergoing chromatin condensation, although many abnormal cells are deleted through apoptosis or Sertoli cell phagocytosis. The few that survive to populate the epididymis exhibit head abnormalities similar to those described in human globozoospermia, thus Csnk2a2 may be a candidate gene for these inherited syndromes.	Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Boston Medical Center; Boston University; Southern Illinois University System; Southern Illinois University	Seldin, DC (corresponding author), Boston Med Ctr, Dept Med, Boston, MA 02118 USA.	dseldin@med-med1.bu.edu		Seldin, David C/0000-0003-0168-2333				Baccetti B, 1996, J SUBMICR CYTOL PATH, V28, P587; BACCETTI B, 1977, ANDROLOGIA, V9, P255; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; CASTELLANI L, 1978, ARCH ANDROLOGY, V1, P291, DOI 10.3109/01485017808988349; CHESTER N, 1995, J BIOL CHEM, V270, P7501, DOI 10.1074/jbc.270.13.7501; COLE A, 1988, BIOL REPROD, V38, P385, DOI 10.1095/biolreprod38.2.385; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; ESCALIER D, 1990, International Journal of Developmental Biology, V34, P287; FAWCETT DW, 1971, DEV BIOL, V26, P220, DOI 10.1016/0012-1606(71)90124-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Mudgal P, 1998, MOL REPROD DEV, V50, P178, DOI 10.1002/(SICI)1098-2795(199806)50:2&lt;178::AID-MRD8&gt;3.0.CO;2-H; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Rubes J, 1998, FERTIL STERIL, V70, P715, DOI 10.1016/S0015-0282(98)00261-1; RUSSELL LD, 1991, AM J ANAT, V192, P97, DOI 10.1002/aja.1001920202; Russo R. O., 1990, Journal of Sustainable Agriculture, V1, P19, DOI 10.1300/J064v01n02_04; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINGH G, 1992, INT J FERTIL, V37, P99; Tawfic S, 1999, J CELL BIOCHEM, V72, P242; TOPPARI J, 1988, CYTOMETRY, V9, P456, DOI 10.1002/cyto.990090509; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TOSELLI P, 1994, LIFE SCI, V55, P621, DOI 10.1016/0024-3205(94)00488-9; VONBERNHARDI R, 1990, ANDROLOGIA, V22, P12; Ward WS, 1999, BIOL REPROD, V60, P702, DOI 10.1095/biolreprod60.3.702; Xu X, 1998, GENOMICS, V48, P79, DOI 10.1006/geno.1997.5154	26	298	314	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					118	121		10.1038/12729	http://dx.doi.org/10.1038/12729			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471512				2022-12-25	WOS:000082337300029
J	Cella, M; Jarrossay, D; Facchetti, F; Alebardi, O; Nakajima, H; Lanzavecchia, A; Colonna, M				Cella, M; Jarrossay, D; Facchetti, F; Alebardi, O; Nakajima, H; Lanzavecchia, A; Colonna, M			Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon	NATURE MEDICINE			English	Article							ALPHA-PRODUCING CELLS; T-CELLS; DENDRITIC CELLS; RECEPTOR; CHEMOKINES; INDUCTION; DISTINCT; MATURE; PROLIFERATION; LYMPHADENITIS	We have identified two cell subsets in human blood based on the lack of lineage markers (lin(-)) and the differential expression of immunoglobulin-like transcript receptor 1 (ILT1) and ILT3. One subset (lin(-)/ILT3(+)/ILT1(+)) is related to myeloid dendritic cells. The other subset (lin(-)/ILi3(+)/ILT1(-)) corresponds to 'plasmacytoid monocytes'. These cells are found in inflamed lymph nodes in and around the high endothelial venules. They express CD62L and CXCR3, and produce extremely large amounts of type I interferon after stimulation with influenza virus or CD40L. These results, with the distinct cell phenotype, indicate that plasmacytoid monocytes represent a specialized cell lineage that enters inflamed lymph nodes at high endothelial venules, where it produces type I interferon. Plasmacytoid monocytes may protect other cells from viral infections and promote survival of antigen-activated T cells.	Beckman Coulter Co, Basel Inst Immunol, Marseille, France; Beckman Coulter Co, Immunotech, Marseille, France; Univ Brescia, Spedali Civili Brescia, Ist Anat Patol, Brescia, Italy	Beckman Coulter Inc.; Beckman Coulter Inc.; Hospital Spedali Civili Brescia; University of Brescia	Colonna, M (corresponding author), Beckman Coulter Co, Basel Inst Immunol, Marseille, France.		Cella, Marina/G-8850-2011; Facchetti, Fabio/E-7190-2010; Cella, Marina/ABA-8564-2020	Facchetti, Fabio/0000-0003-4975-2388; Cella, Marina/0000-0003-1230-1313; Colonna, Marco/0000-0001-5222-4987				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Belardelli F, 1998, CANCER RES, V58, P5795; Bjorck P, 1997, EUR J IMMUNOL, V27, P1266, DOI 10.1002/eji.1830270531; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; CHEHIMI J, 1989, IMMUNOLOGY, V68, P488; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FACCHETTI F, 1989, J PATHOL, V158, P57, DOI 10.1002/path.1711580112; FACCHETTI F, 1989, HUM PATHOL, V20, P588, DOI 10.1016/0046-8177(89)90248-7; FACCHETTI F, 1989, AM J CLIN PATHOL, V92, P42, DOI 10.1093/ajcp/92.1.42; FACCHETTI F, 1988, AM J PATHOL, V133, P15; FACCHETTI F, 1990, AM J SURG PATHOL, V14, P101, DOI 10.1097/00000478-199002000-00001; Facchetti F, 1991, Sarcoidosis, V8, P170; FACCHETTI F, 1991, AM J SURG PATHOL, V15, P1012, DOI 10.1097/00000478-199110000-00014; FACCHETTI F, 1990, AM J DERMATOPATH, V12, P363, DOI 10.1097/00000372-199008000-00006; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; FELDMAN M, 1990, J INTERFERON RES, V10, P435, DOI 10.1089/jir.1990.10.435; FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5; FITZGERALDBOCARSLY P, 1988, J LEUKOCYTE BIOL, V43, P323, DOI 10.1002/jlb.43.4.323; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Grouard G, 1996, NATURE, V384, P364, DOI 10.1038/384364a0; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HORNY HP, 1987, HUM PATHOL, V18, P28, DOI 10.1016/S0046-8177(87)80189-2; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; MULLERHERMELINK HK, 1983, AM J SURG PATHOL, V7, P849, DOI 10.1097/00000478-198307080-00013; Nakajima H, 1999, J IMMUNOL, V162, P5; NEDERMAN T, 1990, BIOLOGICALS, V18, P29, DOI 10.1016/1045-1056(90)90066-9; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PERUSSIA B, 1985, Natural Immunity and Cell Growth Regulation, V4, P120; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; PRASTHOFER EF, 1985, AM J SURG PATHOL, V9, P380; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947	39	1299	1355	2	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					919	923		10.1038/11360	http://dx.doi.org/10.1038/11360			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426316				2022-12-25	WOS:000081684000036
J	Newberry, RD; Stenton, WF; Lorenz, RG				Newberry, RD; Stenton, WF; Lorenz, RG			Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; CD4(+) T-CELLS; PROSTAGLANDIN E-2; TRANSGENIC MICE; GENE DISRUPTION; LAMINA PROPRIA; B-CELLS; EXPRESSION; LIPOPOLYSACCHARIDE; LYMPHOCYTES	Intestinal inflammatory diseases are mediated by dysregulated immune responses to undefined luminal antigens. Feeding hen egg-white lysozyme to mice expressing a transgenic T-cell receptor that recognizes hen egg-white lysozyme peptide 46-61 resulted in no intestinal pathology; however, simultaneous administration of cyclooxygenase-2 inhibitors and dietary hen egg-white lysozyme resulted in increased proliferation of lamina propria mononuclear cells and crypt epithelial cells, crypt expansion and villus blunting. Lamina propria mononuclear cells produce high levels of cyclooxygenase-2-dependent arachidonic acid metabolites, which act as immunomodulators in the immune response to dietary antigen. These findings establish that cyclooxygenzse-2-dependent arachidonic acid metabolites are essential in the development and maintenance of intestinal immune homeostasis.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Lorenz, RG (corresponding author), Washington Univ, Sch Med, Dept Internal Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	lorenz@pathbox.wustl.edu	Lorenz, Robin G/AAJ-1499-2021	Lorenz, Robin G/0000-0002-2514-9819; Newberry, Rodney/0000-0002-4152-5191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055753, R01DK033165] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33165, DK-55753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AABAKKEN L, 1989, SCAND J GASTROENTERO, V24, P48, DOI 10.3109/00365528909091175; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BETZ M, 1991, J IMMUNOL, V146, P108; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832, DOI 10.1016/0016-5085(93)90667-2; Braunstein J, 1997, GUT, V41, P215, DOI 10.1136/gut.41.2.215; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Davidson NJ, 1996, J EXP MED, V184, P241, DOI 10.1084/jem.184.1.241; Demeure CE, 1997, EUR J IMMUNOL, V27, P3526, DOI 10.1002/eji.1830271254; ELLNER JJ, 1979, J IMMUNOL, V123, P2689; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FREUDENBERG MA, 1988, INFECT IMMUN, V56, P1352, DOI 10.1128/IAI.56.5.1352-1357.1988; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gonnella PA, 1998, J IMMUNOL, V160, P4708; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; HO WY, 1994, J EXP MED, V179, P1539, DOI 10.1084/jem.179.5.1539; Hurst SD, 1997, P NATL ACAD SCI USA, V94, P3920, DOI 10.1073/pnas.94.8.3920; Kalinski P, 1997, J IMMUNOL, V159, P28; KAUFMANN HJ, 1987, ANN INTERN MED, V107, P513, DOI 10.7326/0003-4819-107-4-513; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KRUISBEEK AM, 1997, CURRENT PROTOCOLS IM; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LIONETTI P, 1993, GASTROENTEROLOGY, V105, P373, DOI 10.1016/0016-5085(93)90710-T; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Morham SG, 1997, ADV EXP MED BIOL, V407, P131; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nilsen EM, 1998, GASTROENTEROLOGY, V115, P551, DOI 10.1016/S0016-5085(98)70134-9; Parronchi P, 1997, AM J PATHOL, V150, P823; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; SNYDER DS, 1982, NATURE, V299, P163, DOI 10.1038/299163a0; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; Wu CY, 1998, J IMMUNOL, V161, P2723; YAMADA T, 1993, INFLAMMATION, V17, P641, DOI 10.1007/BF00920471; ZIEGLERHEITBROCK HWL, 1995, IMMUNOBIOLOGY, V193, P217	45	227	234	1	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					900	906		10.1038/11341	http://dx.doi.org/10.1038/11341			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426313				2022-12-25	WOS:000081684000033
J	Taniguchi, K; Kohsaka, H; Inoue, N; Terada, Y; Ito, H; Hirokawa, K; Miyasaka, N				Taniguchi, K; Kohsaka, H; Inoue, N; Terada, Y; Ito, H; Hirokawa, K; Miyasaka, N			Induction of the p16(INK4a) senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis	NATURE MEDICINE			English	Article							COLLAGEN-INDUCED ARTHRITIS; ADENOVIRUS-MEDIATED TRANSFER; DEPENDENT KINASE INHIBITORS; CELL-CYCLE ARREST; REPLICATIVE SENESCENCE; FUSION PROTEIN; GLIOMA-CELLS; TGF-BETA; EXPRESSION; SUPPRESSION	Synovial tissue affected by rheumatoid arthritis is characterized by proliferation, which leads to irreversible cartilage and bone destruction. Current and experimental treatments have been aimed mainly at correcting the underlying immune abnormalities, but these treatments often prove ineffective in preventing the invasive destruction. We studied the expression of cyclin-dependent kinase inhibitors in rheumatoid synovial cells as a means of suppressing synovial cell proliferation. Synovial cells derived from hypertrophic synovial tissue readily expressed p16(1NK4a) when they were growth-inhibited. This was not seen in other fibroblasts, including those derived from normal and osteoarthritis-affected synovial tissues. In vivo adenoviral gene therapy with the p16(1NK4a) gene efficiently inhibited the pathology in an animal model of rheumatoid arthritis. Thus, the induction of p16(1NK4a) may provide a new approach to the effective treatment of rheumatoid arthritis.	Tokyo Med & Dent Univ, Dept Internal Med 1, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Dept Internal Med 1, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Dept Pathol & Immunol, Sch Med, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Kohsaka, H (corresponding author), Tokyo Med & Dent Univ, Dept Internal Med 1, Sch Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Apparailly F, 1998, J IMMUNOL, V160, P5213; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bakker AC, 1997, ARTHRITIS RHEUM, V40, P893, DOI 10.1002/art.1780400517; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Feldmann M, 1997, ADV IMMUNOL, V64, P283, DOI 10.1016/S0065-2776(08)60891-3; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; Fueyo J, 1996, ONCOGENE, V12, P103; Ghivizzani SC, 1998, P NATL ACAD SCI USA, V95, P4613, DOI 10.1073/pnas.95.8.4613; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Le CH, 1997, ARTHRITIS RHEUM, V40, P1662, DOI 10.1002/art.1780400916; LOIS AF, 1995, CANCER RES, V55, P4010; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; MATHIAS P, 1994, J VIROL, V68, P6811, DOI 10.1128/JVI.68.10.6811-6814.1994; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Otani K, 1996, J IMMUNOL, V156, P3558; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; ROESSLER BJ, 1993, J CLIN INVEST, V92, P1085, DOI 10.1172/JCI116614; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Song XY, 1998, J CLIN INVEST, V101, P2615, DOI 10.1172/JCI2480; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Wang XQ, 1996, CANCER RES, V56, P2510; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang HD, 1997, J CLIN INVEST, V100, P1951, DOI 10.1172/JCI119726; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; ZVAIFLER NJ, 1987, ARTHRITIS RHEUM, V30, P109, DOI 10.1002/art.1780300117	45	131	151	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					760	767		10.1038/10480	http://dx.doi.org/10.1038/10480			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395320				2022-12-25	WOS:000081926600030
J	Camacho, JA; Obie, C; Biery, B; Goodman, BK; Hu, CA; Almashanu, S; Steel, G; Casey, R; Lambert, M; Mitchell, GA; Valle, D				Camacho, JA; Obie, C; Biery, B; Goodman, BK; Hu, CA; Almashanu, S; Steel, G; Casey, R; Lambert, M; Mitchell, GA; Valle, D			Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter	NATURE GENETICS			English	Article							RAT-LIVER MITOCHONDRIA; ARGININE-BIOSYNTHESIS; PHOSPHATE SYNTHETASE; CARRIER PROTEINS; HHH SYNDROME; IDENTIFICATION; CITRULLINE; QUEBEC; PURIFICATION; MEMBRANE	Neurospora crassa ARG13 and Saccharomyces cerevisiae ARG11 I en code mitochondrial carrier family (MCF) proteins that transport ornithine across the mitochondrial inner membrane,. We used their sequences to identify EST candidates that partially encode orthologous mammalian transporters. We thereby identified such a gene (ORNT1) that maps to 13q14 and whose expression, similar to that of other urea cycle (UC) components, was high in liver and varied with changes in dietary protein. ORNT1 expression, restores ornithine metabolism in fibroblasts from patients with hyperammonaemia-hyperornithinaemia-homocitrullinuria (HHH) syndrome. In a survey of 11 HHH probands, we identified 3 ORNT1 mutant alleles that account for 21 of 22 possible mutant ORNT1 genes in our patients: F188 Delta which is common in French-Canadian HHH patients and encodes an unstable protein; E180K, which encodes a stable, properly targeted protein that is inactive; and a 13q14 microdeletion. Our results show that ORNT1 encodes the mitochondrial ornithine transporter involved in UC function and is defective in HHH syndrome.	Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynaecol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21218 USA; Univ Saskatchewan, Dept Pediat, Saskatoon, SK, Canada; Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; University of Saskatchewan; Universite de Montreal	Valle, D (corresponding author), Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21218 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [C06EY007414] Funding Source: NIH RePORTER; NEI NIH HHS [EY07414] Funding Source: Medline; NICHD NIH HHS [HD24061] Funding Source: Medline; NIGMS NIH HHS [GM07471] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bouchard JP, 1998, NEUROMUSCULAR DISORD, V8, P474, DOI 10.1016/S0960-8966(98)00055-8; BRADFORD NM, 1980, FEBS LETT, V113, P294, DOI 10.1016/0014-5793(80)80612-0; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Braverman N, 1997, NAT GENET, V15, P369, DOI 10.1038/ng0497-369; BRODY LC, 1992, J BIOL CHEM, V267, P330; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; Carter KC, 1998, EUR J HUM GENET, V6, P61, DOI 10.1038/sj.ejhg.5200153; Cayanis E, 1998, GENOMICS, V47, P26, DOI 10.1006/geno.1997.5087; CHARBONNEAU H, 1987, NAISSANCE POPULATION; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; Crabeel M, 1996, J BIOL CHEM, V271, P25011, DOI 10.1074/jbc.271.40.25011; DEBRAEKELEER M, 1991, HUM HERED, V41, P168, DOI 10.1159/000153996; FELL V, 1974, AM J DIS CHILD, V127, P752, DOI 10.1001/archpedi.1974.02110240138023; GAMBLE JG, 1973, J BIOL CHEM, V248, P610; GATFIELD PD, 1975, PEDIATR RES, V9, P488, DOI 10.1203/00006450-197505000-00006; Haust MD, 1996, PATHOL RES PRACT, V192, P271, DOI 10.1016/S0344-0338(96)80230-5; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Huizing M, 1997, AM J HUM GENET, V61, P1239, DOI 10.1086/301628; INDIVERI C, 1994, BBA-BIOENERGETICS, V1188, P293, DOI 10.1016/0005-2728(94)90048-5; Indiveri C, 1998, BIOCHEM BIOPH RES CO, V249, P589, DOI 10.1006/bbrc.1998.9197; INDIVERI C, 1992, EUR J BIOCHEM, V207, P449, DOI 10.1111/j.1432-1033.1992.tb17070.x; Indiveri C, 1997, BIOCHEM J, V327, P349, DOI 10.1042/bj3270349; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kramer R, 1996, KIDNEY INT, V49, P947, DOI 10.1038/ki.1996.133; LEMAY JF, 1992, J PEDIATR-US, V121, P725, DOI 10.1016/S0022-3476(05)81900-6; Liu QY, 1996, GENETICS, V143, P1163; MERANTE F, 1993, AM J HUM GENET, V53, P481; METOKI K, 1984, J INHERIT METAB DIS, V7, P9, DOI 10.1007/BF01805611; MITCHELL GA, METABOLIC MOL BASES; MORIN C, 1993, AM J HUM GENET, V53, P488; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MOUALIJ B, 1997, YEAST, V13, P573; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; PASSARELLA S, 1990, EUR J BIOCHEM, V193, P221, DOI 10.1111/j.1432-1033.1990.tb19326.x; POWERSLEE SG, 1987, J BIOL CHEM, V262, P15683; SCHIMKE RT, 1962, J BIOL CHEM, V237, P459; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; SHIH VE, 1992, PRENATAL DIAG, V12, P717, DOI 10.1002/pd.1970120905; SHIH VE, 1982, CLIN CHIM ACTA, V118, P149, DOI 10.1016/0009-8981(82)90002-X; SHIH VE, 1969, AM J DIS CHILD, V117, P83, DOI 10.1001/archpedi.1969.02100030085009; SIMELL O, 1985, PEDIATR RES, V19, P1283, DOI 10.1203/00006450-198512000-00016; SMITH L, 1992, J PEDIATR GASTR NUTR, V15, P431, DOI 10.1097/00005176-199211000-00011; VALLINA JRP, 1995, PHARM SCI, V1, P185; VICI CD, 1987, PEDIATR RES, V22, P364, DOI 10.1203/00006450-198709000-00025; Vohl MC, 1997, CLIN GENET, V52, P1, DOI 10.1111/j.1399-0004.1997.tb02506.x; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x; YOKOTA S, 1986, HISTOCHEM J, V18, P451, DOI 10.1007/BF01675338; Zammarchi E, 1997, J PEDIATR-US, V131, P440, DOI 10.1016/S0022-3476(97)80072-8	53	140	150	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					151	158		10.1038/9658	http://dx.doi.org/10.1038/9658			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369256				2022-12-25	WOS:000080680900019
J	Rodriguez-Leon, J; Merino, R; Macias, D; Ganan, Y; Santesteban, E; Hurle, JM				Rodriguez-Leon, J; Merino, R; Macias, D; Ganan, Y; Santesteban, E; Hurle, JM			Retinoic acid regulates programmed cell death through BMP signalling	NATURE CELL BIOLOGY			English	Article							MOUSE DEVELOPMENT; APOPTOSIS; LIMB; BETA		Univ Cantabria, Dept Anat & Biol Celular, Santander 39011, Spain; Univ Extremadura, Dept Ciencias Morfol, E-06071 Badajoz, Spain; Univ Extremadura, Dept Biol Anim & Celular, E-06071 Badajoz, Spain	Universidad de Cantabria; Universidad de Extremadura; Universidad de Extremadura	Hurle, JM (corresponding author), Univ Cantabria, Dept Anat & Biol Celular, Santander 39011, Spain.		Gañán, Yolanda/L-7964-2014; Macias, Domingo/L-7950-2014; Leon, Joaquin Maria Rodriguez/S-9814-2019; Leon, Joaquin Maria Rodriguez/C-6957-2013; Merino, Ramón/L-1310-2014	Gañán, Yolanda/0000-0001-9176-2964; Macias, Domingo/0000-0001-7528-9169; Leon, Joaquin Maria Rodriguez/0000-0002-9582-5480; Leon, Joaquin Maria Rodriguez/0000-0002-9582-5480; Merino, Ramón/0000-0002-5306-0635; Hurle, Juan M/0000-0002-4685-025X				ALLES AJ, 1989, TERATOLOGY, V40, P163, DOI 10.1002/tera.1420400210; Chen YP, 1998, J EXP ZOOL, V282, P691; Dupe V, 1999, DEV BIOL, V208, P30, DOI 10.1006/dbio.1998.9176; GAFIAN Y, 1996, DEVELOPMENT, V122, P2349; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; Kastner P, 1997, DEVELOPMENT, V124, P313; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Merino R, 1998, DEV BIOL, V200, P35, DOI 10.1006/dbio.1998.8946; SULIK KK, 1988, DEVELOPMENT, V103, P213; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	15	79	80	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					125	126		10.1038/10098	http://dx.doi.org/10.1038/10098			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559885				2022-12-25	WOS:000083102200021
J	Stowell, MHB; Marks, B; Wigge, P; McMahon, HT				Stowell, MHB; Marks, B; Wigge, P; McMahon, HT			Nucleotide-dependent conformational changes in dynamin: evidence for a mechanochemical molecular spring	NATURE CELL BIOLOGY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAINS; NEUROMUSCULAR-JUNCTIONS; ACIDIC PHOSPHOLIPIDS; GTPASE ACTIVITY; ACTIVATION; MEMBRANE; MICROTUBULES; BINDING	The GTPase dynamin plays an essential part in endocytosis by catalysing the fission of nascent clathrin-coated vesicles from the plasma membrane. Using preformed phosphatidylinositol-4,5-bisphosphate-containing lipid nanotubes as a membrane template for dynamin self-assembly, we investigate the conformational changes that arise during GTP hydrolysis by dynamin. Electron microscopy reveals that, in the GTP-bound state, dynamin rings appear to be tightly packed together. After GTP hydrolysis, the spacing between rings increases nearly twofold. When bound to the nanotubes, dynamin's GTPase activity is cooperative and is increased by three orders of magnitude compared with the activity of unbound dynamin. An increase in the k(cat) (but not the K-m) of GTP hydrolysis accounts for the pronounced cooperativity. These data indicate that a novel, lengthwise ('spring-like') conformational change in a dynamin helix may participate in vesicle fission.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	McMahon, HT (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	hmm@mrc-lmb.cam.ac.uk		STOWELL, MICHAEL/0000-0001-7250-1419				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DEUTSCH JW, 1981, BIOCHEMISTRY-US, V20, P378, DOI 10.1021/bi00505a024; Goldstein AS, 1997, CHEM PHYS LIPIDS, V88, P21, DOI 10.1016/S0009-3084(97)00042-X; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; STEINWEIS PC, 1982, P NATL ACAD SCI USA, V79, P4888; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1998, MOL BIOL CELL, V9, p130A; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	47	297	305	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					27	32		10.1038/8997	http://dx.doi.org/10.1038/8997			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559860				2022-12-25	WOS:000083085300014
J	Takei, K; Slepnev, VI; Haucke, V; De Camilli, P				Takei, K; Slepnev, VI; Haucke, V; De Camilli, P			Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis	NATURE CELL BIOLOGY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; NERVE-TERMINALS; COATED VESICLES; BREAST-CANCER; SH3 DOMAIN; BINDING; FAMILY; IDENTIFICATION; PROTEINS; MEMBRANE	Amphiphysin, a protein that is highly concentrated in nerve terminals, has been proposed to function as a linker between the clathrin coat and dynamin in the endocytosis of synaptic vesicles. Here, using a cell-free system, we provide direct morphological evidence in support of this hypothesis. Unexpectedly, we also find that amphiphysin-1, like dynamin-1, can transform spherical liposomes into narrow tubules. Moreover, amphiphysin-1 assembles with dynamin-1 into ring-like structures around the tubules and enhances the liposome-fragmenting activity of dynamin-1 in the presence of GTP. These results show that amphiphysin binds lipid bilayers, indicate a potential function for amphiphysin in the changes in bilayer curvature that accompany vesicle budding, and imply a close functional partnership between amphiphysin and dynamin in endocytosis.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993; Takei, Kohji/0000-0002-6555-9425				Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; Liu JP, 1996, J NEUROCHEM, V66, P2074; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mundigl O, 1998, J NEUROSCI, V18, P93; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilson-Kubalek EM, 1998, P NATL ACAD SCI USA, V95, P8040, DOI 10.1073/pnas.95.14.8040; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	42	497	504	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					33	39		10.1038/9004	http://dx.doi.org/10.1038/9004			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559861				2022-12-25	WOS:000083085300015
J	Wadsworth, JDF; Hill, AF; Joiner, S; Jackson, GS; Clarke, AR; Collinge, J				Wadsworth, JDF; Hill, AF; Joiner, S; Jackson, GS; Clarke, AR; Collinge, J			Strain-specific prion-protein conformation determined by metal ions	NATURE CELL BIOLOGY			English	Article							CREUTZFELDT-JAKOB-DISEASE; MOLECULAR-BASIS; COPPER-BINDING; VARIANT CJD; BETA; BSE; ENCEPHALOPATHY; REGION	In animals infected with a transmissible spongiform encephalopathy, or prion disease, conformational isomers (known as PrPSc proteins) of the wild-type, host-encoded cellular prion protein (PrPc) accumulate. The infectious agents, prions, are composed mainly of these conformational isomers, with distinct prion isolates or strains being associated with different PrPSc conformations and patterns of glycosylation. Here we show that two different human PrPSc types, seen in clinically distinct subtypes of classical Creutzfeldt-Jakob disease, can be interconverted in vitro by altering their metal-ion occupancy. The dependence of PrPSc conformation on the binding of copper and zinc represents a new mechanism for post-translational modification of PrP and for the generation of multiple prion strains, with widespread implications for both the molecular classification and the pathogenesis of prion diseases in humans and animals.	St Marys Hosp, Imperial Coll, Sch Med, MRC,Prion Unit, London W2 1PG, England; St Marys Hosp, Imperial Coll, Sch Med, Dept Neurogenet, London W2 1PG, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Imperial College London; Imperial College London; University of Bristol	Collinge, J (corresponding author), St Marys Hosp, Imperial Coll, Sch Med, MRC,Prion Unit, Norfolk Pl, London W2 1PG, England.		Hill, Andrew F./AAH-2854-2020; Hill, Andrew F./GZL-4124-2022; Hill, Andrew F/B-4527-2009	Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Jackson, Graham/0000-0002-3125-2011; Wadsworth, Jonathan/0000-0002-4797-2259	Medical Research Council [MC_U123160655] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U123160655] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CARLTON WW, 1969, EXP MOL PATHOL, V10, P274, DOI 10.1016/0014-4800(69)90057-4; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Dawson R.M.C., 1986, DATA BIOCH RES, P399; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PATTISON IH, 1971, NATURE, V230, P115, DOI 10.1038/230115a0; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	33	265	272	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					55	59		10.1038/9030	http://dx.doi.org/10.1038/9030			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559865				2022-12-25	WOS:000083085300019
J	Craig, TA; Benson, LM; Tomlinson, AJ; Veenstra, TD; Naylor, S; Kumar, R				Craig, TA; Benson, LM; Tomlinson, AJ; Veenstra, TD; Naylor, S; Kumar, R			Analysis of transcription complexes and effects of ligands by microelectrospray ionization mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						mass spectrometry; vitamin D receptors; retinoic acid receptors; transcription; DNA response elements	RETINOID-X RECEPTOR; DNA-BINDING DOMAIN; ELECTROSPRAY-IONIZATION; VITAMIN-D; NUCLEAR RECEPTOR; D-3 RECEPTOR; RESPONSE ELEMENTS; MOLECULAR ACTIONS; ACID RECEPTORS; PROTEIN	The human vitamin D receptor (VDR) and retinoid X receptor-alpha (RXR alpha) modulate gene activity by forming homodimeric or heterodimeric complexes with specific DNA sequences and interaction with other elements of the transcriptional apparatus in the presence of their known endogenous ligands 1 alpha,25-dihydroxyvitamin D-3 (1,25-[OH](2)D-3) and 9-cis-retinoic acid (9-c-RA). We used rapid buffer exchange gel filtration in conjunction with microelectrospray ionization mass spectrometry (mu ESI-MS) to study the binding of these receptors to the osteopontin vitamin D response element (OP VDRE). In the absence of DNA, both VDR and RXR alpha existed primarily as monomers, but in the presence of OP VDRE, homodimeric RXR alpha and heterodimeric RXR alpha-VDR complexes were shown to bind OP VDRE. Addition of 9-c-RA increased RXR alpha homodimer-OP VDRE complexes, and addition of 1,25-(OH)2D3 resulted in formation of 1,25-(OH)(2)D-3-VDR-RXR alpha-OP VDRE complexes. Addition of low-affinity binding ligands had no detectable effect on the VDR-RXR alpha-OP VDRE transcription complex. These results demonstrate the utility of mu ESI-MS in analyzing multimeric, high-molecular-weight protein-protein and protein-DNA complexes, and the effects of ligands on these transcriptional complexes.	Mayo Clin, Nephrol Res Unit, Rochester, MN 55905 USA; Mayo Clin, Biomed Mass Spectrometry Facil, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Pharmacol, Rochester, MN 55905 USA; Mayo Clin, Clin Pharmacol Unit, Rochester, MN 55905 USA; Pacific NW Natl Lab, Environm & Mol Sci Lab, Richland, WA 99352 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Naylor, S (corresponding author), Mayo Clin, Nephrol Res Unit, Rochester, MN 55905 USA.	naylor.stephen@mayo.edu; rkumar@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NIDDK NIH HHS [R01 DK025409, DK 25409] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025409] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Bagchi Milan K., 1998, P159; Benjamin DR, 1998, P NATL ACAD SCI USA, V95, P7391, DOI 10.1073/pnas.95.13.7391; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; Cheng XH, 1996, P NATL ACAD SCI USA, V93, P7022, DOI 10.1073/pnas.93.14.7022; Cheng XH, 1996, ANAL BIOCHEM, V239, P35, DOI 10.1006/abio.1996.0287; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Cheskis Boris, 1998, P133; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Craig TA, 1996, BIOCHEM BIOPH RES CO, V218, P902, DOI 10.1006/bbrc.1996.0160; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; Fitzgerald MC, 1996, P NATL ACAD SCI USA, V93, P6851, DOI 10.1073/pnas.93.14.6851; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GOODLETT DR, 1993, BIOL MASS SPECTROM, V22, P181, DOI 10.1002/bms.1200220307; Haussler MR, 1997, J ENDOCRINOL, V154, pS57; Johnson KL, 1997, RAPID COMMUN MASS SP, V11, P939, DOI 10.1002/(SICI)1097-0231(199705)11:8<939::AID-RCM936>3.0.CO;2-3; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Nemirovskiy OV, 1997, J AM SOC MASS SPECTR, V8, P809, DOI 10.1016/S1044-0305(97)00086-X; *PHARM BIOT, 1994, GST FUS SYST MAN; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Potier N, 1998, PROTEIN SCI, V7, P1388; REVELLE L, 1984, BIOCHEMISTRY-US, V23, P1983, DOI 10.1021/bi00304a016; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; Schwartz B L, 1996, Methods Mol Biol, V61, P115; SHETERLINE P, 1995, PROTEIN PROFILE TRAN, V2, P1209; Siuzdak G., 1996, MASS SPECTROMETRY BI; Smith RD, 1997, CHEM SOC REV, V26, P191, DOI 10.1039/cs9972600191; SONE T, 1991, J BIOL CHEM, V266, P23296; Veenstra TD, 1997, BIOCHEMISTRY-US, V36, P3535, DOI 10.1021/bi9628329; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; YANG Q, 1998, ADV CHROMATOGRAPHIC, P95	42	37	37	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1214	1218		10.1038/70767	http://dx.doi.org/10.1038/70767			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585721				2022-12-25	WOS:000084170700031
J	Hukuhara, T; Hayakawa, T; Wijonarko, A				Hukuhara, T; Hayakawa, T; Wijonarko, A			Increased baculovirus susceptibility of armyworm larvae feeding on transgenic rice plants expressing an entomopoxvirus gene	NATURE BIOTECHNOLOGY			English	Article						transgenic rice plants; baculovirus; entomopoxvirus; armyworm	VIRUS ENHANCING FACTOR; NUCLEAR POLYHEDROSIS-VIRUS; PSEUDALETIA-SEPARATA; STRIPE VIRUS; PROTOPLASTS; LEPIDOPTERA; RESISTANT; SEQUENCE; CULTURE	We have introduced an entomopoxvirus gene encoding a virus enhancing factor (EF) into rice, which resulted in high-level accumulation of the EF in the transgenic plants. The introduced gene was stably inherited in the progeny of the primary transformants, as shown by analysis of their genomic DNA. Bioassays for insect susceptibility to baculovirus infection showed that armyworm larvae feeding on the transgenic rice had increased susceptibility to a Nucleopolyhedrovirus. Thus, introduction of the EF gene into plants can be used as a strategy to increase the effectiveness of baculoviruses in insect pest management.	Nihon Univ, Coll Bioresource Sci, Fujisawa, Kanagawa 2528510, Japan; Plantech Res Inst, Yokohama, Kanagawa 2270033, Japan; Tokyo Univ Agr & Technol, Fac Agr, Fuchu, Tokyo 1838509, Japan	Nihon University; Tokyo University of Agriculture & Technology	Hukuhara, T (corresponding author), Nihon Univ, Coll Bioresource Sci, Fujisawa, Kanagawa 2528510, Japan.							BABA A, 1986, PLANT CELL PHYSIOL, V27, P463; BERKSON J, 1955, J AM STAT ASSOC, V50, P529, DOI 10.2307/2280974; BLAK BC, 1997, BACULOVIRUSES, P341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dougherty EM, 1996, BIOL CONTROL, V7, P71, DOI 10.1006/bcon.1996.0067; FUJIMOTO H, 1993, BIO-TECHNOL, V11, P1151, DOI 10.1038/nbt1093-1151; HAYAKAWA T, 1992, P NATL ACAD SCI USA, V89, P9865, DOI 10.1073/pnas.89.20.9865; Hayakawa T., 1997, Recent Research Developments in Agricultural & Biological Chemistry, V1, P51; Hayakawa T, 1996, GENE, V177, P269, DOI 10.1016/0378-1119(96)00297-1; HUKUHARA T, 1995, J INVERTEBR PATHOL, V65, P315, DOI 10.1006/jipa.1995.1050; Hunter-Fujita FR, 1998, INSECT VIRUSES PEST; Jaques R.P., 1985, P285; Kalmakoff J., 1982, P435; KYOZUKA J, 1987, MOL GEN GENET, V206, P408, DOI 10.1007/BF00428879; Miller LK, 1997, BACULOVIRUSES, P217, DOI DOI 10.1007/978; Mitsuhashi W, 1998, J INVERTEBR PATHOL, V71, P186, DOI 10.1006/jipa.1997.4732; MURPHY FA, 1995, VIRUS TAXONOMY, P104; OHIRA K, 1973, PLANT CELL PHYSIOL, V14, P1113; OHTA S, 1990, PLANT CELL PHYSIOL, V31, P805; PFADT RE, 1985, FUNDAMENTALS APPL EN, P247; RICHARDS E, 1973, CURRENT PROTOCOLS MO; SHAPIRO M, 1994, J ECON ENTOMOL, V87, P356, DOI 10.1093/jee/87.2.356; SHIMAMOTO K, 1989, NATURE, V338, P274, DOI 10.1038/338274a0; TANADA Y, 1985, J INVERTEBR PATHOL, V45, P125, DOI 10.1016/0022-2011(85)90001-1; TANADA Y, 1969, J INVERTEBR PATHOL, V13, P394, DOI 10.1016/0022-2011(69)90192-X; Tomita M, 1998, APPL ENTOMOL ZOOL, V33, P277, DOI 10.1303/aez.33.277; Wijonarko A, 1998, J INVERTEBR PATHOL, V72, P82, DOI 10.1006/jipa.1998.4756; XU JH, 1992, J INVERTEBR PATHOL, V60, P259, DOI 10.1016/0022-2011(92)90007-Q; XU JH, 1994, J INVERTEBR PATHOL, V63, P14, DOI 10.1006/jipa.1994.1003; YAMAMOTO T, 1978, J INVERTEBR PATHOL, V31, P48, DOI 10.1016/0022-2011(78)90108-8; ZHU YF, 1991, J GEN VIROL, V72, P763, DOI 10.1099/0022-1317-72-4-763	32	20	24	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1122	1124		10.1038/15110	http://dx.doi.org/10.1038/15110			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545922				2022-12-25	WOS:000083428000033
J	Huynh, T; Abraham, G; Murray, J; Brockbank, K; Hagen, PO; Sullivan, S				Huynh, T; Abraham, G; Murray, J; Brockbank, K; Hagen, PO; Sullivan, S			Remodeling of an acellular collagen graft into a physiologically responsive neovessel	NATURE BIOTECHNOLOGY			English	Article						collagen; biomaterials; tissue engineering; vascular prostheses	INTESTINAL SUBMUCOSA; BLOOD-VESSEL; CELLS; MODEL; EQUIVALENT; CULTURE; WALL	Surgical treatment of vascular disease has become common, creating the need for a readily available, small-diameter vascular graft. However, the use of synthetic materials is limited to grafts larger than 5-6 mm because of the frequency of occlusion observed with smaller-diameter prosthetics. An alternative to synthetic materials would be a biomaterial that could be used in the design of a tissue-engineered graft. We demonstrate that a small-diameter (4 mm) graft constructed from a collagen biomaterial derived from the submucosa of the small intestine and type I bovine collagen has the potential to integrate into the host tissue and provide a scaffold for remodeling into a functional blood vessel. The results obtained using a rabbit arterial bypass model have shown excellent hemostasis and patency. Furthermore, within three months after implantation, the collagen grafts were remodeled into cellularized vessels that exhibited physiological activity in response to vasoactive agents.	Organogenesis Inc, Canton, MA 02021 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; KGB Associates Inc, Charleston, SC 29401 USA	Duke University	Sullivan, S (corresponding author), Organogenesis Inc, Canton, MA 02021 USA.	ssullivan@organo.com	Brockbank, Kelvin/GWV-4265-2022					ABRAHAM GA, 1998, Patent No. 49969; *AM HEART ASS, 1995, HEART STROK FACTS S; BADYLAK SF, 1989, J SURG RES, V47, P74, DOI 10.1016/0022-4804(89)90050-4; Bowlin GL, 1997, CELL TRANSPLANT, V6, P623, DOI 10.1016/S0963-6897(97)00096-1; BREWSTER DC, 1995, VASCULAR SURG, P492; CALLOW AD, 1986, BIOL SYNTHETIC VASCU, P11; CRAMER R, 1973, RADIOLOGY, V109, P585, DOI 10.1148/109.3.585; DAVIDS L, 1999, TISSUE ENG PROSTHETI, P3; DAVIES MG, 1994, J CLIN INVEST, V94, P1680, DOI 10.1172/JCI117513; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; EDWARDS WS, 1966, SURG GYNECOL OBSTETR, V122, P37; EGUSA S, 1968, ACTA MED OKAYAMA, V22, P153; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; GUNDRY SR, 1987, J SURG RES, V43, P75, DOI 10.1016/0022-4804(87)90049-7; HardinYoung J, 1996, BIOTECHNOL BIOENG, V49, P675, DOI 10.1002/(SICI)1097-0290(19960320)49:6<675::AID-BIT9>3.0.CO;2-L; HERRING M, 1978, SURGERY, V84, P498; KEMP PD, 1993, Patent No. 5256418; Kim KM, 1999, AM J PATHOL, V154, P843, DOI 10.1016/S0002-9440(10)65331-X; KOTTKEMARCHANT K, 1989, BIOMATERIALS, V10, P147, DOI 10.1016/0142-9612(89)90017-3; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351; LAWLER MR, 1971, AM J SURG, V122, P517, DOI 10.1016/0002-9610(71)90478-8; LEVESQUE MJ, 1989, BIORHEOLOGY, V26, P345; MATSUDA T, 1995, J THORAC CARDIOV SUR, V110, P988, DOI 10.1016/S0022-5223(05)80166-7; MATSUMOTO T, 1966, SURGERY, V60, P739; MILLS I, 1999, TISSUE ENG PROSTHETI, P425; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; ODONNELL TF, 1984, J VASC SURG, V1, P136; OMALLEY MK, 1986, SURGERY, V99, P36; PARK KD, 1988, J BIOMED MATER RES, V22, P977, DOI 10.1002/jbm.820221103; PASIC M, 1994, ANN THORAC SURG, V58, P677, DOI 10.1016/0003-4975(94)90726-9; SOWTON E, 1991, BRIT HEART J, V66, P325; STEPHEN M, 1977, SURGERY, V81, P314; TERMIN PL, 1993, AAMI CARD SCI TECHN; Tranquillo RT, 1996, BIOMATERIALS, V17, P349, DOI 10.1016/0142-9612(96)85573-6; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Williams S K, 1994, J Invest Surg, V7, P503, DOI 10.3109/08941939409015367; Zarge JI, 1997, PRINCIPLES TISSUE EN, P349; ZIEGLER T, 1995, CELL MATER, V5, P115	39	236	275	4	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1083	1086		10.1038/15062	http://dx.doi.org/10.1038/15062			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545913				2022-12-25	WOS:000083428000024
J	Culver, KW; Hsieh, WT; Huyen, Y; Chen, V; Liu, JL; Khripine, Y; Khorlin, A				Culver, KW; Hsieh, WT; Huyen, Y; Chen, V; Liu, JL; Khripine, Y; Khorlin, A			Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						gene repair; triplexing oligonucleotides; gene therapy; adenosine deaminase	TRIPLE-HELIX FORMATION; GENE-THERAPY; FORMING OLIGONUCLEOTIDES; STRAND BREAKS; BASE-PAIRS; IN-VITRO; DNA; INHIBITION; SEQUENCE; TRANSCRIPTION	A sequence-specific genomic delivery system for the correction of chromosomal mutations was designed by incorporating two different binding domains into a single-stranded oligonucleotide. A repair domain (RD) contained the native sequence of the target region, A third strand-forming domain (TFD) was designed to form a tripler by Hoogsteen interactions. The design was based upon the premise that the RD will rapidly form a heteroduplex that is anchored synergistically by the TFD, Deoxyoligonucleotides were designed to form triplexes in the human adenosine deaminase (ADA) and p53 genes adjacent to known point mutations, Transfection of ADA-deficient human lymphocytes corrected the mutant sequence in 1-2% of cells. Neither the RD or TFD individually corrected the mutation, Transfection of p53 mutant human glioblastoma cells corrected the mutation and induced apoptosis in 7.5% of cells.	Codon Pharmaceut Inc, Gaithersburg, MD 20877 USA		Culver, KW (corresponding author), Novartis Pharmaceut, E Hanover, NJ 07936 USA.	ken.culver@pharma.novartis.com						Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; BLAESE RM, 1990, HUM GENE THER, V1, P327; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Chan PP, 1999, J BIOL CHEM, V274, P11541, DOI 10.1074/jbc.274.17.11541; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; Escude C, 1998, P NATL ACAD SCI USA, V95, P3591, DOI 10.1073/pnas.95.7.3591; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FUJIWARA T, 1994, INT J CANCER, V56, P834, DOI 10.1002/ijc.2910560614; Gamper HB, 1998, J AM CHEM SOC, V120, P2182, DOI 10.1021/ja971397i; Goncz KK, 1998, HUM MOL GENET, V7, P1913, DOI 10.1093/hmg/7.12.1913; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Hanvey J C, 1991, Antisense Res Dev, V1, P307; HIRSCHHORN R, 1995, CLIN IMMUNOL IMMUNOP, V76, pS219, DOI 10.1016/S0090-1229(95)90288-0; HIRSCHHORN R, 1978, CLIN IMMUNOL IMMUNOP, V9, P287, DOI 10.1016/0090-1229(78)90100-9; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; Hussain SP, 1998, CANCER RES, V58, P4023; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kunzelmann K, 1996, GENE THER, V3, P859; LI X, 1995, BIOTECH HISTOCHEM, V70, P234, DOI 10.3109/10520299509108200; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; MARKERT ML, 1989, AM J HUM GENET, V45, P354; PANYUTIN IG, 1994, NUCLEIC ACIDS RES, V22, P4979, DOI 10.1093/nar/22.23.4979; RAO BJ, 1994, P NATL ACAD SCI USA, V91, P6161, DOI 10.1073/pnas.91.13.6161; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325; SETO S, 1986, J IMMUNOL, V136, P2839; Strauss M, 1998, NAT MED, V4, P274, DOI 10.1038/nm0398-274; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sun JS, 1996, CURR OPIN STRUC BIOL, V6, P327, DOI 10.1016/S0959-440X(96)80051-0; Svinarchuk F, 1997, NUCLEIC ACIDS RES, V25, P3459, DOI 10.1093/nar/25.17.3459; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Vlieghe D, 1996, SCIENCE, V273, P1702, DOI 10.1126/science.273.5282.1702; VOLKMANN S, 1995, NUCLEIC ACIDS RES, V23, P1204, DOI 10.1093/nar/23.7.1204; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601	39	62	69	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					989	993		10.1038/13684	http://dx.doi.org/10.1038/13684			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504700				2022-12-25	WOS:000083015700025
J	Heymans, S; Luttun, A; Nuyens, D; Theilmeier, G; Creemers, E; Moons, L; Dyspersin, GD; Cleutjens, JPM; Shipley, M; Angellilo, A; Levi, M; Nube, O; Baker, A; Keshet, E; Lupu, F; Herbert, JM; Smits, JFM; Shapiro, SD; Baes, M; Borgers, M; Collen, D; Daemen, MJAP; Carmeliet, P				Heymans, S; Luttun, A; Nuyens, D; Theilmeier, G; Creemers, E; Moons, L; Dyspersin, GD; Cleutjens, JPM; Shipley, M; Angellilo, A; Levi, M; Nube, O; Baker, A; Keshet, E; Lupu, F; Herbert, JM; Smits, JFM; Shapiro, SD; Baes, M; Borgers, M; Collen, D; Daemen, MJAP; Carmeliet, P			Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure	NATURE MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR FREE-WALL; DEFICIENT MICE; GENE-TRANSFER; EXPRESSION; COLLAGEN; PROLIFERATION; MIGRATION; OCCLUSION; RECEPTOR	Cardiac rupture is a fatal complication of acute myocardial infarction lacking treatment. Here, acute myocardial infarction resulted in rupture in wild-type mice and in mice lacking tissue-type plasminogen activator, urokinase receptor, matrix metalloproteinase stromelysin-1 or metallo-elastase. Instead, deficiency of urokinase-type plasminogen activator (u-PA(-/-)) completely protected against rupture, whereas lack of gelatinase-B partially protected against rupture. However, u-PA(-/-) mice showed impaired scar formation and infarct revascularization, even after treatment with vascular endothelial growth factor, and died of cardiac failure due to depressed contractility, arrhythmias and ischemia. Temporary administration of PA inhibitor-1 or the matrix metalloproteinase-inhibitor TIMP-1 completely protected wild-type mice against rupture but did not abort infarct healing, thus constituting a new approach to prevent cardiac rupture after acute myocardial infarction.	Flanders Interuniv, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Maastricht, Cardiovasc Res Inst, NL-6200 MD Maastricht, Netherlands; Janssen Res Fdn, B-2340 Beerse, Belgium; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Hosp Geneva, Div Infect Dis, CH-1211 Geneva 14, Switzerland; Univ Glasgow, Western Infirm, Dept Med, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Therapeut, Glasgow G11 6NT, Lanark, Scotland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Thrombosis Res Inst, Weston Expt Res Ctr, Vasc Biol Lab, London SW3 6LR, England; Sanofi Rech, Haeobiol Res Dept, F-31036 Toulouse, France	Maastricht University; Johnson & Johnson; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Geneva; University of Glasgow; University of Glasgow; Hebrew University of Jerusalem; Thrombosis Research Institute; Sanofi-Aventis; Sanofi France	Carmeliet, P (corresponding author), Flanders Interuniv, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Baker, Andy/AAO-5250-2021; Lupu, Florea/C-3162-2009; Keshet, Eli/GQR-0445-2022; Luttun, Aernout/AAZ-6540-2020; Carmeliet, Peter/AAQ-5140-2020; Cleutjens, Jack P.M./F-6242-2012; Lupu, Florea/AAV-3257-2021; Nüsse, Oliver/J-8645-2013	Baker, Andy/0000-0003-1441-5576; Lupu, Florea/0000-0003-1249-9278; Luttun, Aernout/0000-0001-7902-9524; Carmeliet, Peter/0000-0001-7961-1821; Cleutjens, Jack P.M./0000-0002-4346-1785; Lupu, Florea/0000-0003-1249-9278; Nüsse, Oliver/0000-0003-0068-8346; Nuyens, Dieter/0000-0001-9390-3273; Levi, Moshe/0000-0002-6225-946X; Heymans, Stephane/0000-0001-9477-7803; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Creemers, Esther/0000-0002-9001-3854; Baes, Myriam/0000-0002-2525-2269; Angelillo-Scherrer, Anne/0000-0003-2872-4863				ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Dalrymple-Hay M J, 1998, Semin Thorac Cardiovasc Surg, V10, P111; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Feldhaus LM, 1998, J MOL CELL CARDIOL, V30, P2475, DOI 10.1006/jmcc.1998.0810; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; George SJ, 1998, HUM GENE THER, V9, P867, DOI 10.1089/hum.1998.9.6-867; HAMSTEN A, 1987, LANCET, V2, P3; Henry M, 1998, ARTERIOSCL THROM VAS, V18, P84, DOI 10.1161/01.ATV.18.1.84; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNOEPFLER PS, 1995, J MOL CELL CARDIOL, V27, P1317, DOI 10.1016/S0022-2828(05)82394-6; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Lee JK, 1998, NAT MED, V4, P1383, DOI 10.1038/3973; LIJNEN HR, 1989, FIBRINOLYSIS, V3, P67, DOI 10.1016/0268-9499(89)90034-9; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lutgens E, 1999, CARDIOVASC RES, V41, P586, DOI 10.1016/S0008-6363(98)00216-8; Nunes I, 1996, INT J OBESITY, V20, pS4; Peuhkurinen K, 1996, AM HEART J, V131, P7, DOI 10.1016/S0002-8703(96)90044-7; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; PRZYKLENK K, 1987, AM HEART J, V114, P1349, DOI 10.1016/0002-8703(87)90536-9; REDDY SG, 1989, AM J CARDIOL, V63, P906, DOI 10.1016/0002-9149(89)90137-9; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Robert V, 1997, LAB INVEST, V76, P729; Rohde LE, 1999, CIRCULATION, V99, P3063, DOI 10.1161/01.CIR.99.23.3063; Schaffer CJ, 1996, INT REV CYTOL, V169, P151, DOI 10.1016/S0074-7696(08)61986-5; SEVERS NJ, 1994, J CARDIOVASC ELECTR, V5, P462, DOI 10.1111/j.1540-8167.1994.tb01185.x; Tyagi SC, 1996, CAN J PHYSIOL PHARM, V74, P983, DOI 10.1139/cjpp-74-8-983; VANDEPLASSCHE G, 1991, CARDIOSCIENCE, V2, P47; Varbella F, 1999, G Ital Cardiol, V29, P163; Zahger D, 1996, AM J CARDIOL, V78, P681, DOI 10.1016/S0002-9149(96)00396-7; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788	39	655	694	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	1999	5	10					1135	1142		10.1038/13459	http://dx.doi.org/10.1038/13459			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502816				2022-12-25	WOS:000082933200039
J	Slater, S; Mitsky, TA; Houmiel, KL; Hao, M; Reiser, SE; Taylor, NB; Tran, M; Valentin, HE; Rodriguez, DJ; Stone, DA; Padgette, SR; Kishore, G; Gruys, KJ				Slater, S; Mitsky, TA; Houmiel, KL; Hao, M; Reiser, SE; Taylor, NB; Tran, M; Valentin, HE; Rodriguez, DJ; Stone, DA; Padgette, SR; Kishore, G; Gruys, KJ			Metabolic engineering of Arabidopsis and Brassica for poly(3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer production	NATURE BIOTECHNOLOGY			English	Article						poly(hydroxyalkanoate); biodegradable polymer; green chemistry; PHA copolymer	BIOSYNTHETIC THREONINE DEAMINASE; ESCHERICHIA-COLI; PLANTS; POLYHYDROXYBUTYRATE; SEQUENCES; PLASTIDS; NAPUS	Poly(hydroxyalkanoates) are natural polymers with thermoplastic properties. One polymer of this class with commercial applicability, poly(3-hydroxybutyrate-co-3-hydroxyvale) (PHBV) can be produced by bacterial fermentation, but the process is not economically competitive with polymer production from petrochemicals, Poly(hydroxyalkanoate) production in green plants promises much lower costs, but producing copolymer with the appropriate monomer composition is problematic. In this study, we have engineered Arabidopsis and Brassica to produce PHBV in leaves and seeds, respectively, by redirecting the metabolic flow of intermediates from fatty acid and amino acid biosynthesis. We present a pathway for the biosynthesis of PHBV in plant plastids, and also report copolymer production, metabolic intermediate analyses, and pathway dynamics.	Monsanto Co, St Louis, MO 63198 USA	Monsanto	Gruys, KJ (corresponding author), Monsanto Co, 700 Chesterfield Pkwy N, St Louis, MO 63198 USA.	kenneth.j.gruys@monsanto.com						ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; BURNS RO, 1979, J BIOL CHEM, V254, P1074; BYRUM D, 1992, FEMS MICROBIOL REV, V102, P247; CASHMORE AR, 1983, GENETIC ENG PLANTS A, P29; CORUZZI G, 1984, EMBO J, V3, P1671, DOI 10.1002/j.1460-2075.1984.tb02031.x; EISENSTEIN E, 1995, BIOCHEMISTRY-US, V34, P9403, DOI 10.1021/bi00029a016; Eschenlauer AC, 1996, INT J BIOL MACROMOL, V19, P121, DOI 10.1016/0141-8130(96)01114-2; FRY J, 1987, PLANT CELL REP, V6, P321, DOI 10.1007/BF00269550; GRUYS KJ, 1998, Patent No. 9800557; Hagelstein P, 1997, J PLANT PHYSIOL, V150, P23, DOI 10.1016/S0176-1617(97)80176-9; Holmes P.A., 1984, Patent US, Patent No. 4477654; HOLMES PA, 1985, PHYS TECHNOL, V16, P32, DOI 10.1088/0305-4624/16/1/305; KANG F, 1994, PLANT J, V6, P795, DOI 10.1046/j.1365-313X.1994.6060795.x; KOIZUMI F, 1995, J MACROMOL SCI PURE, VA32, P759, DOI 10.1080/10601329508010287; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; Lydon J, 1999, BOOK SOIL P, P445; Matthews BF, 1999, BOOK SOIL P, P205; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; PLEDGER WJ, 1973, J BACTERIOL, V114, P183, DOI 10.1128/JB.114.1.183-194.1973; PLEDGER WJ, 1973, J BACTERIOL, V114, P195, DOI 10.1128/JB.114.1.195-207.1973; POIRIER Y, 1992, SCIENCE, V256, P520, DOI 10.1126/science.256.5056.520; POIRIER Y, 1995, BIO-TECHNOL, V13, P142, DOI 10.1038/nbt0295-142; QURESHI AA, 1982, J CHROMATOGR, V249, P333, DOI 10.1016/S0021-9673(00)86343-8; Slater S, 1998, J BACTERIOL, V180, P1979, DOI 10.1128/JB.180.8.1979-1987.1998; STEINBUCHEL A, 1991, BIOMATERIALS NOVEL M, P27; TAILLON BE, 1988, GENE, V63, P245, DOI 10.1016/0378-1119(88)90528-8; Umbarger H. E., 1996, ESCHERICHIA COLI SAL, P442; VANDERLEIJ FR, 1995, CAN J MICROBIOL, V41, P222, DOI 10.1139/m95-191; WILLIS DE, 1987, J CHROMATOGR, V408, P217, DOI 10.1016/S0021-9673(01)81804-5; Ye GN, 1999, PLANT J, V19, P249, DOI 10.1046/j.1365-313X.1999.00520.x	34	141	169	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1011	1016		10.1038/13711	http://dx.doi.org/10.1038/13711			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504704				2022-12-25	WOS:000083015700029
J	Xu, PX; Adams, J; Peters, H; Brown, MC; Heaney, S; Maas, R				Xu, PX; Adams, J; Peters, H; Brown, MC; Heaney, S; Maas, R			Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia	NATURE GENETICS			English	Article							BRANCHIOOTORENAL BOR SYNDROME; RECEPTOR TYROSINE KINASE; C-RET PROTOONCOGENE; EYES ABSENT; DEVELOPMENTAL DEFECTS; VARIABLE EXPRESSIVITY; MULTIPLE STEPS; GENE; PAX2; MUTATION	Haploinsufficiency for human EYA1, a homologue of the Drosophila melanogaster gene eyes absent (eya), results in the dominantly inherited disorders branchio-oto-renal (BOR) syndrome(1-3) and branchio-oto (BO) syndrome(4), which are characterized by craniofacial abnormalities and hearing loss with (BOR) or without (BO) kidney defects. To understand the developmental pathogenesis of organs affected in these syndromes, we inactivated the gene Eya1 in mice. Eya1 heterozygotes show renal abnormalities and a conductive hearing loss similar to BOR syndrome, whereas Eya1 homozygotes lack ears and kidneys due to defective inductive tissue interactions and apoptotic regression of the organ primordia. Inner ear development in Eya1 homozygotes arrests at the otic vesicle stage and all components of the inner ear and specific cranial sensory ganglia fail to form. In the kidney, Eya1 homozygosity results in an absence of ureteric bud outgrowth and a subsequent failure of metanephric induction. Gdnf expression, which is required to direct ureteric bud outgrowth via activation of the c-ret Rtk (refs 5-8), is not detected in Eya1(-/-) metanephric mesenchyme. In Eya1(-/-) ear and kidney development, Six but not Pax expression is Eya1 dependent, similar to a genetic pathway elucidated in the Drosophila eye imaginal disc. Our results indicate that Eya1 controls critical early inductive signalling events involved in ear and kidney formation and integrate Eya1 into the genetic regulatory cascade controlling kidney formation upstream of Gdnf. In addition, our results suggest that an evolutionarily conserved Pax-Eya-Six regulatory hierarchy is used in mammalian ear and kidney development.	Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA; Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Maas, R (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.				NEI NIH HHS [F32 EY006869, R01 EY10123] Funding Source: Medline; NIDCR NIH HHS [R01 DE11697] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006869, R01EY010123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011697] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abdelhak S, 1997, HUM MOL GENET, V6, P2247, DOI 10.1093/hmg/6.13.2247; Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Borycki AG, 1999, DEVELOPMENT, V126, P1665; CHEN A, 1995, AM J MED GENET, V58, P365, DOI 10.1002/ajmg.1320580413; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; FRASER FC, 1980, AM J MED GENET, V7, P341, DOI 10.1002/ajmg.1320070316; Halder G, 1998, DEVELOPMENT, V125, P2181; HEIMLER A, 1986, AM J MED GENET, V25, P15, DOI 10.1002/ajmg.1320250104; Johnson KR, 1999, HUM MOL GENET, V8, P645, DOI 10.1093/hmg/8.4.645; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KONIG R, 1994, EUR J PEDIATR, V153, P446, DOI 10.1007/s004310050171; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kumar S, 1998, HUM MUTAT, V11, P443, DOI 10.1002/(SICI)1098-1004(1998)11:6<443::AID-HUMU4>3.3.CO;2-J; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; OLIVER G, 1995, DEVELOPMENT, V121, P693; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Petersen J, 1998, INTERNET WORLD, V9, P12; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Torres M, 1995, DEVELOPMENT, V121, P4057; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Vincent C, 1997, EUR J HUM GENET, V5, P242, DOI 10.1159/000484770; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; Xu PX, 1997, DEVELOPMENT, V124, P219	29	498	512	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					113	117		10.1038/12722	http://dx.doi.org/10.1038/12722			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471511				2022-12-25	WOS:000082337300028
J	Benzing, T; Brandes, R; Sellin, L; Schermer, B; Lecker, S; Walz, G; Kim, E				Benzing, T; Brandes, R; Sellin, L; Schermer, B; Lecker, S; Walz, G; Kim, E			Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function	NATURE MEDICINE			English	Article							HETEROTRIMERIC G-PROTEINS; C-JUN; BETA-CATENIN; MAP KINASES; PHOSPHORYLATION; ALPHA; REGULATORS; EXPRESSION; RECEPTOR; ELEGANS	The central nervous dysfunctions of lethargy, fever and anorexia are manifestations of sepsis that seem to be mediated by increased cytokine production. Here we demonstrate that tumor necrosis factor (TNF)-alpha, an essential mediator of endotoxin-induced sepsis, prevents the proteasome-dependent degradation of RGS7, a regulator of C-protein signaling. The stabilization of RGS7 by TNF-alpha requires activation of the stress-activated protein kinase p38 and the presence of candidate mitogen-activated protein kinase phosphorylation sites. In vivo, RGS7 is rapidly upregulated in mouse brain after exposure to either endotoxin or TNF-alpha, a response that is nearly abrogated in mice lacking TNF receptor 1. Our findings indicate that TNF-mediated upregulation of RGS7 may contribute to sepsis-induced changes in central nervous function.	Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Univ Hosp Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany; Harvard Med Sch, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Harvard University; Harvard Medical School	Kim, E (corresponding author), Beth Israel Deaconess Med Ctr, Dept Psychiat, 330 Brookline Ave, Boston, MA 02215 USA.	ekim@caregroup.harvard.edu	Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014; Brandes, Ralf/L-3058-2017	Schermer, Bernhard/0000-0002-5194-9000; Brandes, Ralf/0000-0002-8035-0048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH001147] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52897] Funding Source: Medline; NIMH NIH HHS [MH01147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Boone E, 1998, FEBS LETT, V441, P275, DOI 10.1016/S0014-5793(98)01567-1; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Dunn AJ, 1998, ANN NY ACAD SCI, V840, P577, DOI 10.1111/j.1749-6632.1998.tb09596.x; Fang JD, 1997, J NEUROSCI, V17, P5949; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Gold SJ, 1997, J NEUROSCI, V17, P8024; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ingi T, 1998, J NEUROSCI, V18, P7178; KAPAS L, 1992, AM J PHYSIOL, V263, pR708, DOI 10.1152/ajpregu.1992.263.3.R708; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REMICK DG, 1993, INT REV EXP PATHOL, V34, P7; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Saugstad JA, 1998, J NEUROSCI, V18, P905; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SELBY P, 1987, BRIT J CANCER, V56, P803, DOI 10.1038/bjc.1987.294; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; Waage A, 1991, Infect Dis Clin North Am, V5, P781; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014	33	64	66	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					913	918		10.1038/11354	http://dx.doi.org/10.1038/11354			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426315				2022-12-25	WOS:000081684000035
J	Murphy, JC; Wibbenmeyer, JA; Fox, GE; Willson, RC				Murphy, JC; Wibbenmeyer, JA; Fox, GE; Willson, RC			Purification of plasmid DNA using selective precipitation by compaction agents - A scaleable method for the liquid-phase separation of plasmid DNA from RNA.	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE-THERAPY; DELIVERY; SHAPE	A scaleable method for the liquid-phase separation of plasmid DNA from RNA.	Univ Houston, Dept Chem Engn, Houston, TX 77204 USA; Baylor Coll Med, Houston, TX 77030 USA	University of Houston System; University of Houston; Baylor College of Medicine	Murphy, JC (corresponding author), Univ Houston, Dept Chem Engn, Houston, TX 77204 USA.	willson@uh.edu	Willson, richard/AAD-4832-2019					Anderson WF, 1998, NATURE, V392, P25; ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; Horn N, 1996, U.S. patent, Patent No. [5,576,196, 5576196]; HORN NA, 1995, HUM GENE THER, V6, P565, DOI 10.1089/hum.1995.6.5-565; LEZ Z, 1987, ANAL BIOCHEM, V160, P332; Marquet M, 1996, U.S. patent, Patent No. [5,561,064, 5561064]; Parasrampuria DA, 1998, BIOPHARM-APPL T BIO, V11, P38; Rolland AP, 1998, CRIT REV THER DRUG, V15, P143, DOI 10.1615/CritRevTherDrugCarrierSyst.v15.i2.20; Sambrook J., 1989, MOL CLONING LAB MANU, V2; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009	13	84	94	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					822	823		10.1038/11777	http://dx.doi.org/10.1038/11777			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429254				2022-12-25	WOS:000081751400036
J	Mozo, T; Dewar, K; Dunn, P; Ecker, JR; Fischer, S; Kloska, S; Lehrach, H; Marra, M; Martienssen, R; Meier-Ewert, S; Altmann, T				Mozo, T; Dewar, K; Dunn, P; Ecker, JR; Fischer, S; Kloska, S; Lehrach, H; Marra, M; Martienssen, R; Meier-Ewert, S; Altmann, T			A complete BAC-based physical map of the Arabidopsis thaliana genome	NATURE GENETICS			English	Article							RECOMBINANT INBRED LINES; LIBRARY; CONSTRUCTION; CHROMOSOME-2; SEQUENCE; REGIONS; MARKERS; CONTIG; CLONES; PLANT	Arabidopsis thaliana is a small flowering plant that serves as the major model system in plant molecular genetics'. The efforts of many scientists have produced genetic maps that provide extensive coverage of the genome (http://genome-www.stanford.edulArabidopsis/maps.html). Recently, detailed YAC, BAG, P1 and cosmid-based physical maps (that is, representations of genomic regions as sets of overlapping clones of corresponding libraries) have been established that extend over wide genomic areas ranging from several hundreds of kilobases(2,3) to entire chromosome(4-9). These maps provide an entry to gain deeper insight into the A. thaliana genome structure. A. thaliana has been chosen as the subject of the first large-scale project intended to determine the full genome sequence of a plant(10). This sequencing project, together with the increasing interest in map-based gene cloning, has highlighted the requirement for a complete and accurate physical map of this plant species. To supply the scientific community with a high-quality resource, we present here a complete physical map of A. thaliana using essentially the IGF BAC library(11) The map consists of 27 contigs that cover the entire genome, except for the presumptive centromeric regions, nucleolar organization regions (NOR) and telomeric areas. This is the first reported map of a complex organism based entirely on BAC clones and it represents the most homogeneous and complete physical map established to date for any plant genome. Furthermore, the analysis performed here serves as a model for an efficient physical mapping procedure using BAC clones that can be applied to other complex genomes.	Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany; MIT, Ctr Genome Res, Whitehead Inst, Cambridge, MA 02141 USA; Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; GPC Aktiengesell, D-82152 Martinsried, Germany	Max Planck Society; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Pennsylvania; Max Planck Society; Washington University (WUSTL); Cold Spring Harbor Laboratory	Altmann, T (corresponding author), Max Planck Inst Mol Pflanzenphysiol, Karl Liebknecht Str 25, D-14476 Golm, Germany.	altmann@mpimp-golm.mpg.de	Ecker, Joseph R/B-9144-2008; Marra, Marco A/B-5987-2008	Ecker, Joseph R/0000-0001-5799-5895; Marra, Marco A/0000-0001-7146-7175; Altmann, Thomas/0000-0002-3759-360X				Bent E, 1998, PLANT J, V13, P849, DOI 10.1046/j.1365-313X.1998.00082.x; Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Copenhaver GP, 1996, PLANT J, V9, P273, DOI 10.1046/j.1365-313X.1996.09020273.x; Copenhaver GP, 1998, P NATL ACAD SCI USA, V95, P247, DOI 10.1073/pnas.95.1.247; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; Fransz P, 1998, PLANT J, V13, P867, DOI 10.1046/j.1365-313X.1998.00086.x; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; Kotani H, 1997, DNA Res, V4, P371, DOI 10.1093/dnares/4.6.371; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Liu YG, 1996, PLANT J, V10, P733, DOI 10.1046/j.1365-313X.1996.10040733.x; Mara M, 1999, NAT GENET, V22, P265, DOI 10.1038/10327; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Murata M, 1997, PLANT J, V12, P31, DOI 10.1046/j.1365-313X.1997.12010031.x; PALAZZOLO MJ, 1991, P NATL ACAD SCI USA, V88, P8034, DOI 10.1073/pnas.88.18.8034; Round EK, 1997, GENOME RES, V7, P1045, DOI 10.1101/gr.7.11.1045; Sato S, 1998, DNA Res, V5, P163, DOI 10.1093/dnares/5.3.163; Schmidt R, 1997, PLANT J, V11, P563, DOI 10.1046/j.1365-313X.1997.11030563.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; Wang ML, 1997, PLANT J, V12, P711, DOI 10.1046/j.1365-313X.1997.00711.x; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	25	109	129	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1999	22	3					271	275		10.1038/10334	http://dx.doi.org/10.1038/10334			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391215				2022-12-25	WOS:000081125900020
J	Watanabe, N; Kato, T; Fujita, A; Ishizaki, T; Narumiya, S				Watanabe, N; Kato, T; Fujita, A; Ishizaki, T; Narumiya, S			Cooperation between mDia1 and ROCK in Rho-induced actin reorganization	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEIN; LIMB DEFORMITY GENE; SACCHAROMYCES-CEREVISIAE; FOCAL ADHESIONS; CYTOSKELETAL REORGANIZATION; EPITHELIAL-CELLS; STRESS FIBERS; HUMAN HOMOLOG; KINASE; DROSOPHILA	The small GTPase Rho induces the formation of actin stress fibres and mediates the formation of diverse actin structures. However, it remains unclear how Rho regulates its effecters to elicit such functions. Here we show that GTP-bound Rho activates its effector mDia1 by disrupting mDia1's intramolecular interactions. Active mDia1 induces the formation of thin actin stress fibres, which are disorganized in the absence of activity of the Rho-associated kinase ROCK. Moreover, active mDia1 transforms ROCK-induced condensed actin fibres into structures reminiscent of Rho-induced stress fibres. Thus mDia1 and ROCK work concurrently during Rho-induced stress-fibre formation. Intriguingly, mDia1 and ROCK, depending on the balance of the two activities, induce actin fibres of various thicknesses and densities. Thus Rho may induce the formation of different actin structures affected by the balance between mDia1 and ROCK signalling.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan	Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.							Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FRAZIER JA, 1997, CURR BIOL, V7, P414; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Menard R, 1996, P NATL ACAD SCI USA, V93, P1254, DOI 10.1073/pnas.93.3.1254; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Somlyo AP, 1997, NATURE, V389, P908, DOI 10.1038/40002; TAKAISHI K, 1995, ONCOGENE, V11, P39; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Umikawa M, 1998, ONCOGENE, V16, P2011, DOI 10.1038/sj.onc.1201724; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0	42	698	712	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					136	143		10.1038/11056	http://dx.doi.org/10.1038/11056			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559899				2022-12-25	WOS:000083102500011
J	Gerngross, TU				Gerngross, TU			Can biotechnology move us toward a sustainable society?	NATURE BIOTECHNOLOGY			English	Article							POLYSTYRENE; PAPER		Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Dartmouth College	Gerngross, TU (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.	tillman@dartmouth.edu						Alper J, 1999, SCIENCE, V283, P1625, DOI 10.1126/science.283.5408.1625; Atkinson B, 1991, BIOCH ENG BIOTECHNOL; BYROM D, 1993, Patent No. 5364778; CHARLES M, 1994, BIOPROCESS ENG; Hocking M.B., 1993, HDB CHEM TECHNOLOGY; HOCKING MB, 1991, ENVIRON MANAGE, V15, P731, DOI 10.1007/BF02394812; HOCKING MB, 1991, SCIENCE, V251, P504, DOI 10.1126/science.251.4993.504; Lee SY, 1998, POLYM DEGRAD STABIL, V59, P387, DOI 10.1016/S0141-3910(97)00176-6; Lee SY, 1997, NAT BIOTECHNOL, V15, P17, DOI 10.1038/nbt0197-17b; Lee SY, 1996, TRENDS BIOTECHNOL, V14, P431, DOI 10.1016/0167-7799(96)10061-5; PIMENTEL D, 1986, NEW DIRECTIONS AGR A; POOL R, 1989, SCIENCE, V245, P1187, DOI 10.1126/science.245.4923.1187; REESE KM, 1989, CHEM ENG NEWS, V67, P60; SHAPOURI H, 1995, 721 USDA; Ulrich G.D., 1984, GUIDE CHEM ENG PROCE; *US DEP EN, 1991, MAN CONS EN 1991; Van Wegen RJ, 1998, CHEM ENG RES DES, V76, P417, DOI 10.1205/026387698524848; Williams SF, 1996, CHEMTECH, V26, P38; [No title captured]	19	101	102	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					541	544		10.1038/9843	http://dx.doi.org/10.1038/9843			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385316				2022-12-25	WOS:000080716500023
J	Gilroy, DW; Colville-Nash, PR; Willis, D; Chivers, J; Paul-Clark, MJ; Willoughby, DA				Gilroy, DW; Colville-Nash, PR; Willis, D; Chivers, J; Paul-Clark, MJ; Willoughby, DA			Inducible cyclooxygenase may have anti-inflammatory properties	NATURE MEDICINE			English	Article							INHIBITION; SYNTHASE; RATS; EXPRESSION; MODELS	Cyclooxygenase (COX) has two isoforms. Generally, COX 1 is constitutively expressed in most tissues, where it maintains physiological processes(1); inducible COX 2 is considered a pro-inflammatory enzyme and a chief target for the treatment of inflammatory diseases(2). Here we present evidence that COX 2 may have anti-inflammatory properties. In carrageenin-induced pleurisy in rats, the predominant cells at 2 hours are polymorphonuclear leucocytes, whereas mononuclear cells dominate from 24 hours until resolution at 48 hours(3). In this model, COX 2 protein expression peaked initially at 2 hours, associated with maximal prostaglandin E-2 synthesis. However, at 48 hours there was a second increase in COX 2 expression, 350% greater than that at 2 hours. Paradoxically, this coincided with inflammatory resolution and was associated with minimal prostaglandin E-2 synthesis. In contrast, levels of prostaglandin D-2, and 15deoxy Delta(12-14)prostaglandin J(2) were high at 2 hours, decreased as inflammation increased, but were increased again at 48 hours. The selective COX 2 inhibitor NS-398 and the dual COX 1/COX 2 inhibitor indomethacin inhibited inflammation at 2 hours but significantly exacerbated inflammation at 48 hours. This exacerbation was associated with reduced exudate prostaglandin D-2 and 15deoxy Delta(12-14)prostaglandin J(2) concentrations, and was reversed by replacement of these prostaglandins. Thus, COX 2 may be pro-inflammatory during the early phase of a carrageenin-induced pleurisy, dominated by polymorphonuclear leucocytes, but may aid resolution at the later, mononuclear cell-dominated phase by generating an alternative set of anti-inflammatory prostaglandins.	St Bartholomews & Royal London Sch Med & Dent, Dept Expt Pathol, London EC1M 6BQ, England	University of London; Queen Mary University London	Colville-Nash, PR (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Expt Pathol, London EC1M 6BQ, England.	p.r.colville-nash@mds.qmw.ac.uk	Gilroy, Derek W/C-2588-2009; Gilroy, Derek/AAP-7227-2020	Gilroy, Derek/0000-0003-3476-0844				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gilroy DW, 1998, INFLAMMATION, V22, P509, DOI 10.1023/A:1022350111213; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MASSO JM, 1994, AGENTS ACTIONS, V42, P118, DOI 10.1007/BF01983476; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Shigeta JI, 1998, J PHARMACOL EXP THER, V286, P1383; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, 1959, ANN RHEUM DIS, V18, P173; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; UJIHARA M, 1988, ARCH BIOCHEM BIOPHYS, V260, P521, DOI 10.1016/0003-9861(88)90477-8; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WILLIAMS KI, 1988, J PATHOL, V156, P101, DOI 10.1002/path.1711560204; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	19	1043	1091	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	1999	5	6					698	701		10.1038/9550	http://dx.doi.org/10.1038/9550			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371510				2022-12-25	WOS:000080823300040
J	Zhong, J; Peters, AHFM; Lee, K; Braun, RE				Zhong, J; Peters, AHFM; Lee, K; Braun, RE			A double-stranded RNA binding protein required for activation of repressed messages in mammalian germ cells	NATURE GENETICS			English	Article							MESSENGER-RNA; MOUSE; MICE; SPERMATOGENESIS; LOCALIZATION; PROTAMINE	Chromatin packaging in mammalian spermatozoa requires an ordered replacement of the somatic histones by two classes of spermatid-specific basic proteins, the transition proteins and the protamines(1). Temporal expression of transition proteins and protamines during spermatid differentiation is under translational control, and premature translation of protamine 1 leads to precocious nuclear condensation and sterility(2). We have previously suggested that the double-stranded (ds) RNA binding protein Prbp (encoded by the gene Tarbp2) functions as a translational regulator during mouse spermatogenesis(3). Here we show that Prbp is required for proper translational activation of the mRNAs encoding the protamines. We generated mice that carry a targeted disruption of Tarbp2 and determined that they were sterile and severely oligospermic. Using immunohistological analysis, we determined that the endogenous Prm2 mRNA and a reporter mRNA carrying protamine 1 translational-control elements were translated in a mosaic pattern. We showed that failure to synthesize the protamines resulted in delayed replacement of the transition proteins and subsequent failure of spermiation. The timing of Prbp expression suggests that it may function as a chaperone in the assembly of specific translationally regulated ribonucleoprotein particles.	Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Braun, RE (corresponding author), Univ Washington, Dept Genet, Box 357360,1959 NE Pacific, Seattle, WA 98195 USA.			Peters, Antoine/0000-0002-0311-1887	NICHD NIH HHS [U54 HD12629, HD27215] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027215, U54HD012629] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; BRAUN RE, 1990, ENZYME, V44, P120, DOI 10.1159/000468752; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CATIGNOL A, 1993, MOL CELL BIOL, V13, P2193; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; FAJARDO MA, 1994, DEV BIOL, V166, P643, DOI 10.1006/dbio.1994.1344; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; Lee K, 1996, MOL CELL BIOL, V16, P3023; Meistrich ML, 1993, MOL BIOL MALE REPROD, P67; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHUMACHER JM, 1995, BIOL REPROD, V52, P1274, DOI 10.1095/biolreprod52.6.1274; STANKER LH, 1993, MOL IMMUNOL, V30, P1633, DOI 10.1016/0161-5890(93)90436-F; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979	17	134	148	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					171	174		10.1038/9684	http://dx.doi.org/10.1038/9684			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369260	Green Published			2022-12-25	WOS:000080680900023
J	Baguisi, A; Behboodi, E; Melican, DT; Pollock, JS; Destrempes, MM; Cammuso, C; Williams, JL; Nims, SD; Porter, CA; Midura, P; Palacios, MJ; Ayres, SL; Denniston, RS; Hayes, ML; Ziomek, CA; Meade, HM; Godke, RA; Gavin, WG; Overstrom, EW; Echelard, Y				Baguisi, A; Behboodi, E; Melican, DT; Pollock, JS; Destrempes, MM; Cammuso, C; Williams, JL; Nims, SD; Porter, CA; Midura, P; Palacios, MJ; Ayres, SL; Denniston, RS; Hayes, ML; Ziomek, CA; Meade, HM; Godke, RA; Gavin, WG; Overstrom, EW; Echelard, Y			Production of goats by somatic cell nuclear transfer	NATURE BIOTECHNOLOGY			English	Article						nuclear transfer; oocyte; transgenic; antithrombin III; goat	FETAL FIBROBLASTS; SHEEP; AMPLIFICATION; EMBRYOS; GENES; ADULT; LINE; MICE; DNA	In this study, we demonstrate the production of transgenic goats by nuclear transfer of fetal somatic cells. Donor karyoplasts were obtained from a primary fetal somatic cell line derived from a 40-day transgenic female fetus produced by artificial insemination of a nontransgenic adult female with semen from a transgenic male. Live offspring were produced with two nuclear transfer procedures. In one protocol, oocytes at the arrested metaphase II stage were enucleated, electrofused with donor somatic cells, and simultaneously activated. In the second protocol, activated in vivo oocytes were enucleated at the telophase II stage, electrofused with donor somatic cells, and simultaneously activated a second time to induce genome reactivation. Three healthy identical female offspring were born. Genotypic analyses confirmed that all cloned offspring were derived from the donor cell line. Analysis of the milk of one of the transgenic cloned animals showed high-level production of human antithrombin III, similar to the parental transgenic line.	Genzyme Transgen Corp, Framingham, MA 01701 USA; Tufts Univ, Sch Vet Med, Nucl Transfer Lab, North Grafton, MA 01356 USA; Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01356 USA; Genzyme Corp, Cell & Prot Therapeut Dept, Framingham, MA 01701 USA; Louisiana State Univ, Dept Anim Sci, Baton Rouge, LA 70803 USA	Sanofi-Aventis; Tufts University; Tufts University; Sanofi-Aventis; Genzyme Corporation; Louisiana State University System; Louisiana State University	Overstrom, EW (corresponding author), Genzyme Transgen Corp, Framingham, MA 01701 USA.	eoverstrom@infonet.tufts.edu; yechelard@genzyme.com	Jeong, Wonjun/AAM-5937-2020		NICHD NIH HHS [R43 HD35395-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD035395] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AASEN E, 1990, BIO-TECHNOL, V8, P1279, DOI 10.1038/nbt1290-1279; AMILLS M, 1995, VET IMMUNOL IMMUNOP, V48, P313, DOI 10.1016/0165-2427(95)05442-9; BURDON TG, 1992, MOL REPROD DEV, V33, P436, DOI 10.1002/mrd.1080330410; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Clark AJ, 1998, J MAMMARY GLAND BIOL, V3, P337, DOI 10.1023/A:1018723712996; DELEON FAP, 1992, J HERED, V83, P36, DOI 10.1093/oxfordjournals.jhered.a111154; DIBERARDINO D, 1987, J HERED, V78, P225, DOI 10.1093/oxfordjournals.jhered.a110371; EBERT KM, 1993, THERIOGENOLOGY, V39, P121, DOI 10.1016/0093-691X(93)90028-4; Edmunds T, 1998, BLOOD, V91, P4561, DOI 10.1182/blood.V91.12.4561; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; KLINGER K, 1992, AM J HUM GENET, V51, P55; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Meade HM, 1999, GENE EXPRESSION SYSTEMS, P399, DOI 10.1016/B978-012253840-7/50015-8; Ryot K. D., 1989, Indian Journal of Animal Reproduction, V10, P49; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; van de Corput MPC, 1998, HISTOCHEM CELL BIOL, V110, P431, DOI 10.1007/s004180050304; Vignon X, 1998, CR ACAD SCI III-VIE, V321, P735, DOI 10.1016/S0764-4469(98)80014-0; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WHITELAW CBA, 1993, TRANSGENIC RES, V2, P29, DOI 10.1007/BF01977678; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wineland NE, 1998, J AM VET MED ASSOC, V212, P713; Zhang Y, 1998, BIOL REPROD, V58, P266, DOI 10.1095/biolreprod58.1.266	26	753	962	3	96	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					456	461		10.1038/8632	http://dx.doi.org/10.1038/8632			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331804				2022-12-25	WOS:000080074500029
J	Douglas, JT; Miller, CR; Kim, M; Dmitriev, I; Mikheeva, G; Krasnykh, V; Curiel, DT				Douglas, JT; Miller, CR; Kim, M; Dmitriev, I; Mikheeva, G; Krasnykh, V; Curiel, DT			A system for the propagation of adenoviral vectors with genetically modified receptor specificities	NATURE BIOTECHNOLOGY			English	Article						adenoviral vector; artificial receptor; gene therapy; targeting	GROWTH-FACTOR RECEPTOR; TARGETED GENE DELIVERY; ESCHERICHIA-COLI; MODIFIED FIBERS; PENTON BASE; CELL LINE; TROPISM; VIRUS; PROTEIN; TYPE-5	The development of genetically modified adenovirus (Ad) vectors with specificity for a single cell type will require both the introduction of novel tropism determinants and the ablation of endogenous tropism. Consequently, it will not be possible to exploit the native cellular entry pathway in the propagation of these targeted Ad vectors. Based on the concept that Ad enters cells by a two-step process in which a primary receptor serves as a high affinity binding site for the Ad fiber knob, with subsequent internalization mediated by av integrins, we designed two artificial primary receptors. The extracellular domain of one of these synthetic receptors was derived from a single-chain antibody (sFv) with specificity for Ad5 knob, while the second receptor consisted of an icosapeptide identified by biopanning a phage display library against Ad5 knob. Expression of either of these artificial virus-binding receptors in fiber receptor-negative cells possessing cry integrins conferred susceptibility to Ad infection. We then created a novel mechanism for cell binding by genetically modifying both the vector and the target cell. In this approach, six histidine (His) residues were incorporated at the C-terminal of the Ad fiber protein. The resultant Ad vector was able to infect nonpermissive cells displaying the cognate artificial receptor, containing an anti-His sFv. This strategy, comprising a genetically engineered Ad virion and a modified cell line, should be useful in the propagation of targeted Ad vectors that lack the ability to bind the native fiber receptor.	Univ Alabama, Gene Therapy Ctr, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Radiat Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Curiel, DT (corresponding author), Univ Alabama, Gene Therapy Ctr, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL 35294 USA.		Miller, Ryan/B-9365-2008	Miller, Ryan/0000-0002-0096-8762	NATIONAL CANCER INSTITUTE [R01CA074242] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050255] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 74242] Funding Source: Medline; NHLBI NIH HHS [R01 HL 50255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CROMPTON J, 1994, J GEN VIROL, V75, P133, DOI 10.1099/0022-1317-75-1-133; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Goldman CK, 1997, CANCER RES, V57, P1447; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; KIPRIYANOV SM, 1994, MOL IMMUNOL, V31, P1047, DOI 10.1016/0161-5890(94)90100-7; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Krasnykh V, 1998, J VIROL, V72, P1844, DOI 10.1128/JVI.72.3.1844-1852.1998; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Leon RP, 1998, P NATL ACAD SCI USA, V95, P13159, DOI 10.1073/pnas.95.22.13159; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; MICHAEL SI, 1995, GENE THER, V2, P660; Miller CR, 1998, CANCER RES, V58, P5738; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Rancourt C, 1998, CLIN CANCER RES, V4, P2455; REYNOLDS PN, 1998, TUMOR TARGET, V3, P156; Rieder E, 1996, P NATL ACAD SCI USA, V93, P10428, DOI 10.1073/pnas.93.19.10428; Rogers BE, 1997, GENE THER, V4, P1387, DOI 10.1038/sj.gt.3300541; ROGERS BE, 1998, TUMOR TARGET, V3, P25; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wickham TJ, 1997, J VIROL, V71, P7663, DOI 10.1128/JVI.71.10.7663-7669.1997; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1995, GENE THER, V2, P750; Wickham TJ, 1997, J VIROL, V71, P8221, DOI 10.1128/JVI.71.11.8221-8229.1997; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	41	112	128	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					470	475		10.1038/8647	http://dx.doi.org/10.1038/8647			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331807				2022-12-25	WOS:000080074500032
J	Roy, S; Zhang, K; Roth, T; Vinogradov, S; Kao, RS; Kabanov, A				Roy, S; Zhang, K; Roth, T; Vinogradov, S; Kao, RS; Kabanov, A			Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides	NATURE BIOTECHNOLOGY			English	Article						gene therapy; antisense oligonucleotides; basement membrane; block copolymer	HIGH-GLUCOSE; ENDOTHELIAL-CELLS; OVEREXPRESSION; RETINOPATHY; RAT; COLLAGEN; LAMININ	We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothio-cyanate-labeled FN-oligonucleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7% +/- 7.9% of control (p<0.05) at day 2, and 46.7% +/- 4.9% of control (p<0.01) at day 6. In contrast, the p-actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4% +/- 16% of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may he an effective approach for ocular gene therapy.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Univ Massachusetts, Sch Med, Worcester, MA 01655 USA; Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Nebraska System; University of Nebraska Medical Center	Roy, S (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.		Kabanov, Alexander V/N-3356-2013; Kabanov, Alexander/AAY-5751-2020	Kabanov, Alexander V/0000-0002-3665-946X; Kabanov, Alexander/0000-0002-3665-946X	NATIONAL EYE INSTITUTE [R29EY011990] Funding Source: NIH RePORTER; NEI NIH HHS [EY11990-01A1] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CAGLIERO E, 1991, DIABETES, V40, P102, DOI 10.2337/diabetes.40.1.102; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLVIN RB, 1989, FIBRONECTIN, P213; ESSNER E, 1988, EXP EYE RES, V47, P317, DOI 10.1016/0014-4835(88)90014-0; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FITZGERALD MEC, 1990, MICROVASC RES, V39, P15, DOI 10.1016/0026-2862(90)90056-W; Hangai M, 1996, INVEST OPHTH VIS SCI, V37, P2678; KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002; KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P2; MAGNUSON VL, 1991, J BIOL CHEM, V266, P14654; MANDARINO LJ, 1993, EXP EYE RES, V57, P609, DOI 10.1006/exer.1993.1166; Mundigl O, 1998, J NEUROSCI, V18, P93; OSTERBY R, 1990, DIABETES MELLITUS TH, P220; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; ROTH T, 1993, P NATL ACAD SCI USA, V90, P9640, DOI 10.1073/pnas.90.20.9640; Roy S, 1997, DIABETOLOGIA, V40, P1011, DOI 10.1007/s001250050782; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; Roy S, 1996, DIABETOLOGIA, V39, P735; ROY S, 1994, J CLIN INVEST, V93, P438, DOI 10.1172/JCI116979; Roy S, 1996, INVEST OPHTH VIS SCI, V37, P258; SANNA PP, 1992, BIOTECH HISTOCHEM, V67, P346, DOI 10.3109/10520299209110047; SCWARZBAUER JE, 1987, EMBO J, V6, P2573; Vinogradov SV, 1998, BIOCONJUGATE CHEM, V9, P805, DOI 10.1021/bc980048q	23	55	58	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					476	479		10.1038/8654	http://dx.doi.org/10.1038/8654			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331808				2022-12-25	WOS:000080074500033
J	Carballido, JM; Namikawa, R; Carballido-Perrig, N; Antonenko, S; Roncarolo, MG; de Vries, JE				Carballido, JM; Namikawa, R; Carballido-Perrig, N; Antonenko, S; Roncarolo, MG; de Vries, JE			Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice	NATURE MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; PERIPHERAL-BLOOD LYMPHOCYTES; VERSUS-HOST DISEASE; IMMUNOGLOBULIN PRODUCTION; MONONUCLEAR-CELLS; MOUSE; ENGRAFTMENT; GRAFT; IMMUNIZATION; CHIMERAS		Novartis Res Inst, Dept Immunol, A-1235 Vienna, Austria; DNAX Res Inst Mol & Cellular Biol Inc, Dept Human Immunol, Palo Alto, CA 94304 USA; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy	Novartis; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Carballido, JM (corresponding author), Novartis Res Inst, Dept Immunol, Brunner Str 59, A-1235 Vienna, Austria.			RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT00A01, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABEDI MR, 1992, EUR J IMMUNOL, V22, P823, DOI 10.1002/eji.1830220329; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CARBALLIDO JM, 1995, J IMMUNOL, V155, P4162; Delhem N, 1998, J IMMUNOL, V161, P2060; DUCHOSAL MA, 1992, NATURE, V355, P258, DOI 10.1038/355258a0; FRASER CC, 1995, BLOOD, V86, P183, DOI 10.1182/blood.V86.1.183.bloodjournal861183; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; HOFFMANNFEZER G, 1993, BLOOD, V81, P3440; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KROWKA JF, 1991, J IMMUNOL, V146, P3751; KYOIZUMI S, 1992, BLOOD, V79, P1704; MARTENSSON C, 1994, IMMUNOLOGY, V83, P171; MAZINGUE C, 1991, EUR J IMMUNOL, V21, P1763, DOI 10.1002/eji.1830210728; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MURPHY WJ, 1992, EUR J IMMUNOL, V22, P1421, DOI 10.1002/eji.1830220614; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; PFLUMIO F, 1993, INT IMMUNOL, V5, P1509, DOI 10.1093/intimm/5.12.1509; Roncarolo M G, 1996, Semin Immunol, V8, P207, DOI 10.1006/smim.1996.0026; RONCAROLO MG, 1998, CURRENT PROTOCOLS IM; SANDHU J, 1994, J IMMUNOL, V152, P3806; STEIN H, 1982, CLIN HAEMATOL, V11, P531; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817	24	38	40	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					103	106		10.1038/71434	http://dx.doi.org/10.1038/71434			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613834				2022-12-25	WOS:000084583300045
J	Fuks, F; Burgers, WA; Brehm, A; Hughes-Davies, L; Kouzarides, T				Fuks, F; Burgers, WA; Brehm, A; Hughes-Davies, L; Kouzarides, T			DNA methyltransferase Dnmt1 associates with histone deacetylase activity	NATURE GENETICS			English	Article							REPRESS TRANSCRIPTION; TRICHOSTATIN-A; METHYLATION; ACETYLATION; PROTEINS; COMPONENT; INTERACTS; DOMAINS; COMPLEX; MOTIF	The DNA methyltransferase Dnmt1 is responsible for cytosine methylation in mammals and has a role in gene silencing(1-4) DNA methylation represses genes partly by recruitment of the methyl-CpG-binding protein MeCP2, which in turn recruits a histone deacetylase activity(5,6). Here we show that Dnmt1 is itself associated with histone deacetylase activity in vivo. Consistent with this association, we find that one of the known histone deacetylases, HDAC1, has the ability to bind Dnmt1 and can purify methyltransferase activity from nuclear extracts. We have identified a transcriptional repression domain in Dnmt1 that functions, at least partly, by recruiting histone deacetylase activity and shows homology to the repressor domain of the trithorax-related protein HRX (also known as MLL and ALL-1). Our data show a more direct connection between DNA methylation and histone deacetylation than was previously considered. We suggest that the process of DNA methylation, mediated by Dnmt1, may depend on or generate an altered chromatin state via histone deacetylase activity.	Univ Cambridge, Wellcome CRC Inst, Cambridge, England; Univ Cambridge, Dept Pathol, Cambridge, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Cambridge, England.			Kouzarides, Tony/0000-0002-8918-4162; Burgers, Wendy/0000-0003-3396-9398				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	29	749	774	0	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					88	91		10.1038/71750	http://dx.doi.org/10.1038/71750			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615135				2022-12-25	WOS:000084609200023
J	Wyllie, FS; Jones, CJ; Skinner, JW; Haughton, MF; Wallis, C; Wynford-Thomas, D; Faragher, RGA; Kipling, D				Wyllie, FS; Jones, CJ; Skinner, JW; Haughton, MF; Wallis, C; Wynford-Thomas, D; Faragher, RGA; Kipling, D			Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts	NATURE GENETICS			English	Article							LIFE-SPAN; DISSOCIATION; GENE		Brighton Univ, Sch Pharm & Biomol Sci, Brighton, E Sussex, England; Cardiff Univ, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales	University of Brighton; Cardiff University	Faragher, RGA (corresponding author), Brighton Univ, Sch Pharm & Biomol Sci, Crockroft Bldg, Brighton, E Sussex, England.	rgaf@bton.ac.uk		Faragher, Richard/0000-0001-8366-9014				Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bennett SE, 1999, ALFRED BENZON SYMP S, V44, P214; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; Kirkwood TBL., 1999, TIME OUR LIVES; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5	15	251	266	2	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					16	17		10.1038/71630	http://dx.doi.org/10.1038/71630			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615119				2022-12-25	WOS:000084609200008
J	Strauss, S; Boerjan, W; Cairney, J; Campbell, M; Dean, J; Ellis, D; Jouanin, L; Sundberg, B				Strauss, S; Boerjan, W; Cairney, J; Campbell, M; Dean, J; Ellis, D; Jouanin, L; Sundberg, B			Forest biotechnology makes its position known	NATURE BIOTECHNOLOGY			English	Editorial Material									Oregon State Univ, Corvallis, OR 97331 USA; Flanders Interuniv, Ghent, Belgium; Inst Paper Sci & Technol, Atlanta, GA 30318 USA; Univ Oxford, Oxford, England; Univ Georgia, Athens, GA 30602 USA; BC Res, Vancouver, BC, Canada; INRA, F-78026 Versailles, France; Swedish Univ Agr Sci, S-90183 Umea, Sweden	Oregon State University; University of Oxford; University System of Georgia; University of Georgia; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Swedish University of Agricultural Sciences	Strauss, S (corresponding author), Oregon State Univ, Corvallis, OR 97331 USA.		Boerjan, Wout/Y-4158-2019; Dean, Jeffrey F.D./G-2184-2010; Dean, Jeffrey F.D./N-7304-2019	Boerjan, Wout/0000-0003-1495-510X; Dean, Jeffrey F.D./0000-0003-1208-1023; Dean, Jeffrey F.D./0000-0003-1208-1023; Campbell, Malcolm/0000-0002-1396-6651					0	12	12	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1145	1145		10.1038/70652	http://dx.doi.org/10.1038/70652			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585674	Bronze			2022-12-25	WOS:000084170700004
J	van der Vlag, J; Otte, AP				van der Vlag, J; Otte, AP			Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation	NATURE GENETICS			English	Article							EXTRA SEX COMBS; GROUP GENE; COMPLEXES; DROSOPHILA; REGULATOR; IDENTIFICATION; EXPRESSION; HOMOLOGS; PRODUCT; CLONING	Polycomb-group (PcG) proteins form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations(1-3) Components of PcG complexes and their mutual interactions have been identified and analysed through extensive genetic and biochemical analyses. Molecular mechanisms underlying PcG-mediated repression of gene activity, however, have remained largely unknown. Previously we reported the existence of two distinct human PcG protein complexes(4). The EED/EZH protein complex contains the embryonic ectoderm development(4-8) (EED) and enhancer of zeste 2 (EZH2; refs 9,10) PcG proteins. The HPC/HPH PcG complex contains the human polycomb 2 (HPC2; ref. 11), human polyhomeotic(12) (HPH), BMI1 (ref. 13) and RING1 (refs 14,15) proteins. Here we show that EED (refs 4-8) interacts, both in vitro and in vivo, with histone deacetylase (HDAC) proteins(16,17). This interaction is highly specific because the HDAC proteins do not interact with other vertebrate PcG proteins. We further find that histone deacetylation activity co-immunoprecipitates with the EED protein. Finally, the histone deacetylase inhibitor trichostatin A (ref. 17) relieves transcriptional repression mediated by EED, but not by HPC2, a human homologue of polycomb(11). Our data indicate that PcG-mediated repression of gene activity involves histone deacetylation. This mechanistic link between two distinct, global gene repression systems is accomplished through the interaction of HDAC proteins with a particular PcG protein, EED.	Univ Amsterdam, Bioctr, EC Slater Inst Biochem Res, Amsterdam, Netherlands	University of Amsterdam	Otte, AP (corresponding author), Univ Amsterdam, Bioctr, EC Slater Inst Biochem Res, Kruislaan 403, Amsterdam, Netherlands.		Van der Vlag, Johan/E-4636-2010	Van der Vlag, Johan/0000-0001-7843-5918				Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; Mizzen CA, 1999, METHOD ENZYMOL, V304, P675; Monahan SJ, 1998, VIROLOGY, V241, P122, DOI 10.1006/viro.1997.8953; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Strouboulis J, 1999, MOL CELL BIOL, V19, P3958; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	29	427	438	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					474	478		10.1038/70602	http://dx.doi.org/10.1038/70602			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581039				2022-12-25	WOS:000084023900028
J	Verheijen, FW; Verbeek, E; Aula, N; Beerens, CEMT; Havelaar, AC; Joosse, M; Peltonen, L; Aula, P; Galjaard, H; van der Spek, PJ; Mancini, GMS				Verheijen, FW; Verbeek, E; Aula, N; Beerens, CEMT; Havelaar, AC; Joosse, M; Peltonen, L; Aula, P; Galjaard, H; van der Spek, PJ; Mancini, GMS			A new gene, encoding an anion transporter, is mutated in sialic acid storage diseases	NATURE GENETICS			English	Article							SALLA DISEASE; LYSOSOMAL MEMBRANE; MOLECULAR-CLONING; INFANTILE-FORM; PHYSICAL MAP; LOCUS; MONOSACCHARIDES; EXPRESSION; DATABASE; DISORDER	Sialic acid storage diseases (SASD, MIM 269920) are autosomal recessive neurodegenerative disorders that may present as a severe infantile form (ISSD) or a slowly progressive adult form, which is prevalent in Finland(1,2) (Salla disease). The main symptoms are hypotonia, cerebellar ataxia and mental retardation; visceromegaly and coarse features are also present in infantile cases(3). Progressive cerebellar atrophy and dysmyelination have been documented by magnetic resonance imaging (ref. 4). Enlarged lysosomes are seen on electron microscopic studies and patients excrete large amounts of free sialic acid in urine. A H+/anionic sugar symporter mechanism for sialic acid and glucuronic acid(5) is impaired in lysosomal membranes from Salla and ISSD patients(6). The locus for Salla disease was assigned to a region of approximately 200 kb on chromosome 6q14-q15 in a linkage study using Finnish families(7,8). Salla disease and ISSD were further shown to be allelic disorders(9). A physical map with PZ and PAC clones was constructed to cover the 200-kb area flanked by the loci D6S280 and D6S1622, providing the basis for precise physical positioning of the gene(10). Here we describe a new gene, SLC17A5(also known as AST), encoding a protein (sialin) with a predicted transport function that belongs to a family of anion/cation symporters (ACS). Mle found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins. Our observations suggest that mutations in SLC17A5 are the primary cause of lysosomal sialic acid storage diseases.	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Acad Hosp, Erasmus Med Ctr Rotterdam, Rotterdam, Netherlands; Natl Publ Hlth Inst, Dept Human Mol Genet, Helsinki, Finland; Univ Helsinki, Dept Med Genet, Helsinki, Finland; NV Organon, Akzo Nobel, NL-5340 BH Oss, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Finland National Institute for Health & Welfare; University of Helsinki; AkzoNobel; Merck & Company	Verheijen, FW (corresponding author), Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AULA P, 1979, ARCH NEUROL-CHICAGO, V36, P88, DOI 10.1001/archneur.1979.00500380058006; BERRA B, 1995, AM J MED GENET, V58, P24, DOI 10.1002/ajmg.1320580107; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CAMERON PD, 1990, ARCH DIS CHILD, V65, P314, DOI 10.1136/adc.65.3.314; CHONG SS, 1993, GENOMICS, V18, P355, DOI 10.1006/geno.1993.1476; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; HAATAJA L, 1994, AM J HUM GENET, V54, P1042; HAATAJA L, 1994, NEUROPEDIATRICS, V25, P1; Havelaar AC, 1998, J BIOL CHEM, V273, P34568, DOI 10.1074/jbc.273.51.34568; Havelaar AC, 1999, FEBS LETT, V446, P65, DOI 10.1016/S0014-5793(99)00187-8; Lemyre E, 1999, AM J MED GENET, V82, P385, DOI 10.1002/(SICI)1096-8628(19990219)82:5<385::AID-AJMG6>3.3.CO;2-V; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Leppanen P, 1996, GENOMICS, V37, P62, DOI 10.1006/geno.1996.0521; MANCINI GMS, 1992, P NATL ACAD SCI USA, V89, P6609, DOI 10.1073/pnas.89.14.6609; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1991, J CLIN INVEST, V87, P1329, DOI 10.1172/JCI115136; Ni BH, 1996, J NEUROCHEM, V66, P2227; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Peltonen L, 1997, ANN MED, V29, P553, DOI 10.3109/07853899709007481; Sambrook J., 2002, MOL CLONING LAB MANU; Schlemper RJ, 1996, EUR J GASTROEN HEPAT, V8, P33, DOI 10.1097/00042737-199601000-00007; SCHLEUTKER J, 1995, AM J HUM GENET, V57, P893; SCHLEUTKER J, 1995, GENOMICS, V27, P286, DOI 10.1006/geno.1995.1044; STEVENSON RE, 1983, PEDIATRICS, V72, P441; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONDEUR M, 1982, EUR J PEDIATR, V139, P142, DOI 10.1007/BF00441499; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	30	189	198	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					462	465		10.1038/70585	http://dx.doi.org/10.1038/70585			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581036				2022-12-25	WOS:000084023900025
J	Song, WJ; Sullivan, MG; Legare, RD; Hutchings, S; Tan, XL; Kufrin, D; Ratajczak, J; Resende, IC; Haworth, C; Hock, R; Loh, M; Felix, C; Roy, DC; Busque, L; Kurnit, D; Willman, C; Gewirtz, AM; Speck, NA; Bushweller, JH; Li, FP; Gardiner, K; Poncz, M; Maris, JM; Gilliland, DG				Song, WJ; Sullivan, MG; Legare, RD; Hutchings, S; Tan, XL; Kufrin, D; Ratajczak, J; Resende, IC; Haworth, C; Hock, R; Loh, M; Felix, C; Roy, DC; Busque, L; Kurnit, D; Willman, C; Gewirtz, AM; Speck, NA; Bushweller, JH; Li, FP; Gardiner, K; Poncz, M; Maris, JM; Gilliland, DG			Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia	NATURE GENETICS			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PLATELET DISORDER; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATIONS; DEFINITIVE HEMATOPOIESIS; FUSION TRANSCRIPT; GENE; AML1; T(12-21)	Familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399) is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukaemia (AML). Informative recombination events in 6 FPD/AML pedigrees with evidence of linkage to markers on chromosome 21q identified an 880-kb interval containing the disease gene. Mutational analysis of regional candidate genes showed nonsense mutations or intragenic deletion of one allele of the haematopoietic transcription factor CBFA2 (formerly AML1) that co-segregated with the disease in four FPD/AML pedigrees. We identified heterozygous CBFA2 missense mutations that co-segregated with the disease in the remaining two FPD/AML pedigrees at phylogenetically conserved amino acids R166 and R201, respectively. Analysis of bone marrow or peripheral blood cells from affected FPD/AML individuals showed a decrement in megakaryocyte colony formation, demonstrating that CBFA2 dosage affects megakaryopoiesis. Our findings support a model for FPD/AML in which haploinsufficiency of CBFA2 causes an autosomal dominant congenital platelet defect and predisposes to the acquisition of additional mutations that cause leukaemia.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Brown Univ, Women & Infants Hosp, Program Womens Oncol, Providence, RI USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Leicester Royal Infirm, Leicester, Leics, England; St Vincent Hosp, Childrens Ctr Canc & Blood Dis, Indianapolis, IN USA; Univ Montreal, Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H3C 3J7, Canada; Univ Michigan, Med Ctr, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Ctr Canc, Albuquerque, NM 87131 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03756 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA; Eleanor Roosevelt Inst, Denver, CO USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Brown University; Women & Infants Hospital Rhode Island; University of Pennsylvania; University of Pennsylvania; University of Leicester; Universite de Montreal; Universite de Montreal; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of New Mexico; University of New Mexico; Dartmouth College; University of Virginia; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.			Bushweller, John/0000-0002-5386-1758; Roy, Denis-Claude/0000-0002-5921-1692	NATIONAL CANCER INSTITUTE [R01CA078545, R01CA081932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039536] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA81932, R01 CA78545] Funding Source: Medline; NIAID NIH HHS [R29 AI39536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akamatsu Y, 1997, GENE, V185, P111, DOI 10.1016/S0378-1119(96)00644-0; Arepally G, 1998, BLOOD, V92, P2600, DOI 10.1182/blood.V92.7.2600; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BERARDI MJ, IN PRESS STRUCTURE; BUSQUE L, 1993, BLOOD, V82, P337; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOWTON SB, 1985, BLOOD, V65, P557; ERICKSON P, 1992, BLOOD, V80, P1825; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALE RE, 1994, BLOOD, V83, P2899, DOI 10.1182/blood.V83.10.2899.2899; GERRARD JM, 1991, BRIT J HAEMATOL, V79, P246, DOI 10.1111/j.1365-2141.1991.tb04529.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ho CY, 1996, BLOOD, V87, P5218, DOI 10.1182/blood.V87.12.5218.bloodjournal87125218; Horwitz M, 1997, AM J HUM GENET, V61, P873, DOI 10.1086/514894; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Knudson AG, 1997, J CLIN ONCOL, V15, P3280, DOI 10.1200/JCO.1997.15.10.3280; Kowalska MA, 1999, BRIT J HAEMATOL, V104, P220, DOI 10.1046/j.1365-2141.1999.01169.x; Legare RD, 1997, LEUKEMIA, V11, P2111, DOI 10.1038/sj.leu.2400852; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Loh ML, 1998, BLOOD, V92, P4792, DOI 10.1182/blood.V92.12.4792.424k30_4792_4797; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Ratajczak MZ, 1998, BLOOD, V91, P353, DOI 10.1182/blood.V91.1.353.353_353_359; Ratajczak MZ, 1997, BRIT J HAEMATOL, V99, P228, DOI 10.1046/j.1365-2141.1997.3563170.x; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Rowley JD, 1998, J LAB CLIN MED, V132, P244, DOI 10.1016/S0022-2143(98)90036-1; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1999, LEUKEMIA, V13, P19, DOI 10.1038/sj.leu.2401257; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Speck NA, 1999, CANCER RES, V59, p1789S; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WEINBERG RA, 1989, CANCER RES, V49, P3713; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	49	829	852	1	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					166	175		10.1038/13793	http://dx.doi.org/10.1038/13793			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508512				2022-12-25	WOS:000082827500015
J	Sanchez-Prieto, R; de Alava, E; Palomino, T; Guinea, J; Fernandez, V; Cebrian, S; Lleonart, M; Cabello, P; Martin, P; San Roman, C; Bornstein, R; Pardo, J; Martinez, A; Diaz-Espada, F; Barrios, Y; Cajal, SRY				Sanchez-Prieto, R; de Alava, E; Palomino, T; Guinea, J; Fernandez, V; Cebrian, S; Lleonart, M; Cabello, P; Martin, P; San Roman, C; Bornstein, R; Pardo, J; Martinez, A; Diaz-Espada, F; Barrios, Y; Cajal, SRY			An association between viral genes and human oncogenic alterations: The adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1	NATURE MEDICINE			English	Article							CHROMOSOME-TRANSLOCATION; CELL-LINES; EXPRESSION; RECOMBINATION; PROTEIN; P53	Malignant transformation of human cells requires the accumulation of multiple genetic alterations, such as the activation of oncogenes and loss of function of tumor suppressor genes or those related to genomic instability. Among the genetic alterations most frequently found in human tumors are chromosomal translocations' that may result in the expression of chimeric products with transforming capability or are able to change the expression of oncogenes. We show here that the adenovirus early region 1A (E1A) gene can induce a specific human fusion transcript (EWS-FLI1) that is characteristic of Ewing tumors(2). This fusion transcript was detected by RT-PCR in normal human fibroblasts and keratinocytes after expression of the adenovirus E1A gene, as well as in human cell lines immortalized by adenoviruses. Cloning and sequencing of the RT-PCR product showed fusion points between EWS and FLI1 cDNA identical to those detected in Ewing tumors. In addition, we detected a chimeric protein by western blot analysis and immunoprecipitation and a t(11,22) by fluorescent in situ hybridization. This association between a single viral gene and a specific human fusion transcript indicates a direct link between viral genes and chromosome translocations, one of the hallmarks of many human tumors.	Clin Puerta de Hierro, Dept Pathol, Madrid 28035, Spain; Clin Puerta de Hierro, Dept Immunol, Madrid 28035, Spain; Univ Navarra Clin, Dept Pathol, Pamplona 31008, Spain; Hosp Ramon y Cajal, Dept Genet, E-28034 Madrid, Spain; Hosp 12 Octubre, Dept Hematol, E-28041 Madrid, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; University of Navarra; Hospital Universitario Ramon y Cajal; Hospital Universitario 12 de Octubre	Cajal, SRY (corresponding author), Clin Puerta de Hierro, Dept Pathol, San Martin de Porres 4, Madrid 28035, Spain.		IBIS, SARCOMAS/O-1893-2015; LLeonart, Matilde E./Q-2662-2019; de Alava, Enrique/GOH-0368-2022; Sanchez-Prieto, Ricardo/AAY-4271-2021; Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/B-6877-2008; Barrios, Yvelise/AGR-9501-2022; Prieto, Ricardo/AAZ-7221-2021; Ramon y Cajal, Santiago/H-4955-2016	LLeonart, Matilde E./0000-0002-6196-7405; de Alava, Enrique/0000-0001-8400-046X; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Barrios, Yvelise/0000-0002-6994-2034; Bornstein, Rafael/0000-0002-3229-7852; Ramon y Cajal, Santiago/0000-0002-3867-1390; Fernandez-Soria, Victor Manuel/0000-0002-4225-8697				Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; CAJAL SRY, 1995, HISTOL HISTOPATHOL, V10, P811; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FUKAMIZU A, 1994, J BIOL CHEM, V269, P31252; HIORN K, 1998, CELL, V94, P463; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; Mymryk JS, 1996, ONCOGENE, V13, P1581; Sanchez-Prieto R, 1998, CANCER GENE THER, V5, P215; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; SCHRAMAYR S, 1990, J VIROL, V64, P2090, DOI 10.1128/JVI.64.5.2090-2095.1990; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	20	27	27	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1076	1079		10.1038/12516	http://dx.doi.org/10.1038/12516			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470089				2022-12-25	WOS:000082337200046
J	Hoe, NP; Nakashima, K; Lukomski, S; Grigsby, D; Liu, MY; Kordari, P; Dou, SJ; Pan, X; Vuopio-Varkila, J; Salmelinna, S; McGeer, A; Low, DE; Schwartz, B; Schuchat, A; Naidich, S; De Lorenzo, D; Fu, YX; Musser, JM				Hoe, NP; Nakashima, K; Lukomski, S; Grigsby, D; Liu, MY; Kordari, P; Dou, SJ; Pan, X; Vuopio-Varkila, J; Salmelinna, S; McGeer, A; Low, DE; Schwartz, B; Schuchat, A; Naidich, S; De Lorenzo, D; Fu, YX; Musser, JM			Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves	NATURE MEDICINE			English	Article							GROUP-A STREPTOCOCCUS; MOLECULAR EPIDEMIOLOGY; SIZE MUTANTS; INFECTIONS; SEROTYPE; DISEASE; GLYCOPROTEIN; ATLANTA; STRAINS; SPREAD	Serotype M1 group A Streptococcus strains cause epidemic waves of human infections long thought to be mono- or pauciclonal. The gene encoding an extracellular group A Streptococcus protein (streptococcal inhibitor of complement) that inhibits human complement was sequenced in 1,132 M1 strains recovered from population-based surveillance of infections in Canada, Finland and the United States. Epidemic waves are composed of strains expressing a remarkably heterogeneous array of variants of streptococcal inhibitor of complement that arise very rapidly by natural selection on mucosal surfaces. Thus, our results enhance the understanding of pathogen population dynamics in epidemic waves and infectious disease reemergence.	Natl Publ Hlth Inst, Dept Bacteriol, FIN-00300 Helsinki, Finland; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Toronto, ON M5G 1X5, Canada; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Genomics, New York, NY 10013 USA; Univ Texas, Hlth Sci Ctr, Ctr Human Genet, Houston, TX 77030 USA	Finland National Institute for Health & Welfare; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Centers for Disease Control & Prevention - USA; University of Texas System; University of Texas Health Science Center Houston	Musser, JM (corresponding author), NIAID, Rocky Mt Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	jmusser@bcm.tmc.edu	mcgeer, allison/H-7747-2014; Low, Donald/B-1726-2012; McGeer, Allison/AAB-6885-2020; de Lorenzo, David/C-2677-2009	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137; de Lorenzo, David/0000-0003-2042-0961	NIAID NIH HHS [AI-33119] Funding Source: Medline; NIGMS NIH HHS [GM-50428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050428, R29GM050428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; Beall B, 1997, J CLIN MICROBIOL, V35, P1231, DOI 10.1128/JCM.35.5.1231-1235.1997; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; DEMALMANCHE SA, 1994, MED MICROBIOL IMMUN, V183, P299, DOI 10.1007/BF00196680; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; FISCHETTI VA, 1986, J EXP MED, V164, P971, DOI 10.1084/jem.164.4.971; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FITCH WM, 1977, AM NAT, V111, P223, DOI 10.1086/283157; FU YX, 1995, THEOR POPUL BIOL, V48, P172, DOI 10.1006/tpbi.1995.1025; GARCIA O, 1994, J VIROL, V68, P5448; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; Hennessy TW, 1996, NEW ENGL J MED, V334, P1281, DOI 10.1056/NEJM199605163342001; Hoe N, 1999, EMERG INFECT DIS, V5, P254, DOI 10.3201/eid0502.990210; HOLLINGSHEAD SK, 1987, MOL GEN GENET, V207, P196, DOI 10.1007/BF00331578; JONES KF, 1988, P NATL ACAD SCI USA, V85, P8271, DOI 10.1073/pnas.85.21.8271; Krause RM, 1998, EMERGING INFECT; Lubinski JM, 1998, J VIROL, V72, P8257, DOI 10.1128/JVI.72.10.8257-8263.1998; MARTIN DR, 1993, J INFECT DIS, V167, P1112, DOI 10.1093/infdis/167.5.1112; Morelli G, 1997, MOL MICROBIOL, V25, P1047, DOI 10.1046/j.1365-2958.1997.5211882.x; Muotiala A, 1997, J INFECT DIS, V175, P392, DOI 10.1093/infdis/175.2.392; MUSSER JM, 1995, INFECT IMMUN, V63, P994, DOI 10.1128/IAI.63.3.994-1003.1995; Musser JM, 1998, BIOMED RES REP, P185; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PIFFARETTI JC, 1989, P NATL ACAD SCI USA, V86, P3818, DOI 10.1073/pnas.86.10.3818; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128; Swofford D., 1998, PAUP PHYLOGENETIC AN; TAJIMA F, 1989, GENETICS, V123, P585; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; VILLASENOR A, 1998, AM SOC MICR 98 GEN M; Wachsmuth I.K., 1994, VIBRIO CHOLERAE CHOL; Webster RG, 1998, BIOMED RES REP, P275; Zurawski CA, 1998, CLIN INFECT DIS, V27, P150, DOI 10.1086/514632	34	72	73	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					924	929		10.1038/11369	http://dx.doi.org/10.1038/11369			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426317				2022-12-25	WOS:000081684000037
J	Bailey, JE				Bailey, JE			Lessons from metabolic engineering for functional genomics and drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material							CELL-CYCLE REGULATION; ESCHERICHIA-COLI; GROWTH; FLUX		Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bailey, JE (corresponding author), Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland.	bailey@ebiotech.biol.ethz.ch						AIBA S, 1979, BIOTECHNOL BIOENG, V21, P1373, DOI 10.1002/bit.260210806; BIMBAUM S, 1991, J BIOTECHNOL BIOENG, V37, P309; DOMACH MM, 1984, BIOTECHNOL BIOENG, V26, P203, DOI 10.1002/bit.260260303; *ELS SCI LTD, 1998, TRENDS GUID BIOINF; Fell D., 1997, UNDERSTANDING CONTRO; Fell DA, 1998, BIOTECHNOL BIOENG, V58, P121, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<121::AID-BIT2>3.3.CO;2-F; Follstad BD, 1999, BIOTECHNOL BIOENG, V63, P675, DOI 10.1002/(SICI)1097-0290(19990620)63:6<675::AID-BIT5>3.0.CO;2-R; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KOSINSKI MJ, 1992, APPL MICROBIOL BIOT, V36, P782; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; Lee KH, 1996, BIOTECHNOL BIOENG, V50, P273, DOI 10.1002/(SICI)1097-0290(19960505)50:3<273::AID-BIT6>3.0.CO;2-D; Lee KH, 1996, BIOTECHNOL BIOENG, V50, P336, DOI 10.1002/(SICI)1097-0290(19960505)50:3<336::AID-BIT12>3.0.CO;2-L; PAPOUTSAKIS ET, 1984, BIOTECHNOL BIOENG, V26, P174, DOI 10.1002/bit.260260210; SCHAAFF I, 1989, YEAST, V5, P285, DOI 10.1002/yea.320050408; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; Varner J, 1999, METAB ENG, V1, P88, DOI 10.1006/mben.1998.0104	18	109	119	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					616	618		10.1038/10794	http://dx.doi.org/10.1038/10794			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409335				2022-12-25	WOS:000081296900003
J	Cargill, M; Altshuler, D; Ireland, J; Sklar, P; Ardlie, K; Patil, N; Lane, CR; Lim, EP; Kalyanaraman, N; Nemesh, J; Ziaugra, L; Friedland, L; Rolfe, A; Warrington, J; Lipshutz, R; Daley, GQ; Lander, ES				Cargill, M; Altshuler, D; Ireland, J; Sklar, P; Ardlie, K; Patil, N; Lane, CR; Lim, EP; Kalyanaraman, N; Nemesh, J; Ziaugra, L; Friedland, L; Rolfe, A; Warrington, J; Lipshutz, R; Daley, GQ; Lander, ES			Characterization of single-nucleotide polymorphisms in coding regions of human genes	NATURE GENETICS			English	Article							HUMAN LIPOPROTEIN-LIPASE; SEQUENCE VARIATION; HUMAN GENOME; ALLELE; DIVERSITY; MUTATION; DISEASE	A major goal in human genetics is to understand the role of common genetic variants in susceptibility to common diseases. This will require characterizing the nature of gene variation in human populations, assembling an extensive catalogue of single-nucleotide polymorphisms (SNPs) in candidate genes and performing association studies for particular diseases. At present, our knowledge of human gene variation remains rudimentary. Here we describe a systematic survey of SNPs in the coding regions of human genes. We identified SNPs in 106 genes relevant to cardiovascular disease, endocrinology and neuropsychiatry by screening an average of 114 independent alleles using 2 independent screening methods. To ensure high accuracy, all reported SNPs were confirmed by DNA sequencing. We identified 560 SNPs, including 392 coding-region SNPs (cSNPs) divided roughly equally between those causing synonymous and non-synonymous changes. We observed different rates of polymorphism among classes of sites within genes (non-coding, degenerate and non-degenerate) as well as between genes. The cSNPs most likely to influence disease, those that alter the amino acid sequence of the encoded protein, are found at a lower rate and with lower allele frequencies than silent substitutions. This likely reflects selection acting against deleterious alleles during human evolution. The lower allele frequency of missense cSNPs has implications for the compilation of a comprehensive catalogue, as well as for the subsequent application to disease association.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Endocrinol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Hematol, Boston, MA 02114 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Affymetrix; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 1 Kendall Sq,Bldg 300, Cambridge, MA 02139 USA.		Altshuler, David M/A-4476-2009	Altshuler, David M/0000-0002-7250-4107				AYALA FJ, 1994, P NATL ACAD SCI USA, V91, P6787, DOI 10.1073/pnas.91.15.6787; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Harding RM, 1997, AM J HUM GENET, V60, P772; HARRIS H, 1975, PRINCIPLES BIOCH GEN; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, GENETICS, V129, P513; Moriyama EN, 1996, MOL BIOL EVOL, V13, P261, DOI 10.1093/oxfordjournals.molbev.a025563; Nachman MW, 1998, GENETICS, V150, P1133; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; TAJIMA F, 1989, GENETICS, V123, P585; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WATTERSON GA, 1977, THEOR POPUL BIOL, V11, P141, DOI 10.1016/0040-5809(77)90023-5; Wayne ML, 1998, TRENDS ECOL EVOL, V13, P236, DOI 10.1016/S0169-5347(98)01360-3; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Zietkiewicz E, 1997, GENE, V205, P161	32	1430	1606	0	122	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					231	238		10.1038/10290	http://dx.doi.org/10.1038/10290			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391209				2022-12-25	WOS:000081125900014
J	Dove, A				Dove, A			The long arm of DNA	NATURE BIOTECHNOLOGY			English	Article																		Lyons LA, 1997, NAT GENET, V15, P47, DOI 10.1038/ng0197-47; 1998, LLOYDS LIST     1119; 1999, NAT GENET, V21, P243; 1999, NY TIMES        0309, pB1	4	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					649	651		10.1038/10859	http://dx.doi.org/10.1038/10859			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404156				2022-12-25	WOS:000081296900023
J	Ferris, CD; Jaffrey, SR; Sawa, A; Takahashi, M; Brady, SD; Barrow, RK; Tysoe, SA; Wolosker, H; Baranano, DE; Dore, S; Poss, KD; Snyder, SH				Ferris, CD; Jaffrey, SR; Sawa, A; Takahashi, M; Brady, SD; Barrow, RK; Tysoe, SA; Wolosker, H; Baranano, DE; Dore, S; Poss, KD; Snyder, SH			Haem oxygenase-1 prevents cell death by regulating cellular iron	NATURE CELL BIOLOGY			English	Article							HEME OXYGENASE; CARBON-MONOXIDE; PROTEIN; APOPTOSIS; STRESS; IDENTIFICATION; FIBROBLASTS; EXPRESSION; REDUCTASE; NECROSIS	Haem oxygenase-1 (HO1) is a heat-shock protein that is induced by stressful stimuli. Here we demonstrate a cytoprotective role for HO1: cell death produced by serum deprivation, staurosporine or etoposide is markedly accentuated in cells from mice with a targeted deletion of the HO1 gene, and greatly reduced in cells that overexpress HO1. Iron efflux from cells is augmented by HO1 transfection and reduced in HO1-deficient fibroblasts, Iron accumulation in HO1-deficient cells explains their death: iron chelators protect HO1-deficient fibroblasts from cell death. Thus, cytoprotection by HO1 is attributable to its augmentation of iron efflux, reflecting a role for HO1 in modulating intracellular iron levels and regulating cell viability.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA; Skidmore Coll, Dept Chem & Phys, Saratoga Springs, NY 12866 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Skidmore College; Massachusetts Institute of Technology (MIT); Johns Hopkins University; Johns Hopkins University	Ferris, CD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.		Dore, Sylvain/AAG-1470-2020	Dore, Sylvain/0000-0003-3771-5109; Wolosker, Herman/0000-0001-5508-9194; Poss, Kenneth/0000-0002-6743-5709; Jaffrey, Samie/0000-0003-3615-6958	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F30DA005900] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-05900, DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baranano DE, 1999, GASTROENTEROLOGY, V116, pA1188; BOTHWELL TH, 1995, METABOLIC MOL BASES, P2237; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Conrad ME, 1998, SEMIN HEMATOL, V35, P1; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Farinelli SE, 1998, J NEUROSCI, V18, P5112, DOI 10.1523/JNEUROSCI.18-14-05112.1998; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McCord JM, 1998, SEMIN HEMATOL, V35, P5; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Miller SM, 1998, GASTROENTEROLOGY, V114, P239, DOI 10.1016/S0016-5085(98)70473-1; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Ponka P, 1998, SEMIN HEMATOL, V35, P35; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tenhunen R, 1969, Trans Assoc Am Physicians, V82, P363; TRAKSHEL GM, 1986, ARCH BIOCHEM BIOPHYS, V251, P175, DOI 10.1016/0003-9861(86)90064-0; Umbreit JN, 1998, SEMIN HEMATOL, V35, P13; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7786; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848; ZAKHARY R, 1996, P NATL ACAD SCI USA, V93, P765	39	460	476	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					152	157		10.1038/11072	http://dx.doi.org/10.1038/11072			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559901				2022-12-25	WOS:000083102500013
J	Kieber-Emmons, T; Luo, P; Qiu, JP; Chang, TY; O, IS; Blaszczyk-Thurin, M; Steplewski, Z				Kieber-Emmons, T; Luo, P; Qiu, JP; Chang, TY; O, IS; Blaszczyk-Thurin, M; Steplewski, Z			Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses	NATURE BIOTECHNOLOGY			English	Article						vaccine; cancer; mimotype; mimic; carbohydrate; Lewis Y; Meth A	MELANOMA-CELL VACCINE; METH-A SARCOMA; ANTICARBOHYDRATE ANTIBODIES; CAPSULAR POLYSACCHARIDE; CONJUGATE VACCINE; INDUCE ANTIBODIES; BINDING PEPTIDES; SIALYL LEWIS(X); BREAST-CANCER; IMMUNOGENICITY	Tumor-associated carbohydrate (TAC) antigens are important targets in cancer vaccine efforts. Carbohydrates are, however, frequently poor immunogens, in that they are T-cell-independent antigens. Molecular mimicry of TAC by peptides is an alternative approach to generating anti-carbohydrate immune responses. Here we demonstrate that peptide mimotopes can elicit antibody responses that cross-react with representative human TAC antigens. Primary immunization with such a multiple antigenic peptide, along with QS-21 as adjuvant, elicits cytotoxic antibodies reactive with naturally occurring forms of TAC expressed on tumor cells, and vaccination of mice with peptide mimotopes reduced tumor growth and prolonged host survival in a murine tumor model.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute; Jefferson University	Kieber-Emmons, T (corresponding author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	tom@xray.med.upenn.edu		O-Sullivan, InSug/0000-0003-0161-2028	NIAID NIH HHS [AI 45133] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045133] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AbdelMotal UM, 1996, EUR J IMMUNOL, V26, P544, DOI 10.1002/eji.1830260307; ADLURI S, 1995, CANCER IMMUNOL IMMUN, V41, P185, DOI 10.1007/BF01521345; Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; Bohm CM, 1997, SCAND J IMMUNOL, V46, P27, DOI 10.1046/j.1365-3083.1996.d01-91.x; Chapman PB, 1995, SEMIN CANCER BIOL, V6, P367, DOI 10.1016/1044-579X(95)90006-3; Dabelsteen E, 1996, J PATHOL, V179, P358; Fehr T, 1997, J EXP MED, V185, P1785, DOI 10.1084/jem.185.10.1785; FRASSANITO MA, 1995, CANCER RES, V55, P124; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; HELLING F, 1995, CANCER RES, V55, P2783; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; Houghton AN, 1998, NAT MED, V4, P270, DOI 10.1038/nm0398-270; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; Ishikawa D, 1998, FEBS LETT, V441, P20, DOI 10.1016/S0014-5793(98)01511-7; Jiao Y, 1998, JPN J CANCER RES, V89, P657, DOI 10.1111/j.1349-7006.1998.tb03268.x; Jones RC, 1996, ANN SURG ONCOL, V3, P437, DOI 10.1007/BF02305761; KITAMURA K, 1994, P NATL ACAD SCI USA, V91, P12957, DOI 10.1073/pnas.91.26.12957; KITAMURA K, 1995, P NATL ACAD SCI USA, V92, P2805, DOI 10.1073/pnas.92.7.2805; Kudryashov V, 1998, CANCER IMMUNOL IMMUN, V45, P281, DOI 10.1007/s002620050444; Kundu N, 1996, JNCI-J NATL CANCER I, V88, P536, DOI 10.1093/jnci/88.8.536; LIVINGSTON PO, 1995, IMMUNOL REV, V145, P147, DOI 10.1111/j.1600-065X.1995.tb00080.x; Livingston PO, 1997, CANCER IMMUNOL IMMUN, V45, P1, DOI 10.1007/s002620050394; Livingston PO, 1997, CANCER IMMUNOL IMMUN, V45, P10, DOI 10.1007/s002620050395; LONGENECKER BM, 1994, ADV EXP MED BIOL, V353, P105; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MURAI H, 1985, J BIOCHEM-TOKYO, V97, P1129, DOI 10.1093/oxfordjournals.jbchem.a135157; NOGUCHI Y, 1995, P NATL ACAD SCI USA, V92, P2219, DOI 10.1073/pnas.92.6.2219; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Pincus SH, 1998, J IMMUNOL, V160, P293; Putterman C, 1998, J EXP MED, V188, P29, DOI 10.1084/jem.188.1.29; Qiu JP, 1999, HYBRIDOMA, V18, P103, DOI 10.1089/hyb.1999.18.103; Ravindranath MH, 1997, CANCER, V79, P1686, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1686::AID-CNCR8>3.0.CO;2-A; Ravindranath MH, 1998, INT J CANCER, V75, P117, DOI 10.1002/(SICI)1097-0215(19980105)75:1<117::AID-IJC18>3.0.CO;2-D; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; STEPLEWSKI Z, 1991, In Vivo (Attiki), V5, P79; Taki T, 1997, FEBS LETT, V418, P219, DOI 10.1016/S0014-5793(97)01386-0; Tsuyuoka K, 1996, J IMMUNOL, V157, P661; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; Zhang HL, 1997, INFECT IMMUN, V65, P1158, DOI 10.1128/IAI.65.4.1158-1164.1997; ZHANG SL, 1995, CANCER RES, V55, P3364; Zhang SL, 1997, INT J CANCER, V73, P50, DOI 10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.3.CO;2-O	46	100	106	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					660	665		10.1038/10870	http://dx.doi.org/10.1038/10870			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404158				2022-12-25	WOS:000081296900025
J	Gouka, RJ; Gerk, C; Hooykaas, PJJ; Bundock, P; Musters, W; Verrips, CT; de Groot, MJA				Gouka, RJ; Gerk, C; Hooykaas, PJJ; Bundock, P; Musters, W; Verrips, CT; de Groot, MJA			Transformation of Aspergillus awamori by Agrobacterium tumefaciens-mediated homologous recombination	NATURE BIOTECHNOLOGY			English	Article						targeting; integration; cutinase; titration	HETEROLOGOUS PROTEIN-PRODUCTION; FUSARIUM-SOLANI-PISI; INTACT YEAST-CELLS; FILAMENTOUS FUNGI; EXPRESSION SYSTEM; ESCHERICHIA-COLI; MULTIPLE COPIES; GENE; STRAINS; NIGER	Agrobacterium tumefaciens is known to transfer part of its tumor-inducing (Ti) plasmid to the filamentous fungus Aspergillus awamori by illegitimate recombination with the fungal genome. Here, we show that when this Ti DNA shares homology with the A. awamori genome, integration can also occur by homologous recombination, On the basis of this finding, we have developed an efficient method for constructing recombinant mold strains free from bacterial DNA by A. tumefaciens-mediated transformation. Multiple copies of a gene can be integrated rapidly at a predetermined locus in the genome, yielding transformants free of bacterial antibiotic resistance genes or other foreign DNA. Recombinant A. awamori strains were constructed containing up to nine copies of a Fusarium solani pisi cutinase expression cassette integrated in tandem at the pyrG locus. This allowed us to study how mRNA and protein levels are affected by gene copy number, without the influence of chromosomal environmental effects. Cutinase mRNA and protein were maximal with four gene copies, indicating a limitation at the transcriptional level. This transformation system will potentially stimulate market acceptance of derived products by avoiding introduction of bacterial and other foreign DNA into the fungi.	Unilever Res Labs Vlaardingen, NL-3133 AT Vlaardingen, Netherlands; Leiden Univ, Inst Mol Plant Sci, Glusius Lab, NL-2333 AL Leiden, Netherlands	Unilever; Leiden University; Leiden University - Excl LUMC	Gouka, RJ (corresponding author), Unilever Res Labs Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen, Netherlands.	robin.gouka@unilever.com	Hooykaas, Paul JJ/S-4256-2017	Hooykaas, Paul JJ/0000-0002-9736-6927; Musters, C.J.M./0000-0003-1321-6786				Archer DB, 1997, CRIT REV BIOTECHNOL, V17, P273, DOI 10.3109/07388559709146616; ARCHER DB, 1994, ANTON LEEUW INT J G, V65, P245, DOI 10.1007/BF00871952; BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; Bennett J. W., 1991, MORE GENE MANIPULATI, P441; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; DEBLOCK M, 1993, EUPHYTICA, V71, P1, DOI 10.1007/BF00023461; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gouka RJ, 1996, APPL MICROBIOL BIOT, V46, P28, DOI 10.1007/s002530050779; GOUKA RJ, 1995, CURR GENET, V27, P536, DOI 10.1007/BF00314444; Gouka RJ, 1997, APPL MICROBIOL BIOT, V47, P1, DOI 10.1007/s002530050880; Gouka RJ, 1996, APPL ENVIRON MICROB, V62, P1951, DOI 10.1128/AEM.62.6.1951-1957.1996; GWYNNE DI, 1989, BIOCHEM SOC T, V17, P338, DOI 10.1042/bst0170338; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOOYKAAS PJJ, 1979, J GEN MICROBIOL, V110, P99, DOI 10.1099/00221287-110-1-99; KOLAR M, 1988, GENE, V62, P127, DOI 10.1016/0378-1119(88)90586-0; KUBICEKPRANZ EM, 1991, J BIOTECHNOL, V20, P83, DOI 10.1016/0168-1656(91)90037-V; LOWE DA, 1992, HDB APPL MYCOLOGY FU, P681; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; MOZO T, 1991, PLANT MOL BIOL, V16, P917, DOI 10.1007/BF00015085; OFFRINGA R, 1992, THESIS LEIDEN U LEID; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Timberlake WE., 1991, MORE GENE MANIPULATI, P51; VANDENHONDEL CAM, 1991, APPLIED MOL GENETICS, P1; VANDENHONDEL CAMJJ, 1992, ANTON LEEUW INT J G, V61, P153, DOI 10.1007/BF00580623; VANGEMEREN IA, 1995, J BIOTECHNOL, V40, P155, DOI 10.1016/0168-1656(95)00041-N; vanGemeren IA, 1996, APPL MICROBIOL BIOT, V45, P755, DOI 10.1007/s002530050759; VERDOES JC, 1994, GENE, V145, P179, DOI 10.1016/0378-1119(94)90003-5; VERDOES JC, 1993, TRANSGENIC RES, V2, P84, DOI 10.1007/BF01969381; VERDOES JC, 1995, APPL MICROBIOL BIOT, V43, P195, DOI 10.1007/s002530050390; WARD M, 1989, EXP MYCOL, V13, P289, DOI 10.1016/0147-5975(89)90050-9	31	116	148	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					598	601		10.1038/9915	http://dx.doi.org/10.1038/9915			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385327				2022-12-25	WOS:000080716500034
J	Hughes, AE; Ralston, SH; Marken, J; Bell, C; MacPherson, H; Wallace, RGH; van Hul, W; Whyte, MP; Nakatsuka, K; Hovy, L; Anderson, DM				Hughes, AE; Ralston, SH; Marken, J; Bell, C; MacPherson, H; Wallace, RGH; van Hul, W; Whyte, MP; Nakatsuka, K; Hovy, L; Anderson, DM			Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis	NATURE GENETICS			English	Article							CHROMOSOME 18Q	Familial expansile osteolysis(1,2) (FEO, MIM 174810) is a rare, autosomal dominant bone disorder characterized by focal areas of increased bone remodelling. The osteolytic lesions, which develop usually in the long bones during early adulthood, show increased osteoblast and osteoclast activity. Our previous linkage studies mapped the gene responsible for FEO to an interval of less than 5 cM between D18564 and D18551 on chromosome 18q21.2-21.3 in a large Northern Irish family(3,4). The gene encoding receptor activator of nuclear factor-kappa B (RANK; ref. 5), TNFRSF11A, maps to this region. RANK is essential in osteoclast formation(6,7). We identified two heterozygous insertion mutations in exon 1 of TNFRSF11A in affected members of four families with FEO or familial Paget disease of bone (PDB). One was a duplication of 18 bases and the other a duplication of 27 bases, both of which affected the signal peptide region of the RANK molecule. Expression of recombinant forms of the mutant RANK proteins revealed perturbations in expression levels and lack of normal cleavage of the signal peptide. Both mutations caused an increase in RANK-mediated nuclear factor-kappa B (NF-kappa B) signalling in vitro, consistent with the presence of an activating mutation.	Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland; Immunex Res & Dev Corp, Dept Mol Biol, Seattle, WA 98101 USA; Musgrave Pk Hosp, Dept Orthopaed Surg, Belfast, Antrim, North Ireland; Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO USA; Osaka City Hosp, Dept Internal Med 2, Osaka, Japan; Univ Frankfurt, Orthopad Klin, Frankfurt, Germany	Queens University Belfast; University of Aberdeen; University of Antwerp; Washington University (WUSTL); Osaka City General Hospital; Goethe University Frankfurt	Hughes, AE (corresponding author), Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland.		Hughes, Anne/A-1307-2012	Van Hul, Wim/0000-0002-5065-7858				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ENDERLE A, 1979, ARCH ORTHOP TRAUM SU, V94, P127, DOI 10.1007/BF00433578; Haslam SI, 1998, J BONE MINER RES, V13, P911, DOI 10.1359/jbmr.1998.13.6.911; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; HUGHES AE, 1994, HUM MOL GENET, V3, P359, DOI 10.1093/hmg/3.2.359; HUGHES AE, 1996, MOL BIOL PAGETS DIS, P179; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; Ogilvie D J, 1996, Methods Mol Biol, V54, P131; OSTERBERG PH, 1988, J BONE JOINT SURG BR, V70, P255, DOI 10.1302/0301-620X.70B2.3346299; OSTERBERG PH, 1976, BONE DIS CALCITONIN, P185; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	14	368	383	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					45	48		10.1038/71667	http://dx.doi.org/10.1038/71667			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615125	Green Published			2022-12-25	WOS:000084609200013
J	Ogawa, T; Dobrinski, I; Avarbock, MR; Brinster, RL				Ogawa, T; Dobrinski, I; Avarbock, MR; Brinster, RL			Transplantation of male germ line stem cells restores fertility in infertile mice	NATURE MEDICINE			English	Article							TYROSINE KINASE RECEPTOR; C-KIT PROTOONCOGENE; GROWTH-FACTOR; SI-LOCUS; W-LOCUS; SPERMATOGONIAL TRANSPLANTATION; HEREDITARY ANEMIAS; PROTO-ONCOGENE; MUTANT MICE; MOUSE	Azoospermia or oligozoospermia due to disruption of spermatogenesis are common causes of human male infertility. We used the technique of spermatogonial transplantation in two infertile mouse strains, Steel (SI) and dominant white spotting (W), to determine if stem cells from an infertile male were capable of generating spermatogenesis. Transplantation of germ cells from infertile SI/SId mutant male mice to infertile W/W-v or W-v/W-54 mutant male mice restored fertility to the recipient mice. Thus, transplantation of spermatogonial stem cells from an infertile donor to a permissive testicular environment can restore fertility and result in progeny with the genetic makeup of the infertile donor male.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Penn, New Bolton Ctr, Sch Vet Med, Dept Clin Studies, Kennett Square, PA 19348 USA	University of Pennsylvania; Yokohama City University; University of Pennsylvania	Brinster, RL (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3850 Baltimore Ave, Philadelphia, PA 19104 USA.		Dobrinski, Ina/A-1095-2007	Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [R01 HD036504, HD 36504] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avarbock MR, 1996, NAT MED, V2, P693, DOI 10.1038/nm0696-693; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BERNSTEIN SE, 1970, AM J SURG, V119, P448, DOI 10.1016/0002-9610(70)90148-0; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Clouthier DE, 1996, NATURE, V381, P418, DOI 10.1038/381418a0; Dirami G, 1999, BIOL REPROD, V61, P225, DOI 10.1095/biolreprod61.1.225; Dobrinski I, 1999, BIOL REPROD, V61, P1331, DOI 10.1095/biolreprod61.5.1331; Dobrinski I, 1999, MOL REPROD DEV, V53, P142, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;142::AID-MRD3&gt;3.0.CO;2-O; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREENBERG SH, 1978, J UROLOGY, V119, P507, DOI 10.1016/S0022-5347(17)57531-X; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUSZAR D, 1991, DEVELOPMENT, V112, P131; Jiang FX, 1995, INT J ANDROL, V18, P326, DOI 10.1111/j.1365-2605.1995.tb00570.x; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MARTINDUPAN RC, 1993, FERTIL STERIL, V60, P937; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCOSHEN JA, 1975, EXPERIENTIA, V31, P589, DOI 10.1007/BF01932475; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; NAKAYAMA H, 1988, DEVELOPMENT, V102, P117; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ogawa T, 1999, TISSUE CELL, V31, P461, DOI 10.1054/tice.1999.0060; Ogawa T, 1998, TISSUE CELL, V30, P583, DOI 10.1016/S0040-8166(98)80039-6; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Ogawa T, 1999, BIOL REPROD, V60, P515, DOI 10.1095/biolreprod60.2.515; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1959, JNCI-J NATL CANCER I, V23, P557; Russell LD, 1996, J ANDROL, V17, P603; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; Schlatt S, 1999, HUM REPROD, V14, P144, DOI 10.1093/humrep/14.1.144; Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504; Sigman M, 1997, INFERTILITY MALE, P173; SILBER SJ, 1995, HUM REPROD, V10, P503, DOI 10.1093/oxfordjournals.humrep.a135977; Silvers W.K., 1979, COAT COLORS MICE, P206; SORRENTINO V, 1991, ONCOGENE, V6, P149; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	45	251	278	2	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					29	34		10.1038/71496	http://dx.doi.org/10.1038/71496			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613820	Green Accepted			2022-12-25	WOS:000084583300031
J	Stockton, DW; Das, P; Goldenberg, M; D'Souza, RN; Patel, PI				Stockton, DW; Das, P; Goldenberg, M; D'Souza, RN; Patel, PI			Mutation of PAX9 is associated with oligodontia	NATURE GENETICS			English	Article							GENES; MSX1		Univ Texas, Hlth Sci Ctr, Dent Branch, Houston, TX 77225 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Patel, PI (corresponding author), Univ Texas, Hlth Sci Ctr, Dent Branch, Houston, TX 77225 USA.		Patel, Pragna/H-9129-2017	Patel, Pragna/0000-0003-3584-1072; D'Souza, Rena/0000-0002-1505-5173	NEI NIH HHS [EY00375] Funding Source: Medline; NIDCR NIH HHS [DE13368, DE11663] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011663, R01DE013368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Gorlin RJ, 1990, PLAST RECONSTR SURG; GRABER LW, 1978, J AM DENT ASSOC, V96, P266, DOI 10.14219/jada.archive.1978.0054; JORGENSON RJ, 1980, J AM DENT ASSOC, V101, P283, DOI 10.14219/jada.archive.1980.0186; NIEMINEN P, 1995, HUM GENET, V96, P305; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; SEMENZA GL, 1998, PAX PROTEINS, P169; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; Vastardis H, 1996, NAT GENET, V13, P417, DOI 10.1038/ng0896-417; VASTARDIS H, 1996, THESIS HARVARD U	9	371	393	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					18	19		10.1038/71634	http://dx.doi.org/10.1038/71634			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615120				2022-12-25	WOS:000084609200009
J	Li, YP; Chen, W; Liang, YQ; Li, E; Stashenko, P				Li, YP; Chen, W; Liang, YQ; Li, E; Stashenko, P			Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification	NATURE GENETICS			English	Article							PROTON PUMP; RESORPTION; CELLS; PH	Solubilization of bone mineral by osteoclasts depends on the formation of an acidic extracellular compartment through the action of a V-proton pump that has not yet been characterized at the molecular level(1-3). We previously cloned a gene (Atp6i, for V-proton pump, H+ transporting (vacuolar proton pump) member I) encoding a putative osteoclast-specific proton pump subunit, termed OC-116kD (ref, 4), Here we show that targeted disruption of Atp6i in mice results in severe osteopetrosis. Atp6i(-/-) osteoclast-like cells (OCLs) lose the function of extracellular acidification, but retain intracellular lysosomal proton pump activity. The pH in Atp6i(-/-) liver lysosomes and proton transport in microsomes of Atp6i(-/-) kidney are identical to that in wild-type mice. Atp6i(-/-) mice exhibit a normal acid-base balance in blood and urine. Our results demonstrate that Atp6i is unique and necessary for osteoclast-mediated extracellular acidification.	Forsyth Inst, Dept Cytokine Biol, Boston, MA USA; Harvard Univ, Forsyth Inst, Forsyth Dept Oral Biol, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr,Dept Med, Charlestown, MA USA	Harvard University; Forsyth Institute; Harvard University; Forsyth Institute; Harvard School of Dental Medicine; Harvard University; Harvard School of Dental Medicine; Harvard University; Massachusetts General Hospital	Li, YP (corresponding author), Forsyth Inst, Dept Cytokine Biol, Boston, MA USA.	ypli@forsyth.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007378] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44741] Funding Source: Medline; NIDCR NIH HHS [DE-07378] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Blair Harry C., 1992, P259; Chen W, 1998, J BONE MINER RES, V13, P1112, DOI 10.1359/jbmr.1998.13.7.1112; DAVID P, 1994, J BIOL CHEM, V269, P30158; GERRITSEN EJA, 1994, PEDIATRICS, V93, P247; Horton W. A., 1990, GROWTH GENET HORM, V6, P1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; SHIBUTANI T, 1993, J BONE MINER RES, V8, P331; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAMURA T, 1993, J BONE MINER RES, V8, P953; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VAES G, 1968, J CELL BIOL, V39, P676, DOI 10.1083/jcb.39.3.676; WANG SJ, 1992, J OPT SOC AM B, V9, P360, DOI 10.1364/JOSAB.9.000360; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	20	386	402	2	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					447	451		10.1038/70563	http://dx.doi.org/10.1038/70563			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581033				2022-12-25	WOS:000084023900022
J	Ko, S; Deiwick, A; Jager, MD; Dinkel, A; Rohde, F; Fischer, R; Tsui, TY; Rittmann, KL; Wonigeit, K; Schlitt, HJ				Ko, S; Deiwick, A; Jager, MD; Dinkel, A; Rohde, F; Fischer, R; Tsui, TY; Rittmann, KL; Wonigeit, K; Schlitt, HJ			The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat	NATURE MEDICINE			English	Article							DONOR-TYPE MICROCHIMERISM; BONE-MARROW; TRANSPLANTATION TOLERANCE; ORGAN-TRANSPLANTATION; ALLOGENEIC MICROCHIMERISM; LIVER-TRANSPLANTATION; CARDIAC ALLOGRAFTS; CHRONIC REJECTION; QUANTITATIVE PCR; GRAFT ACCEPTANCE	With an organ transplant, hematopoietic donor cells are transferred to the recipient. To study the relevance of the resulting microchimerism for allograft acceptance, we analyzed a rat model of cyclosporine-induced tolerance for strongly incompatible heart allografts. Using a monoclonal antibody that detects a donor-specific CD45 allotype (RT7(a)), we selectively depleted donor leukocytes at different times after transplantation (days 0 or 18). Depletion was similarly effective at both times. However, only depletion on day 0 prevented tolerance induction and was associated with severe acute or chronic graft rejection. This indicates that passenger leukocytes have an essential immunomodulatory effect on the induction phase of allograft acceptance.	Med Hsch Hannover, Viszeral & Transplantat Chirurg Klin, D-30623 Hannover, Germany	Hannover Medical School	Schlitt, HJ (corresponding author), Med Hsch Hannover, Viszeral & Transplantat Chirurg Klin, Carl-Neuberg Str 1, D-30623 Hannover, Germany.		Schlitt, Hans J./ABG-4368-2020					Demetris AJ, 1997, AM J PATHOL, V150, P563; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; Ehl S, 1998, NAT MED, V4, P1015, DOI 10.1038/2001; Heidecke CD, 1996, TRANSPLANTATION, V61, P948, DOI 10.1097/00007890-199603270-00018; Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; KAMPINGA J, 1990, SCAND J IMMUNOL, V31, P699, DOI 10.1111/j.1365-3083.1990.tb02821.x; Khan A, 1996, TRANSPLANTATION, V62, P380, DOI 10.1097/00007890-199608150-00014; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; Lombardi G, 1996, J IMMUNOL, V156, P2769; McSherry C, 1996, TRANSPLANTATION, V62, P1811, DOI 10.1097/00007890-199612270-00023; Murase N, 1997, TRANSPLANTATION, V63, P1840, DOI 10.1097/00007890-199706270-00024; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Raddatz G, 1998, IMMUNOLOGY, V94, P101; Santin AD, 1998, INT J RADIAT BIOL, V73, P699, DOI 10.1080/095530098141951; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P1001, DOI 10.1097/00007890-199310000-00042; Schlitt HJ, 1997, TRANSPL P, V29, P82, DOI 10.1016/S0041-1345(96)00016-4; Schmid C, 1996, TRANSPLANTATION, V61, P1695, DOI 10.1097/00007890-199606270-00005; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SCHWINZER R, 1989, EUR J IMMUNOL, V19, P1841, DOI 10.1002/eji.1830191013; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIEGLING A, 1994, J IMMUNOL METHODS, V177, P23, DOI 10.1016/0022-1759(94)90139-2; SRIWATANAWONGSA V, 1995, NAT MED, V1, P428, DOI 10.1038/nm0595-428; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; Starzl TE, 1998, NEW ENGL J MED, V339, P1905, DOI 10.1056/NEJM199812243392607; Strehlau J, 1996, CLIN NEPHROL, V46, P30; SUN JH, 1995, TRANSPLANTATION, V60, P233, DOI 10.1097/00007890-199508000-00004; THOMAS JM, 1994, TRANSPLANTATION, V57, P101, DOI 10.1097/00007890-199401000-00018; THOMAS JM, 1994, CLIN TRANSPLANT, V8, P195; TOMITA Y, 1994, J IMMUNOL, V153, P1087; TSUI TY, IN PRESS TRANSPLANTA; Ueda M, 1997, CLIN TRANSPLANT, V11, P193; WONIGEIT K, 1979, TRANSPLANT P, V11, P1631; Wood K, 1996, IMMUNOL TODAY, V17, P584, DOI 10.1016/S0167-5699(96)10069-4; Wood PJ, 1996, TRANSPLANTATION, V61, P1440, DOI 10.1097/00007890-199605270-00003	40	112	113	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1292	1297		10.1038/15248	http://dx.doi.org/10.1038/15248			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545996				2022-12-25	WOS:000086550600040
J	Utomo, ARH; Nikitin, AY; Lee, WH				Utomo, ARH; Nikitin, AY; Lee, WH			Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						conditional gene regulation; Cre recombinase; mammary gland; tetracycline-controlled transactivator; whey acidic protein	SITE-SPECIFIC RECOMBINATION; TETRACYCLINE-RESPONSIVE PROMOTER; GENE-EXPRESSION; MAMMALIAN-CELLS; RETINOBLASTOMA GENE; IN-VIVO; SOMATIC MUTAGENESIS; MAMMARY-GLAND; PROTEIN GENE; MOUSE	We have developed a universal system for temporal, spatial, and cell type-specific control of gene expression in mice that (1) integrates the advantages of tetracycline-controlled gene expression and Cre-recombinase-loxP site-mediated gene inactivation, and (2) simplifies schemes of animal crosses by combination of two control elements in a single transgene. Two transgenic strains were generated in which the cell type-specific control was provided by either the retinoblastoma gene promoter or the whey acidic protein promoter. Both promoters drive the expression of the reverse tetracycline-controlled transactivator (rtTA). Placed in cis configuration to the rtTA transcription unit, the rtTA-inducible promoter directs expression of ore recombinase. In both strains crossed with cActXstopXLacZ reporter mice, which have a loxP-stop of transcription/translation-loxP-LacZ cassette driven by chicken beta-actin promoter, Cre-loxP-mediated DNA recombination leading to LacZ expression was accurately regulated in a temporal, spatial, and cell type-specific manner. This approach can be applied to establishment of analogous mouse strains with virtually any promoter as systems to control gene regulation in a variety of cell types.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	leew@uthscsa.edu	Utomo, Ahmad Rusdan H/GPW-8717-2022; Utomo, Ahmad/AAO-5605-2020; utomo, ahmad/CAF-9546-2022; Utomo, Ahmad Rusdan Handoyo/CAJ-0570-2022	Utomo, Ahmad Rusdan H/0000-0003-3092-3714; 	NCI NIH HHS [CA58318] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		A-Mohammadi S, 1998, GENE THER, V5, P76, DOI 10.1038/sj.gt.3300557; Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; ALALI W, 1989, J PERIODONTOL, V60, P582, DOI 10.1902/jop.1989.60.10.582; Anderson WF, 1998, NATURE, V392, P25; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; BOCKER R, 1984, ARZNEIMITTEL-FORSCH, V34-1, P446; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brocard J, 1997, P NATL ACAD SCI USA, V94, P14559, DOI 10.1073/pnas.94.26.14559; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; ChrastBalz J, 1996, NUCLEIC ACIDS RES, V24, P2900, DOI 10.1093/nar/24.15.2900; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; DRYNECKI SM, 1996, P NATL ACAD SCI USA, V93, P6191; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOLUB LM, 1990, J PERIODONTAL RES, V25, P321, DOI 10.1111/j.1600-0765.1990.tb00923.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Kafri T, 1998, P NATL ACAD SCI USA, V95, P11377, DOI 10.1073/pnas.95.19.11377; Kellendonk C, 1996, NUCLEIC ACIDS RES, V24, P1404, DOI 10.1093/nar/24.8.1404; Kellendonk C, 1999, J MOL BIOL, V285, P175, DOI 10.1006/jmbi.1998.2307; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LARSEN T, 1990, J PERIODONTOL, V61, P30, DOI 10.1902/jop.1990.61.1.30; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; NIKITIN AY, 1993, VIRCHOWS ARCH B, V64, P151, DOI 10.1007/BF02915108; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; Porter A, 1998, TRENDS GENET, V14, P73, DOI 10.1016/S0168-9525(97)01326-7; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; Schwenk F, 1998, NUCLEIC ACIDS RES, V26, P1427, DOI 10.1093/nar/26.6.1427; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SORLANO P, 1999, NAT GENET, V21, P70; StOnge L, 1996, NUCLEIC ACIDS RES, V24, P3875, DOI 10.1093/nar/24.19.3875; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; WEBSTER GF, 1994, ARCH DERMATOL, V130, P748, DOI 10.1001/archderm.130.6.748; WIVAGG RT, 1976, J PHARM SCI, V65, P916, DOI 10.1002/jps.2600650630; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; Zinyk DL, 1998, CURR BIOL, V8, P665, DOI 10.1016/S0960-9822(98)70255-6	64	165	180	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1091	1096		10.1038/15073	http://dx.doi.org/10.1038/15073			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545915				2022-12-25	WOS:000083428000026
J	Brower, V				Brower, V			Tumor angiogenesis - new drugs on the block	NATURE BIOTECHNOLOGY			English	Article								Angiogenesis inhibitors could represent a powerful adjunct to traditional cancer treatments, but the most effective routes for therapeutic intervention remain unclear.										Augustin HG, 1998, TRENDS PHARMACOL SCI, V19, P216, DOI 10.1016/S0165-6147(98)01211-5; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645	6	127	159	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					963	968		10.1038/13654	http://dx.doi.org/10.1038/13654			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504695				2022-12-25	WOS:000083015700019
J	Frasson, M; Sahel, JA; Fabre, M; Simonutti, M; Dreyfus, H; Picaud, S				Frasson, M; Sahel, JA; Fabre, M; Simonutti, M; Dreyfus, H; Picaud, S			Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse	NATURE MEDICINE			English	Article							RETINAL-DEGENERATION; CYCLIC-GMP; OUTER-SEGMENT; CONE SURVIVAL; BETA-SUBUNIT; CELLS; DILTIAZEM; PHOSPHODIESTERASE; CONDUCTANCE; TRANSPLANTS	Retinitis pigmentosa is an inherited degenerative disease of photoreceptors leading to blindness. A well-characterized model for this disease is provided by the retinal degeneration mouse, in which the gene for the rod cGMP phosphodiesterase is mutated, as in some affected human families. We report that D-cis-diltiazem, a calcium-channel blocker that also acts at light-sensitive cGMP-gated channels, rescued photoreceptors and preserved visual function in the retinal degeneration mouse. The long record of diltiazem prescription in cardiology should facilitate the design of clinical trials for some forms of retinitis pigmentosa.	Univ Strasbourg 1, Lab Physiopathol Retinienne, F-67091 Strasbourg, France; Univ Strasbourg 1, Lab Physiopathol Cellulaire & Mol Retine, F-67091 Strasbourg, France; Univ Strasbourg 1, Inst Histol, F-67091 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Picaud, S (corresponding author), Univ Strasbourg 1, Lab Physiopathol Retinienne, BP 426,1 Pl Hop, F-67091 Strasbourg, France.		Picaud, Serge/H-4012-2014; Sahel, Jose-Alain/F-3172-2017	Picaud, Serge/0000-0002-0548-5145; Sahel, Jose-Alain/0000-0002-4831-1153				Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BUCKLEY MMT, 1990, DRUGS, V39, P757, DOI 10.2165/00003495-199039050-00009; BUDAVARI S, 1996, MERCK INDEX, P451; COBBS WH, 1985, NATURE, V313, P585, DOI 10.1038/313585a0; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1994, PROG RETIN EYE RES, V13, P31, DOI 10.1016/1350-9462(94)90004-3; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOURAS P, 1994, INVEST OPHTH VIS SCI, V35, P3145; HARMAN JG, 1996, GOODMAN GILMANS PHAR; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; KOCH KW, 1985, J BIOL CHEM, V260, P6788; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; LOLLEY RN, 1977, SCIENCE, V196, P664, DOI 10.1126/science.193183; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357; MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027; NOELL WK, 1958, ARCH OPHTHALMOL-CHIC, V60, P702; PEACHEY NS, 1993, NEUROSCI LETT, V162, P9, DOI 10.1016/0304-3940(93)90547-X; SAHLY I, 1992, P NATL ACAD SCI USA, V89, P435, DOI 10.1073/pnas.89.1.435; Schmitz Y, 1997, NEUROSCIENCE, V78, P1209, DOI 10.1016/S0306-4522(96)00678-1; SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; ULSHAFER RJ, 1980, INVEST OPHTH VIS SCI, V19, P1326; Yu WP, 1996, FEBS LETT, V393, P211, DOI 10.1016/0014-5793(96)00889-7	28	191	200	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1183	1187		10.1038/13508	http://dx.doi.org/10.1038/13508			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502823				2022-12-25	WOS:000082933200046
J	Fray, RG; Throup, JP; Daykin, M; Wallace, A; Williams, P; Stewart, GSAB; Grierson, D				Fray, RG; Throup, JP; Daykin, M; Wallace, A; Williams, P; Stewart, GSAB; Grierson, D			Plants genetically modified to produce N-acylhomoserine lactones communicate with bacteria	NATURE BIOTECHNOLOGY			English	Article						N-acylhomoserine lactones; plant/microbe interactions; biocontrol; rhizosphere	CARBAPENEM ANTIBIOTIC PRODUCTION; ERWINIA-CAROTOVORA; HOMOSERINE LACTONE; PSEUDOMONAS-AERUGINOSA; SIGNAL MOLECULES; GENE-EXPRESSION; LUXI FAMILY; QUORUM; AUTOINDUCER; TRANSFORMATION	N-acylhomoserine lactones (AHLs) play a critical role in plant/microbe interactions, The AHL, N-(3-oxohexanoyl)-1-homoserine lactone (OHHL), induces exoenzymes that degrade the plant cell wall by the pathogenic bacterium Erwinia carotovora. Conversely, the antifungal activity of the biocontrol bacterium Pseudomonas aureofaciens 30-84 is due (at least in part) to phenazine antibiotics whose synthesis is regulated by N-hexanoylhomoserine lactone (HHL). Targeting the product of an AHL synthase gene (yen1) from Yersinia enterocolitica to the chloroplasts of transgenic tobacco plants caused the synthesis in plants of the cognate AHL signaling molecules (OHHL and HHL). The AHLs produced by the transgenic plants were sufficient to induce target gene expression in several recombinant bacterial AHL biosensors and to restore biocontrol activity to an HHL-deficient P. aureofaciens strain. In addition, pathogenicity was restored to an E. carotovora strain rendered avirulent as a consequence of a mutation in the OHHL synthase gene, carl. The ability to generate bacterial quorum-sensing signaling molecules in the plant offers novel opportunities for disease control and for manipulating plant/microbe interactions.	Univ Nottingham, Sch Biol Sci, Loughborough LE12 5RD, Leics, England; Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Fray, RG (corresponding author), Univ Nottingham, Sch Biol Sci, Loughborough LE12 5RD, Leics, England.		Williams, Paul/P-5224-2019; Fray, Rupert G/A-9059-2016; Williams, Paul/A-5629-2011	Williams, Paul/0000-0002-1920-5036; Fray, Rupert G/0000-0002-3935-8945; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAINTON NJ, 1992, BIOCHEM J, V288, P997, DOI 10.1042/bj2880997; BECKER JO, 1993, PESTIC SCI, V37, P355, DOI 10.1002/ps.2780370408; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Camara M, 1998, METHOD MICROBIOL, V27, P319; Chernin LS, 1998, J BACTERIOL, V180, P4435, DOI 10.1128/JB.180.17.4435-4441.1998; DATLA RSS, 1993, PLANT SCI, V94, P139, DOI 10.1016/0168-9452(93)90015-R; DEAN C, 1987, MOL GEN GENET, V206, P465, DOI 10.1007/BF00428887; Draper J., 1988, PLANT GENETIC TRANSF, P69; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Gray KM, 1996, J BACTERIOL, V178, P372, DOI 10.1128/jb.178.2.372-376.1996; Jiang Y, 1998, MOL MICROBIOL, V28, P193, DOI 10.1046/j.1365-2958.1998.00789.x; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; PALVA TK, 1994, MOL PLANT MICROBE IN, V7, P356, DOI 10.1094/MPMI-7-0356; PEROMBELON MCM, 1980, ANNU REV PHYTOPATHOL, V18, P361, DOI 10.1146/annurev.py.18.090180.002045; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; SALMOND GPC, 1995, MOL MICROBIOL, V16, P615, DOI 10.1111/j.1365-2958.1995.tb02424.x; Schripsema J, 1996, J BACTERIOL, V178, P366, DOI 10.1128/jb.178.2.366-371.1996; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; SWIFT S, 1993, MOL MICROBIOL, V10, P511, DOI 10.1111/j.1365-2958.1993.tb00923.x; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; THROUP JP, 1995, MOL MICROBIOL, V17, P345, DOI 10.1111/j.1365-2958.1995.mmi_17020345.x; Toyota K, 1997, BIOL FERT SOILS, V25, P416, DOI 10.1007/s003740050334; Val DL, 1998, J BACTERIOL, V180, P2644, DOI 10.1128/JB.180.10.2644-2651.1998; Winson MK, 1998, FEMS MICROBIOL LETT, V163, P185, DOI 10.1111/j.1574-6968.1998.tb13044.x; Wood DW, 1996, GENE, V168, P49, DOI 10.1016/0378-1119(95)00754-7; Wood DW, 1997, J BACTERIOL, V179, P7663, DOI 10.1128/jb.179.24.7663-7670.1997	30	93	108	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1017	1020		10.1038/13717	http://dx.doi.org/10.1038/13717			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504705				2022-12-25	WOS:000083015700030
J	Gygi, SP; Rist, B; Gerber, SA; Turecek, F; Gelb, MH; Aebersold, R				Gygi, SP; Rist, B; Gerber, SA; Turecek, F; Gelb, MH; Aebersold, R			Quantitative analysis of complex protein mixtures using isotope-coded affinity tags	NATURE BIOTECHNOLOGY			English	Article						gene expression; functional genomics; proteomics; protein profiling; mass spectrometry	MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; IDENTIFICATION; DATABASE; SEQUENCES; PEPTIDES; GENOME; SCALE	We describe an approach for the accurate quantification and concurrent sequence identification of the individual proteins within complex mixtures. The method is based on a class of new chemical reagents termed isotope-coded affinity tags (ICATs) and tandem mass spectrometry. Using this strategy, we compared protein expression in the yeast Saccharomyces cerevisiae, using either ethanol or galactose as a carbon source. The measured differences in protein expression correlated with known yeast metabolic function under glucose-repressed conditions. The method is redundant if multiple cysteinyl residues are present, and the relative quantification is highly accurate because it is based on stable isotope dilution techniques. The ICAT approach should provide a widely applicable means to compare quantitatively global protein expression in cells and tissues.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Aebersold, R (corresponding author), Univ Washington, Dept Mol Biotechnol, Box 357730, Seattle, WA 98195 USA.	ruedi@u.washington.edu		Gerber, Scott/0000-0002-2964-5051; gelb, michael/0000-0001-7000-5219	NCRR NIH HHS [RR11823] Funding Source: Medline; NHGRI NIH HHS [T32HG00035] Funding Source: Medline; NICHD NIH HHS [HD-02274] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002274] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000035] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BLEASBY AJ, 1994, NUCLEIC ACIDS RES, V22, P3574; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; DELEENHEER AP, 1992, MASS SPECTROM REV, V11, P249, DOI 10.1002/mas.1280110402; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Figeys D, 1998, ELECTROPHORESIS, V19, P1811, DOI 10.1002/elps.1150191045; Garrels JI, 1997, ELECTROPHORESIS, V18, P1347, DOI 10.1002/elps.1150180810; Gerber SA, 1999, J AM CHEM SOC, V121, P1102, DOI 10.1021/ja982878k; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; Qin J, 1997, ANAL CHEM, V69, P3995, DOI 10.1021/ac970488v; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	24	3911	4305	10	614	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					994	999		10.1038/13690	http://dx.doi.org/10.1038/13690			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504701				2022-12-25	WOS:000083015700026
J	Huang, Q; Shan, SQ; Braun, RD; Lanzen, J; Anyrhambatla, G; Kong, GH; Borelli, M; Corry, P; Dewhirst, MW; Li, CY				Huang, Q; Shan, SQ; Braun, RD; Lanzen, J; Anyrhambatla, G; Kong, GH; Borelli, M; Corry, P; Dewhirst, MW; Li, CY			Noninvasive visualization of tumors in rodent dorsal skin window chambers - A novel model for evaluating anti-cancer therapies.	NATURE BIOTECHNOLOGY			English	Editorial Material							MICROVASCULAR PERMEABILITY; STEALTH LIPOSOMES; GROWTH; ANGIOGENESIS; VASCULARIZATION; MICROVESSELS; EXPRESSION; INHIBITION; PROTEIN; INVITRO		Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48073 USA	Duke University; Beaumont Health	Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.		Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; 	NATIONAL CANCER INSTITUTE [P01CA042745, R01CA040355] Funding Source: NIH RePORTER; NCI NIH HHS [CA40355, CA42745] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGIRE GH, 1949, J NATL CANCER I, V10, P225; ANDRADE SP, 1987, BRIT J EXP PATHOL, V68, P755; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DEWHIRST M, 1984, BIORHEOLOGY, V21, P539; DEWHIRST M, 1995, STEALTH LIPOSOMES; Fong TAT, 1999, CANCER RES, V59, P99; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GABBIANI G, 1984, J CELL SCI, V66, P39; GREVER M, 1997, CANC PRINCIPLES PRAC, V1, P385; GROSS J, 1981, P NATL ACAD SCI-BIOL, V78, P1176, DOI 10.1073/pnas.78.2.1176; HUANG SK, 1994, CANCER RES, V54, P2186; LEUNIG M, 1992, CANCER RES, V52, P6553; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; MERWIN R, 1950, J NATL CANCER I, V11, P593; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; NICOSIA RF, 1990, LAB INVEST, V63, P115; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; SHUBIK P, 1976, J NATL CANCER I, V57, P769, DOI 10.1093/jnci/57.4.769; WU NZ, 1993, MICROVASC RES, V46, P231, DOI 10.1006/mvre.1993.1049; WU NZ, 1993, CANCER RES, V53, P3765; WU NZ, 1992, CANCER RES, V52, P4265; YUAN F, 1994, CANCER RES, V54, P3352	24	77	80	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1033	1035		10.1038/13736	http://dx.doi.org/10.1038/13736			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504711				2022-12-25	WOS:000083015700034
J	Laberge-le Couteulx, S; Jung, HH; Labauge, P; Houtteville, JP; Lescoat, C; Cecillon, M; Marechal, E; Joutel, A; Bach, JF; Tournier-Lasserve, E				Laberge-le Couteulx, S; Jung, HH; Labauge, P; Houtteville, JP; Lescoat, C; Cecillon, M; Marechal, E; Joutel, A; Bach, JF; Tournier-Lasserve, E			Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas	NATURE GENETICS			English	Article							CHROMOSOME 7Q; GENE; MALFORMATION; PROTEINS; RAS; LOCALIZATION; APOPTOSIS; MICE; RAP1	Cavernous angiomas are vascular malformations mostly located in the central nervous system and characterized by enlarged capillary cavities without intervening brain parenchyma(1). Clinical symptoms include seizures, haemorrhage and focal neurological deficits. Cavernous angiomas prevalence is close to 0.5% in the general population(2). They may be inherited as an autosomal dominant condition in as much as 50% of cases(3). Cerebral cavernous malformations (CCM) loci were previously identified on 7q, 7p and 3q (refs 4,5). A strong founder effect was observed in the Hispano-American population, all families being linked to CCM1 on 7q (refs 4,6,7). CCM1 locus assignment was refined to a 4-cM interval bracketed by D7S2410 and D7S689 (ref. 8). Here we report a physical and transcriptional map of this interval and that CCM1, a gene whose protein product, KRIT1, interacts with RAP1A (also known as KREV1; ref. 9), a member of the RAS family of GTPases, is mutated in CCM1 families. Our data suggest the involvement of the RAP1A signal transduction pathway in vasculogenesis or angiogenesis(10).	Fac Med Necker, INSERM, U25, F-75730 Paris 15, France; CHR Cote Nacre, Serv Neurochirurg, Caen, France; Hop Lariboisiere, Lab Cytogenet, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Tournier-Lasserve, E (corresponding author), Fac Med Necker, INSERM, U25, 156 Rue Vaugirard, F-75730 Paris 15, France.		Tournier-Lasserve, Elisabeth/N-7134-2017; Laberge, Sophie/ABD-7353-2020; Joutel, Anne/K-5601-2017	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Laberge, Sophie/0000-0003-4722-0361; Joutel, Anne/0000-0003-3963-3860				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASHA H, EMBO J, V18, P60599; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Craig HD, 1998, HUM MOL GENET, V7, P1851, DOI 10.1093/hmg/7.12.1851; DUBOVSKY J, 1995, HUM MOL GENET, V4, P453, DOI 10.1093/hmg/4.3.453; Gunel M, 1996, NEW ENGL J MED, V334, P946, DOI 10.1056/NEJM199604113341503; Gunel M, 1996, NEUROSURGERY, V38, P1265; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; JOHNSON EW, 1995, GENOME RES, V5, P368, DOI 10.1101/gr.5.4.368; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Labauge P, 1998, LANCET, V352, P1892, DOI 10.1016/S0140-6736(98)03011-6; Laberge S, 1999, EUR J HUM GENET, V7, P499, DOI 10.1038/sj.ejhg.5200324; OTTEN P, 1989, NEUROCHIRURGIE, V35, P82; PIZON V, 1988, ONCOGENE, V3, P201; Pizon V, 1996, EUR J CELL BIOL, V69, P224; Quarck R, 1996, EUR J CELL BIOL, V70, P269; RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605; Russell DS, 1989, PATHOLOGY TUMOURS NE, P730; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293	22	349	354	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					189	193		10.1038/13815	http://dx.doi.org/10.1038/13815			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508515				2022-12-25	WOS:000082827500018
J	Edwards, DC; Sanders, LC; Bokoch, GM; Gill, GN				Edwards, DC; Sanders, LC; Bokoch, GM; Gill, GN			Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics	NATURE CELL BIOLOGY			English	Article							P21-ACTIVATED KINASE; PROTEIN-KINASE; ZINC-FINGER; ALPHA-PAK; PHOSPHORYLATION; CELLS; RHO; COFILIN; REVEALS	Extracellular signals regulate actin dynamics through small GTPases of the Rho/Rac/Cdc42 (p21) family, Here we show that p21-activated kinase (Pak1) phosphorylates LIM-kinase at threonine residue 508 within LIM-kinase's activation loop, and increases LIM-kinase-mediated phosphorylation of the actin-regulatory protein cofilin tenfold in vitro. In vivo, activated pac or Cdc42 increases association of Pak1 with LIM-kinase; this association requires structural determinants in both the amino-terminal regulatory and the carboxy-terminal catalytic domains of Pak1, A catalytically inactive LIM-kinase interferes with Rac-, Cdc42- and Pak1-dependent cytoskeletal changes. A Pak1-specific inhibitor, corresponding to the Pak1 autoinhibitory domain, blocks LIM-kinase-induced cytoskeletal changes. Activated GTPases can thus regulate actin depolymerization through Pak1 and LIM-kinase.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIDDK NIH HHS [DK13149] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bossemeyer Dirk, 1996, P37, DOI 10.1002/9783527615032.ch2; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HELMANN U, 1995, ANAL BIOCHEM, V224, P451; Johnson LN, 1996, CURR OPIN STRUC BIOL, V6, P762, DOI 10.1016/S0959-440X(96)80005-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MANSER E, 1994, NATURE, V367, P41; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; ZENKE FT, IN PRESS J BIOL CHEM; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	34	820	842	2	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					253	259		10.1038/12963	http://dx.doi.org/10.1038/12963			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559936				2022-12-25	WOS:000083169600012
J	Waibel, R; Alberto, R; Willuda, J; Finnern, R; Schibli, R; Stichelberger, A; Egli, A; Abram, U; Mach, JP; Pluckthun, A; Schubiger, PA				Waibel, R; Alberto, R; Willuda, J; Finnern, R; Schibli, R; Stichelberger, A; Egli, A; Abram, U; Mach, JP; Pluckthun, A; Schubiger, PA			Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex	NATURE BIOTECHNOLOGY			English	Article						organometallic technetium; recombinant proteins; radiolabeling; targeting; imaging	SINGLE-CHAIN FV; ANTIBODY; BINDING; TC-99M; FRAGMENTS; PEPTIDES; RECEPTOR; LIBRARY	We have developed a technetium labeling technology based on a new organometallic chemistry, which involves simple mixing of the novel reagent, a Tc-99m(I)-carbonyl compound, with a His-tagged recombinant protein. This method obviates the labeling of unpaired engineered cysteines, which frequently create problems in large-scale expression and storage of disulfide-containing proteins. In this study, we labeled antibody single-chain Fv fragments to high specific activities (90 mCi/mg), and the label was very stable to serum and all other challenges tested. The pharmacokinetic characteristics were indistinguishable from iodinated scFv fragments, and thus scFV fragments labeled by the new method will be suitable for biodistribution studies. This novel labeling method should be applicable not only to diagnostic imaging with Tc-99m, but also to radioimmunotherapy approaches with Re-186/188, and its use can be easily extended to almost any recombinant protein or synthetic peptide.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Paul Scherrer Inst, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland; Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; Forschungszentrum Rossendorf EV, Inst Radiochem, D-01062 Dresden, Germany	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Lausanne; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR)	Pluckthun, A (corresponding author), Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Alberto, Roger/S-6405-2019; Plückthun, Andreas/C-2746-2009	Alberto, Roger/0000-0001-5978-3394; Plückthun, Andreas/0000-0003-4191-5306; Schibli, Roger/0000-0002-1537-3833				ABRAMS MJ, 1983, INORG CHEM, V22, P2798, DOI 10.1021/ic00162a007; Adams GP, 1998, CANCER RES, V58, P485; Alberto R, 1996, POLYHEDRON, V15, P1079, DOI 10.1016/0277-5387(95)00361-4; Alberto R, 1998, J AM CHEM SOC, V120, P7987, DOI 10.1021/ja980745t; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; Behr TM, 1998, EUR J NUCL MED, V25, P201, DOI 10.1007/s002590050216; Bogdanov A, 1998, BBA-GENE STRUCT EXPR, V1397, P56, DOI 10.1016/S0167-4781(97)00221-2; CHIZZONITE R, 1992, J IMMUNOL, V148, P3117; FRITZBERG AR, 1987, NUKLEARMED, V26, P7; GEORGE AJT, 1995, P NATL ACAD SCI USA, V92, P8358, DOI 10.1073/pnas.92.18.8358; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; LIBERATORE M, 1995, EUR J NUCL MED, V22, P1326, DOI 10.1007/BF00801622; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; Lindner P, 1997, BIOTECHNIQUES, V22, P140, DOI 10.2144/97221rr01; MARTELL AE, 1995, CRITICAL SELECTED ST; NEDELMAN MA, 1993, J NUCL MED, V34, P234; Pietersz GA, 1998, J NUCL MED, V39, P47; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; SATTELBERGER AP, 1995, MANGANESE GROUP, P151; SCHOTT ME, 1992, CANCER RES, V55, P5323; SKERRA A, 1991, BIO-TECHNOL, V9, P273, DOI 10.1038/nbt0391-273; Snider H, 1998, AM J SURG, V176, P305, DOI 10.1016/S0002-9610(98)00207-4; Spradau TW, 1999, NUCL MED BIOL, V26, P1, DOI 10.1016/S0969-8051(98)00060-2; Stalteri MA, 1999, BIOCONJUGATE CHEM, V10, P130, DOI 10.1021/bc9800466; TAILLEFER R, 1988, EUR J NUCL MED, V13, P515; Tiling R, 1998, J NUCL MED, V39, P849; Vallabhajosula S, 1996, J NUCL MED, V37, P1016; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Verhaar MJ, 1996, J NUCL MED, V37, P868; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3	32	262	300	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					897	901		10.1038/12890	http://dx.doi.org/10.1038/12890			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471933				2022-12-25	WOS:000082365800033
J	Chapman, AP; Antoniw, P; Spitali, M; West, S; Stephens, S; King, DJ				Chapman, AP; Antoniw, P; Spitali, M; West, S; Stephens, S; King, DJ			Therapeutic antibody fragments with prolonged in vivo half-lives	NATURE BIOTECHNOLOGY			English	Article						therapeutic antibodies; antibody engineering; polyethylene glycol; pharmacokinetics	ESCHERICHIA-COLI; RECOMBINANT ANTIBODY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; TUMOR-LOCALIZATION; EXPRESSION	Antibody fragments can be isolated rapidly using techniques such as phage display and can be expressed to high levels in microbial systems. However, to date such antibody fragments have been of limited use for many therapeutic applications because they are rapidly cleared from the body. We present a strategy for the site-specific chemical modification of antibody fragments with polyethylene glycol, which results in the production of antibody fragments with long in vivo half-lives and full retention of antigen-binding properties. This technology should allow more rapid and economical production of therapeutic antibodies for chronic disease therapy.	Celltech Therapeut, Slough SL1 4EN, Berks, England	Celltech Group Ltd	Chapman, AP (corresponding author), Celltech Therapeut, 216 Bath Rd, Slough SL1 4EN, Berks, England.							BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; Dickman S, 1998, SCIENCE, V280, P1196, DOI 10.1126/science.280.5367.1196; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Horn U, 1996, APPL MICROBIOL BIOT, V46, P524, DOI 10.1007/s002530050855; Humphreys DP, 1998, J IMMUNOL METHODS, V217, P1, DOI 10.1016/S0022-1759(98)00061-1; KING DJ, 1994, CANCER RES, V54, P6176; KING DJ, 1992, ANTIBODY IMMUNOCONJ, V5, P159; KITAMURA K, 1991, CANCER RES, V51, P4310; Monfardini C, 1998, BIOCONJUGATE CHEM, V9, P418, DOI 10.1021/bc970184f; PEDLEY RB, 1994, BRIT J CANCER, V70, P1126, DOI 10.1038/bjc.1994.459; Pen J., 1996, Transgenic plants: a production system for industrial and pharmaceutical proteins., P149; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Vaughan TJ, 1998, NAT BIOTECHNOL, V16, P535, DOI 10.1038/nbt0698-535; Zeitlin L, 1998, NAT BIOTECHNOL, V16, P1361, DOI 10.1038/4344	16	272	381	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					780	783		10.1038/11717	http://dx.doi.org/10.1038/11717			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429243				2022-12-25	WOS:000081751400027
J	Moore, RJ; Owens, DM; Stamp, G; Arnott, C; Burke, F; East, N; Holdsworth, H; Turner, L; Rollins, B; Pasparakis, M; Kollias, G; Balkwill, F				Moore, RJ; Owens, DM; Stamp, G; Arnott, C; Burke, F; East, N; Holdsworth, H; Turner, L; Rollins, B; Pasparakis, M; Kollias, G; Balkwill, F			Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis	NATURE MEDICINE			English	Article							MULTISTAGE CARCINOGENESIS; CANCER; EXPRESSION; PROMOTION; PREVENTION; METASTASIS; INHIBITION; FOLLICLES; DISEASE	Given the associations between chronic inflammation and epithelial cancer(1,2) , we studied susceptibility to skin carcinogenesis(3,4) in mice deficient for the pro-inflammatory cytokine TNF-alpha (refs. 5,6). TNF-alpha(-/-) mice were resistant to development of benign and malignant skin tumors, whether induced by initiation with DMBA and promotion with TPA or by repeated dosing with DMBA. TNF-alpha(-/-) mice developed 5-10% the number of tumors developed by wild-type mice during initiation/promotion and 25% of those in wild-type mice after repeated carcinogen treatment. TNF-alpha could influence tumor and stromal cells during tumor development. The early stages of TPA promotion are characterized by keratinocyte hyperproliferation and inflammation. These were diminished in TNF-alpha(-/-) mice. TNF-alpha was extensively induced in the epidermis, but not the dermis, in TPA-treated wild-type skin, indicating that dermal inflammation is controlled by keratinocyte TNF-a production. Deletion of a TNF-alpha inducible chemokine also conferred some resistance to skin tumor development. TNF-alpha has little influence on later stages of carcinogenesis, as tumors in wild-type and TNF-alpha(-/-) mice had similar rates of malignant progression. These data provide evidence that a pro-inflammatory cytokine is required for de novo carcinogenesis and that TNF-alpha is important to the early stages of tumor promotion. Strategies that neutralize TNF-alpha production may be useful in cancer treatment and prevention.	Imperial Canc Res Fund, Biol Therapy Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Keratinocyte Lab, London WC2A 3PX, England; Univ London Imperial Coll Sci Technol & Med, Div Invest Sci, Dept Histopathol, London W12 0NN, England; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Hellen Pasteur Inst, Dept Mol Genet, GR-11521 Athens, Greece; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cancer Research UK; Cancer Research UK; Imperial College London; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Balkwill, F (corresponding author), Imperial Canc Res Fund, Biol Therapy Lab, POB 123, London WC2A 3PX, England.		Kollias, George/A-7079-2012; Pasparakis, Manolis/H-9292-2017	Kollias, George/0000-0003-1867-3150; Pasparakis, Manolis/0000-0002-9870-0966; Balkwill, Frances/0000-0002-5587-9759				Arbeit JM, 1996, CANCER SURV, V26, P7; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BROWN DE, 1995, OPERAT RES COMP SCI, V3, P1; CORREA P, 1992, CANCER RES, V52, P6735; Eggermont AMM, 1996, J CLIN ONCOL, V14, P2653, DOI 10.1200/JCO.1996.14.10.2653; Feldmann M, 1997, ADV IMMUNOL, V64, P283, DOI 10.1016/S0065-2776(08)60891-3; FISCHER SM, 1989, CANCER RES, V49, P6693; KOMORI A, 1993, CANCER RES, V53, P1982; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Negus RPM, 1998, J LEUKOCYTE BIOL, V63, P758, DOI 10.1002/jlb.63.6.758; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; Palli D, 1998, GUT, V42, P175, DOI 10.1136/gut.42.2.175; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; Suganuma M, 1996, CANCER RES, V56, P3711; Warzocha K, 1998, BLOOD, V91, P3574; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195	21	702	721	3	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					828	831		10.1038/10552	http://dx.doi.org/10.1038/10552			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395330				2022-12-25	WOS:000081926600040
J	Drenth, JPH; Cuisset, L; Grateau, G; Vasseur, C; van de Velde-Visser, SD; de Jong, JGN; Beckmann, JS; van der Meer, JWM; Delpech, M				Drenth, JPH; Cuisset, L; Grateau, G; Vasseur, C; van de Velde-Visser, SD; de Jong, JGN; Beckmann, JS; van der Meer, JWM; Delpech, M		Int Hyper-IgD Study Grp	Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome	NATURE GENETICS			English	Article							FAMILIAL HIBERNIAN FEVER; HYPERIMMUNOGLOBULINEMIA-D; CLINICAL SPECTRUM; IDENTIFICATION; ACIDURIA; LINKAGE; ATTACKS; 12P13	Hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS; MIM 260920) is a rare, apparently monogenic, autosomal recessive disorder characterized by recurrent episodes of fever accompanied with lymphadenopathy, abdominal distress,joint involvement and skin lesions'.;All patients have high serum IgD values (>100 U/ml) and HIDS 'attacks' are associated with an intense acute phase reaction whose exact pathophysiology remains obscure(2-4). Two other hereditary febrile disorders have been described. Familial Mediterranean fever (MIM 249100) is an autosomal recessive disorder affecting mostly populations from the Mediterranean basin and is caused by mutations in the gene MEFV(refs 5,6). Familial Hibernian fever (MIM 142680), also known as autosomal: dominant familial recurrent-fever, is caused by missense mutations in the gene encoding type 1 tumour necrosis factor receptor(7-10). Here we perform a genome-wide search to map the HIDS; gene. Haplotype analysis:placed the gene at 12q24 between D12S330 and D12S79. We identified the gene MVK,: encoding mevalonate kinase (MK, ATP:mevalonate 5-phosphotransferase; EC 2.7.1.36), as a candidate gene. We characterized 3 missense mutations, a 92-bp loss stemming from a deletion or from exon skipping, and the absence of expression of one allele Functional analysis demonstrated diminished MK activity in: fibroblasts from HIDS-patients. Our data establish MVK as the: gene responsible for HIDS.	Inst Cochin Genet Mol, Lab Genet Mol Humaine, Paris, France; Hop Cochin, Assistance Publ Hopitaux Paris, F-75674 Paris, France; Univ Nijmegen St Radboud Hosp, Dept Med, Div Gen Internal Med, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen St Radboud Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Hotel Dieu, Serv Med Interne, AP HP, Paris, France; Univ Nijmegen St Radboud Hosp, Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands; URA CNRS 1922, Evry, France; Ctr Natl Genotypage, Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Radboud University Nijmegen; Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Delpech, M (corresponding author), Inst Cochin Genet Mol, Lab Genet Mol Humaine, Paris, France.		van der Meer, Jos W.M./C-8521-2013; Drenth, Joost/V-7436-2019; Drenth, J.P.H./H-8025-2014; Beckmann, Jacques S/A-9772-2008	van der Meer, Jos W.M./0000-0001-5120-3690; Beckmann, Jacques S/0000-0002-9741-1900				Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DRENTH JPH, 1994, MEDICINE, V73, P133, DOI 10.1097/00005792-199405000-00002; DRENTH JPH, 1995, BLOOD, V85, P3586, DOI 10.1182/blood.V85.12.3586.bloodjournal85123586; Drenth JPH, 1996, J IMMUNOL, V157, P400; DRENTH JPH, 1995, EUR J CLIN INVEST, V25, P683, DOI 10.1111/j.1365-2362.1995.tb01986.x; DRENTH JPH, 1994, HUM GENET, V94, P616, DOI 10.1007/BF00206953; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; HOFFMAN G, 1986, NEW ENGL J MED, V314, P1610, DOI 10.1056/NEJM198606193142504; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; McDermott EM, 1997, MAYO CLIN PROC, V72, P806, DOI 10.4065/72.9.806; McDermott MF, 1998, AM J HUM GENET, V62, P1446, DOI 10.1086/301886; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Mulley J, 1998, AM J HUM GENET, V62, P884, DOI 10.1086/301793; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Ott J., 1991, ANAL HUMAN GENETIC L; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Potter D, 1997, J BIOL CHEM, V272, P25449, DOI 10.1074/jbc.272.41.25449; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; Yamagishi A, 1996, HUM MUTAT, V7, P23, DOI 10.1002/(SICI)1098-1004(1996)7:1<23::AID-HUMU3>3.3.CO;2-K	21	412	425	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					178	181		10.1038/9696	http://dx.doi.org/10.1038/9696			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369262				2022-12-25	WOS:000080680900025
J	Shea, LD; Smiley, E; Bonadio, J; Mooney, DJ				Shea, LD; Smiley, E; Bonadio, J; Mooney, DJ			DNA delivery from polymer matrices for tissue engineering	NATURE BIOTECHNOLOGY			English	Article						gene therapy; PDGF; plasmid DNA; poly(lactide-co-glycolide); tissue engineering	CONTROLLED-RELEASE; GROWTH	We have proposed engineering tissues by the incorporation and sustained release of plasmids encoding tissue-inductive proteins from polymer matrices. Matrices of poly(lactide-co-glycolide) (PLG) were loaded with plasmid, which was subsequently released over a period ranging from days to a month in vitro. Sustained delivery of plasmid DNA from matrices led to the transfection of large numbers of cells. Furthermore, in vivo delivery of a plasmid encoding platelet-derived growth factor enhanced matrix deposition and blood vessel formation in the developing tissue. This contrasts with direct injection of the plasmid, which did not significantly affect tissue formation. This method of DNA delivery may find utility in tissue engineering and gene therapy applications.	Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mooney, DJ (corresponding author), Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.		Shea, Lonnie D/B-7615-2009	Mooney, David/0000-0001-6299-1194	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013004] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE07057, 1RO1DE13004] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Deuel T.F., 1997, PRINCIPLES TISSUE EN, P133; Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753; Giannobile WV, 1996, BONE, V19, pS23, DOI 10.1016/S8756-3282(96)00127-5; Harris LD, 1998, J BIOMED MATER RES, V42, P396, DOI 10.1002/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.3.CO;2-P; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; Jong YS, 1997, J CONTROL RELEASE, V47, P123, DOI 10.1016/S0168-3659(97)01637-4; Kim BS, 1998, TRENDS BIOTECHNOL, V16, P224, DOI 10.1016/S0167-7799(98)01191-3; Labhasetwar V, 1998, J PHARM SCI, V87, P1347, DOI 10.1021/js980077+; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Langer R, 1998, NATURE, V392, P5; Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; PETERS MC, 1998, TISSUE ENG THERAPEUT, V2, P55; RAINES EW, 1993, BIOL PLATELET DERIVE, P74; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Wong Wai Hung, 1997, P51	18	557	596	0	67	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					551	554		10.1038/9853	http://dx.doi.org/10.1038/9853			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385318				2022-12-25	WOS:000080716500025
J	Hayashi, T; Motulsky, AG; Deeb, SS				Hayashi, T; Motulsky, AG; Deeb, SS			Position of a 'green-red' hybrid gene in the visual pigment array determines colour-vision phenotype	NATURE GENETICS			English	Article							MOLECULAR-GENETICS; TANDEM ARRAY; EXPRESSION; DEFECTS; SEVERITY; LOCUS; XQ28; BLUE	The X-linked red- and green-pigment genes are arranged in a head-to-tail tandem array(1-3). The colour-vision defect of deuteranomaly (in 5% of males of European descent) is associated with a 5'-green-red-3' visual-pigment hybrid gene(4,5), which may also exist in males with normal colour vision(5-7). To explain why males with a normal red, a normal green and a green-red hybrid gene may have either normal or deutan colour vision, we hypothesized that only the first two genes are expressed(8,9) and deuteranomaly results only if the green-red hybrid gene occupies the second position and is expressed preferentially over normal green-pigment genes occupying more distal positions. We used long-range PCR amplification and studied 10 deutan males (8 deuteranomalous and 2 deuteranopic) with 3 visual pigment genes (red, green and green-red hybrid) to investigate whether position of the hybrid gene in the array determined gene expression. The green-red hybrid gene was always at the second position land the first position was always occupied by the red gene). Conversely, in two men with red, green and green-red hybrid genes and normal colour vision, the hybrid gene occupied the third position. When pigment gene mRNA expression was assessed in post-mortem retinae of three men with the red, green and green-red genotype, the green-red hybrid gene was expressed only when located in the second position. We conclude that the green-red hybrid gene will only cause deutan defects when it occupies the second position of the pigment gene array.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Deeb, SS (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.				NEI NIH HHS [EY08395] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008395] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Crognale MA, 1998, VISION RES, V38, P3377, DOI 10.1016/S0042-6989(97)00425-2; DEEB SS, 1992, AM J HUM GENET, V51, P687; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; DRUMMONDBORG M, 1989, P NATL ACAD SCI USA, V86, P983, DOI 10.1073/pnas.86.3.983; FARRELL DF, 1993, NEUROLOGY, V43, P1518, DOI 10.1212/WNL.43.8.1518; FEIL R, 1990, GENOMICS, V6, P367, DOI 10.1016/0888-7543(90)90578-I; Hanna MC, 1997, GENOMICS, V43, P384, DOI 10.1006/geno.1997.4830; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; Kitahara Kenji, 1998, Nippon Ganka Gakkai Zasshi, V102, P837; Macke JP, 1997, INVEST OPHTH VIS SCI, V38, P1040; MERBS SL, 1992, SCIENCE, V258, P464, DOI 10.1126/science.1411542; MILER SA, 1988, NUCLEIC ACIDS RES, V16, P1215; NATHANS J, 1993, AM J HUM GENET, V53, P987; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Neitz J, 1996, SCIENCE, V274, P801, DOI 10.1126/science.274.5288.801; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; Sanocki E, 1997, VISION RES, V37, P1897, DOI 10.1016/S0042-6989(97)00005-9; Sharpe LT, 1998, J NEUROSCI, V18, P10053; Shevell SK, 1997, VISION RES, V37, P1115, DOI 10.1016/S0042-6989(96)00270-2; Sjoberg SA, 1998, VISION RES, V38, P3213, DOI 10.1016/S0042-6989(97)00367-2; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WINDERICKX J, 1992, P NATL ACAD SCI USA, V89, P9710, DOI 10.1073/pnas.89.20.9710; Yamaguchi T, 1997, HUM MOL GENET, V6, P981, DOI 10.1093/hmg/6.7.981	26	71	72	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					90	93		10.1038/8798	http://dx.doi.org/10.1038/8798			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319869				2022-12-25	WOS:000080096300030
J	Huettner, CS; Zhang, P; Van Etten, RA; Tenen, DG				Huettner, CS; Zhang, P; Van Etten, RA; Tenen, DG			Reversibility of acute B-cell leukaemia induced by BCR-ABL1	NATURE GENETICS			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TRANSGENIC MICE; BCR-ABL; TYROSINE KINASE; GENE-EXPRESSION; BONE-MARROW; P210(BCR/ABL); PROMOTER; ANTIGEN	Cancer is thought to arise from multiple genetic events that establish irreversible malignancy. A different mechanism might be present in certain leukaemias initiated by a chromosomal translocation. We have taken a new approach to determine if ablation of the genetic abnormality is sufficient for reversion by generating a conditional transgenic model of BCR-ABL1 (also known as BCR-ABL)-induced leukaemia. This oncogene(1) is the of a reciprocal translocation and is associated with differ-ent forms of leukaemia(2). The most common form, p210 BCR-ABL1, is found in more than 90% of patients with chronic myelogenous leukaemia(3,4) (CML) and in up to 15% of adult patients with de novo acute lymphoblastic leukaemia(5) (ALL). Efforts to establish a useful transgenic model have been hampered by embryonic lethality when the oncogene is expressed during embryogenesis(6,7), by reduced penetrance or by extremely long latency periods(8,9). One model uses the 'knock-in' approach to induce leukaemia by p190 BCR-ABL1 (ref. 10). Given the limitations of models with p210, we used a different experimental approach(11) Lethal leukaemia developed within an acceptable time frame in all animals, and complete remission was achieved by suppression of BCR-ABL1 expression, even after multiple rounds of induction and reversion. Our results demonstrate that BCR-ABL1 is required for both induction and maintenance of leukaemia.	Harvard Univ, Inst Med, Div Hematol Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA USA	Harvard University; Harvard University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Tenen, DG (corresponding author), Harvard Univ, Inst Med, Div Hematol Oncol, Cambridge, MA 02138 USA.	dtenen@caregroup.harvard.edu		Tenen, Daniel/0000-0002-6423-3888				BEDI A, 1994, BLOOD, V83, P2038; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CROSS NCP, 1993, BRIT J HAEMATOL, V84, P67, DOI 10.1111/j.1365-2141.1993.tb03026.x; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KRAIG E, 1983, J EXP MED, V158, P192, DOI 10.1084/jem.158.1.192; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melo JV, 1996, LEUKEMIA, V10, P751; NOWELL PC, 1960, SCIENCE, V132, P1497; Radomska HS, 1998, GENE, V222, P305, DOI 10.1016/S0378-1119(98)00491-0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANETTEN RA, 1993, LEUKEMIA ADV TREATME, P294; VANETTEN RA, 1998, MED MANAGEMENT CHRON, P77	27	320	347	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					57	60		10.1038/71691	http://dx.doi.org/10.1038/71691			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615128				2022-12-25	WOS:000084609200016
J	Festenstein, R; Sharghi-Namini, S; Fox, M; Roderick, K; Tolaini, M; Norton, T; Saveliev, A; Kioussis, D; Singh, P				Festenstein, R; Sharghi-Namini, S; Fox, M; Roderick, K; Tolaini, M; Norton, T; Saveliev, A; Kioussis, D; Singh, P			Heterochromatin protein 1 modifies mammalian PEV in a dose- and chromosomal-context-dependent manner	NATURE GENETICS			English	Article							POSITION-EFFECT VARIEGATION; GENE-EXPRESSION; TRANSGENIC MICE; HIGH-LEVEL; DROSOPHILA; TRANSCRIPTION; COMPLEXES; PROBABILITY; INCREASE; DISEASE	Locus control regions (LCRs) are gene regulatory elements in mammals that can overcome the highly repressive effects normally associated with heterochromatic transgene locations (for example the centromere) in mice(1-3). Deletion of essential LCR sequences renders the cognate gene susceptible to this form of repression, so a proportion of the cells from transgenic mice that would normally express the transgene are silenced-a phenomenon known as position effect variegation(4-6) (PEV). We show here that PEV can also occur when the transgene is non-centromeric and that the extent of variegation can be developmentally regulated. Furthermore, by overexpressing a mammalian homologue (M31) of Drosophila melanogaster heterochromatin protein 1 (HP1; refs 7.8) in transgenic mouse lines that exhibit PEV, it is possible to modify the proportion of cells that silence the transgene in a dose-dependent manner. Thus, we show M31 overexpression to have two contrasting effects which are dependent on chromosomal context: (i) it enhanced PEV in those lines with centromeric or pericentromeric transgene locations; and (ii) it suppressed PEV when the transgene was non-centromeric. Our results indicate that components or modifiers of heterochromatin may have a chromosomal-context-dependent role in gene silencing and activation decisions in mammals.	Natl Inst Med Res, Div Mol Immunol, London NW7 1AA, England; Hammersmith Hosp, MRC, Ctr Clin Sci, Imperial Coll Sci Technol & Med,Dept Med, London, England; UCL, Galton Lab, MRC, Human Biochem Genet Unit, London, England; Babraham Inst, Chromatin Funct Lab, Cambridge, England; Roslin Inst, Nucl Reprogramming Lab, Edinburgh, Midlothian, Scotland	MRC National Institute for Medical Research; Imperial College London; University of London; University College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Festenstein, R (corresponding author), Natl Inst Med Res, Div Mol Immunol, Mill Hill, London NW7 1AA, England.	r-festen@nimr.mrc.ac.uk	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Saveliev, Alexander/0000-0003-0840-4774				APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; EISSENBERG JC, 1992, GENETICS, V131, P345; ELGIN SC, 1996, CURR OPIN GENE DEV, V6, P163; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; Kleinjan DJ, 1998, HUM MOL GENET, V7, P1611, DOI 10.1093/hmg/7.10.1611; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LOCKE J, 1988, GENETICS, V120, P181; Lu BY, 1998, DEVELOPMENT, V125, P2223; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Milot E, 1996, TRENDS GENET, V12, P123, DOI 10.1016/0168-9525(96)30019-X; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Singh PB, 1998, DEV GENET, V22, P85, DOI 10.1002/(SICI)1520-6408(1998)22:1<85::AID-DVG9>3.0.CO;2-3; SINGH PB, 1994, J CELL SCI, V107, P2653; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	29	106	107	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					457	461		10.1038/70579	http://dx.doi.org/10.1038/70579			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581035				2022-12-25	WOS:000084023900024
J	Jones, MK; Wang, HT; Peskar, BM; Levin, E; Itani, RM; Sarfeh, IJ; Tarnawski, AS				Jones, MK; Wang, HT; Peskar, BM; Levin, E; Itani, RM; Sarfeh, IJ; Tarnawski, AS			Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing	NATURE MEDICINE			English	Article							IN-VITRO; PROSTAGLANDIN; INDUCTION; SYNTHASE; DISEASE; CELLS; RATS	Angiogenesis, the formation of new capillary blood vessels, is essential not only for the growth and metastasis of solid tumors, but also for wound and ulcer healing, because without the restoration of blood flow, oxygen and nutrients cannot be delivered to the healing site(1,2). Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin and ibuprofen are the most widely used drugs for pain, arthritis, cardiovascular diseases and, more recently, the prevention of colon cancer and Alzheimer disease(3-7). However, NSAIDs produce gastroduodenal ulcers in about 25% of users (often with bleeding and/or perforations) and delay ulcer healing(8,9), presumably by blocking prostaglandin synthesis from cyclooxygenase (COX)-1 and COX-2 (ref. 10). The hypothesis that the gastrointestinal side effects of NSAIDs result from inhibition of COX-1, but not COX-2 (ref. 11), prompted the development of NSAIDs that selectively inhibit only COX-2 (such as celecoxib and rofecoxib). Our study demonstrates that both selective and nonselective NSAIDs inhibit angiogenesis through direct effects on endothelial cells. We also show that this action involves inhibition of mitogen-activated protein (MAP) kinase (ERK2) activity, interference with ERK nuclear translocation, is independent of protein kinase C and has prostaglandin-dependent and prostaglandin-independent components. Finally, we show that both COX-1 and COX-2 are important for the regulation of angiogenesis. These findings challenge the premise that selective COX-2 inhibitors will not affect the gastrointestinal tract and ulcer/wound healing.	Vet Affairs Med Ctr, Dept Med, Long Beach, CA 90822 USA; Vet Affairs Med Ctr, Dept Surg, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Surg, Irvine, CA 92697 USA; Ruhr Univ Bochum, Dept Expt Clin Med, D-44780 Bochum, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; Ruhr University Bochum	Tarnawski, AS (corresponding author), Vet Affairs Med Ctr, Dept Med, 5901 E 7th St, Long Beach, CA 90822 USA.							DeWitt D L, 1993, Am J Med, V95, p40S, DOI 10.1016/0002-9343(93)90396-7; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIES JF, 1991, J RHEUMATOL, V18, P6; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Goodnight S H, 1996, Curr Opin Hematol, V3, P355; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MCCARTHY DM, 1995, SCNA J GASTROENTEROL, V208, P9; Nicosia RF, 1997, AM J PATHOL, V151, P1379; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; PESKAR BA, 1979, RADIOIMMUNOASSAY DRU, P239; SCHARSCHMIDT LA, 1983, J CLIN INVEST, V71, P1756, DOI 10.1172/JCI110931; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Schuna A A, 1998, J Am Pharm Assoc (Wash), V38, P728; SHEADONOHUE T, 1990, GASTROENTEROLOGY, V98, P284, DOI 10.1016/0016-5085(90)90816-J; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Skopinska-Rozewska E, 1998, INT J TISSUE REACT, V20, P85; Sloane PD, 1998, AM FAM PHYSICIAN, V58, P1577; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TAMAWSKI A, 1991, MECH INJURY PROTECTI, P521; TAMAWSKI A, 1989, GASTROENTEROLOGY, V96, pA505; TARNAWSKI A, 1991, FALK SYMP, V59, P165; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6	25	750	779	0	85	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	DEC	1999	5	12					1418	1423						6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581086				2022-12-25	WOS:000084049700043
J	Toomes, C; James, J; Wood, AJ; Wu, CL; McCormick, D; Lench, N; Hewitt, C; Moynihan, L; Roberts, E; Woods, CG; Markham, A; Wong, M; Widmer, R; Ghaffar, KA; Pemberton, M; Hussein, IR; Temtamy, SA; Davies, R; Read, AP; Sloan, P; Dixon, MJ; Thakker, NS				Toomes, C; James, J; Wood, AJ; Wu, CL; McCormick, D; Lench, N; Hewitt, C; Moynihan, L; Roberts, E; Woods, CG; Markham, A; Wong, M; Widmer, R; Ghaffar, KA; Pemberton, M; Hussein, IR; Temtamy, SA; Davies, R; Read, AP; Sloan, P; Dixon, MJ; Thakker, NS			Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis	NATURE GENETICS			English	Article							PAPILLON-LEFEVRE-SYNDROME; DIPEPTIDYL-PEPTIDASE-I; MOLECULAR-CLONING; LINKAGE ANALYSIS; EXPRESSION; LOCALIZATION; 11Q14-Q21	Papillon-Lefevre syndrome, or keratosis palmoplantaris with periodontopathia (PLS, MIM 245000), is an autosomal recessive disorder that is mainly ascertained by dentists because of the severe periodontitis that afflicts patients(1,2). Both the deciduous and permanent dentitions are affected, resulting in premature tooth loss. Palmoplantar keratosis, varying from mild psoriasiform scaly skin to overt hyperkeratosis, typically develops within the first three years of life. Keratosis also affects other sites such as elbows and knees. Most PLS patients display both periodontitis and hyperkeratosis. some patients have only palmoplantar keratosis or periodontitis, and in rare individuals the periodontitis is mild and of late onset(3-6). The PLS locus has been mapped to chromosome 11q14-q21 (refs 7-9). Using homozygosity mapping in eight small consanguineous families, we have narrowed the candidate region to a 1.2-cM interval between D11S4082 and D11S931. The gene (CTSC) encoding the lysosomal protease cathepsin C (or dipeptidyl aminopeptidase I) lies within this interval. We defined the genomic structure of CTSC and found mutations in all eight families. In two of these families we used a functional assay to demonstrate an almost total loss of cathepsin C activity in PLS patients and reduced activity in obligate carriers.	Univ Manchester, St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Manchester, Turner Dent Sch, Dept Dent Med & Surg, Manchester, Lancs, England; Queens Univ Belfast, Dept Oncol, Belfast City Hosp Tower, Belfast, Antrim, North Ireland; St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; New Childrens Hosp, Dept Immunol & Infect Dis, Westmead, NSW, Australia; Westmead Hosp, Dept Paediat Dent, Dent Clin Sch, Westmead, NSW 2145, Australia; Eins Shams Univ, Dept Oral Diagnosis & Periodontol, Cairo, Egypt; Natl Res Ctr, Dept Human Genet, Cairo, Egypt; Dent Hlth Unit, Manchester, Lancs, England	University of Manchester; University of Manchester; University of Manchester; Belfast City Hospital; Queens University Belfast; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Sydney; University of Sydney; Egyptian Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); University of Manchester	Thakker, NS (corresponding author), Univ Manchester, St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England.		hussein, ibtessam M.R/H-9489-2012; Lench, Nicholas/AAB-1791-2021; Hussein, ibtessam R/L-4020-2014; woods, christopher g/A-1361-2010	Thakker, Nalin/0000-0002-8664-1508; Toomes, Carmel/0000-0001-8373-9545; Lench, Nicholas/0000-0002-6108-0759; Hussein, ibtessam/0000-0001-9909-9888; temtamy, samia/0000-0002-6452-823X; Ghaffar, khaled/0000-0001-5340-789X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROWN J, 1993, SIGHT SOUND, V3, P64; BULLON P, 1993, J CLIN PERIODONTOL, V20, P662, DOI 10.1111/j.1600-051X.1993.tb00712.x; Cigic B, 1999, BIOCHEM BIOPH RES CO, V258, P6, DOI 10.1006/bbrc.1999.0570; Fardal O, 1998, J CLIN PERIODONTOL, V25, P181, DOI 10.1111/j.1600-051X.1998.tb02425.x; FISHER J, 1997, EUR J HUM GENET, V51, P56; GORLIN RJ, 1964, J PEDIATR-US, V65, P895, DOI 10.1016/S0022-3476(64)80014-7; HAMILTON RE, 1974, ORAL SURG ORAL MED O, V37, P754, DOI 10.1016/0030-4220(74)90141-8; Hart T C, 1994, Periodontol 2000, V6, P88, DOI 10.1111/j.1600-0757.1994.tb00029.x; Hart TC, 1998, AM J MED GENET, V79, P134, DOI 10.1002/(SICI)1096-8628(19980901)79:2<134::AID-AJMG9>3.0.CO;2-Q; Kruglyak L, 1998, J COMPUT BIOL, V5, P1, DOI 10.1089/cmb.1998.5.1; KURIBAYASHI M, 1993, J BIOCHEM-TOKYO, V113, P441, DOI 10.1093/oxfordjournals.jbchem.a124064; Laass MW, 1997, HUM GENET, V101, P376, DOI 10.1007/s004390050645; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; Oguzkurt P, 1996, J PEDIATR SURG, V31, P955; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; Pham CTN, 1997, J BIOL CHEM, V272, P10695, DOI 10.1074/jbc.272.16.10695; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Rao NV, 1997, J BIOL CHEM, V272, P10260; SMYTH M, 1994, J NEUROCHEM, V63, P1439; Soskolne WA, 1996, J CLIN PERIODONTOL, V23, P764, DOI 10.1111/j.1600-051X.1996.tb00607.x; TEMPEL TR, 1972, J PERIODONTAL RE S10, V7, P26; WALLACE IJC, 1990, IRISH J MED SCI, V159, P203, DOI 10.1007/BF02937266	25	341	363	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					421	424		10.1038/70525	http://dx.doi.org/10.1038/70525			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581027	Green Published			2022-12-25	WOS:000084023900016
J	Swan, A; Nguyen, T; Suter, B				Swan, A; Nguyen, T; Suter, B			Drosophila Lissencephaly-1 functions with Bic-D and dynein in oocyte determination and nuclear positioning	NATURE CELL BIOLOGY			English	Article							CYTOPLASMIC DYNEIN; MICROTUBULE MOTOR; LIS-1 GENE; BICAUDAL-D; OOGENESIS; PROTEIN; LOCALIZATION; DIFFERENTIATION; SPECIFICATION; MELANOGASTER	Here we show that the Drosophila homologue of Lissencephaly-1, DLis-1, acts together with Bicaudal-D (Bic-D), Egalitarian (Egl), dynein and microtubules to determine oocyte identity. DLis-1 is further required for nurse-cell-to-oocyte transport during oocyte growth, and for the positioning of the nucleus in the oocyte. Immunostaining of DLis-1 protein reveals a cortical localization that is independent of microtubules. DLis-1 may function in this position as a cortical anchor for the other nuclear-localization factors. DLis-1 and Bic-D are further required for nuclear localization in the developing nervous system, indicating that homologues of Bic-D, dynein and Egl-like proteins may also be involved in vertebrate neural migration and that their absence may cause a Miller-Dieker-like lissencephaly.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Suter, B (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.							CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; deCuevas M, 1996, DEVELOPMENT, V122, P3959; Fan SS, 1997, DEVELOPMENT, V124, P1497; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LIN HF, 1994, DEVELOPMENT, V120, P947; Liu Z, 1999, DEVELOPMENT, V126, P4477; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; McGrail M, 1997, DEVELOPMENT, V124, P2409; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAN B, 1994, DEVELOPMENT, V120, P1233; RASMUSSON K, 1994, MOL BIOL CELL, V5, P45, DOI 10.1091/mbc.5.1.45; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Reinsch S, 1998, J CELL SCI, V111, P2283; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; SCHUPBACH T, 1991, GENETICS, V129, P1119; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Swan A, 1996, DEVELOPMENT, V122, P3577; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297	31	180	183	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					444	449		10.1038/15680	http://dx.doi.org/10.1038/15680			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559989				2022-12-25	WOS:000083533100018
J	Appenzeller, C; Andersson, H; Kappeler, F; Hauri, HP				Appenzeller, C; Andersson, H; Kappeler, F; Hauri, HP			The lectin ERGIC-53 is a cargo transport receptor for glycoproteins	NATURE CELL BIOLOGY			English	Article							EARLY SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; LEGUMINOUS LECTINS; PROTEIN ERGIC-53; GOLGI; VESICLES; COMPARTMENT; COMPONENT; COATOMER; DEPENDS	Soluble secretory proteins are transported from the endoplasmic reticulum (ER) to the ER-Golgi intermediate compartment (ERGIC) in vesicles coated with COP-II coat proteins. The sorting of secretory cargo into these vesicles is thought to involve transmembrane cargo-receptor proteins. Here we show that a cathepsin-Z-related glycoprotein binds to the recycling, mannose-specific membrane lectin ERGIC-53. Binding occurs in the ER, is carbohydrate- and calcium-ion-dependent and is affected by untrimmed glucose residues. Binding does not, however, require oligomerization of ERGIC-53, although oligomerization is required for exit of ERGIC-53 from the ER. Dissociation of ERGIC-53 occurs in the ERGIC and is delayed if ERGIC-53 is mislocalized to the ER. These results strongly indicate that ERGIC-53 may function as a receptor facilitating ER-to-ERGIC transport of soluble glycoprotein cargo.	Univ Basel, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Hauri, HP (corresponding author), Univ Basel, Dept Pharmacol Neurobiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Appenzeller-Herzog, Christian/A-2894-2014	Appenzeller-Herzog, Christian/0000-0001-7430-294X				Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; Cacan R, 1999, BIOCHEM BIOPH RES CO, V258, P1, DOI 10.1006/bbrc.1999.0549; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; HAURI HP, 1997, HDB PHYSIOL 14, P605; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Klumperman J, 1998, J CELL SCI, V111, P3411; Lahtinen U, 1999, EUR J BIOCHEM, V260, P392, DOI 10.1046/j.1432-1327.1999.00158.x; MITSUNO M, 1993, P NATL ACAD SCI USA, V90, P5732; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	33	254	264	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					330	334		10.1038/14020	http://dx.doi.org/10.1038/14020			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559958				2022-12-25	WOS:000083169800014
J	Matin, A; Collin, GB; Asada, Y; Varnum, D; Nadeau, JH				Matin, A; Collin, GB; Asada, Y; Varnum, D; Nadeau, JH			Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain	NATURE GENETICS			English	Article							MOUSE CHROMOSOME-18; GENETIC DISSECTION; COMPLEX TRAITS; MICE; TERATOMAS; MUTATION; DEFICIENCY; MAPS	The identification of genes that control susceptibility to testicular germ-cell tumours (TGCTs), the most common cancer affecting young men(1), has been difficult. In laboratory mice, TGCTs arise from primordial germ cells(2,3) in only the 129 inbred strains(4), and susceptibility is under multigenic control. The spontaneously arising mutation Ter (ref. 5) on mouse chromosome 18 (refs 6,7) increases TGCT frequency(5,8) on a 129/Sv background. We originally used Ter in genetic crosses to identify loci that control tumorigenesis. A genome scan of tumour-bearing progeny from backcrosses between the 129/Sv-Ter/+ and MOLF/Ei strains provided modest evidence that MOLF-derived alleles on chromosome 19 enhance development of bilateral TGCTs (ref. 9). To obtain independent evidence for linkage to the MOLF chromosome, we made an autosomal chromosome substitution strain (CSS; or 'consomic strain') in which chromosome 19 of 129/SV+/+ was replaced by its MOLF-derived homologue. The unusually high frequency of TGCTs in this CSS (even in the absence of the Ter mutation) provides evidence confirming the genome survey results, identifies linkage for a naturally occurring strain variant allele that confers susceptibility to TGCTs and illustrates the power of CSSs in complex trait analysis.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Nihon Univ, Sch Dent, Dept Pedodont, Chiba, Japan	Case Western Reserve University; University Hospitals of Cleveland; University Hospitals of Cleveland; Jackson Laboratory; Nihon University	Nadeau, JH (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.				NCI NIH HHS [CA75056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2012, BIOMETRY PRINCIPLES; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; Bonhomme F., 1996, GENETIC VARIANTS STR, P1577; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Collin GB, 1996, MAMM GENOME, V7, P68, DOI 10.1007/s003359900017; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; Moriwaki Kazuo, 1994, pXIII; NOGUCHI T, 1985, JNCI-J NATL CANCER I, V75, P385; Poirier C, 1998, MAMM GENOME, V8, pS353, DOI 10.1007/s003359900664; SAKURAI T, 1994, MAMM GENOME, V5, P333, DOI 10.1007/BF00356550; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SILVER LM, 1995, MOUSE GENETICS CONCE, P15; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; STEVENS LC, 1962, J NATL CANCER I, V28, P247; STEVENS LC, 1957, J NATL CANCER I, V18, P719; Stevens LC, 1983, COLD SPRING HARB C C, P23; Threadgill DW, 1997, MAMM GENOME, V8, P441, DOI 10.1007/s003359900464	23	84	89	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					237	240		10.1038/13874	http://dx.doi.org/10.1038/13874			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508525				2022-12-25	WOS:000082827500028
J	Munch, G; Schicktanz, D; Behme, A; Gerlach, M; Riederer, P; Palm, D; Schinzel, R				Munch, G; Schicktanz, D; Behme, A; Gerlach, M; Riederer, P; Palm, D; Schinzel, R			Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library	NATURE BIOTECHNOLOGY			English	Article						advanced glycation end products; protein crosslinking; peptide library	PICTET-SPENGLER REACTION; END-PRODUCTS; MAILLARD REACTION; CHEMICAL SYNTHESIS; METHYLGLYOXAL; PENTOSIDINE; AMYLOIDOSIS; SUPPORT; DISEASE; LYSINE	Advanced glycation end products (AGEs) contribute to changes in protein conformation, loss of function, and irreversible crosslinking. Using a library of dipeptides on cellulose membranes (SPOT library), we have developed an approach to systematically assay the relative reactivities of amino acid side chains and the N-terminal amino group to sugars and protein-AGEs. The sugars react preferentially with cysteine or tryptophan when both the alpha-amino group and the side chains are free. In peptides with blocked N-terminus and free side chains, cysteine, lysine, and histidine were preferred. Crosslinking of protein-AGEs to dipeptides with free side chains and blocked N termini occurred preferentially to arginine and tryptophan. Dipeptide SPOT libraries are excellent tools for comparing individual reactivities of amino acids for nonenzymatic modifications, and could be extended to other chemically reactive molecules.	Univ Wurzburg, Dept Physiol Chem 1, Wurzburg, Germany; Univ Wurzburg, Hosp Psychiat, Dept Clin Neurochem, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Munch, G (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Wurzburg, Germany.							ALABED Y, 1995, BIOORG MED CHEM LETT, V5, P2929, DOI 10.1016/0960-894X(95)00513-S; De Rosa MC, 1998, BIOPHYS CHEM, V72, P323, DOI 10.1016/S0301-4622(98)00117-3; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRANK R, 1995, J BIOTECHNOL, V41, P259, DOI 10.1016/0168-1656(95)00062-U; Friedman EA, 1997, AM J KIDNEY DIS, V30, P253, DOI 10.1016/S0272-6386(97)90060-3; Hilmes C, 1997, MEAT SCI, V46, P199, DOI 10.1016/S0309-1740(97)00019-3; HIPKISS AR, 1995, FEBS LETT, V371, P81, DOI 10.1016/0014-5793(95)00849-5; Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944; LO TWC, 1994, J BIOL CHEM, V269, P32299; Mayer JP, 1996, TETRAHEDRON LETT, V37, P5633, DOI 10.1016/0040-4039(96)01219-1; Miyata T, 1998, BIOCHEM BIOPH RES CO, V244, P45, DOI 10.1006/bbrc.1998.8203; MIYATA T, 1994, BIOCHEMISTRY-US, V33, P12215, DOI 10.1021/bi00206a026; MIYAZAKI S, 1995, AM J NEPHROL, V15, P535, DOI 10.1159/000168903; Mohan R, 1996, TETRAHEDRON LETT, V37, P3963, DOI 10.1016/0040-4039(96)00773-3; Molina F, 1996, PEPTIDE RES, V9, P151; Moreaux V, 1997, J AGR FOOD CHEM, V45, P1905, DOI 10.1021/jf9605005; Nakamura K, 1997, BIOCHEM BIOPH RES CO, V232, P227, DOI 10.1006/bbrc.1997.6262; Obayashi H, 1996, BIOCHEM BIOPH RES CO, V226, P37, DOI 10.1006/bbrc.1996.1308; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; Reineke U, 1998, PROTEIN SCI, V7, P951; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; Vlassara H, 1996, ANN MED, V28, P419, DOI 10.3109/07853899608999102; Wang MF, 1999, J AGR FOOD CHEM, V47, P48, DOI 10.1021/jf980804m; WellsKnecht KJ, 1996, NEPHROL DIAL TRANSPL, V11, P41	27	96	103	1	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1006	1010		10.1038/13704	http://dx.doi.org/10.1038/13704			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504703				2022-12-25	WOS:000083015700028
J	Grady, RM; Grange, RW; Lau, KS; Maimone, MM; Nichol, MC; Stull, JT; Sanes, JR				Grady, RM; Grange, RW; Lau, KS; Maimone, MM; Nichol, MC; Stull, JT; Sanes, JR			Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies	NATURE CELL BIOLOGY			English	Article							NITRIC-OXIDE SYNTHASE; TORPEDO ELECTRIC ORGAN; SKELETAL-MUSCLE; BETA-DYSTROBREVIN; SODIUM-CHANNELS; DEFICIENT MICE; MDX MOUSE; PROTEIN; COMPLEX; FAMILY	A dystrophin-containing glycoprotein complex (DGC) links the basal lamina surrounding each muscle fibre to the fibre's cytoskeleton, providing both structural support and a scaffold for signalling molecules. Mutations in genes encoding several DGC components disrupt the complex and lead to muscular dystrophy. Here we show that mice deficient in alpha-dystrobrevin, a cytoplasmic protein of the DGC, exhibit skeletal and cardiac myopathies. Analysis of double and triple mutants indicates that alpha-dystrobrevin acts largely through the DGC, Structural components of the DGC are retained in the absence of alpha-dystrobrevin, but a DGC-associated signalling protein, nitric oxide synthase, is displaced from the membrane and nitric-oxide-mediated signalling is impaired. These results indicate that both signalling and structural functions of the DGC are required for muscle stability, and implicate alpha-dystrobrevin in the former.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; SUNY Syracuse, Dept Anat & Cell Biol, Syracuse, NY 13210 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); State University of New York (SUNY) System; Washington University (WUSTL)	Grady, RM (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave, St Louis, MO 63110 USA.							Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Ambrose HJ, 1997, GENOMICS, V39, P359, DOI 10.1006/geno.1996.4515; Anderson JT, 1996, J BIOL CHEM, V271, P6605, DOI 10.1074/jbc.271.12.6605; Balasubramanian S, 1998, FEBS LETT, V432, P133, DOI 10.1016/S0014-5793(98)00804-7; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Bredt DS, 1998, P NATL ACAD SCI USA, V95, P14592, DOI 10.1073/pnas.95.25.14592; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Chao DS, 1998, J NEUROCHEM, V71, P784; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Crosbie RH, 1998, HUM MOL GENET, V7, P823, DOI 10.1093/hmg/7.5.823; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DIMARIO JX, 1991, DEV BIOL, V148, P314, DOI 10.1016/0012-1606(91)90340-9; Engel AG, 1994, MYOLOGY, pP1133; Gee SH, 1998, J NEUROSCI, V18, P128; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Iwata Y, 1998, FEBS LETT, V423, P173, DOI 10.1016/S0014-5793(98)00085-4; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KARNEYA S, 1999, J BIOL CHEM, V274, P2193; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Metzinger L, 1997, HUM MOL GENET, V6, P1185, DOI 10.1093/hmg/6.7.1185; Ozawa E, 1998, MUSCLE NERVE, V21, P421, DOI 10.1002/(SICI)1097-4598(199804)21:4<421::AID-MUS1>3.3.CO;2-W; Pall EA, 1996, J BIOL CHEM, V271, P3817; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; Puca AA, 1998, FEBS LETT, V425, P7, DOI 10.1016/S0014-5793(98)00097-0; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SadouletPuccio HM, 1996, BRAIN PATHOL, V6, P25, DOI 10.1111/j.1750-3639.1996.tb00780.x; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Thompson M, 1998, SIGHT SOUND, V8, P17; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; YANG L, 1995, AUDIT NEUROSCI, V1, P1; YOSHIDA M, 1995, FEBS LETT, V367, P311, DOI 10.1016/0014-5793(95)00574-S	49	265	270	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					215	220		10.1038/12034	http://dx.doi.org/10.1038/12034			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559919				2022-12-25	WOS:000083102700016
J	Stenman, J; Finne, P; Stahls, A; Grenman, R; Stenman, UH; Palotie, A; Orpana, A				Stenman, J; Finne, P; Stahls, A; Grenman, R; Stenman, UH; Palotie, A; Orpana, A			Accurate determination of relative messenger RNA levels by RT-PCR	NATURE BIOTECHNOLOGY			English	Editorial Material							POLYMERASE CHAIN-REACTION; DNA; QUANTITATION; ASSAY; CELLS; HYBRIDIZATION; AMPLIFICATION; TITRATION; PRODUCT; GENES		Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Lab, Helsinki, Finland; Univ Helsinki, Haartman Inst, Helsinki, Finland; Univ Turku, Cent Hosp, FIN-20520 Turku, Finland; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Turku; University of California System; University of California Los Angeles	Stenman, J (corresponding author), Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland.			Palotie, Aarno/0000-0002-2527-5874; Finne, Patrik/0000-0002-3742-1576; Stenman, Jakob/0000-0001-9543-3957; Stenman, Ulf-Hakan/0000-0002-2695-3454				ALARD P, 1993, BIOTECHNIQUES, V15, P730; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; Chen XN, 1997, P NATL ACAD SCI USA, V94, P10756, DOI 10.1073/pnas.94.20.10756; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; IHALAINEN J, 1994, BIOTECHNIQUES, V16, P938; Ikonen E, 1992, PCR Methods Appl, V1, P234; Karttunen L, 1996, GENOME RES, V6, P392, DOI 10.1101/gr.6.5.392; KATO H, 1984, JPN J CANCER RES, V75, P433; KUBO Y, 1995, CANCER RES, V55, P989; LIVAK KJ, 1995, PCR METH APPL, V4, P357; PANNETIER C, 1993, NUCLEIC ACIDS RES, V21, P577, DOI 10.1093/nar/21.3.577; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Schutze K, 1998, NAT BIOTECHNOL, V16, P737, DOI 10.1038/nbt0898-737; Suomalainen A, 1998, METH MOL B, V86, P121; SYVANEN AC, 1990, GENOMICS, V8, P684, DOI 10.1016/0888-7543(90)90255-S; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01	20	21	27	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					720	722		10.1038/10942	http://dx.doi.org/10.1038/10942			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10409357				2022-12-25	WOS:000081296900036
J	Sullivan, LS; Heckenlively, JR; Bowne, SJ; Zuo, J; Hide, WA; Gal, A; Denton, M; Inglehearn, CF; Blanton, SH; Daiger, SP				Sullivan, LS; Heckenlively, JR; Bowne, SJ; Zuo, J; Hide, WA; Gal, A; Denton, M; Inglehearn, CF; Blanton, SH; Daiger, SP			Mutations in a novel retina-specific gene cause autosomal dominant retinitis pigmentosa	NATURE GENETICS			English	Article							RECESSIVE MUTATIONS; ALPHA-SUBUNIT; PROTEIN; PHOSPHODIESTERASE; DOUBLECORTIN; LINKAGE; REGION; TULP1; MOUSE; ABCR	Inherited retinal diseases are a common cause of visual impairment in children and young adults, often resulting in severe loss of vision in later life. The most frequent form of inherited retinopathy is retinitis pigmentosa (RP), with an approximate incidence of 1 in 3,500 individuals worldwide(1,2). RP is characterized by night blindness and progressive degeneration of the midperipheral retina, accompanied by bone spicule-like pigmentary deposits and a reduced or absent electroretinogram (ERG). The disease process culminates in severe reduction of visual fields or blindness. RP is genetically heterogeneous, with autosomal dominant, autosomal recessive and X-linked forms. Here we have identified two mutations in a novel retina-specific gene from chromosome 8q that cause the RP1 form of autosomal dominant RP in three unrelated families. The protein encoded by this gene is 2,156 amino acids and its function is currently unknown, although the amino terminus has similarity to that of the doublecortin protein, whose gene (DCX) has been implicated in lissencephaly in humans(17). Two families have a nonsense mutation in codon 677 of this gene (Arg677stop), whereas the third family has a nonsense mutation in codon 679 (Gln679stop). In one family, two individuals homozygous for the mutant gene have more severe retinal disease compared with heterozygotes.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX 77030 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Western Cape, S African Natl Bioinformat Inst, ZA-7535 Bellville, South Africa; Univ Hosp Eppendorf, Inst Human Genet, Hamburg, Germany; Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Leeds, Mol Med Unit, Leeds LS2 9JT, W Yorkshire, England; Univ Virginia, Dept Pediat, Charlottesville, VA 22903 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles; St Jude Children's Research Hospital; South African National Biodiversity Institute; University of the Western Cape; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Otago; University of Leeds; University of Virginia	Sullivan, LS (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, 6901 Bertner St, Houston, TX 77030 USA.		Inglehearn, Chris/GYD-9783-2022; Blanton, Susan Halloran/ABF-1323-2021; Hide, Winston/R-3815-2019; Hide, Winston Hide/C-7217-2009; Hide, Winston A/V-2727-2017	Hide, Winston/0000-0002-8621-3271; Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston A/0000-0002-8621-3271	NATIONAL EYE INSTITUTE [R01EY007142] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007142-12A2, EY07142, R01 EY007142] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banerjee P, 1998, NAT GENET, V18, P177, DOI 10.1038/ng0298-177; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Daiger SP, 1997, DEGENERATIVE RETINAL DISEASES, P277; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174; Hannan AJ, 1999, J NEUROSCI RES, V55, P650, DOI 10.1002/(SICI)1097-4547(19990301)55:5<650::AID-JNR12>3.3.CO;2-J; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HECKENLIVELY JR, 1997, PRINCIPALS PRACTICES, P2555; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; INGLEHEARN CF, IN PRESS J MED GENET; JIMENEZ JB, 1991, HUM GENET, V86, P265; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Matsumoto N, 1999, GENOMICS, V56, P179, DOI 10.1006/geno.1998.5673; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; Roderick TH, 1997, GENOMICS, V42, P393, DOI 10.1006/geno.1997.4717; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Sossey-Alaoui K, 1998, HUM MOL GENET, V7, P1327, DOI 10.1093/hmg/7.8.1327; Xu SY, 1996, HUM GENET, V98, P741, DOI 10.1007/s004390050296	28	130	137	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					255	259		10.1038/10314	http://dx.doi.org/10.1038/10314			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391212	Green Accepted			2022-12-25	WOS:000081125900017
J	Hansen, MST; Smith, GJ; Kafri, T; Molteni, V; Siegel, JS; Bushman, FD				Hansen, MST; Smith, GJ; Kafri, T; Molteni, V; Siegel, JS; Bushman, FD			Integration complexes derived from HIV vectors for rapid assays in vitro	NATURE BIOTECHNOLOGY			English	Article						HIV; integrase; AIDS; retroviral vector; quantitative PCR; TaqMan	IMMUNODEFICIENCY-VIRUS TYPE-1; PREINTEGRATION COMPLEXES; DNA INVITRO; REVERSE-TRANSCRIPTASE; PROTEIN INVITRO; NUCLEIC-ACIDS; IN-VITRO; INHIBITION; MOLECULES; CELLS	Of three enzymes encoded by HIV-reverse transcriptase, protease, and integrase-only the first two have been exploited clinically as inhibitor targets. Efforts to develop inhibitors of purified integrase protein have yielded many compounds, but none with clinical utility. A different source of integration activity for studies in vitro is provided by replication intermediates isolated from HIV-infected cells. These preintegration complexes (PICs) can direct integration of the endogenously synthesized viral cDNA into an added target DNA in vitro. Despite their authentic activities, assays of PICs have not been widely used due to technical obstacles, particularly the requirement for handling large amounts of infectious HIV. Here, we describe greatly improved methods for producing PICs using HIV-based vectors that are capable of establishing an integrated provirus but not a spreading infection. We also report the development of a PIC integration assay using DNA-coated microtiter plates, which speeds assays of PIC integration in vitro. We used this method to screen a library of chemicals related to known integrase inhibitors and found a new compound, quinalizarin sulfate, that displayed enhanced activity against PICs.	Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; Althea Technol, San Diego, CA 92121 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem, La Jolla, CA USA	Salk Institute; Salk Institute; University of California System; University of California San Diego	Bushman, FD (corresponding author), Salk Inst Biol Studies, Infect Dis Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bushman@salk.edu	Siegel, Jay/E-6415-2011	Siegel, Jay/0000-0002-3226-3521	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056553] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34786] Funding Source: Medline; NIGMS NIH HHS [GM56553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Bushman F, 1998, P NATL ACAD SCI USA, V95, P11041, DOI 10.1073/pnas.95.19.11041; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHU BCF, 1983, NUCLEIC ACIDS RES, V11, P6513, DOI 10.1093/nar/11.18.6513; Coffin J, 1997, RETROVIRUSES; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; Ellis R J, 1990, Semin Cell Biol, V1, P1; Farnet C, 1997, CELL, V88, P1; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742; Farnet CM, 1998, ANTIMICROB AGENTS CH, V42, P2245, DOI 10.1128/AAC.42.9.2245; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; GHOSH SS, 1987, NUCLEIC ACIDS RES, V15, P5353, DOI 10.1093/nar/15.13.5353; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hansen MST, 1998, GENET ENG P, V20, P41; Hansen MST, 1997, J VIROL, V71, P3351, DOI 10.1128/JVI.71.4.3351-3356.1997; Hazuda DJ, 1997, J VIROL, V71, P7005, DOI 10.1128/JVI.71.9.7005-7011.1997; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; King PJ, 1998, J VIROL, V72, P8420, DOI 10.1128/JVI.72.10.8420-8424.1998; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; LUND V, 1988, NUCLEIC ACIDS RES, V16, P10861, DOI 10.1093/nar/16.22.10861; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; RASMUSSEN SR, 1991, ANAL BIOCHEM, V198, P138, DOI 10.1016/0003-2697(91)90518-X; Robinson WE, 1996, P NATL ACAD SCI USA, V93, P6326, DOI 10.1073/pnas.93.13.6326; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535	38	42	48	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					578	582		10.1038/9886	http://dx.doi.org/10.1038/9886			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385323				2022-12-25	WOS:000080716500030
J	Kobayashi, T; Beuchat, MH; Lindsay, M; Frias, S; Palmiter, RD; Sakuraba, H; Parton, RG; Gruenberg, J				Kobayashi, T; Beuchat, MH; Lindsay, M; Frias, S; Palmiter, RD; Sakuraba, H; Parton, RG; Gruenberg, J			Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport	NATURE CELL BIOLOGY			English	Article							NIEMANN-PICK-DISEASE; HOMEOSTASIS; PROTEINS; VESICLES; DENSITY; FUSION; GENE	The fate of free cholesterol released after endocytosis of low-density lipoproteins remains obscure. Here we report that late endosomes have a pivotal role in intracellular cholesterol transport. We find that in the genetic disease Niemann-Pick type C (NPC), and in drug-treated cells that mimic NPC, cholesterol accumulates in late endosomes and sorting of the lysosomal enzyme receptor is impaired. Our results show that the characteristic network of lysobisphosphatidic acid-rich membranes contained within multivesicular late endosomes regulates cholesterol transport, presumably by acting as a collection and distribution device. The results also suggest that similar endosomal defects accompany the anti-phospholipid syndrome and NPC.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Tokyo Metropolitan Inst Med Sci, Dept Clin Genet, Bunkyo Ku, Tokyo 113, Japan; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia	University of Geneva; University of Washington; University of Washington Seattle; Tokyo Metropolitan Institute of Medical Science; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Queensland; University of Queensland	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.		Parton, Robert G/C-5673-2009; Kobayashi, Toshihide/B-6298-2015; KOBAYASHI, TOSHIHIDE/S-8313-2019	Parton, Robert G/0000-0002-7494-5248; Kobayashi, Toshihide/0000-0002-4811-7270; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270				AlarconSegovia D, 1996, J RHEUMATOL, V23, P1319; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ASHERSOU RA, 1996, ANTIPOSPHOLIPID SYND; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Kobayashi T, 1998, SEMIN CELL DEV BIOL, V9, P517, DOI 10.1006/scdb.1998.0257; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Koike T, 1998, BBA-MOL BASIS DIS, V1406, P327, DOI 10.1016/S0925-4439(98)00019-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; OMURA K, 1989, BRAIN DEV-JPN, V11, P57, DOI 10.1016/S0387-7604(89)80010-5; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; Sakuraba H, 1999, NEUROLOGY, V52, P372, DOI 10.1212/WNL.52.2.372; SOKOL J, 1988, J BIOL CHEM, V263, P6411; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805	27	513	522	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					113	118		10.1038/10084	http://dx.doi.org/10.1038/10084			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559883				2022-12-25	WOS:000083102200019
J	Simpson, F; Hussain, NK; Qualmann, B; Kelly, RB; Kay, BK; McPherson, PS; Schmid, SL				Simpson, F; Hussain, NK; Qualmann, B; Kelly, RB; Kay, BK; McPherson, PS; Schmid, SL			SH3-domain-containing proteins function at distinct steps in clathrin-coated vesicle formation	NATURE CELL BIOLOGY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SRC HOMOLOGY-3 DOMAINS; DYNAMIN GTPASE; SH3 DOMAIN; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; BINDING PROTEINS; NERVE-TERMINALS; EPS15 HOMOLOGY; AMPHIPHYSIN	Several SH3-domain-containing proteins have been implicated in endocytosis by virtue of their interactions with dynamin; however, their functions remain undefined. Here we report the efficient reconstitution of ATP-, GTP-, cytosol- and dynamin-dependent formation of clathrin-coated vesicles in permeabilized 3T3-L1 cells. The SH3 domains of intersectin, endophilin I, syndapin I and amphiphysin II inhibit coated-vesicle formation in vitro through interactions with membrane-associated proteins. Most of the SH3 domains tested selectively inhibit late events involving membrane fission, but the SH3A domain of intersectin uniquely inhibits intermediate events leading to the formation of constricted coated pits. These results suggest that interactions between SH3 domains and their partners function sequentially in endocytic coated-vesicle formation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	McGill University; Scripps Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.	mcpm@musica.mcgill.ca	Simpson, Fiona/J-2721-2012; Simpson, Fiona/ABE-1276-2020	Simpson, Fiona/0000-0002-0271-781X; Simpson, Fiona/0000-0002-0271-781X; Schmid, Sandra/0000-0002-1690-7024				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Estes PS, 1996, J NEUROSCI, V16, P5443; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; GILLERT A, 1997, J CELL SCI, V110, P3105; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Harlow E., 1988, ANTIBODIES LAB MANUA; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; LAMAZE C, 1993, MOL BIOL CELL, V3, P1181; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	50	222	228	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					119	124		10.1038/10091	http://dx.doi.org/10.1038/10091			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559884				2022-12-25	WOS:000083102200020
J	Weiner, OD; Servant, G; Welch, MD; Mitchison, TJ; Sedat, JW; Bourne, HR				Weiner, OD; Servant, G; Welch, MD; Mitchison, TJ; Sedat, JW; Bourne, HR			Spatial control of actin polymerization during neutrophil chemotaxis	NATURE CELL BIOLOGY			English	Article							HUMAN ARP2/3 COMPLEX; LISTERIA-MONOCYTOGENES; POLYMORPHONUCLEAR LEUKOCYTES; F-ACTIN; PROTEINS ARP2; FILAMENTS; ACANTHAMOEBA; PROFILIN; PURIFICATION; CYTOSKELETON	Neutrophils respond to chemotactic stimuli by increasing the nucleation and polymerization of actin filaments, but the location and regulation of these processes are not well understood. Here, using a permeabilized-cell assay, we show that chemotactic stimuli cause neutrophils to organize many discrete sites of actin polymerization, the distribution of which is biased by external chemotactic gradients. Furthermore, the Arp2/3 complex, which can nucleate actin polymerization, dynamically redistributes to the region of living neutrophils that receives maximal chemotactic stimulation, and the least-extractable pool of the Arp2/3 complex colocalizes with sites of actin polymerization. Our observations indicate that chemoattractant-stimulated neutrophils may establish discrete foci of actin polymerization that are similar to those generated at the posterior surface of the intracellular bacterium Listeria monocytogenes. We propose that asymmetrical establishment and/or maintenance of sites of actin polymerization produces directional migration of neutrophils in response to chemotactic gradients.	Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA.	h_bourne@quickmail.ucsf.edu	Weiner, Orion D/F-2576-2011	Weiner, Orion D/0000-0002-1778-6543	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM027800-27] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AMREIN PC, 1980, BLOOD, V56, P442; [Anonymous], 1997, DECONVOLUTION IMAGES; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; Chan B, 1998, J DIGIT IMAGING, V11, P199, DOI 10.1007/BF03168304; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; GERISCH G, 1981, J CELL SCI, V52, P1; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1997, BIOCHEM J, V328, P105; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; MULLINS RD, IN PRESS CURR BIOL; OKABE S, 1991, J NEUROSCI, V11, P1918; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; REDMOND T, 1993, CELL MOTIL CYTOSKEL, V26, P7, DOI 10.1002/cm.970260103; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Sechi AS, 1997, J CELL BIOL, V137, P155, DOI 10.1083/jcb.137.1.155; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Tilney Lewis G., 1993, Trends in Microbiology, V1, P25, DOI 10.1016/0966-842X(93)90021-I; TUCKER KA, 1987, BLOOD, V70, P372; WATTS RG, 1991, CELL MOTIL CYTOSKEL, V19, P159, DOI 10.1002/cm.970190304; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; ZIGMOND SH, 1974, NATURE, V249, P450, DOI 10.1038/249450a0; ZIGMOND SH, 1972, EXP CELL RES, V73, P383, DOI 10.1016/0014-4827(72)90062-6; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	42	214	233	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					75	81		10.1038/10042	http://dx.doi.org/10.1038/10042			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559877	Green Accepted			2022-12-25	WOS:000083102200013
J	Cairns, MJ; Hopkins, TM; Witherington, C; Wang, L; Sun, LQ				Cairns, MJ; Hopkins, TM; Witherington, C; Wang, L; Sun, LQ			Target site selection for an RNA-cleaving catalytic DNA	NATURE BIOTECHNOLOGY			English	Article						deoxyribozyme; oligonucleotide; DNAzyme; secondary structure; RNA accessibility	ACCESSIBLE SITES; ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; HYBRIDIZATION; DUPLEXES; RIBOZYMES; LIBRARIES; PROBES	A small catalytic DNA, known as the 10-23 DNA enzyme or deoxyribozyme, has been shown to efficiently hydrolyze RNA at purine-pyrimidine (R-Y) junctions in vitro. Although these potentially cleavable junctions are ubiquitous, they are often protected from deoxyribozyme activity by RNA secondary structure. We have developed a multiplex cleavage assay for screening the entire length of a target RNA molecule for deoxyribozyme cleavage sites that are efficient, both in terms of kinetics and accessibility. This strategy allowed us to simultaneously compare the RNA cleaving activity of 80 deoxyribozymes for a model target gene (HPV16 E6), and an additional 60 deoxyribozymes against the rat c-myc target. The human papilloma virus (HPV) target was used primarily to characterize the multiplex system and determine its validity. The c-myc target, coupled with a smooth muscle cell proliferation assay, allowed us to assess the relationship between in vitro cleavage efficiency and c-myc gene suppression in cell culture. The multiplex reaction approach streamlines the process of revealing effective deoxyribozymes in a functional assay and provides accessibility data that may also be applicable to site selection for other hybridization-based agents.	Johnson & Johnson Res Labs, Sydney, NSW 2001, Australia	Johnson & Johnson	Sun, LQ (corresponding author), Johnson & Johnson Res Labs, GPO Box 3331, Sydney, NSW 2001, Australia.			Cairns, Murray/0000-0003-2490-2538				Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176; Birikh KR, 1997, RNA, V3, P429; CAMPBELL TB, 1995, RNA, V1, P598; Gyi JI, 1998, BIOCHEMISTRY-US, V37, P73, DOI 10.1021/bi9719713; HENDRY P, 1992, NUCLEIC ACIDS RES, V20, P5737, DOI 10.1093/nar/20.21.5737; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; Ho SP, 1998, NAT BIOTECHNOL, V16, P59, DOI 10.1038/nbt0198-59; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; Le Tinevez R, 1998, NUCLEIC ACIDS RES, V26, P2273, DOI 10.1093/nar/26.10.2273; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; Lima WF, 1997, J BIOL CHEM, V272, P626; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Majlessi M, 1998, NUCLEIC ACIDS RES, V26, P2224, DOI 10.1093/nar/26.9.2224; Matveeva O, 1997, NUCLEIC ACIDS RES, V25, P5010, DOI 10.1093/nar/25.24.5010; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029	20	127	145	5	66	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					480	486		10.1038/8658	http://dx.doi.org/10.1038/8658			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331809				2022-12-25	WOS:000080074500034
J	Gaidarov, I; Santini, F; Warren, RA; Keen, JH				Gaidarov, I; Santini, F; Warren, RA; Keen, JH			Spatial control of coated-pit dynamics in living cells	NATURE CELL BIOLOGY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY-LIPOPROTEIN; CLATHRIN ASSEMBLY PROTEINS; SINGLE-PARTICLE TRACKING; VESICLE FORMATION; MEMBRANE SKELETON; EPITHELIAL-CELLS; PLASMA-MEMBRANE; SURFACE; MICROFILAMENTS	Here we visualize new aspects of the dynamics of endocytotic clathrin-coated pits and vesicles in mammalian cells by using a fusion protein consisting of green fluorescent protein and clathrin light chain a. Clathrin-coated pits invaginating from the plasma membrane show definite, but highly limited, mobility within the membrane that is relaxed upon treatment with latrunculin B, an inhibitor of actin assembly, indicating that an actin-based framework may be involved in the mobility of these pits. Transient, motile coated vesicles that originate from coated pits can be detected, with multiple vesicles occasionally appearing to emanate from a single pit. Despite their seemingly random distribution, coated pits tend to form repeatedly at defined sites while excluding other regions. This spatial regulation of coated-pit assembly and function is attributable to the attachment of the coated pits to the membrane skeleton.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Keen, JH (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA.							AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON CM, 1992, J CELL SCI, V101, P415; Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; ANDERSON RGW, 1978, CELL, V15, P919, DOI 10.1016/0092-8674(78)90276-3; Bretscher MS, 1998, CURR OPIN CELL BIOL, V10, P537, DOI 10.1016/S0955-0674(98)80070-7; BRODSKY FM, 1985, J CELL BIOL, V101, P2055, DOI 10.1083/jcb.101.6.2055; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; DAVOUST J, 1990, ENDOCYTOSIS, P385; Estes PS, 1996, J NEUROSCI, V16, P5443; GHOSH RN, 1994, BIOPHYS J, V66, P1301, DOI 10.1016/S0006-3495(94)80939-7; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; JIN AJ, 1993, BIOPHYS J, V65, P1523, DOI 10.1016/S0006-3495(93)81189-5; KANASEKI T, 1969, J CELL BIOL, V42, P202, DOI 10.1083/jcb.42.1.202; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1981, J BIOL CHEM, V256, P2538; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; Ludin B, 1998, TRENDS CELL BIOL, V8, P72, DOI 10.1016/S0962-8924(97)01169-0; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MAUPIN P, 1983, J CELL BIOL, V96, P51, DOI 10.1083/jcb.96.1.51; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NICOL A, 1987, J HISTOCHEM CYTOCHEM, V35, P499, DOI 10.1177/35.4.2880891; PLEASURE IT, 1994, THESIS T JEFFERSON U; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; Santini F, 1998, MOL BIOL CELL, V9, P1177, DOI 10.1091/mbc.9.5.1177; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; Saxton MJ, 1997, ANNU REV BIOPH BIOM, V26, P373, DOI 10.1146/annurev.biophys.26.1.373; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Warren RA, 1997, J BIOL CHEM, V272, P2116; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239	48	351	353	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					1	7		10.1038/8971	http://dx.doi.org/10.1038/8971			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559856				2022-12-25	WOS:000083085300010
J	Kitao, S; Shimamoto, A; Goto, M; Miller, RW; Smithson, WA; Lindor, NM; Furuichi, Y				Kitao, S; Shimamoto, A; Goto, M; Miller, RW; Smithson, WA; Lindor, NM; Furuichi, Y			Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome	NATURE GENETICS			English	Article							WERNERS-SYNDROME GENES; MOLECULAR-CLONING; BLOOMS-SYNDROME; IN-VIVO; INSTABILITY; HELICASE; HOMOLOG; SGS1; INTERACTS; MOSAICISM	Rothmund-Thomson syndrome (RTS; also known as poikiloderma congenitale) is a rare, autosomal recessive genetic disorder characterized by abnormalities in skin and skeleton, juvenile cataracts, premature ageing and a predisposition to neoplasia(1-4). Cytogenetic studies indicate that cells from affected patients show genomic instability often associated with chromosomal rearrangements causing an acquired somatic mosaicism(5-9). The gene(s) responsible for RTS remains unknown. The genes responsible for Werner(10) and Bloom(11) syndromes (WRN and BLM, respectively) have been identified as homologues of Escherichia coli RecQ, which encodes a DNA helicase(12) that unwinds double-stranded DNA into single-stranded DNAs. Other eukaryotic homologues thus far identified are human RECQL (refs 13,14), Saccharomyces cerevisiae SGS1 (refs 15,16) and Schizosaccharomyces pombe rqh1(+) (ref, 17). We recently cloned two new human helicase genes, RECQL4 at 8q24.3 and RECQL5 at 17q25, which encode members of the RecQ helicase family(18), Here, we report that three RTS patients carried two types of compound heterozygous mutations in RECQL4, The fact that the mutated alleles were inherited from the parents in one affected family and were not found in ethnically matched controls suggests that mutation of RECQL4 at human chromosome 8q24.3 is responsible for at least some cases of RTS.	AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan; Tokyo Metropolitan Otsuka Hosp, Toshima Ku, Tokyo 1700005, Japan; NCI, Bethesda, MD 20892 USA; Mayo Clin, Rochester, MN USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Furuichi, Y (corresponding author), AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan.							DERKALOUSTIAN VM, 1990, AM J MED GENET, V37, P336, DOI 10.1002/ajmg.1320370308; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Lindor NM, 1996, CLIN GENET, V49, P124; Miozzo M, 1998, INT J CANCER, V77, P504; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; ORSTAVIK KH, 1994, J MED GENET, V31, P570, DOI 10.1136/jmg.31.7.570; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROTHMUND A, 1868, ARCH KLIN EXP OPHTHA, V4, P159; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Thomson MS, 1936, BRIT J DERMATOL, V48, P221; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; VENNOS EM, 1992, J AM ACAD DERMATOL, V27, P750, DOI 10.1016/0190-9622(92)70249-F; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YING KL, 1990, J MED GENET, V27, P258, DOI 10.1136/jmg.27.4.258; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	19	519	534	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					82	84		10.1038/8788	http://dx.doi.org/10.1038/8788			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319867				2022-12-25	WOS:000080096300028
J	Feng, H; Zhong, WW; Punkosdy, G; Gu, SB; Zhou, L; Seabolt, EK; Kipreos, ET				Feng, H; Zhong, WW; Punkosdy, G; Gu, SB; Zhou, L; Seabolt, EK; Kipreos, ET			CUL-2 is required for the G1-to-S-phase transition and mitotic chromosome condensation in Caenorhabditis elegans	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-CYCLE EXIT; C-ELEGANS; F-BOX; DEGRADATION; PHOSPHORYLATION; PROTEOLYSIS; MITOSIS; RNA; G1	The human cullin protein CUL-2 functions in a ubiquitin-ligase complex with the von Hippel-Lindau (VHL) tumour suppressor protein. Here we show that, in Caenorhabditis elegans, cul-2 is expressed in proliferating cells and is required at two distinct points in the cell cycle, the G1-to-S-phase transition and mitosis. cul-2 mutant germ cells undergo a G1-phase arrest that correlates with accumulation of CKI-1, a member of the CIP/KIP family of cyclin-dependent-kinase inhibitors. In cul-2 mutant embryos, mitotic chromosomes are unable to condense, leading to unequal DNA segregation, chromosome bridging and the formation of multiple nuclei.	Univ Georgia, Dept Cell Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Kipreos, ET (corresponding author), Univ Georgia, Dept Cell Biol, Athens, GA 30602 USA.	ekipreos@cb.uga.edu	Feng, Hui/L-4343-2019; Feng, Hui/D-4423-2019	Feng, Hui/0000-0003-1318-821X	NIGMS NIH HHS [R01 GM55297] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055297] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hong Y, 1998, DEVELOPMENT, V125, P3585; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; LONGERGAN KM, 1999, MOL CELL BIOL, V18, P732; MAINS PE, 1990, GENETICS, V126, P593; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Plasterk RHA, 1995, METHOD CELL BIOL, V48, P59; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seydoux G, 1995, METHOD CELL BIOL, V48, P323; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X	29	104	112	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					486	492		10.1038/70272	http://dx.doi.org/10.1038/70272			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587644				2022-12-25	WOS:000084136100016
J	Cappellen, D; De Oliveira, C; Ricol, D; de Medina, SGD; Bourdin, J; Sastre-Garau, X; Chopin, D; Thiery, JP; Radvanyi, F				Cappellen, D; De Oliveira, C; Ricol, D; de Medina, SGD; Bourdin, J; Sastre-Garau, X; Chopin, D; Thiery, JP; Radvanyi, F			Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas	NATURE GENETICS			English	Letter							GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; THANATOPHORIC DYSPLASIA; SKELETAL DISORDERS; GENE; TRANSLOCATION; EXPRESSION		CNRS, Lab Morphogenese Cellulaire & Progress Tumorale, UMR 144, Inst Curie,Sect Rech, Paris 05, France; Inst Curie, Med Sect, Dept Pathol, F-75248 Paris 05, France; CHU Henri Mondor, Ctr Rech Chirurg, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Radvanyi, F (corresponding author), CNRS, Lab Morphogenese Cellulaire & Progress Tumorale, UMR 144, Inst Curie,Sect Rech, 26 Rue Ulm, Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Sastre-Garau, Xavier/0000-0001-5992-2083; Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424				Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Delezoide AL, 1997, HUM MOL GENET, V6, P1899, DOI 10.1093/hmg/6.11.1899; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; MURGUE B, 1994, CANCER RES, V54, P5206; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Naski MC, 1998, DEVELOPMENT, V125, P4977; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1	16	569	658	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					18	20		10.1038/12615	http://dx.doi.org/10.1038/12615			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471491				2022-12-25	WOS:000082337300009
J	Tomazin, R; Boname, J; Hegde, NR; Lewinsohn, DM; Altschuler, Y; Jones, TR; Cresswell, P; Nelson, JA; Riddell, SR; Johnson, DC				Tomazin, R; Boname, J; Hegde, NR; Lewinsohn, DM; Altschuler, Y; Jones, TR; Cresswell, P; Nelson, JA; Riddell, SR; Johnson, DC			Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4(+) T cells	NATURE MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; HEAVY-CHAINS; HLA-DM; EXPRESSION; GENE; DEGRADATION; PROTEASOME; LYMPHOCYTES	Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that causes life-threatening disease in patients who are immunosuppressed for bone marrow or tissue transplantation or who have AIDS (ref. 1). HCMV establishes lifelong latent infections and, after periodic: reactivation from latency, uses a panel of immune evasion proteins to survive and replicate in the face of robust, fully primed host immunity(2,3). Monocyte/macrophages are important host cells for HCMV, serving as a latent reservoir and as a means of dissemination throughout the body(4). Macrophages and other HCMV-permissive cells, such as endothelial and glial cells, can express MHC class II proteins and present antigens to CD4+ T lymphocytes. Here, we show that the HCMV protein US2 causes degradation of two essential proteins in the MHC class II antigen presentation pathway: HLA-DR-c( and DM-a. This was unexpected, as US2 has been shown to cause degradation of MHC class I (refs. 5,6), which has only limited homology with class II proteins. Expression of US2 in cells reduced or abolished their ability to present antigen to CD4+ T lymphocytes. Thus, US2 may allow HCMV-infected macrophages to remain relatively 'invisible' to CD4+ T cells, a property that would be important after virus reactivation.	Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Portland VA Med Ctr, Div Pulm & Crit Care Med, Portland, OR 97207 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Wyeth Ayerst Res, Dept Biol Mol, Pearl River, NY 10965 USA; Yale Univ, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; University of California System; University of California San Francisco; Pfizer; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center	Johnson, DC (corresponding author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.		Hegde, Nagendra R/H-3132-2019; Lewinsohn, David/I-4936-2013	Hegde, Nagendra R/0000-0001-5260-2159; Boname, Jessica/0000-0002-5149-5934; Lewinsohn, David/0000-0001-9906-9494	NATIONAL EYE INSTITUTE [R01EY011245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024178, R01AI041754] Funding Source: NIH RePORTER; NEI NIH HHS [EY11245] Funding Source: Medline; NIAID NIH HHS [AI24178, AI41754] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASTA PV, 1987, J IMMUNOL, V138, P1275; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Cresswell P, 1999, CURR OPIN IMMUNOL, V11, P61, DOI 10.1016/S0952-7915(99)80011-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Dusseljee S, 1998, J CELL SCI, V111, P2217; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fish KN, 1998, J VIROL, V72, P6657, DOI 10.1128/JVI.72.8.6657-6664.1998; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Johnson DC, 1998, CURR TOP MICROBIOL, V232, P149; Jones TR, 1997, J VIROL, V71, P2970, DOI 10.1128/JVI.71.4.2970-2979.1997; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; LIGAS MW, 1988, J VIROL, V62, P1486, DOI 10.1128/JVI.62.5.1486-1494.1988; Miller DM, 1998, J EXP MED, V187, P675, DOI 10.1084/jem.187.5.675; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nordeng TW, 1998, CURR TOP MICROBIOL, V232, P179; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schust DJ, 1998, J EXP MED, V188, P497, DOI 10.1084/jem.188.3.497; SODERBERGNAUCLE.C, 1998, PERSISTENT VIRAL INF, P209; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	28	203	210	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1039	1043		10.1038/12478	http://dx.doi.org/10.1038/12478			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470081				2022-12-25	WOS:000082337200038
J	Wang, YF; Tao, L; Mitchell, E; Bravery, C; Berlingieri, P; Armstrong, P; Vaughan, R; Underwood, J; Lehner, T				Wang, YF; Tao, L; Mitchell, E; Bravery, C; Berlingieri, P; Armstrong, P; Vaughan, R; Underwood, J; Lehner, T			Allo-immunization elicits CD8(+) T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GP120 ENVELOPE GLYCOPROTEIN; RECEPTOR CXCR4; MACAQUES; VACCINE; LYMPHOCYTES; ENTRY; REPLICATION; INDIVIDUALS; PROTECTION	We assessed the potential for an allogeneic-based vaccine against HIV infection in women who were allo-immunized with their partners' mononuclear leucocytes to prevent spontaneous recurrent abortion. Within 1 month of allo-immunization, there was significant upregulation in the concentrations of CD8 cell-derived suppressor factor activity, RANTES, and macrophage inflammatory proteins 1 alpha and 1 beta. Allo-immunization also downregulated the proportion of cells with CCR5 and CXCR4 receptors. We also found a dose-dependent decrease in HIV infectivity of CD4+ cells in vitro after allo-immunization with both primary and T-cell line adapted HIV-1. This study provides a rational basis for an alternative or complementary strategy of allo-immunization against HIV infection.	Guys Hosp, Guys Kings & St Thomas Med & Dent Sch, Dept Immunobiol, London SE1 9RT, England; Guys Hosp, Guys Kings & St Thomas Med & Dent Sch, Dept Tissue Typing, London SE1 9RT, England; Royal London Hosp, Dept Gynaecol, London E1 2AD, England; St Marys Hosp, Imperial Coll, Dept Obstet & Gynaecol, Fac Med, London W2 1PG, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Barts Health NHS Trust; Royal London Hospital; Imperial College London	Lehner, T (corresponding author), Guys Hosp, Guys Kings & St Thomas Med & Dent Sch, Dept Immunobiol, 3rd Floor,Med Sch Bldg, London SE1 9RT, England.	thomas.lehner@kcl.ac.uk						Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; Bruhl P, 1996, AIDS RES HUM RETROV, V12, P31, DOI 10.1089/aid.1996.12.31; Bunce M., 1997, Tissue Antigens, V50, P100, DOI 10.1111/j.1399-0039.1997.tb02847.x; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; CELUM CL, 1994, ARCH INTERN MED, V154, P1129, DOI 10.1001/archinte.154.10.1129; CLERICI M, 1993, EUR J IMMUNOL, V23, P2022, DOI 10.1002/eji.1830230845; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Kishore R, 1996, J Obstet Gynaecol Res, V22, P177; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MORLUCHI H, 1999, J IMMUNOL, V162, P7543; MOWBRAY JF, 1987, LANCET, V2, P679; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Pinto LA, 1998, BLOOD, V92, P3346, DOI 10.1182/blood.V92.9.3346.421k40_3346_3354; PLUMMER FA, 1993, 9 INT C AIDS HIV STD; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SHEARER GM, 1993, SCIENCE, V262, P161, DOI 10.1126/science.8211133; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; STOTT J, 1994, NEUVIERNE COLL CENT, P219; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Wang YF, 1998, P NATL ACAD SCI USA, V95, P5223, DOI 10.1073/pnas.95.9.5223; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	37	97	100	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	1999	5	9					1004	1009		10.1038/12440	http://dx.doi.org/10.1038/12440			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470076				2022-12-25	WOS:000082337200033
J	Ikeda, K; Ichikawa, T; Wakimoto, H; Silver, JS; Deisboeck, TS; Finkelstein, D; Harsh, GR; Louis, DN; Bartus, RT; Hochberg, FH; Chiocca, EA				Ikeda, K; Ichikawa, T; Wakimoto, H; Silver, JS; Deisboeck, TS; Finkelstein, D; Harsh, GR; Louis, DN; Bartus, RT; Hochberg, FH; Chiocca, EA			Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses	NATURE MEDICINE			English	Article							HERPES-SIMPLEX VIRUS-1; THYMIDINE KINASE GENE; IN-VIVO; RIBONUCLEOTIDE REDUCTASE; BRADYKININ ANALOG; DNA-SYNTHESIS; HUMAN GLIOMA; HUMAN SERUM; MUTANT; VECTOR	The occurrence of multiple tumors in an organ heralds a rapidly fatal course. Although intravascular administration may deliver oncolytic viruses/vectors to each of these tumors, its efficiency is impeded by an antiviral activity present in complement-depleted plasma of rodents and humans. Here, this activity was shown to interact with complement in a calcium-dependent fashion, and antibody neutralization studies indicated preimmune IgM has a contributing role. Short-term exposure to cyclophosphamide (CPA) partially suppressed this activity in rodents and humans. At longer time points, cyclophosphamide also abrogated neutralizing antibody responses. Cyclophosphamide treatment of rats with large single or multiple intracerebral tumors substantially increased viral survival and propagation, leading to neoplastic regression.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurooncol Labs, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosurg Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Alkermes, Cambridge, MA 02111 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Alkermes	Chiocca, EA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurooncol Labs, Charlestown, MA 02129 USA.		Wakimoto, Hiroaki/H-4533-2019	Wakimoto, Hiroaki/0000-0001-8225-241X	NATIONAL CANCER INSTITUTE [P01CA069246] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 69246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreansky S, 1997, CANCER RES, V57, P1502; Barnett FH, 1999, CANCER GENE THER, V6, P14, DOI 10.1038/sj.cgt.7700003; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Black KL, 1997, J NEUROSURG, V86, P603, DOI 10.3171/jns.1997.86.4.0603; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; BOVIATSIS EJ, 1994, GENE THER, V1, P323; Bui LA, 1997, HUM GENE THER, V8, P2173, DOI 10.1089/hum.1997.8.18-2173; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; COCHRANE CG, 1970, J IMMUNOL, V105, P55; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Elliott PJ, 1996, EXP NEUROL, V141, P214, DOI 10.1006/exnr.1996.0156; Fehr T, 1998, NAT MED, V4, P945, DOI 10.1038/nm0898-945; Fike JR, 1998, J NEURO-ONCOL, V37, P199, DOI 10.1023/A:1005874206814; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; Herrlinger U, 1998, GENE THER, V5, P809, DOI 10.1038/sj.gt.3300643; HUEMER HP, 1988, INTERVIROLOGY, V29, P68; JAMES K, 1982, AM J MED TECHNOL, V48, P735; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Kucharczuk JC, 1997, CANCER RES, V57, P466; LeMay DR, 1998, HUM GENE THER, V9, P989, DOI 10.1089/hum.1998.9.7-989; Lubinski JM, 1998, J VIROL, V72, P8257, DOI 10.1128/JVI.72.10.8257-8263.1998; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Pyles RB, 1997, HUM GENE THER, V8, P533, DOI 10.1089/hum.1997.8.5-533; Rainov NG, 1995, HUM GENE THER, V6, P1543, DOI 10.1089/hum.1995.6.12-1543; Rampling R, 1998, NAT MED, V4, P133, DOI 10.1038/nm0298-133c; ROIZMAN B, 1968, J VIROL, V2, P83, DOI 10.1128/JVI.2.1.83-84.1968; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; Welsh RM, 1998, J VIROL, V72, P4650, DOI 10.1128/JVI.72.6.4650-4656.1998; WOOD MJA, 1994, GENE THER, V1, P283	38	257	290	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					881	887		10.1038/11320	http://dx.doi.org/10.1038/11320			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426310				2022-12-25	WOS:000081684000030
J	Bulyk, ML; Gentalen, E; Lockhart, DJ; Church, GM				Bulyk, ML; Gentalen, E; Lockhart, DJ; Church, GM			Quantifying DNA-protein interactions by double-stranded DNA arrays	NATURE BIOTECHNOLOGY			English	Article						dsDNA arrays; restriction enzymes; DNA-protein interactions	DENSITY OLIGONUCLEOTIDE ARRAYS; ECORI RESTRICTION ENDONUCLEASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; COGNATE DNA; BAM-HI; RECOGNITION; BINDING; GENOME; SEQUENCE	We have created double-stranded oligonucleotide arrays to perform highly parallel investigations of DNA-protein interactions. Arrays of single-stranded DNA oligonucleotides, synthesized by a combination of photolithography and solid-state chemistry, have been used for a variety of applications, including large-scale mRNA expression monitoring, genotyping, and sequence-variation analysis. We converted a single-stranded to a double-stranded array by synthesizing a constant sequence at every position on an array and then annealing and enzymatically extending a complementary primer. The efficiency of second-strand synthesis was demonstrated by incorporation of fluorescently labeled dNTPs (2'-deoxyribonucleoside 5'-triphosphates) and by terminal transferase addition of a fluorescently labeled ddNTP. The accuracy of second-strand synthesis was demonstrated by digestion of the arrayed double-stranded DNA (dsDNA) on the array with sequence-specific restriction enzymes. We showed dam methylation of dsDNA arrays by digestion with Dpnl, which cleaves when its recognition site is methylated. This digestion demonstrated that the dsDNA arrays can be further biochemically modified and that the DNA is accessible for interaction with DNA-binding proteins. This dsDNA array approach could be extended to explore the spectrum of sequence-specific protein binding sites in genomes.	Harvard Univ, Grad Biophys Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Harvard University; Harvard Medical School; Affymetrix	Church, GM (corresponding author), Harvard Univ, Grad Biophys Program, Boston, MA 02115 USA.	church@salt2.med.harvard.edu		Gentalen, Erik/0000-0002-7982-2431; church, george/0000-0001-6232-9969				BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; Cho RJ, 1998, P NATL ACAD SCI USA, V95, P3752, DOI 10.1073/pnas.95.7.3752; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; GEORGE J, 1980, J BIOL CHEM, V255, P6521; Gunderson KL, 1998, GENOME RES, V8, P1142, DOI 10.1101/gr.8.11.1142; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KUZMIN NP, 1984, MOL BIOL+, V18, P166; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOCKHART DJ, 1996, Patent No. 5556752; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; McGall GH, 1997, J AM CHEM SOC, V119, P5081, DOI 10.1021/ja964427a; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; NASRI M, 1987, NUCLEIC ACIDS RES, V15, P7677, DOI 10.1093/nar/15.19.7677; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, V1; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15070; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SUZUKI M, 1995, PROTEIN ENG, V8, P329, DOI 10.1093/protein/8.4.329; Swartz DR, 1996, SCANNING MICROSCOPY SUPPLEMENT 10, 1996, P273; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1990, BIOCHEMISTRY-US, V29, P4682, DOI 10.1021/bi00471a024; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018	47	194	229	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					573	577		10.1038/9878	http://dx.doi.org/10.1038/9878			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385322				2022-12-25	WOS:000080716500029
J	Knight, JC; Udalova, I; Hill, AVS; Greenwood, BM; Peshu, N; Marsh, K; Kwiatkowski, D				Knight, JC; Udalova, I; Hill, AVS; Greenwood, BM; Peshu, N; Marsh, K; Kwiatkowski, D			A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria	NATURE GENETICS			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; DISEASE; SUSCEPTIBILITY; MACROPHAGES; PROTECTION	Genetic Variation in cytokine promoter regions is postulated to influence susceptibility to infection, but the molecular mechanisms by which such polymorphisms might affect gene, regulation are unknown. Through systematic DNA footprinting of the TNF (encoding tumour necrosis factor, TNF) promoter region, we have identified a single nucleotide polymorphism (SNP) that causes the helix-turn-helix transcription factor OCT-1 to bind to a novel region of complex protein-DNA interactions and alters gene expression in human monocytes. The OCT-1-binding genotype, found in approximately 5% of Africans, is associated with fourfold increased susceptibility to cerebral malaria in large case-control studies of West African and East African populations, after correction for other known TNF polymorphisms and linked HLA alleles.	Inst Mol Med, Mol Infect Dis Grp, Oxford OX3 9DS, England; Inst Mol Med, Mol Immunol Grp, Oxford OX3 9DS, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Med Res Council Labs, Fajara, Senegal; Wellcome Clin Res Unit, Kilifi, Kenya	University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Knight, JC (corresponding author), Inst Mol Med, Mol Infect Dis Grp, Oxford OX3 9DS, England.		Knight, Julian Charles/W-2399-2019; HILL, Adrian V>S>/C-1306-2008; Knight, Julian/C-7242-2009	Knight, Julian Charles/0000-0002-0377-5536; Knight, Julian/0000-0002-0377-5536; Udalova, Irina/0000-0002-6716-2528; Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; Brinkman BMN, 1996, J INFLAMM, V46, P32; Brinkman BMN, 1997, BRIT J RHEUMATOL, V36, P516; Brinkman BMN, 1997, J INFECT DIS, V175, P188, DOI 10.1093/infdis/175.1.188; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; Conway DJ, 1997, INFECT IMMUN, V65, P1003, DOI 10.1128/IAI.65.3.1003-1006.1997; DALFONSO S, 1994, IMMUNOGENETICS, V39, P150; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; HAMANN A, 1995, BIOCHEM BIOPH RES CO, V211, P833, DOI 10.1006/bbrc.1995.1887; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Hohler T, 1997, J INVEST DERMATOL, V109, P562, DOI 10.1111/1523-1747.ep12337469; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; LEWONTIN RC, 1964, GENETICS, V49, P49; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; MOLYNEUX ME, 1989, Q J MED, V71, P441; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Roy S, 1997, J INFECT DIS, V176, P530, DOI 10.1086/517282; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; Stuber F, 1996, J INFLAMM, V46, P42; UDALOVA IA, 1995, DOKL AKAD NAUK+, V342, P413; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; Wu GD, 1997, J BIOL CHEM, V272, P2396; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; Zuckerkandl E, 1997, J MOL EVOL, V44, pS2, DOI 10.1007/PL00000048	39	372	402	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					145	150		10.1038/9649	http://dx.doi.org/10.1038/9649			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369255				2022-12-25	WOS:000080680900018
J	Kozyraki, R; Fyfe, J; Kristiansen, M; Gerdes, C; Jacobsen, C; Cui, SY; Christensen, EI; Aminoff, M; de la Chapelle, A; Krahe, R; Verroust, PJ; Moestrup, SK				Kozyraki, R; Fyfe, J; Kristiansen, M; Gerdes, C; Jacobsen, C; Cui, SY; Christensen, EI; Aminoff, M; de la Chapelle, A; Krahe, R; Verroust, PJ; Moestrup, SK			The intrinsic factor-vitamin B-12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein	NATURE MEDICINE			English	Article							FACTOR-COBALAMIN RECEPTOR; YOLK-SAC; SR-BI; TERATOGENIC ANTIBODIES; BRUSH-BORDER; PROTEIN; IDENTIFICATION; INHIBITION; TARGET; CELLS	Cubilin is the intestinal receptor for the endocytosis of intrinsic factor-vitamin B-12. However, several lines of evidence, including a high expression in kidney and yolk sac, indicate it may have additional functions. We isolated apolipoprotein A-I (apoA-I), the main protein of high-density lipoprotein (HDL), using cubilin affinity chromatography. Surface plasmon resonance analysis demonstrated a high-affinity binding of apoA-I and HDL to cubilin, and cubilin-expressing yolk sac cells showed efficient I-125-HDL endocytosis that could be inhibited by IgG antibodies against apoA-I and cubilin. The physiological relevance of the cubilin-apoA-I interaction was further emphasized by urinary apoA-I loss in some known cases of functional cubilin deficiency. Therefore, cubilin is a receptor in epithelial apoA-I/HDL metabolism.	Aarhus Univ, Dept Med Biochem, Aarhus, Denmark; Michigan State Univ, Dept Microbiol, E Lansing, MI 48824 USA; Aarhus Univ Hosp, Dept Med & Cardiol A, Aarhus, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus C, Denmark; Ohio State Univ, Div Human Canc Genet, Dept Immunol & Microbiol, Ctr Comprehens Canc, Columbus, OH USA; Univ Helsinki, Folkhalsan Inst Genet, FIN-00014 Helsinki, Finland; Hop Tenon, Inst Natl Sante & Rech Med, U489, Paris, France	Aarhus University; Michigan State University; Aarhus University; Aarhus University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Helsinki; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Moestrup, SK (corresponding author), Aarhus Univ, Dept Med Biochem, Aarhus, Denmark.		Kozyraki, Renata/G-5321-2017; Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Madsen, Mette/0000-0001-7241-6505; Kozyraki, Renata/0000-0001-9779-5898	NCI NIH HHS [P30 CA16058] Funding Source: Medline; NIDDK NIH HHS [DK45341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aminoff M, 1999, NAT GENET, V21, P309, DOI 10.1038/6831; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GLASS C, 1985, J BIOL CHEM, V260, P744; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; Hatch F T, 1968, Adv Lipid Res, V6, P1; Hatzopoulos AK, 1998, J LIPID RES, V39, P495; HOMANICS GE, 1995, TERATOLOGY, V51, P1, DOI 10.1002/tera.1420510102; IMERSLUND O, 1960, Acta Paediatr Suppl, V49(Suppl 119), P1; KolfClauw M, 1996, TERATOLOGY, V54, P115, DOI 10.1002/(SICI)1096-9926(199609)54:3<115::AID-TERA1>3.0.CO;2-2; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kozyraki R, 1998, BLOOD, V91, P3593; LEPANSE S, 1995, EUR J CELL BIOL, V67, P120; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; MOESTRUP SK, J BIOL CHEM, V5235, P98; PLUMP AS, 1997, J LIPID RES, V36, P1933; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAHALI D, 1993, AM J PATHOL, V142, P1654; SAKU K, 1984, METABOLISM, V33, P432, DOI 10.1016/0026-0495(84)90143-4; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wyne KL, 1998, J LIPID RES, V39, P518	33	212	218	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					656	661		10.1038/9504	http://dx.doi.org/10.1038/9504			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371504				2022-12-25	WOS:000080823300034
J	Kruglyak, L				Kruglyak, L			Prospects for whole-genome linkage disequilibrium mapping of common disease genes	NATURE GENETICS			English	Article							SEQUENCE VARIATION; ALLELE MODEL; POPULATIONS; EXPANSION; BIOLOGY	Recently attention has focused on the use of whole-genome linkage disequilibrium (LD) studies to map common disease genes. Such studies would employ a dense map of single nucleotide polymorphisms (SNPs) to detect association between a marker and disease. Construction of SNP maps is currently underway. An essential issue yet to be settled is the required marker density of such maps. Here, I use population simulations to estimate the extent of LD surrounding common gene variants in the general human population as well as in isolated populations. Two main conclusions emerge from these investigations. First, a useful level of LD is unlikely to extend beyond an average distance of roughly 3 kb in the general population, which implies that approximately 500,000 SNPs will be required for whole-genome studies. Second, the extent of LD is similar in isolated populations unless the founding bottleneck is very narrow or the frequency of the variant is low (<5%).	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Kruglyak, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Peng, Bo/A-6920-2009; Holloway, John/B-5424-2009	Peng, Bo/0000-0001-8225-2284; Holloway, John/0000-0001-9998-0464				AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; Camp NJ, 1997, AM J HUM GENET, V61, P1424, DOI 10.1086/301648; CARLSON CS, 1998, AM J HUM GENET, V63, pA284; Chapman NH, 1998, AM J HUM GENET, V63, P1872, DOI 10.1086/302139; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; DONNELLY P, 1995, ANNU REV GENET, V29, P40; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Hudson R, 1991, OXFORD SURVEYS EVOLU, V7, P1; HUDSON RR, 1985, GENETICS, V109, P611; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; HUDSON RR, 1992, MECH MOL EVOLUTION, P23; JORDE LB, 1995, AM J HUM GENET, V56, P11; KAPLAN N, 1992, AM J HUM GENET, V51, P333; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; Landegren U, 1998, GENOME RES, V8, P769, DOI 10.1101/gr.8.8.769; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Li W. H, 1997, MOL EVOLUTION; MullerMyhsok B, 1997, SCIENCE, V275, P1328; Reich DE, 1998, P NATL ACAD SCI USA, V95, P8119, DOI 10.1073/pnas.95.14.8119; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; ROBERTSON A, 1983, PROC R SOC SER B-BIO, V219, P253, DOI 10.1098/rspb.1983.0073; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; Terwilliger JD, 1998, HUM HERED, V48, P138, DOI 10.1159/000022794; Thompson EA, 1997, AM J HUM GENET, V60, P197; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077	31	1032	1087	0	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					139	144		10.1038/9642	http://dx.doi.org/10.1038/9642			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369254				2022-12-25	WOS:000080680900017
J	Hoessel, R; Leclerc, S; Endicott, JA; Nobel, MEM; Lawrie, A; Tunnah, P; Leost, M; Damiens, E; Marie, D; Marko, D; Niederberger, E; Tang, WC; Eisenbrand, G; Meijer, L				Hoessel, R; Leclerc, S; Endicott, JA; Nobel, MEM; Lawrie, A; Tunnah, P; Leost, M; Damiens, E; Marie, D; Marko, D; Niederberger, E; Tang, WC; Eisenbrand, G; Meijer, L			Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases	NATURE CELL BIOLOGY			English	Article							CRYSTAL-STRUCTURES; PROTEIN-KINASE; HUMAN CDK2; ROSCOVITINE	Indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases. Here we identify indirubin and its analogues as potent inhibitors of cyclin-dependent kinases (CDKs), The crystal structure of CDK2 in complex with indirubin derivatives shows that indirubin interacts with the kinase's ATP-binding site through van der Waals interactions and three hydrogen bonds. Indirubin-3'-monoxime inhibits the proliferation of a large range of cells, mainly through arresting the cells in the G2/M phase of the cell cycle. These results have implications for therapeutic optimization of indigoids.	CNRS, Biol Stn, Cell Cycle Lab, F-29682 Roscoff, Bretagne, France; Univ Kaiserslautern, Dept Chem, Div Food Chem & Environm Toxicol, D-67663 Kaiserslautern, Germany; CNRS, Biol Stn, Phytoplankton Grp, F-29682 Roscoff, Bretagne, France; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Oxford Ctr Mol Sci, Oxford OX1 3QU, England; Univ Lille 1, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS); University of Oxford; University of Oxford; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Eisenbrand, G (corresponding author), CNRS, Biol Stn, Cell Cycle Lab, BP 74, F-29682 Roscoff, Bretagne, France.	eisenbra@rhrk.uni-kl.de; meijer@sb-roscoff.fr	Marko, Doris/B-9354-2014; Eisenbrand, Gerhard/AEQ-0284-2022; MEIJER, Laurent/ABE-7465-2021	Marko, Doris/0000-0001-6568-2944; Eisenbrand, Gerhard/0000-0003-4079-2463; , laurent/0000-0003-3511-4916; Endicott, Jane/0000-0003-4868-0116				[Anonymous], 1992, CHIN DRUGS PLANT ORI; [Anonymous], 1983, CHIN TRADIT HERB DRU; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balfour-Paul Jenny, 1998, INDIGO; BROWN NR, IN PRESS J BIOL CHEM; Chang CN, 1985, ADV CHINESE MED MAT, P369; CHANG HM, 1987, PHARMACOL APPL CHINE, V2; CHEN DH, 1983, CHINESE TRAD HERB DR, V15, P6; Cooperative Group of Clinical Therapy of Indirubin, 1980, CHINESE J INTERN MED, V1, P132; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Du D.J., 1981, CHINESE TRAD HERB DR, V12, P406; Gan WJ, 1985, CHIN ACAD MED SCI BE, V6, P611; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU YC, 1989, ACTA PHARMACOL SIN, V24, P629; HAN R, 1994, STEM CELLS, V12, P53, DOI 10.1002/stem.5530120110; HURRY JB, 1930, WOOD PLANT DYE; Institute of Haematology Chinese Academy of Medical Sciences, 1979, CHINESE J INTERN MED, V18, P83; Institute of Hematology Chinese Academy of Medical Sciences, 1979, CHINESE J INTERN MED, V15, P86; JI X, 1991, Biomedical and Environmental Sciences, V4, P332; JI XJ, 1981, ACTA PHARM SIN, V16, P146; Jiang S., 1986, CHINICAL J HEMATOLOG, V7, P30; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LEE K, 1979, NATL MED J CHINA, V59, P129; Li CM, 1996, B CHEM SOC JPN, V69, P1621, DOI 10.1246/bcsj.69.1621; LIU CX, 1984, ACTA PHARMACOL SIN, V5, P137; Ma M Z, 1983, J Tradit Chin Med, V3, P245; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P56; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; *SICH I TRAD CHIN, 1981, CHIN TRAD HERB DRUGS, V12, P27; WAN J-H, 1981, Acta Pharmacologica Sinica, V2, P241; WANG JH, 1981, ACTA PHARM SINICA, V2, P241; Wu G.Y., 1980, CHIN MED J, V60, P451; WU GY, 1982, SCI SIN B-CHEM B A M, V25, P1071; Wu K M, 1985, Yao Xue Xue Bao, V20, P821; WU LM, 1979, COMM CHINESE HERBAL, V9, P6; ZHANG L, 1985, ACTA ACAD MED SIN, V7, P112; Zhang Z N, 1985, J Tradit Chin Med, V5, P246; Zheng Q.T, 1979, COMM CHIN HERB MED, V10, P19; Zheng Q.T., 1979, COMM CHIN HERB MED, V10, P35; ZHU YP, 1995, PHARM WORLD SCI, V17, P103, DOI 10.1007/BF01872386; 1995, CHINESE PHARMACOPOEI, V1	48	701	749	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					60	67		10.1038/9035	http://dx.doi.org/10.1038/9035			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559866				2022-12-25	WOS:000083085300020
J	de Winter, JP; Rooimans, MA; van der Weel, L; van Berkel, CGM; Alon, N; Bosnoyan-Collins, L; de Groot, J; Zhi, Y; Waisfisz, Q; Pronk, JC; Arwert, F; Mathew, CG; Scheper, RJ; Hoatlin, ME; Buchwald, M; Joenje, H				de Winter, JP; Rooimans, MA; van der Weel, L; van Berkel, CGM; Alon, N; Bosnoyan-Collins, L; de Groot, J; Zhi, Y; Waisfisz, Q; Pronk, JC; Arwert, F; Mathew, CG; Scheper, RJ; Hoatlin, ME; Buchwald, M; Joenje, H			The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM	NATURE GENETICS			English	Article							ANEMIA		Free Univ Amsterdam, Dept Clin Genet & Human Genet, Amsterdam, Netherlands; Univ Toronto, Dept Med & Mol Genet, Toronto, ON, Canada; Free Univ Amsterdam Hosp, Dept Pathol, Amsterdam, Netherlands; Oregon Hlth Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; Guys Hosp, Div Med & Mol Genet, GKT Sch Med, London SE1 9RT, England	Vrije Universiteit Amsterdam; University of Toronto; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Oregon Health & Science University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Joenje, H (corresponding author), Free Univ Amsterdam, Dept Clin Genet & Human Genet, Amsterdam, Netherlands.		Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Waisfisz, Quinten/0000-0002-7384-9182	NHLBI NIH HHS [HL50301, HL56045] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056045, R29HL056045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; Waisfisz Q, 1999, AM J HUM GENET, V64, P1400, DOI 10.1086/302385; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341	11	217	222	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					15	16		10.1038/71626	http://dx.doi.org/10.1038/71626			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615118				2022-12-25	WOS:000084609200007
J	Maddox, PS; Bloom, KS; Salmon, ED				Maddox, PS; Bloom, KS; Salmon, ED			The polarity and dynamics of microtubule assembly in the budding yeast Saccharomyces cerevisiae	NATURE CELL BIOLOGY			English	Article							MITOTIC SPINDLE; CELL-CYCLE; ANAPHASE; PROTEIN; FLUX; MICROSCOPY; MITOSIS; DYNEIN; FUSION; KAR3	Microtubule assembly in Saccharomyces cerevisiae is initiated from sites within spindle pole bodies (SPBs) in the nuclear envelope. Microtubule plus ends are thought to be organized distal to the SPBs, while minus ends are proximal. Several hypotheses for the function of microtubule motor proteins in force generation and regulation of microtubule assembly propose that assembly and disassembly occur at minus ends as well as at plus ends. Here we analyse microtubule assembly relative to the SPBs in haploid yeast cells expressing green fluorescent protein fused to alpha-tubulin, a microtubule subunit, Throughout the cell cycle, analysis of fluorescent speckle marks on cytoplasmic astral microtubules reveals that there is no detectable assembly or disassembly at minus ends. After laser-photobleaching, metaphase spindles recover about 63% of the bleached fluorescence, with a half-life of about 1 minute. After anaphase onset, photobleached marks in the interpolar spindle are persistent and do not move relative to the SPBs, In late anaphase, the elongated spindles disassemble at the microtubule plus ends, These results show for astral and anaphase interpolar spindle microtubules, and possibly for metaphase spindle microtubules, that microtubule assembly and disassembly occur at plus, and not minus, ends.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Maddox, PS (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [R37 GM024364, R37 GM032238, R01 GM024364, R01 GM032238-14, GM24364, GM32238, R01 GM032238] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032238, R37GM032238, R01GM024364, R37GM024364] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1998, J CELL BIOL, V141, P703, DOI 10.1083/jcb.141.3.703; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Huyett A, 1998, J CELL SCI, V111, P295; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Lee L, 1999, J CELL BIOL, V144, P947, DOI 10.1083/jcb.144.5.947; Maddox P, 1999, J CELL BIOL, V144, P977, DOI 10.1083/jcb.144.5.977; Mallavarapu A, 1999, CURR BIOL, V9, P1423, DOI 10.1016/S0960-9822(00)80090-1; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; Salmon ED, 1998, METHOD CELL BIOL, V56, P185, DOI 10.1016/S0091-679X(08)60427-6; SALMON ED, 1986, APPLICATIONS FLUORES, P377; Saunders WS, 1999, CURR OPIN CELL BIOL, V11, P129, DOI 10.1016/S0955-0674(99)80016-7; SAWIN KE, 1994, MOL BIOL CELL, V5, P217, DOI 10.1091/mbc.5.2.217; SAXTON WM, 1987, J CELL BIOL, V105, P575; Shaw SL, 1997, CURR BIOL, V7, P701, DOI 10.1016/S0960-9822(06)00299-5; Shaw SL, 1997, J CELL BIOL, V139, P985, DOI 10.1083/jcb.139.4.985; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Theesfeld CL, 1999, J CELL BIOL, V146, P1019, DOI 10.1083/jcb.146.5.1019; TODD M, 1997, J CELL BIOL, V138, P1023; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; Waterman-Storer CM, 1998, BIOPHYS J, V75, P2059, DOI 10.1016/S0006-3495(98)77648-9; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wein H, 1996, J CELL BIOL, V133, P595, DOI 10.1083/jcb.133.3.595; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687	32	196	200	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					36	41		10.1038/71357	http://dx.doi.org/10.1038/71357			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620805	Green Accepted, Green Submitted			2022-12-25	WOS:000084843600017
J	Smith, T; Groom, A; Zhu, B; Turski, L				Smith, T; Groom, A; Zhu, B; Turski, L			Autoimmune encephalomyelitis ameliorated by AMPA antagonists	NATURE MEDICINE			English	Article							MULTIPLE-SCLEROSIS; BASIC-PROTEIN; MYELIN	Multiple sclerosis is an immune-mediated disorder of the central nervous system leading to progressive decline of motor and sensory functions and permanent disability(1,2). The therapy of multiple sclerosis is only partially effective, despite anti-inflammatory, immunosuppresive and immunomodulatory measures(3). White matter inflammation and loss of myelin, the pathological hallmarks of multiple sclerosis, are thought to determine disease severity(4,5). Experimental autoimmune encephalomyelitis reproduces the features of multiple sclerosis in rodents and in nonhuman primates(6,7). The dominant early clinical symptom of acute autoimmune encephalomyelitis is progressive ascending muscle weakness(6). However, demyelination may not be profound and its extent may not correlate with severity of neurological decline(8), indicating that targets unrelated to myelin or oligodendrocytes may contribute to the pathogenesis of acute autoimmune encephalomyelitis. Here we report that within the spinal cord in the course of autoimmune encephalomyelitis not only myelin but also neurons are subject to lymphocyte attack and may degenerate. Blockade of glutamate AMPA receptors ameliorated the neurological sequelae of autoimmune encephalomyelitis, indicating the potential for AMPA antagonists in the therapy of multiple sclerosis.	UCL, Eisai London Res Labs, London WC1E 6BT, England	Eisai Co Ltd; University of London; University College London	Turski, L (corresponding author), UCL, Eisai London Res Labs, Bernard Katz Bldg,Gower St, London WC1E 6BT, England.	terence_smith@eisai.net; lechoslaw.turski@solvay.com						Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CARNEGIE PR, 1974, NATURE, V249, P147, DOI 10.1038/249147a0; DUNKLEY PR, 1974, BIOCHEM J, V141, P243, DOI 10.1042/bj1410243; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; HardinPouzet H, 1997, GLIA, V20, P79, DOI 10.1002/(SICI)1098-1136(199705)20:1<79::AID-GLIA8>3.0.CO;2-0; HUMBLE JG, 1956, BRIT J HAEMATOL, V2, P283, DOI 10.1111/j.1365-2141.1956.tb06700.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 1996, J NEUROPATH EXP NEUR, V55, P211, DOI 10.1097/00005072-199602000-00010; Jm C., 1868, GAZ HOPITAUX, P554; MARTIN R, 1997, MULTIPLE SCLEROSIS C, P221; Matute C, 1998, P NATL ACAD SCI USA, V95, P10229, DOI 10.1073/pnas.95.17.10229; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MIKHAILOVSKAYA EV, 1997, CYTOL GENET, V31, P81; Nakamura R, 1994, Rinsho Shinkeigaku, V34, P679; Paxinos G., 1998, RAT BRAIN STEROTAXIC; PRINEAS JW, 1997, GREENFIELDS NEUROPAT, V1, P813; Rudick RA, 1997, NEW ENGL J MED, V337, P1604, DOI 10.1056/NEJM199711273372207; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; Stover JF, 1997, EUR J CLIN INVEST, V27, P1038, DOI 10.1046/j.1365-2362.1997.2250774.x; Tarnawa I, 1998, RESTOR NEUROL NEUROS, V13, P41; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; WEKERLE H, 1994, ANN NEUROL, V36, P547; [No title captured]	25	391	411	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					62	66		10.1038/71548	http://dx.doi.org/10.1038/71548			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613825				2022-12-25	WOS:000084583300036
J	Breithaupt, H				Breithaupt, H			The new antibiotics	NATURE BIOTECHNOLOGY			English	Article							GENES											Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Hancock REW, 1998, CURR OPIN MICROBIOL, V1, P493, DOI 10.1016/S1369-5274(98)80079-9; HARVEY J, 1998, USE MISUSE ANTIBIO 1; STROHL WR, 1997, BIOTECHNOLOGY ANTIBI; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	8	86	106	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1165	1169		10.1038/70705	http://dx.doi.org/10.1038/70705			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585711				2022-12-25	WOS:000084170700020
J	Li, JY; Shen, H; Himmel, KL; Dupuy, AJ; Largaespada, DA; Nakamura, T; Shaughnessy, JD; Jenkins, NA; Copeland, NG				Li, JY; Shen, H; Himmel, KL; Dupuy, AJ; Largaespada, DA; Nakamura, T; Shaughnessy, JD; Jenkins, NA; Copeland, NG			Leukaemia disease genes: large-scale cloning and pathway predictions	NATURE GENETICS			English	Article							POLYMERASE CHAIN-REACTION; DNA; LEUKEMIAS; PROTEIN; MICE; TRISTETRAPROLIN; ACTIVATION; NEOPLASMS; FRAGMENTS; LYMPHOMAS		NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA; Univ Minnesota, Ctr Canc, Dept Genet Cell Biol & Dev, Minneapolis, MN USA; JST, PRESTO, Tokyo, Japan; Japanese Fdn Canc Res, Tokyo, Japan; Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System; University of Minnesota Twin Cities; Japan Science & Technology Agency (JST); Japanese Foundation for Cancer Research; University of Arkansas System; University of Arkansas Medical Sciences	Copeland, NG (corresponding author), NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21701 USA.		Largaespada, David/C-9832-2014	Dupuy, Adam/0000-0002-8561-4911				Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; CABLE S, 1992, VIRCHOWS ARCH B, V62, P221, DOI 10.1007/BF02899685; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1999, ANIMAL MODELS CANC P, P53; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ericsson J, 1999, J BIOL CHEM, V274, P14508, DOI 10.1074/jbc.274.20.14508; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ogawa S, 1996, ONCOGENE, V13, P183; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Shannon K, 1995, Curr Opin Hematol, V2, P305; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SORENSEN AB, 1993, J VIROL, V67, P7118; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Valk PJM, 1997, NUCLEIC ACIDS RES, V25, P4419, DOI 10.1093/nar/25.21.4419; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VITOLS S, 1985, LANCET, V2, P1150; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	30	194	221	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					348	353		10.1038/15531	http://dx.doi.org/10.1038/15531			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610183				2022-12-25	WOS:000083792200027
J	Woolhouse, MEJ; Hagan, P				Woolhouse, MEJ; Hagan, P			Seeking the ghost of worms past	NATURE MEDICINE			English	Editorial Material							SCHISTOSOMA-HAEMATOBIUM; INFECTION; RESPONSES; IMMUNITY; CHEMOTHERAPY; EPIDEMIOLOGY; PATTERNS; MANSONI; IGG4; IGE		Univ Edinburgh, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland; Univ Glasgow, IBLS, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Edinburgh; University of Glasgow	Woolhouse, MEJ (corresponding author), Univ Edinburgh, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.			Hagan, Paul/0000-0002-3516-2283				ANDERSON RM, 1985, NATURE, V315, P493, DOI 10.1038/315493a0; BUTTERWORTH AE, 1992, IMMUNOL INVEST, V21, P391, DOI 10.3109/08820139209069381; FISHER A. C., 1934, TRANS ROY SAC TROP MED AND HYG, V28, P277, DOI 10.1016/S0035-9203(34)90066-3; Grogan JL, 1996, J INFECT DIS, V173, P1242, DOI 10.1093/infdis/173.5.1242; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; Mutapi F, 1997, PARASITE IMMUNOL, V19, P255, DOI 10.1046/j.1365-3024.1997.d01-206.x; Mutapi F, 1998, PARASITE IMMUNOL, V20, P595, DOI 10.1046/j.1365-3024.1998.00192.x; Mutapi F, 1998, J INFECT DIS, V178, P289, DOI 10.1086/517456; vanDam GJ, 1996, J INFECT DIS, V173, P1232, DOI 10.1093/infdis/173.5.1232; WOOLHOUSE MEJ, 1991, NATURE, V351, P757, DOI 10.1038/351757a0; Woolhouse MEJ, 1998, PARASITOL TODAY, V14, P428, DOI 10.1016/S0169-4758(98)01318-0	12	95	95	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1225	1227		10.1038/15169	http://dx.doi.org/10.1038/15169			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545976				2022-12-25	WOS:000086550600018
J	Ghabrial, A; Schupbach, T				Ghabrial, A; Schupbach, T			Activation of a meiotic checkpoint regulates translation of Gurken during Drosophila oogenesis	NATURE CELL BIOLOGY			English	Article							EUKARYOTIC INITIATION FACTOR-4A; DOUBLE-STRAND BREAKS; RECOMBINATION; MELANOGASTER; HOMOLOG; VASA; MEIOSIS; REPAIR; OOCYTE; YEAST	The genes okra and spindle-B act during meiosis in Drosophila to repair double-stranded DNA breaks (DSBs) associated with meiotic recombination. Unexpectedly, mutations in these genes cause dorsoventral patterning defects during oogenesis. These defects result from a failure to accumulate Gurken protein, which is required to initiate dorsoventral patterning during oogenesis. Here we find that the block in Gurken accumulation in the oocyte cytoplasm reflects activation of a meiotic checkpoint in response to the persistence of DSBs in the nucleus. We also show that Vasa is a target of this meiotic checkpoint, and so may mediate the checkpoint-dependent translational regulation of Gurken.	Princeton Univ, Dept Mol Biol, HHMI, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University	Schupbach, T (corresponding author), Princeton Univ, Dept Mol Biol, HHMI, Princeton, NJ 08544 USA.		Ghabrial, Amin/ABB-1364-2020; Ghabrial, Amin S/J-4586-2013	Ghabrial, Amin S/0000-0002-6160-3003	NCI NIH HHS [P01 CA 41086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bentley NJ, 1997, BIOL CHEM, V378, P1267; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOYD JB, 1981, GENETICS, V97, P607; BUELT MK, 1994, J BIOL CHEM, V269, P29367; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; Ghabrial A, 1998, GENE DEV, V12, P2711, DOI 10.1101/gad.12.17.2711; Gonzalez-Reyes A, 1997, DEVELOPMENT, V124, P4927; Gowen JW, 1933, J EXP ZOOL, V65, P83, DOI 10.1002/jez.1400650106; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kooistra R, 1997, MOL CELL BIOL, V17, P6097, DOI 10.1128/MCB.17.10.6097; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; McKim KS, 1998, GENE DEV, V12, P2932, DOI 10.1101/gad.12.18.2932; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; Olsen LC, 1997, MECH DEVELOP, V66, P95, DOI 10.1016/S0925-4773(97)00099-3; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Sekelsky JJ, 1998, GENETICS, V148, P1587; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Spradling Allan C., 1993, P1; Styhler S, 1998, DEVELOPMENT, V125, P1569; Tomancak P, 1998, DEVELOPMENT, V125, P1723; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	30	171	175	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					354	357		10.1038/14046	http://dx.doi.org/10.1038/14046			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559962				2022-12-25	WOS:000083169800018
J	Khan, MS; Maliga, P				Khan, MS; Maliga, P			Fluorescent antibiotic resistance marker for tracking plastid transformation in higher plants	NATURE BIOTECHNOLOGY			English	Article						aminoglycoside 3 ''-adenylyl transferase; green fluorescent protein; plastid transformation; rice; spectinomycin and streptomycin resistance; tobacco	CHLOROPLAST GENOME; NICOTIANA-TABACUM; VITAL MARKER; PROTEIN; TOBACCO; GENE; EXPRESSION; GFP; PROTOPLASTS; CELLS	Plastid transformation in higher plants is accomplished through a gradual process, during which all the 300-10,000 plastid genome copies are uniformly altered. Antibiotic resistance genes incorporated in the plastid genome facilitate maintenance of transplastomes during this process. Given the high number of plastid genome copies in a cell, transformation unavoidably yields chimeric tissues, which requires the identification of transplastomic cells in order to regenerate plants. In the chimeric tissue, however, antibiotic resistance is not cell autonomous: transplastomic and wild-type sectors both have a resistant phenotype because of phenotypic masking by the transgenic cells. We report a system of marker genes for plastid transformation, termed FLARE-S, which is obtained by translationally fusing aminoglycoside 3"-adenyltransferase with the Aequorea victoria green fluorescent protein. 3"-adenyltransferase (FLARE-S) confers resistance to both spectinomycin and streptomycin. The utility of FLARE-S is shown by tracking segregation of individual transformed and wild-type plastids in tobacco and rice plants after bombardment with FLARE-S vector DNA and selection for spectinomycin and streptomycin resistance, respectively. This method facilitates the extension of plastid transformation to nongreen plastids in embryogenic cells of cereal crops.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Maliga, P (corresponding author), Rutgers State Univ, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	maliga@waksman.rutgers.edu	Khan, Muhammad Sarwar/Q-8307-2019; khan, Muhammad Sarwar/F-4370-2015	Khan, Muhammad Sarwar/0000-0001-7194-8622				BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x; BENDICH AJ, 1987, BIOESSAYS, V6, P279, DOI 10.1002/bies.950060608; CARRER H, 1993, MOL GEN GENET, V241, P49, DOI 10.1007/BF00280200; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHINAULT AC, 1986, PLASMID, V15, P119, DOI 10.1016/0147-619X(86)90048-X; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; Epel BL, 1996, GENE, V173, P75, DOI 10.1016/0378-1119(95)00678-8; FROMM H, 1987, EMBO J, V6, P3233, DOI 10.1002/j.1460-2075.1987.tb02640.x; GOLDS T, 1993, BIO-TECHNOL, V11, P95, DOI 10.1038/nbt0193-95; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hibberd JM, 1998, PLANT J, V16, P627, DOI 10.1046/j.1365-313x.1998.00328.x; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maliga P, 1998, TRENDS PLANT SCI, V3, P4, DOI 10.1016/S1360-1385(97)87981-2; MALIGA P, 1993, TRENDS BIOTECHNOL, V11, P101, DOI 10.1016/0167-7799(93)90059-I; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; MOLL B, 1990, MOL GEN GENET, V221, P245, DOI 10.1007/BF00261727; MULLER AJ, 1978, MOL GEN GENET, V161, P67, DOI 10.1007/BF00266616; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; ONEILL C, 1993, PLANT J, V3, P729, DOI 10.1111/j.1365-313X.1993.00729.x; Pang SZ, 1996, PLANT PHYSIOL, V112, P893, DOI 10.1104/pp.112.3.893; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; Rouwendal GJA, 1997, PLANT MOL BIOL, V33, P989, DOI 10.1023/A:1005740823703; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Sikdar SR, 1998, PLANT CELL REP, V18, P20, DOI 10.1007/s002990050525; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; THOMPSON JA, 1986, PLANT SCI, V47, P123, DOI 10.1016/0168-9452(86)90059-2; ZHANG W, 1988, THEOR APPL GENET, V76, P835, DOI 10.1007/BF00273668; ZOUBENKO OV, 1994, NUCLEIC ACIDS RES, V22, P3819, DOI 10.1093/nar/22.19.3819; [No title captured]	42	173	229	0	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					910	915		10.1038/12907	http://dx.doi.org/10.1038/12907			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471936				2022-12-25	WOS:000082365800036
J	Nyberg-Hoffman, C; Aguilar-Cordova, E				Nyberg-Hoffman, C; Aguilar-Cordova, E			Instability of adenoviral vectors during transport and its implication for clinical studies	NATURE MEDICINE			English	Article									Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine	Aguilar-Cordova, E (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, MC 3-2374,1102 Bates,Suite 1170, Houston, TX 77030 USA.				NCRR NIH HHS [MO1RR00188] Funding Source: Medline; PHS HHS [P50-58204] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Budavari S., 1989, MERCK INDEX; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; MCQUARRIE DA, 1987, GEN CHEM, P360; NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808; WADE LG, 1991, ORGANIC CHEM, P1139	5	60	65	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					955	957		10.1038/11400	http://dx.doi.org/10.1038/11400			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426323				2022-12-25	WOS:000081684000043
J	Rust, S; Rosier, M; Funke, H; Real, J; Amoura, Z; Piette, JC; Deleuze, JF; Brewer, HB; Duverger, N; Denefle, P; Assmann, G				Rust, S; Rosier, M; Funke, H; Real, J; Amoura, Z; Piette, JC; Deleuze, JF; Brewer, HB; Duverger, N; Denefle, P; Assmann, G			Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1	NATURE GENETICS			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; ABC TRANSPORTERS; A-I; RECEPTOR; CHOLESTEROL; CLONING; 9Q31	Tangier disease (TD) was first discovered nearly 40 years ago in two siblings living on Tangier Island(1). This autosomal co-dominant condition is characterized in the homozygous state by the absence of HDL-cholesterol (HDL-C) from plasma, hepatosplenomegaly, peripheral neuropathy and frequently premature coronary artery disease(1) (CAD). In heterozygotes, HDL-C levels are about one-half those of normal individuals(1). Impaired cholesterol efflux from macrophages leads to the presence of foam cells throughout the body, which may explain the increased risk of coronary heart disease in some TD families(2). We report here refining of our previous linkage of the TD gene(3) to a 1-cM region between markers D9S271 and D9S1866 on chromosome 9q31, in which we found the gene encoding human ATP cassette-binding transporter 1 (ABC1). We also found a change in ABC1 expression level on cholesterol loading of phorbol ester-treated THP1 macrophages, substantiating the role of ABC1 in cholesterol efflux. We cloned the full-length cDNA and sequenced the gene in two unrelated families with four TD homozygotes. In the first pedigree, a 1-bp deletion in exon 13, resulting in truncation of the predicted protein to approximately one-fourth of its normal size, co-segregated with the disease phenotype. An in-frame insertion-deletion in exon 12 was found in the second family. Our findings indicate that defects in ABC1, encoding a member of the ABC transporter superfamily, are the cause of TD.	Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Rhone Poulenc Rorer, Core Genom Biotechno Dept, F-91006 Evry, France; Rhone Poulenc Rorer, Dept Cardiovasc, F-91006 Evry, France; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Valencia, Dept Med, Hosp Clin, Valencia 46010, Spain; Hop La Pitie Salpetriere, Serv Med Interne, Paris, France; NHLBI, NIH, Bethesda, MD 20892 USA	University of Munster; University of Munster; University of Valencia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rust, S (corresponding author), Univ Munster, Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.	Rusts@uni-muenster.de	Amoura, Zahir/P-5325-2017; AMOURA, Zahir/P-5324-2017	AMOURA, Zahir/0000-0003-0292-9043				Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; FERRANS VJ, 1975, AM J PATHOL, V78, P101; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Kobayashi K, 1998, NATURE, V394, P388, DOI 10.1038/28653; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; Miyake M, 1997, GENOMICS, V40, P284, DOI 10.1006/geno.1996.4584; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Wada M, 1998, HUM MOL GENET, V7, P203, DOI 10.1093/hmg/7.2.203; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742	22	1208	1269	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	1999	22	4					352	355		10.1038/11921	http://dx.doi.org/10.1038/11921			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431238				2022-12-25	WOS:000081772500016
J	Springer, JE; Azbill, RD; Knapp, PE				Springer, JE; Azbill, RD; Knapp, PE			Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury	NATURE MEDICINE			English	Article							CYTOCHROME-C; DNA FRAGMENTATION; BRAIN INJURY; CONTUSION; PROTEOLYSIS; INHIBITOR; CLEAVAGE; PROTEIN; RATS	Traumatic spinal cord injury often results in complete loss of voluntary motor and sensory function below the site of injury. The long-term neurological deficits after spinal cord trauma may be due in part to widespread apoptosis of neurons and oligodendroglia in regions distant from and relatively unaffected by the initial injury(1-4). The caspase family of cysteine proteases regulates the execution of the mammalian apoptotic cell death program(5-7). Caspase-3 cleaves several essential downstream substrates involved in the expression of the apoptotic phenotype in vitro, including gelsolin, PAK2, fodrin, nuclear lamins and the inhibitory subunit of DNA fragmentation facto(8-12). Caspase-3 activation in vitro can be triggered by upstream events, leading to the release of cytochrome c from the mitochondria and the subsequent transactivation of procaspase-9 by Apaf-1 (refs. 13-15). We report here that these upstream and downstream components of the caspase-3 apoptotic pathway are activated after traumatic spinal cord injury in rats, and occur early in (sic) the injury site and hours to days later in oligodendroglia adjacent to and distant from the injury site. Given these findings, targeting the upstream events of the caspase-3 cascade has therapeutic potential in the treatment of acute traumatic injury to the spinal cord.	Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	University of Kentucky	Springer, JE (corresponding author), Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, 800 Rose St, Lexington, KY 40536 USA.			Azbill, David/0000-0001-7989-1771	NINDS NIH HHS [NS-30248] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030248] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu N, 1996, J MOL NEUROSCI, V7, P1, DOI 10.1007/BF02736844; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu XZ, 1997, J NEUROSCI, V17, P5395; NAKAMURA S, 1998, J NEUROSCI, V18, P3659; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	25	357	384	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					943	946		10.1038/11387	http://dx.doi.org/10.1038/11387			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426320				2022-12-25	WOS:000081684000040
J	Diehl, L; den Boer, AT; Schoenberger, SP; van der Voort, EIH; Schumacher, TNM; Melief, CJM; Offringa, R; Toes, REM				Diehl, L; den Boer, AT; Schoenberger, SP; van der Voort, EIH; Schumacher, TNM; Melief, CJM; Offringa, R; Toes, REM			CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy	NATURE MEDICINE			English	Article							IMMUNE-RESPONSES; DENDRITIC CELLS; IN-VIVO; HELP; INDUCTION; MOUSE; IMMUNOPATHOLOGY; INFLAMMATION; ENHANCEMENT; OUTGROWTH	The outcome of antigen recognition by naive CD8(+) cytotoxic T lymphocytes (CTLs) in the periphery is orchestrated by CD4(+) T-helper cells, and can either lead to priming or tolerization. The presence of T-helper cells favors the induction of CTL immunity, whereas the absence of T-helper cells can result in CTL tolerance. The action of T helper cells in CTL priming is mediated by CD40-CD40 ligand interactions. We demonstrate here that triggering of CD40 in vivo can considerably enhance the efficacy of peptide-based anti-tumor vaccines. The combination of a tolerogenic peptide vaccine containing a minimal essential CTL epitope with an activating antibody against CD40 converts tolerization into strong CTL priming. Moreover, CD40 ligation can provide an already protective tumor-specific peptide vaccine with the capacity to induce therapeutic CTL immunity in tumor-bearing mice. These findings indicate that the CD40-CD40 ligand pair can act as a 'switch', determining whether naive peripheral CTLs are primed or tolerized, and support the clinical use of CD40-stimulating agents as components of anti-cancer vaccines.	Leiden Univ, Ctr Med, Dept Immunohaematol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Bloodbank, NL-2300 RA Leiden, Netherlands; La Jolla Inst Allergy & Immunol, Div Immune Regulat, San Diego, CA 92121 USA; Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; Univ Tubingen, Dept Immunol, D-72076 Tubingen, Germany	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; La Jolla Institute for Immunology; Netherlands Cancer Institute; Eberhard Karls University of Tubingen	Toes, REM (corresponding author), Leiden Univ, Ctr Med, Dept Immunohaematol, Albinusdreef 2,POB 9600, NL-2300 RA Leiden, Netherlands.		Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Toes, Rene/0000-0002-9618-6414				AICHELE P, 1994, P NATL ACAD SCI USA, V91, P444, DOI 10.1073/pnas.91.2.444; Aichele P, 1997, IMMUNITY, V6, P519, DOI 10.1016/S1074-7613(00)80340-4; AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ANDERTON SM, 1993, EUR J IMMUNOL, V23, P33, DOI 10.1002/eji.1830230107; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Ding L, 1996, J IMMUNOL, V157, P1389; Dullforce P, 1998, NAT MED, V4, P88, DOI 10.1038/nm0198-088; Ehl S, 1998, J EXP MED, V187, P763, DOI 10.1084/jem.187.5.763; Fayolle C, 1996, IMMUNOLOGY, V89, P41, DOI 10.1046/j.1365-2567.1996.d01-704.x; FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; Haanen JBAG, 1999, EUR J IMMUNOL, V29, P1168, DOI 10.1002/(SICI)1521-4141(199904)29:04<1168::AID-IMMU1168>3.0.CO;2-J; HOWELL CD, 1994, CLIN IMMUNOL IMMUNOP, V72, P76, DOI 10.1006/clin.1994.1109; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Lin KY, 1996, CANCER RES, V56, P21; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; REES MA, 1990, P NATL ACAD SCI USA, V87, P2765, DOI 10.1073/pnas.87.7.2765; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Schoenberger SP, 1998, CANCER RES, V58, P3094; SHCOENBERGER SP, 1998, NATURE, V393, P480; Toes REM, 1998, J IMMUNOL, V160, P4449; Toes REM, 1996, J IMMUNOL, V156, P3911; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996	32	386	428	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					774	779		10.1038/10495	http://dx.doi.org/10.1038/10495			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395322				2022-12-25	WOS:000081926600032
J	Holcik, M; Lefebvre, C; Yeh, CL; Chow, T; Korneluk, RG				Holcik, M; Lefebvre, C; Yeh, CL; Chow, T; Korneluk, RG			A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection	NATURE CELL BIOLOGY			English	Article							CELL-DEATH; TRANSLATION; INITIATION; APOPTOSIS; LIFE; IAP		Childrens Hosp Eastern Ontario, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada; Apoptogen Inc, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1A4, Canada; Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; McGill University; University of Ottawa	Korneluk, RG (corresponding author), Childrens Hosp Eastern Ontario, Solange Gauthier Karsh Mol Genet Lab, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Holcik, Martin/A-9768-2008; Holcik, Martin/E-5372-2011; Holcik, Martin/AAC-6660-2019	Holcik, Martin/0000-0002-1922-5299				Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1997, APOPTOSIS, V2, P423, DOI 10.1023/A:1026465926478; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Merrick WC., 1996, TRANSLATION CONTROL, P31; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	13	259	271	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					190	192		10.1038/11109	http://dx.doi.org/10.1038/11109			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559907				2022-12-25	WOS:000083102500019
J	Cafaro, A; Caputo, A; Fracasso, C; Maggiorella, MT; Goletti, D; Baroncelli, S; Pace, M; Sernicola, L; Koanga-Mogtomo, ML; Betti, M; Borsetti, A; Belli, R; Akerblom, L; Corrias, F; Butto, S; Heeney, J; Verani, P; Titti, F; Ensoli, B				Cafaro, A; Caputo, A; Fracasso, C; Maggiorella, MT; Goletti, D; Baroncelli, S; Pace, M; Sernicola, L; Koanga-Mogtomo, ML; Betti, M; Borsetti, A; Belli, R; Akerblom, L; Corrias, F; Butto, S; Heeney, J; Verani, P; Titti, F; Ensoli, B			Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; TRANS-ACTIVATOR GENE; KAPOSIS-SARCOMA; ATTENUATED SIV; GROWTH-FACTOR; CELL-GROWTH; TNF-ALPHA; HTLV-III; NEF GENE	Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4(+) T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Univ Ferrara, Dept Exp & Diagnost Med, I-44100 Ferrara, Italy; Natl Vet Inst, Dept Virol, Biomed Ctr, S-75183 Uppsala, Sweden; Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk ZH, Netherlands	Istituto Superiore di Sanita (ISS); University of Ferrara; National Veterinary Institute SVA	Ensoli, B (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Buttò, Stefano/J-9324-2018; Cafaro, Aurelio/K-5314-2016; borsetti, alessandra/K-4103-2016; goletti, delia/AAM-6577-2020; maggiorella, maria teresa/K-4072-2016; Caputo, Antonella/ABE-7851-2020; Ensoli, Barbara/J-9169-2016	borsetti, alessandra/0000-0002-5401-135X; maggiorella, maria teresa/0000-0001-5058-476X; Caputo, Antonella/0000-0002-1241-0299; Ensoli, Barbara/0000-0002-0545-8737; Goletti, Delia/0000-0001-8360-4376; Heeney, Jonathan/0000-0003-2702-1621; Cafaro, Aurelio/0000-0001-9675-6344; Butto, Stefano/0000-0002-3289-2686				ALMOND NM, 1998, AIDS, V12, P133; Ando K, 1997, J IMMUNOL, V158, P5283; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BUONAGURO L, 1995, J VIROL, V69, P7971, DOI 10.1128/JVI.69.12.7971-7981.1995; Burton DR, 1998, NAT MED, V4, P495, DOI 10.1038/nm0598supp-495; Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3; CASELLI E, IN PRESS J IMMUNOL; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; CHEN ZW, 1992, J IMMUNOL, V149, P4060; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Davis D, 1997, VACCINE, V15, P1661, DOI 10.1016/S0264-410X(97)00084-4; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; EZZELL C, 1997, J NIH RES, V9, P21; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FIORE JR, 1991, AIDS, V5, P1034, DOI 10.1097/00002030-199108000-00021; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FROEBEL KS, 1994, AIDS RES HUM RETROV, V2, P83; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; Gringeri A, 1998, J Hum Virol, V1, P293; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; *HUM RETR AIDS, 1995, COMP AN NUCL AIDS AM; JASSOY C, 1993, J VIROL, V67, P2844, DOI 10.1128/JVI.67.5.2844-2852.1993; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kim DT, 1997, J IMMUNOL, V159, P1666; LAMHAMEDICHERRADI S, 1992, AIDS, V6, P1249, DOI 10.1097/00002030-199211000-00002; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOVGREN J, 1994, J IMMUNOL METHODS, V173, P119, DOI 10.1016/0022-1759(94)90289-5; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RATNER A, 1993, J IMMUNOL, V150, P4303; RE C, 1995, J ACQ IMMUN DEF SYND, V10, P408; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; REISS P, 1990, J MED VIROL, V30, P163, DOI 10.1002/jmv.1890300303; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; RODMAN TC, 1993, P NATL ACAD SCI USA, V90, P7719, DOI 10.1073/pnas.90.16.7719; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sodora DL, 1998, AIDS RES HUM RETROV, V14, P171, DOI 10.1089/aid.1998.14.171; Stott EJ, 1998, J GEN VIROL, V79, P423; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Titti F, 1997, J GEN VIROL, V78, P2529, DOI 10.1099/0022-1317-78-10-2529; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VENET A, 1992, J IMMUNOL, V148, P2899; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WHATMORE AM, 1995, J VIROL, V69, P5117, DOI 10.1128/JVI.69.8.5117-5123.1995; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zagury J F, 1998, J Hum Virol, V1, P282; ZAGURY JF, 1996, CELL PHARM, V3, P123; Zauli G, 1996, J IMMUNOL, V157, P2216	58	265	284	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					643	650		10.1038/9488	http://dx.doi.org/10.1038/9488			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371502	Bronze			2022-12-25	WOS:000080823300032
J	Ochiya, T; Takahama, Y; Nagahara, S; Sumita, Y; Hisada, A; Itoh, H; Nagai, Y; Terada, M				Ochiya, T; Takahama, Y; Nagahara, S; Sumita, Y; Hisada, A; Itoh, H; Nagai, Y; Terada, M			New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet	NATURE MEDICINE			English	Article							DIRECT GENE-TRANSFER; SKELETAL-MUSCLE INVIVO; INTRAMUSCULAR INJECTION; MOUSE MUSCLE; EXPRESSION; MICE; VACCINATION; ADENOVIRUS; COLLAGEN; VECTOR		Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Mfg Technol Res Labs, Ibaraki, Osaka 567, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Discovery Res Labs 3, Ibaraki, Osaka 567, Japan; Koken Biosci Inst, Shinjuku Ku, Tokyo 169, Japan	National Cancer Center - Japan	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 104, Japan.		Ochiya, Takahiro/AAH-7585-2019					Anwer K, 1998, HUM GENE THER, V9, P659, DOI 10.1089/hum.1998.9.5-659; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; FUJIOKA K, 1995, J CONTROL RELEASE, V33, P307, DOI 10.1016/0168-3659(94)00107-6; Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; Jong YS, 1997, J CONTROL RELEASE, V47, P123, DOI 10.1016/S0168-3659(97)01637-4; Jorgensen L G, 1991, Eur J Vasc Surg, V5, P87, DOI 10.1016/S0950-821X(05)80933-8; KAMER FM, 1984, ARCH OTOLARYNGOL, V110, P93; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; Kumar V, 1996, NAT MED, V2, P857, DOI 10.1038/nm0896-857; Levy MY, 1996, GENE THER, V3, P201; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419; Monahan PE, 1998, GENE THER, V5, P40, DOI 10.1038/sj.gt.3300548; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RUBIN AL, 1973, J CLIN PHARMACOL, V13, P309, DOI 10.1002/j.1552-4604.1973.tb00217.x; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sambrook J., 2002, MOL CLONING LAB MANU; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; THOMASON DB, 1990, AM J PHYSIOL, V258, pC578, DOI 10.1152/ajpcell.1990.258.3.C578; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; Truong-Le VL, 1998, HUM GENE THER, V9, P1709, DOI 10.1089/hum.1998.9.12-1709; Vitiello L, 1996, GENE THER, V3, P396; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363	30	198	216	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					707	710		10.1038/9560	http://dx.doi.org/10.1038/9560			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371512				2022-12-25	WOS:000080823300042
J	Klein, L; Klugmann, M; Nave, KA; Tuohy, VK; Kyewski, B				Klein, L; Klugmann, M; Nave, KA; Tuohy, VK; Kyewski, B			Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN PROTEOLIPID PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; ENCEPHALITOGENIC DETERMINANT; DEMYELINATING DISEASES; BASIC-PROTEIN; SJL MICE; TOLERANCE	Intrathymic expression of tissue-specific self antigens may be involved in immunological tolerance and protection from autoimmune disease. We have analyzed the role of T-cell tolerance to proteolipid protein (PLP), the main protein of the myelin sheath, in susceptibility to experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Intrathymic expression of PLP was largely restricted to the shorter splice variant, DM20. Expression of DM20 by thymic epithelium was sufficient to confer T-cell tolerance to all epitopes of PLP in EAE-resistant C57BL/6 mice. In contrast, the major T-cell epitope in SJL/J mice was only encoded by the central nervous system-specific exon of PLP, but not by thymic DM20. Thus, lack of tolerance to this epitope offers an explanation for the exquisite susceptibility of SJL/J mice to EAE. As PLP expression in the human thymus is also restricted to the DM20 isoform, these findings have implications for selection of the autoimmune T-cell repertoire in multiple sclerosis.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Cleveland Clinic Foundation	Kyewski, B (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, INF 280, D-69120 Heidelberg, Germany.	b.kyewski@dkfz-heidelberg.de	Klein, Ludger/G-8785-2011; Nave, Klaus-Armin/C-8883-2011	Klein, Ludger/0000-0003-2054-071X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037476, R01NS036054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 36054, NS 37476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alferink J, 1999, IMMUNOL REV, V169, P255, DOI 10.1111/j.1600-065X.1999.tb01320.x; Anderton S, 1999, IMMUNOL REV, V169, P123, DOI 10.1111/j.1600-065X.1999.tb01311.x; Butterfield RJ, 1998, J IMMUNOL, V161, P1860; Chang JT, 1999, J EXP MED, V189, P969, DOI 10.1084/jem.189.6.969; Egwuagu CE, 1997, J IMMUNOL, V159, P3109; Encinas JA, 1996, J IMMUNOL, V157, P2186; Encinas JA, 1999, NAT GENET, V21, P158, DOI 10.1038/5941; Fritz RB, 1996, J NEUROSCI RES, V45, P471, DOI 10.1002/(SICI)1097-4547(19960815)45:4<471::AID-JNR17>3.0.CO;2-3; GREER JM, 1992, J IMMUNOL, V149, P783; Greer JM, 1996, J IMMUNOL, V156, P371; Hanahan D, 1998, CURR OPIN IMMUNOL, V10, P656, DOI 10.1016/S0952-7915(98)80085-X; Harrington CJ, 1998, IMMUNITY, V8, P571, DOI 10.1016/S1074-7613(00)80562-2; Heath VL, 1998, J AUTOIMMUN, V11, P309, DOI 10.1006/jaut.1998.0210; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Klein L, 1998, J EXP MED, V188, P5, DOI 10.1084/jem.188.1.5; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; Kojima K, 1997, INT IMMUNOL, V9, P897, DOI 10.1093/intimm/9.6.897; KYEWSKI BA, 1986, J EXP MED, V163, P231, DOI 10.1084/jem.163.2.231; MARKOVICPLESE S, 1995, J IMMUNOL, V155, P982; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MCRAE BL, 1995, J EXP MED, V182, P75, DOI 10.1084/jem.182.1.75; MILLER SD, 1995, IMMUNOL REV, V144, P225, DOI 10.1111/j.1600-065X.1995.tb00071.x; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; Oukka M, 1996, IMMUNITY, V4, P545, DOI 10.1016/S1074-7613(00)80481-1; Pribyl TM, 1996, J NEUROSCI RES, V45, P812; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Segal BM, 1996, J EXP MED, V184, P771, DOI 10.1084/jem.184.2.771; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Sospedra M, 1998, J IMMUNOL, V161, P5918; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Stockinger B, 1999, Adv Immunol, V71, P229; Targoni OS, 1998, J EXP MED, V187, P2055, DOI 10.1084/jem.187.12.2055; Trotter JL, 1998, J NEUROIMMUNOL, V84, P172, DOI 10.1016/S0165-5728(97)00260-9; TUOHY VK, 1995, J NEUROIMMUNOL, V56, P161, DOI 10.1016/0165-5728(94)00143-C; Tuohy VK, 1998, IMMUNOL REV, V164, P93, DOI 10.1111/j.1600-065X.1998.tb01211.x; TUOHY VK, 1988, J IMMUNOL, V140, P1868; Tuohy VK, 1997, J CLIN INVEST, V99, P1682, DOI 10.1172/JCI119331; TUOHY VK, 1989, J IMMUNOL, V142, P1523; Tuohy VK, 1999, J EXP MED, V189, P1033, DOI 10.1084/jem.189.7.1033; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Vanderlugt CL, 1998, IMMUNOL REV, V164, P63, DOI 10.1111/j.1600-065X.1998.tb01208.x; Voskuhl RR, 1998, IMMUNOL REV, V164, P81, DOI 10.1111/j.1600-065X.1998.tb01210.x; Wekerle H, 1996, IMMUNOL REV, V149, P231, DOI 10.1111/j.1600-065X.1996.tb00907.x; Wekerle H, 1993, Curr Opin Neurobiol, V3, P779, DOI 10.1016/0959-4388(93)90153-P; Yu M, 1996, J EXP MED, V183, P1777, DOI 10.1084/jem.183.4.1777	46	305	307	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					56	61		10.1038/71540	http://dx.doi.org/10.1038/71540			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613824				2022-12-25	WOS:000084583300035
J	Katayama, T; Imaizumi, K; Sato, N; Miyoshi, K; Kudo, T; Hitomi, J; Morihara, T; Yoneda, T; Gomi, F; Mori, Y; Nakano, Y; Takeda, J; Tsuda, T; Itoyama, Y; Murayama, O; Takashima, A; St George-Hyslop, P; Takeda, M; Tohyama, M				Katayama, T; Imaizumi, K; Sato, N; Miyoshi, K; Kudo, T; Hitomi, J; Morihara, T; Yoneda, T; Gomi, F; Mori, Y; Nakano, Y; Takeda, J; Tsuda, T; Itoyama, Y; Murayama, O; Takashima, A; St George-Hyslop, P; Takeda, M; Tohyama, M			Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response	NATURE CELL BIOLOGY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; IRE1P KINASE; IN-VIVO; GENE; INDUCTION; CHROMOSOME-1; COMPARTMENT	Missense mutations in the human presenilin-1 (PSI) gene, which is found on chromosome 14, cause early-onset familial Alzheimer's disease (FAD), FAD-linked PSI variants alter proteolytic processing of the amyloid precursor protein and cause an increase in vulnerability to apoptosis induced by various cell stresses, However, the mechanisms responsible for these phenomena are not clear, Here we report that mutations in PSI affect the unfolded-protein response (UPR), which responds to the increased amount of unfolded proteins that accumulate in the endoplasmic reticulum (ER) under conditions that cause ER stress. PSI mutations also lead to decreased expression of GRP78/Bip, a molecular chaperone, present in the ER, that can enable protein folding. Interestingly, GRP78 levels are reduced in the brains of Alzheimer's disease patients, The downregulation of UPR signalling by PSI mutations is caused by disturbed function of IRE1, which is the proximal sensor of conditions in the ER lumen, Overexpression of GRP78 in neuroblastoma cells bearing PS1 mutants almost completely restores resistance to ER stress to the level of cells expressing wild-type PS1, These results show that mutations in PS1 may increase vulnerability to ER stress by altering the UPR signalling pathway.	Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5320031, Japan; Japn Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Clin Neurosci Psychiat, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med H3, Dept Social & Environm Med, Suita, Osaka 5650871, Japan; Tohoku Univ, Sch Med, Dept Neurol, Aoba Ku, Sendai, Miyagi 9808574, Japan; RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; Univ Toronto, Dept Med Neurol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 1A8, Canada	Osaka University; Mitsubishi Tanabe Pharma Corporation; Japan Science & Technology Agency (JST); Osaka University; Osaka University; Tohoku University; RIKEN; University of Toronto	Imaizumi, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Morihara, Takashi/AAK-2709-2021; Longo, Kenneth A/A-5631-2010	Gomi, Fumi/0000-0003-0807-8817				Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bruce AJ, 1996, P NATL ACAD SCI USA, V93, P2312, DOI 10.1073/pnas.93.6.2312; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOMER CJ, 1991, CANCER RES, V51, P6574; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; GUO Q, 1999, J NEUROSCI, V5, P101; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SUGAWARA S, 1993, CANCER RES, V53, P6001; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	30	457	473	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					479	485		10.1038/70265	http://dx.doi.org/10.1038/70265			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587643				2022-12-25	WOS:000084136100015
J	Ostermeier, M; Shim, JH; Benkovic, SJ				Ostermeier, M; Shim, JH; Benkovic, SJ			A combinatorial approach to hybrid enzymes independent of DNA homology	NATURE BIOTECHNOLOGY			English	Article						incremental truncation; DNA shuffling; hybrid enzymes; in vitro evolution; glycinade ribonucleotide transformylase	GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; IN-VITRO RECOMBINATION; MOLECULAR EVOLUTION; DIRECTED EVOLUTION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; KINETIC MECHANISM; RANDOM INSERTION; PROTEIN; MUTAGENESIS	We present a methodology, termed incremental truncation for the creation of hybrid enzymes (ITCHY), that creates combinatorial fusion libraries between genes in a manner that is independent of DNA homology. We compared the ability of ITCHY and DNA shuffling to create interspecies fusion libraries between fragments of the Escherichia coli and human glycinamide ribonucleotide transformylase genes, which have only 50% identity on the DNA level. Sequencing of several randomly selected positives from each library illustrated that ITCHY identified a more diverse set of active fusion points including those in regions of nonhomology and those with crossover points that diverged from the sequence alignment. Furthermore, some of the hybrids found by ITCHY that were fused at nonhomologous locations had activities that were greater than or equal to the activity of the hybrids found by DNA shuffling.	Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA.	sjb1@psu.edu	Ostermeier, Marc/A-2697-2010	Ostermeier, Marc/0000-0003-0900-3665	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024129, R01GM024129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24129, GM18560] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIMI J, 1990, NUCLEIC ACIDS RES, V18, P6665, DOI 10.1093/nar/18.22.6665; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Betton JM, 1997, NAT BIOTECHNOL, V15, P1276, DOI 10.1038/nbt1197-1276; Biondi RM, 1998, NUCLEIC ACIDS RES, V26, P4946, DOI 10.1093/nar/26.21.4946; Bogarad LD, 1999, P NATL ACAD SCI USA, V96, P2591, DOI 10.1073/pnas.96.6.2591; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Caperelli CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P98, DOI 10.1006/abbi.1997.9947; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Hallet B, 1997, NUCLEIC ACIDS RES, V25, P1866, DOI 10.1093/nar/25.9.1866; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; KAN CC, 1992, J PROTEIN CHEM, V11, P467, DOI 10.1007/BF01025023; Nixon AE, 1997, P NATL ACAD SCI USA, V94, P1069, DOI 10.1073/pnas.94.4.1069; Nixon AE, 1998, TRENDS BIOTECHNOL, V16, P258, DOI 10.1016/S0167-7799(98)01204-9; Ostermeier M, 1999, BIOORGAN MED CHEM, V7, P2139, DOI 10.1016/S0968-0896(99)00143-1; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Shao ZX, 1998, NUCLEIC ACIDS RES, V26, P681, DOI 10.1093/nar/26.2.681; Shim JH, 1998, BIOCHEMISTRY-US, V37, P8776, DOI 10.1021/bi980244k; SMITH JM, 1987, J BIOL CHEM, V262, P10565; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; TOMB JF, 1989, BIOTECHNIQUES, V7, P932; Varney MD, 1997, J MED CHEM, V40, P2502, DOI 10.1021/jm9607459; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715; WU R, 1976, BIOCHEMISTRY-US, V15, P734, DOI 10.1021/bi00649a003; ZEBALA J, 1991, GENE, V100, P51, DOI 10.1016/0378-1119(91)90349-G; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	36	184	307	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1205	1209		10.1038/70754	http://dx.doi.org/10.1038/70754			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585719				2022-12-25	WOS:000084170700029
J	Wildt, S; Deuschle, U				Wildt, S; Deuschle, U			cobA, a red fluorescent transcriptional reporter for Escherichia coli, yeast, and mammalian cells	NATURE BIOTECHNOLOGY			English	Article						reporter gene; red fluorescence; cobA; uroporphyrinogen III methyltransferase	UROPORPHYRINOGEN-III METHYLTRANSFERASE; GENE-EXPRESSION; FISSION YEAST; ARABIDOPSIS; PROTEIN; BIOSYNTHESIS; LUCIFERASE; METHYLASE; SELECTION; SIROHEME	We demonstrate the use of Propionibacterium freudenreichii uroporphyrinogen III methyltransferase (cobA) as a reporter of gene expression in Escherichia coli, fission yeast, and mammalian cells. Overexpression of cobA in cells resulted in bright red fluorescence that was visualized with standard fluorescence microscopy and fluorescence-activated cell sorting analysis at the single-cell level. As with green fluorescent protein (GFP), no addition of exogenous substrate was required. When expressed in Chinese hamster ovary cells from a bicistronic transcript cobA and GFP gave rise to fluorescence signals of similar intensity. The bright red fluorescence generated by the cobA reporter promises a better signal-to-noise ratio than blue and green fluorescent reporter systems, as autofluorescence and light scattering of cells, media, and materials are reduced in the red wavelengths.	Hoffmann La Roche Ag, Div Pharma, Preclin CNS Res & GeneTechnol, CH-4002 Basel, Switzerland	Roche Holding	Deuschle, U (corresponding author), Hoffmann La Roche Ag, Div Pharma, Preclin CNS Res & GeneTechnol, CH-4002 Basel, Switzerland.	ulrich.deuschle@roche.com						AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHOU PL, 1995, BIOSCI BIOTECH BIOCH, V59, P1817, DOI 10.1271/bbb.59.1817; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Leustek T, 1997, J BIOL CHEM, V272, P2744, DOI 10.1074/jbc.272.5.2744; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MORENO S, 1991, METHOD ENZYMOL, V194, P795; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Plautz JD, 1996, GENE, V173, P83, DOI 10.1016/0378-1119(95)00700-8; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; ROESSNER CA, 1995, BIOTECHNIQUES, V19, P760; Sakakibara H, 1996, PLANT J, V10, P883, DOI 10.1046/j.1365-313X.1996.10050883.x; SATTLER I, 1995, J BACTERIOL, V177, P1564, DOI 10.1128/jb.177.6.1564-1569.1995; SCOTT AI, 1994, CIBA F SYMP, V180, P285; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; Tsien RY, 1999, NAT BIOTECHNOL, V17, P956, DOI 10.1038/13648; WARREN MJ, 1990, BIOCHEM J, V265, P725, DOI 10.1042/bj2650725; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	27	35	46	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1175	1178		10.1038/70713	http://dx.doi.org/10.1038/70713			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585713				2022-12-25	WOS:000084170700023
J	Dewey, RA; Morrissey, G; Cowsill, CM; Stone, D; Bolognani, F; Dodd, NJF; Southgate, TD; Klatzmann, D; Lassmann, H; Castro, MG; Lowenstein, PR				Dewey, RA; Morrissey, G; Cowsill, CM; Stone, D; Bolognani, F; Dodd, NJF; Southgate, TD; Klatzmann, D; Lassmann, H; Castro, MG; Lowenstein, PR			Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials	NATURE MEDICINE			English	Article							MAGNETIZATION-TRANSFER; FAS LIGAND; TUMOR-REGRESSION; MALIGNANT GLIOMA; IN-VIVO; VECTOR; RAT; CELLS; BETA; GANCICLOVIR	The long-term consequences of adenovirus-mediated conditional cytotoxic gene therapy for gliomas remain uncharacterized. We report here detection of active brain inflammation 3 months after successful inhibition of syngeneic glioma growth. The inflammatory infiltrate consisted of activated macrophages/microglia and astrocytes, and T lymphocytes positive for leucosyalin, CD3 and CD8, and included secondary demyelination. We detected strong widespread herpes simplex virus 1 thymidine kinase immunoreactivity and vector genomes throughout large areas of the brain. Thus, patient evaluation and the design of clinical trials in ongoing and future gene therapy for brain glioblastoma must address not only tumor-killing efficiency, but also long-term active brain inflammation, loss of myelin fibers and persistent transgene expression.	Univ Manchester, Sch Med, Mol Med & Gene Therapy Unit, Manchester M13 9PT, Lancs, England; Univ Manchester, Dept Med Biophys, Manchester M13 9PT, Lancs, England; Univ Paris 06, CNRS, Hop La Pitie Salpetriere, Lab Biol & Therapeut Pathol Immunitaires, F-75651 Paris, France; Univ Vienna, Inst Neurol, A-1090 Vienna, Austria	University of Manchester; University of Manchester; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Vienna	Lowenstein, PR (corresponding author), Univ Manchester, Sch Med, Mol Med & Gene Therapy Unit, Room 1-302 Stopford Bldg, Manchester M13 9PT, Lancs, England.		Castro, Maria/ABC-5182-2021; Lassmann, Hans/Z-2269-2019	Castro, Maria/0000-0003-2237-2756; Lassmann, Hans/0000-0001-8617-5052; Klatzmann, David/0000-0002-0054-3422; Dewey, Ricardo/0000-0003-1677-2745; Stone, Daniel/0000-0003-1619-7541				Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; BARBA D, 1994, P NATL ACAD SCI USA, V91, P4348, DOI 10.1073/pnas.91.10.4348; BECKWITH J, 1995, HUM GENOME NEWS, V6, P6; Blomer U, 1997, J VIROL, V71, P6641; Byrnes AP, 1996, J NEUROSCI, V16, P3045; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; Cartmell T, 1999, J NEUROSCI, V19, P1517; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; COTTEN M, 1994, GENE THER, V1, P239; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DEWEY RA, 1998, ABSTR SOC NEUR 2, V2165; Dion LD, 1996, J VIROL METHODS, V56, P99, DOI 10.1016/0166-0934(95)01973-1; Easton RM, 1998, MOL CELL NEUROSCI, V11, P334, DOI 10.1006/mcne.1998.0690; Eck SL, 1996, HUM GENE THER, V7, P1465, DOI 10.1089/hum.1996.7.12-1465; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FREEMAN SM, 1993, CANCER RES, V53, P5274; Freeman SM, 1997, LANCET, V349, P2, DOI 10.1016/S0140-6736(97)22001-5; Gagandeep S, 1996, CANCER GENE THER, V3, P83; Geddes BJ, 1997, NAT MED, V3, P1402, DOI 10.1038/nm1297-1402; Ghodsi A, 1998, HUM GENE THER, V9, P2331, DOI 10.1089/hum.1998.9.16-2331; Goodman JC, 1996, HUM GENE THER, V7, P1241, DOI 10.1089/hum.1996.7.10-1241; Gratas C, 1997, BRAIN PATHOL, V7, P863, DOI 10.1111/j.1750-3639.1997.tb00889.x; Hauss-Wegrzyniak B, 1998, BRAIN RES, V794, P211, DOI 10.1016/S0006-8993(98)00227-3; Hermens WTJMC, 1998, BRAIN RES BULL, V47, P133, DOI 10.1016/S0361-9230(98)00042-2; Izquierdo M, 1996, GENE THER, V3, P491; IZQUIERDO M, 1995, GENE THER, V2, P66; Klatzmann D, 1998, HUM GENE THER, V9, P2595, DOI 10.1089/hum.1998.9.17-2595; Klinkert WEF, 1997, J NEUROIMMUNOL, V72, P163, DOI 10.1016/S0165-5728(96)00183-X; KRUSE CA, 1994, J NEURO-ONCOL, V22, P191, DOI 10.1007/BF01052919; KURKI T, 1995, MAGN RESON IMAGING, V13, P501, DOI 10.1016/0730-725X(95)00006-3; LEE KH, 1995, HEARING RES, V87, P9, DOI 10.1016/0378-5955(95)00072-C; LOWENSTEIN PR, 1995, BRAIN RES, V676, P80, DOI 10.1016/0006-8993(95)00091-4; Maron A, 1996, GENE THER, V3, P315; Morelli AE, 1999, J GEN VIROL, V80, P571, DOI 10.1099/0022-1317-80-3-571; PEREZCRUET MJ, 1994, J NEUROSCI RES, V39, P506, DOI 10.1002/jnr.490390417; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; RAM Z, 1994, J NEUROSURG, V81, P256, DOI 10.3171/jns.1994.81.2.0256; SALOMON B, 1995, MOL CELL BIOL, V15, P5322; SHERING AF, 1994, J COMP NEUROL, V347, P433, DOI 10.1002/cne.903470309; Shering AF, 1997, J GEN VIROL, V78, P445, DOI 10.1099/0022-1317-78-2-445; Smith JG, 1997, HUM GENE THER, V8, P943, DOI 10.1089/hum.1997.8.8-943; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113; WOLFF SD, 1994, RADIOLOGY, V192, P593, DOI 10.1148/radiology.192.3.8058919	45	273	282	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1256	1263		10.1038/15207	http://dx.doi.org/10.1038/15207			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545991				2022-12-25	WOS:000086550600035
J	Labib, K; Diffley, JFX; Kearsey, SE				Labib, K; Diffley, JFX; Kearsey, SE			G1-phase and B-type cyclins exclude the DNA-replication factor Mcm4 from the nucleus	NATURE CELL BIOLOGY			English	Article							CELL-CYCLE; S-PHASE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; FISSION YEAST; G1 CYCLINS; ORIGINS; PROTEIN; INITIATION; COMPLEXES	Cyclin-dependent kinases (CDKs) activate the firing of replication origins during the S phase of the cell cycle, They also block re-initiation of DNA replication within a single cell cycle, by preventing the assembly of prereplicative complexes at origins. We show here that, in budding yeast, CDKs exclude the essential prereplicative-complex component Mcm4 from the nucleus. Although origin firing can be triggered by the B-type cyclins only, both G1-phase and B-type cyclins cause exit of Mcm4 from the nucleus. These results suggest that G1 cyclins may diminish the cell's capacity to assemble prereplicative complexes before B-type cyclins trigger origin firing during S phase.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Dept Zool, Oxford OX1 3PS, England		Diffley, JFX (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Diffley, John/0000-0001-5184-7680				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; Detweiler CS, 1998, P NATL ACAD SCI USA, V95, P2384, DOI 10.1073/pnas.95.5.2384; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donaldson AD, 1998, MOL CELL, V2, P173, DOI 10.1016/S1097-2765(00)80127-6; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; LABIB K, 1995, J CELL SCI, V108, P3285; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sanchez M, 1999, J CELL SCI, V112, P2381; Sanders DB, 1997, REV MEX AST ASTR, V6, P42; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	48	167	168	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					415	422		10.1038/15649	http://dx.doi.org/10.1038/15649			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559985				2022-12-25	WOS:000083533100014
J	Marcelino, J; Carpten, JD; Suwairi, WM; Gutierrez, OM; Schwartz, S; Robbins, C; Sood, R; Makalowska, I; Baxevanis, A; Johnstone, B; Laxer, RM; Zemel, L; Kim, CA; Herd, JK; Ihle, J; Williams, C; Johnson, M; Raman, V; Alonso, LG; Brunoni, D; Gerstein, A; Papadopoulos, N; Bahabri, SA; Trent, JM; Warman, ML				Marcelino, J; Carpten, JD; Suwairi, WM; Gutierrez, OM; Schwartz, S; Robbins, C; Sood, R; Makalowska, I; Baxevanis, A; Johnstone, B; Laxer, RM; Zemel, L; Kim, CA; Herd, JK; Ihle, J; Williams, C; Johnson, M; Raman, V; Alonso, LG; Brunoni, D; Gerstein, A; Papadopoulos, N; Bahabri, SA; Trent, JM; Warman, ML			CACP, encoding a secreted proteoglycan, is mutated in camptodactyly-arthropathy-coxa vara-pericarditis syndrome	NATURE GENETICS			English	Article							ADENOMATOUS POLYPOSIS; FAMILIAL ARTHROPATHY; RHEUMATOID-ARTHRITIS; CONTRACTURES; SYNOVIOCYTES; PATHOLOGY; SYNOVITIS; FEATURES; FINGERS		Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Human Genet, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Natl Human Genome Res Inst, Canc Genet Branch, NIH, Bethesda, MD USA; Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD USA; King Faisal Specialist Hosp & Res Ctr, Riyadh Armed Forces Hosp, Dept Pediat, Riyadh, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh, Saudi Arabia; Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA; Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada; Newington Childrens Hosp, Div Rheumatol, Hartford, CT USA; Univ Sao Paulo, Dept Genet, Sao Paulo, Brazil; E Tennessee State Univ, James H Quillen Coll Med, Dept Pediat, Johnson City, TN 37614 USA; Univ Tubingen, Childrens Hosp, Div Rheumatol, Tubingen, Germany; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Univ Fed Sao Paulo, Paulista Sch Med, Inst Med Genet, Sao Paulo, Brazil; Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); King Faisal Specialist Hospital & Research Center; Prince Sultan Military Medical City; King Faisal Specialist Hospital & Research Center; Case Western Reserve University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Universidade de Sao Paulo; East Tennessee State University; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Universidade Federal de Sao Paulo (UNIFESP); Columbia University	Warman, ML (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.	mlw14@po.cwru.edu	Brunoni, Decio/K-3155-2012; Papadopoulos, Nickolas/K-7272-2012; Makalowska, Izabela/AAU-2682-2021; Makalowska, Izabela/AAF-4967-2021; Sivaraman, Vidya/AAI-5010-2021; Alonso, Luis/I-2841-2013	Makalowska, Izabela/0000-0002-8144-5671; Alonso, Luis/0000-0002-1704-6676; Sivaraman, Vidya/0000-0003-3077-6726; Kim, Chong/0000-0002-1754-1300; Baxevanis, Andy/0000-0002-5370-0014	NIAMS NIH HHS [AR43827] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043827] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATHREYA BH, 1978, ARTHRITIS RHEUM-US, V21, P429, DOI 10.1002/art.1780210405; Bahabri SA, 1998, ARTHRITIS RHEUM, V41, P730, DOI 10.1002/1529-0131(199804)41:4<730::AID-ART22>3.0.CO;2-Y; BULUTLAR G, 1986, ARTHRITIS RHEUM, V29, P436, DOI 10.1002/art.1780290321; CASE JP, 1989, AM J PATHOL, V135, P1055; DAVID G, 1991, BIOCHEM SOC T, V19, P816, DOI 10.1042/bst0190816; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Ferlanti ES, 1999, BIOINFORMATICS, V15, P422, DOI 10.1093/bioinformatics/15.5.422; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; Flannery CR, 1999, BIOCHEM BIOPH RES CO, V254, P535, DOI 10.1006/bbrc.1998.0104; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GRAHAM WR, 1990, SOUTHERN MED J, V83, P973, DOI 10.1097/00007611-199008000-00030; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; LEVICK JR, 1984, HDB PHYSL 2, V4, P917; MARTINEZLAVIN M, 1983, NEW ENGL J MED, V309, P224, DOI 10.1056/NEJM198307283090407; McRorie ER, 1997, BRIT J RHEUMATOL, V36, P100; MERBERG DM, 1993, INT CONGR SER, V1042, P45; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; OCHI T, 1983, ARTHRITIS RHEUM, V26, P896, DOI 10.1002/art.1780260711; Ponta H, 1998, INT J BIOCHEM CELL B, V30, P299, DOI 10.1016/S1357-2725(97)00152-0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Sambrook J., 2002, MOL CLONING LAB MANU; Schumacher BL, 1999, J ORTHOP RES, V17, P110, DOI 10.1002/jor.1100170117; SCHUMACHER BL, 1994, ARCH BIOCHEM BIOPHYS, V311, P144, DOI 10.1006/abbi.1994.1219; SOREN A, 1978, HISTODIAGNOSIS CLIN; TURNER KJ, 1991, BLOOD S, V78, P279; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VERMA UN, 1995, J RHEUMATOL, V22, P2349; WALLIS WJ, 1985, ARTHRITIS RHEUM, V28, P1096, DOI 10.1002/art.1780281004; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6	31	219	229	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					319	322		10.1038/15496	http://dx.doi.org/10.1038/15496			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545950				2022-12-25	WOS:000083792200021
J	Marguet, D; Luciani, MF; Moynault, A; Williamson, P; Chimini, G				Marguet, D; Luciani, MF; Moynault, A; Williamson, P; Chimini, G			Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey	NATURE CELL BIOLOGY			English	Article							BINDING CASSETTE TRANSPORTER; PHOSPHOLIPID ASYMMETRY; MEDIATED PHAGOCYTOSIS; BLOOD-CELLS; C-ELEGANS; ABC1; RECOGNITION		CNRS, INSERM, Ctr Immunol, F-13288 Marseille 09, France; Amherst Coll, Dept Biol, Amherst, MA 01002 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Amherst College	Chimini, G (corresponding author), CNRS, INSERM, Ctr Immunol, Case 906, F-13288 Marseille 09, France.	chimini@ciml.univ-mrs.fr	Marguet, Didier/AGO-5421-2022; Marguet, Didier/B-9946-2008	Marguet, Didier/0000-0003-3198-5095; 				Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Moynault A, 1998, BIOCHEM SOC T, V26, P629, DOI 10.1042/bst0260629; REN Y, 1995, J IMMUNOL, V154, P2366; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	17	135	139	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					454	456		10.1038/15690	http://dx.doi.org/10.1038/15690			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559991				2022-12-25	WOS:000083533100020
J	Cho, RJ; Mindrinos, M; Richards, DR; Sapolsky, RJ; Anderson, M; Drenkard, E; Dewdney, L; Reuber, TL; Stammers, M; Federspiel, N; Theologis, A; Yang, WH; Hubbell, E; Au, M; Chung, EY; Lashkari, D; Lemieux, B; Dean, C; Lipshutz, RJ; Ausubel, FM; Davis, RW; Oefner, PJ				Cho, RJ; Mindrinos, M; Richards, DR; Sapolsky, RJ; Anderson, M; Drenkard, E; Dewdney, L; Reuber, TL; Stammers, M; Federspiel, N; Theologis, A; Yang, WH; Hubbell, E; Au, M; Chung, EY; Lashkari, D; Lemieux, B; Dean, C; Lipshutz, RJ; Ausubel, FM; Davis, RW; Oefner, PJ			Genome-wide mapping with biallelic markers in Arabidopsis thaliana	NATURE GENETICS			English	Article							DENSITY OLIGONUCLEOTIDE ARRAYS; MUTATION DETECTION; YEAST GENOME; PLANT; DNA; HYBRIDIZATION; POLYMORPHISMS; INFORMATION; LINKAGE; RPS2	Single-nucleotide polymorphisms, as well as small insertions and deletions (here referred to collectively as simple nucleotide polymorphisms, or SNPs), comprise the largest set of sequence variants in most organisms(1,2). Positional cloning based on SNPs may accelerate the identification of human disease traits and a range of biologically informative mutations(3-6). The recent application of high-density oligonucleotide arrays to allele identification has made it feasible to genotype thousands of biallelic SNPs in a single experiment(3,7). It has yet to be established, however, whether SNP detection using oligonucleotide arrays can be used to accelerate the mapping of traits in diploid genomes. The cruciferous weed Arabidopsis thaliana is an attractive model system for the construction and use of biallelic SNP maps. Although important biological processes ranging from fertilization and cell fate determination(8-11) to disease resistance(12,13) have been modelled in A. thaliana, identifying mutations in this organism has been impeded by the lack of a high-density genetic: map consisting of easily genotyped DNA markers(14). We report here the construction of a biallelic genetic map in A. thaliana with a resolution of 3.5 cM and its use in mapping Eds16, a gene involved in the defence response to the fungal pathogen Erysiphe orontii. Mapping of this trait involved the high-throughput generation of meiotic maps of F-2 individuals using high-density oligonucleotide probe array-based genotyping. We developed a software package called InterMap and used it to automatically delimit Eds16 to a 7-cM interval on chromosome 1. These results are the first demonstration of biallelic mapping in diploid genomes and establish means for generalizing SNP-based maps to virtually any genetic organism.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Genencor, Palo Alto, CA 94304 USA; Univ Nottingham, Div Plant Sci Univ Pk, Nottingham Arabidopsis Stock Ctr, Nottingham NG7 2RD, England; John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UH, Norfolk, England; Stanford DNA Sequencing & Technol Ctr, Palo Alto, CA 94304 USA; Plant Gene Express Ctr Genome Sequencing Lab, Albany, CA 94710 USA; Affymetrix Inc, Santa Clara, CA 95051 USA; Incyte Pharmaceut, Fremont, CA 94555 USA; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	Stanford University; Stanford University; Harvard University; Massachusetts General Hospital; University of Nottingham; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Stanford University; Affymetrix; Incyte; York University - Canada	Oefner, PJ (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.	oefner@genome.stanford.edu	Cho, Raymond/AAO-8125-2020	Cho, Raymond/0000-0001-6090-6603; Hubbell, Earl/0000-0001-7301-3759; Stammers, Melanie/0000-0003-0369-8611; Reuber, Lynne/0000-0001-7806-2437	NHGRI NIH HHS [3R37 HG00198-23] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R37HG000198] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adam L, 1996, PLANT J, V9, P341, DOI 10.1046/j.1365-313X.1996.09030341.x; Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.0.CO;2-A; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Hoogendoorn B, 1999, HUM GENET, V104, P89, DOI 10.1007/s004390050915; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Kwok PY, 1996, GENOMICS, V31, P123, DOI 10.1006/geno.1996.0019; LANDVIK JY, 1987, POLAR RES, V5, P1; Li JM, 1998, METH MOL B, V82, P55; Liu YG, 1996, PLANT J, V10, P733, DOI 10.1046/j.1365-313X.1996.10040733.x; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Meinke DW, 1998, SCIENCE, V282, P662, DOI 10.1126/science.282.5389.662; MEYEROWITZ EM, 1994, CURR OPIN GENET DEV, V4, P602, DOI 10.1016/0959-437X(94)90079-I; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; O'Donovan MC, 1998, GENOMICS, V52, P44, DOI 10.1006/geno.1998.5411; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; Sawa S, 1999, PLANT CELL, V11, P69, DOI 10.1105/tpc.11.1.69; Volko SM, 1998, GENETICS, V149, P537; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Winzeler EA, 1997, CURR OPIN GENET DEV, V7, P771, DOI 10.1016/S0959-437X(97)80039-1; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194	26	206	235	1	35	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					203	207		10.1038/13833	http://dx.doi.org/10.1038/13833			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508518				2022-12-25	WOS:000082827500021
J	Piedrahita, JA; Oetama, B; Bennett, GD; van Waes, J; Kamen, BA; Richardson, J; Lacey, SW; Anderson, RGW; Finnell, RH				Piedrahita, JA; Oetama, B; Bennett, GD; van Waes, J; Kamen, BA; Richardson, J; Lacey, SW; Anderson, RGW; Finnell, RH			Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development	NATURE GENETICS			English	Article							NEURAL-TUBE DEFECTS; FOLATE-DEFICIENCY; IN-VIVO; HOMOCYSTEINE; EXPRESSION; RECEPTOR; RATS	Periconceptional folic acid supplementation reduces the occurrence of several human congenital malformations, including craniofacial, heart and neural tube defects(1-4). Although the underlying mechanism is unknown, there may be a maternal-to-fetal folate-transport defect or an inherent fetal biochemical disorder that is neutralized by supplementation. Previous experiments have identified a folate-binding protein(5-7) (Folbp1) that functions as a membrane receptor to mediate the high-affinity internalization and delivery of folate to the cytoplasm of the cell(8-10). In vitro, this receptor facilitates the accumulation of cellular folate a thousand-fold relative to the media, suggesting that it may be essential in cytoplasmic folate delivery in vivo. The importance of an adequate intracellular folate pool for normal embryogenesis has long been recognized in humans(11-16) and experimental animals(17-19). To determine whether Folbp1 is involved in maternal-to-fetal folate transport, we inactivated Folbp1 in mice. We also produced mice lacking Folbp2, another member of the folate receptor family that is GPI anchored but binds folate poorly(20). Folbp2(-/-) embryos developed normally, but Folbp 1(-/-) embryos had severe morphogenetic abnormalities and died in utero by embryonic day (E) 10. Supplementing pregnant Folbp1(+/-) dams with folinic acid reversed this phenotype in nullizygous pups. Our results suggest that Folbp1 has a critical role in folate homeostasis during development, and that functional defects in the human homologue (FOLR1) of Folbp1 may contribute to similar defects in humans.	Texas A&M Univ, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Div Gastroenterol, Dallas, TX 75235 USA; Univ Nebraska, Med Ctr, Ctr Human Mol Genet, Omaha, NE 68198 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System; University of Nebraska Medical Center	Finnell, RH (corresponding author), Texas A&M Univ, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA.	rfinnell@unmc.edu	Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35396] Funding Source: Medline; NIEHS NIH HHS [P30-ES09106, ES07165] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BIRN H, 1993, AM J PHYSIOL, V264, pC302, DOI 10.1152/ajpcell.1993.264.2.C302; BOWER C, 1993, BRIT J NUTR, V69, P827, DOI 10.1079/BJN19930083; BRANDNER M, 1969, ANN RADIOL-RADIOL CL, V12, pR703; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; EMERSON DJ, 1962, AM J OBSTET GYNECOL, V84, P356, DOI 10.1016/0002-9378(62)90132-1; FORD JE, 1969, P NUTR SOC, V28, pA39; GOETSCH C, 1962, AM J OBSTET GYNECOL, V83, P1474, DOI 10.1016/S0002-9378(16)35992-0; GOLDEN JA, 1995, PEDIATRICS, V95, P506; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HJELLE JT, 1991, AM J PHYSIOL, V260, pC338, DOI 10.1152/ajpcell.1991.260.2.C338; Ma GT, 1997, DEVELOPMENT, V124, P907; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S; MILUNSKY A, 1968, J PEDIATR-US, V72, P790, DOI 10.1016/S0022-3476(68)80430-5; NELSON M M, 1949, J Nutr, V38, P11; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; REFSUM H, 1989, CLIN CHEM, V35, P1921; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SHAW EB, 1968, AM J DIS CHILD, V115, P477, DOI 10.1001/archpedi.1968.02100010479013; SHAW GM, 1994, TERATOLOGY, V49, P143, DOI 10.1002/tera.1420490210; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1298; WELTMAN S, 1994, VITAMIN RECEPTORS VI, P105; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P2847	30	288	294	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					228	232		10.1038/13861	http://dx.doi.org/10.1038/13861			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508523				2022-12-25	WOS:000082827500026
J	Singh-Gasson, S; Green, RD; Yue, YJ; Nelson, C; Blattner, F; Sussman, MR; Cerrina, F				Singh-Gasson, S; Green, RD; Yue, YJ; Nelson, C; Blattner, F; Sussman, MR; Cerrina, F			Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array	NATURE BIOTECHNOLOGY			English	Article						oligonucleotide microarrays; digital micromirror device; DNA chips; maskless lithography; I-line; ultraviolet; optical lithography		Oligonucleotide microarrays, also called "DNA chips," are currently made by a light-directed chemistry that requires a large number of photolithographic masks for each chip. Here we describe a maskless array synthesizer (MAS) that replaces the chrome masks with virtual masks generated on a computer, which are relayed to a digital micromirror array. A 1:1 reflective imaging system forms an ultraviolet image of the virtual mask on the active surface of the glass substrate, which is mounted in a flow cell reaction chamber connected to a DNA synthesizer. Programmed chemical coupling cycles follow light exposure, and these steps are repeated with different virtual masks to grow desired oligonucleotides in a selected pattern. This instrument has been used to synthesize oligonucleotide microarrays containing more than 76,000 features measuring 16 mu m(2). The oligonucleotides were synthesized at high repetitive yield and, after hybridization, could readily discriminate single-base pair mismatches. The MAS is adaptable to the fabrication of DNA chips containing probes for thousands of genes, as well as any other solid-phase combinatorial chemistry to be performed in high-density microarrays.	Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Dept Elect & Comp Engn, Ctr Nanotechnol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sussman, MR (corresponding author), Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA.			Nelson, Clark/0000-0002-8796-8326				Cadet J., 1990, BIOORGANIC PHOTOCHEM, V1, P1; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GOVE RJ, 1997, TEXAS INSTRUMENTS WH; McGall GH, 1997, J AM CHEM SOC, V119, P5081, DOI 10.1021/ja964427a; OFFNER A, 1975, OPT ENG, V14, P130, DOI 10.1117/12.7978742; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; SAMPSELL JB, 1994, J VAC SCI TECHNOL B, V12, P3242, DOI 10.1116/1.587506; SMITH WJ, 1990, MODERN OPTICAL ENG, P345; WELFORD WT, 1991, USEFUL OPTICS	9	523	656	5	103	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					974	978		10.1038/13664	http://dx.doi.org/10.1038/13664			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504697				2022-12-25	WOS:000083015700022
J	Coy, DL; Hancock, WO; Wagenbach, M; Howard, J				Coy, DL; Hancock, WO; Wagenbach, M; Howard, J			Kinesin's tail domain is an inhibitory regulator of the motor domain	NATURE CELL BIOLOGY			English	Article							HEAVY-CHAIN; DROSOPHILA KINESIN; MICROTUBULE MOVEMENT; ELECTRON-MICROSCOPY; ORGANELLE TRANSPORT; CRYSTAL-STRUCTURE; COILED COILS; LIGHT-CHAINS; BINDING; MYOSIN	When not bound to cargo, the motor protein kinesin is in an inhibited state that has low microtubule-stimulated ATPase activity. Inhibition serves to minimize the dissipation of ATP and to prevent mislocalization of kinesin in the cell. Here we show that this inhibition is relieved when kinesin binds to an artificial cargo. Inhibition is mediated by kinesin's tail domain: deletion of the tail activates the ATPase without need of cargo binding, and inhibition is re-established by addition of exogenous tail peptide. Both ATPase and motility assays indicate that the tail does not prevent kinesin from binding to microtubules, but rather reduces the motor's stepping rate.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Coy, DL (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.		Howard, Jonathon/J-7492-2016; Howard, Jonathon/D-4229-2011; Hancock, William/E-7653-2016	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196; Hancock, William/0000-0001-5547-8755	NIAMS NIH HHS [AR40593] Funding Source: Medline; NIGMS NIH HHS [GM08268] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040593, R37AR040593] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMOS LA, 1987, J CELL SCI, V87, P105; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Berne R. M., 1993, PHYSIOLOGY, V3; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; Coy David L., 1994, Current Opinion in Neurobiology, V4, P662, DOI 10.1016/0959-4388(94)90007-8; Coy DL, 1999, J BIOL CHEM, V274, P3667, DOI 10.1074/jbc.274.6.3667; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; Fersht A., 1985, ENZYME STRUCTURE MEC; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HOWARD J, 1993, METHOD CELL BIOL, V39, P137, DOI 10.1016/S0091-679X(08)60167-3; HUANG TG, 1994, J BIOL CHEM, V269, P16502; Hurd DD, 1996, GENETICS, V144, P1075; JIANG MY, 1995, BIOPHYS J S, V68, P283; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	38	228	232	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					288	292		10.1038/13001	http://dx.doi.org/10.1038/13001			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559941				2022-12-25	WOS:000083169600017
J	Saigoh, K; Wang, YL; Suh, TG; Yamanishi, T; Sakai, Y; Kiyosawa, H; Harada, T; Ichihara, N; Wakana, S; Kikuchi, T; Wada, K				Saigoh, K; Wang, YL; Suh, TG; Yamanishi, T; Sakai, Y; Kiyosawa, H; Harada, T; Ichihara, N; Wakana, S; Kikuchi, T; Wada, K			Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice	NATURE GENETICS			English	Article							AXONAL DYSTROPHY GAD; PGP 9.5; MUTANT MOUSE; NEURODEGENERATIVE DISEASES; DEUBIQUITINATING ENZYMES; SENSORY NEURONS; NERVE-TERMINALS; DEGENERATION; PROTEIN; AXONOPATHY	The gracile axonal dystrophy (gad) mouse is an autosomal recessive mutant that shows sensory ataxia at an early stage, followed by motor ataxia at a later stage(1). Pathologically, the mutant is characterized by 'dying-back' type axonal degeneration and formation of spheroid bodies in nerve terminals(2-5) Recent pathological observations have associated brain ageing and neurodegenerative diseases with progressive accumulation of ubiquitinated protein conjugates(6,7). In gad mice, accumulation of amyloid beta-protein and ubiquitin-positive deposits occur retrogradely along the sensory and motor nervous systems(8,9). We previously reported that the gad mutation was transmitted by a gene on chromosome 5 (refs 10,11). Here we find that the gad mutation is caused by an in-frame deletion including exons 7 and 8 of Uchl1, encoding the ubiquitin carboxy-terminal hydrolase (UCH) isozyme (Uch-ll) selectively expressed in the nervous system and testis(12-15). The gad allele encodes a truncated Uch-ll lacking a segment of 42 amino acids containing a catalytic residue(16). As Uch-ll is thought to stimulate protein degradation by generating free monomeric ubiquitin(16-18), the gad mutation appears to affect protein turnover. Our data suggest that altered function of the ubiquitin system directly causes neurodegeneration, The gad mouse provides a useful model for investigating human neurodegenerative disorders.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Anim Models Human Dis, Tokyo 1878502, Japan; Kinki Univ, Sch Med, Dept Neurol, Osaka 5898511, Japan; Cent Inst Expt Anim, Dept Genet, Kawasaki, Kanagawa 216, Japan	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Kindai University (Kinki University)	Wada, K (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Degenerat Neurol Dis, Tokyo 1878502, Japan.		Saigoh, Kazumasa/AAG-2956-2020; saigoh, Kazumasa/AFK-6417-2022; saigoh, Kazumasa/AAG-4678-2022	Saigoh, Kazumasa/0000-0002-0905-5935; 				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; Arnold J, 1998, PROG BRAIN RES, V117, P23; BIZZI A, 1991, BRAIN RES, V548, P292, DOI 10.1016/0006-8993(91)91135-N; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; DAY INM, 1987, FEBS LETT, V210, P157, DOI 10.1016/0014-5793(87)81327-3; DAY INM, 1990, BIOCHEM J, V268, P521, DOI 10.1042/bj2680521; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Harada T, 1998, J NEUROSCI, V18, P3336; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; ICHIHARA N, 1995, BRAIN RES, V695, P173, DOI 10.1016/0006-8993(95)00729-A; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; KAJIMOTO Y, 1992, J BIOCHEM-TOKYO, V112, P28, DOI 10.1093/oxfordjournals.jbchem.a123860; KIKUCHI T, 1990, ACTA NEUROPATHOL, V80, P145, DOI 10.1007/BF00308917; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MIURA H, 1993, NEUROPATH APPL NEURO, V19, P41, DOI 10.1111/j.1365-2990.1993.tb00403.x; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; ODA K, 1992, NEUROPATH APPL NEURO, V18, P265, DOI 10.1111/j.1365-2990.1992.tb00789.x; Ophoff RA, 1998, TRENDS PHARMACOL SCI, V19, P121, DOI 10.1016/S0165-6147(98)01182-1; SUH JG, 1995, GENOMICS, V27, P549, DOI 10.1006/geno.1995.1091; Wakana S, 1997, MAMM GENOME, V8, P698, DOI 10.1007/s003359900542; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WU J, 1996, ALZHEIMERS RES, V2, P163; YAMAZAKI K, 1988, P SOC EXP BIOL MED, V187, P209; YAMAZAKI K, 1987, JPN J GENET, V62, P479, DOI 10.1266/jjg.62.479	30	431	441	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					47	51		10.1038/12647	http://dx.doi.org/10.1038/12647			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471497				2022-12-25	WOS:000082337300014
J	Anthony, RG; Reichelt, S; Hussey, PJ				Anthony, RG; Reichelt, S; Hussey, PJ			Dinitroaniline herbicide-resistant transgenic tobacco plants generated by co-overexpression of a mutant alpha-tubulin and a beta-tubulin	NATURE BIOTECHNOLOGY			English	Article						dinitroaniline herbicide resistance; alpha- and beta-tubulin; microtubules; transgenic tobacco	ELEUSINE-INDICA; GENES	Dinitroaniline herbicides are used for the selective control of weeds in arable crops. Dinitroaniline herbicide resistance in the invasive weed goosegrass was previously shown to stem from a spontaneous mutation in an alpha-tubulin gene. We transformed and regenerated tobacco plants with an alpha/beta-tubulin double gene construct containing the mutant a-tubulin gene and showed that expression of this construct confers a stably inherited dinitroaniline-resistant phenotype in tobacco. In all transformed lines, the transgene alpha- and beta-tubulins increased the cytoplasmic pool of tubulin approximately 1.5-fold while repressing endogenous alpha- and beta-tubulin synthesis by up to 45% in some tissues. Transgene alpha- and beta-tubulin were overexpressed in every plant tissue analyzed and comprised approximately 66% of the total tubulin in these tissues. Immunolocalization studies revealed that transgene alpha- and beta-tubulins were incorporated into all four microtubule arrays, indicating that they are functional. The majority of the alpha/beta-tubulin pools are encoded by the transgenes, which implies that the mutant alpha-tubulin and the beta-tubulin can perform the majority, if not all, of the roles of microtubules in both juvenile and adult tobacco plants.	Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Hussey, PJ (corresponding author), Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.			Hussey, Patrick/0000-0002-7349-8722; Reichelt, Stefanie/0000-0003-4151-0712				Anthony RG, 1998, PLANT J, V16, P297, DOI 10.1046/j.1365-313x.1998.00296.x; Anthony RG, 1999, TRENDS PLANT SCI, V4, P112, DOI 10.1016/S1360-1385(99)01378-3; Anthony RG, 1998, NATURE, V393, P260, DOI 10.1038/30484; APPLEBY AP, 1989, WEED TECHNOL, V3, P198, DOI 10.1017/S0890037X00031626; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Cleveland Don W., 1994, V13, P47; CRONIN KE, 1993, Patent No. 24637; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; ELLIS JR, 1994, PLANT PHYSIOL, V105, P15, DOI 10.1104/pp.105.1.15; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GonzalezGaray ML, 1996, J CELL BIOL, V135, P1525, DOI 10.1083/jcb.135.6.1525; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUSSEY PJ, 1990, PLANT MOL BIOL, V15, P957, DOI 10.1007/BF00039438; HUSSEY PJ, 1985, FEBS LETT, V181, P131; MOREJOHN LC, 1987, PLANTA, V172, P252, DOI 10.1007/BF00394595; MUDGE LC, 1984, WEED SCI, V32, P591, DOI 10.1017/S0043174500059610; Raff Elizabeth C., 1994, V13, P85; Smertenko A, 1997, PLANTA, V201, P349, DOI 10.1007/s004250050077; SUMIDA S, 1976, PLANT CELL PHYSIOL, V17, P1351; VAUGHN KC, 1987, PLANT PHYSIOL, V83, P956, DOI 10.1104/pp.83.4.956; WALDIN TR, 1992, PLANTA, V188, P258, DOI 10.1007/BF00216822; Yamamoto E, 1998, PLANT CELL, V10, P297, DOI 10.1105/tpc.10.2.297	22	34	37	5	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					712	716		10.1038/10931	http://dx.doi.org/10.1038/10931			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404167				2022-12-25	WOS:000081296900034
J	Calogero, S; Grassi, F; Aguzzi, A; Voigtlander, T; Ferrier, P; Ferrari, S; Bianchi, ME				Calogero, S; Grassi, F; Aguzzi, A; Voigtlander, T; Ferrier, P; Ferrari, S; Bianchi, ME			The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice	NATURE GENETICS			English	Article							MOBILITY GROUP-1 PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID RECEPTOR; ACTIVATION; INTERACTS; COMPLEX	High mobility group 1 (HMG1) protein is an abundant component of all mammalian nuclei, and related proteins exist in all eukaryotes(1,2). HMG1 binds linear DNA with moderate affinity and no sequence specificity(3), but bends the double helix significantly on binding through the minor groove(4). It binds with high affinity to DNA that is already sharply bent, such as linker DNA at the entry and exit of nucleosomes(5-7); thus, it is considered a structural protein of chromatin, HMG1 is also recruited to DNA by interactions with proteins required,for basal and regulated transcriptions(8-13) and V(D)J recombination(14,15). Here we generate mice harbouring deleted Hmg1. Hmg1(-/-) pups are born alive, hut die within 24 hours due to hypoglycaemia, Hmg1-deficient mice survive for several days if given glucose parenterally, then waste away with pleiotropic defects (but no alteration in the immune repertoire). Cell lines lacking Hmg1 grow normally, but the activation of gene expression by the glucocorticoid receptor (GR, encoded by the gene Grl1) is impaired. Thus, Hmg1 is not essential for the overall organization of chromatin in the cell nucleus, but is critical for proper transcriptional control by specific transcription factors.	San Raffaele Sci Inst, DIBIT, I-20132 Milan, Italy; Univ Milan, Dipartimento Biol & Genet Sci Med, I-20132 Milan, Italy; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; CNRS Marseille Luminy, Ctr Immunol, INSERM, F-13288 Marseille, France; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy	University of Milan; University of Zurich; University Zurich Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Milan	Bianchi, ME (corresponding author), San Raffaele Sci Inst, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Aguzzi, Adriano/A-3351-2008; Bianchi, Marco Emilio/K-3417-2018	Bianchi, Marco Emilio/0000-0002-5329-6445; Aguzzi, Adriano/0000-0002-0344-6708; GRASSI, FABIO/0000-0003-3348-1712				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; FERRARI S, 1994, J BIOL CHEM, V269, P28803; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; NODA C, 1985, BIOCHEM BIOPH RES CO, V132, P232, DOI 10.1016/0006-291X(85)91012-5; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; REUE K, 1988, J BIOL CHEM, V263, P6857; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; Vaccari T, 1998, GENOMICS, V49, P247, DOI 10.1006/geno.1998.5214; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; YOOWARREN H, 1981, J BIOL CHEM, V256, P224; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	26	428	454	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					276	280		10.1038/10338	http://dx.doi.org/10.1038/10338			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391216				2022-12-25	WOS:000081125900021
J	Husain, SR; Kreitman, RJ; Pastan, I; Puri, RK				Husain, SR; Kreitman, RJ; Pastan, I; Puri, RK			Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft- model	NATURE MEDICINE			English	Article							CIRCULARLY PERMUTED INTERLEUKIN-4; HUMAN CHORIONIC-GONADOTROPIN; HUMAN-IMMUNODEFICIENCY-VIRUS; ENDOTHELIAL GROWTH-FACTOR; PSEUDOMONAS EXOTOXIN; CELL-LINE; CARCINOMA-CELLS; EXPRESSION; TOXIN; INFECTION	The elusive and enigmatic origin of AIDS-associated Kaposi's sarcoma (AIDS-KS) makes it a complex tumor and therefore difficult to treat. Here we demonstrate that AIDS-KS cells express surface interleukin-4 (IL-4) receptors, and that IL-4 toxin (IL-4(38-37)-PE38KDEL) is specifically cytotoxic to these cells. Intratumoral, intraperitoneal and intravenous administration of IL-4 toxin in nude mice with established subcutaneous AIDS-KS tumors caused considerable antitumor activity in a dose-dependent manner, with highest dose producing durable complete responses. Metabolic changes, including cachexia and lymphopenia, induced by KS tumors were prevented by IL-4 toxin treatment. This report establishes IL-4(38-37)-PE38KDEL as an experimental therapeutic agent for the treatment of AIDS-KS.	US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Lab Mol Tumor Biol, Bethesda, MD 20892 USA; NCI, Div Basic Sci, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Puri, RK (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Lab Mol Tumor Biol, Bethesda, MD 20892 USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; Arora N, 1999, CANCER RES, V59, P183; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Cai J, 1997, INVEST NEW DRUG, V15, P279, DOI 10.1023/A:1005958123893; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Gill PS, 1996, NEW ENGL J MED, V335, P1261, DOI 10.1056/NEJM199610243351702; Gill PS, 1997, NEW ENGL J MED, V336, P670; GILL PS, 1997, NEW ENGL J MED, V226, P1115; HERMANS P, 1994, BRIT J HAEMATOL, V87, P413, DOI 10.1111/j.1365-2141.1994.tb04934.x; Hermans P, 1998, J Hum Virol, V1, P82; Husain SR, 1997, MOL MED, V3, P327, DOI 10.1007/BF03401811; Husain SR, 1998, CANCER RES, V58, P3649; Husain SR, 1997, CLIN CANCER RES, V3, P151; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; KREITMAN RJ, 1994, P NATL ACAD SCI USA, V91, P6889, DOI 10.1073/pnas.91.15.6889; KREITMAN RJ, 1995, CANCER RES, V55, P3357; Krown SE, 1998, J INTERF CYTOK RES, V18, P209, DOI 10.1089/jir.1998.18.209; LOUIE S, 1995, J ACQ IMMUN DEF SYND, V8, P455, DOI 10.1097/00042560-199504120-00004; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MASOOD R, 1994, AIDS RES HUM RETROV, V10, P969, DOI 10.1089/aid.1994.10.969; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1996, J IMMUNOL, V156, P2972; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OBIRI NI, 1994, CLIN EXP IMMUNOL, V95, P148; OBIRI NI, 1993, J CLIN INVEST, V91, P83; PAL LH, 1996, NAT MED, V2, P350; PAUL P, 1991, MICROW OPT TECHN LET, V4, P77, DOI 10.1002/mop.4650040207; Puri R. K., 1995, CYTOKINES INTERLEUKI, P143; Puri RK, 1996, CELL IMMUNOL, V171, P80, DOI 10.1006/cimm.1996.0176; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; Puri RK, 1996, CANCER RES, V56, P5631; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; RUSZCZAK Z, 1987, AM J DERMATOPATH, V9, P388, DOI 10.1097/00000372-198710000-00004; Samaniego F, 1999, J NATL CANCER I, V91, P135, DOI 10.1093/jnci/91.2.135; Samaniego F, 1997, J IMMUNOL, V158, P1887; Samaniego F, 1996, IMMUNOLOGY HIV INFEC, P437; SCULLY PA, 1988, AM J PATHOL, V130, P244; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; TEMPLETON AC, 1988, KAPOSIS SARCOMA PATH, P23; Tulpule A, 1997, ANN ONCOL, V8, P79, DOI 10.1023/A:1008205424763; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; ZHANG YM, 1994, AM J PATHOL, V144, P51	48	52	57	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					817	822		10.1038/10541	http://dx.doi.org/10.1038/10541			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395328				2022-12-25	WOS:000081926600038
J	Bickerstaff, MCM; Botto, M; Hutchinson, WL; Herbert, J; Tennent, GA; Bybee, A; Mitchell, DA; Cook, HT; Butler, PJG; Walport, MJ; Pepys, MB				Bickerstaff, MCM; Botto, M; Hutchinson, WL; Herbert, J; Tennent, GA; Bybee, A; Mitchell, DA; Cook, HT; Butler, PJG; Walport, MJ; Pepys, MB			Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity	NATURE MEDICINE			English	Article							C-REACTIVE PROTEIN; SYSTEMIC LUPUS-ERYTHEMATOSUS; SMALL NUCLEAR RIBONUCLEOPROTEIN; ACUTE-PHASE PROTEINS; MICE; BINDS; PENTRAXINS; ANTIBODIES; CLEARANCE; INVITRO	Serum amyloid P component (SAP), a highly conserved plasma protein named for its universal presence in amyloid deposits', is the single normal circulating protein that shows specific calcium-dependent binding to DNA and chromatin in physiological conditions(2,3). The avid binding of SAP displaces Hi-type histones and thereby solubilizes native long chromatin, which is otherwise profoundly insoluble at the physiological ionic strength of extracellular fluids(4). Furthermore, SAP binds in vivo both to apoptotic cells(5), the surface blebs of which bear chromatin fragments(6), and to nuclear debris released by necrosis(7). SAP may therefore participate in handling of chromatin exposed by cell death(2-4,7). Here we show that mice with targeted deletion of the SAP genes spontaneously develop antinuclear autoimmunity and severe glomerulonephritis, a phenotype resembling human systemic lupus erythematosus, a serious autoimmune disease. The SAP(-/-) mice also have enhanced anti-DNA responses to immunization with extrinsic chromatin, and we demonstrate that degradation of long chromatin is retarded in the presence of SAP both in vitro and in vivo. These findings indicate that SAP has an important physiological role, inhibiting the formation of pathogenic autoantibodies against chromatin and DNA, probably by binding to chromatin and regulating its degradation.	Imperial Coll Sch Med, Hammersmith Hosp, Immunol Med Unit, London W12 0NN, England; Imperial Coll Sch Med, Hammersmith Hosp, Rheumatol Sect, London W12 0NN, England; Imperial Coll Sch Med, Hammersmith Hosp, Dept Histopathol, London W12 0NN, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Imperial College London; Imperial College London; Imperial College London; MRC Laboratory Molecular Biology	Pepys, MB (corresponding author), Imperial Coll Sch Med, Hammersmith Hosp, Immunol Med Unit, London W12 0NN, England.		Mitchell, Daniel A/A-6580-2009	Mitchell, Daniel A/0000-0003-0936-6212; Walport, Mark/0000-0001-7220-5273				Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; BREATHNACH SM, 1989, J EXP MED, V170, P1433, DOI 10.1084/jem.170.4.1433; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; Burlingame RW, 1996, J IMMUNOL, V156, P4783; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DUCLOS TW, 1989, J IMMUNOL, V143, P2553; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Gauthier VJ, 1996, J IMMUNOL, V156, P1151; HINTNER H, 1988, J INVEST DERMATOL, V91, P22, DOI 10.1111/1523-1747.ep12463283; HUGHES CRV, 1998, J R COLL PHYSICIANS, V32, P260; HUTCHINSON WL, 1994, J CLIN INVEST, V94, P1390, DOI 10.1172/JCI117474; ISENBERG DA, 1987, ANN RHEUM DIS, V46, P448, DOI 10.1136/ard.46.6.448; MATHER SJ, 1987, J NUCL MED, V28, P1034; MOLDEN DP, 1984, AM J CLIN PATHOL, V82, P57, DOI 10.1093/ajcp/82.1.57; NAKAYAMA S, 1984, J IMMUNOL, V132, P1336; PEPYS MB, 1977, IMMUNOLOGY, V33, P491; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1994, CLIN EXP IMMUNOL, V97, P152; PEPYS MB, 1982, CLIN RHEUM DIS, V8, P91; PEPYS MB, 1979, NATURE, V278, P259, DOI 10.1038/278259a0; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Pepys MB, 1997, AMYLOID, V4, P274, DOI 10.3109/13506129709003838; REICHLIN M, 1994, J CLIN INVEST, V93, P443, DOI 10.1172/JCI116980; RORDORF C, 1982, J EXP MED, V156, P1268, DOI 10.1084/jem.156.4.1268; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9	28	399	427	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					694	697		10.1038/9544	http://dx.doi.org/10.1038/9544			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371509				2022-12-25	WOS:000080823300039
J	Scheel, J; Srinivasan, J; Honnert, U; Henske, A; Kurzchalia, TV				Scheel, J; Srinivasan, J; Honnert, U; Henske, A; Kurzchalia, TV			Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans	NATURE CELL BIOLOGY			English	Article							MAP KINASE CASCADE; MICRODOMAINS; EXPRESSION; PROTEIN; GENES; RAS		Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany; Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; Max Delbruck Ctr Mol Med, Dept Cell Biol, D-13092 Berlin, Germany	Max Planck Society; Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kurzchalia, TV (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany.		Srinivasan, Jagan/B-6215-2015	Srinivasan, Jagan/0000-0001-5449-7938				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9	16	97	104	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					127	129		10.1038/10100	http://dx.doi.org/10.1038/10100			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559886				2022-12-25	WOS:000083102200022
J	Barrett, MT; Sanchez, CA; Prevo, LJ; Wong, DJ; Galipeau, PC; Paulson, TG; Rabinovitch, PS; Reid, BJ				Barrett, MT; Sanchez, CA; Prevo, LJ; Wong, DJ; Galipeau, PC; Paulson, TG; Rabinovitch, PS; Reid, BJ			Evolution of neoplastic cell lineages in Barrett oesophagus	NATURE GENETICS			English	Article							HIGH-GRADE DYSPLASIA; ALLELIC LOSSES; ENDOSCOPIC SURVEILLANCE; ESOPHAGEAL ADENOCARCINOMA; GENETIC ALTERATIONS; ULCERATIVE-COLITIS; CLONAL EVOLUTION; CANCER; PROGRESSION; POPULATIONS		Fred Hutchinson Canc Res Ctr, Program Canc Biol, GI Oncol, Seattle, WA 98104 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98104 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Reid, BJ (corresponding author), Fred Hutchinson Canc Res Ctr, Program Canc Biol, GI Oncol, 1124 Columbia St, Seattle, WA 98104 USA.		Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NATIONAL CANCER INSTITUTE [R01CA061202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007742] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA61202, R01 CA061202] Funding Source: Medline; NIDDK NIH HHS [DK07742-03, T32 DK007742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett MT, 1996, ONCOGENE, V12, P1873; Barrett MT, 1996, CANCER RES, V56, P4351; Barrett MT, 1996, ONCOGENE, V13, P1867; Bedi GC, 1996, CANCER RES, V56, P2484; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; BOLAND CR, 1995, NAT MED, V1, P902, DOI 10.1038/nm0995-902; Califano J, 1996, CANCER RES, V56, P2488; CORREA P, 1990, CANCER RES, V50, P4737; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; LEVINE DS, 1991, GASTROENTEROLOGY, V101, P1198, DOI 10.1016/0016-5085(91)90068-V; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PETERSEN SE, 1980, FLOW CYTOMETRY, V4, P412; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; ROZEN P, 1995, GASTROENTEROLOGY, V108, P1361, DOI 10.1016/0016-5085(95)90683-5; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SPECHLER SJ, 1987, ANN INTERN MED, V106, P902, DOI 10.7326/0003-4819-106-6-902; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Wong DJ, 1997, CANCER RES, V57, P2619; Wu TT, 1998, AM J PATHOL, V153, P287, DOI 10.1016/S0002-9440(10)65570-8	29	359	366	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					106	109		10.1038/8816	http://dx.doi.org/10.1038/8816			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319873	Green Accepted			2022-12-25	WOS:000080096300034
J	Long, EM; Martin, HL; Kreiss, JK; Rainwater, SMJ; Lavreys, L; Jackson, DJ; Rakwar, J; Mandaliya, K; Overbaugh, J				Long, EM; Martin, HL; Kreiss, JK; Rainwater, SMJ; Lavreys, L; Jackson, DJ; Rakwar, J; Mandaliya, K; Overbaugh, J			Gender differences in HIV-1 diversity at time of infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GENITAL SECRETIONS; TRANSMISSION; BLOOD; SEROCONVERSION; HETEROGENEITY; POPULATIONS; WOMEN	To develop an HIV-1 vaccine with global efficacy, it is important to identify and characterize the viruses that are transmitted, particularly to individuals living in areas of high incidence. Several studies have shown that virus from the blood of acutely infected adults was homogeneous, even when the virus population in the index case was genetically diverse(1-4). In contrast to those results with mainly male cohorts in America and Europe, in several cases a heterogeneous virus population has been found early in infection in women in Africa(5,6). Thus, we more closely compared the diversity of transmitted HIV-1 in men and women who became infected through heterosexual contact. We found that women from Kenya were often infected by multiple virus variants, whereas men from Kenya were not. Moreover, a heterogeneous virus was present in the women before their seroconversion, and in each woman it was derived from a single index case, indicating that diversity was most likely to be the result of transmission of multiple variants. Our data indicate that there are important differences in the transmitted virus populations in women and men, even when cohorts from the same geographic region who are infected with the same subtypes of HIV-1 are compared.	Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Coast Prov Gen Hosp, Mombasa, Kenya	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi	Overbaugh, J (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.			Starke, Michelle/0000-0003-3239-4801	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038518, R21AI033873, N01AI035173, R01AI038518] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33873, AI38518, N01-AI35173-119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; DELWART EL, 1995, PCR METH APPL, V4, pS202; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; HAJJAR AM, 1997, J CLIN MICROBIOL, P2349; Kampinga GA, 1997, VIROLOGY, V227, P63, DOI 10.1006/viro.1996.8318; Karlsson AC, 1998, AIDS, V12, P839, DOI 10.1097/00002030-199808000-00005; Martin HL, 1998, J INFECT DIS, V178, P1053, DOI 10.1086/515654; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MERTENS TE, 1996, AIDS, V10, P5221; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999; Overbaugh J, 1996, AIDS RES HUM RETROV, V12, P107, DOI 10.1089/aid.1996.12.107; POSS M, 1995, J VIROL, V69, P8118, DOI 10.1128/JVI.69.12.8118-8122.1995; Rakwar J, 1999, AIDS, V13, P607, DOI 10.1097/00002030-199904010-00010; SWOFFORD DL, 1999, PAUP STAR PHYLOGENET; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	19	160	162	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					71	75						5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613827				2022-12-25	WOS:000084583300038
J	Wu, GQ; Markowitz, GS; Li, L; D'Agati, VD; Factor, SM; Geng, L; Tibara, S; Tuchman, J; Cai, YQ; Park, JH; van Adelsberg, J; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S				Wu, GQ; Markowitz, GS; Li, L; D'Agati, VD; Factor, SM; Geng, L; Tibara, S; Tuchman, J; Cai, YQ; Park, JH; van Adelsberg, J; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S			Cardiac defects and renal failure in mice with targeted mutations in Pkd2	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; HEART; GENE; ENCODES; PROTEIN; MOUSE	PKD2, mutations in which cause autosomal dominant polycystic kidney disease(1) (ADPKD), encodes an integral membrane glycoprotein(2) with similarity to calcium channel subunits(1,3). We induced two mutations in the mouse homologue Pkd2 (ref. 4): an unstable allele (WS25; hereafter denoted pkd2(WS25)) that can undergo homologous-recombination-based somatic rearrangement to form a null allele; and a true null mutation (WS183; hereafter denoted Pkd2(-)). We examined these mutations to understand the function of polycystin-2, the protein product of Pkd2, and to provide evidence that kidney and liver cyst formation associated with Pkd2 deficiency occurs by a two-hit mechanism(4-9). Pkd2(-/-) mice die in utero between embryonic day (E) 13.5 and parturition. They have structural defects in cardiac septation and cyst formation in maturing nephrons and pancreatic ducts. Pancreatic ductal cysts also occur in adult pkd2(WS25/-) mice, suggesting that this clinical manifestation of ADPKD also occurs by a two-hit mechanism. As in human ADPKD, formation of kidney cysts in adult pkd2(WS25/-) mice is associated with renal failure and early death (median survival, 65 weeks versus 94 weeks for controls). Adult Pkd2(+/-) mice have intermediate survival in the absence of cystic disease or renal failure, providing the first indication of a deleterious effect of haploinsufficiency at Pkd2 on long-term survival. Our studies advance our understanding of the function of polycystin-2 in development and our mouse models recapitulate the complex human ADPKD phenotype.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University; Columbia University; Yale University	Somlo, S (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06510 USA.	stefan.somlo@yale.edu	Kucherlapati, Raju/ABC-8807-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051041, R01DK054053] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1 DK54053, R01 DK051041] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardaji A, 1998, AM J KIDNEY DIS, V32, P970, DOI 10.1016/S0272-6386(98)70071-X; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Clark TG, 1999, DEVELOPMENT, V126, P2631; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; Emmons SW, 1999, NATURE, V401, P339, DOI 10.1038/43810; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gittes GK, 1996, DEVELOPMENT, V122, P439; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Hateboer N, 1999, LANCET, V353, P103, DOI 10.1016/S0140-6736(98)03495-3; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; HUSTON J, 1993, J AM SOC NEPHROL, V3, P1871; Koptides M, 1999, HUM MOL GENET, V8, P509, DOI 10.1093/hmg/8.3.509; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Markowitz GS, 1999, AM J PHYSIOL-RENAL, V277, pF17, DOI 10.1152/ajprenal.1999.277.1.F17; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Pei Y, 1999, J AM SOC NEPHROL, V10, P1524; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; Stockelman MG, 1998, AM J PHYSIOL-RENAL, V275, pF154, DOI 10.1152/ajprenal.1998.275.1.F154; Torra R, 1999, AM J HUM GENET, V65, P345, DOI 10.1086/302501; Torra R, 1997, CLIN NEPHROL, V47, P19; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	28	271	280	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					75	78		10.1038/71724	http://dx.doi.org/10.1038/71724			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615132				2022-12-25	WOS:000084609200020
J	Brown, NR; Noble, MEM; Endicott, JA; Johnson, LN				Brown, NR; Noble, MEM; Endicott, JA; Johnson, LN			The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases	NATURE CELL BIOLOGY			English	Article							CRYSTAL-STRUCTURE; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; COMPLEX; RECOGNITION; MECHANISM; P34(CDC2); BINDING	Progression through the eukaryotic cell cycle is driven by the orderly activation of cyclin-dependent kinases (CDKs). For activity, CDKs require association with a cyclin and phosphorylation by a separate protein kinase at a conserved threonine residue (T160 in CDK2). Here we present the structure of a complex consisting of phosphorylated CDK2 and cyclin A together with an optimal peptide substrate, HHASPRK. This structure provides an explanation for the specificity of CDK2 towards the proline that follows the phosphorylatable serine of the substrate peptide, and the requirement for the basic residue in the P+3 position of the substrate. We also present the structure of phosphorylated CDK2 plus cyclinA3 in complex with residues 658-668 from the CDK2 substrate p107. These residues include the RXL motif required to target p107 to cyclins. This structure explains the specificity of the RXL motif for cyclins.	Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Johnson, LN (corresponding author), Univ Oxford, Mol Biophys Lab, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.			Noble, Martin/0000-0002-3595-9807; Endicott, Jane/0000-0003-4868-0116				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SCHREUDER HA, 1988, J APPL CRYSTALLOGR, V21, P426, DOI 10.1107/S0021889888004108; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; SKAMNAKI VT, IN PRESS BIOCHEMISTR; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	35	464	471	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					438	443		10.1038/15674	http://dx.doi.org/10.1038/15674			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559988				2022-12-25	WOS:000083533100017
J	Lu, ZR; Kopeckova, P; Kopecek, J				Lu, ZR; Kopeckova, P; Kopecek, J			Polymerizable Fab ' antibody fragments for targeting of anticancer drugs	NATURE BIOTECHNOLOGY			English	Article						polymerizable Fab '; HPMA copolymer; drug targeting; chlorin e(6); anticancer drug	CELLS IN-VITRO; MONOCLONAL-ANTIBODIES; THERAPY; ANTIGENS; AFFINITY; INVIVO; SYSTEM; MICE	We have designed a new pathway for the synthesis of targeted polymeric drug delivery systems, using polymerizable antibody Fab' fragments (MA-Fab'). The targeted systems can be directly prepared by copolymerization of the MA-Fab', N-(2-hydroxypropyl)methacrylamide (HPMA) and drug-containing monomers. Both MA-Fab' and the Fab'-targeted copolymers can effectively bind to target cells. An MA-Fab' (from OV-TL 16 Ab) targeted HPMA copolymer containing mesochlorin e(6) (Mce(6)) was synthesized by copolymerization of MA-Fab', HPMA, and MA-GFLG-Mce(6). The targeted copolymer exhibited a higher cytotoxicity toward OVCAR-3 human ovarian carcinoma cells than the nontargeted Mce(6)-containing copolymer or free Mce(6). The targeted copolymer was internalized more efficiently by OVCAR-3 cells than the nontargeted copolymer.	Univ Utah, Dept Pharmaceut & Pharmaceut Chem CCCD, Salt Lake City, UT 84112 USA; Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kopecek, J (corresponding author), Univ Utah, Dept Pharmaceut & Pharmaceut Chem CCCD, Salt Lake City, UT 84112 USA.				NATIONAL CANCER INSTITUTE [R01CA051578] Funding Source: NIH RePORTER; NCI NIH HHS [CA51578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUDITOREHARGREAVES K, 1987, CLIN CHEM, V33, P1509; BOERMAN O, 1989, ANTICANCER RES, V9, P551; BOERMAN O, 1990, ANTICANCER RES, V10, P1289; CALOFFA VR, 1999, 9 INT S REC ADV DRUG, P46; Delgado C, 1996, BRIT J CANCER, V73, P175, DOI 10.1038/bjc.1996.32; DROBNIK J, 1976, MAKROMOL CHEM, V177, P2833; Fritzberg AR, 1996, J MOL RECOGNIT, V9, P309, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<309::AID-JMR275>3.0.CO;2-#; FRITZBERG AR, 1994, J CONTROL RELEASE, V28, P167, DOI 10.1016/0168-3659(94)90163-5; KOPECEK J, 1973, EUR POLYM J, V9, P7, DOI 10.1016/0014-3057(73)90063-3; KOPECEK J, 1991, Patent No. 5037883; LU ZR, 1998, P INT S CONTR REL BI, V25, P788; MAEDA H, 1992, BIOCONJUGATE CHEM, V3, P351, DOI 10.1021/bc00017a001; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Omelyanenko V, 1998, INT J CANCER, V75, P600, DOI 10.1002/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C; PARHAM P, 1983, J IMMUNOL, V131, P2895; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; Peterson CM, 1996, CANCER RES, V56, P3980; Putnam D, 1995, ADV POLYM SCI, V122, P55, DOI 10.1007/3540587888_14; REJMANOVA P, 1983, MAKROMOL CHEM, V184, P2009; RIHOVA B, 1988, CLIN IMMUNOL IMMUNOP, V46, P100; Vasey PA, 1999, CLIN CANCER RES, V5, P83	22	118	135	3	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1101	1104		10.1038/15085	http://dx.doi.org/10.1038/15085			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545917				2022-12-25	WOS:000083428000028
J	Ma, JY; Lindquist, S				Ma, JY; Lindquist, S			De novo generation of a PrPSc-like conformation in living cells	NATURE CELL BIOLOGY			English	Article							PRION PROTEIN; SCRAPIE PRION; FREE CONVERSION; RESISTANT; DISEASES; AGENT	Conformational conversion of the cellular PrPc protein to PrPSc is a central aspect of the prion diseases, but how PrP initially converts to this conformation remains a mystery. Here we show that PrP expressed in the yeast cytoplasm, instead of the endoplasmic reticulum, acquires the characteristics of PrPSc, namely detergent insolubility and a distinct pattern of protease resistance. Neuroblastoma cells cultured under reducing, glycosylation-inhibiting conditions produce PrP with the same characteristics. We therefore describe what is, to our knowledge, the first conversion of full-length PrP in a heterologous system, show the importance of reducing and deglycosylation conditions in PrP conformational transitions, and suggest a model for initiating events in sporadic and inherited prion diseases.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave MC1028, Chicago, IL 60637 USA.							BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holkeri H, 1998, J CELL SCI, V111, P749; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	23	95	100	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					358	361		10.1038/14053	http://dx.doi.org/10.1038/14053			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559963				2022-12-25	WOS:000083169800019
J	Kogerman, P; Grimm, T; Kogerman, L; Krause, D; Unden, AB; Sandstedt, B; Toftgard, R; Zaphiropoulos, PG				Kogerman, P; Grimm, T; Kogerman, L; Krause, D; Unden, AB; Sandstedt, B; Toftgard, R; Zaphiropoulos, PG			Mammalian Suppressor-of-Fused modulates nuclear-cytoplasmic shuttling of GLI-1	NATURE CELL BIOLOGY			English	Article							HEDGEHOG SIGNALING PATHWAY; BASAL-CELL CARCINOMA; TRANSCRIPTION FACTOR; CUBITUS-INTERRUPTUS; HUMAN HOMOLOG; GENE ENCODES; PROTEIN; DIFFERENTIATION; MUTATIONS	Sonic hedgehog, Patched and Gli are components of a mammalian signalling pathway that has been conserved during evolution and which has a central role in the control of pattern formation and cellular proliferation during development. Here we identify the human Suppressor-of-Fused (SUFUH) complementary DNA and show that the gene product interacts physically with the transcriptional effector GLI-1, can sequester GLI-1 in the cytoplasm, but can also interact with GLI-1 on DNA. Functionally, SUFUH inhibits transcriptional activation by GLI-1, as well as osteogenic differentiation in response to signalling from Sonic hedgehog. Localization of GLI-1 is influenced by the presence of a nuclear-export signal, and GLI-1 becomes constitutively nuclear when this signal is mutated or nuclear export is inhibited. These results show that SUFUH is a conserved negative regulator of GLI-1 signalling that may affect nuclear-cytoplasmic shuttling of GLI-1 or the activity of GLI-1 in the nucleus and thereby modulate cellular responses.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Hosp, Dept Dermatol, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Pathol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Toftgard, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.	Rune.Toftgard@cnt.ki.se	Kogerman, Priit/B-6333-2008	Zaphiropoulos, Peter/0000-0003-4298-3861				Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PHAM A, 1995, GENETICS, V140, P587; Roessler E, 1997, HUM MOL GENET, V6, P1847, DOI 10.1093/hmg/6.11.1847; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Unden AB, 1997, CANCER RES, V57, P2336; Viegas-Pequignot E., 1992, PRACTICAL APPROACHES, P137; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049	34	379	390	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					312	319		10.1038/13031	http://dx.doi.org/10.1038/13031			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559945				2022-12-25	WOS:000083169600021
J	Chang, CCJ; Chen, TT; Cox, BW; Dawes, GN; Stemmer, WPC; Punnonen, J; Patten, PA				Chang, CCJ; Chen, TT; Cox, BW; Dawes, GN; Stemmer, WPC; Punnonen, J; Patten, PA			Evolution of a cytokine using DNA family shuffling	NATURE BIOTECHNOLOGY			English	Article						DNA shuffling; cytokines; interferon; molecular breeding; pharmaceutical proteins	HUMAN GROWTH-HORMONE; INTERFERON-ALPHA; RECEPTOR; INTERLEUKIN-2; RECOMBINATION; MECHANISMS; PROTEINS; DOMAINS; CELLS; IL-2	DNA shuffling of a family of over 20 human interferon-alpha (Hu-IFN-alpha) genes was used to derive variants with increased antiviral and antiproliferation activities in murine cells, A clone with 135,000-fold improved specific activity over Hu-IFN-alpha 2a was obtained in the first cycle of shuffling, After a second cycle of selective shuffling, the most active clone was improved 285,000-fold relative to Hu-IFN-alpha 2a and 185-fold relative to Hu-IFN-alpha 1, Remarkably, the three most active clones were more active than the native murine IFN-alpha s. These chimeras are derived from up to five parental genes but contained no random point mutations. These results demonstrate that diverse cytokine gene families can be used as starting material to rapidly evolve cytokines that are more active, or have superior selectivity profiles, than native cytokine genes.	Maxygen Inc, Santa Clara, CA 95051 USA		Patten, PA (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.							ALLEGRETTA M, 1986, J CLIN IMMUNOL, V6, P481, DOI 10.1007/BF00915254; Blatt LM, 1996, J INTERF CYTOK RES, V16, P489, DOI 10.1089/jir.1996.16.489; BURBANK L, 1914, L BURBANK HIS METHOD, V1, P176; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Dusheiko G, 1997, HEPATOLOGY, V26, pS112, DOI 10.1002/hep.510260720; FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUNKE I, 1994, ANN HEMATOL, V68, P49; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAIDANE JBS, 1924, CAMBRIDGE PHIL SOC T, V23, P19; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; HORISBERGER MA, 1995, PHARMACOL THERAPEUT, V66, P507, DOI 10.1016/0163-7258(95)00008-5; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; KONRAD M, 1989, TRENDS BIOTECHNOL, V7, P175, DOI 10.1016/0167-7799(89)90095-4; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lynch M., 1998, GENETICS ANAL QUANTI; Moore JC, 1997, J MOL BIOL, V272, P336, DOI 10.1006/jmbi.1997.1252; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCAROZZA AM, 1992, J INTERFERON RES, V12, P35, DOI 10.1089/jir.1992.12.35; SCHOMBURG A, 1993, J CANCER RES CLIN, V119, P745, DOI 10.1007/BF01195347; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; TYMMS MJ, 1990, GENET ANAL-BIOMOL E, V7, P53, DOI 10.1016/0735-0651(90)90041-D; UZE G, 1994, J MOL BIOL, V243, P245, DOI 10.1006/jmbi.1994.1651; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; vanderMeide PH, 1997, BIOTHERAPY, V10, P39, DOI 10.1007/BF02678216; VIAL T, 1994, DRUG SAFETY, V10, P115, DOI 10.2165/00002018-199410020-00003; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	32	110	214	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					793	797		10.1038/11737	http://dx.doi.org/10.1038/11737			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429246				2022-12-25	WOS:000081751400030
J	Miller, HI				Miller, HI			Nasty taste from G-8 GM food policy	NATURE BIOTECHNOLOGY			English	Editorial Material									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)									0	1	1	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					730	730		10.1038/11613	http://dx.doi.org/10.1038/11613			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429217	Bronze			2022-12-25	WOS:000081751400004
J	Kirk, AD; Burkly, LC; Batty, DS; Baumgartner, RE; Berning, JD; Buchanan, K; Fechner, JH; Germond, RL; Kampen, RL; Patterson, NB; Swanson, SJ; Tadaki, DK; TenHoor, CN; White, L; Knechtle, SJ; Harlan, DM				Kirk, AD; Burkly, LC; Batty, DS; Baumgartner, RE; Berning, JD; Buchanan, K; Fechner, JH; Germond, RL; Kampen, RL; Patterson, NB; Swanson, SJ; Tadaki, DK; TenHoor, CN; White, L; Knechtle, SJ; Harlan, DM			Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates	NATURE MEDICINE			English	Article							CD40 LIGAND; ENDOTHELIAL-CELLS; T-CELLS; HELP; LYMPHOCYTES; ACTIVATION; TOLERANCE; SURVIVAL; GAMMA	CD154 is the ligand for the receptor CD40. This ligand-receptor pair mediates endothelial and antigen-presenting cell activation, and facilitates the interaction of these cells with T cells and platelets. We demonstrate here that administration of a CD154-specific monoclonal antibody (hu5C8) allows for renal allotransplantation in outbred, MHC-mismatched rhesus monkeys without acute rejection. The effect persisted for more than 10 months after therapy termination, and no additional drug was required to achieve extended graft survival. Indeed, the use of tacrolimus or chronic steroids seemed to antagonize the anti-rejection effect. Monkeys treated with antibody against CD154 remained healthy during and after therapy. The mechanism of action does not require global depletion of T or B cells. Long-term survivors lost their mixed lymphocyte reactivity in a donor-specific manner, but still formed donor-specific antibody and generated T cells that infiltrated the grafted organ without any obvious effect on graft function. Thus, therapy with antibody against CD154 is a promising agent for clinical use in human allotransplantation.	USN, Med Res Ctr, Immune Cell Biol Program, Bethesda, MD 20889 USA; Univ Wisconsin, Sch Med, Div Transplantat, Madison, WI 53792 USA; Walter Reed Army Med Ctr, Organ Transplant Serv, Washington, DC 20307 USA; Biogen Inc, Cambridge Ctr 14, Cambridge, MA 02142 USA	United States Department of Defense; United States Navy; University of Wisconsin System; University of Wisconsin Madison; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Biogen	Kirk, AD (corresponding author), USN, Med Res Ctr, Immune Cell Biol Program, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.		Kirk, Allan D./B-6905-2012; Fechner, John/C-5962-2016	Fechner, John/0000-0002-8220-7237; Kirk, Allan/0000-0003-2004-5962; Knechtle, Stuart/0000-0002-1625-385X				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HARLAN DM, 1998, CRAFT, V1, P63; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KIRK AD, 1995, HUM IMMUNOL, V43, P113, DOI 10.1016/0198-8859(94)00158-M; Kirk AD, 1997, TRANSPLANTATION, V64, P1716, DOI 10.1097/00007890-199712270-00015; Knapp LA, 1997, TISSUE ANTIGENS, V50, P170, DOI 10.1111/j.1399-0039.1997.tb02856.x; Knechtle SJ, 1997, TRANSPLANTATION, V63, P1, DOI 10.1097/00007890-199701150-00002; Konieczny BT, 1998, J IMMUNOL, V160, P2059; Laman JD, 1996, CRIT REV IMMUNOL, V16, P59, DOI 10.1615/CritRevImmunol.v16.i1.40; Larsen CP, 1997, CURR OPIN IMMUNOL, V9, P641, DOI 10.1016/S0952-7915(97)80043-X; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; Markees TG, 1998, J CLIN INVEST, V101, P2446, DOI 10.1172/JCI2703; PIRSCH JD, 1997, CURR OPIN ORGAN TRAN, V2, P76; PLAZ KP, 1991, TRANSPLANTATION, V51, P27; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Yang YP, 1996, SCIENCE, V273, P1862, DOI 10.1126/science.273.5283.1862	23	663	708	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					686	693		10.1038/9536	http://dx.doi.org/10.1038/9536			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371508				2022-12-25	WOS:000080823300038
J	Ales, E; Tabares, L; Poyato, JM; Valero, V; Lindau, M; de Toledo, GA				Ales, E; Tabares, L; Poyato, JM; Valero, V; Lindau, M; de Toledo, GA			High calcium concentrations shift the mode of exocytosis to the kiss-and-run mechanism	NATURE CELL BIOLOGY			English	Article							ADRENAL CHROMAFFIN CELLS; MOUSE MAST-CELLS; FUSION PORE; SYNAPTIC VESICLES; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; SECRETORY PRODUCTS; ENDOCYTOSIS; CA2+; MEMBRANE	Exocytosis, the fusion of secretory vesicles with the plasma membrane to allow release of the contents of the vesicles into the extracellular environment, and endocytosis, the internalization of these vesicles to allow another round of secretion, are coupled. It is, however, uncertain whether exocytosis and endocytosis are tightly coupled, such that secretory vesicles fuse only transiently with the plasma membrane before being internalized (the 'kiss-and-run' mechanism), or whether endocytosis occurs by an independent process following complete incorporation of the secretory vesicle into the plasma membrane. Here we investigate the fate of single secretory vesicles after fusion with the plasma membrane by measuring capacitance changes and transmitter release in rat chromaffin cells using the cell-attached patch-amperometry technique. We show that raised concentrations of extracellular calcium ions shift the preferred mode of exocytosis to the kiss-and-run mechanism in a calcium-concentration-dependent manner. We propose that, during secretion of neurotransmitters at synapses, the mode of exocytosis is modulated by calcium to attain optimal conditions for coupled exocytosis and endocytosis according to synaptic activity.	Univ Sevilla, Fac Med, Dept Fisiol Med & Biofis, E-41009 Seville, Spain; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	University of Sevilla; Cornell University	de Toledo, GA (corresponding author), Univ Sevilla, Fac Med, Dept Fisiol Med & Biofis, E-41009 Seville, Spain.		Ales, Eva/E-6315-2010; Alvarez de Toledo, Guillermo/I-2888-2015; Tabares, Lucia/K-8768-2015; Lindau, Manfred/ABD-3449-2021	Ales, Eva/0000-0002-5536-4616; Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Tabares, Lucia/0000-0002-4027-4044; Lindau, Manfred/0000-0002-5722-9557				Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow Robert H., 1995, P245; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; Morgan A, 1997, SEMIN CELL DEV BIOL, V8, P141, DOI 10.1006/scdb.1996.0133; Moser T, 1997, P NATL ACAD SCI USA, V94, P6735, DOI 10.1073/pnas.94.13.6735; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Smith C, 1997, J CELL BIOL, V139, P885, DOI 10.1083/jcb.139.4.885; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VERDUGO P, 1987, BIORHEOLOGY, V24, P625; VONGERSDORFF H, 1994, NATURE, V370, P652, DOI 10.1038/370652a0; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	34	318	322	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					40	44		10.1038/9012	http://dx.doi.org/10.1038/9012			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559862				2022-12-25	WOS:000083085300016
J	Gaertig, J; Gao, Y; Tishgarten, T; Clark, TG; Dickerson, HW				Gaertig, J; Gao, Y; Tishgarten, T; Clark, TG; Dickerson, HW			Surface display of a parasite antigen in the ciliate Tetrahymena thermophila	NATURE BIOTECHNOLOGY			English	Article						Tetrahymena; parasite antigen; beta-tubulin; paclitaxel; vaccine	ICHTHYOPHTHIRIUS-MULTIFILIIS; IMMOBILIZATION ANTIGENS; PROTOZOAN TETRAHYMENA; LYSOSOMAL-ENZYMES; BETA-TUBULIN; GENE; TRANSFORMATION; EXPRESSION; VECTOR; MACRONUCLEUS	The ciliated protozoan, Tetrahymena thermophila, offers an attractive medium for the expression of heterologous proteins and could prove particularly useful for the display of foreign proteins on the cell surface. Although progress has been made in transformation of Tetrahymena with heterologous DMA, methods that permit reliable expression of foreign genes have been lacking. Using a mutant strain of T: thermophila carrying a negatively selectable allele of a beta-tubulin gene, we have been able to direct foreign genes to this locus by homologous recombination. Transformed cell lines producing foreign proteins were readily identified and, in at least one case, targeting of proteins to the plasma membrane was accomplished.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Georgia, Dept Med Microbiol & Parasitol, Athens, GA 30602 USA; Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY 14853 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Cornell University	Gaertig, J (corresponding author), Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.		Gaertig, Jacek/F-1553-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; CALZONE FJ, 1983, J BIOL CHEM, V258, P6887; CALZONE FJ, 1982, THESIS U ROCHESTER R; CassidyHanley D, 1997, GENETICS, V146, P135; CLARK TG, 1992, P NATL ACAD SCI USA, V89, P6363, DOI 10.1073/pnas.89.14.6363; Clark TG, 1996, P NATL ACAD SCI USA, V93, P6825, DOI 10.1073/pnas.93.13.6825; CLARK TG, 1996, ANN REV FISH DEV, V5, P113; GAERTIG J, 1994, P NATL ACAD SCI USA, V91, P4549, DOI 10.1073/pnas.91.10.4549; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Geisse S, 1996, PROTEIN EXPRES PURIF, V8, P271, DOI 10.1006/prep.1996.0101; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; HUNSELER P, 1992, DEV GENET, V13, P167, DOI 10.1002/dvg.1020130211; James DJ, 1996, BIO-TECHNOL, V14, P56, DOI 10.1038/nbt0196-56; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KIY T, 1993, EXP CELL RES, V205, P286, DOI 10.1006/excr.1993.1088; KIY T, 1991, APPL MICROBIOL BIOT, V35, P14; KIY T, 1993, FEMS MICROBIOL LETT, V106, P117, DOI 10.1111/j.1574-6968.1993.tb05944.x; KIY T, 1992, APPL MICROBIOL BIOT, V38, P141; KIY T, 1992, APPL MICROBIOL BIOT, V37, P576; Lin TL, 1996, INFECT IMMUN, V64, P4085, DOI 10.1128/IAI.64.10.4085-4090.1996; LIN TL, 1992, J PROTOZOOL, V39, P457, DOI 10.1111/j.1550-7408.1992.tb04832.x; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; NIGRELLI RF, 1976, T AM MICROSC SOC, V95, P607, DOI 10.2307/3225383; PAN WJ, 1995, MOL CELL BIOL, V15, P3372; PAN WJ, 1995, NUCLEIC ACIDS RES, V23, P1561, DOI 10.1093/nar/23.9.1561; Preer J.R. Jr, 1986, P301; Rees S, 1996, BIOTECHNIQUES, V20, P102; TIEDTKE A, 1988, J CELL PHYSIOL, V136, P554, DOI 10.1002/jcp.1041360324; XU CH, 1995, J EUKARYOT MICROBIOL, V42, P558, DOI 10.1111/j.1550-7408.1995.tb05905.x; YAO MC, 1989, MOL CELL BIOL, V9, P1092, DOI 10.1128/MCB.9.3.1092; YU GL, 1989, P NATL ACAD SCI USA, V86, P8487, DOI 10.1073/pnas.86.21.8487	35	64	77	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					462	465		10.1038/8638	http://dx.doi.org/10.1038/8638			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331805				2022-12-25	WOS:000080074500030
J	Weikert, S; Papac, D; Briggs, J; Cowfer, D; Tom, S; Gawlitzek, M; Lofgren, J; Mehta, S; Chisholm, V; Modi, N; Eppler, S; Carroll, K; Chamow, S; Peers, D; Berman, P; Krummen, L				Weikert, S; Papac, D; Briggs, J; Cowfer, D; Tom, S; Gawlitzek, M; Lofgren, J; Mehta, S; Chisholm, V; Modi, N; Eppler, S; Carroll, K; Chamow, S; Peers, D; Berman, P; Krummen, L			Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins	NATURE BIOTECHNOLOGY			English	Article						glycosylation; glycosyltransferase overexpression; recombinant protein expression; Chinese hamster ovary cells	TISSUE-PLASMINOGEN ACTIVATOR; LINKED OLIGOSACCHARIDES; INTERFERON-GAMMA; CHO CELLS; EXPRESSION; ALPHA-2,6-SIALYLTRANSFERASE; CULTURE; ERYTHROPOIETIN	We have engineered two Chinese hamster ovary cell lines secreting different recombinant glycoproteins to express high levels of human beta 1,4-galactosyltransferase (GT, E.C. 2.4.1.38) and/or alpha 2,3-sialyltransferase (ST, E.C. 2.4.99.6). N-linked oligosaccharide structures synthesized by cells overexpressing the glycosyltransferases showed greater homogeneity compared with control cell lines. When GT was overexpressed, oligosaccharides terminating with GlcNAc were significantly reduced compared with controls, whereas overexpression of ST resulted in sialylation of greater than or equal to 90% of available branches. As expected, GT overexpression resulted in reduction of oligosaccharides terminating with GlcNAc, whereas overexpression of ST resulted in sialylation of greater than or equal to 90% of available branches. The more highly sialylated glycoproteins had a significantly longer mean residence time in a rabbit model of pharmacokinetics. These experiments demonstrate the feasibility of genetically engineering cell lines to produce therapeutics with desired glycosylation patterns.	Genentech Inc, Dept Cell Culture & Fermentat Res & Dev, S San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, S San Francisco, CA 94080 USA; Genentech Inc, Dept Recovery Sci, S San Francisco, CA 94080 USA; Genentech Inc, Dept Biol Mol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Metab & Pharmacokinet, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mfg Sci, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Krummen, L (corresponding author), Genentech Inc, Dept Cell Culture & Fermentat Res & Dev, S San Francisco, CA 94080 USA.			Modi, Nishit/0000-0002-5111-867X; Briggs, John/0000-0001-6165-097X				Andersen Dana C., 1994, Current Opinion in Biotechnology, V5, P546, DOI 10.1016/0958-1669(94)90072-8; ANUMULA KR, 1995, ANAL BIOCHEM, V230, P24, DOI 10.1006/abio.1995.1432; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; FUKUDA MN, 1989, BLOOD, V73, P84; GOOCHEE CF, 1992, FRONTIERS BIOPROCESS, V2, P198; GRABENHORST E, 1995, EUR J BIOCHEM, V232, P718, DOI 10.1111/j.1432-1033.1995.718zz.x; GRAMER MJ, 1993, BIOTECHNOL PROGR, V9, P366, DOI 10.1021/bp00022a003; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; JEFFRIES R, 1996, ANTIBODY ENG CHEM IM, V65, P111; JENKINS N, 1994, ENZYME MICROB TECH, V16, P354, DOI 10.1016/0141-0229(94)90149-X; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; LEE UE, 1989, J BIOL CHEM, V164, P13848; LEE YC, 1983, J BIOL CHEM, V258, P199; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P114, DOI 10.1016/0167-7799(92)90192-X; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MINCH SL, 1995, BIOTECHNOL PROGR, V11, P348, DOI 10.1021/bp00033a015; Monaco L, 1996, CYTOTECHNOLOGY, V22, P197, DOI 10.1007/BF00353939; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; *STAT CONS INC, 1986, AM STAT, V40, P52; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WASLEY LC, 1991, BLOOD, V77, P2624; WEN DX, 1992, J BIOL CHEM, V267, P2512	27	161	218	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1116	1121		10.1038/15104	http://dx.doi.org/10.1038/15104			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545921				2022-12-25	WOS:000083428000032
J	Symula, DJ; Frazer, KA; Ueda, Y; Denefle, P; Stevens, ME; Wang, ZE; Locksley, R; Rubin, EM				Symula, DJ; Frazer, KA; Ueda, Y; Denefle, P; Stevens, ME; Wang, ZE; Locksley, R; Rubin, EM			Functional screening of an asthma QTL in YAC transgenic mice	NATURE GENETICS			English	Article							T-CELL DEVELOPMENT; GENE; LINKAGE	Many quantitative trait loci (QTLs) contributing to genetically complex conditions have been discovered, but few causative genes have been identified. This is mainly due to the large size of QTLs and the subtle connection between genotype and quantitative phenotype associated with these conditions(1,2) Transgenic mice have been successfully used to analyse well-characterized genes suspected of contributing to quantitative traits(3-5). Although this approach is powerful for examining one gene at a time, it can be impractical for surveying the large genomic intervals containing many genes that are typically associated with QTLs. To screen for genes contributing to an asthma QTL mapped to human chromosome 5q3 (refs 6,7), we characterized a panel of large-insert 5q31 transgenics based on studies demonstrating that altering gene dosage frequently affects quantitative phenotypes normally influenced by that gene. This panel of human YAC transgenics, propagating a 1Mb interval of chromosome 5q31 containing 6 cytokine genes and 17 partially characterized genes(8), was screened for quantitative changes in several asthma-associated phenotypes. Multiple independent transgenic lines with altered IgE response to antigen treatment shared a 180-kb region containing 5 genes, including those encoding human interleukin 4 (IL4) and interleukin 13(IL 13), which induce IgE class switching in B cells(9). Further analysis of these mice and mice transgenic for mouse Il14 and Il13 demonstrated that moderate changes in Il4 and Il13 expression affect asthma-associated phenotypes in vivo. This functional screen of large-insert transgenics enabled us to identify genes that influence the QTL phenotype in vivo.	Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Rhone Poulenc Rorer Res Dev, Vitry Sur Seine, France	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Sanofi-Aventis	Rubin, EM (corresponding author), Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA.	emrubin@lbl.gov		Frazer, Kelly/0000-0002-6060-8902	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, P01HL056385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56385, HL-07279] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289; Chomarat Pascale, 1998, P133; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Dausset J, 1992, Behring Inst Mitt, P13; de Vries J E, 1996, Eur Respir J Suppl, V22, p58s; deVries JE, 1996, CHEM IMMUNOL, V63, P204; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; FAVRE N, 1993, J IMMUNOL METHODS, V164, P213, DOI 10.1016/0022-1759(93)90314-W; Fowell DJ, 1997, IMMUNITY, V6, P559, DOI 10.1016/S1074-7613(00)80344-1; Frazer KA, 1997, GENOME RES, V7, P495, DOI 10.1101/gr.7.5.495; Georges M, 1997, GENOME RES, V7, P663, DOI 10.1101/gr.7.7.663; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Jacinto SM, 1999, AM J PHYSIOL-RENAL, V276, pF315, DOI 10.1152/ajprenal.1999.276.2.F315; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LABITLEBOUTEILLER C, 1995, J IMMUNOL METHODS, V181, P29, DOI 10.1016/0022-1759(94)00323-O; LEHMANN EL, 1975, NONPARAMETRICS STATI, P123; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; Ollmann MM, 1998, SCIENCE, V281, P1615; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PENNOCK BE, 1979, J APPL PHYSIOL, V46, P399, DOI 10.1152/jappl.1979.46.2.399; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; REINER SL, 1994, J IMMUNOL METHODS, V175, P275, DOI 10.1016/0022-1759(94)90370-0; RUBIN EM, 1994, TRENDS GENET, V10, P199, DOI 10.1016/0168-9525(94)90256-9; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4783, DOI 10.1093/nar/21.20.4783; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3	29	43	46	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	1999	23	2					241	244		10.1038/13880	http://dx.doi.org/10.1038/13880			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508526				2022-12-25	WOS:000082827500029
J	Wong, FS; Karttunen, J; Dumont, C; Wen, L; Visintin, I; Pilip, IM; Shastri, N; Pamer, EG; Janeway, CA				Wong, FS; Karttunen, J; Dumont, C; Wen, L; Visintin, I; Pilip, IM; Shastri, N; Pamer, EG; Janeway, CA			Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library	NATURE MEDICINE			English	Article							CD8(+) T-CELLS; NOD MICE; EXPRESSION CLONING; INSULIN; MOUSE; ANTIGEN; GENE; RARE; CD4+; PROTECTION	Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed at an early age by an immune process that involves both CD4 and CD8 T lymphocytes. The identification of autoantigens in diabetes is very important for the design of antigen-specific immunotherapy. By screening a pancreatic islet cDNA library, we have identified the autoantigen recognized by highly pathogenic CD8 T cells in the non-obese diabetic mouse, one of the best animal models for human diabetes. This is the first identification, to our knowledge, of a CD8 T-cell epitope in an autoimmune disease. The peptide recognized by the cells is in the same region of the insulin B chain as the epitope recognized by previously isolated pathogenic CD4 T cells. This has very important implications for the potential use of insulin in preventative therapy.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of California System; University of California Berkeley	Wong, FS (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 310 Cedar St, New Haven, CT 06520 USA.			Wen, Li/0000-0002-8805-2934; Wong, F. Susan/0000-0002-2812-8845	NIDDK NIH HHS [DK-53015] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053015] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEKKESKOV S, 1990, NATURE, V347, P782, DOI 10.1038/347782a0; Bennett ST, 1997, NAT GENET, V17, P350, DOI 10.1038/ng1197-350; BERGEROT I, 1994, J AUTOIMMUN, V7, P655, DOI 10.1006/jaut.1994.1050; BERGMAN B, 1994, DIABETES, V43, P197, DOI 10.2337/diabetes.43.2.197; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Carel JC, 1996, HORM RES, V45, P44, DOI 10.1159/000184829; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; DiLorenzo TP, 1998, P NATL ACAD SCI USA, V95, P12538, DOI 10.1073/pnas.95.21.12538; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; French MB, 1997, DIABETES, V46, P924; Harrison LC, 1996, J EXP MED, V184, P2167, DOI 10.1084/jem.184.6.2167; Hutchings P, 1998, J AUTOIMMUN, V11, P127, DOI 10.1006/jaut.1997.0184; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Kay TWH, 1996, J IMMUNOL, V157, P3688; KELLER RJ, 1993, LANCET, V341, P927, DOI 10.1016/0140-6736(93)91215-8; Malarkannan S, 1996, P NATL ACAD SCI USA, V93, P13991, DOI 10.1073/pnas.93.24.13991; Malarkannan S, 1996, J IMMUNOL, V157, P4464; NAGATA M, 1994, J IMMUNOL, V152, P2042; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; SANDERSON S, 1995, J EXP MED, V182, P1751, DOI 10.1084/jem.182.6.1751; SANTAMARIA P, 1995, J IMMUNOL, V154, P2494; Serreze DV, 1997, J IMMUNOL, V158, P3978; SERREZE DV, 1994, DIABETES, V43, P505, DOI 10.2337/diabetes.43.3.505; SHIMIZU J, 1993, J IMMUNOL, V151, P1723; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; Wang B, 1996, EUR J IMMUNOL, V26, P1762, DOI 10.1002/eji.1830260815; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; WICKER LS, 1994, DIABETES, V43, P500, DOI 10.2337/diabetes.43.3.500; Wong FS, 1996, J EXP MED, V183, P67, DOI 10.1084/jem.183.1.67; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878; Zekzer D, 1997, DIABETES, V46, P1124, DOI 10.2337/diabetes.46.7.1124; 1995, TRANSPLANT P, V27, P3377	35	338	356	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1026	1031		10.1038/12465	http://dx.doi.org/10.1038/12465			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470079				2022-12-25	WOS:000082337200036
J	Headon, DJ; Overbeek, PA				Headon, DJ; Overbeek, PA			Involvement of a novel Tnf receptor homologue in hair follicle induction	NATURE GENETICS			English	Article							FACTOR LIGAND SUPERFAMILY; ECTODERMAL DYSPLASIA; EDA GENE; MOUSE; TABBY; PROTEIN; DOMAIN; MICE; MUTATIONS; CLONING	Although inductive interactions are known to be essential for specification of cell fate in many vertebrate tissues, the signals and receptors responsible for transmitting this information remain largely unidentified. Mice with mutations in the downless (dl) gene have defects in hair follicle induction, lack sweat glands and have malformed teeth(1). These structures originate as ectodermal placodes, which invaginate into the underlying mesenchyme and differentiate to form specific organs(2-4). Positional cloning of the dl gene began with identification of the transgenic family OVE1. One branch of the family, dl(OVE1B), Carries an approximately 600-kb deletion at the dl locus caused by transgene integration. The mutated locus has been physically mapped in this family(5), and a 200-kb mouse YAC clone, YAC D9, has been identified and shown to rescue the dl phenotype in the spontaneous dl(Jackson) (dl(J), recessive) and Dl(sleek) (Dl(slk), dominant negative) mutants(6), Here we report the positional cloning of the dl gene, which encodes a novel member of the tumour necrosis factor (Tnf) receptor (Tnfr) family. The mutant phenotype and dl expression pattern suggests that this gene encodes a receptor that specifies hair follicle fate. Its ligand is likely to be the product of the tabby (Ta) gene, as Ta mutants have a phenotype identical to that of dl (ref. 1) mutants and Ta encodes a Tnf-like protein.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Overbeek, PA (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Overbeek, Paul/0000-0001-9784-2084	NHLBI NIH HHS [HL49953] Funding Source: Medline; NIAMS NIH HHS [AR45316] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045316] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BYRNE C, 1994, DEVELOPMENT, V120, P2369; FALCONER DS, 1953, Z INDUKT ABSTAMM VER, V85, P210, DOI 10.1007/BF00309836; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; GRUNEBERG H, 1971, J EMBRYOL EXP MORPH, V25, P1; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Gruss HJ, 1996, INT J CLIN LAB RES, V26, P143, DOI 10.1007/BF02592977; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HARDY MH, 1969, ADV BIOL SKIN, V9, P35; KAGHAD M, 1985, EMBO J, V4, P2911, DOI 10.1002/j.1460-2075.1985.tb04022.x; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LYON MF, 1996, GENETIC VARIANTS STR; Majumder K, 1998, MAMM GENOME, V9, P863, DOI 10.1007/s003359900884; MANN SJ, 1962, ANAT RECORD, V144, P135, DOI 10.1002/ar.1091440208; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Montonen O, 1998, J HISTOCHEM CYTOCHEM, V46, P281, DOI 10.1177/002215549804600301; NAUNSMITH JH, 1998, TRENDS BIOL SCI, V23, P74; PENNYCUIK PR, 1984, GENET RES, V43, P51, DOI 10.1017/S0016672300025714; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; Sengel P., 1976, MORPHOGENESIS SKIN; SHAWLOT W, 1989, MOL BIOL MED, V6, P299; SOAFER JA, 1974, GENET RES, V23, P219; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Vielkind U, 1996, ACTA ANAT, V157, P183	29	292	308	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					370	374		10.1038/11943	http://dx.doi.org/10.1038/11943			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431242				2022-12-25	WOS:000081772500020
J	Flugel, A; Willem, M; Berkowicz, T; Wekerle, H				Flugel, A; Willem, M; Berkowicz, T; Wekerle, H			Gene transfer into CD4(+) T lymphocytes: Green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; TOLERANCE INDUCTION; ENCEPHALOMYELITIS; EXPRESSION; LINES; ANTIGEN; VACCINATION; ACTIVATION; APOPTOSIS		Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Wekerle, H (corresponding author), Max Planck Inst Neurobiol, Dept Neuroimmunol, Am Klopferspitz 18A, D-82152 Martinsried, Germany.	hWekerle@neuro.mpg.de						Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; BARBARESE E, 1992, J NEUROIMMUNOL, V39, P151, DOI 10.1016/0165-5728(92)90184-M; Bauer J, 1995, CURR OPIN IMMUNOL, V7, P839, DOI 10.1016/0952-7915(95)80057-3; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739; Chiocchetti A, 1997, BBA-GENE STRUCT EXPR, V1352, P193, DOI 10.1016/S0167-4781(97)00010-9; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Ebert O, 1997, GENE THER, V4, P296, DOI 10.1038/sj.gt.3300394; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KORNER H, 1995, P NATL ACAD SCI USA, V92, P11066, DOI 10.1073/pnas.92.24.11066; KRAMER R, 1995, NAT MED, V1, P1162, DOI 10.1038/nm1195-1162; LUDOWYK PA, 1992, J NEUROIMMUNOL, V37, P237, DOI 10.1016/0165-5728(92)90008-9; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER JB, 1989, J ATMOS OCEAN TECH, V6, P980, DOI 10.1175/1520-0426(1989)006<0980:VOTMP>2.0.CO;2; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; Qin LH, 1997, HUM GENE THER, V8, P2019, DOI 10.1089/hum.1997.8.17-2019; QIN YF, 1992, EUR J IMMUNOL, V22, P1193, DOI 10.1002/eji.1830220513; Quinn ER, 1998, HUM GENE THER, V9, P1457, DOI 10.1089/hum.1998.9.10-1457; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; Rudoll T, 1996, GENE THER, V3, P695; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WEINBERG AD, 1994, J IMMUNOL, V152, P4712; WEKERLE H, 1994, ANN NEUROL, V36, pS47, DOI 10.1002/ana.410360714; WOFFENDIN C, 1994, P NATL ACAD SCI USA, V91, P11581, DOI 10.1073/pnas.91.24.11581; ZEINE R, 1992, J NEUROIMMUNOL, V40, P57, DOI 10.1016/0165-5728(92)90213-5	31	113	116	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					843	847		10.1038/10567	http://dx.doi.org/10.1038/10567			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395334				2022-12-25	WOS:000081926600044
J	Mara, M; Kucaba, T; Sekhon, M; Hillier, L; Martienssen, R; Chinwalla, A; Crockett, J; Fedele, J; Grover, H; Gund, C; McCombie, WR; McDonald, K; McPherson, J; Mudd, N; Parnell, L; Schein, J; Seim, R; Shelby, P; Waterston, R; Wilson, R				Mara, M; Kucaba, T; Sekhon, M; Hillier, L; Martienssen, R; Chinwalla, A; Crockett, J; Fedele, J; Grover, H; Gund, C; McCombie, WR; McDonald, K; McPherson, J; Mudd, N; Parnell, L; Schein, J; Seim, R; Shelby, P; Waterston, R; Wilson, R			zA map for sequence analysis of the Arabidopsis thaliana genome	NATURE GENETICS			English	Article							BAC LIBRARY; CLONES; YEAST; DNA	Arabidopsis thaliana has emerged as a model system for studies of plant genetics and development, and its genome has been targeted for sequencing(1) by an international consortium (the Arabidopsis Genome Initiative; http://genome-www. stanford.edu/Arabidopsis/agi.html). To support the genome-sequencing effort, we fingerprinted more than 20,000 BACs (ref. 2) from two high-quality publicly available libraries(3-5), generating an estimated 17-fold redundant coverage of the genome, and used the fingerprints to nucleate assembly of the data by computer. Subsequent manual revision of the assemblies resulted in the incorporation of 19,661 fingerprinted BACs into 169 ordered sets of overlapping clones ('contigs'), each containing at least 3 clones. These contigs are ideal for parallel selection of BACs for large-scale sequencing and have supported the generation of more than 5.8 Mb of finished genome sequence submitted to GenBank; analysis of the sequence has confirmed the integrity of contigs constructed using this fingerprint data. Placement of contigs onto chromosomes can now be performed, and is being pursued by groups involved in both sequencing and positional cloning studies. To our knowledge, these data provide the first example of whole-genome random PAC fingerprint analysis of a eucaryote, and have provided a model essential to efforts aimed at generating similar databases of fingerprint contigs to support sequencing of other complex genomes, including that of human.	Washington Univ, Genome Sequencing Ctr, St Louis, MO 63108 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Washington University (WUSTL); Cold Spring Harbor Laboratory	Mara, M (corresponding author), Washington Univ, Genome Sequencing Ctr, 4444 Forest Pk Blvd, St Louis, MO 63108 USA.	mmarra@alu.wustl.edu	Marra, Marco A/B-5987-2008; Wilson, Richard K./AAF-4139-2019; Schein, Jacquie E/G-3674-2015; McPherson, John D/D-2633-2017	Marra, Marco A/0000-0001-7146-7175; Wilson, Richard K./0000-0002-1992-1358; McPherson, John D/0000-0001-8049-9347; Chinwalla, Asif/0000-0001-7831-3996; McCombie, W. Richard/0000-0003-1899-0682				Bevan M, 1997, PLANT CELL, V9, P476, DOI 10.1105/tpc.9.4.476; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHOI S, 1995, WEEDS WORLD, V2, P17; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mozo T, 1998, PLANT J, V16, P377, DOI 10.1046/j.1365-313x.1998.00299.x; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; Parsons JD, 1995, COMPUT APPL BIOSCI, V11, P615; RILES L, 1993, GENETICS, V134, P81; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; SULSTON J, 1989, COMPUT APPL BIOSCI, V5, P101; SULSTON J, 1988, COMPUT APPL BIOSCI, V4, P125; Wilson RK, 1997, GENOME ANAL, V1, P397; WONG GK, 1997, P NATL ACAD SCI USA, V13, P5225	20	93	105	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	1999	22	3					265	270		10.1038/10327	http://dx.doi.org/10.1038/10327			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391214				2022-12-25	WOS:000081125900019
J	Wagner, J; Akerud, P; Castro, DS; Holm, PC; Canals, JM; Snyder, EY; Perlmann, T; Arenas, E				Wagner, J; Akerud, P; Castro, DS; Holm, PC; Canals, JM; Snyder, EY; Perlmann, T; Arenas, E			Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes	NATURE BIOTECHNOLOGY			English	Article						cell therapy; differentiation; Parkinson's disease; progenitor cells; tyrosine hydroxylase	CENTRAL-NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; NGFI-B; NEURONS; NURR1; RECEPTOR; PROGENITOR; BRAIN; GENE; GDNF	The implementation of neural stem cell lines as a source material for brain tissue transplants is currently limited by the ability to induce specific neurochemical phenotypes in these cells. Here, we show that coordinated induction of a ventral mesencephalic dopaminergic phenotype in an immortalized multipotent neural stem cell line can be achieved in vitro. This process requires both the overexpression of the nuclear receptor Nurr1 and factors derived from local type 1 astrocytes. Over 80% of cells obtained by this method demonstrate a phenotype indistinguishable from that of endogenous dopaminergic neurons. Moreover, this procedure yields an unlimited number of cells that can engraft in vivo and that may constitute a useful source material for neuronal replacement in Parkinson's disease.	Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, S-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Arenas, E (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Mol Neurobiol Lab, S-17177 Stockholm, Sweden.	ernest@cajal.mbb.ki.se	Holm, Pontus/G-2747-2010; Arenas, Ernest/AAO-5231-2020; Castro, Diogo S/I-6217-2016; Canals, Josep M/M-3846-2014	Arenas, Ernest/0000-0003-0197-6577; Castro, Diogo S/0000-0001-8178-9565; Canals, Josep M/0000-0001-6829-7670				ALTMAN J, 1995, RAT NERVOUS SYSTEM, P1054; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; DENISDONINI S, 1984, NATURE, V307, P641, DOI 10.1038/307641a0; Eichele G, 1997, TRENDS GENET, V13, P343, DOI 10.1016/S0168-9525(97)01218-3; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; HYMAN C, 1994, J NEUROSCI, V14, P335; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; OMALLEY EK, 1992, BRAIN RES, V582, P65, DOI 10.1016/0006-8993(92)90317-3; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Rosenthal A, 1998, NEURON, V20, P169, DOI 10.1016/S0896-6273(00)80445-6; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Snyder EY, 1996, CLIN NEUROSCI, V3, P310; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Zetterstrom RH, 1996, MOL BRAIN RES, V41, P111, DOI 10.1016/0169-328X(96)00074-5; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	34	302	373	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					653	659		10.1038/10862	http://dx.doi.org/10.1038/10862			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404157				2022-12-25	WOS:000081296900024
J	Charrad, RS; Li, Y; Delpech, B; Balitrand, N; Clay, D; Jasmin, C; Chomienne, C; Smadja-Joffe, F				Charrad, RS; Li, Y; Delpech, B; Balitrand, N; Clay, D; Jasmin, C; Chomienne, C; Smadja-Joffe, F			Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia	NATURE MEDICINE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; MURINE MACROPHAGES; CELL-ADHESION; EXPRESSION; HYALURONATE; RECEPTOR; LYMPHOCYTES; PRECURSORS; ACTIVATION	Blockage in myeloid differentiation characterizes acute myeloid leukemia (AML); the stage of the blockage defines distinct AML subtypes (AML1/2 to AML5). Differentiation therapy in AML has recently raised interest because the survival of AML3 patients has been greatly improved using the differentiating agent retinoic acid. However, this molecule is ineffective in other AML subtypes. The CD44 surface antigen, on leukemic blasts from most AML patients, is involved in myeloid differentiation. Here, we report that ligation of CD44 with specific anti-CD44 monoclonal antibodies or with hyaluronan, its natural ligand, can reverse myeloid differentiation blockage in AML1/2 to AML5 subtypes. The differentiation of AML blasts was evidenced by the ability to produce oxidative bursts, the expression of lineage antigens and cytological modifications, all specific to normal differentiated myeloid cells. These results indicate new possibilities for the development of CD44-targeted differentiation therapy in the AML1/2 to AML5 subtypes.	Hop Paul Brousse, INSERM, U268, Lab Differenciat Hematopoiet Normale & Leucem, F-94807 Villejuif, France; Ctr Henri Becquerel, Oncol Mol Lab, F-76000 Rouen, France; Univ Paris 07, Hop St Louis, Biol Cellulaire Hematol Lab, Inst Hematol,EP CNRS 107, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Smadja-Joffe, F (corresponding author), Hop Paul Brousse, INSERM, U268, Lab Differenciat Hematopoiet Normale & Leucem, 14 Ave PV Couturier, F-94807 Villejuif, France.			CHOMIENNE, Christine/0000-0001-5513-5752				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AYROLDI E, 1995, BLOOD, V86, P2672; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERTRAND P, 1985, J NEUROCHEM, V45, P434, DOI 10.1111/j.1471-4159.1985.tb04006.x; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; CHOMIENNE C, 1990, BLOOD, V76, P1710; CONOVER EJ, 1980, PRACTICAL NONPARAMET, V5, P213; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DELFINO DV, 1994, J IMMUNOL, V152, P5171; DELPECH B, 1985, ANAL BIOCHEM, V149, P555, DOI 10.1016/0003-2697(85)90613-X; DENNING SM, 1990, J IMMUNOL, V144, P7; GALANDRINI R, 1994, J IMMUNOL, V153, P21; Ghaffari S, 1996, LEUKEMIA, V10, P1773; GHAFFARI S, 1995, BLOOD, V86, P2976; GOYERT SM, 1997, LEUKOCYTES TYPING, V6, P963; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; GUNJI Y, 1992, BLOOD, V80, P429; HUET S, 1989, J IMMUNOL, V143, P798; KANNAGI R, 1997, LEUKOCYTES TYPING, V6, P348; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MENDELSOHN N, 1980, CANCER RES, V40, P1469; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MORIMOTO K, 1994, BLOOD, V83, P657; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROWLEY JD, 1977, LANCET, V1, P549; SAMBROOK J, 1989, MOL CLONING LAB MANU, P700; Slack JL, 1999, CANC TREAT, V99, P75; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TERSTAPPEN LWMM, 1991, LEUKEMIA, V5, P315; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; ZHONG Z, 1995, J CELL BIOL, V130, P485	39	135	145	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					669	676		10.1038/9518	http://dx.doi.org/10.1038/9518			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371506				2022-12-25	WOS:000080823300036
J	Kroschewski, R; Hall, A; Mellman, I				Kroschewski, R; Hall, A; Mellman, I			Cdc42 controls secretory and endocytic transport to the basolateral plasma membrane of MDCK cells	NATURE CELL BIOLOGY			English	Article							TO-GOLGI TRANSPORT; RAC1 SMALL GTPASES; ACTIN CYTOSKELETON; CYCLE PROGRESSION; EPITHELIAL-CELLS; LIVING CELLS; RHO; POLARITY; PROTEINS; YEAST	Cdc42 is a Rho-family GTPase that in yeast is important in establishing polarized bud growth. Here we show that Cdc42 is also essential in establishing and maintaining polarity in epithelial cells. Functional deletion of Cdc42 in Madin-Darby canine kidney (MDCK) cells results in the selective depolarization of basolateral membrane proteins; the polarity of apical proteins remains unaffected. This phenotype does not reflect major alterations in the actin cytoskeleton, but rather results from the selective inhibition of membrane traffic to the basolateral plasma membrane in both the endocytic and the secretory pathways. Thus, Cdc42 plays a critical part in epithelial-cell polarity, by, unexpectedly, regulating the fidelity of membrane transport.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	Yale University; University of London; University College London	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St,POB 208002, New Haven, CT 06520 USA.	ira.mellnan@yale.edu	Mellman, Ira/ABG-5896-2020; Eckhardt, Erik/G-1567-2010	Kroschewski, Ruth/0000-0002-6032-2568				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DRUBIN DG, 1996, CELL, V84, P355; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herskowitz I, 1995, COLD SPRING HARB SYM, V60, P717, DOI 10.1101/SQB.1995.060.01.078; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keller P, 1997, J CELL SCI, V110, P3001; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; Mellian I, 1995, COLD SPRING HARB SYM, V60, P745, DOI 10.1101/SQB.1995.060.01.080; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1	38	278	282	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					8	13		10.1038/8977	http://dx.doi.org/10.1038/8977			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559857				2022-12-25	WOS:000083085300011
J	Vanhaesebroeck, B; Jones, GE; Allen, WE; Zicha, D; Hooshmand-Rad, R; Sawyer, C; Wells, C; Waterfield, MD; Ridley, AJ				Vanhaesebroeck, B; Jones, GE; Allen, WE; Zicha, D; Hooshmand-Rad, R; Sawyer, C; Wells, C; Waterfield, MD; Ridley, AJ			Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages	NATURE CELL BIOLOGY			English	Article							PHOSPHOINOSITIDE 3-KINASE; DNA-SYNTHESIS; S6 KINASE; PHOSPHATIDYLINOSITOL; ACTIVATION; CDC42; RAS		Ludwig Inst Canc Res, Univ Coll London Branch, London W1P 8BT, England; Kings Coll London, Randall Inst, London WC2B 5RL, England; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London	Vanhaesebroeck, B (corresponding author), Ludwig Inst Canc Res, Univ Coll London Branch, 91 Riding House St, London W1P 8BT, England.	bartvanh@ludwig.ucl.ac.uk	Jones, Gareth E/H-2282-2012	Jones, Gareth E/0000-0001-5879-3048; Zicha, Daniel/0000-0002-8808-8064; Ridley, Anne/0000-0001-8186-5708; Box, Carol/0000-0002-8919-8724	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Allen WE, 1997, J CELL SCI, V110, P707; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	15	197	200	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					69	71		10.1038/9045	http://dx.doi.org/10.1038/9045			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559867				2022-12-25	WOS:000083085300021
J	Li, FZ; Ackermann, EJ; Bennett, CF; Rothermel, AL; Plescia, J; Tognin, S; Villa, A; Marchisio, PC; Altieri, DC				Li, FZ; Ackermann, EJ; Bennett, CF; Rothermel, AL; Plescia, J; Tognin, S; Villa, A; Marchisio, PC; Altieri, DC			Pleiotropic cell-division defects and apoptosis induced by interference with survivin function	NATURE CELL BIOLOGY			English	Article							CENTROSOME; P21(CIP1/WAF1); DEATH; CYTOKINESIS; EXPRESSION; ACTIVATION; CHECKPOINT; CLEAVAGE; MITOSIS; DAMAGE	Here we investigate the role of the control of apoptosis in normal cell division. We show that interference with the expression or function of the apoptosis inhibitor survivin causes caspase-dependent cell death in the G2/M phase of the cell cycle, and a cell-division defect characterized by centrosome dysregulation, multipolar mitotic spindles and multinucleated, polyploid cells. Use of a dominant-negative survivin mutant or antisense survivin complementary DNA disrupts a supramolecular assembly of survivin, caspase-3 and the cyclin-dependent-kinase inhibitor p21(Waf1/Cip1) within centrosomes, and results in caspase-dependent cleavage of p21, Polyploidy induced by survivin antagonists is accentuated in p21-deficient cells, and corrected by exogenous expression of p21. These findings show that control of apoptosis and preservation of p21 integrity within centrosomes by survivin are required for normal mitotic progression.	Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA; DIBIT, San Raffaele Sci Inst, I-20132 Milan, Italy	Yale University; Isis Pharmaceuticals Inc; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Altieri, DC (corresponding author), Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, 295 Congress Ave, New Haven, CT 06536 USA.	dario.altieri@yale.edu	Li, Fengzhi/GXF-0115-2022; Villa, Antonello/B-4781-2012	Villa, Antonello/0000-0002-3820-8072	Telethon [E.1104] Funding Source: Medline	Telethon(Fondazione Telethon)		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Krajewska M, 1997, CANCER RES, V57, P1605; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MCKAY RA, 1998, J BIOL CHEM, V396, P580; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Moudjou M, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P111; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Pihan GA, 1998, CANCER RES, V58, P3974; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	35	527	600	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					461	466		10.1038/70242	http://dx.doi.org/10.1038/70242			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587640				2022-12-25	WOS:000084136100012
J	van Oudenaarden, A; Theriot, JA				van Oudenaarden, A; Theriot, JA			Cooperative symmetry-breaking by actin polymerization in a model for cell motility	NATURE CELL BIOLOGY			English	Article							LISTERIA-MONOCYTOGENES; FLUORESCENCE MICROSCOPY; SURFACE PROTEIN; XENOPUS EGG; FILAMENTS; LOCOMOTION; POLARITY; EXTRACTS; MOVEMENT; PROFILIN	Polymerizing networks of actin filaments are capable of exerting significant mechanical forces, used by eukaryotic cells and their prokaryotic pathogens to change shape or to move. Here we show that small beads coated uniformly with a protein that catalyses actin polymerization are initially surrounded by symmetrical clouds of actin filaments. This symmetry is broken spontaneously, after which the beads undergo directional motion. We have developed a stochastic theory, in which each actin filament is modelled as an elastic brownian ratchet, that quantitatively accounts for the observed emergent symmetry-breaking behaviour. Symmetry-breaking can only occur for polymers that have a significant subunit off-rate, such as the biopolymers actin and tubulin.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Theriot, JA (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		van Oudenaarden, Alexander/AAA-1705-2019; Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929, AI369929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORNENS M, 1991, NEW BIOL, V3, P627; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; Doi M., 1986, THEORY POLYM DYNAMIC, V1st ed.; DOLD, 1994, CELL MOTIL CYTOSKELE, V28, P97; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Elson EL, 1999, BIOCHEM SOC SYMP, V65, P299; EUTENEUER U, 1984, NATURE, V310, P58, DOI 10.1038/310058a0; GERHART J, 1989, DEVELOPMENT, V107, P37; HILL TL, 1982, INT REV CYTOL, V78, P1, DOI 10.1016/S0074-7696(08)60105-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KOCKS C, 1993, J CELL SCI, V105, P699; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; Laine RO, 1998, INFECT IMMUN, V66, P3775, DOI 10.1128/IAI.66.8.3775-3782.1998; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Ma L, 1998, J CELL BIOL, V140, P1125; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Miyata H, 1999, P NATL ACAD SCI USA, V96, P2048, DOI 10.1073/pnas.96.5.2048; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Nabi IR, 1999, J CELL SCI, V112, P1803; OLIVER T, 1994, CELL BIOL, V5, P139; OTT A, 1993, PHYS REV E, V48, pR1642, DOI 10.1103/PhysRevE.48.R1642; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Riveline D, 1997, PHYS REV E, V56, pR1330, DOI 10.1103/PhysRevE.56.R1330; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P1; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Theriot JA, 1998, METHOD ENZYMOL, V298, P114, DOI 10.1016/S0076-6879(98)98013-2; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Verkhovsky AB, 1999, CURR BIOL, V9, P11, DOI 10.1016/S0960-9822(99)80042-6; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	38	114	117	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					493	499		10.1038/70281	http://dx.doi.org/10.1038/70281			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587645				2022-12-25	WOS:000084136100017
J	Birchler, M; Viti, F; Zardi, L; Spiess, B; Neri, D				Birchler, M; Viti, F; Zardi, L; Spiess, B; Neri, D			Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment	NATURE BIOTECHNOLOGY			English	Article						recombinant antibody; angiogenesis; photo dynamic therapy; fibronectin isoform; ED-B domain	PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; FIBRONECTIN ISOFORM; DISPLAY LIBRARY; MARKER; CARCINOMA; DELIVERY; CANCER; DOMAIN	Molecules that selectively target and occlude new blood vessels would be useful for diagnosis and treatment of pathologies associated with angiogenesis. We show that a phage-derived human antibody fragment (L19) with high affinity for the ED-B domain of fibronectin, a marker of angiogenesis, selectively localizes to newly formed blood vessels in a rabbit model of ocular angiogenesis. The L19 antibody, chemically coupled to a photosensitizer and irradiated with red light, mediates complete and selective occlusion of ocular neovasculature and promotes apoptosis of the corresponding endothelial cells. These results demonstrate that new ocular blood vessels can be distinguished immunochemically from preexisting ones and suggest that the targeted delivery of photosensitizers may be effective in treating angiogenesis-related pathologies.	ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Ist Nazl Ric Canc, I-16132 Genoa, Italy; Univ Zurich, Vet Chirurg Klin, ETH Zurich, Dept Appl Life Sci, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Genoa; IRCCS AOU San Martino IST; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Neri, D (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, Einsteinstr, CH-8093 Zurich, Switzerland.		Neri, Dario/P-4368-2016; Spiess, Bernhard/G-6277-2011	Neri, Dario/0000-0001-5234-7370; 				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Fattorusso R, 1999, STRUCTURE, V7, P381, DOI 10.1016/S0969-2126(99)80051-3; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLLI S, 1994, CANCER RES, V54, P2643; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088; HUANG H, 1997, SCIENCE, V275, P547; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6; LEVY JG, 1995, TRENDS BIOTECHNOL, V13, P14, DOI 10.1016/S0167-7799(00)88895-2; LU XM, 1992, J IMMUNOL METHODS, V156, P85; MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480; Murdter TE, 1997, CANCER RES, V57, P2440; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769; REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rowe PM, 1998, LANCET, V351, P1496, DOI 10.1016/S0140-6736(05)78884-X; Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092; Tarli L, 1999, BLOOD, V94, P192, DOI 10.1182/blood.V94.1.192.413k22_192_198; van den Bergh H, 1998, ENDOSCOPY, V30, P392, DOI 10.1055/s-2007-1001289; Viti F, 1999, CANCER RES, V59, P347; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YARMUSH ML, 1993, CRIT REV THER DRUG, V10, P197; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x; Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243	32	111	136	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					984	988		10.1038/13679	http://dx.doi.org/10.1038/13679			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504699				2022-12-25	WOS:000083015700024
J	Matz, MV; Fradkov, AF; Labas, YA; Savitsky, AP; Zaraisky, AG; Markelov, ML; Lukyanov, SA				Matz, MV; Fradkov, AF; Labas, YA; Savitsky, AP; Zaraisky, AG; Markelov, ML; Lukyanov, SA			Fluorescent proteins from nonbioluminescent Anthozoa species	NATURE BIOTECHNOLOGY			English	Article						green fluorescent protein; fluorophore; Anthozoa	EXTINCTION COEFFICIENTS; BIOLUMINESCENCE; EXCITATION	We have cloned six fluorescent proteins homologous to the green fluorescent protein (GFP) from Aequorea victoria, Two of these have spectral characteristics dramatically different from GFP, emitting at yellow and red wavelengths. All the proteins were isolated from nonbioluminescent reef corals, demonstrating that GFP-like proteins are not always functionally linked to bioluminescence. The new proteins share the same beta-can fold first observed in GFP, and this provided a basis for the comparative analysis of structural features important for fluorescence. The usefulness of the new proteins for in vivo labeling was demonstrated by expressing them in mammalian cell culture and in mRNA microinjection assays in Xenopus embryos.	Russian Acad Sci, Inst Bioorgan Chem, Moscow 117871, Russia; Russian Acad Sci, Inst Ecol & Evolut, Moscow 17071, Russia; Russian Acad Sci, Inst Biochem, Moscow 17071, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Research Center of Biotechnology RAS; Russian Academy of Sciences	Lukyanov, SA (corresponding author), Russian Acad Sci, Inst Bioorgan Chem, Moscow 117871, Russia.		Zaraisky, Andrey G/Q-2323-2016; Savitsky, Alexander P/O-9799-2015; Lukyanov, Sergey/F-9140-2014; Matz, Mikhail V/K-4392-2017	Zaraisky, Andrey G/0000-0003-4681-8169; Savitsky, Alexander P/0000-0002-6820-2341; Matz, Mikhail V/0000-0001-5453-9819				Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; CATALASTUCKI R, 1959, NATURE, V183, P949, DOI 10.1038/183949a0; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; DELBEEK JC, 1994, REEF AQUARIUM COMPRE, V2; DELGRAVE S, 1995, BIOTECHNOLOGY, V13, P151; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hastings JW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P17; HELM R, 1995, NATURE, V373, P663; JOHNSON FH, 1962, J CELL COMPAR PHYSL, V60, P85, DOI 10.1002/jcp.1030600111; Kawaguti S., 1944, Palao Tropical Biological Station Studies Tokyo, V2, P617; Kendall JM, 1998, TRENDS BIOTECHNOL, V16, P216, DOI 10.1016/S0167-7799(98)01184-6; LABAS YA, 1973, BIOPHYSICS LIVING CE, V4, P83; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Matz M, 1999, NUCLEIC ACIDS RES, V27, P1558, DOI 10.1093/nar/27.6.1558; MAZEL CH, 1995, MAR ECOL PROG SER, V120, P185, DOI 10.3354/meps120185; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Morin J.G., 1974, pUnpaginated; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; Rees JF, 1998, J EXP BIOL, V201, P1211; SCHLICHTER D, 1994, OECOLOGIA, V99, P124, DOI 10.1007/BF00317092; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Ward W.W., 1979, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V4, P1; WARD WW, 1979, J BIOL CHEM, V254, P781; Ward WW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P45; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; ZARAISKY AG, 1995, DEVELOPMENT, V121, P3839	32	1372	1635	5	230	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					969	973		10.1038/13657	http://dx.doi.org/10.1038/13657			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504696				2022-12-25	WOS:000083015700021
J	Lembo, PMC; Grazzini, E; Cao, J; Hubatsch, DA; Pelletier, M; Hoffert, C; St-Onge, S; Pou, C; Labrecque, J; Groblewski, T; O'Donnell, D; Payza, K; Ahmad, S; Walker, P				Lembo, PMC; Grazzini, E; Cao, J; Hubatsch, DA; Pelletier, M; Hoffert, C; St-Onge, S; Pou, C; Labrecque, J; Groblewski, T; O'Donnell, D; Payza, K; Ahmad, S; Walker, P			The receptor for the orexigenic peptide melanin-concentrating hormone is a G-protein-coupled receptor	NATURE CELL BIOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; RAT-BRAIN; INTERNALIZATION; ACTIVATION	Gene-knockout studies of melanin-concentrating hormone (MCH) and its effect on feeding and energy balance have firmly established MCH as an orexigenic (appetite-stimulating) peptide hormone. Here we identify MCH as the ligand for the orphan receptor SLC-1. The rat SLC-1 is activated by nanomolar concentrations of MCH and is coupled to the G protein G alpha(i/o). The pattern of SLC-1 messenger RNA expression coincides with the distribution of MCH-containing nerve terminals and is consistent with the known central effects of MCH, Our identification of an MCH receptor could have implications for the development of new anti-obesity therapies.	AstraZeneca R&D, Montreal, PQ H4S 1ZP, Canada	AstraZeneca	Ahmad, S (corresponding author), AstraZeneca R&D, 7171 Frederick Banting,Ville St Laurent, Montreal, PQ H4S 1ZP, Canada.	Sultan.Ahmad@arcm.ca.astra.com						Awaji T, 1998, MOL ENDOCRINOL, V12, P1099, DOI 10.1210/me.12.8.1099; BAKER BI, 1983, GEN COMP ENDOCR, V50, P423, DOI 10.1016/0016-6480(83)90263-0; BAKER BI, 1994, TRENDS ENDOCRIN MET, V5, P120, DOI 10.1016/1043-2760(94)90093-0; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Drmota T, 1999, BIOCHEM J, V340, P529, DOI 10.1042/0264-6021:3400529; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; DROZDZ R, 1995, P 23 EUR PEPT S, P785; FULWILER CE, 1984, BRAIN RES REV, V7, P229, DOI 10.1016/0165-0173(84)90012-2; FULWILER CE, 1985, NEUROSCI LETT, V53, P289, DOI 10.1016/0304-3940(85)90553-1; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Kakinoki Y, 1997, J BIOL CHEM, V272, P32308, DOI 10.1074/jbc.272.51.32308; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; Lakaye B, 1998, BBA-MOL CELL RES, V1401, P216, DOI 10.1016/S0167-4889(97)00135-3; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; O'Donnell D, 1999, J COMP NEUROL, V409, P469; Paxinos G., 1998, RAT BRAIN ATLAS; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	27	202	215	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					267	271		10.1038/12978	http://dx.doi.org/10.1038/12978			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559938				2022-12-25	WOS:000083169600014
J	Hulett, MD; Freeman, C; Hamdorf, BJ; Baker, RT; Harris, MJ; Parish, CR				Hulett, MD; Freeman, C; Hamdorf, BJ; Baker, RT; Harris, MJ; Parish, CR			Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis	NATURE MEDICINE			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; SULFATE-DEGRADING ENZYMES; FLAVOBACTERIUM-HEPARINUM; SUBSTRATE-SPECIFICITY; BASEMENT-MEMBRANES; FIBROBLAST GROWTH; DEGRADATION; CELLS; ENDOGLYCOSIDASE; INHIBITION	The endoglycosidase heparanase is an important in the degradation of the extracellular matrix by invading cells, notably metastatic tumor cells and migrating leukocytes. Here we report the cDNA sequence of the human platelet enzyme, which encodes a unique protein of 543 amino acids, and the identification of highly homologous sequences in activated mouse T cells and in a highly metastatic rat adenocarcinoma. Furthermore, the expression of heparanase mRNA in rat tumor cells correlates with their metastatic potential. Exhaustive studies have shown only one heparanase sequence, consistent with the idea that this enzyme is the dominant endoglucuronidase in mammalian tissues.	Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Canberra, ACT 2601, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Med, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; John Curtin School of Medical Research	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Canberra, ACT 2601, Australia.		Hulett, Mark D/C-4160-2012	Hulett, Mark/0000-0003-2072-5968; Parish, Christopher/0000-0001-7740-0430				BARNER M, 1986, J CELL PHYSIOL, V128, P299, DOI 10.1002/jcp.1041280223; BARTLE RG, 1995, PUBLISH RES Q, V11, P3, DOI 10.1007/BF02680421; CAMPBELL JH, 1992, EXP CELL RES, V200, P156, DOI 10.1016/S0014-4827(05)80084-9; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DEVOUGE MW, 1994, INT J CANCER, V56, P286, DOI 10.1002/ijc.2910560224; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V229, P770, DOI 10.1006/bbrc.1996.1879; GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213; Gonzalez-Stawinski GV, 1999, BBA-PROTEIN STRUCT M, V1429, P431, DOI 10.1016/S0167-4838(98)00254-4; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; GRAHAM LD, 1994, BIOCHEM J, V301, P917, DOI 10.1042/bj3010917; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HERSHKOVIZ R, 1995, J AUTOIMMUN, V8, P741, DOI 10.1006/jaut.1995.0055; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LASKOV R, 1991, INT J CANCER, V47, P92, DOI 10.1002/ijc.2910470117; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; Messer M, 1997, COMP BIOCHEM PHYS B, V118, P403, DOI 10.1016/S0305-0491(97)00162-4; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; PARISH CR, 1992, INT J CANCER, V52, P378, DOI 10.1002/ijc.2910520309; PARISH CR, 1999, UNPUB CANC RES; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rechter M, 1999, BIOCHEM BIOPH RES CO, V255, P657, DOI 10.1006/bbrc.1999.0181; RICOVERI W, 1986, CANCER RES, V46, P3855; Sambrook J., 2002, MOL CLONING LAB MANU; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEWELL RF, 1989, BIOCHEM J, V264, P777, DOI 10.1042/bj2640777; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	44	453	531	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					803	809		10.1038/10525	http://dx.doi.org/10.1038/10525			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395326				2022-12-25	WOS:000081926600036
J	Link, AJ; Eng, J; Schieltz, DM; Carmack, E; Mize, GJ; Morris, DR; Garvik, BM; Yates, JR				Link, AJ; Eng, J; Schieltz, DM; Carmack, E; Mize, GJ; Morris, DR; Garvik, BM; Yates, JR			Direct analysis of protein complexes using mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						protein identification; mass spectrometry; multidimensional chromatography; ribosome; yeast genome	YEAST RIBOSOMAL-PROTEINS; AMINO-ACID-SEQUENCES; LOW-FEMTOMOLE LEVEL; SACCHAROMYCES-CEREVISIAE; LIQUID-CHROMATOGRAPHY; IDENTIFICATION; PEPTIDES; DATABASE; NOMENCLATURE; SEPARATION	We describe a rapid, sensitive process for comprehensively identifying proteins in macromolecular complexes that uses multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS/MS) to separate and fragment peptides. The SEQUEST algorithm, relying upon translated genomic sequences, infers amino acid sequences from the fragment ions. The method was applied to the Saccharomyces cerevisiae ribosome leading to the identification of a novel protein component of the yeast and human 40S subunit. By offering the ability to identify >100 proteins in a single run, this process enables components in even the largest macromolecular complexes to be analyzed comprehensively.	Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Inst, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Yates, JR (corresponding author), Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA.	jyates@u.washington.edu	Abrams, William R/A-5782-2008; Eng, Jimmy K/I-4202-2012; Morris, David/G-4503-2011	Eng, Jimmy K/0000-0001-6352-6737; 	NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM52095] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Battaner E, 1971, METHOD ENZYMOL, V20, P446; Chantrel Y, 1998, GENETICS, V148, P559; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; GIDDINGS JC, 1987, J HIGH RES CHROMATOG, V10, P319, DOI 10.1002/jhrc.1240100517; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Link AJ, 1997, INT J MASS SPECTROM, V160, P303, DOI 10.1016/S0168-1176(96)04489-8; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; LUNDELL N, 1992, CHROMATOGRAPHIA, V34, P369, DOI 10.1007/BF02268370; MAGER WH, 1991, MOL CELL BIOCHEM, V104, P181; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Opiteck GJ, 1997, ANAL CHEM, V69, P1518, DOI 10.1021/ac961155l; OTAKA E, 1981, MOL GEN GENET, V181, P176, DOI 10.1007/BF00268424; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ruan H, 1997, MRNA FORMATION FUNCT, P305, DOI 10.1016/B978-012587545-5/50017-; TAKAHASHI N, 1985, J CHROMATOGR, V326, P407, DOI 10.1016/S0021-9673(01)87466-5; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	30	1890	2029	2	322	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					676	682		10.1038/10890	http://dx.doi.org/10.1038/10890			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404161				2022-12-25	WOS:000081296900028
J	Liu, XY; Dangel, AW; Kelley, RI; Zhao, W; Denny, P; Botcherby, M; Cattanach, B; Peters, J; Hunsicker, PR; Mallon, AM; Strivens, MA; Bate, R; Miller, W; Rhodes, M; Brown, SDM; Herman, GE				Liu, XY; Dangel, AW; Kelley, RI; Zhao, W; Denny, P; Botcherby, M; Cattanach, B; Peters, J; Hunsicker, PR; Mallon, AM; Strivens, MA; Bate, R; Miller, W; Rhodes, M; Brown, SDM; Herman, GE			The gene mutated in bare patches and striated mice encodes a novel 3 beta-hydroxysteroid dehydrogenase	NATURE GENETICS			English	Article							LEMLI-OPITZ-SYNDROME; STR CRITICAL REGIONS; CHOLESTEROL-BIOSYNTHESIS; STEROL BIOSYNTHESIS; REDUCTASE GENE; HUMAN XQ28; MUTATIONS; MOUSE; 7-DEHYDROCHOLESTEROL; TRANSCRIPTS	X-linked dominant disorders that are exclusively lethal prenatally in hemizygous males have been described in human and (1). None of the genes responsible has been isolated in mouse either species; The bare patches (Bpa):and striated (Str) mouse mutations were originally identified in female offspring of X-irradiated males(2) (3). Subsequently, additional independent alleles were described. We have previously mapped these X-linked dominant, male-lethal mutations to an overlapping region:of 600 kb that is homologous to human Xq28 (ref. 4) and identified several candidate genes in this: interval(5). Here we report mutations in one of these genes, Nsdhl, encoding an NAD(P)H steroid dehydrogenase-like protein, in two independent Bpa and three independent Str alleles. Quantitative analysis of sterols from tissues of affected Bpa mice support a role for Nsdhl in cholesterol biosynthesis. Our results demonstrate that Bpa and Sfr are allelic mutations and identify the first mammalian locus associated with an X-linked dominant, male-lethal phenotype. They also expand the spectrum of phenotypes associated with abnormalities of cholesterol metabolism.	Ohio State Univ, Childrens Hosp Res Fdn, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; Johns Hopkins Univ, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21205 USA; MRC, Mouse Genome Ctr, Didcot OX11 ORD, Oxon, England; MRC, Mammalian Genet Lab, Didcot OX11 ORD, Oxon, England; MRC, Human Genome Mapping Project Resource Ctr, Cambridge, England; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Penn State Univ, Dept Comp Sci, University Pk, PA 16802 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; United States Department of Energy (DOE); Oak Ridge National Laboratory; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Herman, GE (corresponding author), Ohio State Univ, Childrens Hosp Res Fdn, Columbus, OH 43205 USA.			Denny, Paul/0000-0003-4659-6893	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034953] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM005110] Funding Source: NIH RePORTER; MRC [MC_U142684171] Funding Source: UKRI; Medical Research Council [MC_U142684171] Funding Source: Medline; NINDS NIH HHS [R01 NS34953] Funding Source: Medline; NLM NIH HHS [R01 LM05110] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANGEL T, 1993, GENOME, V4, P171; AnsariLari MA, 1996, BIOTECHNIQUES, V21, P34; Antoine JP, 1996, REV MATH PHYS, V8, P1, DOI 10.1142/S0129055X96000020; BJORCK S, 1987, QUATERNARY RES, V28, P1, DOI 10.1016/0033-5894(87)90030-5; CHATTERJEE A, 1995, MAMM GENOME, V6, P802, DOI 10.1007/BF00539008; Clayton PT, 1998, ARCH DIS CHILD, V78, P185, DOI 10.1136/adc.78.2.185; Cunniff C, 1997, AM J MED GENET, V68, P263, DOI 10.1002/(SICI)1096-8628(19970131)68:3<263::AID-AJMG4>3.3.CO;2-5; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; GIBSON KM, 1990, J LIPID RES, V31, P515; HAPPLE R, 1983, HUM GENET, V63, P24, DOI 10.1007/BF00285392; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Heiss NS, 1996, GENOME RES, V6, P478, DOI 10.1101/gr.6.6.478; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kelley RI, 1998, AM J HUM GENET, V63, P322, DOI 10.1086/301987; Kelley RI, 1999, AM J MED GENET, V83, P213, DOI 10.1002/(SICI)1096-8628(19990319)83:3<213::AID-AJMG15>3.0.CO;2-C; KELLEY RI, 1995, CLIN CHIM ACTA, V236, P45, DOI 10.1016/0009-8981(95)06038-4; Levin ML, 1996, GENOME RES, V6, P465, DOI 10.1101/gr.6.6.465; Payne AH, 1997, STEROIDS, V62, P169, DOI 10.1016/S0039-128X(96)00177-8; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; PHILLIPS RJ, 1963, GENET RES, V4, P151, DOI 10.1017/S0016672300003499; PHILLIPS RJ, 1973, GENET RES, V22, P91, DOI 10.1017/S0016672300012866; PUCK JM, 1989, AM J HUM GENET, V44, P724; REED V, 1994, NAT GENET, V8, P11, DOI 10.1038/ng0994-11; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; Wassif CA, 1998, AM J HUM GENET, V63, P55, DOI 10.1086/301936; Waterham HR, 1998, AM J HUM GENET, V63, P329, DOI 10.1086/301982	30	123	126	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					182	187		10.1038/9700	http://dx.doi.org/10.1038/9700			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369263				2022-12-25	WOS:000080680900026
J	Weber, JD; Taylor, LJ; Roussel, MF; Sherr, CJ; Bar-Sagi, D				Weber, JD; Taylor, LJ; Roussel, MF; Sherr, CJ; Bar-Sagi, D			Nucleolar Arf sequesters Mdm2 and activates p53	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR P53; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; INK4A LOCUS; P19(ARF); PRODUCT; PROTEIN; DEGRADATION; SENESCENCE	The Ink4/Arf locus encodes two tumour-suppressor proteins, p16(ink4a) and p19(Arf), that govern the antiproliferative functions of the retinoblastoma and p53 proteins, respectively. Here we show that Arf binds to the product of the Mdm2 gene and sequesters it into the nucleolus, thereby preventing negative-feedback regulation of p53 by Mdm2 and leading to the activation of p53 in the nucleoplasm. Arf and Mdm2 co-localize in the nucleolus in response to activation of the oncoprotein Myc and as mouse fibroblasts undergo replicative senescence. These topological interactions of Arf and Mdm2 point towards a new mechanism for p53 activation.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Sherr, CJ (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.		Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139; Bar-Sagi, Dafna/0000-0003-2597-8948; Weber, Jason/0000-0002-1069-6983; Taylor, Laura/0000-0002-4031-6312				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Fomproix N, 1998, J CELL SCI, V111, P359; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hara E, 1996, MOL CELL BIOL, V16, P859; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUNA RMD, 1995, NATURE, V378, P203; McCarthy S A, 1997, Methods Mol Biol, V85, P137; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	39	746	765	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					20	26		10.1038/8991	http://dx.doi.org/10.1038/8991			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559859				2022-12-25	WOS:000083085300013
J	Cushman, DW; Ondetti, MA				Cushman, DW; Ondetti, MA			Design of angiotensin converting enzyme inhibitors	NATURE MEDICINE			English	Editorial Material							BOTHROPS-JARARACA; RABBIT LUNG; PEPTIDES; VENOM				Cushman, DW (corresponding author), 20 Lake Shore Dr, W Windsor, NJ 08550 USA.							Burnett J C Jr, 1999, J Hypertens Suppl, V17, pS37; BYERS LD, 1973, BIOCHEMISTRY-US, V12, P2070, DOI 10.1021/bi00735a008; CASE DB, 1976, AM J MED, V61, P790, DOI 10.1016/0002-9343(76)90160-1; CHEUNG HS, 1973, BIOCHIM BIOPHYS ACTA, V293, P451, DOI 10.1016/0005-2744(73)90352-5; CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; CUSHMAN DW, 1982, ADV PHARMACOL THER, V3, P249; FERREIRA SH, 1970, BIOCHEMISTRY-US, V9, P2583, DOI 10.1021/bi00815a005; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; MONZINGO AF, 1982, BIOCHEMISTRY-US, V21, P3390, DOI 10.1021/bi00257a022; NG KKF, 1967, NATURE, V216, P762, DOI 10.1038/216762a0; ONDETTI MA, 1994, ANNU REV PHARMACOL, V34, P1; ONDETTI MA, 1971, BIOCHEMISTRY-US, V10, P4033, DOI 10.1021/bi00798a004; ONDETTI MA, 1984, CRC CR REV BIOCH MOL, V16, P381, DOI 10.3109/10409238409108720; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; PEART WS, 1975, NEW ENGL J MED, V292, P302, DOI 10.1056/NEJM197502062920609; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; STEITZ TA, 1967, J BIOL CHEM, V242, P4662; Summers J. B., 1998, ANNU REP MED CHEM, V33, P131; Weber MA, 1997, J HYPERTENS, V15, pS31, DOI 10.1097/00004872-199715066-00007	20	165	175	0	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1110	1112		10.1038/13423	http://dx.doi.org/10.1038/13423			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502801				2022-12-25	WOS:000082933200022
J	Li, H; Arber, S; Jessell, TM; Edlund, H				Li, H; Arber, S; Jessell, TM; Edlund, H			Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9	NATURE GENETICS			English	Article							HEDGEHOG; DIFFERENTIATION; MESENCHYME; NOTOCHORD	The initial stages of pancreatic development occur early during mammalian embryogenesis(1), but the genes governing this process remain largely unknown. The homeodomain protein Pdx1 is expressed in the developing pancreatic anlagen from the approximately 10-somite stage(2,3), and mutations in the gene Pdx1 prevent the development of the pancreas(3-5). The initial stages of pancreatic development, however, still occur in Pdx1-deficient mice(3). Hlxb9 (encoding Hb9; ref. 6) is a homeobox gene that in humans has been linked to dominant inherited sacral agenesis(7) and we show here that Hb9 is expressed at early stages of mouse pancreatic development and later in differentiated beta-cells. H1xb9 has an essential function in the initial stages of pancreatic development. In absence of Hlxb9 expression, the dorsal region of the gut epithelium fails to initiate a pancreatic differentiation program. In contrast, the ventral pancreatic endoderm develops but exhibits a later and more subtle perturbation in beta-cell differentiation and in islet cell organization, Thus, dorsally Hlxb9 is required for specifying the gut epithelium to a pancreatic fate and ventrally for ensuring proper endocrine cell differentiation.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; Columbia Univ, Ctr Neurobiol & Behav, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Umea University; Columbia University; Howard Hughes Medical Institute	Edlund, H (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.	helena.edlund@micro.umu.se		Edlund, Helena/0000-0002-3553-7348; Arber, Silvia/0000-0002-6261-250X				Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; ARBER S, IN PRESS NEURON; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kim SK, 1997, DEVELOPMENT, V124, P4243; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ross AJ, 1998, NAT GENET, V20, P358, DOI 10.1038/3828; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; WESSELLS NK, 1967, DEV BIOL, V15, P237, DOI 10.1016/0012-1606(67)90042-5	16	292	306	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					67	70						4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471501				2022-12-25	WOS:000082337300018
J	Nusbaum, C; Slonim, DK; Harris, KL; Birren, BW; Steen, RG; Stein, LD; Miller, J; Dietrich, WF; Nahf, R; Wang, V; Merport, O; Castle, AB; Husain, Z; Farino, G; Gray, D; Anderson, MO; Devine, R; Horton, LT; Ye, WJ; Wu, XY; Kouyoumjian, V; Zemsteva, IS; Wu, Y; Collymore, AJ; Courtney, DF; Tam, J; Cadman, M; Haynes, AR; Heuston, C; Marsland, T; Southwell, A; Trickett, P; Strivens, MA; Ross, MT; Makalowski, W; Xu, YX; Boguski, MS; Carter, NP; Denny, P; Brown, SDM; Hudson, TJ; Lander, ES				Nusbaum, C; Slonim, DK; Harris, KL; Birren, BW; Steen, RG; Stein, LD; Miller, J; Dietrich, WF; Nahf, R; Wang, V; Merport, O; Castle, AB; Husain, Z; Farino, G; Gray, D; Anderson, MO; Devine, R; Horton, LT; Ye, WJ; Wu, XY; Kouyoumjian, V; Zemsteva, IS; Wu, Y; Collymore, AJ; Courtney, DF; Tam, J; Cadman, M; Haynes, AR; Heuston, C; Marsland, T; Southwell, A; Trickett, P; Strivens, MA; Ross, MT; Makalowski, W; Xu, YX; Boguski, MS; Carter, NP; Denny, P; Brown, SDM; Hudson, TJ; Lander, ES			A YAC-based physical map of the mouse genome	NATURE GENETICS			English	Article							RESOLUTION; SYSTEM	A physical map of the mouse genome is an essential tool for both positional cloning and genomic sequencing in this key model system for biomedical research, Indeed, the construction of a mouse physical map with markers spaced at an average interval of 300 kb is one of the stated goals of the Human Genome Project(1). Here we report the results of a project at the Whitehead Institute/MIT Center for Genome Research to construct such a physical map of the mouse. We built the map by screening sequenced-tagged sites (STSs) against a large-insert yeast artificial chromosome (YAC) library and then integrating the STS-content information with a dense genetic map. The integrated map shows the location of 9,787 loci, providing landmarks with an average spacing of approximately 300 kb and affording YAC coverage of approximately 92% of the mouse genome. We also report the results of a project at the MRC UK Mouse Genome Centre targeted at chromosome X. The project produced a YAC-based map containing 619 loci (with 121 loci in common with the Whitehead map and 498 additional loci), providing especially dense coverage of this sex chromosome. The YAC-based physical map directly facilitates positional cloning of mouse mutations by providing ready access to most of the genome. More generally, use of this map in addition to a newly constructed radiation hybrid (RH) map(2) provides a comprehensive framework for mouse genomic studies.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MRC, UK Mouse Genome Ctr, Harwell OX11 0RD, Berks, England; MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; Sanger Ctr Wellcome Trust Genome Campus, Cambridge CB10 1SA, England; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; Johns Hopkins Univ, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Wellcome Trust Sanger Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Johns Hopkins University; McGill University; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		wang, vicky/AAO-6474-2020	Denny, Paul/0000-0003-4659-6893; Hudson, Thomas/0000-0002-1376-4849; Makalowski, Wojciech/0000-0003-2303-9541; Slonim, Donna/0000-0003-3357-437X; Xu, Ethan/0000-0002-7496-0835	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANAND R, 1991, GENOMICS, V9, P124, DOI 10.1016/0888-7543(91)90229-8; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DENNY P, 1999, MOUSE GENETICS TRANS; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; EVANS EP, 1996, GENETIC VARIANTS STR, P1446; Haldi ML, 1996, MAMM GENOME, V7, P767, DOI 10.1007/s003359900228; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; RABBITTS P, 1995, NAT GENET, V9, P369, DOI 10.1038/ng0495-369; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Soderlund C, 1995, COMPUT APPL BIOSCI, V11, P645; Strivens MA, 1997, MAMM GENOME, V8, P467, DOI 10.1007/s003359900478; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962	15	58	66	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					388	393		10.1038/11967	http://dx.doi.org/10.1038/11967			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431246				2022-12-25	WOS:000081772500024
J	Lunde, E; Munthe, LA; Vabo, A; Sandlie, I; Bogen, B				Lunde, E; Munthe, LA; Vabo, A; Sandlie, I; Bogen, B			Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells	NATURE BIOTECHNOLOGY			English	Article						recombinant immunoglobulin; MHC class II; antigen processing; vaccination; immunization	COMPLEX CLASS-II; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-D; TH2 CLONES; HLA-DR; RECEPTOR; PEPTIDES; MOLECULES; RESPONSES; REGION	We have developed a strategy for improving the stimulation of T cells during immune responses by constructing recombinant antibodies that enhance the delivery of antigen to antigen-presenting cells, such as B cells. These antibodies have variable regions specific for surface molecules on B cells, and a constant region with an inserted antigen. In vitro, such antibodies make B cells approximately 1000-fold more efficient at presenting antigen and stimulating specific T cells. In vivo, the antibodies turn B cells of the spleen into potent stimulators of T cells. This approach may be useful for the generation of new vaccines.	Univ Oslo, Inst Immunol & Rheumatol, N-0172 Oslo, Norway; Univ Oslo, Dept Biol, Oslo, Norway	University of Oslo; University of Oslo	Lunde, E (corresponding author), Univ Oslo, Inst Immunol & Rheumatol, Fr Qvamsgt 1, N-0172 Oslo, Norway.		Munthe, Ludvig/GRJ-3355-2022	Munthe, Ludvig A/0000-0002-0344-3654				ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BAIER G, 1995, J VIROL, V69, P2357, DOI 10.1128/JVI.69.4.2357-2365.1995; BIKOFF EK, 1988, EUR J IMMUNOL, V18, P341, DOI 10.1002/eji.1830180304; BOGEN B, 1989, EMBO J, V8, P1947, DOI 10.1002/j.1460-2075.1989.tb03599.x; BOGEN B, 1990, EUR J IMMUNOL, V20, P2359, DOI 10.1002/eji.1830201030; BOGEN B, 1992, EUR J IMMUNOL, V22, P703, DOI 10.1002/eji.1830220313; Bogen B, 1996, EUR J IMMUNOL, V26, P2671, DOI 10.1002/eji.1830261119; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; BOGEN B, 1986, EUR J IMMUNOL, V16, P1379, DOI 10.1002/eji.1830161111; BONA C, 1994, CELL MOL BIOL, V40, P21; CASTEN LA, 1988, J IMMUNOL, V140, P404; CHANG TL, 1990, J IMMUNOL, V145, P2803; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; ESPOSITOFARESE ME, 1995, J IMMUNOL, V155, P1725; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Gerloni M, 1997, NAT BIOTECHNOL, V15, P876, DOI 10.1038/nbt0997-876; HUCK S, 1986, NUCLEIC ACIDS RES, V14, P1779, DOI 10.1093/nar/14.4.1779; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KAWAMURA H, 1986, J IMMUNOL, V136, P58; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAURITZSEN GF, 1991, SCAND J IMMUNOL, V33, P647, DOI 10.1111/j.1365-3083.1991.tb02537.x; LEES A, 1990, J IMMUNOL, V145, P3594; LESK A, 1992, ANTIBODY ENG PRACTIC; LIEBERMAN R, 1978, SPRINGER SEMIN IMMUN, V1, P7, DOI 10.1007/BF00198644; LUCAS B, 1995, J EXP MED, V181, P1623, DOI 10.1084/jem.181.5.1623; Lunde E, 1997, MOL IMMUNOL, V34, P1167, DOI 10.1016/S0161-5890(97)00143-0; Munthe LA, 1996, CELL IMMUNOL, V170, P283, DOI 10.1006/cimm.1996.0162; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; Rudensky A, 1993, Chem Immunol, V57, P134; SAOUDI A, 1995, J EXP MED, V182, P335, DOI 10.1084/jem.182.2.335; SNIDER DP, 1987, J IMMUNOL, V139, P1609; SNIDER DP, 1989, J IMMUNOL, V143, P59; SNODGRASS HR, 1992, EUR J IMMUNOL, V22, P2169, DOI 10.1002/eji.1830220832; SQUIRE CM, 1994, J IMMUNOL, V152, P4388; TISCH R, 1987, P NATL ACAD SCI USA, V84, P3831, DOI 10.1073/pnas.84.11.3831; Xiong SD, 1997, NAT BIOTECHNOL, V15, P882, DOI 10.1038/nbt0997-882; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469	41	51	57	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					670	675		10.1038/10883	http://dx.doi.org/10.1038/10883			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404160				2022-12-25	WOS:000081296900027
J	Pinto, YM; Kok, RA; Baulcombe, DC				Pinto, YM; Kok, RA; Baulcombe, DC			Resistance to rice yellow mottle virus (RYMV) in cultivated African rice varieties containing RYMV transgenes	NATURE BIOTECHNOLOGY			English	Article						cultivated African rice; virus resistance; RYMV; posttranscriptional gene silencing	DISCHARGE PARTICLE-ACCELERATION; PLANTS; GENE; EXPRESSION; BOMBARDMENT; SEQUENCE; GENOME; DNA	The disease caused by rice yellow mottle virus (RYMV) is a serious problem for African rice growers in large-scale irrigated programs. As there are very few suitable natural sources of RYMV resistance, we have investigated a transgenic approach using widely grown, RYMV-susceptible cultivars of rice and a transgene encoding the RNA-dependent RNA polymerase of RYMV. Transformed lines were resistant to RYMV strains from different African locations. In the most extreme examples there was complete suppression of virus multiplication. Resistance was stable over at least three generations. Subject to satisfactory field testing, these transgenic lines may be suitable for introduction into RYMV-affected rice-growing areas. In the most resistant line, transcription analysis indicated that the resistance derives from an RNA-based mechanism associated with posttranscriptional gene silencing.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.			Baulcombe, David/0000-0003-0780-6878				ALBAR A, 1995, ETUDE RICE YELLOW MO, P10; Arencibia A, 1998, MOL BREEDING, V4, P99, DOI 10.1023/A:1009627409668; AWODERU VA, 1991, TROP PEST MANAGE, V37, P356, DOI 10.1080/09670879109371614; BAKKER W, 1974, 829 CTR AGR PUBL DOC, P152; Bendahmane A, 1997, THEOR APPL GENET, V95, P153, DOI 10.1007/s001220050543; CHRISTOU P, 1991, BIO-TECHNOL, V9, P957, DOI 10.1038/nbt1091-957; COOLEY J, 1995, THEOR APPL GENET, V90, P97, DOI 10.1007/BF00221001; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; FAUQUET C, 1977, PLANT DIS REP, V61, P443; FOMBA SN, 1988, PLANT DIS, V72, P641, DOI 10.1094/PD-72-0641; HAYAKAWA T, 1992, P NATL ACAD SCI USA, V89, P9865, DOI 10.1073/pnas.89.20.9865; *IITA, 1985, IITA ANN REP INT I T; Ingelbrecht IL, 1999, PLANT PHYSIOL, V119, P1187, DOI 10.1104/pp.119.4.1187; Itoh K, 1997, MOL GEN GENET, V255, P351, DOI 10.1007/s004380050506; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Kohli A, 1998, P NATL ACAD SCI USA, V95, P7203, DOI 10.1073/pnas.95.12.7203; Kumpatla SP, 1997, PLANT PHYSIOL, V115, P361, DOI 10.1104/pp.115.2.361; LINDBO JA, 1992, MOL PLANT MICROBE IN, V5, P144, DOI 10.1094/MPMI-5-144; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; MAKINEN K, 1995, J GEN VIROL, V76, P2817, DOI 10.1099/0022-1317-76-11-2817; Morino K, 1999, PLANT J, V17, P275, DOI 10.1046/j.1365-313X.1999.00373.x; MUELLER E, 1995, PLANT J, V7, P1001, DOI 10.1046/j.1365-313X.1995.07061001.x; NGON A, 1994, VIROLOGY, V206, P287; Oard JH, 1996, MOL BREEDING, V2, P359, DOI 10.1007/BF00437914; Rubio T, 1999, MOL PLANT MICROBE IN, V12, P87, DOI 10.1094/MPMI.1999.12.2.87; Sambrook J., 2002, MOL CLONING LAB MANU; SANFORD JC, 1985, J THEOR BIOL, V113, P395, DOI 10.1016/S0022-5193(85)80234-4; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; STARN M, 1997, PLANT J, V12, P63; Takano M, 1997, PLANT J, V11, P353, DOI 10.1046/j.1365-313X.1997.11030353.x; Vain P, 1998, THEOR APPL GENET, V96, P266, DOI 10.1007/s001220050735; VAIN P, 1993, PLANT CELL REP, V12, P84, DOI 10.1007/BF00241940; *WARDA, 1994, WARDA ANN REP W AFR; Zheng HH, 1997, THEOR APPL GENET, V94, P522, DOI 10.1007/s001220050446	34	62	93	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					702	707		10.1038/10917	http://dx.doi.org/10.1038/10917			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404165				2022-12-25	WOS:000081296900032
J	Beck, JA; Lloyd, S; Hafezparast, M; Lennon-Pierce, M; Eppig, JT; Festing, MFW; Fisher, EMC				Beck, JA; Lloyd, S; Hafezparast, M; Lennon-Pierce, M; Eppig, JT; Festing, MFW; Fisher, EMC			Genealogies of mouse inbred strains	NATURE GENETICS			English	Editorial Material							PCR-ANALYZED MICROSATELLITES; GENETIC-VARIATION; MICE; POLYMORPHISMS; EVOLUTION; C57BL/10; COMPLEX; ORIGIN; 129/SV; FVB/N	The mouse is a prime organism of choice for modelling human disease. Over 450 inbred strains of mice have been described, providing a wealth of different genotypes and phenotypes for genetic and other studies. As new strains are generated and others become extinct, it is useful to review periodically what strains are available and how they are related to each other, particularly in the light of available DNA polymorphism data from microsatellite and other markers. We describe the origins and relationships of inbred mouse strains, 90 years after the generation of the first inbred strain. Given the large collection of inbred strains available, and that published information on these strains is incomplete, we propose that all genealogical and genetic data on inbred strains be submitted to a common electronic database to ensure this valuable information resource is preserved and used efficiently.	Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Neurogenet, London, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, MRC Prion Unit, London, England; Jackson Lab, Bar Harbor, ME 04609 USA; Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England	Imperial College London; Imperial College London; University of London; University College London; Jackson Laboratory; University of Leicester	Fisher, EMC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Neurogenet, London, England.		Hafezparast, Majid/H-6728-2018; Hafezparast, Majid/N-8292-2019; Fisher, Elizabeth MC/C-2168-2008	Hafezparast, Majid/0000-0002-5262-7150; Fisher, Elizabeth MC/0000-0003-2850-9936	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000330, P41HG000330] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00330] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; ATCHLEY WR, 1993, MOL BIOL EVOL, V10, P1150; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; BONHOMME F, 1987, BIOL J LINN SOC, V30, P51, DOI 10.1111/j.1095-8312.1987.tb00288.x; Bonhomme F., 1996, GENETIC VARIANTS STR, P1577; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; CUI SL, 1993, LAB ANIM, V27, P116, DOI 10.1258/002367793780810397; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; DAVISSON MT, 1996, GENETIC VARIANTS STR, P1532; Festing M., 1997, Mouse Genome, V95, P845; FESTING MFW, 1989, GENET RES, V53, P45, DOI 10.1017/S0016672300027853; FESTING MFW, 1975, FOOD COSMET TOXICOL, V13, P369, DOI 10.1016/S0015-6264(75)80302-6; FESTING MFW, 1996, GENETIC VARIANTS STR, P1537; Festing MFW, 1979, INBRED STRAINS BIOME; FITCH WM, 1985, SCIENCE, V228, P1169, DOI 10.1126/science.4001935; FOWLIS GA, 1992, MAMM GENOME, V3, P192, DOI 10.1007/BF00355718; Ginsburg Benson E., 1992, V8, P3; HILGERS J, 1988, GENET RES, V51, P29, DOI 10.1017/S0016672300023910; KEELER CE, 1931, LAB MOUSE ISTS ORIGI; KLEIN J, 1975, PRINCIPLES IMMUNOGEN; Le Voyer TE, 1999, MAMM GENOME, V10, P542, DOI 10.1007/s003359901040; MARONPOT RR, 1983, ENV SCI RES, V27, P341; Martin JE, 1997, TRENDS GENET, V13, P254, DOI 10.1016/S0168-9525(97)01193-1; Matin A, 1998, MAMM GENOME, V9, P668, DOI 10.1007/s003359900842; Matouk C, 1996, MAMM GENOME, V7, P603, DOI 10.1007/s003359900178; MCCLIVE PJ, 1994, IMMUNOGENETICS, V39, P286, DOI 10.1007/BF00188793; Morse H., 1978, ORIGINS INBRED MICE; Neuhaus IM, 1997, MAMM GENOME, V8, P506, DOI 10.1007/s003359900485; Panoutsakopoulou V, 1997, MAMM GENOME, V8, P357, DOI 10.1007/s003359900441; Peirce JL, 1998, MAMM GENOME, V9, P942, DOI 10.1007/s003359900904; POTTER M, 1979, INBRED GENETICALLY D, V1, P16; ROUTMAN EJ, 1995, MAMM GENOME, V6, P401, DOI 10.1007/BF00355640; Russell E S, 1985, Annu Rev Genet, V19, P1, DOI 10.1146/annurev.ge.19.120185.000245; Silver L. M., 1995, MOUSE GENETICS; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Slingsby JH, 1996, IMMUNOGENETICS, V43, P72; STAATS JOAN, 1966, P45; STAATS JOAN, 1966, P1; Takeda T, 1997, EXP GERONTOL, V32, P105, DOI 10.1016/S0531-5565(96)00036-8; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; TAYLOR BA, 1972, J HERED, V63, P83, DOI 10.1093/oxfordjournals.jhered.a108235; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W	44	625	645	1	45	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					23	+		10.1038/71641	http://dx.doi.org/10.1038/71641			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615122				2022-12-25	WOS:000084609200010
J	Sohocki, MM; Bowne, SJ; Sullivan, LS; Blackshaw, S; Cepko, CL; Payne, AM; Bhattacharya, SS; Khaliq, S; Mehdi, SQ; Birch, DG; Harrison, WR; Elder, FFB; Heckenlively, JR; Daiger, SP				Sohocki, MM; Bowne, SJ; Sullivan, LS; Blackshaw, S; Cepko, CL; Payne, AM; Bhattacharya, SS; Khaliq, S; Mehdi, SQ; Birch, DG; Harrison, WR; Elder, FFB; Heckenlively, JR; Daiger, SP			Mutations in a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis	NATURE GENETICS			English	Article							RETINITIS-PIGMENTOSA; HOMEOBOX GENE; PROTEIN; CRX	Leber congenital amaurosis (LCA, MIM 204000) accounts for at least 5% of all inherited retinal disease(1) and is the most severe inherited retinopathy with the earliest age of onset(2). Individuals affected with LCA are diagnosed at birth or in the first few months of life with severely impaired vision or blindness, nystagmus and an abnormal or flat electroretinogram (ERG). Mutations in GUCY2D (ref. 3), RPE65 (ref. 4) and CRX (ref. 5) are known to cause LCA, but one study identified disease-causing GUCY2D mutations in only 8 of 15 families whose LCA locus maps to 17p13.1 (ref. 3), suggesting another LCA locus might be located on 17p13.1. Confirming this prediction, the LCA in one Pakistani family mapped to 17p13.1, between D17S849 and D17S960-a region that excludes GUCY2D. The LCA in this family has been designated LCA4 (ref. 6). We describe here a new photoreceptor/pineal-expressed gene, AIPL1 (encoding aryl-hydrocarbon interacting protein-like 1), that maps within the LCA4 candidate region and whose protein contains three tetratricopeptide (TPR) motifs, consistent with nuclear transport or chaperone activity. A homozygous nonsense mutation at codon 278 is present in all affected members of the original LCA4 family. AIPL1 mutations may cause approximately 20% of recessive LCA, as disease-causing mutations were identified in 3 of 14 LCA families not tested previously for linkage.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Houston, TX USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA USA; UCL, Dept Mol Genet, Inst Ophthalmol, London, England; Dr AQ Khan Res Labs, Biomed & Genet Engn Div, Islamabad, Pakistan; Retina Fdn SW, Dallas, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Lab Med, Houston, TX USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of London; University College London; Retina Foundation of the Southwest; University of Texas System; University of Texas Health Science Center Houston; University of California System; University of California Los Angeles	Daiger, SP (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77225 USA.	sdaiger@utsph.sph.uth.tmc.edu	Khaliq, Shagufta/G-2337-2015; Bhattacharya, Shom/N-2926-2016; Payne, annette/F-8877-2013; Mehdi, Syed Qasim/L-2385-2015	Bhattacharya, Shom/0000-0002-1601-6344; Payne, annette/0000-0002-2009-0141; Birch, David/0000-0002-6594-2897	NATIONAL EYE INSTITUTE [R01EY007142] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007142, R01 EY007142-12A2, EY07142] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		FOXMAN SG, 1985, ARCH OPHTHALMOL-CHIC, V103, P1502; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; GREENBERG J, 1994, HUM MOL GENET, V3, P915, DOI 10.1093/hmg/3.6.915; HADLEY ME, 1996, ENDOCRINOLOGY, P458; HAMEED A, IN PRESS INVEST OPHT; KAPLAN J, 1990, HUM GENET, V85, P635; Ma Q, 1997, J BIOL CHEM, V272, P8878; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; Sohocki MM, 1999, GENOMICS, V58, P29, DOI 10.1006/geno.1999.5810	12	216	222	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					79	83		10.1038/71732	http://dx.doi.org/10.1038/71732			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615133	Green Accepted			2022-12-25	WOS:000084609200021
J	Ballinger, MD; Shyamala, V; Forrest, LD; Deuter-Reinhard, M; Doyle, LV; Wang, JX; Panganiban-Lustan, L; Stratton, JR; Apell, G; Winter, JA; Doyle, MV; Rosenberg, S; Kavanaugh, WM				Ballinger, MD; Shyamala, V; Forrest, LD; Deuter-Reinhard, M; Doyle, LV; Wang, JX; Panganiban-Lustan, L; Stratton, JR; Apell, G; Winter, JA; Doyle, MV; Rosenberg, S; Kavanaugh, WM			Semirational design of a potent, artificial agonist of fibroblast growth factor receptors	NATURE BIOTECHNOLOGY			English	Article						fibroblast growth factor; protein design; receptors; ligands; cytokines; mimetics; angiogenesis	RABBIT MODEL; BINDING; DIMERIZATION; ACTIVATION; ISCHEMIA; OLIGOMERIZATION; ANGIOGENESIS; SPECIFICITY; PEPTIDES; DOMAINS	Fibroblast growth factors (FGFs) are being investigated in human clinical trials as treatments for angina, claudication, and stroke. We designed a molecule structurally unrelated to all FGFs, which potently mimicked basic FGF activity, by combining domains that (1) bind FGF receptors (2) bind heparin, and (3) mediate dimerization. A 26-residue peptide identified by phage display specifically bound FGF receptor (FGFR) Ic extracellular domain but had no homology with FGFs. When fused with the c-jun leucine zipper domain, which binds heparin and forms homodimers, the polypeptide specifically reproduced the mitogenic and morphogenic activities of basic FGF with similar potency (EC50= 240 pM). The polypeptide required interaction with heparin for activity, demonstrating the importance of heparin for FGFR activation even with designed ligands structurally unrelated to FGF. Our results demonstrate the feasibility of engineering potent artificial agonists for the receptor tyrosine kinases, and have important implications for the design of nonpeptidic ligands for FGF receptors. Furthermore, artificial FGFR agonists may be useful alternatives to FGF in the treatment of ischemic vascular disease.	Chiron Corp, Oakland, CA 94608 USA	Novartis	Kavanaugh, WM (corresponding author), Chiron Corp, 4560 Horton St,Room 4-4144, Oakland, CA 94608 USA.	Mike_Kavanaugh@cc.chiron.com						ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; BAFFOUR R, 1992, J VASC SURG, V16, P181, DOI 10.1016/0741-5214(92)90106-I; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CLAUDE P, 1988, NEURON, V1, P783, DOI 10.1016/0896-6273(88)90126-2; CRAMERI R, 1995, GENE, V160, P139, DOI 10.1016/0378-1119(95)00190-H; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; DOYLE MV, 1996, COMBINATORIAL LIB SY, P171; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HARADA K, 1994, J CLIN INVEST, V94, P623, DOI 10.1172/JCI117378; HULME EC, 1993, RECEPTOR LIGAND INTE, P101; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANDAU C, 1995, AM HEART J, V129, P924, DOI 10.1016/0002-8703(95)90113-2; LAZAROUS DF, 1995, CIRCULATION, V91, P145, DOI 10.1161/01.CIR.91.1.145; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; Shyamala V, 1999, ANAL BIOCHEM, V266, P140, DOI 10.1006/abio.1998.2922; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	38	57	79	2	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1199	1204		10.1038/70746	http://dx.doi.org/10.1038/70746			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585718				2022-12-25	WOS:000084170700028
J	Gutierrez-Campos, R; Torres-Acosta, JA; Saucedo-Arias, LJ; Gomez-Lim, MA				Gutierrez-Campos, R; Torres-Acosta, JA; Saucedo-Arias, LJ; Gomez-Lim, MA			The use of cysteine proteinase inhibitors to engineer resistance against potyviruses in transgenic tobacco plants	NATURE BIOTECHNOLOGY			English	Article						genetic engineering; transgenic plants; potyvirus; tobacco etch virus; tobacco; proteinase inhibitors; virus resistance	EXPRESSION; VIRUS; ORYZACYSTATIN; CYSTATINS; CLONING; RICE; RNA; MULTICYSTATIN; PRODUCTS; SEEDS	As the processing mechanism of all known potyviruses involves the activity of cysteine proteinases, we asked whether constitutive expression of a rice cysteine proteinase inhibitor gene could induce resistance against two important potyviruses, tobacco etch virus (TEV) and potato virus Y (PVY), in transgenic tobacco plants. Tobacco lines expressing the foreign gene at varying levels were examined for resistance against TEV and PVY infection. There was a clear, direct correlation between the level of oryzacystatin message, inhibition of papain (a cysteine proteinase), and resistance to TEV and PVY in all lines tested. The inhibitor was ineffective against tobacco mosaic virus (TMV) infection because processing of this virus does not involve cysteine proteinases. These results show that plant cystatins can be used against different potyviruses and potentially also against other viruses, whose replication involves cysteine proteinase activity.	Ctr Invest & Estudios Avanzados, Dept Ingn Genet, Unidad Irapuato, Irapuato, Mexico; Univ Autonoma Aguascalientes, Ctr Basico, Dept Quim, Aguascalientes 20100, Ags, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Universidad Autonoma de Aguascalientes	Gomez-Lim, MA (corresponding author), Ctr Invest & Estudios Avanzados, Dept Ingn Genet, Unidad Irapuato, Apartado Postal 629, Irapuato, Mexico.			gomez lim, MIGUEL ANGEL/0000-0002-5589-0720				ABE K, 1987, J BIOL CHEM, V262, P16793; AOKI H, 1995, ANTIMICROB AGENTS CH, V39, P846, DOI 10.1128/AAC.39.4.846; AUDY P, 1994, MOL PLANT MICROBE IN, V7, P15, DOI 10.1094/MPMI-7-0015; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DOPICO B, 1993, PLANT MOL BIOL, V21, P437, DOI 10.1007/BF00028802; DOUGHERTY WG, 1993, MICROBIOL REV, V57, P781, DOI 10.1128/MMBR.57.4.781-822.1993; DOUGHERTY WG, 1980, VIROLOGY, V101, P466, DOI 10.1016/0042-6822(80)90460-2; DOUGHERTY WG, 1988, ANNU REV PHYTOPATHOL, V26, P123, DOI 10.1146/annurev.py.26.090188.001011; FERNANDES KVS, 1993, PLANT MOL BIOL, V23, P215, DOI 10.1007/BF00021433; GAN SS, 1995, SCIENCE, V270, P1986, DOI 10.1126/science.270.5244.1986; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; HAMILL JD, 1991, PLANT CELL REP, V10, P221, DOI 10.1007/BF00232562; HEINS ME, 1991, J AGR FOOD CHEM, V39, P1515; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HOSOYAMA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1500, DOI 10.1271/bbb.58.1500; Irie K, 1996, PLANT MOL BIOL, V30, P149, DOI 10.1007/BF00017809; KASSCHAU KD, 1995, VIROLOGY, V209, P268, DOI 10.1006/viro.1995.1254; LINDBO JA, 1992, MOL PLANT MICROBE IN, V5, P144, DOI 10.1094/MPMI-5-144; LING K, 1991, BIO-TECHNOL, V9, P752, DOI 10.1038/nbt0891-752; LOMONOSSOFF GP, 1995, ANNU REV PHYTOPATHOL, V33, P323, DOI 10.1146/annurev.py.33.090195.001543; LOPEZGOMEZ R, 1992, HORTSCIENCE, V27, P440, DOI 10.21273/HORTSCI.27.5.440; MACHLEIDT W, 1993, INNOVATIONS PROTEASE, P349; MAITI IB, 1993, P NATL ACAD SCI USA, V90, P6110, DOI 10.1073/pnas.90.13.6110; MASOUD SA, 1993, PLANT MOL BIOL, V21, P655, DOI 10.1007/BF00014548; ORR GL, 1994, J INSECT PHYSIOL, V40, P893, DOI 10.1016/0022-1910(94)90023-X; REGNER F, 1992, PLANT CELL REP, V11, P30, DOI 10.1007/BF00231835; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH DS, 1987, J VIROL, V61, P912, DOI 10.1128/JVI.61.3.912-915.1987; Spall VE, 1997, SEMIN VIROL, V8, P15, DOI 10.1006/smvy.1997.0102; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; URWIN PE, 1995, PLANT J, V8, P1021; WALDRON C, 1993, PLANT MOL BIOL, V23, P801, DOI 10.1007/BF00021535	34	125	139	1	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1223	1226		10.1038/70781	http://dx.doi.org/10.1038/70781			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585723				2022-12-25	WOS:000084170700033
J	Patel, S; Robb-Gaspers, LD; Stellato, KA; Shon, M; Thomas, AP				Patel, S; Robb-Gaspers, LD; Stellato, KA; Shon, M; Thomas, AP			Coordination of calcium signalling by endothelial-derived nitric oxide in the intact liver	NATURE CELL BIOLOGY			English	Article								Calcium ions (Ca2+) and nitric oxide (NO) are key signalling molecules that are implicated in the regulation of numerous cellular processes. Here we show that, in the intact liver, stimulation of endothelial cells by bradykinin coordinates the propagation of vasopressin-dependent intercellular Ca2+ waves across hepatic plates, and markedly increases the frequency of Ca2+ oscillations in individual hepatocytes. Modulation of Ca2+ oscillations by bradykinin is lost following isolation of hepatocytes, but restored in co-cultures of hepatocytes and endothelial cells. The sensitizing effects of bradykinin are mimicked by NO donors and abrogated by NO inhibitors. Thus, crosstalk between NO and Ca2+ signalling pathways through the microvasculature is probably an important mechanism for the coordination of liver function and may have a function in other organs.	Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Thomas, AP (corresponding author), Univ Med & Dent New Jersey, Dept Physiol & Pharmacol, Newark, NJ 07103 USA.		Thomas, Andrew/C-6755-2013; Gaspers, Lawrence/W-8766-2019; Patel, Sandip/O-9591-2015	Gaspers, Lawrence/0000-0002-5620-3283; Patel, Sandip/0000-0001-7247-2013; Thomas, Andrew/0000-0002-9026-7467				Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102	5	47	50	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					467	471		10.1038/70249	http://dx.doi.org/10.1038/70249			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587641				2022-12-25	WOS:000084136100013
J	Cote, PD; Moukhles, H; Lindenbaum, M; Carbonetto, S				Cote, PD; Moukhles, H; Lindenbaum, M; Carbonetto, S			Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses	NATURE GENETICS			English	Article							BETA-DYSTROGLYCAN; BASEMENT-MEMBRANE; AGRIN RECEPTOR; LAMININ; MUSCLE; UTROPHIN; COMPLEX; IDENTIFICATION; GLYCOPROTEINS; ASSOCIATION		McGill Univ, Montreal Gen Hosp, Res Inst, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	McGill University	Carbonetto, S (corresponding author), McGill Univ, Montreal Gen Hosp, Res Inst, Neurosci Res Ctr, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Cote, Patrice/0000-0002-4189-7526				BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DICKSON G, 1992, J CELL SCI, V103, P1223; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; FRITZ JD, 1995, PEDIATR RES, V37, P693, DOI 10.1203/00006450-199506000-00004; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; Montanaro F, 1998, J NEUROSCI, V18, P1250; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PETERSON AC, 1978, BIOCHEM GENET, V16, P681, DOI 10.1007/BF00484725; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	31	197	198	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					338	342		10.1038/15519	http://dx.doi.org/10.1038/15519			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610181				2022-12-25	WOS:000083792200025
J	DelPrincipe, F; Egger, M; Niggli, E				DelPrincipe, F; Egger, M; Niggli, E			Calcium signalling in cardiac muscle: refractoriness revealed by coherent activation	NATURE CELL BIOLOGY			English	Article							RAT VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; CA2+ RELEASE; RYANODINE RECEPTOR; CAGED CALCIUM; CONFOCAL MICROSCOPY; EXCHANGE CURRENT; SKELETAL-MUSCLE; HEART-MUSCLE; PHOTOLYSIS	Contraction of cardiac myocytes is governed by calcium-ion (Ca2+)-induced Ca2+ release (CICR) from the sarcoplasmic reticulum through Ca2+-release channels. Ca2+ release occurs by concerted activation of numerous elementary Ca2+ events,'Ca2+ sparks', that are triggered and locally, controlled by Ca2+ influx into the cell through plasmalemmal L-type Ca2+ channels. Because of the positive feedback inherent in CICR, an as-yet-unidentified control mechanism is required to restrain the amplification of Ca2+ signalling and to terminate Ca2+ release from the sarcoplasmic reticulum, Here we use ultraviolet-laser flash and two-photon photolysis of caged Ca2+ to study spatiotemporal features of the termination and refractoriness of Ca2+ release, Coherent and simultaneous activation of all Ca2+-release sites within a cardiac myocyte unmasked a prominent refractoriness, recovering monotonically within about 1 second. In contrast, selective activation of a few Ca2+-release sites was not followed by a refractoriness of Ca2+ release from the sarcoplasmic reticulum. This discrepancy is consistent with the idea that a functional depletion of Ca2+ from the cellular sarcoplasmic-reticulum network may underlie the refractoriness of CICR observed after a whole-cell Ca2+ transient. These results also imply the requirement for further mechanisms to terminate spatially limited subcellular Ca2+-release events such as Ca2+ sparks.	Univ Bern, Dept Physiol, CH-3012 Bern, Switzerland	University of Bern	Niggli, E (corresponding author), Univ Bern, Dept Physiol, Buhlpl 5, CH-3012 Bern, Switzerland.		Niggli, Ernst/AAL-4351-2020; Niggli, Ernst/C-4884-2015	Niggli, Ernst/0000-0003-4670-4903; Niggli, Ernst/0000-0003-4670-4903				BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BRANDT NR, 1993, J MEMBRANE BIOL, V131, P219, DOI 10.1007/BF02260110; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CONNOLLY R, 1971, J GEN PHYSIOL, V57, P697; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Diaz ME, 1997, J PHYSIOL-LONDON, V501, P3, DOI 10.1111/j.1469-7793.1997.003bo.x; DONOSO P, 1995, BIOPHYS J, V68, P507, DOI 10.1016/S0006-3495(95)80212-2; EllisDavies GCR, 1996, BIOPHYS J, V70, P1006, DOI 10.1016/S0006-3495(96)79644-3; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Gyorke I, 1998, BIOPHYS J, V75, P2801, DOI 10.1016/S0006-3495(98)77723-9; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAN S, 1994, J PHYSIOL-LONDON, V480, P411, DOI 10.1113/jphysiol.1994.sp020371; Langer GA, 1996, BIOPHYS J, V70, P1169, DOI 10.1016/S0006-3495(96)79677-7; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; Lipp P, 1998, J PHYSIOL-LONDON, V508, P801, DOI 10.1111/j.1469-7793.1998.801bp.x; LIPP P, 1993, BIOPHYS J, V65, P2272, DOI 10.1016/S0006-3495(93)81316-X; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; Lukyanenko V, 1998, J PHYSIOL-LONDON, V507, P667, DOI 10.1111/j.1469-7793.1998.667bs.x; NABAUER M, 1990, AM J PHYSIOL, V258, P189; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NIGGLI E, 1993, BIOPHYS J, V65, P882, DOI 10.1016/S0006-3495(93)81105-6; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; Satoh H, 1997, AM J PHYSIOL-HEART C, V272, pH657, DOI 10.1152/ajpheart.1997.272.2.H657; Sham JSK, 1998, P NATL ACAD SCI USA, V95, P15096, DOI 10.1073/pnas.95.25.15096; SPENCER CI, 1995, J PHYSIOL-LONDON, V488, P267, DOI 10.1113/jphysiol.1995.sp020965; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Tanaka H, 1998, J PHYSIOL-LONDON, V508, P145, DOI 10.1111/j.1469-7793.1998.145br.x; Trafford AW, 1998, CARDIOVASC RES, V37, P710, DOI 10.1016/S0008-6363(97)00266-6; Vornanen M, 1997, CARDIOVASC RES, V33, P611, DOI 10.1016/S0008-6363(96)00259-3; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X	31	73	78	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					323	329		10.1038/14013	http://dx.doi.org/10.1038/14013			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559957				2022-12-25	WOS:000083169800013
J	Neirynck, S; Deroo, T; Saelens, X; Vanlandschoot, P; Jou, WM; Fiers, W				Neirynck, S; Deroo, T; Saelens, X; Vanlandschoot, P; Jou, WM; Fiers, W			A universal influenza A vaccine based on the extracellular domain of the M2 protein	NATURE MEDICINE			English	Article							HEPATITIS-B VIRUS; INTEGRAL MEMBRANE-PROTEIN; CORE PARTICLES; A VIRUSES; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; VIRAL PROTEIN; GENE; AMANTADINE; NEURAMINIDASE	The antigenic variation of influenza virus represents a major health problem. However, the extracellular domain of the minor, virus-coded M2 protein is nearly invariant in all influenza A strains. We genetically fused this M2 domain to the hepatitis B virus core (HBc) protein to create fusion gene coding for M2HBc; this gene was efficiently expressed in Escherichia coli. Intraperitoneal or intranasal administration of purified M2HBc particles to mice provided 90-100% protection against a lethal virus challenge. The protection was mediated by antibodies, as it was transferable by serum. The enhanced immunogenicity of the M2 extracellular domain exposed on HBc particles allows broad-spectrum, long-lasting protection against influenza A infections.	State Univ Ghent, Dept Biol Mol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium	Ghent University	Fiers, W (corresponding author), State Univ Ghent, Dept Biol Mol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Saelens, Xavier/N-5728-2015	, Xavier/0000-0002-3861-6965				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; APPLEYARD G, 1977, J GEN VIROL, V36, P249, DOI 10.1099/0022-1317-36-2-249; BAEZ M, 1980, J INFECT DIS, V141, P362, DOI 10.1093/infdis/141.3.362; BELSHE RB, 1988, J VIROL, V62, P1508, DOI 10.1128/JVI.62.5.1508-1512.1988; BLACK RA, 1993, J GEN VIROL, V74, P143, DOI 10.1099/0022-1317-74-1-143; BORISOVA GP, 1989, FEBS LETT, V259, P121, DOI 10.1016/0014-5793(89)81509-1; Chen Z, 1998, VACCINE, V16, P1544, DOI 10.1016/S0264-410X(98)00043-7; CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0; COHEN BJ, 1982, NATURE, V296, P677, DOI 10.1038/296677a0; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Deroo T, 1996, VACCINE, V14, P561, DOI 10.1016/0264-410X(95)00157-V; FANG RX, 1981, CELL, V25, P315, DOI 10.1016/0092-8674(81)90049-0; HAY AJ, 1979, J GEN VIROL, V42, P189, DOI 10.1099/0022-1317-42-1-189; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; Johansson BE, 1998, VACCINE, V16, P1009, DOI 10.1016/S0264-410X(97)00279-X; JOHANSSON BE, 1989, J VIROL, V63, P1239, DOI 10.1128/JVI.63.3.1239-1246.1989; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAMB RA, 1981, P NATL ACAD SCI-BIOL, V78, P4170, DOI 10.1073/pnas.78.7.4170; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LUBECK MD, 1978, J VIROL, V28, P710, DOI 10.1128/JVI.28.3.710-716.1978; MIN JW, 1980, CELL, V19, P683; NASSAL M, 1988, GENE, V66, P279, DOI 10.1016/0378-1119(88)90364-2; Nicholson KG, 1998, TXB INFLUENZA, P219; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; REMAUT E, 1983, NUCLEIC ACIDS RES, V11, P4677, DOI 10.1093/nar/11.14.4677; SCHODEL F, 1992, J VIROL, V66, P106; SLEPUSHKIN VA, 1995, VACCINE, V13, P1399, DOI 10.1016/0264-410X(95)92777-Y; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TREANOR JJ, 1990, J VIROL, V64, P1375, DOI 10.1128/JVI.64.3.1375-1377.1990; Tsuji M, 1998, J VIROL, V72, P6907, DOI 10.1128/JVI.72.8.6907-6910.1998; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998; Ulrich R, 1998, ADV VIRUS RES, V50, P141, DOI 10.1016/S0065-3527(08)60808-8; *US DEP HHS, 1982, CONC PROC LAB BAS IN, pB7; VERHOEYEN M, 1980, NATURE, V286, P771, DOI 10.1038/286771a0; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; ZEBEDEE SL, 1988, J VIROL, V62, P2762, DOI 10.1128/JVI.62.8.2762-2772.1988; ZEBEDEE SL, 1989, NUCLEIC ACIDS RES, V17, P2870, DOI 10.1093/nar/17.7.2870; ZHOU XZ, 1995, P NATL ACAD SCI USA, V92, P3009, DOI 10.1073/pnas.92.7.3009	44	599	738	1	69	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1157	1163		10.1038/13484	http://dx.doi.org/10.1038/13484			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502819				2022-12-25	WOS:000082933200042
J	Chen, C; Kolodner, RD				Chen, C; Kolodner, RD			Gross chromosomal rearrangements in Saccharomyces cerevisiae replication and recombination defective mutants	NATURE GENETICS			English	Article							NIJMEGEN BREAKAGE SYNDROME; INDUCED DNA-REPLICATION; PROTEIN-A; REPAIR; YEAST; TRANSLOCATIONS; GENE; METABOLISM; DELETIONS; LEUKEMIA	Cancer progression is often associated with the accumulation of gross chromosomal rearrangements (GCRs), such as translocations, deletion of a chromosome arm, interstitial deletions or inversions(1-3). In many instances, GCRs inactivate tumour-suppressor genes or generate novel fusion proteins that initiate carcinogenesis(3,4). The mechanism underlying GCR formation appears to involve interactions between DNA sequences of little or no homology(5-8). We previously demonstrated that mutations in the gene encoding the largest subunit of the Saccharomyces cerevisiae single-stranded DNA binding protein (RFA1) increase microhomology-medialed GCR formations. To further our understanding of GCR formation, we have developed a novel mutator assay in 5. cerevisiae that allows specific detection of such events. In this assay, the rate of GCR formation was increased 600-5,000-fold by mutations in RFA1, RAD27, MRE11, XRS2 and RAD50, but was minimally affected by mutations in RAD51, RAD54, RAD57, YKU70, YKU80, LIG4 and POL30. Genetic analysis of these mutants suggested that at least three distinct pathways can suppress GCRs: two that suppress microhomology-mediated GCRs (RFA1 and RAD27) and one that suppresses non-homology-mediated GCRs (RAD50/MRE11/XRS2).	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA.		Chen, Clark C/C-8714-2013	Chen, Clark C/0000-0001-6258-9277	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026017, R01GM050006, R01GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50006, GM26017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amin NS, 1996, GENETICS, V144, P479; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Bosco G, 1998, GENETICS, V150, P1037; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen SH, 1998, J POLYM RES-TAIWAN, V5, P9, DOI 10.1007/s10965-006-0034-y; CHRZANOWSKA KH, 1995, AM J MED GENET, V57, P462, DOI 10.1002/ajmg.1320570321; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GILMAN JG, 1987, BRIT J HAEMATOL, V67, P369, DOI 10.1111/j.1365-2141.1987.tb02360.x; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LUZI P, 1995, HUM MOL GENET, V4, P2335, DOI 10.1093/hmg/4.12.2335; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Maniar HS, 1997, GENETICS, V145, P891; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Merrill BJ, 1998, GENETICS, V148, P611; MITELMAN F, 1991, CATALOG CHROMOSOME A; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; NINIO J, 1991, GENETICS, V129, P957; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHIKANO T, 1993, CANCER GENET CYTOGEN, V71, P22, DOI 10.1016/0165-4608(93)90198-U; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsukamoto Y, 1997, MOL GEN GENET, V255, P543, DOI 10.1007/s004380050527; Tsukamoto Y, 1996, GENETICS, V142, P383; Umezu K, 1998, GENETICS, V148, P989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2	29	330	331	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					81	85		10.1038/12687	http://dx.doi.org/10.1038/12687			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471504				2022-12-25	WOS:000082337300021
J	Rottner, K; Behrendt, B; Small, JV; Wehland, J				Rottner, K; Behrendt, B; Small, JV; Wehland, J			VASP dynamics during lamellipodia protrusion	NATURE CELL BIOLOGY			English	Article							MAMMALIAN-CELLS; ACTIN; FILAMENTS		Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria; Gesell Biotechnol Forsch mbH, Abt Zellbiol, D-38124 Braunschweig, Germany	Austrian Academy of Sciences; Gesellschaft fur Biotechnologische Forschung mbH	Small, JV (corresponding author), Austrian Acad Sci, Inst Mol Biol, Billrothstr 11, A-5020 Salzburg, Austria.	jvsmall@imb.oeaw.ac.at	Rottner, Klemens/AAE-5030-2020	Rottner, Klemens/0000-0003-4244-4198				Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Ballestrem C, 1998, J CELL SCI, V111, P1649; BUCKLEY IK, 1975, J MICROSC-OXFORD, V104, P107, DOI 10.1111/j.1365-2818.1975.tb04010.x; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SMITH GA, 1999, J CELL BIOL, V144, P1245; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009	17	265	267	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					321	322		10.1038/13040	http://dx.doi.org/10.1038/13040			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559946				2022-12-25	WOS:000083169600022
J	Schott, JJ; Alshinawi, C; Kyndt, F; Probst, V; Hoorntje, TM; Hulsbeek, M; Wilde, AAM; Escande, D; Mannens, MMAM; Le Marec, H				Schott, JJ; Alshinawi, C; Kyndt, F; Probst, V; Hoorntje, TM; Hulsbeek, M; Wilde, AAM; Escande, D; Mannens, MMAM; Le Marec, H			Cardiac conduction defects associate with mutations in SCN5A	NATURE GENETICS			English	Letter							DILATED CARDIOMYOPATHY; DISEASE; GENE; MAPS; EXCITABILITY; TISSUE; SODIUM; BLOCK		Hop Hotel Dieu, Lab Physiolpathol & Pharmacol Cellulaires & Mol, INSERM, Nantes, France; Hop G&R Laennec, Nantes, France; Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Utrecht Hosp, Dept Pediat Cardiol, Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center	Le Marec, H (corresponding author), Hop Hotel Dieu, Lab Physiolpathol & Pharmacol Cellulaires & Mol, INSERM, CJF96-01, Nantes, France.		Le Marec, Hervé/D-2718-2015; KYNDT, Florence/D-6370-2015; probst, vincent/D-4996-2015; Schott, jean-Jacques/F-8842-2013	Le Marec, Hervé/0000-0002-8288-8693; KYNDT, Florence/0000-0001-6651-1696; probst, vincent/0000-0002-5492-8619; Schott, jean-Jacques/0000-0002-9578-9475; Bezzina, Connie/0000-0002-0633-3514				Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; BRINK PA, 1995, CIRCULATION, V91, P1633, DOI 10.1161/01.CIR.91.6.1633; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; DEMEEUS A, 1995, CIRC RES, V77, P735, DOI 10.1161/01.RES.77.4.735; KASS S, 1994, NAT GENET, V7, P546, DOI 10.1038/ng0894-546; KRAWCZAK M, 1992, HUM GENET, V90, P41; KULBERTUS HE, 1975, CARDIAC ARRHYTHMIAS, P16; LENEGRE J, 1964, PROG CARDIOVASC DIS, V6, P317; LEV M, 1970, CIRCULATION, V42, P409, DOI 10.1161/01.CIR.42.3.409; Messina DN, 1997, AM J HUM GENET, V61, P909, DOI 10.1086/514896; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Rohr S, 1998, CIRC RES, V83, P781, DOI 10.1161/01.RES.83.8.781; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Shaw RM, 1997, CIRC RES, V81, P727; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236	16	440	468	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					20	21		10.1038/12618	http://dx.doi.org/10.1038/12618			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471492				2022-12-25	WOS:000082337300010
J	Subramanian, A; Ranganathan, P; Diamond, SL				Subramanian, A; Ranganathan, P; Diamond, SL			Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells	NATURE BIOTECHNOLOGY			English	Article						gene transfer; endothelium; lipofection; nuclear import	ADENOVIRUS-DEPENDENT RELEASE; PROTEIN IMPORT PATHWAY; GENE-TRANSFER; ENDOTHELIAL-CELLS; CATIONIC LIPOSOMES; PLASMID DNA; ARTERIAL-WALL; ACIDIC PH; DELIVERY; EXPRESSION	Lipofection of nondividing cells is inefficient because much of the transfected DNA is retained in endosomes, and that which escapes to the cytoplasm enters the nucleus at low rates. To improve the final rate-limiting step of nuclear import, we conjugated a nonclassical nuclear localization signal (NLS) containing the M9 sequence of heterogeneous nuclear ribonucleoprotein (hnRNP) A1, to a cationic peptide scaffold derived from a scrambled sequence of the SV40 T-antigen consensus NLS (ScT). The ScT was added to improve DNA binding of the M9 sequence. Lipofection of confluent endothelium with plasmid complexed with the M9-ScT conjugate resulted in 83% transfection and a 63-fold increase in marker gene expression. The M9-ScT conjugate localized fluorescent plasmid into the nucleus of permeabilized cells, and addition of the nuclear pore blocker wheat germ agglutinin prevented nuclear import. This method of gene transfer may lead to viral- and lipid-free transfection of nondividing cells.	Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diamond, SL (corresponding author), Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, Philadelphia, PA 19104 USA.				PHS HHS [R21-14014] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X; Edgell CJS, 1998, BIOTECHNIQUES, V25, P264, DOI 10.2144/98252gt01; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FLUGELMAN MY, 1992, CIRCULATION, V85, P1110, DOI 10.1161/01.CIR.85.3.1110; Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; GO YM, 1998, AM J PHYSIOL, V274, pH1; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; HONG Z, 1995, CHIN MED J, V108, P332; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LEMERCHAND P, 1993, CIRC RES, V72, P1132; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; SCHACHTNER SK, 1995, CIRC RES, V76, P701, DOI 10.1161/01.RES.76.5.701; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; SETH P, 1984, J BIOL CHEM, V259, P4350; SETH P, 1994, J VIROL, V68, P1204, DOI 10.1128/JVI.68.2.1204-1206.1994; SETH P, 1994, J VIROL, V51, P60650; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; Subramanian A, 1997, TISSUE ENG, V3, P39, DOI 10.1089/ten.1997.3.39; SUBRAMANIAN A, 1997, ANN BIOMED ENG, V25, P428; SUNG WL, 1993, CIRC RES, V73, P797; Tseng WC, 1997, J BIOL CHEM, V272, P25641, DOI 10.1074/jbc.272.41.25641; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91	36	201	215	1	24	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					873	877		10.1038/12860	http://dx.doi.org/10.1038/12860			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471928				2022-12-25	WOS:000082365800028
J	Wade, PA; Gegonne, A; Jones, PL; Ballestar, E; Aubry, F; Wolffe, AP				Wade, PA; Gegonne, A; Jones, PL; Ballestar, E; Aubry, F; Wolffe, AP			Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation	NATURE GENETICS			English	Article							PROTEIN; GENE; IDENTIFICATION; METASTASIS; FAMILY; MTA1	Methylation of DNA at the dinucleotide CpG is essential for mammalian development and is correlated with stable transcriptional silencing(1-3). This transcriptional silencing has recently been linked at a molecular level to histone deacetylation MeCP2 (refs 4,5). We previously purified a histone deacetylase through the demonstration of a physical association between histone deacetylases and the methyl CpG-binding protein complex from Xenopus laevis egg extracts that consists of six subunits, including an Rpd3-like deacetylase, the RbA p48/p46 histone-binding protein and the nucleosome-stimulated ATPase Mi-2 (ref. 6). Similar species were subsequently isolated from human cell lines(7-9), implying functional conservation across evolution. This complex represents the most abundant form of deacetylase in amphibian eggs and cultured mammalian cells(6-9). Here we identify the remaining three subunits of this across enzyme complex, One of them binds specifically to methylated DNA in vitro and molecular cloning reveals a similarity to a known methyl CpG-binding protein. Our data substantiate the mechanistic link between DNA methylation, histone deacetylation and transcriptional silencing.	NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; INSERM, U435, F-35042 Rennes, France	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Institut National de la Sante et de la Recherche Medicale (Inserm)	Wade, PA (corresponding author), NICHHD, Mol Embryol Lab, NIH, Bldg 18T Room 106, Bethesda, MD 20892 USA.	awlme@helix.nih.gov	Aubry, Florence/I-2746-2015; Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X; Ballestar, Esteban/0000-0002-1400-2440				Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 1995, J CELL SCI, P37; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Martienssen R, 1999, NAT GENET, V22, P6, DOI 10.1038/8708; Moore DD, 1995, GLOB MOB SURV; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Siegfried Z, 1997, CURR BIOL, V7, pR305, DOI 10.1016/S0960-9822(06)00144-8; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; Solari F, 1999, DEVELOPMENT, V126, P2483; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; VAUTIER D, 1994, MOL REPROD DEV, V38, P119, DOI 10.1002/mrd.1080380202; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	669	688	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					62	66		10.1038/12664	http://dx.doi.org/10.1038/12664			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471500				2022-12-25	WOS:000082337300017
J	Nakashima, M; Sonoda, K; Watanabe, T				Nakashima, M; Sonoda, K; Watanabe, T			Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1	NATURE MEDICINE			English	Article							HUMAN UTERINE; EXPRESSION; MELANOMA; CANCER; LYMPHOCYTES; MECHANISMS; ESCAPE	Tumor-associated antigens that can be recognized by the immune system include the MAGE-family, p53, MUC-1, HER2/neu and p21ras (refs. 1-6). Despite their expression of these distinct antigens, tumor elimination by the immune system is often inefficient. Postulated mechanisms include insufficient expression of co-stimulatory or adhesion molecules by tumor cells, or defective processing and presentation of antigens on their cell surfaces(7-10) Tumor cells may also evade immune attack by expressing CD95 (APO-1/Fas) ligand or other molecules that induce apoptosis in activated T cells(11-13). Here we describe RCAS1 (receptor-binding cancer antigen expressed on SiSo cells), a membrane molecule expressed on human cancer cells. RCAS1 acts as a ligand for a putative receptor present on various human cell lines and normal peripheral lymphocytes such as T, B and NK cells. The receptor expression was enhanced by activation of the lymphocytes. RCAS1 inhibited the in vitro growth of receptor-expressing cells and induced apoptotic cell death. Given these results, tumor cells may evade immune surveillance by expression of RCAS1, which would suppress clonal expansion and induce apoptosis in RCAS1 receptor-positive immune cells.	Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Obstet & Gynecol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Watanabe, T (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BECKER JC, 1993, INT IMMUNOL, V5, P1501, DOI 10.1093/intimm/5.12.1501; CLAUDE DG, 1996, NAT MED, V2, P1367; Edward Michael, 1995, Current Opinion in Oncology, V7, P185, DOI 10.1097/00001622-199503000-00015; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; GOSSEN M, 1995, SCIENCE, V268, P17636; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAKU T, IN PRESS CLIN CANC R; MELIEF CJM, 1991, RES IMMUNOL, V142, P425, DOI 10.1016/0923-2494(91)90042-H; Munker R, 1997, HEMATOL CELL THER, V39, P75, DOI 10.1007/s00282-997-0075-7; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peiper M, 1997, EUR J IMMUNOL, V27, P1115, DOI 10.1002/eji.1830270511; Runger T M, 1994, Curr Opin Oncol, V6, P188; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; SONODA K, 1995, INT J ONCOL, V6, P1099; Sonoda K, 1996, CANCER, V77, P1501, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3; Sonoda K, 1998, CLIN CANCER RES, V4, P1517; SUSANNE S, 1996, NAT MED, V2, P1361; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; WHITESIDE TL, 1995, CURR OPIN IMMUNOL, V7, P704, DOI 10.1016/0952-7915(95)80080-8; [No title captured]	25	218	240	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					938	942		10.1038/11383	http://dx.doi.org/10.1038/11383			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426319				2022-12-25	WOS:000081684000039
J	Wang, JL; Liu, R; Liu, LS; Chowdhury, R; Barzilai, N; Tan, JZ; Rossetti, L				Wang, JL; Liu, R; Liu, LS; Chowdhury, R; Barzilai, N; Tan, JZ; Rossetti, L			The effect of leptin on Lep expression is tissue-specific and nutritionally regulated	NATURE MEDICINE			English	Article							OBESE GENE-EXPRESSION; BODY-WEIGHT; FOOD-INTAKE; OB/OB MICE; RECEPTOR; IDENTIFICATION; HUMANS; INSULIN; MOUSE; HYPOTHALAMUS	Leptin, the product of the Obese (Lep) gene, orchestrates behavioral and metabolic responses to nutrient intake. Here, we demonstrate tissue-specific autoregulation of Lep. Moderate increases in circulating leptin considerably decreased Lep expression in adipose tissue and induced lep expression in skeletal muscle, a tissue that normally does not express this gene. Changes in nutrient availability resulted in rapid alterations in Lep autoregulation. These findings demonstrate negative feedback regulation of Lep in fat, and indicate that leptin secretion can function as a vehicle of 'cross-talk' between adipose tissue and skeletal muscle, leading to tissue-specific modulation of the 'leptin signal'.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045024, R01DK048321, R37DK048321, R01DK045024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45024, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; CONSIDINE RV, 1996, NEW ENGL J MED, V334, P324; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jacob RJ, 1997, DIABETES, V46, P150, DOI 10.2337/diabetes.46.1.150; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kim YB, 1998, DIABETES, V47, pA317; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; ZHANG Y, 1994, NATURE, V372, P42; Zhang YY, 1997, BIOCHEM BIOPH RES CO, V240, P492, DOI 10.1006/bbrc.1997.7622	40	64	66	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					895	899		10.1038/11335	http://dx.doi.org/10.1038/11335			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426312				2022-12-25	WOS:000081684000032
J	Lewis, J; Oyler, GA; Ueno, K; Fannjiang, YR; Chau, BN; Vornov, J; Korsmeyer, SJ; Zou, SF; Hardwick, JM				Lewis, J; Oyler, GA; Ueno, K; Fannjiang, YR; Chau, BN; Vornov, J; Korsmeyer, SJ; Zou, SF; Hardwick, JM			Inhibition of virus-induced neuronal apoptosis by Bax	NATURE MEDICINE			English	Article							DRUG-INDUCED APOPTOSIS; CELL-DEATH; BCL-2; CONVERSION; MODULATION; BCL-X(L); PROTEIN; MICE	The Bax protein is widely known as a pro-apoptotic Bcl-2 family member that when overexpressed can trigger apoptosis in multiple cell types and is important for the developmental cell death of neurons(1,2). However, Bax was found here to be a potent inhibitor of neuronal cell death in mice infected with Sindbis virus. Newborn mice, which are highly susceptible to a fatal infection with neurotropic Sindbis virus, were significantly protected from neuronal apoptosis and fatal disease when infected with a recombinant Sindbis virus encoding Bax. Deletion of the N terminus of Bax, which mimics cleaved Bax, converted Bax into a pro-apoptotic factor in vivo. As mice mature during the first week after birth, they acquire resistance to a fatal Sindbis virus infection(3,4). However, Bax-deficient mice remained very sensitive to fatal disease compared with their control littermates, indicating that endogenous Bax functions as a survival factor and contributes to age-dependent resistance to Sindbis virus-induced mortality. The protective effects of Bax were reproduced in cultured hippocampal neurons but not in cultured dorsal root ganglia neurons. These findings indicate that cell-specific factors determine the anti-apoptotic versus pro-apoptotic function of Bax.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Kagoshima 8908520, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol & Med, Boston, MA 02115 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Kagoshima University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Hardwick, JM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, E5132,SPH,615 N Wolfe St, Baltimore, MD 21205 USA.		Vornov, James/F-6794-2013	Vornov, James/0000-0003-1965-5456	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034175] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34175] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Hardwick JM, 1999, CELL DEATH AND DISEASES OF THE NERVOUS SYSTEM, P295; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIRSCH DG, IN PRESS J BIOL CHEM; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1996, J VIROL, V70, P1828, DOI 10.1128/JVI.70.3.1828-1835.1996; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Middleton G, 1996, DEVELOPMENT, V122, P695; Oh JH, 1997, NEUROREPORT, V8, P1851, DOI 10.1097/00001756-199705260-00012; Thomas A, 1996, ONCOGENE, V12, P1055; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; White FA, 1998, J NEUROSCI, V18, P1428; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	25	89	93	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					832	835		10.1038/10556	http://dx.doi.org/10.1038/10556			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395331				2022-12-25	WOS:000081926600041
J	Hacia, JG; Fan, JB; Ryder, O; Jin, L; Edgemon, K; Ghandour, G; Mayer, RA; Sun, B; Hsie, L; Robbins, CM; Brody, LC; Wang, D; Lander, ES; Lipshutz, R; Fodor, SPA; Collins, FS				Hacia, JG; Fan, JB; Ryder, O; Jin, L; Edgemon, K; Ghandour, G; Mayer, RA; Sun, B; Hsie, L; Robbins, CM; Brody, LC; Wang, D; Lander, ES; Lipshutz, R; Fodor, SPA; Collins, FS			Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays	NATURE GENETICS			English	Article							HUMAN-EVOLUTION; GENE; CHIMPANZEE; DIVERSITY; PRIMATES; SEQUENCES; LINKAGE; NUCLEAR; REGION; GENOME	Here we report the application of high-density oligonucleotide array (DNA chip)-based analysis to determine the distant history of single nucleotide polymorphisms (SNPs) in current human populations. We analysed orthologues for 397 human SNP sites (identified in CEPH:pedigrees from Amish, Venezuelan and Utah populations(1)) from 23 common chimpanzee, 19 pygmy chimpanzee and 11 gorilla genomic DNA samples. From this data we determined 214 proposed ancestral alleles (the sequence found in the last common ancestor of humans and chimpanzees). In a diverse human population set, we found that SNP alleles with higher frequencies were more likely to be ancestral than less frequently occurring alleles, There were, however, exceptions. We also found three shared human/pygmy chimpanzee polymorphisms, all involving CpG dinucleotides, and two shared human/gorilla polymorphisms, one involving a CpG dinucleotide. We demonstrate that mi;microarray-based assays allow rapid comparative sequence analysis of intra- and interspecies genetic variation.	Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Affymetrix, Santa Clara, CA 95051 USA; Zool Soc San Diego, Ctr Reprod Endangered Species, San Diego, CA 92112 USA; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China; Univ Texas, Inst Human Genet, Houston, TX 77225 USA; Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Affymetrix; Zoological Society of San Diego; Fudan University; University of Texas System; Massachusetts Institute of Technology (MIT); Whitehead Institute	Collins, FS (corresponding author), Natl Human Genome Res Inst, Bldg 49-3A14, Bethesda, MD 20892 USA.		Jin, Li/C-1468-2009; Jin, Li/M-5063-2019	Jin, Li/0000-0002-4546-2415; Sun, Bryan/0000-0002-0740-0125	NHGRI NIH HHS [5POLHGO1323-03] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000120, P01HG001323, Z01HG000120] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bergstrom TF, 1998, NAT GENET, V18, P237, DOI 10.1038/ng0398-237; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Clark AG, 1997, P NATL ACAD SCI USA, V94, P7730, DOI 10.1073/pnas.94.15.7730; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Cooper G, 1998, HUM MOL GENET, V7, P1425, DOI 10.1093/hmg/7.9.1425; CrouauRoy B, 1996, HUM MOL GENET, V5, P1131, DOI 10.1093/hmg/5.8.1131; DEEB SS, 1994, P NATL ACAD SCI USA, V91, P7262, DOI 10.1073/pnas.91.15.7262; Garner KJ, 1996, MOL PHYLOGENET EVOL, V6, P39, DOI 10.1006/mpev.1996.0056; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Jaeger EEM, 1998, IMMUNOGENETICS, V47, P115; Kimura MA, 1985, NEUTRAL THEORY MOL E; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; MARTINKO JM, 1993, IMMUNOGENETICS, V37, P274; MORIN PA, 1994, SCIENCE, V265, P1193, DOI 10.1126/science.7915048; MOUNTAIN JL, 1994, P NATL ACAD SCI USA, V91, P6515, DOI 10.1073/pnas.91.14.6515; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Ruvolo M, 1996, MOL PHYLOGENET EVOL, V5, P202, DOI 10.1006/mpev.1996.0014; SAVATIER P, 1985, J MOL BIOL, V182, P21, DOI 10.1016/0022-2836(85)90024-5; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WATKINS DI, 1995, CRIT REV IMMUNOL, V15, P1; WATTERSON GA, 1977, THEOR POPUL BIOL, V11, P141, DOI 10.1016/0040-5809(77)90023-5; Wise CA, 1997, MOL BIOL EVOL, V14, P707, DOI 10.1093/oxfordjournals.molbev.a025810; Yang AS, 1996, J MOL BIOL, V258, P240, DOI 10.1006/jmbi.1996.0246	28	297	371	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					164	167		10.1038/9674	http://dx.doi.org/10.1038/9674			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369258				2022-12-25	WOS:000080680900021
J	Borisjuk, NV; Borisjuk, LG; Logendra, S; Petersen, F; Gleba, Y; Raskin, I				Borisjuk, NV; Borisjuk, LG; Logendra, S; Petersen, F; Gleba, Y; Raskin, I			Production of recombinant proteins in plant root exudates	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; transgenic plants; recombinant proteins; protein secretion; hydroponic	GREEN-FLUORESCENT PROTEIN; CELLS; EXPRESSION; SECRETION; EXTRACTION	The large-scale production of recombinant proteins in plants is limited by relatively low yields and difficulties in extraction and purification. These problems were addressed by engineering tobacco plants to continuously secrete recombinant proteins from their roots into a simple hydroponic medium. Three heterologous proteins of diverse origins (green fluorescent protein of jellyfish, human placental alkaline phosphatase [SEAP], and bacterial xylanase) were produced using the root secretion method (rhizo-secretion). Protein secretion was dependent on the presence of the endoplasmic reticulum signal peptide fused to the recombinant protein sequence. All three secreted proteins retained their biological activity and, as shown for SEAP, accumulated in much higher amounts in the medium than in the root tissue.	Rutgers State Univ, Cook Coll, Biotech Ctr, New Brunswick, NJ 08901 USA; Rutgers State Univ, Cook Coll, Dept Biochem & Microbiol, New Brunswick, NJ 08903 USA; Inst Cell Biol & Genet Engn, UA-252650 Kiev, Ukraine	Rutgers State University New Brunswick; Rutgers State University New Brunswick; National Academy of Sciences Ukraine; Institute of Cell Biology & Genetic Engineering of the National Academy of Sciences of Ukraine	Raskin, I (corresponding author), Rutgers State Univ, Cook Coll, Biotech Ctr, Foran Hall, New Brunswick, NJ 08901 USA.	raskin@aesop.rutgers.edu	Borisjuk, Nikolai/AAI-3809-2020	Borisjuk, Nikolai/0000-0001-5250-9771; Borisjuk, Ljudmilla/0000-0001-6910-0841; Gleba, Yuri/0000-0003-4675-7474				BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BIELY P, 1988, METHOD ENZYMOL, V160, P536; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Conrad U, 1998, PLANT MOL BIOL, V38, P101, DOI 10.1023/A:1006029617949; Davis SJ, 1998, PLANT MOL BIOL, V36, P521, DOI 10.1023/A:1005991617182; DENECKE J, 1990, PLANT CELL, V2, P51, DOI 10.1105/tpc.2.1.51; FIREK S, 1993, PLANT MOL BIOL, V23, P861, DOI 10.1007/BF00021540; Hawes M., 1992, ADV PLANT PATHOL, V8, P119; HERBERS K, 1995, BIO-TECHNOL, V13, P63, DOI 10.1038/nbt0195-63; Hood EE, 1997, MOL BREEDING, V3, P291, DOI 10.1023/A:1009676322162; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Marschner H, 1986, MINERAL NUTR HIGHER; Ni M, 1996, PLANT MOL BIOL, V30, P77, DOI 10.1007/BF00017804; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Reichel C, 1996, P NATL ACAD SCI USA, V93, P5888, DOI 10.1073/pnas.93.12.5888; REISMAN HB, 1993, CRIT REV BIOTECHNOL, V13, P195, DOI 10.1080/0738855031874353; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEPHERD T, 1993, ANN BOT-LONDON, V72, P155, DOI 10.1006/anbo.1993.1094; SMITH RA, 1985, SCIENCE, V229, P1219, DOI 10.1126/science.3939723; TERRY ME, 1980, PLANT PHYSIOL, V66, P321, DOI 10.1104/pp.66.2.321; URSIN VM, 1993, PLANT PHYSIOL, V102, P1033, DOI 10.1104/pp.102.3.1033; Wongsamuth R, 1997, BIOTECHNOL BIOENG, V54, P401, DOI 10.1002/(SICI)1097-0290(19970605)54:5&lt;401::AID-BIT1&gt;3.0.CO;2-I	24	146	184	2	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					466	469		10.1038/8643	http://dx.doi.org/10.1038/8643			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331806				2022-12-25	WOS:000080074500031
J	Pastey, MK; Gower, TL; Spearman, PW; Crowe, JE; Graham, BS				Pastey, MK; Gower, TL; Spearman, PW; Crowe, JE; Graham, BS			A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3	NATURE MEDICINE			English	Article							CELL-FUSION; POTENT INHIBITORS; GLYCOPROTEINS; INFECTION; PROTEIN; RSV; REPLICATION; ATTACHMENT; REGIONS; DOMAIN	The fusion glycoproteins of human respiratory syncytial virus (RSV) and human parainfluenza virus type-3 (PIV-3) mediate virus entry and syncytium formation. Interaction between the fusion protein of RSV and RhoA, a small GTPase, facilitates virus-induced syncytium formation. We show here a RhoA-derived peptide inhibits RSV and syncytium formation induced by RSV and PIV-3, both in vitro by inhibition of cell-to-cell fusion and in vivo by reduction of peak titer by 2 log(10) in RSV-infected mice. These findings indicate that the interaction between these two paramyxovirus fusion proteins and RhoA is an important target for new antiviral strategies.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Graham, BS (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 221 Kirkland Hall, Nashville, TN 37232 USA.		Graham, Barney S./AAC-5898-2019; Crowe, James/B-5549-2009	Graham, Barney S./0000-0001-8112-0853; Crowe, James/0000-0002-0049-1079	NCI NIH HHS [P30 CA068485, CA68485] Funding Source: Medline; NIAID NIH HHS [R01-AI-33933, R01 AI033933] Funding Source: Medline; NIDDK NIH HHS [DK20593, P30 DK020593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033933, Z01AI005030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROETI B, 1988, BIOCHEMISTRY-US, V27, P5654, DOI 10.1021/bi00415a039; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; COLLINS PL, 1991, J GEN VIROL, V72, P3095, DOI 10.1099/0022-1317-72-12-3095; Collins PL, 1996, FIELDS VIROLOGY, P1313; DAYA M, 1988, VIROLOGY, V163, P276, DOI 10.1016/0042-6822(88)90267-X; Dutch RE, 1998, J VIROL, V72, P7745, DOI 10.1128/JVI.72.10.7745-7753.1998; Feldman SA, 1999, J VIROL, V73, P6610, DOI 10.1128/JVI.73.8.6610-6617.1999; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; HEMINWAY BR, 1994, VIROLOGY, V200, P801, DOI 10.1006/viro.1994.1245; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Karron RA, 1997, P NATL ACAD SCI USA, V94, P13961, DOI 10.1073/pnas.94.25.13961; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156; Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186; LEVINE S, 1987, J GEN VIROL, V68, P2521, DOI 10.1099/0022-1317-68-9-2521; MURPHY BR, 1989, VACCINE, V7, P533, DOI 10.1016/0264-410X(89)90278-8; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Pastey MK, 1999, J VIROL, V73, P7262, DOI 10.1128/JVI.73.9.7262-7270.1999; Pastey MK, 1997, J GEN VIROL, V78, P1885, DOI 10.1099/0022-1317-78-8-1885; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; RUSSELL R, 1994, VIROLOGY, V199, P160, DOI 10.1006/viro.1994.1108; SCHEID A, 1972, VIROLOGY, V50, P640, DOI 10.1016/0042-6822(72)90418-7; SYLWESTER A, 1993, J CELL SCI, V106, P941; WELLIVER R, 1982, J PEDIATR-US, V101, P180, DOI 10.1016/S0022-3476(82)80113-3; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Yang CL, 1997, J VIROL, V71, P8490, DOI 10.1128/JVI.71.11.8490-8496.1997; Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459	27	64	70	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					35	40		10.1038/71503	http://dx.doi.org/10.1038/71503			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613821	Green Published			2022-12-25	WOS:000084583300032
J	Tournebize, R; Popov, A; Kinoshita, K; Ashford, AJ; Rybina, S; Pozniakovsky, A; Mayer, TU; Walczak, CE; Karsenti, E; Hyman, AA				Tournebize, R; Popov, A; Kinoshita, K; Ashford, AJ; Rybina, S; Pozniakovsky, A; Mayer, TU; Walczak, CE; Karsenti, E; Hyman, AA			Control of microtubule dynamics by the antagonistic activities of XMAP215 and XKCM1 in Xenopus egg extracts	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID SEPARATION; SPINDLE POLE BODY; MITOTIC SPINDLE; PLUS-END; PROTEIN; INSTABILITY; COMPONENT; P93(DIS1); CLONING; DISEASE	Microtubules are dynamic polymers that move stochastically between periods of growth and shrinkage, a property known as dynamic instability, Here, to investigate the mechanisms regulating microtubule dynamics in Xenopus egg extracts, we have cloned the complementary DNA encoding the microtubule-associated protein XMAP215 and investigated the function of the XMAP215 protein. Immunodepletion of XMAP215 indicated that it is a major microtubule-stabilizing factor in Xenopus egg extracts. During interphase, XMAP215 stabilizes microtubules primarily by opposing the activity of the destabilizing factor XKCM1, a member of the kinesin superfamily. These results indicate that microtubule dynamics in Xenopus egg extracts are regulated by a balance between a stabilizing factor, XMAP215, and a destabilizing factor, XKCM1.	European Mol Biol Lab, Cell Biol Program, D-69117 Heidelberg, Germany; Indiana Univ, Med Sci Program, Bloomington, IN 47405 USA	European Molecular Biology Laboratory (EMBL); Indiana University System; Indiana University Bloomington	Tournebize, R (corresponding author), European Mol Biol Lab, Cell Biol Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.	hyman@embl-heidelberg.de	Hyman, Anthony A/B-3917-2017; Tournebize, Regis/K-7847-2018; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Tournebize, Regis/0000-0003-3718-3130; Kinoshita, Kazuhisa/0000-0002-0882-4296; Mayer, Thomas/0000-0001-6954-2287	NIGMS NIH HHS [R01 GM059618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA H, 1990, J BIOL CHEM, V265, P13849; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Andersen SSL, 1997, J CELL BIOL, V139, P975, DOI 10.1083/jcb.139.4.975; ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; CHAPIN SJ, 1991, J CELL SCI, V98, P27; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Diamantopoulos GS, 1999, J CELL BIOL, V144, P99, DOI 10.1083/jcb.144.1.99; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; Harlow E., 1988, ANTIBODIES LAB MANUA; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Matthews LR, 1998, J CELL BIOL, V141, P1159, DOI 10.1083/jcb.141.5.1159; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nakaseko Y, 1996, GENES CELLS, V1, P633, DOI 10.1046/j.1365-2443.1996.00253.x; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Severin FF, 1997, NATURE, V388, P888, DOI 10.1038/42270; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Vasquez RJ, 1999, CELL MOTIL CYTOSKEL, V43, P310, DOI 10.1002/(SICI)1097-0169(1999)43:4<310::AID-CM4>3.3.CO;2-A; Vaughan KT, 1999, J CELL SCI, V112, P1437; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; WEST RR, 1991, J BIOL CHEM, V266, P21886; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359	42	236	240	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					13	19		10.1038/71330	http://dx.doi.org/10.1038/71330			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620801	Green Submitted			2022-12-25	WOS:000084843600013
J	Brown, KL; Stewart, K; Ritchie, DL; Mabbott, NA; Williams, A; Fraser, H; Morrison, WI; Bruce, ME				Brown, KL; Stewart, K; Ritchie, DL; Mabbott, NA; Williams, A; Fraser, H; Morrison, WI; Bruce, ME			Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells	NATURE MEDICINE			English	Article							B-CELL; MOUSE SCRAPIE; CRUCIAL ROLE; MICE; PRP; PATHOGENESIS; PATHOLOGY; RESPONSES; SPLEENS; IMMUNE	The immune system is central in the pathogenesis of scrapie and other transmissible spongiform encephalopathies (TSEs) or 'prion' diseases(1). After infecting by peripheral (intraperitoneal or oral) routes, most TSE agents replicate in spleen and lymph nodes before neuroinvasion(2). Characterization of the cells supporting replication in these tissues is essential to understanding early pathogenesis and may indicate potential targets for therapy, for example, in 'new variant' Creutzfeldt-Jakob disease. The host 'prion' protein (PrP) is required for TSE agent replication(3,4) and accumulates in modified forms in infected tissues. Abnormal PrP is detected readily on follicular dendritic cells (FDCs) in lymphoid tissues of patients with 'new variant' Creutzfeldt-Jakob disease(5), sheep with natural scrapie(6) and mice experimentally infected with scrapie(7). The normal protein is present on FDCs in uninfected mice(7) and, at lower levels, on lymphocytes(8). Studies using severe combined immunodeficiency (SCID) mice, with and without bone marrow (BM) grafts, have indicated involvement of FDCs and/or lymphocytes in scrapie pathogenesis(9). To clarify the separate roles of FDCs and lymphocytes, we produced chimeric mice with a mismatch in PrP status between FDCs and other cells of the immune system, by grafting bone marrow from PrP-deficient knockout mice(4) into PrP-expressing mice and vice versa. Using these chimeric models, we obtained strong evidence that FDCs themselves produce PrP and that replication of a mouse-passaged scrapie strain in spleen depends on PrP-expressing FDCs rather than on lymphocytes or other bone marrow-derived cells.	Inst Anim Hlth, Neuropathogenesis Unit, Edinburgh EH9 3JF, Midlothian, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland; Inst Anim Hlth, Newbury RG20 7NN, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Edinburgh; University of Glasgow; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Bruce, ME (corresponding author), Inst Anim Hlth, Neuropathogenesis Unit, Ogston Bldg,W Mains Rd, Edinburgh EH9 3JF, Midlothian, Scotland.		Mabbott, Neil/AAF-8777-2020	Mabbott, Neil/0000-0001-7395-1796				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BRUCE ME, 1989, NEUROSCI LETT, V102, P1, DOI 10.1016/0304-3940(89)90298-X; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; FRASER H, 1987, VET MICROBIOL, V13, P211, DOI 10.1016/0378-1135(87)90084-8; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; KAPASI ZF, 1993, J IMMUNOL, V150, P2648; KIMBERLIN RH, 1979, J COMP PATHOL, V89, P551, DOI 10.1016/0021-9975(79)90046-X; Klein MA, 1998, NAT MED, V4, P1429, DOI 10.1038/4022; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOSCO MH, 1992, J IMMUNOL, V148, P2331; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; Mabbott NA, 1998, IMMUNOL TODAY, V19, P201, DOI 10.1016/S0167-5699(98)01253-5; Mabbott NA, 1997, IMMUNOLOGY, V92, P161, DOI 10.1046/j.1365-2567.1997.00331.x; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MCBRIDE PA, 1992, J PATHOL, V168, P413, DOI 10.1002/path.1711680412; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Raeber AJ, 1999, EMBO J, V18, P2702, DOI 10.1093/emboj/18.10.2702; RITCHIE DL, 1999, J CELL PATHOL, V4, P3; Tkachuk M, 1998, J EXP MED, V187, P469, DOI 10.1084/jem.187.4.469; vanKeulen LJM, 1996, J CLIN MICROBIOL, V34, P1228, DOI 10.1128/JCM.34.5.1228-1231.1996	22	301	307	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1308	1312		10.1038/15264	http://dx.doi.org/10.1038/15264			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545999				2022-12-25	WOS:000086550600043
J	Heaney, AP; Horwitz, GA; Wang, ZY; Singson, R; Melmed, S				Heaney, AP; Horwitz, GA; Wang, ZY; Singson, R; Melmed, S			Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis	NATURE MEDICINE			English	Article							CELLS	Pituitary tumors are commonly encountered, and result from clonal expansion of a single mutated cell(1). Hypothalamic hormones, local growth factors and circulating sex steroid hormones promote pituitary tumor growth and expansion into large invasive tumors(2). Estrogen acting directly through its receptor and by stimulation of fibroblast growth factor regulates prolactin synthesis and secretion(3-4). Fibroblast growth factor-2 (bFGF) modulates angiogenesis, tumor formation and progression in many tissues, including the anterior pituitary(5-8). A pituitary tumor-derived transforming gene (PTTG) has been isolated, which is tumorigenic in vivo, regulates bFGF secretion, and inhibits chromatid separation(9-11). The human PTTG family consists of at least three homologous genes, of which PTTG1 is located on chromosome 5q33(12) and is expressed at low levels in most normal human tissues but is highly expressed in malignant human cell lines and in pituitary tumors(13). We report here that pituitary pttg is regulated in vivo and in vitro by estrogen. Maximal induction of rat pituitary pttg mRNA in vivo occurred early in pituitary transformation (normal cell to hypertrophic/hyperplastic cell), coincident with bFGF and vascular endothelial growth factor induction and pituitary angiogenesis. We also demonstrate that pttg expression is induced by bFGF, and show concordant pttg and bFGF expression in experimental and human pituitary adenomas. As bFGF and estrogen both induce pttg, and pttg expression coincides with the early lactotrophic hyperplastic response, angiogenesis and prolactinoma development, we propose a previously unknown paracrine growth factor-mediated mechanism for pituitary tumor pathogenesis and potentially other estrogen-regulated tumors.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90048 USA.				NATIONAL CANCER INSTITUTE [R01CA075979] Funding Source: NIH RePORTER; NCI NIH HHS [CA75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIRD A, 1985, P NATL ACAD SCI USA, V82, P5545, DOI 10.1073/pnas.82.16.5545; Gothard LQ, 1996, MOL ENDOCRINOL, V10, P185, DOI 10.1210/me.10.2.185; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KOVACS K, 1978, HORM METAB RES, V10, P409, DOI 10.1055/s-0028-1093402; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Prezant TR, 1999, J CLIN ENDOCR METAB, V84, P1149, DOI 10.1210/jc.84.3.1149; SCHECHTER J, 1988, J CLIN ENDOCR METAB, V67, P713, DOI 10.1210/jcem-67-4-713; Scully KM, 1997, MOL ENDOCRINOL, V11, P674, DOI 10.1210/me.11.6.674; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Serri O, 1996, J CLIN ENDOCR METAB, V81, P3177, DOI 10.1210/jc.81.9.3177; Shimon I, 1997, J CLIN ENDOCR METAB, V82, P1675, DOI 10.1210/jc.82.6.1675; SHUPNIK MA, 1991, J BIOL CHEM, V266, P17084; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; STEFANEANU L, 1994, J CLIN ENDOCR METAB, V78, P83, DOI 10.1210/jc.78.1.83; WEINER RI, 1995, PROLACTIN BASIC CLIN, P641; WIKLUND J, 1981, ENDOCRINOLOGY, V109, P1700, DOI 10.1210/endo-109-5-1700; Wilson CB, 1997, J CLIN ENDOCR METAB, V82, P2381, DOI 10.1210/jc.82.8.2381; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZIMMERING MB, 1993, J CLIN ENDOCR METAB, V76, P1182; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	22	280	301	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1317	1321		10.1038/15275	http://dx.doi.org/10.1038/15275			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10546001				2022-12-25	WOS:000086550600045
J	Liu, PS; Li, WP; Machleidt, T; Anderson, RGW				Liu, PS; Li, WP; Machleidt, T; Anderson, RGW			Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells	NATURE CELL BIOLOGY			English	Article							TRANS-GOLGI-NETWORK; MEMBRANE-PROTEIN; BINDING-PROTEIN; PLASMA-MEMBRANE; IN-VITRO; CHOLESTEROL; VIP21-CAVEOLIN; COMPONENT; VESICLES; TRANSLOCATION	Caveolin-1 is a protein component (of relative molecular mass 22,000) of the striated coat that decorates the cytoplasmic surface of caveolae membranes. Previous biochemical and molecular tests have indicated that caveolin-1 is an integral membrane protein that is cc-translationally inserted into endoplasmic-reticulum membranes of fibroblast and epithelial cells such that its carboxy- and amino-terminal ends are in the cytoplasm. Here we identify caveolin-1 in the secretory pathway of exocrine cells. Secretion of caveolin-1 from pancreatic acinar cells and a transfected exocrine cell line, but not from Chinese hamster ovary cells, is stimulated by the secretagogues secretin, cholecystokinin and dexamethasone. The secreted caveolin-1 co-fractionates with apolipoproteins, indicating that it may be secreted in a complex with lipids.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.	anders06@utsw.swmed.edu	Liu, Pingsheng/B-7124-2012		NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM52016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Hailstones D, 1998, J LIPID RES, V39, P369; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; KONGSHAUG M, 1989, BRIT J CANCER, V59, P184, DOI 10.1038/bjc.1989.38; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; ROTH J, 1989, METHOD CELL BIOL, V31, P513; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525	34	101	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					369	375		10.1038/14067	http://dx.doi.org/10.1038/14067			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559965				2022-12-25	WOS:000083169800021
J	Persidis, A				Persidis, A			Autoimmune disease drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material									RheoGene, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), RheoGene, 706 Forest St, Charlottesville, VA 22903 USA.							Bastenie P A, 1975, Bull Mem Acad R Med Belg, V130, P517; Benvenga S, 1999, J ENDOCRINOL INVEST, V22, P535, DOI 10.1007/BF03343605; BERTRAM U, 1965, ACTA ALLERGOL, V20, P472, DOI 10.1111/j.1398-9995.1965.tb03082.x; DEALMEIDA M, 1991, HUM REPROD, V6, P405, DOI 10.1093/oxfordjournals.humrep.a137350; Eilat D, 1999, IMMUNOL TODAY, V20, P339, DOI 10.1016/S0167-5699(99)01457-7; Giovannoni G, 1999, J ROY COLL PHYS LOND, V33, P315; Komai K, 1999, J NEUROL SCI, V166, P126, DOI 10.1016/S0022-510X(99)00125-2; MICHALSKI JP, 1975, NEW ENGL J MED, V293, P1228, DOI 10.1056/NEJM197512112932404; MINCHINTON RM, 1982, LANCET, V2, P391; Nikezic-Ardolic M, 1999, LUPUS, V8, P375, DOI 10.1177/096120339900800509; Persidis A, 1999, NAT BIOTECHNOL, V17, P726, DOI 10.1038/10954; Piccirillo CA, 1999, HUM GENE THER, V10, P1915, DOI 10.1089/10430349950017275; Puxeddu A, 1965, Haematologica, V50, P1073; Sundermann A, 1965, Folia Haematol Int Mag Klin Morphol Blutforsch, V84, P387; WACHSMUTH ED, 1972, BMJ-BRIT MED J, V3, P623, DOI 10.1136/bmj.3.5827.623; Willenborg DO, 1996, J IMMUNOL, V157, P1973; Wong FS, 1999, NAT MED, V5, P1026, DOI 10.1038/12465	17	14	14	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1038	1039		10.1038/13748	http://dx.doi.org/10.1038/13748			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504714	Bronze			2022-12-25	WOS:000083015700035
J	Swingler, S; Mann, A; Jacque, JM; Brichacek, B; Sasseville, VG; Williams, K; Lackner, AA; Janoff, EN; Wang, R; Fisher, D; Stevenson, M				Swingler, S; Mann, A; Jacque, JM; Brichacek, B; Sasseville, VG; Williams, K; Lackner, AA; Janoff, EN; Wang, R; Fisher, D; Stevenson, M			HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE-DERIVED MACROPHAGES; INFLAMMATORY PROTEIN-1-BETA; CHEMOKINE RECEPTOR; NONDIVIDING CELLS; VIRAL REPLICATION; BETA-CHEMOKINES; DENDRITIC CELLS; VPR PROTEIN; T-CELLS	Infection of macrophage lineage cells is a feature of primate lentivirus replication, and several properties of primate lentiviruses seem to have evolved to promote the infection of macrophages. Here we demonstrate that the accessory gene product Nef induces the production of two CC-chemokines, macrophage inflammatory proteins 1 alpha and 1 beta, by HIV-1-infected macrophages. Adenovirus-mediated expression of Nef in primary macrophages was sufficient for chemokine induction. Supernatants from Nef-expressing macrophages induced both the chemotaxis and activation of resting T lymphocytes, permitting productive HIV-1 infection. These results indicate a role for Nef in lymphocyte recruitment and activation at sites of virus replication.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Vet Adm Med Ctr, Minneapolis, MN 55417 USA; Univ Massachusetts, Med Ctr, Dept Cardiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Massachusetts System; University of Massachusetts Worcester	Stevenson, M (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.		Jacque, Jean-Marc/B-6875-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039445, K99AI139445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030769, R01NS035732] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR011589] Funding Source: Medline; NHLBI NIH HHS [R01 HL057880] Funding Source: Medline; NIAID NIH HHS [R01 AI032890, R01 AI037475, R37 AI037475, R01 AI049152, AI39445] Funding Source: Medline; NIMH NIH HHS [R01 MH064411] Funding Source: Medline; NINDS NIH HHS [NS30769, R01 NS030769, NS35732] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Canque B, 1996, BLOOD, V87, P2011; CHOE H, 1996, CELL, V85, P1; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dairaghi DJ, 1998, BLOOD, V91, P2905, DOI 10.1182/blood.V91.8.2905.2905_2905_2913; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Esser R, 1996, BLOOD, V88, P3474, DOI 10.1182/blood.V88.9.3474.bloodjournal8893474; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GRUBER MF, 1995, J IMMUNOL, V154, P5528; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; HITT M, 1995, METH MOL G, V7, P13; Jansson M, 1996, P NATL ACAD SCI USA, V93, P15382, DOI 10.1073/pnas.93.26.15382; KALTER DC, 1991, J IMMUNOL, V146, P298; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sasseville VG, 1996, AM J PATHOL, V149, P1459; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Ullum H, 1998, J INFECT DIS, V177, P331, DOI 10.1086/514192; Van Kooten Cees, 1997, Frontiers in Bioscience (online), V2, pD1; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZACK JA, 1995, ADV EXP MED BIOL, V374, P27; ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zou WP, 1997, J VIROL, V71, P1227, DOI 10.1128/JVI.71.2.1227-1236.1997	52	303	307	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					997	1003		10.1038/12433	http://dx.doi.org/10.1038/12433			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470075	Green Accepted			2022-12-25	WOS:000082337200032
J	Wood, DW; Wu, W; Belfort, G; Derbyshire, V; Belfort, M				Wood, DW; Wu, W; Belfort, G; Derbyshire, V; Belfort, M			A genetic system yields self-cleaving inteins for bioseparations	NATURE BIOTECHNOLOGY			English	Article						mini-intein mutants; pH-sensitive cleavage; function of conserved residues	PROTEIN-SPLICING DOMAIN; ENDONUCLEASE; MODULATION; DEFINITION; MECHANISM; CLEAVAGE; SEQUENCE; SITE	A self-cleaving element for use in bioseparations has been derived from a naturally occurring, 43 kDa protein splicing element (intein) through a combination of protein engineering and random mutagenesis. A mini-intein (18 kDa) previously engineered for reduced size had compromised activity and was therefore subjected to random mutagenesis and genetic selection. In one selection a mini-intein was isolated with restored splicing activity, while in another, a mutant was isolated with enhanced, pH-sensitive C-terminal cleavage activity. The enhanced-cleavage mutant has utility in affinity fusion-based protein purification. These mutants also provide new insights into the structural and functional roles of some conserved residues in protein splicing.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; Rensselaer Polytech Inst, Isermann Dept Chem Engn, Troy, NY 12180 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Rensselaer Polytechnic Institute	Belfort, M (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.		Wood, David W/B-2992-2012	Belfort, Marlene/0000-0002-1592-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039422, R37GM039422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39422, GM44844] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Derbyshire V, 1997, J MOL BIOL, V265, P494, DOI 10.1006/jmbi.1996.0754; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 1998, CHEM BIOL, V5, pR251, DOI 10.1016/S1074-5521(98)90109-0; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; Shao ZX, 1996, CURR OPIN STRUC BIOL, V6, P513, DOI 10.1016/S0959-440X(96)80117-5; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Stoddard BL, 1998, NAT STRUCT BIOL, V5, P3, DOI 10.1038/nsb0198-3; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	21	200	214	1	59	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					889	892		10.1038/12879	http://dx.doi.org/10.1038/12879			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471931				2022-12-25	WOS:000082365800031
J	Bodzioch, M; Orso, E; Klucken, T; Langmann, T; Bottcher, L; Diederich, W; Drobnik, W; Barlage, S; Buchler, C; Porsch-Ozcurumez, M; Kaminski, WE; Hahmann, HW; Oette, K; Rothe, G; Aslanidis, C; Lackner, KJ; Schmitz, G				Bodzioch, M; Orso, E; Klucken, T; Langmann, T; Bottcher, L; Diederich, W; Drobnik, W; Barlage, S; Buchler, C; Porsch-Ozcurumez, M; Kaminski, WE; Hahmann, HW; Oette, K; Rothe, G; Aslanidis, C; Lackner, KJ; Schmitz, G			The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease	NATURE GENETICS			English	Article							APOLIPOPROTEIN-A-I; CELLULAR CHOLESTEROL; ABC TRANSPORTERS; PHOSPHOLIPIDS; FIBROBLASTS; RECEPTOR; EFFLUX	Tangier disease (TD) is an autosomal recessive disorder of lipid metabolism(1). It is characterized by absence of plasma high-density lipoprotein (HDL) and deposition of cholesteryl esters in the reticulo-endothelial system with splenomegaly and enlargement of tonsils and lymph nodes(.)(2) Although low HDL cholesterol is associated with an increased risk for coronary artery disease, this condition is not consistently found in TD pedigrees. Metabolic studies in TD patients have revealed a rapid catabolism of HDL and its precursors(2). In contrast to normal mononuclear phagocytes (MNP), MNP from TD individuals degrade internalized HDL in unusual lysosomes, indicating a defect in cellular lipid metabolism(3,4). HDL-mediated cholesterol efflux and intracellular lipid trafficking and turnover are abnormal in TD fibroblasts(5-7), which have a reduced in vitro growth rates. The TD locus has been mapped to chromosome 9q31 (ref. 9). Here we present evidence that TD is caused by mutations in ABC1, encoding a member of the ATP-binding cassette (ABC) transporter family, located on chromosome 9q22-31 (ref. 10), We have analysed five kindreds with TD and identified seven different mutations, including three that are expected to impair the function of the gene product. The identification of ABC1 as the TD locus has implications for the understanding of cellular HDL metabolism and reverse cholesterol transport, and its association with premature cardiovascular disease.	Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany; Klin Schwabenland, D-88315 Isny Neutrauchbturg, Germany; Univ Cologne, Fac Med, D-50924 Cologne, Germany	University of Regensburg; University of Cologne	Schmitz, G (corresponding author), Univ Regensburg, Inst Clin Chem & Lab Med, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.		Özcürümez, Mustafa/AAQ-3250-2021; Langmann, Thomas/HHZ-9814-2022; Özcürümez, Mustafa K./GRS-4840-2022; Buechler, Christa/AAH-3004-2020	Özcürümez, Mustafa/0000-0002-4360-5005; Langmann, Thomas/0000-0001-6826-529X; Özcürümez, Mustafa K./0000-0002-4360-5005; Schmitz, Gerd/0000-0002-1325-1007				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ASSMANN G, 1977, J CLIN INVEST, V59, P565, DOI 10.1172/JCI108672; ASSMANN G, 1989, METABOLIC BASIS INHE, P1267; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Drobnik W, 1999, ARTERIOSCL THROM VAS, V19, P28, DOI 10.1161/01.ATV.19.1.28; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; FREDRICKSON D, 1961, ANN INTERN MED, V55, P1016, DOI 10.7326/0003-4819-55-6-1016; GIBBELS E, 1985, J NEUROL, V232, P283, DOI 10.1007/BF00313867; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1998, NAT GENET, V20, P96, DOI 10.1038/1770; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; SCHMITZ G, 1990, ARTERIOSCLEROSIS, V10, P1010, DOI 10.1161/01.ATV.10.6.1010; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; von Eckardstein A, 1998, J LIPID RES, V39, P987	29	1289	1353	0	43	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					347	351		10.1038/11914	http://dx.doi.org/10.1038/11914			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431237				2022-12-25	WOS:000081772500015
J	Matsue, H; Matsue, K; Walters, M; Okumura, K; Yagita, H; Takashima, A				Matsue, H; Matsue, K; Walters, M; Okumura, K; Yagita, H; Takashima, A			Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells	NATURE MEDICINE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; LIGAND-INDUCED APOPTOSIS; STIMULATING FACTOR-I; FAS-LIGAND; PRESENTING CELLS; T-CELLS; CONTACT HYPERSENSITIVITY; AUTOIMMUNE-DISEASES; MURINE EPIDERMIS; DEATH RECEPTORS	Dendritic cells (DCs) are special subsets of antigen-presenting cells characterized by their highly potent capacity to activate immunologically naive T cells. Here we report that DCs that are transfected with CD95 ligand (CD95L) cDNA, called 'killer' DCs, deliver death signals, instead of activation signals, to T cells after antigen-specific interaction. Injection of antigen-pulsed killer DCs into mice before sensitization induced antigen-specific immunosuppression. When administered after sensitization, killer DCs suppressed immune responses almost completely after subsequent challenge. Thus, killer DCs represent an entirely new immunomodulatory protocol, which may become directly applicable in preventing and even treating T cell-mediated inflammatory diseases.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA; Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; CREST Japan Sci & Technol Corp, Chiyoda Ku, Tokyo 101, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Juntendo University; Japan Science & Technology Agency (JST)	Matsue, H (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035068, R01AR043777] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI43262] Funding Source: Medline; NIAMS NIH HHS [R01-AR43777, R01-AR35068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett SRM, 1998, J EXP MED, V188, P1977, DOI 10.1084/jem.188.11.1977; Bhardwaj N, 1997, J EXP MED, V186, P795, DOI 10.1084/jem.186.6.795; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CLARESALZLER MJ, 1992, J CLIN INVEST, V90, P741, DOI 10.1172/JCI115946; CRUZ PD, 1989, J INVEST DERMATOL, V92, P160, DOI 10.1111/1523-1747.ep12276682; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Johnson LL, 1997, J EXP MED, V186, P1799, DOI 10.1084/jem.186.11.1799; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kayagaki N, 1997, P NATL ACAD SCI USA, V94, P3914, DOI 10.1073/pnas.94.8.3914; Khoury SJ, 1996, J IMMUNOL, V157, P3700; KITAJIMA T, 1995, J IMMUNOL, V155, P5190; Kitajima T, 1996, J IMMUNOL, V157, P2340; Kronin V, 1996, J IMMUNOL, V157, P3819; Liblau R, 1997, IMMUNOL TODAY, V18, P599, DOI 10.1016/S0167-5699(97)01171-7; Lu LN, 1997, J IMMUNOL, V158, P5676; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Matsue H, 1999, J IMMUNOL, V162, P5287; MATSUE H, 1993, J IMMUNOL, V151, P6012; MORIKAWA Y, 1993, CELL IMMUNOL, V152, P200, DOI 10.1006/cimm.1993.1279; MORIKAWA Y, 1992, IMMUNOLOGY, V77, P81; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOONAN FP, 1981, IMMUNOLOGY, V43, P527; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shurin MR, 1996, CANCER IMMUNOL IMMUN, V43, P158, DOI 10.1007/s002620050317; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789; TAKASHIMA A, 1995, J IMMUNOL, V154, P5128; Timares L, 1998, P NATL ACAD SCI USA, V95, P13147, DOI 10.1073/pnas.95.22.13147; TOEWS GB, 1980, J IMMUNOL, V124, P445; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; XU S, 1995, EUR J IMMUNOL, V25, P1018, DOI 10.1002/eji.1830250424; XU S, 1995, J IMMUNOL, V154, P2697; Zhang H, 1999, J IMMUNOL, V162, P1423; Zhang HG, 1998, NAT BIOTECHNOL, V16, P1045, DOI 10.1038/3488	47	138	141	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					930	937		10.1038/11375	http://dx.doi.org/10.1038/11375			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426318				2022-12-25	WOS:000081684000038
J	Whitcombe, D; Theaker, J; Guy, SP; Brown, T; Little, S				Whitcombe, D; Theaker, J; Guy, SP; Brown, T; Little, S			Detection of PCR products using self-probing amplicons and fluorescence	NATURE BIOTECHNOLOGY			English	Article						homogeneous assays; fluorescent probes; diagnostics; PCR; ARMS; single-tube genotyping; multiplexing	POLYMERASE CHAIN-REACTION; MOLECULAR BEACONS; DNA; AMPLIFICATION; ASSAY; POLYMORPHISM; MUTATIONS; PROBES; ARMS	Molecular diagnostics is progressing from low-throughput, heterogeneous, mostly manual technologies to higher throughput, closed-tube, and automated methods. Fluorescence is the favored signaling technology for such assays, and a number of techniques rely on energy transfer between a fluorophore and a proximal quencher molecule, In these methods, dual-labeled probes hybridize to an amplicon and changes in the quenching of the fluorophore are detected. We describe a new technology that is simple to use, gives highly specific information, and avoids the major difficulties of the alternative methods, It uses a primer with an integral tail that is used to probe an extension product of the primer, The probing of a target sequence is thereby converted into a unimolecular event, which has substantial benefits in terms of kinetics, thermodynamics, assay design, and probe reliability.	AstraZeneca Diagnost, Northwich CW9 7RA, Cheshire, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	AstraZeneca; University of Southampton	Whitcombe, D (corresponding author), AstraZeneca Diagnost, Gadbrook Pk, Northwich CW9 7RA, Cheshire, England.		Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Brown, Tom/0000-0002-6538-3036				Brownie J, 1997, NUCLEIC ACIDS RES, V25, P3235, DOI 10.1093/nar/25.16.3235; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; FERRIE RM, 1992, AM J HUM GENET, V51, P251; FERRIE RM, 1998, Patent No. 152242; Gelmini S, 1997, CLIN CHEM, V43, P752; Gibson NJ, 1997, CLIN CHEM, V43, P1336; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Ibrahim MS, 1997, MOL CELL PROBE, V11, P143, DOI 10.1006/mcpr.1996.0093; Ibrahim MS, 1998, ANAL CHEM, V70, P2013, DOI 10.1021/ac971091u; ISHIGURO T, 1995, ANAL BIOCHEM, V229, P207, DOI 10.1006/abio.1995.1404; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Nazarenko IA, 1997, NUCLEIC ACIDS RES, V25, P2516, DOI 10.1093/nar/25.12.2516; NEWTON CR, 1993, NUCLEIC ACIDS RES, V21, P1155, DOI 10.1093/nar/21.5.1155; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Tseng SY, 1997, ANAL BIOCHEM, V245, P207, DOI 10.1006/abio.1996.9970; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; VANDERVELDEN PA, 1993, HUM MOL GENET, V2, P1753; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02	21	545	794	3	99	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					804	807		10.1038/11751	http://dx.doi.org/10.1038/11751			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429248				2022-12-25	WOS:000081751400032
J	Cuozzo, JW; Kaiser, CA				Cuozzo, JW; Kaiser, CA			Competition between glutathione and protein thiols for disulphide-bond formation	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CYSTEINE BIOSYNTHESIS; YEAST; GENE; DISULFIDE; EXPRESSION; CARBOXYPEPTIDASE; SYNTHETASE; OXIDATION	It has long been assumed that the oxidized form of glutathione, the tripeptide glutamate-cysteine-glycine, is a source of oxidizing equivalents needed for the formation of disulphide bonds in proteins within the endoplasmic reticulum (ER), although the in vivo function of glutathione in the ER has never been studied directly. Here we show that the major pathway for oxidation in the yeast ER, defined by the protein Ero1, is responsible for the oxidation of both glutathione and protein thiols. However, mutation and overexpression studies show that glutathione competes with protein thiols for the oxidizing machinery. Thus, contrary to expectation, cellular glutathione contributes net reducing equivalents to the ER; these reducing equivalents can buffer the ER against transient hyperoxidizing conditions.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kaiser, CA (corresponding author), MIT, Dept Biol, Room 68-533,77 Massachusetts Ave, Cambridge, MA 02139 USA.			Cuozzo, John/0000-0002-6229-0395	NIGMS NIH HHS [GM46941, GM18715] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CHANDLER ML, 1975, BIOCHEMISTRY-US, V14, P2107, DOI 10.1021/bi00681a010; CHEREST H, 1993, J BACTERIOL, V175, P5366, DOI 10.1128/JB.175.17.5366-5374.1993; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LIU HP, 1992, GENETICS, V132, P665; MEISTER A, 1988, J BIOL CHEM, V263, P17205; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; ONO BI, 1988, J BACTERIOL, V170, P5883, DOI 10.1128/jb.170.12.5883-5889.1988; PASZEWSKI A, 1992, CURR GENET, V22, P273, DOI 10.1007/BF00317920; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; SCHMIDT M, 1996, BIOTECHNIQUES, V21, P884; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41	31	252	263	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					130	135		10.1038/11047	http://dx.doi.org/10.1038/11047			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559898				2022-12-25	WOS:000083102500010
J	Dalum, I; Butler, DM; Jensen, MR; Hindersson, P; Steinaa, L; Waterston, AM; Grell, SN; Feldmann, M; Elsner, HI; Mouritsen, S				Dalum, I; Butler, DM; Jensen, MR; Hindersson, P; Steinaa, L; Waterston, AM; Grell, SN; Feldmann, M; Elsner, HI; Mouritsen, S			Therapeutic antibodies elicited by immunization against TNF-alpha	NATURE BIOTECHNOLOGY			English	Article						TNF-alpha; vaccination; active immunization; autoantibodies; anti-TNF-alpha; collagen-induced arthritis (CIA); cachexia; chronic inflammatory disease	TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODIES; FUSION PROTEIN; SELF PROTEIN; T-CELLS; MICE; DISEASE; DETERMINANTS	Tumor necrosis factor-alpha (TNF-alpha) is critically involved in the pathogenesis of several chronic inflammatory diseases. Monoclonal antibodies against TNF-alpha are currently used for the treatment of rheumatoid arthritis and Crohn's disease. This report describes a simple and effective method for active immunization against self TNF-alpha. This vaccination approach leads to a T-cell-dependent polyclonal and sustainable anti-TNF-alpha autoantibody response that declines upon discontinuation of booster injections. The autoantibodies are elicited by injecting modified recombinant TNF-alpha molecules containing foreign immunodominant T-helper epitopes. In mice immunized with such molecules, the symptoms of experimental cachexia and type II collagen-induced arthritis are ameliorated. These results suggest that vaccination against TNF-alpha may be a useful approach for the treatment of rheumatoid arthritis and other chronic inflammatory diseases.	M&E Biotech AS, DK-2970 Horsholm, Denmark; Kennedy Inst Rheumatol, London, England	University of Oxford	Mouritsen, S (corresponding author), M&E Biotech AS, 6 Kogle Alle, DK-2970 Horsholm, Denmark.			Steinaa, Lucilla/0000-0003-3691-3971				BLOOM JW, 1993, J IMMUNOL, V151, P2707; CERAMI A, 1985, IMMUNOL LETT, V11, P173, DOI 10.1016/0165-2478(85)90165-8; Dalum I, 1997, MOL IMMUNOL, V34, P1113, DOI 10.1016/S0161-5890(97)00147-8; Dalum I, 1996, J IMMUNOL, V157, P4796; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Neurath MF, 1997, EUR J IMMUNOL, V27, P1743, DOI 10.1002/eji.1830270722; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUFF MR, 1980, J IMMUNOL, V125, P1671; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHASTRI N, 1986, J IMMUNOL, V137, P911; STAINES NA, 1994, BRIT J RHEUMATOL, V33, P798; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; WILLIAMS RO, 1995, IMMUNOLOGY, V84, P433; WILLIAMS RO, 1992, J IMMUNOL METHODS, V147, P93, DOI 10.1016/S0022-1759(12)80033-0; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784	25	121	143	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					666	669		10.1038/10878	http://dx.doi.org/10.1038/10878			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404159				2022-12-25	WOS:000081296900026
J	Maines, JZ; Wasserman, SA				Maines, JZ; Wasserman, SA			Post-transcriptional regulation of the meiotic Cdc25 protein Twine by the Dazl orthologue Boule	NATURE CELL BIOLOGY			English	Article							DROSOPHILA SPERMATOGENESIS; POSTMEIOTIC STAGES; BETA-TUBULIN; Y-CHROMOSOME; HOMOLOG; GENE; MEIOSIS; ENCODES; MELANOGASTER; AZOOSPERMIA	Boule, a Drosophila orthologue of the vertebrate Dazl fertility factors, is a testis-specific regulator of meiotic entry and germline differentiation. Mutations inactivating either Boule, which is an RNA-binding protein, or Twine, which is a Cdc25-type phosphatase, block meiotic entry in males. Here we show that twins and boule interact genetically. We also find that protein expression from twine messenger RNA correlates with cytoplasmic accumulation of Boule and is markedly reduced by boule mutations. Remarkably, heterologous expression of Twine rescues the boule meiotic-entry defect, indicating that the essential function of Boule at the transition from G2 to M phase during meiosis is in the control of Twine translation.	Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wasserman, SA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CASTRILLON DH, 1993, GENETICS, V135, P489; CENCI G, 1994, J CELL SCI, V107, P3521; Cheng MH, 1998, DEV BIOL, V204, P567, DOI 10.1006/dbio.1998.9098; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COURTOT C, 1992, DEVELOPMENT, V116, P405; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Houston DW, 1998, DEVELOPMENT, V125, P171; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; KEMPHUES KJ, 1980, CELL, V21, P445, DOI 10.1016/0092-8674(80)90481-X; Li KJ, 1998, J CELL BIOL, V141, P455, DOI 10.1083/jcb.141.2.455; MICHIELS F, 1993, EUR J CELL BIOL, V62, P66; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; RUGGIU M, 1997, NATURE, V389, P74; SIGRIST S, 1995, MECH DEVELOP, V53, P247, DOI 10.1016/0925-4773(95)00441-3; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; White-Cooper H, 1998, DEVELOPMENT, V125, P125	21	124	133	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					171	174		10.1038/11091	http://dx.doi.org/10.1038/11091			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559904				2022-12-25	WOS:000083102500016
J	Lee, PP; Yee, C; Savage, PA; Fong, L; Brockstedt, D; Weber, JS; Johnson, D; Swetter, S; Thompson, J; Greenberg, PD; Roederer, M; Davis, MM				Lee, PP; Yee, C; Savage, PA; Fong, L; Brockstedt, D; Weber, JS; Johnson, D; Swetter, S; Thompson, J; Greenberg, PD; Roederer, M; Davis, MM			Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients	NATURE MEDICINE			English	Article							MARROW-DERIVED CELLS; INFILTRATING LYMPHOCYTES; EXPRESSION; CARCINOMA; CD8(+); GROWTH; SIGNAL; MICE; IMMUNOTHERAPY; STIMULATION	We identified circulating CD8(+) T-cell populations specific for the tumor-associated antigens (TAAs) MART-1 (27-35) or tyrosinase (368-376) in six of eleven patients with metastatic melanoma using peptide/HLA-A*0201 tetramers. These TAA-specific populations were of two phenotypically distinct types: one, typical for memory/effector T cells; the other, a previously undescribed phenotype expressing both naive and effector cell markers. This latter type represented more than 2% of the total CD8(+) T cells in one patient, permitting detailed phenotypic and functional analysis. Although these cells have many of the hallmarks of effector T cells, they were functionally unresponsive, unable to directly lyse melanoma target cells or produce cytokines in response to mitogens. In contrast, CD8(+) T cells from the same patient were able to lyse EBV-pulsed target cells and showed robust allogeneic responses. Thus, the clonally expanded TAA-specific population seems to have been selectively rendered anergic in vivo. Peptide stimulation of the TAA-specific T-cell populations in other patients failed to induce substantial upregulation of CD69 expression, indicating that these cells may also have functional defects, leading to blunted activation responses. These data demonstrate that systemic TAA-specific T-cell responses can develop de novo in cancer patients, but that antigen-specific unresponsiveness may explain why such cells are unable to control tumor growth.	Stanford Univ, Howard Hughes Med Inst, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Ctr Blood, Stanford, CA 94305 USA; Stanford Univ, Dept Surg, Div Surg Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA; Palo Alto Vet Adm Hosp, Palo Alto, CA USA; Univ Washington, Dept Med, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90033 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Southern California	Davis, MM (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Microbiol & Immunol, Stanford, CA 94305 USA.		Ferris, Laura/I-7689-2012; Roederer, Mario/G-1887-2011	Davis, Mark/0000-0001-6868-657X; Lee, Peter P./0000-0002-2660-4377	NCI NIH HHS [K08 CA72976, CA-81543, CA-42509] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042509, K08CA072976, R21CA081543] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barth RJ, 1996, CANCER, V78, P1168, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1168::AID-CNCR2>3.0.CO;2-6; Beagley KW, 1998, CRIT REV IMMUNOL, V18, P237, DOI 10.1615/CritRevImmunol.v18.i3.40; Bell EB, 1998, IMMUNOL TODAY, V19, P60, DOI 10.1016/S0167-5699(97)01211-5; BOON T, 1994, IMPORTANT ADV ONCOL, V130, P53; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Chai JG, 1998, J IMMUNOL, V160, P3655; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Cormier JN, 1998, INT J CANCER, V75, P517, DOI 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.3.CO;2-M; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; FINKE JH, 1993, CANCER RES, V53, P5613; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; HE XS, IN PRESS P NATL ACAD; HUANG AYC, 1994, CIBA F SYMP, V187, P229; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KAMINSKI MJ, 1993, CANCER RES, V53, P4014; Kawakami Y, 1997, IMMUNOL RES, V16, P313, DOI 10.1007/BF02786397; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Ku CC, 1997, IMMUNOL REV, V160, P139, DOI 10.1111/j.1600-065X.1997.tb01034.x; Lahat N, 1998, THYROID, V8, P361, DOI 10.1089/thy.1998.8.361; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Maeurer MJ, 1996, J CLIN INVEST, V98, P1633, DOI 10.1172/JCI118958; Maeurer MJ, 1996, MELANOMA RES, V6, P11, DOI 10.1097/00008390-199602000-00003; Maio M, 1996, IMMUNOL TODAY, V17, P405, DOI 10.1016/0167-5699(96)30014-5; Marrogi AJ, 1997, INT J CANCER, V74, P492, DOI 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z; McMichael AJ, 1998, J EXP MED, V187, P1367, DOI 10.1084/jem.187.9.1367; Merogi AJ, 1997, HUM PATHOL, V28, P321, DOI 10.1016/S0046-8177(97)90131-3; MIZOGUCHI H, 1992, SCIENCE, V258, P1795, DOI 10.1126/science.1465616; NAKAGOMI H, 1993, CANCER RES, V53, P5610; NATALI PG, 1989, P NATL ACAD SCI USA, V86, P6719, DOI 10.1073/pnas.86.17.6719; OCHOA AC, 1995, IMP ADV ONCOL, V55, P43; Ogg GS, 1998, J EXP MED, V188, P1203, DOI 10.1084/jem.188.6.1203; RIDDELL SR, 1991, REV INFECT DIS, V13, pS966; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Shiohara T, 1997, J INVEST DERMATOL, V109, P271, DOI 10.1111/1523-1747.ep12335465; Sperling AI, 1996, J IMMUNOL, V157, P3909; SUNDSTEDT A, 1995, J IMMUNOL, V154, P6306; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; Trimble LA, 1998, BLOOD, V91, P585, DOI 10.1182/blood.V91.2.585.585_585_594; Yannelli JR, 1996, INT J CANCER, V65, P413, DOI 10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#; Yee C, 1996, J IMMUNOL, V157, P4079; Yee C, 1997, CURR OPIN IMMUNOL, V9, P702, DOI 10.1016/S0952-7915(97)80052-0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	46	912	986	2	59	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	1999	5	6					677	685		10.1038/9525	http://dx.doi.org/10.1038/9525			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	205LR	10371507				2022-12-25	WOS:000080823300037
J	Stone, EM; Lotery, AJ; Munier, FL; Heon, E; Piguet, B; Guymer, RH; Vandenburgh, K; Cousin, P; Nishimura, D; Swiderski, RE; Silvestri, G; Mackey, DA; Hageman, GS; Bird, AC; Sheffield, VC; Schorderet, DF				Stone, EM; Lotery, AJ; Munier, FL; Heon, E; Piguet, B; Guymer, RH; Vandenburgh, K; Cousin, P; Nishimura, D; Swiderski, RE; Silvestri, G; Mackey, DA; Hageman, GS; Bird, AC; Sheffield, VC; Schorderet, DF			A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy	NATURE GENETICS			English	Article							AGE-RELATED MACULOPATHY; BEAVER DAM EYE; MACULAR DEGENERATION; GENE; FIBRILLIN; PROTEIN; DRUSEN; PREVALENCE; FAMILY; DNA	Malattia Leventinese (ML) and Doyne honeycomb retinal dystrophy (DHRD) refer to two autosomal dominant diseases characterized by yellow-white deposits known as drusen that accumulate beneath the retinal pigment epithelium(1-4) (RPE). Both loci were mapped to chromosome 2p16-21 (refs 5,6) and this genetic interval has been subsequently narrowed(6) (7). The importance of these diseases is due in large part to their close phenotypic similarity to age-related macular degeneration (AMD), a disorder with a strong genetic: components(8-10) that accounts for approximately 50% of registered blindness in the Western world(11-14). Just as in ML and DHRD, the early hallmark of AMD is the presence of drusen(15) (16). Here we use a combination of positional and candidate gene methods to identify a single non-conservative mutation (Arg345Trp) in the gene EFEMP1 (for EGF-containing fibrillin-like extracellular matrix protein 1) in all families studied. This change was not present in 477 control individuals or in 494 patients with age-related macular degeneration. Identification of this mutation may aid in the development of an animal model for drusen, as well as in the identification of other genes involved in human macular degeneration.	Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; Hop Jules Gonin, Lausanne, Switzerland; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Eye Res Inst Canada, Toronto, ON, Canada; Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Parkville, Vic 3052, Australia; Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland; Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia; Moorfields Eye Hosp, Inst Ophthalmol, London, England; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA USA	University of Iowa; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Toronto; Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne; University of Iowa; University of Tasmania; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Howard Hughes Medical Institute; University of Iowa	Stone, EM (corresponding author), Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.		Mackey, David A/H-5340-2014	Mackey, David A/0000-0001-7914-4709; Stone, Edwin M./0000-0003-3343-4414; Lotery, Andrew/0000-0001-5541-4305; Guymer, Robyn/0000-0002-9441-4356; Sheffield, Val/0000-0002-6282-0835; Silvestri, Giuliana/0000-0001-5662-5374	NEI NIH HHS [EY10539, EY11515] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010539, R01EY011515] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; BUFFONE GJ, 1985, CLIN CHEM, V31, P164; Collins T., 1913, OPHTHALMOSCOPE, V11, P537; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Doyne R., 1899, T OPHTHAL SOC UK, V19, P71; Edwards AO, 1998, AM J OPHTHALMOL, V126, P417, DOI 10.1016/S0002-9394(98)00097-X; Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9; Fingert JH, 1998, GENOME RES, V8, P377, DOI 10.1101/gr.8.4.377; FORNI S, 1962, Ophthalmologica, V143, P313; Gregory CY, 1996, HUM MOL GENET, V5, P1055, DOI 10.1093/hmg/5.7.1055; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014; Ikegawa S, 1996, GENOMICS, V35, P590, DOI 10.1006/geno.1996.0402; Jay M, 1996, EYE, V10, P469, DOI 10.1038/eye.1996.103; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Saemisch T, 1925, HDB GESAMMTEN AUGENH, P1; SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57; SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WELLISZ T, 1993, J LONG-TERM EFF MED, V3, P223	30	339	352	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	1999	22	2					199	202		10.1038/9722	http://dx.doi.org/10.1038/9722			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	202YX	10369267				2022-12-25	WOS:000080680900030
J	Ramratnam, B; Mittler, JE; Zhang, LQ; Boden, D; Hurley, A; Fang, F; Macken, CA; Perelson, AS; Markowitz, M; Ho, DD				Ramratnam, B; Mittler, JE; Zhang, LQ; Boden, D; Hurley, A; Fang, F; Macken, CA; Perelson, AS; Markowitz, M; Ho, DD			The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy	NATURE MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; RAPID TURNOVER; LIFE-SPAN; IN-VIVO; INFECTION; LYMPHOCYTES	Replication-competent HIV-1 can be isolated from infected patients despite prolonged plasma virus suppression by anti-retroviral treatment(1-3). Recent studies have identified resting, memory CDC T lymphocytes as a long-lived latent reservoir of HIV-1 (refs. 4,5). Cross-sectional analyses indicate that the reservoir is rather small, between 10(3) and 10(7) cells per patient(5,6). In individuals whose plasma viremia levels are well suppressed by anti-retroviral therapy, peripheral blood mononuclear cells containing replication-competent HIV-1 were found to decay with a mean half-life of approximately 6 months(7), close to the decay characteristics of memory lymphocytes in humans and monkeys(8-10). In contrast, little decay was found in a less-selective patient population(11). We undertook this study to address this apparent discrepancy. Using a quantitative micro-culture assay, we demonstrate here that the latent reservoir decays with a mean half-life of 6.3 months in patients who consistently maintain plasma HIV-1 RNA levels of fewer than 50 copies/ml. Slower decay rates occur in individuals who experience intermittent episodes of plasma viremia. Our findings indicate that the persistence of the latent reservoir of HIV-1 despite prolonged treatment is due not only to its slow intrinsic decay characteristics but also to the inability of current drug regimens to completely block HIV-1 replication.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.		Abrams, William R/A-5782-2008; Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387, U01AI041534] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [AI41534, AI40387] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altice FL, 1998, ANN INTERN MED, V129, P503, DOI 10.7326/0003-4819-129-6-199809150-00015; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gunthard HF, 1999, VIROLOGY, V259, P154, DOI 10.1006/viro.1999.9774; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Macken C, 1999, J IMMUNOL METHODS, V222, P13, DOI 10.1016/S0022-1759(98)00133-1; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	25	392	402	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					82	85		10.1038/71577	http://dx.doi.org/10.1038/71577			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613829				2022-12-25	WOS:000084583300040
J	Manley, K; Shirley, TL; Flaherty, L; Messer, A				Manley, K; Shirley, TL; Flaherty, L; Messer, A			Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice	NATURE GENETICS			English	Article							TRINUCLEOTIDE-REPEAT; SACCHAROMYCES-CEREVISIAE; (CAG)(N) REPEAT; GENE; DNA; PHENOTYPE; EXPANSION; SPERM; RECOMBINATION; INACTIVATION	Huntington disease (HD), an autosomal dominant, progressive neurodegenerative disorder, is caused by an expanded CAG repeat sequence leading to an increase in the number of glutamine residues in the encoded protein(1). The normal CAG repeat range is 5-36, whereas 38 or more repeats are found in the diseased state; the severity of disease is roughly proportional to the number of CAG repeats(1-5). HD shows anticipation, in which subsequent generations display earlier disease onsets due to intergenerational repeat expansion(1-6). For longer repeat lengths, somatic instability of the repeat size has been observed both in human cases at autopsy(7,8) and in transgenic mouse models containing either a genomic fragment of human HD exon 1 (ref. 9) or an expanded repeat inserted into the endogenous mouse gene Hdh (ref. 10). With increasing repeat number, the protein changes conformation and becomes increasingly prone to aggregation(11), suggesting important functional correlations between repeat length and pathology. Because dinucleotide repeat instability is known to increase when the mismatch repair enzyme MSH2 is missing(12-15), we examined instability of the HD CAC repeat by crossing transgenic mice carrying exon 1 of human HD (ref, 16) with Msh2(-/-) mice(15), Our results show that Msh2 is required for somatic instability of the CAC repeat.	New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Messer, A (corresponding author), New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst, Albany, NY USA.	messer@wadsworth.org			NIDDK NIH HHS [DK 52822] Funding Source: Medline; NINDS NIH HHS [NS37299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052822] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; DEROOIJ KE, 1995, HUM GENET, V95, P270, DOI 10.1007/BF00225192; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Giovannone B, 1997, HUM MUTAT, V10, P458, DOI 10.1002/(SICI)1098-1004(1997)10:6<458::AID-HUMU7>3.0.CO;2-9; Goellner GM, 1997, AM J HUM GENET, V60, P879; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V240, P239, DOI 10.1006/bbrc.1997.7643; LEEFLANG EP, 1995, HUM MOL GENET, V4, P1519; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Manley K, 1999, BRAIN RES, V835, P74, DOI 10.1016/S0006-8993(99)01451-1; Morgan LJ, 1996, MAMM GENOME, V7, P553, DOI 10.1007/s003359900164; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Reitmair AH, 1997, CANCER RES, V57, P3765; Saparbaev M, 1996, GENETICS, V142, P727; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; TROTTIER Y, 1994, J MED GENET, V31, P377, DOI 10.1136/jmg.31.5.377; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; ZUHLKE C, 1993, HUM MOL GENET, V2, P2063, DOI 10.1093/hmg/2.12.2063	27	285	290	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					471	473		10.1038/70598	http://dx.doi.org/10.1038/70598			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581038				2022-12-25	WOS:000084023900027
J	Aszterbaum, M; Epstein, J; Oro, A; Douglas, V; LeBoit, PE; Scott, MP; Epstein, EH				Aszterbaum, M; Epstein, J; Oro, A; Douglas, V; LeBoit, PE; Scott, MP; Epstein, EH			Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice	NATURE MEDICINE			English	Article							BASAL-CELL CARCINOMA; HUMAN HOMOLOG; IN-VIVO; SONIC HEDGEHOG; NEVUS SYNDROME; SKIN-CANCER; EXPRESSION; MUTATIONS; GENE; TRICHOEPITHELIOMAS	Basal cell carcinomas, the commonest human skin cancers, consistently have abnormalities of the hedgehog signaling pathway and often have PTCH gene mutations. We report here that Ptch(+/-) mice develop primordial follicular neoplasms resembling human trichoblastomas, and that exposure to ultraviolet radiation or ionizing radiation results in an increase in the number and size of these tumors and a shift in their histologic features so that they more closely resemble human basal cell carcinoma. The mouse basal cell carcinomas and trichoblastoma-like tumors resemble human basal cell carcinomas in their loss of normal hemidesmosomal components, presence of p53 mutations, frequent loss of the normal remaining Ptch allele, and activation of hedgehog target gene transcription. The Ptch mutant mice provide the first mouse model, to our knowledge, of ultraviolet and ionizing radiation-induced basal cell carcinoma-like tumors, and also demonstrate that Ptch inactivation and hedgehog target gene activation are essential for basal cell carcinoma tumorigenesis.	Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94110 USA; Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Dermatol & Pathol, San Francisco, CA 94115 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University; University of California System; University of California San Francisco; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Epstein, EH (corresponding author), Univ Calif San Francisco, Dept Dermatol, Bldg 100,Room 269,1001 Potrero Ave, San Francisco, CA 94110 USA.			Oro, Anthony/0000-0002-6261-138X	NCI NIH HHS [CA81888] Funding Source: Medline; NIAMS NIH HHS [AR39959, AR4311] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA081888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039959] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Bahadoran P, 1997, BRIT J DERMATOL, V136, P35, DOI 10.1111/j.1365-2133.1997.tb08743.x; BOGOVSKI P, 1994, TUMOURS MOUSE PATHOL, V2, P11; BONIFAS JM, 1994, HUM MOL GENET, V3, P447, DOI 10.1093/hmg/3.3.447; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DELLAPORTA G, 1960, J NATL CANCER I, V25, P573; Epstein J.H., 1985, MODELS DERMATOLOGY, V2, P303; EPSTEIN JH, 1965, J NATL CANCER I, V34, P741; FAIRLEY JA, 1995, BRIT J DERMATOL, V133, P385, DOI 10.1111/j.1365-2133.1995.tb02665.x; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GARRIGUE JL, 1994, CONTACT DERMATITIS, V30, P231, DOI 10.1111/j.1600-0536.1994.tb00650.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grando SA, 1996, ARCH DERMATOL, V132, P1185, DOI 10.1001/archderm.132.10.1185; Green J, 1998, BRIT J DERMATOL, V139, P911; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HASHIMOTO K, 1972, J INVEST DERMATOL, V59, P380, DOI 10.1111/1523-1747.ep12627507; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kallassy M, 1997, CANCER RES, V57, P4731; Karagas MR, 1996, J NATL CANCER I, V88, P1848, DOI 10.1093/jnci/88.24.1848; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRESS S, 1992, CANCER RES, V52, P6400; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MILLER SJ, 1993, J INVEST DERMATOL, V100, pS288, DOI 10.1111/1523-1747.ep12470169; NISHIGORI C, 1996, J INVEST DERMATOL S, V1, P143; OMalley S, 1997, J NEUROSURG, V86, P286, DOI 10.3171/jns.1997.86.2.0286; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; Raffel C, 1997, CANCER RES, V57, P842; SMOLLER BR, 1994, BRIT J DERMATOL, V131, P28, DOI 10.1111/j.1365-2133.1994.tb08453.x; VANDERRIET P, 1994, CANCER RES, V54, P25; Vorechovsky I, 1997, CANCER RES, V57, P4677; WALSH N, 1990, MODERN PATHOL, V3, P599; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	39	319	328	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1285	1291		10.1038/15242	http://dx.doi.org/10.1038/15242			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545995				2022-12-25	WOS:000086550600039
J	Nicola, AV; Chen, W; Helenius, A				Nicola, AV; Chen, W; Helenius, A			Co-translational folding of an alphavirus capsid protein in the cytosol of living cells	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; NASCENT POLYPEPTIDE; ESCHERICHIA-COLI; AMINO-ACIDS; RIBOSOME; AUTOPROTEASE; CHAINS; CONFORMATION; MEMBRANE	The Semliki Forest Virus capsid protein contains a chymotrypsin-like protease domain that must fold before it can autocatalytically cleave the protein from a larger polyprotein precursor. Here we analyse this cleavage in living mammalian and prokaryotic cells, and find that it occurs immediately after the emergence of the protease domain from the ribosome during protein synthesis. The acquisition of the native conformation of this domain thus occurs rapidly and at the same time as translation. It does not require termination of translation or release from the ribosome, and nor does it involve Hsp70 binding. These results provide direct evidence that protein folding can occur co-translationally in the cytosol of both prokaryotes and eukaryotes.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06250 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Yale University	Helenius, A (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.							ALIPERTI G, 1978, VIROLOGY, V90, P366, DOI 10.1016/0042-6822(78)90321-5; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Choi HK, 1997, PROTEINS, V27, P345, DOI 10.1002/(SICI)1097-0134(199703)27:3<345::AID-PROT3>3.0.CO;2-C; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; FORSELL K, 1995, J VIROL, V69, P1556, DOI 10.1128/JVI.69.3.1556-1563.1995; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GREISERWILKE I, 1989, J GEN VIROL, V70, P743, DOI 10.1099/0022-1317-70-3-743; GROLLMAN AP, 1968, P NATL ACAD SCI USA, V61, P719, DOI 10.1073/pnas.61.2.719; HAHN CS, 1990, J VIROL, V64, P3069, DOI 10.1128/JVI.64.6.3069-3073.1990; HAHN CS, 1985, P NATL ACAD SCI USA, V82, P4648, DOI 10.1073/pnas.82.14.4648; Hardesty Boyd, 1999, Current Opinion in Structural Biology, V9, P111, DOI 10.1016/S0959-440X(99)80014-1; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; Makeyev EV, 1996, FEBS LETT, V378, P166, DOI 10.1016/0014-5793(95)01438-1; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; McGinnes LW, 1996, VIROLOGY, V224, P465, DOI 10.1006/viro.1996.0553; MELANCON P, 1987, J VIROL, V61, P1301, DOI 10.1128/JVI.61.5.1301-1309.1987; NATHANS D, 1964, P NATL ACAD SCI USA, V51, P585, DOI 10.1073/pnas.51.4.585; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PETERS T, 1982, J BIOL CHEM, V257, P8847; PURVIS IJ, 1987, J MOL BIOL, V193, P413, DOI 10.1016/0022-2836(87)90230-0; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	36	123	126	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					341	345		10.1038/14032	http://dx.doi.org/10.1038/14032			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559960				2022-12-25	WOS:000083169800016
J	Puri, V; Watanabe, R; Dominguez, M; Sun, XF; Wheatley, CL; Marks, DL; Pagano, RE				Puri, V; Watanabe, R; Dominguez, M; Sun, XF; Wheatley, CL; Marks, DL; Pagano, RE			Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid storage diseases	NATURE CELL BIOLOGY			English	Article							HUMAN SKIN FIBROBLASTS; GOLGI-APPARATUS; LIVING CELLS; ANALOG; MUCOLIPIDOSIS; TRANSPORT; IV		Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942, R01GM022942] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22942] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH G, 1977, AM J HUM GENET, V29, P610; Brown RE, 1998, J CELL SCI, V111, P1; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; PAGANO RE, IN PRESS METHODS ENZ; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; SCRIVER CR, 1995, METABOLIC MOL BASES, P2427	14	249	255	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					386	388		10.1038/14084	http://dx.doi.org/10.1038/14084			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559968				2022-12-25	WOS:000083169800024
J	Geisler, R; Rauch, GJ; Baier, H; van Bebber, F; Bross, L; Dekens, MPS; Finger, K; Fricke, C; Gates, MA; Geiger, H; Geiger-Rudolph, S; Gilmour, D; Glaser, S; Gnugge, L; Habeck, H; Hingst, K; Holley, S; Keenan, J; Kirn, A; Knaut, H; Lashkari, D; Maderspacher, F; Martyn, U; Neuhauss, S; Neumann, C; Nicolson, T; Pelegri, F; Ray, R; Rick, JM; Roehl, H; Roeser, T; Schauerte, HE; Schier, AF; Schonberger, U; Schonthaler, HB; Schulte-Merker, S; Seydler, C; Talbot, WS; Weiler, C; Nusslein-Volhard, C; Haffter, P				Geisler, R; Rauch, GJ; Baier, H; van Bebber, F; Bross, L; Dekens, MPS; Finger, K; Fricke, C; Gates, MA; Geiger, H; Geiger-Rudolph, S; Gilmour, D; Glaser, S; Gnugge, L; Habeck, H; Hingst, K; Holley, S; Keenan, J; Kirn, A; Knaut, H; Lashkari, D; Maderspacher, F; Martyn, U; Neuhauss, S; Neumann, C; Nicolson, T; Pelegri, F; Ray, R; Rick, JM; Roehl, H; Roeser, T; Schauerte, HE; Schier, AF; Schonberger, U; Schonthaler, HB; Schulte-Merker, S; Seydler, C; Talbot, WS; Weiler, C; Nusslein-Volhard, C; Haffter, P			A radiation hybrid map of the zebrafish genome	NATURE GENETICS			English	Article							DANIO-RERIO; CHROMOSOMES; VERTEBRATE; GENES	Recent large-scale mutagenesis screens have made the zebrafish the first vertebrate organism to allow a forward genetic approach to the discovery of developmental control genes(1-3). Mutations can be cloned positionally, or placed on a simple sequence length polymorphism (SSLP) map(4-6) to match them with mapped candidate genes and expressed sequence tags(7,8) (ESTs). To facilitate the mapping of candidate genes and to increase the density of markers available for positional cloning, we have created a radiation hybrid (RH) map of the zebrafish genome. This technique is based on somatic cell hybrid lines produced by fusion of lethally irradiated cells of the species of interest with a rodent cell line. Random fragments of the donor chromosomes are integrated into recipient chromosomes or retained as separate minichromosomesg (9,10) The radiation-induced breakpoints can be used for mapping in a manner analogous to genetic mapping, but at higher resolution and without a need for polymorphism. Genome-wide maps exist for the human, based on three RH panels of different resolutions(11-13), as well as for the dog(14) rat(15) and mouse(16, 17). For our map of the zebrafish genome, we used an existing RH panel (18, 19) and 1,451 sequence tagged site (STS) markers, including SSLPs, cloned candidate genes and ESTs. Of these, 1,275 (87.9%) have significant linkage to at least one other marker. The fraction of ESTs with significant linkage, which can be used as an estimate of map coverage, is 87.9%. We found the average marker retention frequency to be 18.4%. One cR(3000) is equivalent to 61 kb, resulting in a potential resolution of approximately 350 kb.	Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; NYU, Med Ctr, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA; Stanford Univ, Sch Med, Beckman Ctr B407, Stanford, CA 94305 USA	Max Planck Society; New York University; Stanford University	Geisler, R (corresponding author), Max Planck Inst Entwicklungsbiol, Spemannstr 35, D-72076 Tubingen, Germany.		Geisler, Robert/K-6201-2013; Neuhauss, Stephan/AAX-9915-2020; Schönthaler, Helia/AAG-4767-2021	Geisler, Robert/0000-0002-3909-8311; Neuhauss, Stephan/0000-0002-9615-480X; Gilmour, Darren/0000-0001-7613-090X; Knaut, Holger/0000-0002-8399-8720; Dekens, Marcus P.S./0000-0003-1689-3491; Maderspacher, Florian/0000-0003-4324-8455; Schier, Alexander Franz/0000-0001-7645-5325	NCRR NIH HHS [R01RR12349] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012349] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Driever W, 1996, DEVELOPMENT, V123, P37; Gates MA, 1999, GENOME RES, V9, P334; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Haffter P, 1996, INT J DEV BIOL, V40, P221; Haffter P, 1996, DEVELOPMENT, V123, P1; HINEGARDNER R, 1972, AM NAT, V106, P621, DOI 10.1086/282801; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUKRIEDE N, IN PRESS P NATL ACAD; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Knapik EW, 1996, DEVELOPMENT, V123, P451; Kwok C, 1999, METHOD CELL BIOL, V60, P287; Kwok C, 1998, NUCLEIC ACIDS RES, V26, P3562, DOI 10.1093/nar/26.15.3562; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737	24	225	228	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					86	89		10.1038/12692	http://dx.doi.org/10.1038/12692			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471505				2022-12-25	WOS:000082337300022
J	Shimkets, RA; Lowe, DG; Tai, JTN; Sehl, P; Jin, HK; Yang, RH; Predki, PF; Rothberg, BEG; Murtha, MT; Roth, ME; Shenoy, SG; Windemuth, A; Simpson, JW; Simons, JF; Daley, MP; Gold, SA; McKenna, MP; Hillan, K; Went, GT; Rothberg, JM				Shimkets, RA; Lowe, DG; Tai, JTN; Sehl, P; Jin, HK; Yang, RH; Predki, PF; Rothberg, BEG; Murtha, MT; Roth, ME; Shenoy, SG; Windemuth, A; Simpson, JW; Simons, JF; Daley, MP; Gold, SA; McKenna, MP; Hillan, K; Went, GT; Rothberg, JM			Gene expression analysis by transcript profiling coupled to a gene database query	NATURE BIOTECHNOLOGY			English	Article						cardiac hypertrophy; differential gene expression; transcript profiling; oligonucleotide poisoning	MESSENGER-RNA EXPRESSION; CARDIAC-HYPERTROPHY; PRESSURE-OVERLOAD; RAT-HEART; DNA MICROARRAY; ADULT-RAT; HYBRIDIZATION; CDNA; SEQUENCE; MUSCLE	We describe an mRNA profiling technique for determining differential gene expression that utilizes, but does not require, prior knowledge of gene sequences, This method permits high-throughput reproducible detection of most expressed sequences with a sensitivity of greater than 1 part in 100,000, Gene identification by database query of a restriction endonuclease fingerprint, confirmed by competitive PCR using gene-specific oligonucleotides, facilitates gene discovery by minimizing isolation procedures. This process, called GeneCalling, was validated by analysis of the gene expression profiles of normal and hypertrophic rat hearts following in vivo pressure overload.	CuraGen Corp, New Haven, CT 06511 USA; Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Shimkets, RA (corresponding author), CuraGen Corp, 555 Long Wharf Dr, New Haven, CT 06511 USA.	Rshimket@curagen.com	Daley, Michael/HHN-1017-2022	Daley, Michael/0000-0003-4673-8214				ANVERSA P, 1980, J MOL CELL CARDIOL, V12, P781, DOI 10.1016/0022-2828(80)90080-2; Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; BATRA S, 1991, J CARDIOVASC PHARM, V17, pS151, DOI 10.1097/00005344-199117002-00037; BHALERAO J, 1995, J BIOL CHEM, V270, P16385, DOI 10.1074/jbc.270.27.16385; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; CHAPMAN D, 1990, CIRC RES, V67, P787, DOI 10.1161/01.RES.67.4.787; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; DAY ML, 1987, HYPERTENSION, V9, P485, DOI 10.1161/01.HYP.9.5.485; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Drmanac S, 1996, GENOMICS, V37, P29, DOI 10.1006/geno.1996.0517; Engelmann GL, 1996, MOL CELL BIOCHEM, V164, P47, DOI 10.1007/BF00408640; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; IVANOVA NB, 1995, NUCLEIC ACIDS RES, V23, P2954, DOI 10.1093/nar/23.15.2954; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KATO K, 1995, NUCLEIC ACIDS RES, V23, P3685, DOI 10.1093/nar/23.18.3685; KIMURA S, 1989, HEART CIRC PHYSL, V25, pH1006; KORECKY B, 1978, AM J PHYSIOL, V234, pH123, DOI 10.1152/ajpheart.1978.234.2.H123; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Milosavljevic A, 1996, GENOMICS, V37, P77, DOI 10.1006/geno.1996.0523; MILOSAVLJEVIC A, 1995, GENOMICS, V27, P83, DOI 10.1006/geno.1995.1009; Milosavljevic A, 1996, GENOME RES, V6, P132, DOI 10.1101/gr.6.2.132; PARADIS P, 1992, BIOCHEM CELL BIOL, V70, P593, DOI 10.1139/o92-090; Pepe G, 1997, J MOL CELL CARDIOL, V29, P1877, DOI 10.1006/jmcc.1997.0426; Sage EH, 1997, NAT MED, V3, P144; SAMUEL JL, 1991, J CLIN INVEST, V88, P1737, DOI 10.1172/JCI115492; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SPRINGHORN JP, 1989, BIOCHEM J, V258, P73, DOI 10.1042/bj2580073; vandenHeuvel GB, 1996, KIDNEY INT, V49, P752, DOI 10.1038/ki.1996.104; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	40	135	176	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					798	803		10.1038/11743	http://dx.doi.org/10.1038/11743			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429247				2022-12-25	WOS:000081751400031
J	Kotlyarov, A; Neininger, A; Schubert, C; Eckert, R; Birchmeier, C; Volk, HD; Gaestel, M				Kotlyarov, A; Neininger, A; Schubert, C; Eckert, R; Birchmeier, C; Volk, HD; Gaestel, M			MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-SHOCK PROTEINS; CYTOKINE BIOSYNTHESIS; NUCLEAR EXPORT; P38; PHOSPHORYLATION; STRESS; CELLS; IDENTIFICATION; EXPRESSION	MAPKAP kinase 2 (MK2) is one of several kinases that are regulated through direct phosphorylation by p38 MAP kinase, By introducing a targeted mutation into the mouse MK2 gene, we have determined the physiological function of MK2 in vivo. Mice that lack MK2 show increased stress resistance and survive LPS-induced endotoxic shock. This is due to a reduction of -90 % in the production of tumor necrosis factor-alpha (TNF-alpha) and not to a change in signalling from the TNF receptor. The level and stability of TNF-alpha mRNA is not reduced and TNF-alpha secretion is not affected. We conclude that MK2 is an essential component in the inflammatory response which regulates biosynthesis of TNF-alpha at a post-transcriptional level.	Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, D-06120 Halle, Germany; Humboldt Univ, Inst Med Immunol, D-10098 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Martin Luther University Halle Wittenberg; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gaestel, M (corresponding author), Univ Halle Wittenberg, Innovat Kolleg Zellspezialisierung, Hoher Weg 8, D-06120 Halle, Germany.		volk, hans-dieter/AAV-8053-2021; Gaestel, Matthias/A-6560-2013	volk, hans-dieter/0000-0002-7743-6668; Gaestel, Matthias/0000-0002-4944-4652; Schubert, Carola/0000-0002-9116-9105				Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Cano E, 1996, ONCOGENE, V12, P805; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; PIZZEY JA, 1983, NATURE, V305, P315, DOI 10.1038/305315a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Simon C, 1998, CANCER RES, V58, P1135; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	33	654	696	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	1999	1	2					94	97		10.1038/10061	http://dx.doi.org/10.1038/10061			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HW	10559880				2022-12-25	WOS:000083102200016
J	Sharp, DJ; Yu, KR; Sisson, JC; Sullivan, W; Scholey, JM				Sharp, DJ; Yu, KR; Sisson, JC; Sullivan, W; Scholey, JM			Antagonistic microtubule-sliding motors position mitotic centrosomes in Drosophila early embryos	NATURE CELL BIOLOGY			English	Article							KINESIN-LIKE PROTEIN; SPINDLE FUNCTION; FISSION YEAST; ASPERGILLUS-NIDULANS; GENE; MORPHOGENESIS; ORGANIZATION; SEGREGATION; REQUIRES; ANAPHASE	The positioning of centrosomes, or microtubule-organizing centres, within cells plays a critical part in animal development. Here we show that, in Drosophila embryos undergoing mitosis, the positioning of centrosomes within bipolar spindles and between daughter nuclei is determined by a balance of opposing forces generated by a bipolar kinesin motor, KLP61F, that is directed to microtubule plus ends, and a carboxy-terminal kinesin motor, Ncd, that is directed towards microtubule minus ends. This activity maintains the spacing between separated centrosomes during prometaphase and metaphase, and repositions centrosomes and daughter nuclei during late anaphase and telophase. surprisingly, we do not observe a function for KLP61F in the initial separation of centrosomes during prophase. Our data indicate that KLP61F and Ncd may function by crosslinking and sliding antiparallel spindle microtubules in relation to one another, allowing KLP61F to push centrosomes apart and Ncd to pull them together.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs 317, Santa Cruz, CA 95064 USA	University of California System; University of California Davis; University of California System; University of California Santa Cruz	Scholey, JM (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.							Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; COLE DG, 1994, J BIOL CHEM, V269, P22913; Endow SA, 1996, J CELL SCI, V109, P2429; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Francis-Lang H, 1999, METH MOL B, V122, P223; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kashina AS, 1996, NATURE, V384, P225, DOI 10.1038/384225a0; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KELLOGG DR, 1991, COLD SPRING HARB SYM, V56, P649; LEWIS EB, 1952, GENETICS, V37, P600; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCINTOSH JR, 1969, NATURE, V224, P659, DOI 10.1038/224659a0; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; Pidoux AL, 1996, MOL BIOL CELL, V7, P1639, DOI 10.1091/mbc.7.10.1639; RAPPAPORT R, 1996, CYTOKINESIS ANIMAL C, P1; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	32	196	199	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	1999	1	1					51	54		10.1038/9025	http://dx.doi.org/10.1038/9025			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245BA	10559864				2022-12-25	WOS:000083085300018
J	King, SJ; Schroer, TA				King, SJ; Schroer, TA			Dynactin increases the processivity of the cytoplasmic dynein motor	NATURE CELL BIOLOGY			English	Article							SINGLE KINESIN MOLECULES; ACTIN-RELATED PROTEIN; MICROTUBULES; BRAIN; PURIFICATION; COMPONENT; COMPLEX; TRANSPORT; MOVEMENT; MYOSIN	Cytoplasmic dynein supports long-range intracellular movements of cargo in vivo but does not appear to be a processive motor protein by itself. We show here that the dynein activator, dynactin, binds microtubules and increases the average length of cytoplasmic-dynein-driven movements without affecting the velocity or microtubule-stimulated ATPase kinetics of cytoplasmic dynein. Enhancement of microtubule binding and motility by dynactin are both inhibited by an antibody to dynactin's microtubule-binding domain. These results indicate that dynactin acts as a processivity factor for cytoplasmic-dynein-based motility and provide the first evidence that cytoskeletal motor processivity can be affected by extrinsic factors.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	King, SJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	schroer@jhu.edu		Schroer, Trina/0000-0002-5065-1835	NIGMS NIH HHS [F32 GM 19061, GM 44589, R01 GM044589] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044589, F32GM019061, R56GM044589] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; AMOS LA, 1989, J CELL SCI, V93, P19; Bingham JB, 1998, METHOD ENZYMOL, V298, P171, DOI 10.1016/S0076-6879(98)98017-X; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; Farshori P, 1997, BIOCHEM BIOPH RES CO, V232, P810, DOI 10.1006/bbrc.1997.6379; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; HUANG TG, 1994, J BIOL CHEM, V269, P16493; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHNAPP BJ, 1986, METHOD ENZYMOL, V134, P561; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P1575, DOI 10.1021/bi00005a013; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; VALLEE RB, 1988, NATURE, V332, P561, DOI 10.1038/332561a0; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634	35	555	564	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					20	24		10.1038/71338	http://dx.doi.org/10.1038/71338			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620802				2022-12-25	WOS:000084843600014
J	McGuirt, WT; Prasad, SD; Griffith, AJ; Kunst, HPM; Green, GE; Shpargel, KB; Runge, C; Huybrechts, C; Mueller, RF; Lynch, E; King, MC; Brunner, HG; Cremers, CWRJ; Takanosu, M; Li, SW; Arita, M; Mayne, R; Prockop, DJ; Van Camp, G; Smith, RJH				McGuirt, WT; Prasad, SD; Griffith, AJ; Kunst, HPM; Green, GE; Shpargel, KB; Runge, C; Huybrechts, C; Mueller, RF; Lynch, E; King, MC; Brunner, HG; Cremers, CWRJ; Takanosu, M; Li, SW; Arita, M; Mayne, R; Prockop, DJ; Van Camp, G; Smith, RJH			Mutations in COL11A2 cause non-syndromic hearing loss (DFNA13)	NATURE GENETICS			English	Article							AUTOSOMAL-DOMINANT; STICKLER-SYNDROME; XI COLLAGEN; MOLECULAR HETEROGENEITY; TECTORIAL MEMBRANE; FIBRILLAR COLLAGEN; COCHLEAR PATHOLOGY; II COLLAGEN; GENE; IMPAIRMENT	We report that mutation of COL11A2 causes deafness previously mapped to the DFNA13 locus on chromosome 6p. We found two families (one American and one Dutch) with autosomal dominant, non-syndromic hearing loss to have mutations in COL11A2 that are predicted to affect the triple-helix domain of the collagen protein. In both families, deafness is non-progressive and predominantly affects middle frequencies. Mice with a targeted disruption of Col11a2 also were shown to have hearing loss. Electron microscopy of the tectorial membrane of these mice revealed loss of organization of the collagen fibrils. Our findings revealed a unique ultrastructural malformation of inner-ear architecture associated with non-syndromic hearing loss, and suggest that tectorial membrane abnormalities may be one aetiology of sensorineural hearing loss primarily affecting the mid-frequencies.	Univ Iowa, Dept Otolaryngol Head & Neck Surg, Mol Otolayngol Res Labs, Iowa City, IA 52242 USA; Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA; Univ Nijmegen Hosp, Dept Otorhinolaryngol, NL-6500 HB Nijmegen, Netherlands; Univ Antwerp, Dept Genet, Antwerp, Belgium; St James Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Med Coll Penn & Hahnemann Univ, Ctr Gene Therapy, Philadelphia, PA USA	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Radboud University Nijmegen; University of Antwerp; Saint James's University Hospital; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; Drexel University	Smith, RJH (corresponding author), Univ Iowa, Dept Otolaryngol Head & Neck Surg, Mol Otolayngol Res Labs, Iowa City, IA 52242 USA.	richard-smith@uiowa.edu	Kunst, Henricus P.M./J-6456-2012; Cremers, C.W.R.J./L-4254-2015; Van Camp, Guy/F-3386-2013; Brunner, Han/C-9928-2013	Kunst, Henricus P.M./0000-0003-1162-6394; Van Camp, Guy/0000-0001-5105-9000; Shpargel, Karl/0000-0002-9658-456X; Smith, Richard/0000-0003-1201-6731; Runge, Christina/0000-0003-0330-5857; King, Mary-Claire/0000-0001-9426-1743	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000054, R29DC000054, R01DC003544, T32DC000040] Funding Source: NIH RePORTER; NIDCD NIH HHS [Z01-DC00054-01, R01-DC03544, 5-T32-DC00040] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALAKOKKO L, IN PRESS KELLYS TXB; Bleasel JF, 1998, HUM MUTAT, V12, P172, DOI 10.1002/(SICI)1098-1004(1998)12:3<172::AID-HUMU4>3.0.CO;2-J; BONAVENTURE J, 1995, BIOCHEM J, V307, P823, DOI 10.1042/bj3070823; Brown MR, 1997, AM J HUM GENET, V61, P924, DOI 10.1086/514892; Busler DE, 1996, BIOTECHNIQUES, V21, P1002; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; Gates GA, 1999, ARCH OTOLARYNGOL, V125, P654, DOI 10.1001/archotol.125.6.654; Jacobson J, 1990, J Am Acad Audiol, V1, P37; Khetarpal U, 1998, ACTA OTO-LARYNGOL, V118, P177; Kikuti YY, 1997, GENOMICS, V42, P422, DOI 10.1006/geno.1997.4745; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KORKKO J, 1993, AM J HUM GENET, V53, P55; KUNST D, IN PRESS LARYNGOSCOP; LEAKE PA, 1988, HEARING RES, V33, P11, DOI 10.1016/0378-5955(88)90018-4; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER CA, 1994, HEARING RES, V78, P11, DOI 10.1016/0378-5955(94)90039-6; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; Pihlajamaa T, 1998, AM J MED GENET, V80, P115, DOI 10.1002/(SICI)1096-8628(19981102)80:2<115::AID-AJMG5>3.0.CO;2-O; ROBERTSON NG, 1994, GENOMICS, V23, P42, DOI 10.1006/geno.1994.1457; Sirko-Osadsa D, 1998, J PEDIATR-US, V132, P368, DOI 10.1016/S0022-3476(98)70466-4; SLEPECKY NB, 1992, ACTA OTO-LARYNGOL, V112, P611, DOI 10.3109/00016489209137449; SPOENDLIN H, 1974, ARCH OTO-RHINO-LARYN, V208, P137, DOI 10.1007/BF00453927; Spranger J, 1998, PEDIATR RADIOL, V28, P745, DOI 10.1007/s002470050459; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STEINMANN B, 1986, J BIOL CHEM, V261, P8958; THALMANN I, 1993, CONNECT TISSUE RES, V29, P191, DOI 10.3109/03008209309016826; Tsuprun V, 1997, HEARING RES, V110, P107, DOI 10.1016/S0378-5955(97)00068-3; VanCamp G, 1997, AM J HUM GENET, V60, P758; vanSteensel MAM, 1997, AM J MED GENET, V70, P315; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Vuoristo MM, 1996, ANN NY ACAD SCI, V785, P343, DOI 10.1111/j.1749-6632.1996.tb56304.x; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	38	181	195	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					413	419		10.1038/70516	http://dx.doi.org/10.1038/70516			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581026				2022-12-25	WOS:000084023900015
J	Li, YS; Li, XC; Zheng, XX; Wells, AD; Turka, LA; Strom, TB				Li, YS; Li, XC; Zheng, XX; Wells, AD; Turka, LA; Strom, TB			Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance	NATURE MEDICINE			English	Article							CYCLOSPORINE-A; CD28 COSTIMULATION; CARDIAC ALLOGRAFTS; REJECTION; SURVIVAL; EXPRESSION; RAPAMYCIN; RESPONSES; RECEPTOR; PATHWAYS	The alloimmune response against fully MHC-mismatched allografts, compared with immune responses to nominal antigens, entails an unusually large clonal size of alloreactive T cells(1). Thus, induction of peripheral allograft tolerance established in the absence of immune system ablation and reconstitution is a challenging task in transplantation. Here, we determined whether a reduction in the mass of alloreactive T cells due to apoptosis is an essential initial step for induction of stable allograft tolerance with non-lymphoablative therapy. Blocking both CD28-B7 and CD40-CD40 ligand interactions (co-stimulation blockade) inhibited proliferation of alloreactive T cells in vivo while allowing cell cycle-dependent T-cell apoptosis of proliferating T cells, with permanent engraftment of cardiac allografts but not skin allografts. Treatment with rapamycin plus co-stimulation blockade resulted in massive apoptosis of alloreactive T cells and produced stable skin allograft tolerance, a very stringent test of allograft tolerance. In contrast, treatment with cyclosporine A and co-stimulation blockade abolished T-cell proliferation and apoptosis, as well as the induction of stable allograft tolerance. Our data indicate that induction of T-cell apoptosis and peripheral allograft tolerance is prevented by blocking both signal 1 and signal 2 of T-cell activation.	Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr,Div Immunol, Boston, MA 02215 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Pennsylvania	Strom, TB (corresponding author), Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr,Div Immunol, Boston, MA 02215 USA.		Strom, Terry B./E-9268-2010	Strom, Terry B./0000-0002-7570-0736; Li, Xian Chang/0000-0002-5981-2762	NIAID NIH HHS [P01 AI041521, R01AI42298, P0 AI/GF 41521] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI041521, R01AI042298] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3; Dai ZH, 1998, J IMMUNOL, V161, P1659; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Li XC, 1998, J IMMUNOL, V161, P2241; Li XC, 1998, TRANSPLANTATION, V65, pS169; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Song HK, 1999, J IMMUNOL, V162, P2467; Sykes M, 1996, CURR OPIN IMMUNOL, V8, P694, DOI 10.1016/S0952-7915(96)80088-4; Tivol EA, 1997, J IMMUNOL, V158, P5091; Warrens A N, 1994, Transpl Immunol, V2, P103, DOI 10.1016/0966-3274(94)90036-1; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; YAZDANBAKHSH K, 1995, P NATL ACAD SCI USA, V92, P437, DOI 10.1073/pnas.92.2.437	22	586	606	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1298	1302		10.1038/15256	http://dx.doi.org/10.1038/15256			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545997				2022-12-25	WOS:000086550600041
J	Mahadevappa, M; Warrington, JA				Mahadevappa, M; Warrington, JA			A high-density probe array sample preparation method using 10-to 100-fold fewer cells	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE-EXPRESSION; MICROARRAY		Affymetrix Inc, High Throughput Screening, Santa Clara, CA 95051 USA	Affymetrix	Mahadevappa, M (corresponding author), Affymetrix Inc, High Throughput Screening, 3380 Cent Expressway, Santa Clara, CA 95051 USA.							*AFF INC, 1998, EUK EXPR AN TARG PRE; Berne RM., 1988, PHYSIOLOGY, VSecond ed.; Choi SY, 1996, J BIOCHEM MOL BIOL, V29, P272; Endege WO, 1999, BIOTECHNIQUES, V26, P542, DOI 10.2144/99263cr04; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Phillips Jennifer, 1996, Methods (Orlando), V10, P283, DOI 10.1006/meth.1996.0104; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	17	137	143	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1999	17	11					1134	1136		10.1038/15124	http://dx.doi.org/10.1038/15124			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	251CX	10545926				2022-12-25	WOS:000083428000036
J	Zhang, LH; Xu, JL; Birch, RG				Zhang, LH; Xu, JL; Birch, RG			Engineered detoxification confers resistance against a pathogenic bacterium	NATURE BIOTECHNOLOGY			English	Article						disease resistance; antipathogenesis; transgenic plants; sugarcane; albicidin detoxification	LEAF SCALD DISEASE; XANTHOMONAS-ALBILINEANS; PANTOEA-DISPERSA; SUGARCANE; EXPRESSION; PLANTS; GENE; PHASEOLICOLA; CHLOROSIS; MARKER	We generated transgenic sugarcane plants that express an albicidin detoxifying gene (albD), which was cloned from a bacterium that provides biocontrol against leaf scald disease. Plants with albicidin detoxification capacity equivalent to 1-10 ng of AlbD enzyme per mg of leaf protein did not develop chlorotic disease symptoms in inoculated leaves, whereas all untransformed control plants developed severe symptoms. Transgenic lines with high AlbD activity in young stems were also protected against systemic multiplication of the pathogen, which is the precursor to economic disease. We have shown that genetic modification to express a toxin-resistance gene can confer resistance to both disease symptoms and multiplication of a toxigenic pathogen in its host.	Univ Queensland, Dept Bot, Brisbane, Qld 4072, Australia	University of Queensland	Birch, RG (corresponding author), Univ Queensland, Dept Bot, Brisbane, Qld 4072, Australia.							ANZAI H, 1989, MOL GEN GENET, V219, P492, DOI 10.1007/BF00259626; BEVAN MW, 1983, NATURE, V304, P184, DOI 10.1038/304184a0; BIRCH RG, 1985, J GEN MICROBIOL, V131, P1069; BIRCH RG, 1987, PHYSIOL MOL PLANT P, V30, P199, DOI 10.1016/0885-5765(87)90033-6; BIRCH RG, 1987, PHYSIOL MOL PLANT P, V30, P207, DOI 10.1016/0885-5765(87)90034-8; BIRCH RG, 1983, PHYTOPATHOLOGY, V73, P1368, DOI 10.1094/Phyto-73-1368; Bower R, 1996, MOL BREEDING, V2, P239, DOI 10.1007/BF00564201; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; DELAFUENTEMARTINEZ JM, 1992, BIO-TECHNOL, V10, P905, DOI 10.1038/nbt0892-905; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; HANSOM S, 1999, IN PRESS P INT SOC S; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; LEA P, 1993, PLANT BIOCH MOL BIOL; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; PATIL SS, 1976, NATURE, V259, P486, DOI 10.1038/259486a0; PATIL SS, 1974, PHYTOPATHOLOGY, V64, P590, DOI 10.1094/Phyto-64-590; Ricaud C, 1989, DIS SUGARCANE MAJOR, P39, DOI [10.1016/B978-0-444-42797-7.50007-7, DOI 10.1016/B978-0-444-42797-7.50007-7]; ROTT P, 1994, PLANT DIS, V78, P241, DOI 10.1094/PD-78-0241; Rudolph K., 1976, PHYSL PLANT PATHOLOG, P207; SAMBROOK J, 1979, MOL CLONING LAB MANU; WALTON JD, 1993, ANNU REV PHYTOPATHOL, V31, P275, DOI 10.1146/annurev.py.31.090193.001423; Zhang L, 1996, LETT APPL MICROBIOL, V22, P132, DOI 10.1111/j.1472-765X.1996.tb01126.x; Zhang LH, 1997, P NATL ACAD SCI USA, V94, P9984, DOI 10.1073/pnas.94.18.9984	24	69	86	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1021	1024		10.1038/13721	http://dx.doi.org/10.1038/13721			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504706				2022-12-25	WOS:000083015700031
J	Carrie, A; Jun, L; Bienvenu, T; Vinet, MC; McDonell, N; Couvert, P; Zemni, R; Cardona, A; Van Buggenhout, G; Frints, S; Hamel, B; Moraine, C; Ropers, HH; Strom, T; Howell, GR; Whittaker, A; Ross, MT; Kahn, A; Fryns, JP; Beldjord, C; Marynen, P; Chelly, J				Carrie, A; Jun, L; Bienvenu, T; Vinet, MC; McDonell, N; Couvert, P; Zemni, R; Cardona, A; Van Buggenhout, G; Frints, S; Hamel, B; Moraine, C; Ropers, HH; Strom, T; Howell, GR; Whittaker, A; Ross, MT; Kahn, A; Fryns, JP; Beldjord, C; Marynen, P; Chelly, J			A new member of the IL-1 receptor family highly expressed in hippocampus and involved in X-linked mental retardation	NATURE GENETICS			English	Article							LONG-TERM POTENTIATION; MICRODELETION; MUTATIONS; MEMORY; IDENTIFICATION; INTERLEUKIN-1; CLONING; REGION; GENE	We demonstrate here the importance of interleukin signalling pathways in cognitive function and the normal physiology of the CNS. Thorough investigation of an MRX critical region in Xp22.1-21.3 enabled us to identify a new gene expressed in brain that is responsible for a non-specific form of X-linked mental retardation. This gene encodes a 696 amino acid protein that has homology to IL-l receptor accessory proteins. Non-overlapping deletions and a nonsense mutation in this gene were identified in patients with cognitive impairment only. Its high level of expression in post-natal brain structures involved in the hippocampal memory system suggests a specialized role for this new gene in the physiological processes underlying memory and learning abilities.	CHU Cochin, INSERM, U129, IGGM, F-75014 Paris, France; Univ Hosp Gasthuisberg VIB, B-3000 Louvain, Belgium; Inst Pasteur, Lab Technol Cellulaires, F-75724 Paris 15, France; Clin Genet Univ, Ctr Human Genet, UZ Gasthuisberg, B-3000 Louvain, Belgium; Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Ctr Hosp Tours, Serv Genet, Hop Bretonneau, F-37044 Tours, France; Max Planck Inst Mol Genet, Berlin, Germany; Abt Med Genet, D-80336 Munich, Germany; Sanger Ctr, Cambridge, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Flanders Institute for Biotechnology (VIB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; KU Leuven; University Hospital Leuven; Radboud University Nijmegen; CHU Tours; Max Planck Society; Wellcome Trust Sanger Institute	Chelly, J (corresponding author), CHU Cochin, INSERM, U129, IGGM, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	chelly@infobiogen.fr	Chelly, Jamel/J-7528-2015; Glover, Vivette/M-2711-2016	Chelly, Jamel/0000-0002-0939-8719; Glover, Vivette/0000-0001-6543-1651; Couvert, Philippe/0000-0002-7607-2057; Frints, Suzanna G.M./0000-0002-5027-8364	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Bianchi M, 1998, BIOL SIGNAL RECEPT, V7, P45; Bienvenu T, 1998, HUM MOL GENET, V7, P1311, DOI 10.1093/hmg/7.8.1311; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Billuart P, 1996, HUM MOL GENET, V5, P977, DOI 10.1093/hmg/5.7.977; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CASSEL JC, 1995, NEUROSCIENCE, V69, P1, DOI 10.1016/0306-4522(95)00241-A; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CrumeyrolleArias M, 1996, HISTOCHEM J, V28, P801, DOI 10.1007/BF02272153; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; des Portes V, 1999, AM J MED GENET, V85, P263, DOI 10.1002/(SICI)1096-8628(19990730)85:3<263::AID-AJMG15>3.0.CO;2-0; des Portes V, 1998, CLIN GENET, V53, P136; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FERRERO GB, 1995, HUM MOL GENET, V4, P1821, DOI 10.1093/hmg/4.10.1821; FRIES MH, 1993, AM J MED GENET, V46, P363, DOI 10.1002/ajmg.1320460404; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Gedeon AK, 1996, AM J MED GENET, V64, P158, DOI 10.1002/(SICI)1096-8628(19960712)64:1<158::AID-AJMG26>3.3.CO;2-V; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HAGBERG B, 1983, BRAIN DEV-JPN, V5, P441, DOI 10.1016/S0387-7604(83)80072-2; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; KOCSIS B, 1994, J NEUROSCI, V14, P7040; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHRACH H., 1990, GENOME ANAL, P39; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MOSER HW, 1983, PRINCIPLES PRACTICE; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; Raeymaekers P, 1996, AM J MED GENET, V64, P7; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9	40	234	247	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					25	31		10.1038/12623	http://dx.doi.org/10.1038/12623			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471494				2022-12-25	WOS:000082337300011
J	Lacroix-Desmazes, S; Moreau, A; Sooryanarayana; Bonnemain, C; Stieltjes, N; Pashov, A; Sultan, Y; Hoebeke, J; Kazatchkine, MD; Kaveri, SV				Lacroix-Desmazes, S; Moreau, A; Sooryanarayana; Bonnemain, C; Stieltjes, N; Pashov, A; Sultan, Y; Hoebeke, J; Kazatchkine, MD; Kaveri, SV			Catalytic activity of antibodies against factor VIII in patients with hemophilia A	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-C; FACTOR-IXA; FACTOR XA; VONWILLEBRAND-FACTOR; COFACTOR ACTIVITY; LIGHT CHAIN; THROMBIN; INACTIVATION; INHIBITION; CLEAVAGE	Hemophilia A is an X chromosome-linked recessive disorder resulting in defective or deficient factor VIII (FVIII) molecules, which, in its severe form, is a life-threatening and crippling hemorrhagic disease. Infusion of homologous FVIII to patients with severe hemophilia A results, in 25% of patients, in the emergence of alloantibodies against FVIII (inhibitors)(ref. 1) that inhibit FVIII procoagulant activity by steric hindrance of the interaction of FVIII either with stabilizing molecules(2), with molecules essential for its activity(3,4) Or With activating molecules(5). Here, we report on the proteolysis of FVIII by alloantibodies of two patients with severe hemophilia A, demonstrating a previously unknown mechanism by which FVIII inhibitors may prevent the pro-coagulant function of FVIII. The kinetic parameters of FVIII hydrolysis indicate a functional role for the catalytic immune response in the inactivation of FVIII in vivo. The characterization of alloantibodies against FVIII as site-specific proteases may provide new approaches to the treatment of FVIII inhibitors.	INSERM U430, F-75014 Paris, France; Univ Paris 06, Hop Broussais, F-75014 Paris, France; Hop Cochin, Ctr Hemophiles, F-75674 Paris, France; IBMC, CNRS, UPR 9021, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Lacroix-Desmazes, S (corresponding author), INSERM U430, F-75014 Paris, France.		Pashov, Anastas/AAE-7997-2019	Pashov, Anastas/0000-0002-6033-3566; Lacroix-Desmazes, Sebastien/0000-0001-5625-8447				ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BRONSHTEIN IB, 1992, FEBS LETT, V314, P259, DOI 10.1016/0014-5793(92)81484-4; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; GALLACHER G, 1991, BIOCHEM J, V279, P871, DOI 10.1042/bj2790871; GILLES JGG, 1993, BLOOD, V82, P2452; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LEYTE A, 1990, J BIOL CHEM, V226, P740; LI L, 1995, J IMMUNOL, V154, P3328; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; NEUENSCHWANDER PF, 1992, ARCH BIOCHEM BIOPHYS, V296, P426, DOI 10.1016/0003-9861(92)90593-L; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; Paul S, 1997, J IMMUNOL, V159, P1530; PAUL S, 1990, J BIOL CHEM, V265, P11910; REGAN LM, 1994, J BIOL CHEM, V269, P9445; RICKARD KA, 1995, HAEMOPHILIA, V1, P8, DOI 10.1111/j.1365-2516.1995.tb00104.x; Saenko EL, 1996, J BIOL CHEM, V271, P27424, DOI 10.1074/jbc.271.44.27424; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; Zhong DG, 1998, BLOOD, V92, P136, DOI 10.1182/blood.V92.1.136.413k35_136_142	25	170	184	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1044	1047		10.1038/12483	http://dx.doi.org/10.1038/12483			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470082				2022-12-25	WOS:000082337200039
J	Millecamps, S; Kiefer, H; Navarro, V; Geoffroy, MC; Robert, JJ; Finiels, F; Mallet, J; Barkats, M				Millecamps, S; Kiefer, H; Navarro, V; Geoffroy, MC; Robert, JJ; Finiels, F; Mallet, J; Barkats, M			Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression	NATURE BIOTECHNOLOGY			English	Article						neuron-specific expression; adenoviral vectors; gene transfer; central nervous system gene therapy; motor neuron disease	SODIUM-CHANNEL GENE; RECEPTOR GENE; RAT MODEL; DISEASE; THERAPY; VECTOR; BRAIN; PROTEIN; MUSCLE	Neuron-restrictive silencer elements (NRSEs) were used to target the gene expression of adenoviral vectors specifically to neuron cells in the central nervous system. By generating adenoviral constructs in which NRSE sequences were placed upstream from the ubiquitous phosphoglycerate kinase promoter, the specificity of expression of a luciferase reporter gene was tested in both cell lines and primary cultures. Whereas transgene expression was negligible in nonneuronal cells following infection with an adenovirus containing 12 NRSEs, neuronal cells strongly expressed luciferase when infected with the same adenovirus. The NRSEs restricted expression of the luciferase gene to neuronal cells in vivo when adenoviruses were injected both intramuscularly into mice and intracerebrally into rats. This NRSE strategy may avoid side effects resulting from the ectopic expression of therapeutic genes in the treatment of neurological diseases. In particular, it may allow the direct transfection of motor neurons without promoting transgene expression within inoculated muscles or the secretion of transgene products into the bloodstream.	Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR C9923, Paris, France; Rhone Poulenc Rorer, Vitry Sur Seine, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis	Mallet, J (corresponding author), Hop La Pitie Salpetriere, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, CNRS, UMR C9923, Paris, France.	mallet@infobiogen.fr	Kiefer, Helene/AAY-9185-2020; Kiefer, Hélène/Q-2752-2018; Millecamps, Stéphanie/W-7184-2018	Kiefer, Hélène/0000-0002-6631-741X; Millecamps, Stéphanie/0000-0002-0745-6735; Navarro, Vincent/0000-0003-0077-8114; Geoffroy, Marie-Claude/0000-0001-8298-467X				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Anderson WF, 1998, NATURE, V392, P25; Barkats M, 1998, PROG NEUROBIOL, V55, P333, DOI 10.1016/S0301-0082(98)00028-8; Barkats M, 1997, NEUROSCIENCE, V78, P703, DOI 10.1016/S0306-4522(96)00526-X; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; BilangBleuel A, 1997, P NATL ACAD SCI USA, V94, P8818, DOI 10.1073/pnas.94.16.8818; Chen HH, 1997, P NATL ACAD SCI USA, V94, P1645, DOI 10.1073/pnas.94.5.1645; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Corti O, 1999, NAT BIOTECHNOL, V17, P349, DOI 10.1038/7901; Finiels F, 1995, NEUROREPORT, V6, P2473, DOI 10.1097/00001756-199512150-00009; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GHADGE GD, 1995, GENE THER, V2, P132; Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429; Hawrot E, 1979, Methods Enzymol, V58, P574; HORELLOU P, 1994, NEUROREPORT, V6, P49, DOI 10.1097/00001756-199412300-00014; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; LE GLS, 1993, SCIENCE, V259, P988; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOULLIER P, 1993, TRANSPLANTATION, V56, P427, DOI 10.1097/00007890-199308000-00034; Peel AL, 1997, GENE THER, V4, P16, DOI 10.1038/sj.gt.3300358; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Sendtner M, 1997, NAT MED, V3, P380, DOI 10.1038/nm0497-380; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Wood IC, 1996, J BIOL CHEM, V271, P14221, DOI 10.1074/jbc.271.24.14221	29	42	48	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					865	869		10.1038/12849	http://dx.doi.org/10.1038/12849			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471926				2022-12-25	WOS:000082365800026
J	Brini, M; Pinton, P; King, MP; Davidson, M; Schon, EA; Rizzuto, R				Brini, M; Pinton, P; King, MP; Davidson, M; Schon, EA; Rizzuto, R			A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency	NATURE MEDICINE			English	Article							RAGGED-RED FIBERS; MTDNA MUTATION; CELLS; ATP; HOMEOSTASIS; METABOLISM; TRNA(LYS); RESPONSES; AEQUORIN; EPILEPSY	In recent years, genetic defects of the mitochondrial genome (mtDNA) were shown to be associated with a heterogeneous group of disorders, known as mitochondrial diseases(1,2), but the cellular events deriving from the molecular lesions and the mechanistic basis of the specificity of the syndromes are still incompletely understood. Mitochondrial calcium (Ca2+) homeostasis depends on close contacts with the endoplasmic reticulum(3) and is essential in modulating organelle function(4-6). Given the strong dependence of mitochondrial Ca2+ uptake on the membrane potential and the intracellular distribution of the organelle, both of which may be altered in mitochondrial diseases, we investigated the occurrence of defects in mitochondrial Ca2+ handling in living cells with either the tRNA(Lys) mutation of MERRF (myoclonic epilepsy with ragged-red fibers)(7-9) or the ATPase mutation of NARP (neurogenic muscle weakness, ataxia and retinitis pigmentosa)(10-13). There was a derangement of mitochondrial Ca2+ homeostasis in MERRF, but not in NARP cells, whereas cytosolic Ca2+ responses were normal in both cell types. Treatment of MERRF cells with drugs affecting organellar Ca2+ transport mostly restored both the agonist-dependent mitochondrial Ca2+ uptake and the ensuing stimulation of ATP production. These results emphasize the differences in the cellular pathogenesis of the various mtDNA defects and indicate specific pharmacological approaches to the treatment of some mitochondrial diseases.	Univ Padua, Dept Biomed Sci, I-35100 Padua, Italy; Univ Padua, Dept Biochem, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Study Biomembranes, I-35100 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Ferrara; Columbia University; Columbia University	Rizzuto, R (corresponding author), Univ Padua, Dept Biomed Sci, I-35100 Padua, Italy.		Brini, Marisa/K-5189-2016; Rizzuto, Rosario/B-6312-2008; Pinton, Paolo/J-8025-2012	Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766, NS28828] Funding Source: Medline; Telethon [850] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, R01NS028828, P50NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allue I, 1996, BIOCHEM J, V319, P463, DOI 10.1042/bj3190463; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; COX DA, 1993, J BIOL CHEM, V268, P938; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MOUDY AM, 1995, P NATL ACAD SCI USA, V92, P729, DOI 10.1073/pnas.92.3.729; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096	22	138	140	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					951	954		10.1038/11396	http://dx.doi.org/10.1038/11396			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426322				2022-12-25	WOS:000081684000042
J	Monreal, AW; Ferguson, BM; Headon, DJ; Street, SL; Overbeek, PA; Zonana, J				Monreal, AW; Ferguson, BM; Headon, DJ; Street, SL; Overbeek, PA; Zonana, J			Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia	NATURE GENETICS			English	Article							AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ECTODYSPLASIN-A; EDA GENE; RECEPTOR; PROTEIN; IDENTIFICATION; ACTIVATION; APOPTOSIS; ENCODES; TABBY	X-linked hypohidrotic ectodermal dysplasia results in abnormal morphogenesis of teeth, hair and eccrine sweat glands(1). The gene (ED1) responsible for the disorder has been identified(2-4), as well as the analogous X-linked gene (Ta) in the mouse(5,6). Autosomal recessive disorders, phenotypically indistinguishable from the X-linked forms, exist in humans(7) and at two separate loci (crinkled, cr, and downless, dl) in mice(8). Dominant disorders, possibly allelic to the recessive loci, are seen in both species(9,10) (ED3, Dl(slk)). A candidate gene has recently been identified at the dl locus(11) that is mutated in both dl and Dl(slk) mutant alleles. We isolated and characterized its human DL homologue, and identified mutations in three families displaying recessive inheritance and two with dominant inheritance. The disorder does not map to the candidate gene locus in all autosomal recessive families, implying the existence of at least one additional human locus. The putative protein is predicted to have a single transmembrane domain, and shows similarity to two separate domains of the tumour necrosis factor receptor (TNFR) family(12,13).	Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Oregon Health & Science University; Baylor College of Medicine; Baylor College of Medicine	Ferguson, BM (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, 3181 SW San Jackson Pk Rd, Portland, OR 97201 USA.			Overbeek, Paul/0000-0001-9784-2084	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011311] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45316] Funding Source: Medline; NIDCR NIH HHS [DE11311] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arnold C, 1991, PCR Methods Appl, V1, P39; Baala L, 1999, AM J HUM GENET, V64, P651, DOI 10.1086/302239; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; BELDJORD C, 1988, NUCLEIC ACIDS RES, V16, P4927, DOI 10.1093/nar/16.11.4927; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; CLARKE A, 1987, J MED GENET, V24, P659, DOI 10.1136/jmg.24.11.659; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Ferguson BM, 1998, J MED GENET, V35, P112, DOI 10.1136/jmg.35.2.112; Ferguson BM, 1997, HUM MOL GENET, V6, P1589, DOI 10.1093/hmg/6.9.1589; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Ho LL, 1998, AM J HUM GENET, V62, P1102, DOI 10.1086/301839; Infante AJ, 1998, J PEDIATR-US, V133, P629, DOI 10.1016/S0022-3476(98)70102-7; JORGENSON RJ, 1987, J CRAN GENET DEV BIO, V7, P403; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Konrad M, 1995, GENOMICS, V30, P514, DOI 10.1006/geno.1995.1272; Majumder K, 1998, MAMM GENOME, V9, P863, DOI 10.1007/s003359900884; Malek NP, 1998, RECENT RES CANCER, V147, P97; Monreal AW, 1998, AM J HUM GENET, V63, P380, DOI 10.1086/301984; Munoz F, 1997, AM J HUM GENET, V61, P94; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Padanilam B. J., 1992, Human Molecular Genetics, V1, P407, DOI 10.1093/hmg/1.6.407; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Sundberg, 1994, HDB MOUSE MUTATIONS; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; ZONANA J, 1992, AM J HUM GENET, V51, P1036	31	290	300	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					366	369		10.1038/11937	http://dx.doi.org/10.1038/11937			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431241				2022-12-25	WOS:000081772500019
J	Sutterluty, H; Chatelain, E; Marti, A; Wirbelauer, C; Senften, M; Muller, U; Krek, W				Sutterluty, H; Chatelain, E; Marti, A; Wirbelauer, C; Senften, M; Muller, U; Krek, W			p45(SKP2) promotes p27(Kip1) degradation and induces S phase in quiescent cells	NATURE CELL BIOLOGY			English	Article							DEPENDENT-KINASE INHIBITOR; F-BOX PROTEIN; CYCLIN-A; DNA-REPLICATION; HUMAN CUL-1; BREAST-CANCER; COMPLEX; REGULATORS; EXPRESSION; SKP1	The F-box protein p45(SKP2) is the substrate-targeting subunit of the ubiquitin-protein ligase SCFSKP2 and is frequently overexpressed in transformed cells. Here we report that expression of p45(SKP2) in untransformed fibroblasts activates DNA synthesis in cells that would otherwise growth-arrest. Expression of p45(SKP2) in quiescent fibroblasts promotes p27(Kip1) degradation, allows the generation of cyclin-A-dependent kinase activity and induces S phase. Coexpression of a degradation-resistant p27(Kip1) mutant suppresses p45(SKP2)-induced cyclin-A-kinase activation and S-phase entry. We propose that p45(SKP2) is important in the progression from quiescence to S phase and that the ability of p45(SKP2) to promote p27(Kip1) degradation is a key aspect of its S-phase-inducing function. In transformed cells, p45(SKP2) may contribute to deregulated initiation of DNA replication by interfering with p27(Kip1) function.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Krek, W (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.			Sutterluty-Fall, Hedwig/0000-0001-9249-9299				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Ludin B, 1996, GENE, V173, P107, DOI 10.1016/0378-1119(95)00899-3; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	43	612	635	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					207	214		10.1038/12027	http://dx.doi.org/10.1038/12027			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559918				2022-12-25	WOS:000083102700015
J	Diaz, GA; Banikazemi, M; Oishi, K; Desnick, RJ; Gelb, BD				Diaz, GA; Banikazemi, M; Oishi, K; Desnick, RJ; Gelb, BD			Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; ANEMIA SYNDROME	Thiamine-responsive megaloblastic anaemia syndrome (TRMA; MIM 249270) is an autosomal recessive disorder with features that include megaloblastic anaemia, mild thrombocytopenia and leucopenia, sensorineural deafness and diabetes mellitus(1-3). Treatment with pharmacologic doses of thiamine ameliorates the megaloblastic anaemia and diabetes mellitus. A defect in the plasma membrane transport of thiamine has been demonstrated in erythrocytes and cultured skin fibroblasts from TRMA patients(4-6). The gene causing TRMA was assigned to 1q23.2-q23.3 by linkage analysis(7). Here we report the cloning of a new gene, SLC19A2, identified from high-throughput genomic sequences due to homology with SLC19A1, encoding reduced folate carrier 1 (refs 8-10). We cloned the entire coding region by screening a human fetal brain cDNA library. SLC19A2 encodes a protein (of 497 aa) predicted to have 12 transmembrane domains. We identified 2 frameshift mutations in exon 2, a 1-bp insertion and a 2-bp deletion, among four Iranian families with TRMA. The sequence homology and predicted structure of SLC19A2, as well as its role in TRMA, suggest that its gene product is a thiamine carrier, the first to be identified in complex eukaryotes.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Gelb, BD (corresponding author), Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA.		Diaz, George/AAF-6199-2021	Oishi, Kimihiko/0000-0001-9446-8912	NICHD NIH HHS [5 P30 HD 28822, P01-HD28822] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Banikazemi M, 1999, MOL GENET METAB, V66, P193, DOI 10.1006/mgme.1998.2799; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Enjo F, 1997, J BIOL CHEM, V272, P19165, DOI 10.1074/jbc.272.31.19165; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laforenza U, 1998, J MEMBRANE BIOL, V161, P151, DOI 10.1007/s002329900322; MANDEL H, 1984, NEW ENGL J MED, V311, P836, DOI 10.1056/NEJM198409273111307; Neufeld EJ, 1997, AM J HUM GENET, V61, P1335, DOI 10.1086/301642; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; RINDI G, 1992, J INHERIT METAB DIS, V15, P231, DOI 10.1007/BF01799637; RINDI G, 1994, J INHERIT METAB DIS, V17, P667, DOI 10.1007/BF00712009; ROGERS LE, 1969, J PEDIATR-US, V74, P494, DOI 10.1016/S0022-3476(69)80031-4; Singleton CK, 1997, GENE, V199, P111, DOI 10.1016/S0378-1119(97)00354-5; Stagg AR, 1999, J CLIN INVEST, V103, P723, DOI 10.1172/JCI3895; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VIANA MB, 1978, J PEDIATR-US, V93, P235, DOI 10.1016/S0022-3476(78)80503-4; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WILSON JD, 1998, HARRISONS PRINCIPLES, P480; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468	19	169	176	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					309	312		10.1038/10385	http://dx.doi.org/10.1038/10385			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391223				2022-12-25	WOS:000081125900028
J	Mutis, T; Gillespie, G; Schrama, E; Falkenburg, JHF; Moss, P; Goulmy, E				Mutis, T; Gillespie, G; Schrama, E; Falkenburg, JHF; Moss, P; Goulmy, E			Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; BYSTANDER ACTIVATION; CELL PRECURSORS; H-Y; ABSENCE; IDENTIFICATION; RECIPIENTS; VIVO; HA-1	Graft-versus-host disease (GvHD) is a chief complication of allogeneic bone marrow transplantation(1). In HLA-identical bone marrow transplantation, GvHD may be induced by disparities in minor histocompatibility antigens (mHags) between the donor and the recipient, with the antigen being present in the recipient and not in the donort(2). Cytotoxic T lymphocytes (CTLs) specific for mHags of the recipients can be isolated from the blood of recipients with severe GvHD (ref. 3). A retrospective study demonstrated an association between mismatch for mHags HA-1, -2, -4 and -5 and the occurrence of GvHD in adult recipients of bone marrow from HLA genotypically identical donors(4). Tetrameric HLA-peptide complexes have been used to visualize and quantitate antigen-specific CTLs in HIV-infected individuals and during Epstein-Barr virus and lymphocytic choriomeningitis virus infections(5-8). Here we show the direct ex vivo visualization of mHag-specific CTLs during GvHD using tetrameric HLA-class and 1-mHag HA-1 and HY peptide complexes. In the peripheral blood of 17 HA-1 or HY mismatched marrow recipients, HA-1-and MY-specific CTLs were detected as early as 14 days after bone marrow transplantation. The tetrameric complexes demonstrated a significant increase in HA-1- and MY-specific CTLs during acute and chronic GvHD, which decreased after successful GvHD treatment. HLA class 1-mHag peptide tetramers may serve as clinical tools for the diagnosis and monitoring of GvHD patients.	Leiden Univ, Ctr Med, Dept Immunohaematol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Ctr Med, Blood Bank, NL-2300 RC Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Hematol, NL-2300 RC Leiden, Netherlands; Univ Hosp, Dept Hematol, Birmingham, W Midlands, England; John Radcliffe Hosp, Mol Immunol Grp, Oxford OX3 9DU, England	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; University of Birmingham; University of Oxford	Mutis, T (corresponding author), Leiden Univ, Ctr Med, Dept Immunohaematol, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.							Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; DEBUEGER M, 1993, BONE MARROW TRANSPL, V11, P363; den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Ehl S, 1997, J EXP MED, V185, P1241, DOI 10.1084/jem.185.7.1241; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7; Gratwohl A, 1998, BLOOD, V92, p320A; HAMILTON BL, 1984, TRANSPLANTATION, V38, P357, DOI 10.1097/00007890-198410000-00009; HOROWITZ MM, 1990, BLOOD, V75, P555; Liem LM, 1996, BONE MARROW TRANSPL, V18, P73; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NIEDERWIESER D, 1993, BLOOD, V81, P2200; SCHWARER AP, 1993, LANCET, V341, P203, DOI 10.1016/0140-6736(93)90067-Q; THEOBALD M, 1993, BLOOD, V82, P298, DOI 10.1182/blood.V82.1.298.bloodjournal821298; TSOI MS, 1980, J IMMUNOL, V125, P2258; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; Wilke M, 1998, TISSUE ANTIGENS, V52, P312, DOI 10.1111/j.1399-0039.1998.tb03053.x; Zarozinski CC, 1997, J EXP MED, V185, P1629, DOI 10.1084/jem.185.9.1629	24	215	226	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					839	842		10.1038/10563	http://dx.doi.org/10.1038/10563			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395333				2022-12-25	WOS:000081926600043
J	Kojima, T; Kitamura, T				Kojima, T; Kitamura, T			A signal sequence trap based on a constitutively active cytokine receptor	NATURE BIOTECHNOLOGY			English	Article						signal sequence trap; retrovirus cDNA library	SECRETED PROTEINS; MOLECULAR-CLONING; MPL; IDENTIFICATION; MEMBER; GROWTH; SUPERFAMILY; EXPRESSION; CDNA	Targeting of secreted and cell-surface proteins to the cell membrane is mediated by a short hydrophobic stretch of amino acids, termed the signal sequence. We have developed a method that detects signal sequences in cDNA fragments based on their ability to redirect a constitutively active mutant of a cytokine receptor to the cell surface, thereby permitting interleukin-3 (IL-3)-independent growth of Ba/F3 cells. Retrovirus-mediated expression of the fusions in IL-3-dependent cells was followed by selection of clones for growth in the absence of IL-3. Infection of cells with 5x10(6) viral particles in a pilot experiment led to the isolation of 150 known and 48 novel cDNA clones, and all the known cDNA clones were found to encode secreted and cell-surface proteins. In addition, we isolated type II membrane proteins, which have not been detected by existing signal sequence trap strategies.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 108, Japan	University of Tokyo	Kitamura, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.		Kitamura, Toshio/AAA-2071-2021					KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KAISER CA, 1986, MOL CELL BIOL, V6, P2382, DOI 10.1128/MCB.6.7.2382; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; LEE F, 1985, P NATL ACAD SCI USA, V82, P4360, DOI 10.1073/pnas.82.13.4360; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	14	77	92	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					487	490		10.1038/8666	http://dx.doi.org/10.1038/8666			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331810				2022-12-25	WOS:000080074500035
J	Garrett, SD; Lee, HA; Morgan, MRA				Garrett, SD; Lee, HA; Morgan, MRA			A nonisotopic estrogen receptor-based assay to detect estrogenic compounds	NATURE BIOTECHNOLOGY			English	Article						human estrogen receptor; phytoestrogens; estrogens; rapid screening; flavonoids	SOYBEAN FOODS; BINDING; ISOFLAVONES; GENISTEIN; PHYTOESTROGENS; CHEMICALS; DAIDZEIN; SYSTEM; BETA	We have used the ligand binding domain of the recombinant human estrogen receptor (hER) to develop a nonisotopic assay for detection of estrogenic compounds. The assay is based on competition of the estrogenic ligand with 17 beta-estradiol for binding to the receptor, which leaves 17 beta-estradiol free to bind to an anti-17 beta-estradiol antibody. Unbound anti-17 beta-estradiol antibody then binds to immobilized 17 beta-estradiol-protein conjugate (to which hER is unable to bind for steric reasons), and is detected by an enzyme-labeled anti-rabbit IgG antibody. We used the assay to detect estrogenic compounds (mainly members of the flavonoid group of plant polyphenols) in a variety of commonly consumed plant foods.	Inst Food Res, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Lee, HA (corresponding author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	heather.lee@bbsrc.ac.uk						ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; Anthony MS, 1996, J NUTR, V126, P43, DOI 10.1093/jn/126.1.43; Bolger R, 1998, ENVIRON HEALTH PERSP, V106, P551, DOI 10.1289/ehp.98106551; Clarkson TB, 1998, P SOC EXP BIOL MED, V217, P365; COWARD L, 1993, J AGR FOOD CHEM, V41, P1961, DOI 10.1021/jf00035a027; Creeke PI, 1998, FOOD AGR IMMUNOL, V10, P325, DOI 10.1080/09540109809354996; ERLANGER BF, 1957, J BIOL CHEM, V228, P713; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAGGBLAD J, 1995, BIOTECHNIQUES, V18, P146; JONES LA, 1995, ENVIRON HEALTH PERSP, V103, P63, DOI 10.2307/3432510; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lapcik O, 1998, J STEROID BIOCHEM, V64, P261, DOI 10.1016/S0960-0760(97)00199-4; LEWIS DFV, 1995, J STEROID BIOCHEM, V52, P55, DOI 10.1016/0960-0760(94)00151-B; Liggins J, 1998, ANAL BIOCHEM, V264, P1, DOI 10.1006/abio.1998.2825; MIKSICEK RJ, 1994, J STEROID BIOCHEM, V49, P153, DOI 10.1016/0960-0760(94)90005-1; MIKSICEK RJ, 1995, P SOC EXP BIOL MED, V208, P44; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Murphy PA, 1997, J AGR FOOD CHEM, V45, P4635, DOI 10.1021/jf970590t; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; REDEUILH G, 1985, J BIOL CHEM, V260, P3996; SEIELSTAD DA, 1995, MOL ENDOCRINOL, V9, P647, DOI 10.1210/me.9.6.647; Seifert M, 1999, ANAL CHIM ACTA, V386, P191, DOI 10.1016/S0003-2670(99)00044-6; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; WANG HJ, 1994, J AGR FOOD CHEM, V42, P1666, DOI 10.1021/jf00044a016; WIESE TE, 1997, CHEM IND, V24, P648	25	37	40	0	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1219	1222		10.1038/70773	http://dx.doi.org/10.1038/70773			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585722				2022-12-25	WOS:000084170700032
J	Wells, AD; Li, XC; Li, YS; Walsh, MC; Zheng, XX; Wu, ZH; Nunez, G; Tang, AM; Sayegh, M; Hancock, WW; Strom, TB; Turka, LA				Wells, AD; Li, XC; Li, YS; Walsh, MC; Zheng, XX; Wu, ZH; Nunez, G; Tang, AM; Sayegh, M; Hancock, WW; Strom, TB; Turka, LA			Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance	NATURE MEDICINE			English	Article							CLONAL EXPANSION; SELF-TOLERANCE; CD40 LIGAND; SURVIVAL; LYMPHOCYTES; MICE; EXPRESSION; ALLOGRAFTS; BCL-X(L); DELETION	The mechanisms of allograft tolerance have been classified as deletion, anergy, ignorance and suppression/regulation. Deletion has been implicated in central tolerance(1), whereas peripheral tolerance has generally been ascribed to clonal anergy and/or active immunoregulatory states(2). Here, we used two distinct systems to assess the requirement for T-cell deletion in peripheral tolerance induction. in mice transgenic for Bcl-x(L), T cells were resistant to passive cell death through cytokine withdrawal, whereas T cells from interleukin-2-deficient mice did not undergo activation-induced cell death. Using either agents that block co-stimulatory pathways or the immunosuppressive drug rapamycin, which we have shown here blocks the proliferative component of interleukin-2 signaling but does not inhibit priming for activation-induced cell death, we found that mice with defective passive or active T-cell apoptotic pathways were resistant to induction of transplantation tolerance. Thus, deletion of activated T cells through activation-induced cell death or growth factor withdrawal seems necessary to achieve peripheral tolerance across major histocompatibility complex barriers.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02142 USA; LeukoSite Inc, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Michigan System; University of Michigan; Harvard University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Turka, LA (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.		Strom, Terry B./E-9268-2010; Nuñez, Gabriel/A-7160-2014	Strom, Terry B./0000-0002-7570-0736; Li, Xian Chang/0000-0002-5981-2762	NIAID NIH HHS [AI34665, AI37798, AI37691] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037798, R01AI037691] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Dai ZH, 1998, J IMMUNOL, V161, P1659; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Gudmundsdottir H, 1999, J IMMUNOL, V162, P5212; Hancock WW, 1996, P NATL ACAD SCI USA, V93, P13967, DOI 10.1073/pnas.93.24.13967; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Li XC, 1998, J IMMUNOL, V161, P2241; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SAYEGH MH, 1995, J EXP MED, V181, P1869, DOI 10.1084/jem.181.5.1869; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Sykes M, 1990, Semin Immunol, V2, P401; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Tran HM, 1997, J IMMUNOL, V159, P2232; Van Parijs L, 1998, SCIENCE, V280, P243; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873	24	483	503	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	NOV	1999	5	11					1303	1307		10.1038/15260	http://dx.doi.org/10.1038/15260			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545998				2022-12-25	WOS:000086550600042
J	Amir, RE; Van den Veyver, IB; Wan, M; Tran, CQ; Francke, U; Zoghbi, HY				Amir, RE; Van den Veyver, IB; Wan, M; Tran, CQ; Francke, U; Zoghbi, HY			Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2	NATURE GENETICS			English	Article							CHROMOSOME INACTIVATION; HISTONE DEACETYLASE; EXCLUSION MAP; INHERITANCE; GENE; DNA; LOCALIZATION; LINKAGE; FAMILY; SITES	Rett syndrome(1) (RTT, MIM 312750) is a progressive neurodevelopmental disorder and one of the most common causes of mental retardation in females, with an incidence of 1 in 10,000-15,000 (ref. 2). Patients with classic RTT appear to develop normally until 6-18 months of age, then gradually lose speech and purposeful hand use, and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation and stereotypic hand movements(3). After initial regression, the condition stabilizes and patients usually survive into adulthood. As RTT occurs almost exclusively in females, it has been proposed that RTT is caused by an X-linked dominant mutation with lethality in hemizygous males(3-8). Previous exclusion mapping studies using RTT families mapped the locus to Xq28 (refs 6,7,9-11). Using a systematic gene screening approach, we have identified mutations in the gene (MECP2) encoding X-linked methyl-CpG-binding protein 2 (MeCP2) as the cause of some Eases of RTT. MeCP2 selectively binds CpG dinucleotides in the mammalian genome and mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A (refs 12,13). In 5 of 21 sporadic patients, we found 3 de novo missense mutations in the region encoding the highly conserved methyl-binding domain (MBD) as well as a de novo frameshift and a de novo nonsense mutation, both of which disrupt the transcription repression domain (TRD). In two affected half-sisters of a RTT family, we found segregation of an additional missense mutation not detected in their obligate carrier mother. This suggests that the mother is a germline mosaic for this mutation. Our study reports the first disease-causing mutations in RTT and points to abnormal epigenetic regulation as the mechanism underlying the pathogenesis of RTT.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.		Van den Veyver, Ignatia B/AAF-4510-2021	Van den Veyver, Ignatia B/0000-0002-0651-5924; Zoghbi, Huda/0000-0002-0700-3349	NICHD NIH HHS [HD242346, HD 24064] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; AMIR RE, IN PRESS AM J MED GE; ARCHIDIACONO N, 1991, HUM GENET, V86, P604; Coy JF, 1999, HUM MOL GENET, V8, P1253, DOI 10.1093/hmg/8.7.1253; CURTIS ARJ, 1993, HUM GENET, V90, P551; DEsposito M, 1996, MAMM GENOME, V7, P533, DOI 10.1007/s003359900157; ELLISON KA, 1992, AM J HUM GENET, V50, P278; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; GANGULY A, 1994, P NATL ACAD SCI USA, V91, P5217; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; HAGBERG B, 1985, ACTA PAEDIATR SCAND, V74, P405, DOI 10.1111/j.1651-2227.1985.tb10993.x; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Rett A., 1966, WIENER MED WOCHENSCH, V116, P723; Schanen C, 1998, AM J HUM GENET, V63, P267, DOI 10.1086/301932; Schanen NC, 1997, AM J HUM GENET, V61, P634, DOI 10.1086/515525; Sirianni N, 1998, AM J HUM GENET, V63, P1552, DOI 10.1086/302105; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; Wan MH, 1998, AM J MED GENET, V78, P169, DOI 10.1002/(SICI)1096-8628(19980630)78:2<169::AID-AJMG14>3.3.CO;2-D; ZOGHBI H, 1988, J CHILD NEUROL, V3, P576; ZOGHBI HY, 1990, BRAIN DEV-JPN, V12, P131, DOI 10.1016/S0387-7604(12)80194-X	26	3465	3562	8	330	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					185	188		10.1038/13810	http://dx.doi.org/10.1038/13810			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508514				2022-12-25	WOS:000082827500017
J	den Hollander, AI; ten Brink, JB; de Kok, YJM; van Soest, S; van den Born, LI; van Driel, MA; van de Pol, DJR; Payne, AM; Bhattacharya, SS; Kellner, U; Hoyng, CB; Westerveld, A; Brunner, HG; Bleeker-Wagemakers, EM; Deutman, AF; Heckenlively, JR; Cremers, FPM; Bergen, AAB				den Hollander, AI; ten Brink, JB; de Kok, YJM; van Soest, S; van den Born, LI; van Driel, MA; van de Pol, DJR; Payne, AM; Bhattacharya, SS; Kellner, U; Hoyng, CB; Westerveld, A; Brunner, HG; Bleeker-Wagemakers, EM; Deutman, AF; Heckenlively, JR; Cremers, FPM; Bergen, AAB			Mutations in a human homologue of Drosophila crumbs cause retinitis pigmentosa (RP12)	NATURE GENETICS			English	Article							EPIDERMAL GROWTH-FACTOR; EPITHELIAL-CELL LINE; PROTEIN; LAMININ; SEQUENCE; DOMAINS; GENE; PROTEOGLYCAN; EXPRESSION; RECEPTOR	Retinitis pigmentosa (RP) comprises a clinically and genetically heterogeneous group of diseases that afflicts approximately 1.5 million people worldwide. Affected individuals suffer from a progressive degeneration of the photoreceptors, eventually resulting in severe visual impairment. To isolate candidate genes for chorioretinal diseases, we cloned cDNAs specifically or preferentially expressed in the human retina and the retinal pigment epithelium (RPE) through a novel suppression subtractive hybridization (SSH) method(1,2). One of these cDNAs (RET3C11) mapped to chromosome 1q31-q32.1, a region harbouring a gene involved in a severe form of autosomal recessive RP characterized by a typical preservation of the para-arteriolar RPE (RP12; ref. 3). The full-length cDNA encodes an extracellular protein with 19 EGF-like domains, 3 laminin A G-like domains and a C-type lectin domain. This protein is homologous to the Drosophila melanogaster protein crumbs (CRB), and denoted CRB1 (crumbs homologue 1). In ten unrelated RP patients with preserved para-arteriolar RPE, we identified a homozygous AluY insertion disrupting the ORF, five homozygous missense mutations and four compound heterozygous mutations in CRB1. The similarity to CRB suggests a role for CRB1 in cell-cell interaction and possibly in the maintenance of cell polarity in the retina. The distinct RPE abnormalities observed in RP12 patients suggest that CRB1 mutations trigger a novel mechanism of photoreceptor degeneration.	Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Netherlands Ophthalm Res Inst, NL-1100 AC Amsterdam, Netherlands; Hosp Eye, Rotterdam, Netherlands; UCL, Inst Ophthalmol, London, England; Free Univ Berlin, Univ Clin Benjamin Franklin, Dept Ophthalmol, D-1000 Berlin, Germany; Univ Nijmegen Hosp, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands; Univ Amsterdam, Inst Human Genet, Amsterdam, Netherlands; Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA	Radboud University Nijmegen; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Rotterdam Eye Hospital; University of London; University College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Radboud University Nijmegen; University of Amsterdam; University of California System; University of California Los Angeles	Cremers, FPM (corresponding author), Univ Nijmegen Hosp, Dept Human Genet, Geert Grooteplein 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.	F.Cremers@antrg.azn.nl	Bergen, Arthur/J-3637-2013; Hoyng, C.B./H-8050-2014; van Driel, Marc/D-5844-2013; Payne, annette/F-8877-2013; Bhattacharya, Shom/N-2926-2016; Hollander, Anneke den/N-4911-2014; Brunner, Han/C-9928-2013; Cremers, Frans/A-5625-2014	Payne, annette/0000-0002-2009-0141; Bhattacharya, Shom/0000-0002-1601-6344; Cremers, Frans/0000-0002-4954-5592; Bergen, Arthur/0000-0002-6333-9576				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; den Hollander AI, 1999, GENOMICS, V58, P240, DOI 10.1006/geno.1999.5823; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; HECKENLIVELY JR, 1982, BRIT J OPHTHALMOL, V66, P26, DOI 10.1136/bjo.66.1.26; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KERE J, 1992, GENOMICS, V14, P241, DOI 10.1016/S0888-7543(05)80212-5; KNUST E, 1987, EMBO J, V6, P761, DOI 10.1002/j.1460-2075.1987.tb04818.x; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; PATTHY L, 1992, FEBS LETT, V298, P182, DOI 10.1016/0014-5793(92)80051-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; van Soest S, 1999, CYTOGENET CELL GENET, V84, P22, DOI 10.1159/000015204; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VANDENBORN LI, 1994, AM J OPHTHALMOL, V118, P430, DOI 10.1016/S0002-9394(14)75792-7; VANSOEST S, 1994, GENOMICS, V22, P499, DOI 10.1006/geno.1994.1422; Vidaud Dominique, 1993, European Journal of Human Genetics, V1, P30; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5	30	367	376	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					217	221		10.1038/13848	http://dx.doi.org/10.1038/13848			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508521				2022-12-25	WOS:000082827500024
J	Gerard, M; Hernandez, L; Wevrick, R; Stewart, CL				Gerard, M; Hernandez, L; Wevrick, R; Stewart, CL			Disruption of the mouse necdin gene results in early post-natal lethality	NATURE GENETICS			English	Article							PRADER-WILLI-SYNDROME; SYNDROME REGION; GROWTH SUPPRESSOR; IMPRINTING-CENTER; NUCLEAR-PROTEIN; EXPRESSED GENE; DELETION; IDENTIFICATION; SNRPN	Prader-Willi syndrome (PWS) is a neurobehavioural disorder characterized by neonatal respiratory depression, hypotonia and failure to thrive in infancy, followed by hyperphagia and obesity among other symptoms(1,2). PWS is caused by the loss of one or more paternally expressed genes on chromosome 15q11-q13, which can be due to gene deletions, maternal uniparental disomy or mutations disrupting the imprinting mechanism. Imprinted genes mapped to this region include SNRPN (refs 3,4), ZNF127 (ref. 5), IPW (ref. 6) and NDN (which encodes the DNA-binding protein necdin; refs 7-10). The mouse homologues of these genes map to mouse chromosome 7 in a region syntenic with human chromosome 15q11-q13 (refs 7,11). Imprinting of the human genes is under the control of an imprinting center (IC), a long-range, cis-acting element located in the 5 ' region of SNRPN (ref. 12). A related control element was isolated in the mouse Snrpn genomic region which, when deleted on the paternally inherited chromosome, resulted in the loss of expression of all four genes and early post-natal lethality(13). To determine the possible contribution of Ndn to the PWS phenotype, we generated Ndn mutant mice. Heterozygous mice inheriting the mutated maternal allele were indistinguishable from their wild-type littermates. Mice carrying a paternally inherited Ndn deletion allele demonstrated early post-natal lethality. This is the first example of a single gene being responsible for phenotypes associated with PWS.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Canc & Dev Biol Lab, Frederick, MD 21702 USA; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Alberta	Stewart, CL (corresponding author), CEA Saclay, SBGM, F-91191 Gif Sur Yvette, France.		GERARD, Matthieu/D-2235-2014	GERARD, Matthieu/0000-0001-8956-0597; Wevrick, Rachel/0000-0002-3343-5794				AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; GLENN CC, 1993, HUM MOL GENET, V2, P1377, DOI 10.1093/hmg/2.9.1377; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HOLM VA, 1993, PEDIATRICS, V91, P398; Horsthemke B, 1997, J CELL PHYSIOL, V173, P237, DOI 10.1002/(SICI)1097-4652(199711)173:2<237::AID-JCP28>3.0.CO;2-B; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Jong MTC, 1999, HUM MOL GENET, V8, P795, DOI 10.1093/hmg/8.5.795; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; Sutcliffe JS, 1997, LANCET, V350, P1520, DOI 10.1016/S0140-6736(05)63943-8; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; Tsai TF, 1999, NAT GENET, V22, P15, DOI 10.1038/8722; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Watrin F, 1997, EUR J HUM GENET, V5, P324, DOI 10.1159/000484784; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; WHARTON RH, 1989, DEV MED CHILD NEUROL, V31, P231; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393	22	169	174	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					199	202		10.1038/13828	http://dx.doi.org/10.1038/13828			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508517				2022-12-25	WOS:000082827500020
J	Groner, W; Winkelman, JW; Harris, AG; Ince, C; Bouma, GJ; Messmer, K; Nadeau, RG				Groner, W; Winkelman, JW; Harris, AG; Ince, C; Bouma, GJ; Messmer, K; Nadeau, RG			Orthogonal polarization spectral imaging: A new method for study of the microcirculation	NATURE MEDICINE			English	Article							CAPILLARY DENSITY; IN-VIVO; SKIN; LIGHT; MICROSCOPY; SYSTEM		Cytometr Inc, Philadelphia, PA 19106 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany; Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1105 AZ Amsterdam, Netherlands	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Munich; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Nadeau, RG (corresponding author), Cytometr Inc, 615 Chestnut St, Philadelphia, PA 19106 USA.			Bouma, Gerrit/0000-0002-2772-7475				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bussau LJ, 1998, J ANAT, V192, P187, DOI 10.1046/j.1469-7580.1998.19220187.x; DAVIS E, 1966, CLIN CAPILLARY MICRO; Fagrell B, 1997, J INTERN MED, V241, P349, DOI 10.1046/j.1365-2796.1997.125148000.x; Fagrell B., 1990, CLIN CAPILLAROSCOPY; FENTON BM, 1979, MICROVASC RES, V18, P153, DOI 10.1016/0026-2862(79)90025-6; Forst T, 1998, CLIN SCI, V94, P255, DOI 10.1042/cs0940255; Harris AG, 1996, AM J PHYSIOL-HEART C, V271, pH2388, DOI 10.1152/ajpheart.1996.271.6.H2388; Harris AG, 1997, INT J MICROCIRC, V17, P322, DOI 10.1159/000179247; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; Kortum G., 1969, SPECTROSCOPY-US, P5; LIPOWSKY HH, 1982, MICROVASC RES, V24, P42, DOI 10.1016/0026-2862(82)90041-3; MACKINTOSH FC, 1989, PHYS REV B, V40, P9342, DOI 10.1103/PhysRevB.40.9342; Nolte D, 1995, INT J MICROCIRC, V15, P244, DOI 10.1159/000179025; Nolte D, 1995, INT J MICROCIRC, V15, P9, DOI 10.1159/000179088; PEELE JD, 1977, CLIN CHEM, V123, P2238; PITTMAN RN, 1975, J APPL PHYSIOL, V38, P321, DOI 10.1152/jappl.1975.38.2.321; PITTMAN RN, 1975, J APPL PHYSIOL, V38, P315, DOI 10.1152/jappl.1975.38.2.315; RAJADHYAKSHA M, 1995, J INVEST DERMATOL, V104, P946, DOI 10.1111/1523-1747.ep12606215; SCHMITT JM, 1992, APPL OPTICS, V31, P6535, DOI 10.1364/AO.31.006535; STAR WM, 1988, PHYS MED BIOL, V33, P437, DOI 10.1088/0031-9155/33/4/004; WINKELMAN, 1991, Patent No. 4998553; WOLF S, 1994, HYPERTENSION, V23, P464, DOI 10.1161/01.HYP.23.4.464	23	577	668	5	52	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1209	1213		10.1038/13529	http://dx.doi.org/10.1038/13529			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502828				2022-12-25	WOS:000082933200051
J	Kety, SS				Kety, SS			Mental illness and the sciences of brain and behavior	NATURE MEDICINE			English	Editorial Material							SCHIZOPHRENIA; ADOPTEES; VIRUSES; GENE		McLean Hosp, Belmont, MA 02478 USA	Harvard University; McLean Hospital	Kety, SS (corresponding author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA.							ERLENMEYERKIMLING N, 1992, J PSYCHIAT RES, V26, P221, DOI 10.1016/0022-3956(92)90028-M; Folstein Marshal F., J PSYCHIATR RES, V12, P189, DOI [10.1016/0022-3956(75)90026-6, DOI 10.1016/0022-3956(75)90026-6, DOI 10.1016/0022-3956(68)90026-5]; HESTON LL, 1966, BRIT J PSYCHIAT, V112, P819, DOI 10.1192/bjp.112.489.819; HIGGINS J, 1976, J PSYCHIAT RES, V13, P1, DOI 10.1016/0022-3956(76)90004-2; HOLZMAN PS, 1988, ARCH GEN PSYCHIAT, V45, P641; HOLZMAN PS, 1992, J PSYCHIATR RES, V26, P427, DOI 10.1016/0022-3956(92)90044-O; Kety S S, 1975, Proc Annu Meet Am Psychopathol Assoc, P147; KETY SS, 1950, AM J MED, V8, P205, DOI 10.1016/0002-9343(50)90363-9; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KETY SS, 1959, SCIENCE, V129, P1528, DOI 10.1126/science.129.3362.1528; KETY SS, 1992, J PSYCHIAT RES, V26, P247, DOI 10.1016/0022-3956(92)90031-I; KETY SS, 1994, ARCH GEN PSYCHIAT, V51, P442; KETY SS, 1951, PHARMACOL REV, V3, P1; Kety SS, 1944, AM HEART J, V27, P601, DOI 10.1016/S0002-8703(44)90553-3; KNIGHT JG, 1982, LANCET, V2, P1073; LAING P, 1989, P NATL ACAD SCI USA, V86, P1998, DOI 10.1073/pnas.86.6.1998; Landau WM, 1955, T AM NEUROL ASSOC, V80, P125; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; MIRSKY AF, 1992, J PSYCHIAT RES, V26, P383, DOI 10.1016/0022-3956(92)90042-M; MURRAY RM, 1992, J PSYCHIAT RES, V26, P225, DOI 10.1016/0022-3956(92)90029-N; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; ROSENTHAL D, 1968, TRANSMISSION SCHIZOP, P155; Sokoloff L., 1961, REGIONAL CHEM PHYSL, P107	24	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1113	1116		10.1038/13427	http://dx.doi.org/10.1038/13427			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502802				2022-12-25	WOS:000082933200023
J	Nielsen, E; Severin, F; Backer, JM; Hyman, AA; Zerial, M				Nielsen, E; Severin, F; Backer, JM; Hyman, AA; Zerial, M			Rab5 regulates motility of early endosomes on microtubules	NATURE CELL BIOLOGY			English	Article							ENDOCYTIC CARRIER VESICLES; FUSION INVITRO; GDP/GTP EXCHANGE; MAMMALIAN-CELLS; MEMBRANE-FUSION; GTPASE ACTIVITY; PROTEIN; KINESIN; MOTOR; EXOCYTOSIS	The small GTPase Rab5 regulates membrane docking and fusion in the early endocytic pathway. Here we reveal a new role for Rab5 in the regulation of endosome interactions with the microtubule network. Using Rab5 fused to green fluorescent protein we show that Rab5-positive endosomes move on microtubules in vivo. In vitro, Rab5 stimulates both association of early endosomes with microtubules and early-endosome motility towards the minus ends of microtubules. Moreover, similarly to endosome membrane docking and fusion, Rab5-dependent endosome movement depends on the phosphatidylinositol-3-OH kinase hVPS34. Thus, Rab5 functionally links regulation of membrane transport, motility and intracellular distribution of early endosomes.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Max Planck Society; European Molecular Biology Laboratory (EMBL); Yeshiva University; Albert Einstein College of Medicine	Zerial, M (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr, D-01307 Dresden, Germany.		Hyman, Tony/F-1923-2011; Severin, Fedor/AAD-5444-2019; Hyman, Anthony/B-3917-2017	Hyman, Anthony/0000-0003-3664-154X; Severin, Fedor/0000-0001-6703-1256	NIGMS NIH HHS [GM559692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Blocker A, 1997, J CELL BIOL, V137, P113, DOI 10.1083/jcb.137.1.113; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; Bornens M, 1999, METHOD CELL BIOL, V61, P13; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; DArrigo A, 1997, EUR J CELL BIOL, V72, P95; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Ferhat L, 1998, EUR J NEUROSCI, V10, P1383, DOI 10.1046/j.1460-9568.1998.00159.x; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Hoang E, 1999, EXP EYE RES, V69, P57, DOI 10.1006/exer.1999.0671; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCBIDE HM, IN PRESS CELL; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Saito N, 1997, NEURON, V18, P425, DOI 10.1016/S0896-6273(00)81243-X; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	45	389	401	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					376	382		10.1038/14075	http://dx.doi.org/10.1038/14075			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559966				2022-12-25	WOS:000083169800022
J	Chen, K; Baram, TZ; Soltesz, I				Chen, K; Baram, TZ; Soltesz, I			Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; INHIBITORY SYNAPTIC TRANSMISSION; RECEPTOR SUBUNIT EXPRESSION; RAT HIPPOCAMPAL SLICES; PROTEIN-KINASE-A; GABA(A) RECEPTORS; INCREASED NUMBER; MINIATURE IPSCS; DENTATE GYRUS	Febrile (fever-induced) seizures affect 3-5% of infants and young children. Despite the high incidence of febrile seizures, their contribution to the development of epilepsy later in life has remained controversial. Combining a new rat model of complex febrile seizures and patch clamp techniques, we determined that hyperthermia-induced seizures in the immature rat cause a selective presynaptic increase in inhibitory synaptic transmission in the hippocampus that lasts into adulthood. The long-lasting nature of these potent alterations in synaptic communication after febrile seizures does not support the prevalent view of the 'benign' nature of early-life febrile convulsions.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu	Baram, Tallie Z/J-6447-2014		NINDS NIH HHS [NS38580, R37 NS035439, NS35439, R01 NS035439, R01 NS038580] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038580, R01NS035439, R37NS035439] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOUKHALIL B, 1993, EPILEPSIA, V34, P878, DOI 10.1111/j.1528-1157.1993.tb02105.x; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; Auger C, 1997, NEURON, V19, P139, DOI 10.1016/S0896-6273(00)80354-2; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; Berg AT, 1997, J CLIN NEUROPHYSIOL, V14, P102, DOI 10.1097/00004691-199703000-00003; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bonci A, 1997, J NEUROSCI, V17, P796; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brunson KL, 1998, DEV BRAIN RES, V111, P119, DOI 10.1016/S0165-3806(98)00130-8; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; CAMFIELD P, 1997, EPILEPSY COMPREHENSI, P1305; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CENDES F, 1993, NEUROLOGY, V43, P1083, DOI 10.1212/WNL.43.6.1083; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; DOZE VA, 1995, J NEUROPHYSIOL, V74, P43, DOI 10.1152/jn.1995.74.1.43; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; HJERESEN DL, 1988, DEV PSYCHOBIOL, V21, P261, DOI 10.1002/dev.420210307; Hollrigel GS, 1997, J NEUROSCI, V17, P5119; Holmes GL, 1998, NEURON, V21, P1231, DOI 10.1016/S0896-6273(00)80642-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JENSEN FE, 1992, EPILEPSIA, V33, P971, DOI 10.1111/j.1528-1157.1992.tb01746.x; Jensen FE, 1998, J NEUROPHYSIOL, V79, P73, DOI 10.1152/jn.1998.79.1.73; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; Kondo S, 1997, J PHYSIOL-LONDON, V498, P165, DOI 10.1113/jphysiol.1997.sp021849; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; Liu XB, 1997, NEUROREPORT, V8, P1475, DOI 10.1097/00001756-199704140-00030; MACCAFERRI G, 1995, NEURON, V15, P137, DOI 10.1016/0896-6273(95)90071-3; McBain CJ, 1997, CAN J PHYSIOL PHARM, V75, P488, DOI 10.1139/cjpp-75-5-488; MOSHE SL, 1983, DEV BRAIN RES, V7, P81, DOI 10.1016/0165-3806(83)90083-4; Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Owens J, 1997, ANN NEUROL, V41, P187, DOI 10.1002/ana.410410210; SCHWARTZKROIN PA, 1984, ELECTROPHYSIOLOGY EP, P389; Shinnar S, 1998, ANN NEUROL, V43, P411, DOI 10.1002/ana.410430402; SHINNAR S, 1990, CURRENT THERAPY NEUR; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; Smith KL, 1998, J NEUROPHYSIOL, V79, P106, DOI 10.1152/jn.1998.79.1.106; Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309, DOI 10.1038/7217; Toth Z, 1998, J NEUROSCI, V18, P4285; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wasterlain CG, 1997, EPILEPSIA, V38, P728, DOI 10.1111/j.1528-1157.1997.tb01244.x; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Xie Z, 1995, CAN J PHYSIOL PHARM, V73, P1706, DOI 10.1139/y95-734	50	227	229	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1999	5	8					888	894		10.1038/11330	http://dx.doi.org/10.1038/11330			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426311	Green Published, Green Accepted			2022-12-25	WOS:000081684000031
J	McPherron, AC; Lawler, AM; Lee, SJ				McPherron, AC; Lawler, AM; Lee, SJ			Regulation of anterior posterior patterning of the axial skeleton by growth differentiation factor 11	NATURE GENETICS			English	Article							BETA SUPERFAMILY; NEURAL TISSUE; MOUSE EMBRYO; HOX GENES; CELLS; EMBRYOGENESIS; EXPRESSION; MEMBER	The bones that comprise the axial skeleton have distinct morphological features characteristic of their positions along the anterior/posterior axis. We previously described a novel TGF-beta family member, myostatin (encoded by the gene Mstn, formerly Gdf8), that has an essential role in regulating skeletal muscle mass(1). We also identified a gene related to Mstn by low-stringency screening(1). While the work described here was being completed, the cloning of this gene, designated Gdf11 (also called Bmp11), was also reported by other groups(2,3). Here we show that Gdf11, a new transforming growth factor beta (TGF beta) superfamily member, has an important role in establishing this skeletal pattern. During early mouse embryogenesis, Gdf11 is expressed in the primitive streak and tail bud regions, which are sites where new mesodermal cells are generated. Homozygous mutant mice carrying a targeted deletion of Cdf11 exhibit anteriorly directed homeotic transformations throughout the axial skeleton and posterior displacement of the hindlimbs. The effect of the mutation is dose dependent, as Cdf11(+/-) mice have a milder phenotype than Gdf11(-/-) mice. Mutant embryos show alterations in patterns of Hox gene expression, suggesting that Gdf11 acts upstream of the Hox genes. Our findings suggest that Gdf11 is a secreted signal that acts globally to specify positional identity along the anterior/posterior axis.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Lee, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.							Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Durston AJ, 1997, CELL MOL LIFE SCI, V53, P339, DOI 10.1007/PL00000610; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC., 1996, GROWTH FACTORS CYTOK, P357, DOI [10.1016/s1874-5687(96)80016-4, DOI 10.1016/S1874-5687(96)80016-4]; Nakashima M, 1999, MECH DEVELOP, V80, P185, DOI 10.1016/S0925-4773(98)00205-6; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; PETERSON RL, 1992, MECH DEVELOP, V37, P151, DOI 10.1016/0925-4773(92)90077-W; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; TAM PPL, 1992, DEVELOPMENT, V115, P703; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	16	338	390	0	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					260	264		10.1038/10320	http://dx.doi.org/10.1038/10320			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391213				2022-12-25	WOS:000081125900018
J	Hols, P; Kleerebezem, M; Schanck, AN; Ferain, T; Hugenholtz, J; Delcour, J; de Vos, WM				Hols, P; Kleerebezem, M; Schanck, AN; Ferain, T; Hugenholtz, J; Delcour, J; de Vos, WM			Conversion of Lactococcus lactis from homolactic to homoalanine fermentation through metabolic engineering	NATURE BIOTECHNOLOGY			English	Article						alanine; alanine racemase; alanine dehydrogenase; Lactococcus lactis	ALPHA-ACETOLACTATE SYNTHASE; CATABOLIC ALANINE RACEMASE; ESCHERICHIA-COLI; LACTOBACILLUS-PLANTARUM; SUBSP LACTIS; MOLECULAR-CLONING; ZYMOMONAS-MOBILIS; ACID BACTERIA; DEHYDROGENASE; GENE	We report the engineering of Lactococcus lactis to produce the amino acid L-alanine. The primary end product of sugar metabolism in wild-type L. lactis is lactate (homolactic fermentation). The terminal enzymatic reaction (pyruvate + NADH-->L-lactate + NAD(+)) is performed by L-lactate dehydrogenase (L-LDH). We rerouted the carbon flux toward alanine by expressing the Bacillus sphaericus alanine dehydrogenase (L-AlaDH; pyruvate + NADH + NH4+-->L-alanine + NAD(+) + H2O). Expression of L-AlaDH in an L-LDH-deficient strain permitted production of alanine as the sole end product (homoalanine fermentation). Finally, stereospecific production (>99%) of L-alanine was achieved by disrupting the gene encoding alanine racemase, opening the door to the industrial production of this stereoisomer in food products or bioreactors.	NIZO Food Res, Microbial Ingredients Sect, NL-6710 BA Ede, Netherlands; Univ Catholique Louvain, Genet Mol Lab, B-1348 Louvain, Belgium; Univ Catholique Louvain, Chim Phys & Cristallog Lab, B-1348 Louvain, Belgium	NIZO Food Research; Universite Catholique Louvain; Universite Catholique Louvain	Hols, P (corresponding author), NIZO Food Res, Microbial Ingredients Sect, POB 20, NL-6710 BA Ede, Netherlands.		Kleerebezem, Michiel/AAT-2078-2021	Kleerebezem, Michiel/0000-0001-8552-2235				BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEN JD, 1988, GENE, V64, P155, DOI 10.1016/0378-1119(88)90489-1; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; deVos WM, 1996, ANTON LEEUW INT J G, V70, P223, DOI 10.1007/BF00395934; ELMANNS B, 1995, BIOSCOPE, V2, P39; Ferain T, 1996, J BACTERIOL, V178, P7311, DOI 10.1128/jb.178.24.7311-7315.1996; FERAIN T, 1994, J BACTERIOL, V176, P596, DOI 10.1128/jb.176.3.596-601.1994; FERRARI E, 1985, BIO-TECHNOL, V3, P1003, DOI 10.1038/nbt1185-1003; FOUCAUD C, 1995, LETT APPL MICROBIOL, V21, P10, DOI 10.1111/j.1472-765X.1995.tb00994.x; FURUI M, 1983, J FERMENT TECHNOL, V61, P587; Galkin A, 1997, APPL ENVIRON MICROB, V63, P4651, DOI 10.1128/AEM.63.12.4651-4656.1997; HASHIMOTO S, 1993, BIOTECHNOL LETT, V15, P1117, DOI 10.1007/BF00131200; HILLIER AJ, 1982, METHOD ENZYMOL, V89, P362; HIROSE Y, 1979, MICROBIAL TECHNOLOGY, P211; Hols P, 1997, J BACTERIOL, V179, P3804, DOI 10.1128/jb.179.11.3804-3807.1997; KITAI A, 1972, MICROBIAL PRODUCTION, P325; Kuipers OP, 1997, TRENDS BIOTECHNOL, V15, P135, DOI 10.1016/S0167-7799(97)01029-9; KURODA SI, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00456a025; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENHOUTS KJ, 1989, APPL ENVIRON MICROB, V55, P394, DOI 10.1128/AEM.55.2.394-400.1989; LEUCHTENBERGER W, 1996, PRODUCTS PRIMARY MET, V6, P465; LOBOCKA M, 1994, J BACTERIOL, V176, P1500, DOI 10.1128/jb.176.5.1500-1510.1994; MOU L, 1976, J DAIRY RES, V43, P275, DOI 10.1017/S0022029900015831; OHASHIMA T, 1979, EUR J BIOCHEM, V100, P29, DOI 10.1111/j.1432-1033.1979.tb02030.x; OHTA K, 1991, APPL ENVIRON MICROB, V57, P893, DOI 10.1128/AEM.57.4.893-900.1991; OHTA T, 1994, APPL MICROBIOL BIOT, V42, P246, DOI [10.1007/BF00902724, 10.1007/s002530050245]; Orlygsson J, 1995, ANTON LEEUW INT J G, V68, P273, DOI 10.1007/BF00874136; PLATTEEUW C, 1995, APPL ENVIRON MICROB, V61, P3967, DOI 10.1128/AEM.61.11.3967-3971.1995; Ravot G, 1996, APPL ENVIRON MICROB, V62, P2657, DOI 10.1128/AEM.62.7.2657-2659.1996; Sambrook J., 2002, MOL CLONING LAB MANU; SNOEP JL, 1992, J BACTERIOL, V174, P4838, DOI 10.1128/JB.174.14.4838-4841.1992; STARRENBURG MJC, 1991, APPL ENVIRON MICROB, V57, P3535, DOI 10.1128/AEM.57.12.3535-3540.1991; UHLENBUSCH I, 1991, APPL ENVIRON MICROB, V57, P1360, DOI 10.1128/AEM.57.5.1360-1366.1991; VEGARUD G, 1983, J DAIRY SCI, V66, P2294, DOI 10.3168/jds.S0022-0302(83)82085-2; VOS P, 1989, J BACTERIOL, V171, P2795, DOI 10.1128/jb.171.5.2795-2802.1989; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; YAMAMOTO T, 1985, PHYSIOL BEHAV, V35, P411, DOI 10.1016/0031-9384(85)90317-8	40	137	153	0	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					588	592		10.1038/9902	http://dx.doi.org/10.1038/9902			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385325				2022-12-25	WOS:000080716500032
J	Cheng, SWG; Davies, KP; Yung, E; Beltran, RJ; Yu, J; Kalpana, GV				Cheng, SWG; Davies, KP; Yung, E; Beltran, RJ; Yu, J; Kalpana, GV			c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function	NATURE GENETICS			English	Article							TRANSCRIPTIONAL REPRESSION; PROTEIN; GROWTH; TRANSFORMATION; INTEGRASE; MACHINES; NETWORK; DOMAIN; SNF5	Chromatin organization plays a key role in the regulation of gene expression(1,2). The evolutionarily conserved SWI/SNF complex is one of several multiprotein complexes that activate transcription by remodelling chromatin in an ATP-dependent manner(3-5). SWI2/SNF2 is an ATPase whose homologues, BRG1 and hBRM, mediate cell-cycle arrest(6,7); the SNF5 homologue, INI1/hSNF5, appears to be a tumour suppressor(8,9). A search for INI1-interacting proteins using the two-hybrid system(10,11) led to the isolation of c-MYC, a transactivator(12,13). The c-MYC-INI1 interaction was observed both in vitro and in vivo. The c-MYC basic helix-loop-helix (bHLH) and leucine zipper (Zip) domains and the INI1 repeat 1 (Rpt1) region were required for this interaction. c-MYC-mediated transactivation was inhibited by a deletion fragment of INI1 and the ATPase mutant of BRG1/hSNF2 in a dominant-negative manner contingent upon the presence of the c-MYC bHLH-Zip domain. Our results suggest that the SWI/SNF complex is necessary for c-MYC-mediated transactivation and that the c-MYC-INI1 interaction helps recruit the complex.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Columbia University	Kalpana, GV (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,U821, Bronx, NY 10461 USA.	kalpana@aecom.yu.edu		Yung, Eric/0000-0002-7328-7204; Davies, Kelvin/0000-0002-0201-9210; Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI039951, R21AI039951, R01AI039951] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39951] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Biegel JA, 1999, CANCER RES, V59, P74; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Young KH, 1998, BIOL REPROD, V58, P302, DOI 10.1095/biolreprod58.2.302	23	298	312	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					102	105		10.1038/8811	http://dx.doi.org/10.1038/8811			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319872				2022-12-25	WOS:000080096300033
J	Humes, HD; Buffington, DA; MacKay, SM; Funke, AJ; Weitzel, WF				Humes, HD; Buffington, DA; MacKay, SM; Funke, AJ; Weitzel, WF			Replacement of renal function in uremic animals with a tissue-engineered kidney	NATURE BIOTECHNOLOGY			English	Article						tissue engineering; cell therapy; kidney tubule cells	CRITICALLY ILL PATIENTS; BIOARTIFICIAL PANCREAS; GROWTH-FACTORS; FAILURE; TUBULE	Current renal substitution therapy with hemodialysis or hemofiltration has been the only successful long-term ex vivo organ substitution therapy to date. Although this approach is life sustaining, it is still unacceptably suboptimal with poor clinical outcomes of patients with either chronic end-stage renal disease or acute renal failure. This current therapy utilizes synthetic membranes to substitute for the small solute clearance function of the renal glomerulus but does not replace the transport, metabolic, and endocrinologic functions of the tubular cells. The addition of tubule cell replacement therapy in a tissue-engineered bioartificial kidney comprising both biologic and synthetic components will likely optimize renal replacement to improve clinical outcomes. This report demonstrates that the combination of a synthetic hemofiltration device and a renal tubule cell therapy device containing porcine renal tubule cells in an extracorporeal perfusion circuit successfully replaces filtration, transport, metabolic, and endocrinologic functions of the kidney in acutely uremic dogs.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Humes, HD (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.	dhumes@umich.edu		Westover, Angela/0000-0002-7556-9838; Humes, David/0000-0002-4309-1614; Buffington, Deborah/0000-0002-1541-2003	NIDDK NIH HHS [DK-48175, DK-39255, DK-50539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R44DK050539, R43DK050539, R43DK048175, P50DK039255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY CA, 1996, KIDNEY, P334; BIDLACK JM, 1976, COMP BIOCHEM PHYS B, V55, P161, DOI 10.1016/0305-0491(76)90223-6; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; CURTHOYS NP, 1983, MINER ELECTROL METAB, V9, P236; Gage FH, 1998, NATURE, V392, P18; Humes HD, 1996, AM J PHYSIOL-RENAL, V271, pF42, DOI 10.1152/ajprenal.1996.271.1.F42; HUMES HD, 1992, EXP CELL RES, V201, P8, DOI 10.1016/0014-4827(92)90342-6; Humes HD, 1997, AM J KIDNEY DIS, V30, pS28, DOI 10.1016/S0272-6386(97)90539-4; HUMES HD, 1995, KIDNEY INT, V48, pS26; Humes HD, 1997, P ASSOC AM PHYSICIAN, V109, P547; HUMES HD, IN PRESS KIDNEY INT; Humes HD, 1995, BIOMEDICAL ENG HDB, P1807; KNOX FG, 1983, CIRC RES, V52, P491, DOI 10.1161/01.RES.52.5.491; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LEHMANN J, 1983, RENAL ENDOCRINOLOGYE, P114; MacKay SM, 1998, ASAIO J, V44, P179, DOI 10.1097/00002480-199805000-00011; Maki T, 1996, DIABETES, V45, P342, DOI 10.2337/diabetes.45.3.342; MEHTA RL, 1994, SEMIN NEPHROL, V14, P64; NIKOLOVSKI J, IN PRESS CELL TRANSP; ONeil JJ, 1997, TRANSPLANT P, V29, P2116, DOI 10.1016/S0041-1345(97)00255-8; PITTS RF, 1945, SCIENCE, V102, P49, DOI 10.1126/science.102.2638.49; PITTS RF, 1945, SCIENCE, V102, P81, DOI 10.1126/science.102.2639.81; PITTS RF, 1948, FED PROC, V7, P418; SCHOOLWERTH AC, 1991, KIDNEY INT, V40, P961, DOI 10.1038/ki.1991.301; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Watanabe FD, 1997, ANN SURG, V225, P484, DOI 10.1097/00000658-199705000-00005; Yagi N, 1997, SEMIN NEPHROL, V17, P306; ZAROWITZ BJ, 1986, J CLIN PHARMACOL, V26, P686, DOI 10.1002/j.1552-4604.1986.tb02973.x; 1998, AM J KIDNEY DIS S1, V32, P669	29	209	243	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					451	455		10.1038/8626	http://dx.doi.org/10.1038/8626			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331803				2022-12-25	WOS:000080074500028
J	Jeddeloh, JA; Stokes, TL; Richards, EJ				Jeddeloh, JA; Stokes, TL; Richards, EJ			Maintenance of genomic methylation requires a SW12/SNF2-like protein	NATURE GENETICS			English	Article							DNA METHYLATION; HISTONE DEACETYLASE; PLANT DEVELOPMENT; ARABIDOPSIS; MUTATIONS; TRANSCRIPTION; SUPERFAMILY; NEUROSPORA; MUTANTS	Altering cytosine methylation by genetic means leads to a variety of developmental defects in mice(1), plants(2-5) and fungi(6,7) Deregulation of cytosine methylation also has a role in human carcinogenesis(8). In some cases, these defects have been tied to the inheritance of epigenetic alterations (such as chromatin imprints and DNA methylation patterns) that do not involve changes in DNA sequence(3,8-10). Using a forward genetic screen, we identified a gene (DDM1, decrease in DNA methylation) from the flowering plant Arabidopsis thaliana required to maintain normal cytosine methylation patterns(11). Additional ddm1 alleles (som4, 5, 6, 7, 8) were isolated in a selection for mutations that relieved transgene silencing(12) (E.J.R., unpublished data). Loss of DDM1 function causes a 70% reduction of genomic cytosine methylation, with most of the immediate hypomethylation occurring in repeated sequences(11). In contrast, many low-copy sequences initially retain their methylation in ddm1 homozygotes, but lose methylation over time as the mutants are propagated through multiple generations by self-pollination(3,13). The progressive effect of ddm1 mutations on low-copy sequence methylation suggests that ddm1 mutations compromise the efficiency of methylation of newly incorporated cytosines after DNA replication. In parallel with the slow decay of methylation during inbreeding, ddm1 mutants accumulate heritable alterations (mutations or stable epialleles) at dispersed sites in the genome that lead to morphological abnormalities(3,5,14). Here we report that DDM1 encodes a SWI2/SNF2-like protein, implicating chromatin remodelling as an important process for maintenance of DNA methylation and genome integrity.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Richards, EJ (corresponding author), Washington Univ, Dept Biol, 1 Brookings Dr, St Louis, MO 63130 USA.	richards@biology.wustl.edu	Richards, Eric/E-6866-2012	Richards, Eric/0000-0002-8665-7470				Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; CHOI S, 1995, WEEDS WORLD, V2, P17; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; ELSEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; FOSS HM, 1993, SCIENCE, V262, P1737, DOI 10.1126/science.7505062; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jarvis CD, 1996, GENE, V169, P203, DOI 10.1016/0378-1119(95)00843-8; Jeddeloh JA, 1998, GENE DEV, V12, P1714, DOI 10.1101/gad.12.11.1714; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAKUTANI T, 1995, NUCLEIC ACIDS RES, V23, P130, DOI 10.1093/nar/23.1.130; Kakutani T, 1997, PLANT J, V12, P1447, DOI 10.1046/j.1365-313x.1997.12061447.x; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Malagnac F, 1997, CELL, V91, P281, DOI 10.1016/S0092-8674(00)80410-9; Martienssen R, 1998, CURR OPIN GENET DEV, V8, P240, DOI 10.1016/S0959-437X(98)80147-0; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Richards EJ, 1997, TRENDS GENET, V13, P319, DOI 10.1016/S0168-9525(97)01199-2; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Scheid OM, 1998, P NATL ACAD SCI USA, V95, P632, DOI 10.1073/pnas.95.2.632; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	31	537	562	0	22	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					94	97		10.1038/8803	http://dx.doi.org/10.1038/8803			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319870				2022-12-25	WOS:000080096300031
J	Kaessmann, H; Heissig, F; von Haeseler, A; Paabo, S				Kaessmann, H; Heissig, F; von Haeseler, A; Paabo, S			DNA sequence variation in a non-coding region of low recombination on the human X chromosome	NATURE GENETICS			English	Article							EVOLUTION; DISTRIBUTIONS; POLYMORPHISMS; SITES	DNA sequence variation has become a major source of insight regarding the origin and history of our species(1-5) as well as an important tool for the identification of allelic variants associated with disease. Comparative sequencing of DNA has to date focused mainly on mitochondrial (mt) DNA, which due to its apparent lack of recombination and high evolutionary rate lends itself well to the study of human evolution(1). These advantages also entail limitations. For example, the high mutation rate of mtDNA results in multiple substitutions that make phylogenetic analysis difficult and, because mtDNA is maternally inherited, it reflects only the history of females. For the history of males, the non-recombining part of the paternally inherited Y chromosome can be studied(2). The extent of variation on the Y chromosome is so low that variation at particular sites known to be polymorphic rather than entire sequences are typically determined(6). It is currently unclear how some forms of analysis (such as the coalescent) should be applied to such data, Furthermore, the lack of recombination means that selection at any locus affects all 59 Mb of DNA. To gauge the extent and pattern of point substitutional variation in non-coding parts of the human genome, we have sequenced 10 kb of non-coding DNA in a region of low recombination at Xq13.3. Analysis of this sequence in 69 individuals representing all major linguistic groups reveals the highest overall diversity in Africa, whereas deep divergences also exist in Asia. The time elapsed since the most recent common ancestor (MRCA) is 535.000+/-119.000 years, We expect this type of nuclear locus to provide more answers about the genetic origin and history of humans.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany	Max Planck Society	Kaessmann, H (corresponding author), Max Planck Inst Evolutionary Anthropol, Inselstr 22, D-04103 Leipzig, Germany.		von Haeseler, Arndt/HCI-9958-2022; Kaessmann, Henrik/B-4989-2013	von Haeseler, Arndt/0000-0002-3366-4458; Kaessmann, Henrik/0000-0001-7563-839X				ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; CHARLESWORTH B, 1993, GENETICS, V134, P1289; Foley R, 1998, GENOME RES, V8, P339, DOI 10.1101/gr.8.4.339; GRIFFITHS RC, 1995, MATH BIOSCI, V127, P77, DOI 10.1016/0025-5564(94)00044-Z; GRIFFITHS RC, 1994, THEOR POPUL BIOL, V46, P131, DOI 10.1006/tpbi.1994.1023; Hammer MF, 1997, GENETICS, V145, P787; Harding RM, 1997, AM J HUM GENET, V60, P772; Harris EE, 1999, P NATL ACAD SCI USA, V96, P3320, DOI 10.1073/pnas.96.6.3320; Kimmel M, 1998, GENETICS, V148, P1921; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Nachman MW, 1998, GENETICS, V150, P1133; Nagaraja R, 1997, GENOME RES, V7, P210, DOI 10.1101/gr.7.3.210; NELSON DL, 1995, CYTOGENET CELL GENET, V71, P308; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Robinson BH, 1996, J INHERIT METAB DIS, V19, P452, DOI 10.1007/BF01799106; Ruhlen M, 1991, GUIDE WORLDS LANGUAG; SATTA Y, 1998, FRONT BIOSCI, V3, P459; SHERRY ST, 1994, HUM BIOL, V66, P761; Stoneking M, 1997, GENOME RES, V7, P1061, DOI 10.1101/gr.7.11.1061; STONEKING M, 1997, PROGR POPULATION GEN, P1; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; TAJIMA F, 1989, GENETICS, V123, P585; TAKAHATA N, 1995, ANNU REV ECOL SYST, V26, P342; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; WARD RH, 1993, P NATL ACAD SCI USA, V90, P10663, DOI 10.1073/pnas.90.22.10663; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WEISS G, 1996, SCIENCE, V272, P1358; Wilson JF, 1998, BIOL CHEM, V379, P1287; Wolpoff M. H., 1997, RACE HUMAN EVOLUTION	31	184	188	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					78	81		10.1038/8785	http://dx.doi.org/10.1038/8785			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319866				2022-12-25	WOS:000080096300027
J	Das Gupta, R; Kolodner, RD				Das Gupta, R; Kolodner, RD			Novel dominant mutations in Saccharomyces cerevisiae MSH6	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; HMUTS-ALPHA; GENE; DNA; MUTAGENESIS; ALLELES; HMSH2; PMS2	Inherited mutations in the mismatch repair (MMR) genes MSH2 and MLH1 are found in most hereditary nonpolyposis colon cancer (HNPCC) patients studied(1). Eukaryotic MMR uses two partially redundant mispair-recognition complexes, Msh2p -Msh6p and Msh2p-Msh3p (ref. 2). Inactivation of MSH2 causes high rates of accumulation of both base-substitution and frameshift mutations. Mutations in MSH6 or MSH3 cause partial defects in MMR, with inactivation of MSH6 resulting in high rates of base-substitution mutations and low rates of frameshift mutations; inactivation of MSH3 results in low rates of frameshift mutations. These different mutator phenotypes provide an explanation for the observation that MSH2 mutations are common in HNPCC families, whereas mutations in MSH3 and MSH6 are rare(1,3-5). We have identified novel missense mutations in Saccharomyces cerevisiae MSH6 that appear to inactivate both Msh2p-Msh6p- and Msh2p-Msh3p-dependent MMR. Our work suggests that such mutations may underlie some cases of inherited cancer susceptibility similar to those caused by MSH2 mutations.	Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med & Canc Ctr, Sch Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med & Canc Ctr, Sch Med, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama Y, 1997, CANCER RES, V57, P3920; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 1999, J BIOL CHEM, V274, P16115, DOI 10.1074/jbc.274.23.16115; Clark AB, 1999, NUCLEIC ACIDS RES, V27, P736, DOI 10.1093/nar/27.3.736; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Jeyaprakash A, 1996, MOL CELL BIOL, V16, P3008; JEYAPRAKASH A, 1994, MUTAT RES LETT, V325, P21, DOI 10.1016/0165-7992(94)90023-X; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolodner RD, 1999, CANCER RES, V59, P5068; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Rose MD., 1990, METHODS YEAST GENETI; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; Umezu K, 1998, GENETICS, V148, P989; Verma L, 1999, J MED GENET, V36, P678; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; WILLIAMSON MS, 1985, GENETICS, V110, P609; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612	27	51	52	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					53	56		10.1038/71684	http://dx.doi.org/10.1038/71684			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615127				2022-12-25	WOS:000084609200015
J	Momeni, P; Glockner, G; Schmidt, O; von Holtum, D; Albrecht, B; Gillessen-Kaesbach, G; Hennekam, R; Meinecke, P; Zabel, B; Rosenthal, A; Horsthemke, B; Ludecke, HJ				Momeni, P; Glockner, G; Schmidt, O; von Holtum, D; Albrecht, B; Gillessen-Kaesbach, G; Hennekam, R; Meinecke, P; Zabel, B; Rosenthal, A; Horsthemke, B; Ludecke, HJ			Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhino-phalangeal syndrome type I	NATURE GENETICS			English	Article							LANGER-GIEDION SYNDROME; LOCALIZATION; SEQUENCE; EXT1	Tricho-rhino-phalangeal syndrome type I (TRPS I, MIM 190350) is a malformation syndrome characterized by craniofacial and skeletal abnormalities and is inherited in an autosomal dominant manner(1). TRPS I patients have sparse scalp hair, a bulbous tip of the nose, a long flat philtrum, a thin upper vermilion border and protruding ears. Skeletal abnormalities include cone-shaped epiphyses at the phalanges, hip malformations and short stature. We assigned TRPS1 to human chromosome 8q24. It maps proximal of EXT1, which is affected in a subgroup of patients with multiple cartilaginous exostoses and deleted in all patients with TRPS type II (TRPS II, or Langer-Giedion syndrome, MIM 150230; refs 2-5). We have positionally cloned a gene that spans the chromosomal breakpoint of two patients with TRPS I and is deleted in five patients with TRPS I and an interstitial deletion(4,6). Northern-blot analyses revealed transcripts of 7 and 10.5 kb. TRPS1 has seven exons and an ORF of 3.843 bp. The predicted protein sequence has two potential nuclear localization signals and an unusual combination of different zinc-finger motifs, including IKAROS-like and GATA-binding sequences. We identified six different nonsense mutations in ten unrelated patients. Our findings suggest that haploinsufficiency for this putative transcription factor causes TRPS I.	Univ Essen Gesamthsch Klinikum, Inst Human Genet, D-4300 Essen, Germany; Inst Mol Biotechnol, Abt Genomanal, Jena, Germany; Univ Amsterdam, Dept Clin Genet & Pediat, Amsterdam, Netherlands; Altonaer Kinderkrankenhaus, Abt Med Genet, Hamburg, Germany; Klinikum Univ Mainz, Kinderklin & Poliklin, Mainz, Germany	University of Duisburg Essen; University of Amsterdam; University of Hamburg; University Medical Center Hamburg-Eppendorf	Ludecke, HJ (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Human Genet, D-4300 Essen, Germany.	hj.luedecke@uni-essen.de	Glöckner, Gernot/A-7800-2010	Glöckner, Gernot/0000-0002-9061-1061				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Antonarakis SE, 1998, HUM MUTAT, V11, P1; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Dai KS, 1998, J MOL CELL CARDIOL, V30, P2365, DOI 10.1006/jmcc.1998.0797; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GIEDION A, 1973, HELV PAEDIATR ACTA, V28, P249; Glockner G, 1998, GENOME RES, V8, P1060; HOU J, 1995, GENOMICS, V29, P87, DOI 10.1006/geno.1995.1218; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; Kalff-Suske M, 1999, HUM MOL GENET, V8, P1769, DOI 10.1093/hmg/8.9.1769; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LUDECKE HJ, 1995, HUM MOL GENET, V4, P31, DOI 10.1093/hmg/4.1.31; LUDECKE HJ, IN PRESS HUM GENET; Nardmann J, 1997, HUM GENET, V99, P638, DOI 10.1007/s004390050420; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; YI Y, 1999, HUM MOL GENET, V8, P533	19	217	234	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2000	24	1					71	74		10.1038/71717	http://dx.doi.org/10.1038/71717			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615131				2022-12-25	WOS:000084609200019
J	Park, F; Ohashi, K; Chiu, W; Naldini, L; Kay, MA				Park, F; Ohashi, K; Chiu, W; Naldini, L; Kay, MA			Efficient lentiviral transduction of liver requires cell cycling in vivo	NATURE GENETICS			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MEDIATED GENE-TRANSFER; IN-VIVO; VECTOR; INTEGRATION; EXPRESSION; DELIVERY; MICE; HEPATOCYTES; PERSISTENT	Human-immunodeficiency-virus (HIV)-based lentiviral vectors are a promising tool for in vivo gene therapy(1). Unlike Moloney-murine-leukaemia-based retroviruses (MLV), lentiviruses are believed to stably transduce quiescent (non-cycling) cells in various organs(2-6). No previous studies, however, have directly established the cell-cycle status of any transduced cell type at the time of vector administration in vivo. In vitro studies using wild-type HIV or HIV-based vectors have shown that, in some cases, cell-cycle activation is required for infection, even though cellular mitosis is not an absolute requirement for integration(7-9). Even if the block in reverse transcription is overcome in quiescent T cells, productive infection by HIV cannot be rescued in the absence of cell-cycle activation(7,10). The potential use of these vectors for gene therapy prompted our study, which establishes a cell-cycle requirement for efficient transduction of hepatocytes in vivo.	Stanford Univ, Dept Pediat & Genet, Stanford, CA 94305 USA; Univ Turin, Sch Med, Canc Res Inst, Turin, Italy	Stanford University; University of Turin	Kay, MA (corresponding author), Stanford Univ, Dept Pediat & Genet, Stanford, CA 94305 USA.		Naldini, Luigi/E-9083-2012; Park, Frank/I-4590-2019	Park, Frank/0000-0003-2324-2937; Kay, Mark/0000-0002-2799-2615; NALDINI, Luigi/0000-0002-7835-527X	NHLBI NIH HHS [R01-HL53682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreadis ST, 1997, J VIROL, V71, P7541, DOI 10.1128/JVI.71.10.7541-7548.1997; Blomer U, 1997, J VIROL, V71, P6641; BRANCHEREAU S, 1994, HUM GENE THER, V5, P803, DOI 10.1089/hum.1994.5.7-803; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Gao CH, 1999, HUM GENE THER, V10, P911, DOI 10.1089/10430349950018319; Higgins GM, 1931, ARCH PATHOL, V12, P186; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KAY MA, 1992, HUM GENE THER, V3, P641, DOI 10.1089/hum.1992.3.6-641; Korin YD, 1999, J VIROL, V73, P6526, DOI 10.1128/JVI.73.8.6526-6532.1999; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; Liu ML, 1996, J VIROL, V70, P2497, DOI 10.1128/JVI.70.4.2497-2502.1996; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Patijn GA, 1998, HEPATOLOGY, V28, P707, DOI 10.1002/hep.510280317; Poeschla E, 1996, P NATL ACAD SCI USA, V93, P11395, DOI 10.1073/pnas.93.21.11395; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; Sutton RE, 1999, J VIROL, V73, P3649, DOI 10.1128/JVI.73.5.3649-3660.1999; YOSHIMURA S, 1989, TRANSPL P, V21, P911; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	26	172	181	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					49	52		10.1038/71673	http://dx.doi.org/10.1038/71673			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615126				2022-12-25	WOS:000084609200014
J	Potocki, L; Chen, KS; Park, SS; Osterholm, DE; Withers, MA; Kimonis, V; Summers, AM; Meschino, WS; Anyane-Yeboa, K; Kashork, CD; Shaffer, LG; Lupski, JR				Potocki, L; Chen, KS; Park, SS; Osterholm, DE; Withers, MA; Kimonis, V; Summers, AM; Meschino, WS; Anyane-Yeboa, K; Kashork, CD; Shaffer, LG; Lupski, JR			Molecular mechanism for duplication 17p11.2 - the homologous recombination reciprocal of the Smith-Magenis microdeletion	NATURE GENETICS			English	Article							MARIE-TOOTH-DISEASE; GENE; TYPE-1A; REARRANGEMENTS; BREAKPOINTS; DELETIONS; CMT1A; HNPP	Recombination between repeated sequences at Various loci of the human genome are known to give rise to DNA rearrangements associated with many genetic disorders'. Perhaps the most extensively characterized genomic region prone to rearrangement is 17p12, which is associated with the peripheral neuropathies, hereditary neuropathy with liability to pressure palsies (HNPP) and Charcot-Marie-Tooth disease type 1A (CMT1A; ref. 2). Homologous recombination between 24-kb flanking repeats, termed CMT1A-REPs, results in a 1.5-Mb deletion that is associated with HNPP, and the reciprocal duplication product is associated with CMT1A (ref. 2). Smith-Magenis syndrome (SMS) is a multiple congenital anomalies, mental retardation syndrome associated with a chromosome 17 microdeletion, del(17)(p11.2p11.2) (refs 3,4). Most patients (>90%) carry deletions of the same genetic markers and define a common deletion(5-7). We report seven unrelated patients with de novo duplications of the same region deleted in SMS. A unique junction fragment, of the same apparent size, was identified in each patient by pulsed field gel electrophoresis (PFGE). Further molecular analyses suggest that the de novo 17p11.2 duplication is preferentially paternal in origin, arises from unequal crossing over due to homologous recombination between flanking repeat gene clusters and probably represents the reciprocal recombination product of the SMS deletion. The clinical phenotype resulting from duplication [dup(17)(p11.2p11.2)] is milder than that associated with deficiency of this genomic region. This mechanism of reciprocal deletion and duplication via homologous recombination may not only pertain to the 17p11.2 region, but may also be common to other regions of the genome where interstitial microdeletion syndromes have been defined.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Hosp, Houston, TX 77030 USA; So Illinois Univ, Sch Med, Dept Pediat, Springfield, IL USA; N York Gen Hosp, Dept Genet, Toronto, ON, Canada; Columbia Univ, Dept Pediat, New York, NY 10027 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Southern Illinois University System; Southern Illinois University; University of Toronto; University Toronto Affiliates; North York General Hospital; Columbia University	Lupski, JR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Park, Sung Sup/J-2756-2012; Chen, Ken-Shiung/A-2204-2011	Anyane-Yeboa, Kwame/0000-0002-4977-9719; Park, Sung Sup/0000-0003-3754-4848	NCI NIH HHS [P01CA75719] Funding Source: Medline; NICHD NIH HHS [K08HD01149, HD2406402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA075719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amos-Landgraf JM, 1999, AM J HUM GENET, V65, P370, DOI 10.1086/302510; Buiting K, 1998, CYTOGENET CELL GENET, V81, P247, DOI 10.1159/000015039; CHEN HK, 1995, BONE, V17, P175; Chen K-S, 1996, MENTAL RETARD DEV DI, V2, P122; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Christian SL, 1999, HUM MOL GENET, V8, P1025, DOI 10.1093/hmg/8.6.1025; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; Elsea SH, 1997, CYTOGENET CELL GENET, V79, P276, DOI 10.1159/000134742; GREENBERG F, 1991, AM J HUM GENET, V49, P1207; Greenberg F, 1996, AM J MED GENET, V62, P247, DOI 10.1002/(SICI)1096-8628(19960329)62:3<247::AID-AJMG9>3.3.CO;2-9; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Juyal RC, 1996, AM J HUM GENET, V58, P998; KOZMA C, 1991, AM J MED GENET, V41, P446, DOI 10.1002/ajmg.1320410413; Lopes J, 1997, NAT GENET, V17, P136, DOI 10.1038/ng1097-136; Lupski JR, 1998, MOL MED, V4, P3, DOI 10.1007/BF03401724; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Osborne LR, 1997, GENOMICS, V45, P402, DOI 10.1006/geno.1997.4923; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; Pereira MM, 1996, J SOL-GEL SCI TECHN, V7, P59, DOI 10.1007/BF00401884; Potocki L, 1999, AM J HUM GENET, V64, P471, DOI 10.1086/302240; Repetto GR, 1998, AM J MED GENET, V79, P82, DOI 10.1002/(SICI)1096-8628(19980901)79:2<82::AID-AJMG2>3.0.CO;2-P; Roa BB, 1996, HUM GENET, V97, P642; Shaffer LG, 1997, AM J MED GENET, V69, P325, DOI 10.1002/(SICI)1096-8628(19970331)69:3<325::AID-AJMG20>3.0.CO;2-S; Zhao Q, 1998, GENOMICS, V49, P394, DOI 10.1006/geno.1998.5285	27	238	243	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2000	24	1					84	87		10.1038/71743	http://dx.doi.org/10.1038/71743			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	271TH	10615134	Green Published			2022-12-25	WOS:000084609200022
J	Quintana-Murci, L; Semino, O; Bandelt, HJ; Passarino, G; McElreavey, K; Santachiara-Benerecetti, AS				Quintana-Murci, L; Semino, O; Bandelt, HJ; Passarino, G; McElreavey, K; Santachiara-Benerecetti, AS			Genetic evidence of an early exit of Homo sapiens sapiens from Africa through eastern Africa	NATURE GENETICS			English	Article							HUMAN MITOCHONDRIAL-DNA; MTDNA VARIATION; CONTROL REGION; NEW-WORLD; POPULATIONS; ORIGIN; POLYMORPHISMS; DIVERSITY; SEQUENCE; EVOLUTION	The out-of-Africa scenario(1) has hitherto provided little evidence for the precise route by which modern humans left Africa. Two major routes of dispersal have been hypothesized: one through North Africa into the Levant, documented by fossil remains(2), and one through Ethiopia along South Asia, for which little, if any, evidence exists(3). Mitochondrial DNA (mtDNA) can be used to trace maternal ancestry, The geographic distribution and variation of mtDNAs can be highly informative in defining potential range expansions and migration routes in the distant past. The mitochondrial haplogroup M, first regarded as an ancient marker of East-Asian origin(4,5), has been found at high frequency in India(6) and Ethiopia(7), raising the question of its origin. (A haplogroup is a group of haplotypes that share some sequence variations.) Its variation and geographical distribution suggest that Asian haplogroup M separated from eastern-African haplogroup M more than 50.000 years ago. Two other variants (489C and 10873C) also support a single origin of haplogroup M in Africa. These findings, together with the virtual absence of haplogroup M in the Levant and its high frequency in the South-Arabian peninsula, render Rn the first genetic indicator for the hypothesized exit route from Africa through eastern Africa/western India. This was possibly the only successful early dispersal event of modern humans out of Africa.	Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy; Univ Hamburg, Math Seminar, D-2000 Hamburg, Germany; Univ Calabria, Dipartimento Biol Cellulare, Calabria, Italy; Inst Pasteur, Unite Immunogenet Humaine, Paris, France	University of Pavia; University of Hamburg; University of Calabria; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Santachiara-Benerecetti, AS (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol, Via Palestro 3, I-27100 Pavia, Italy.		Quintana-Murci, Lluis/AAB-7468-2022; Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284; Quintana-Murci, Lluis/0000-0003-2429-6320; SEMINO, Ornella/0000-0002-9675-9403				BANDELT HJ, 1995, GENETICS, V141, P743; Brown MD, 1998, AM J HUM GENET, V63, P1852, DOI 10.1086/302155; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHEN YS, 1995, AM J HUM GENET, V57, P133; CorteReal HBSM, 1996, ANN HUM GENET, V60, P331, DOI 10.1111/j.1469-1809.1996.tb01196.x; EXCOFFIER L, 1989, AM J HUM GENET, V44, P73; Forster P, 1996, AM J HUM GENET, V59, P935; GRAVEN L, 1995, MOL BIOL EVOL, V12, P334; HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532; Jin L, 1999, P NATL ACAD SCI USA, V96, P3796, DOI 10.1073/pnas.96.7.3796; Kolman CJ, 1996, GENETICS, V142, P1321; Krings M, 1999, AM J HUM GENET, V64, P1166, DOI 10.1086/302314; Lahr Marta Mirazon, 1994, Evolutionary Anthropology, V3, P48, DOI 10.1002/evan.1360030206; LEWIN R, 1987, SCIENCE, V237, P1292, DOI 10.1126/science.3114877; Lutz S, 1998, INT J LEGAL MED, V111, P67, DOI 10.1007/s004140050117; Lutz S, 1999, INT J LEGAL MED, V112, P145; Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204; MOUNTAIN JL, 1995, AM J HUM GENET, V56, P979; OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z; OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B; Passarino G, 1996, AM J HUM GENET, V59, P927; Passarino G, 1998, AM J HUM GENET, V62, P420, DOI 10.1086/301702; Rando JC, 1998, ANN HUM GENET, V62, P531, DOI 10.1046/j.1469-1809.1998.6260531.x; Schurr TG, 1999, AM J PHYS ANTHROPOL, V108, P1, DOI 10.1002/(SICI)1096-8644(199901)108:1<1::AID-AJPA1>3.0.CO;2-1; Starikovskaya YB, 1998, AM J HUM GENET, V63, P1473, DOI 10.1086/302087; STRINGER CB, 1989, NATURE, V338, P756, DOI 10.1038/338756a0; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Torroni A, 1998, AM J HUM GENET, V62, P1137, DOI 10.1086/301822; TORRONI A, 1993, AM J HUM GENET, V53, P563; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Watson E, 1997, AM J HUM GENET, V61, P691, DOI 10.1086/515503	31	371	383	0	90	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	DEC	1999	23	4					437	441		10.1038/70550	http://dx.doi.org/10.1038/70550			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581031				2022-12-25	WOS:000084023900020
J	Smith, LEH; Shen, W; Perruzzi, C; Soker, S; Kinose, F; Xu, XH; Robinson, G; Driver, S; Bischoff, J; Zhang, B; Schaeffer, JM; Senger, DR				Smith, LEH; Shen, W; Perruzzi, C; Soker, S; Kinose, F; Xu, XH; Robinson, G; Driver, S; Bischoff, J; Zhang, B; Schaeffer, JM; Senger, DR			Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor	NATURE MEDICINE			English	Article							PROLIFERATIVE DIABETIC-RETINOPATHY; ACTIVATED PROTEIN-KINASE; FACTOR-I; CELL-PROLIFERATION; FACTOR EXPRESSION; FOLLOW-UP; IGF-I; MELLITUS; HORMONE; MOUSE	Although insulin-like growth factor 1 (IGF-1) has been associated with retinopathy, proof of a direct relationship has been lacking. Here we show that an IGF-1 receptor antagonist suppresses retinal neovascularization in vivo, and infer that interactions between IGF-1 and the IGF-1 receptor are necessary for induction of maximal neovascularization by vascular endothelial growth factor (VEGF). IGF-1 receptor regulation of VEGF action is mediated at least in part through control of VEGF activation of p44/42 mitogen- activated protein kinase, establishing a hierarchical relationship between IGF-1 and VECF receptors. These findings establish an essential role for IGF-1 in angiogenesis and demonstrate a new target for control of retinopathy. They also explain why diabetic retinopathy initially increases with the onset of insulin treatment. IGF-1 levels, low in untreated diabetes, rise with insulin therapy, permitting VEGF-induced retinopathy.	Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Merck Res Labs, Rahway, NJ 07065 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Merck & Company	Smith, LEH (corresponding author), Harvard Univ, Sch Med, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.	smith_lo@a1.tch.harvard.edu	BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974	NATIONAL EYE INSTITUTE [R01EY008670] Funding Source: NIH RePORTER; NEI NIH HHS [EY08670] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMIEL SA, 1984, DIABETES, V33, P1175, DOI 10.2337/diabetes.33.12.1175; Bischoff J, 1997, MICROCIRCULATION-LON, V4, P279, DOI 10.3109/10739689709146791; Borgstrom P, 1998, PROSTATE, V35, P1; Boulton M, 1998, BRIT J OPHTHALMOL, V82, P561, DOI 10.1136/bjo.82.5.561; CAPETANDES A, 1990, INVEST OPHTH VIS SCI, V31, P1738; Chantelau E, 1997, BMJ-BRIT MED J, V315, P1105; Chantelau E, 1997, BRIT J OPHTHALMOL, V81, P169; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; DAMATO R, 1993, MICROVASC RES, V46, P135, DOI 10.1006/mvre.1993.1042; Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647; DILLS DG, 1990, DIABETES, V39, P191, DOI 10.2337/diabetes.39.2.191; DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401; HANSSEN KF, 1985, ACTA ENDOCRINOL-COP, V110, P57; HAYRY P, 1995, FASEB J, V9, P1336; HOLLY JMP, 1988, J ENDOCRINOL, V118, P353, DOI 10.1677/joe.0.1180353; HYER SL, 1989, METABOLISM, V38, P586, DOI 10.1016/0026-0495(89)90222-9; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; MERIMEE TJ, 1970, J CLIN INVEST, V49, P1096, DOI 10.1172/JCI106325; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MOSKALETS E, 1994, J DIABETES COMPLICAT, V8, P45, DOI 10.1016/1056-8727(94)90010-8; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Pfeiffer A, 1997, DIABETES, V46, pS26, DOI 10.2337/diab.46.2.S26; Pierce EA, 1997, ARCH OPHTHALMOL-CHIC, V115, P427; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHAMOON H, 1995, ARCH OPHTHALMOL-CHIC, V113, P36; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARP PS, 1987, DIABETOLOGIA, V30, P199, DOI 10.1007/BF00270416; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706; SONKSEN PH, 1993, HORM RES, V40, P68, DOI 10.1159/000183770; Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WRIGHT AD, 1969, BRIT MED J, V2, P346, DOI 10.1136/bmj.2.5653.346; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZIMMERGALLER IE, 1995, INT OPHTHALMOL CLIN, V35, P37, DOI 10.1097/00004397-199503540-00005	54	430	462	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	1999	5	12					1390	1395		10.1038/70963	http://dx.doi.org/10.1038/70963			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	262DE	10581081				2022-12-25	WOS:000084049700038
J	Asaoka-Taguchi, M; Yamada, M; Nakamura, A; Hanyu, K; Kobayashi, S				Asaoka-Taguchi, M; Yamada, M; Nakamura, A; Hanyu, K; Kobayashi, S			Maternal Pumilio acts together with Nanos in germline development in Drosophila embryos	NATURE CELL BIOLOGY			English	Article							SEGMENTATION GENE HUNCHBACK; POSTERIOR MORPHOGEN NANOS; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; POLE CELLS; TRANSLATIONAL CONTROL; PATTERN-FORMATION; XENOPUS OOCYTES; VEGETAL CORTEX; BODY PATTERN	The maternal RNA-binding proteins Pumilio (Pum) and Nanos (Nos) act together to specify the abdomen in Drosophila embryos. Both proteins later accumulate in pole cells, the germline progenitors. Nos is required for pole cells to differentiate into functional germline. Here we show that Pum is also essential for germline development in embryos, First, a mutation in pum causes a defect in pole-cell migration into the gonads. Second, in such pole cells, the expression of a germline-specific marker (PZ198) is initiated prematurely. Finally, pum mutation causes premature mitosis in the migrating pole cells. We show that Rum inhibits pole-cell division by repressing translation of cyclin B messenger RNA. As these phenotypes are indistinguishable from those produced by nos mutation, we conclude that Pum acts together with Nos to regulate these germline-specific events.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba	Kobayashi, S (corresponding author), Leica Microsyst KK, Shinagawa Ku, E Tower 7F,Gate City Osaki,Oosaki 1-11-2, Tokyo 1410032, Japan.	skob@sakura.cc.tsukuba.ac.jp	Yamada, Masashi/AAI-1059-2020; Yamada, Masashi/AAQ-1314-2021; Nakamura, Akira/V-6869-2019	Yamada, Masashi/0000-0002-8660-1653; Nakamura, Akira/0000-0001-6506-9146; Asaoka, Miho/0000-0001-5591-8626				Asaoka M, 1998, MECH DEVELOP, V78, P153, DOI 10.1016/S0925-4773(98)00164-6; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; Bate Michael, 1993, P1013; BEAMS HW, 1974, INT REV CYTOL, V39, P413, DOI 10.1016/S0074-7696(08)60944-4; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CURTIS D, 1995, DEVELOPMENT, V121, P1899; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; EDDY EM, 1975, INT REV CYTOL, V43, P229; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; Forbes A, 1998, DEVELOPMENT, V125, P679; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; KLOC M, 1995, DEVELOPMENT, V121, P287; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; KOBAYASHI S, 1993, DEVELOPMENT, V117, P885; LAWSON KA, 1994, CIBA F SYMP, V182, P68; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; Lin HF, 1997, DEVELOPMENT, V124, P2463; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Seydoux G, 1997, DEVELOPMENT, V124, P2191; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STROME S, 1994, CIBA F SYMP, V182, P31; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; Su TT, 1998, DEV BIOL, V196, P160, DOI 10.1006/dbio.1998.8855; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; Thummel CS, 1992, DROS INF SERV, V71, P150; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; Van Doren M, 1998, CURR BIOL, V8, P243; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wharton RP, 1998, MOL CELL, V1, P863, DOI 10.1016/S1097-2765(00)80085-4; Williamson A, 1996, ANNU REV CELL DEV BI, V12, P365, DOI 10.1146/annurev.cellbio.12.1.365; ZALOKAR M, 1976, DEV BIOL, V49, P425, DOI 10.1016/0012-1606(76)90185-8; Zamore PD, 1997, RNA, V3, P1421	48	244	249	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					431	437		10.1038/15666	http://dx.doi.org/10.1038/15666			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559987				2022-12-25	WOS:000083533100016
J	Lyko, F; Ramsahoye, BH; Kashevsky, H; Tudor, M; Mastrangelo, MA; Orr-Weaver, TL; Jaenisch, R				Lyko, F; Ramsahoye, BH; Kashevsky, H; Tudor, M; Mastrangelo, MA; Orr-Weaver, TL; Jaenisch, R			Mammalian (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila	NATURE GENETICS			English	Article							SEQUENCE SPECIFICITY; EUKARYOTIC DNA; BINDING; EXPRESSION; CELLS; GENE; HYPOMETHYLATION; TRANSCRIPTION; PURIFICATION; ACTIVATION		Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Wales Coll Med, Dept Haematol, Cardiff CF4 4XN, S Glam, Wales; MIT, Dept Biol, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Cardiff University; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Tudor, Matthew/0000-0001-8766-195X	NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NIGMS NIH HHS [R01 GM039341, GM39341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039341, R29GM039341] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Lei H, 1996, DEVELOPMENT, V122, P3195; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; PATEL CV, 1987, ANAL BIOCHEM, V164, P164, DOI 10.1016/0003-2697(87)90381-2; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Wines DR, 1996, CHROMOSOMA, V104, P332, DOI 10.1007/s004120050123; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	31	158	168	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					363	366		10.1038/15551	http://dx.doi.org/10.1038/15551			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545955				2022-12-25	WOS:000083792200030
J	Malecki, MT; Jhala, US; Antonellis, A; Fields, L; Doria, A; Orban, T; Saad, M; Warram, JH; Montminy, M; Krolewski, AS				Malecki, MT; Jhala, US; Antonellis, A; Fields, L; Doria, A; Orban, T; Saad, M; Warram, JH; Montminy, M; Krolewski, AS			Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus	NATURE GENETICS			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GENE; YOUNG; P300; DIFFERENTIATION; RECOGNITION; BINDING; REGION; DIMER		Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Krolewski, AS (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA.		Doria, Alessandro/H-9157-2018	Doria, Alessandro/0000-0002-3830-4304	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK047475] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36836, DK-47475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHRISTIE MR, 1990, J EXP MED, V172, P789, DOI 10.1084/jem.172.3.789; Doria A, 1999, DIABETES CARE, V22, P253, DOI 10.2337/diacare.22.2.253; Dupont S, 1999, DIABETOLOGIA, V42, P480, DOI 10.1007/s001250051182; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Furuta H, 1998, DIABETES, V47, P1356, DOI 10.2337/diabetes.47.8.1356; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; Ji LN, 1997, DIABETES, V46, P876, DOI 10.2337/diabetes.46.5.876; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Sharma A, 1999, MOL CELL BIOL, V19, P704; Tamimi R, 1996, GENOMICS, V34, P418, DOI 10.1006/geno.1996.0306; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yokoyama M, 1996, MOL BRAIN RES, V42, P135, DOI 10.1016/S0169-328X(96)00154-4; Yoon YS, 1998, NEUROSCI LETT, V251, P17, DOI 10.1016/S0304-3940(98)00490-X	25	424	465	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					323	328		10.1038/15500	http://dx.doi.org/10.1038/15500			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545951				2022-12-25	WOS:000083792200022
J	Zhong, S; Delva, L; Rachez, C; Cenciarelli, C; Gandini, D; Zhang, H; Kalantry, S; Freedman, LP; Pandolfi, PP				Zhong, S; Delva, L; Rachez, C; Cenciarelli, C; Gandini, D; Zhang, H; Kalantry, S; Freedman, LP; Pandolfi, PP			A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RAR alpha and T18 oncoproteins	NATURE GENETICS			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; GENE-PRODUCT; HISTONE ACETYLTRANSFERASE; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; THYROID-HORMONE; PROTEIN; EXPRESSION; TRANSACTIVATION	PML and Tif1a are fused to RARA and Braf, respectively, resulting in the production of PML-RAR alpha and Tif1 alpha-B-Raf (T18) oncoproteins. Here we show that PML, Tif1 alpha and RXR alpha/RAR alpha function together in a transcription complex that is dependent on retinoic acid (RA). We found that PML acts as a ligand-dependent coactivator of RXR alpha/RAR alpha. PML interacts with Tif1 alpha and CBP. In Pml(-/-) cells, the RA-dependent induction of genes such as RARB2 and the ability of Tif1 alpha and CBP to act as transcriptional coactivators on RA are impaired. We show that both PML and Tif1 alpha are growth suppressors required for the growth-inhibitory activity of RA. T18, similar to PML-RAR alpha, disrupts the RA-dependent activity of this complex in a dominant-negative manner resulting in a growth advantage. Our data define a new pathway for the control of cell growth and tumorigenesis, and provide a new model for the pathogenesis of acute promyelocytic leukaemia (APL).	Cornell Univ, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Cell Biol Program, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Grad Sch Med Sci, New York, NY USA	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org		DELVA, Laurent/0000-0002-1086-3964; Rachez, Christophe/0000-0001-8502-4738	NCI NIH HHS [CA74031, CA-08748, CA71692] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071692, R01CA074031, R37CA071692, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boddy MN, 1996, ONCOGENE, V13, P971; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VOMBAUR E, 1995, EMBO J, V15, P110; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547	48	112	118	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	1999	23	3					287	295		10.1038/15463	http://dx.doi.org/10.1038/15463			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610177				2022-12-25	WOS:000083792200016
J	Gohongi, T; Fukumura, D; Boucher, Y; Yun, CO; Soff, GA; Compton, C; Todoroki, T; Jain, RK				Gohongi, T; Fukumura, D; Boucher, Y; Yun, CO; Soff, GA; Compton, C; Todoroki, T; Jain, RK			Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor beta 1	NATURE MEDICINE			English	Article							ENDOTHELIAL-CELLS; GROWTH-FACTOR-BETA-1; CANCER; CARCINOMA; MICROENVIRONMENT; PROLIFERATION; METASTASIS; EXPRESSION; MICE	Angiogenesis inhibitors produced by a primary tumor can create a systemic anti-angiogenic environment and maintain metastatic tumor cells in a state of dormancy(1,2). We show here that the gallbladder microenvironment modulates the production of transforming growth factor (TGF)-beta 1, a multifunctional cytokine that functions as an endogenous anti-angiogenic and antitumor factor in a cranial window preparation. We found that a wide variety of human gallbladder tumors express TGF-beta 1 irrespective of histologic type. We implanted a gel impregnated with basic fibroblast growth factor(3) or Mz-ChA-2 tumor in the cranial windows of mice without tumors or mice with subcutaneous or gallbladder tumors to study angiogenesis and tumor growth at a secondary site. Angiogenesis, leukocyte-endothelial interaction in vessels and tumor growth in the cranial window were substantially inhibited in mice with gallbladder tumors. The concentration of TGF-beta 1 in the plasma of mice with gallbladder tumors was 300% higher than that in the plasma of mice without tumors or with subcutaneous tumors. In contrast, there was no difference in the plasma levels of other anti- and pro-angiogenic factors. Treatment with neutralizing antibody against TGF-beta 1 reversed both angiogenesis suppression and inhibition of leukocyte rolling induced by gallbladder tumors. TGF-beta 1 also inhibited Mz-ChA-2 tumor cell proliferation. Our results indicate that the production of anti-angiogenesis/proliferation factors is regulated by tumor-host interactions.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA; Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA; Univ Tsukuba, Inst Clin Med, Dept Surg, Tsukuba, Ibaraki 305, Japan	Harvard University; Harvard Medical School; Massachusetts General Hospital; Northwestern University; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Tsukuba	Jain, RK (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Edwin L Steele Lab, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017; Yun, Chae-Ok/P-3698-2015	Jain, Rakesh K/0000-0001-7571-3548; Yun, Chae-Ok/0000-0002-9466-4531	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA56591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dellian M, 1996, AM J PATHOL, V149, P59; Engle SJ, 1999, CANCER RES, V59, P3379; Fajardo LF, 1996, LAB INVEST, V74, P600; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; GAJDUSEK CM, 1993, J CELL PHYSIOL, V157, P133, DOI 10.1002/jcp.1041570118; GAMBLE JR, 1993, J IMMUNOL, V150, P4494; ITO N, 1995, CANCER LETT, V89, P45, DOI 10.1016/0304-3835(94)03651-X; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Nakanishi Y, 1997, INT J GYNECOL PATHOL, V16, P256, DOI 10.1097/00004347-199707000-00011; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497; ROBERTS BV, 1999, MICROVASC RES, V57, P118; Sckell A, 1998, CANCER RES, V58, P5866; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; TODOROKI T, 1991, WORLD J SURG, V15, P357, DOI 10.1007/BF01658729; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WALKER RA, 1992, EUR J CANCER, V28A, P641, DOI 10.1016/S0959-8049(05)80116-9; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	25	113	115	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1203	1208		10.1038/13524	http://dx.doi.org/10.1038/13524			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502827	Green Submitted			2022-12-25	WOS:000082933200050
J	Muller, JMM; Rabouille, C; Newman, R; Shorter, J; Freemont, P; Schiavo, G; Warren, G; Shima, DT				Muller, JMM; Rabouille, C; Newman, R; Shorter, J; Freemont, P; Schiavo, G; Warren, G; Shima, DT			An NSF function distinct from ATPase-dependent SNARE disassembly is essential for Golgi membrane fusion	NATURE CELL BIOLOGY			English	Article							SYNAPTIC VESICLES; IN-VITRO; T-SNARE; VESICULAR TRANSPORT; ATTACHMENT PROTEINS; CRYSTAL-STRUCTURE; HELA-CELLS; COMPLEX; DOCKING; FRAGMENTS	The precise biochemical role of N-ethylmaleimide-sensitive factor (NSF) in membrane fusion mediated by SNARE proteins is unclear. To provide further insight into the function of NSF, we have introduced a mutation into mammalian NSF that, in Drosophila dNSF-1, leads to temperature-sensitive neuroparalysis. This mutation is like the comatose mutation and renders the mammalian NSF temperature sensitive for fusion of postmitotic Golgi vesicles and tubules into intact cisternae. Unexpectedly, at the temperature that is permissive for membrane fusion, this mutant NSF binds to, but cannot disassemble, SNARE complexes and exhibits almost no ATPase activity. A well-characterized NSF mutant containing an inactivating point mutation in the catalytic site of its ATPase domain is equally active in the Golgi-reassembly assay. These data indicate that the need for NSF during postmitotic Golgi membrane fusion may be distinct from its ATPase-dependent ability to break up SNARE pairs.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Mol Struct Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Mol Neuropathobiol Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK; Cancer Research UK	Shima, DT (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Shorter, James/ABE-7307-2020; Shorter, James/E-8207-2011	Shorter, James/0000-0001-5269-8533; Schiavo, Giampietro/0000-0002-4319-8745				Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Cabrera-Poch N, 1998, BBA-MOL CELL RES, V1404, P139, DOI 10.1016/S0167-4889(98)00051-2; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; Hui N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P46; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; INOUE A, 1992, J BIOL CHEM, V267, P10613; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1998, FEBS LETT, V423, P113, DOI 10.1016/S0014-5793(98)00072-6; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	50	54	55	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					335	340		10.1038/14025	http://dx.doi.org/10.1038/14025			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559959				2022-12-25	WOS:000083169800015
J	Rehling, P; Darsow, T; Katzmann, DJ; Emr, SD				Rehling, P; Darsow, T; Katzmann, DJ; Emr, SD			Formation of AP-3 transport intermediates requires Vps41 function	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-TRANSPORT; ENDOPLASMIC-RETICULUM; YEAST VACUOLE; ALKALINE-PHOSPHATASE; COMPLEX; ADAPTER; PATHWAY; VESICLES; CLATHRIN	Transport of a subset of membrane proteins to the yeast vacuole requires the function of the AP-3 adaptor protein complex. To define the molecular requirements of vesicular transport in this pathway, we used a biochemical approach to analyse the formation and content of the AP-3 transport intermediate. A vam3(tsf) (vacuolar t-SNARE) mutant blocks vesicle docking and fusion with the vacuole and causes the accumulation of 50-130-nanometre membrane vesicles, which we isolated and showed by biochemical analysis and immunocytochemistry to contain both AP-3 adaptors and alkaline phosphatase (ALP) pathway cargoes. Inactivation of AP-3 or the protein Vps41 blocks formation of this vesicular intermediate. Vps41 binds to the AP-3 delta-adaptin subunit, suggesting that they function together in the formation of ALP pathway transport intermediates at the late Golgi.	Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Emr, SD (corresponding author), Univ Calif San Diego, Div Cellular & Mol Med, La Jolla, CA 92093 USA.	semr@ucsd.edu		Darsow, Tamara/0000-0002-6650-6368	NCI NIH HHS [CA58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Burd CG, 1998, SEMIN CELL DEV BIOL, V9, P527, DOI 10.1006/scdb.1998.0255; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scheier LM, 1996, J SUBST ABUSE, V8, P271, DOI 10.1016/S0899-3289(96)90315-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	39	96	103	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	1999	1	6					346	353		10.1038/14037	http://dx.doi.org/10.1038/14037			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NL	10559961				2022-12-25	WOS:000083169800017
J	Rigaut, G; Shevchenko, A; Rutz, B; Wilm, M; Mann, M; Seraphin, B				Rigaut, G; Shevchenko, A; Rutz, B; Wilm, M; Mann, M; Seraphin, B			A generic protein purification method for protein complex characterization and proteome exploration	NATURE BIOTECHNOLOGY			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; GENETIC-ANALYSIS; YEAST; IDENTIFICATION; GENOME; GELS; U1	We have developed a generic procedure to purify proteins expressed at their natural level under native conditions using a novel tandem affinity purification (TAP) tag. The TAP tag allows the rapid purification of complexes from a relatively small number of cells without prior knowledge of the complex composition, activity, or function. Combined with mass spectrometry, the TAP strategy allows for the identification of proteins interacting with a given target protein. The TAP method has been tested in yeast but should be applicable to other cells or organisms.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Seraphin, B (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834; Seraphin, Bertrand/0000-0002-5168-1921				Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; Ford C F, 1991, Protein Expr Purif, V2, P95, DOI 10.1016/1046-5928(91)90057-P; FORTES P, 1999, IN PRESS GENES DEV, V3; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gottschalk A, 1998, RNA, V4, P374; Puig O, 1998, YEAST, V14, P1139; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Sheibani N, 1999, PREP BIOCHEM BIOTECH, V29, P77, DOI 10.1080/10826069908544695; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; 1998, Patent No. 115448	16	2135	2267	7	237	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					1030	1032		10.1038/13732	http://dx.doi.org/10.1038/13732			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504710				2022-12-25	WOS:000083015700033
J	Evans, MJ; Gurer, C; Loike, JD; Wilmut, I; Schnieke, AE; Schon, EA				Evans, MJ; Gurer, C; Loike, JD; Wilmut, I; Schnieke, AE; Schon, EA			Mitochondrial DNA genotypes in nuclear transfer-derived cloned sheep	NATURE GENETICS			English	Article							MATERNAL INHERITANCE; FETAL FIBROBLASTS; HUMAN OOCYTES; SEGREGATION; MTDNA; TRANSPLANTATION; MUTATION; DISEASE; EMBRYOS; GENOME	Eukaryotic cells contain two distinct genomes. One is located in the nucleus (nDNA) and is transmitted in a mendelian fashion, whereas the other is located in mitochondria (mtDNA) and is transmitted by maternal inheritance. Cloning of mammals(1-6) typically has been achieved via nuclear transfer, in which a donor somatic cell is fused by electoporation with a recipient enucleated oocyte. During this whole-cell electrofusion, nDNA as well as mtDNA ought to be transferred to the oocyte(7, 8). Thus, the cloned progeny should harbour mtDNAs from both the donor and recipient cytoplasms, resulting in heteroplasmy. Although the confirmation of nuclear transfer has been established using somatic cell-specific nDNA markers, no similar analysis of the mtDNA genotype has been reported. We report here the origin of the mtDNA in Dolly, the first animal cloned from an established adult somatic cell line, and in nine other nuclear transfer-derived sheep generated from fetal cells. The mtDNA of each of the ten nuclear-transfer sheep was derived exclusively from recipient enucleated oocytes, with no detectable contribution from the respective somatic donor cells. Thus, although these ten sheep are authentic nuclear clones, they are in fact genetic chimaeras, containing somatic cell-derived nuclear DNA but oocyte-derived mtDNA.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; PPL Therapeut, Roslin EH25 9PP, Midlothian, Scotland; Roslin Inst, Roslin EH25 9PP, Midlothian, Scotland	Columbia University; Columbia University; Columbia University; Columbia University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Schon, EA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.			Schnieke, Angelika/0000-0002-5761-9635; Evans, Matthew/0000-0002-4991-3877	NICHD NIH HHS [P01 HD032062, HD32062] Funding Source: Medline; NINDS NIH HHS [P01 NS011766, NS11766, R01 NS028828-10A1, NS28828] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011766, R01NS028828, P50NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AnkelSimons F, 1996, P NATL ACAD SCI USA, V93, P13859, DOI 10.1073/pnas.93.24.13859; BUCHANAN FC, 1993, MAMM GENOME, V4, P258, DOI 10.1007/BF00417432; CHEN X, 1995, AM J HUM GENET, V57, P239; CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269; Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889; Ferlin T, 1997, J PEDIATR-US, V131, P447, DOI 10.1016/S0022-3476(97)80074-1; GAERTIG J, 1988, J CELL SCI, V89, P253; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Meirelles FV, 1998, GENETICS, V148, P877; Meirelles FV, 1997, GENETICS, V145, P445; Meng L, 1997, BIOL REPROD, V57, P454, DOI 10.1095/biolreprod57.2.454; PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2; Pinkert CA, 1997, TRANSGENIC RES, V6, P379, DOI 10.1023/A:1018431316831; RUBENSTEIN DS, 1995, CAMB Q HEALTHC ETHIC, V4, P316, DOI 10.1017/S0963180100006071; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Sekirina GG, 1997, ZYGOTE, V5, P97, DOI 10.1017/S0967199400003762; Shitara H, 1998, GENETICS, V148, P851; SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wood NJ, 1996, ANIM GENET, V27, P25, DOI 10.1111/j.1365-2052.1996.tb01173.x	30	169	199	2	35	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					90	93		10.1038/12696	http://dx.doi.org/10.1038/12696			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471506	Green Accepted			2022-12-25	WOS:000082337300023
J	Rodriguez, A; Oliver, H; Zou, H; Chen, P; Wang, XD; Abrams, JM				Rodriguez, A; Oliver, H; Zou, H; Chen, P; Wang, XD; Abrams, JM			Dark is a Drosophila homologue of Apaf-1/CED-4 and functions in an evolutionarily conserved death pathway	NATURE CELL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; MELANOTIC TUMOR-FORMATION; CYTOCHROME-C; APOPTOSIS; CED-4; MELANOGASTER; GENE; ACTIVATION; SURVIVAL; PROTEASE	Here we identify a new gene, dark, which encodes a Drosophila homologue of mammalian Apaf-1 and Caenorhabditis elegans CED-4, cell-death proteins. Like Apaf-1, but in contrast to CED-4, Dark contains a carboxyterminal WD-repeat domain necessary for interactions with the mitochondrial protein cytochrome c. Dark selectively associates with another protein involved in apoptosis, the fly apical caspase, Dredd. Dark-induced cell killing is suppressed by caspase-inhibitory peptides and by a dominant-negative mutant Dredd protein, and enhanced by removal of the WD domain. Loss-of-function mutations in dark attenuate programmed cell deaths during development, causing hyperplasia of the central nervous system, and other abnormalities including ectopic melanotic tumours and defective wings. Moreover, ectopic cell killing by the Drosophila cell-death activators, Reaper, Grim and Hid, is substantially suppressed in dark mutants. These findings establish dark as an important apoptosis effector in Drosophila and raise profound evolutionary considerations concerning the relationship between mitochondrial components and the apoptosis-promoting machinery.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rodriguez, A (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	abrams@utsw.swmed.edu		Oliver, George/0000-0001-5106-8935	NIA NIH HHS [R01 AG12466] Funding Source: Medline; NIGMS NIH HHS [GMR01-57158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rodriguez A, 1998, AM J HUM GENET, V62, P514, DOI 10.1086/301775; Rodriguez A, 1996, GENETICS, V143, P929; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STULTZ CM, 1997, PROTEIN STRUCTURAL B, pB22; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Varkey J, 1999, J CELL BIOL, V144, P701, DOI 10.1083/jcb.144.4.701; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATSON KL, 1991, DEV GENET, V12, P173, DOI 10.1002/dvg.1020120302; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN J, 1993, CELL, V75, P1; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	282	285	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	1999	1	5					272	279		10.1038/12984	http://dx.doi.org/10.1038/12984			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	246NJ	10559939				2022-12-25	WOS:000083169600015
J	Withers, DJ; Burks, DJ; Towery, HH; Altamuro, SL; Flint, CL; White, ME				Withers, DJ; Burks, DJ; Towery, HH; Altamuro, SL; Flint, CL; White, ME			Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling	NATURE GENETICS			English	Article							FACTOR-I RECEPTOR; ENDOCRINE PANCREAS; GROWTH-FACTORS; MICE; GENE; SUBSTRATE-2; EXPRESSION; APOPTOSIS; PHOSPHORYLATION; RAT	Insulin receptor substrates (Irs proteins) mediate the pleiotropic effects of insulin and Igf-l (insulin-like growth factor-1), including regulation of glucose homeostasis and cell growth and survival. We intercrossed mice heterozygous for two null alleles (Irs1(+/-) and Irs2(+/-)) and investigated growth and glucose metabolism in mice with viable genotypes. Our experiments revealed that Irs-1 and Irs-2 are critical for embryonic and post-natal growth, with Irs-l having the predominant role. By contrast, both Irs-l and Irs-2 function in peripheral carbohydrate metabolism, but Irs-2 has the major role in beta-cell development and compensation for peripheral insulin resistance. To establish a role for the Igf-l receptor in beta-cells, we intercrossed mice heterozygous for null alleles of Igf1r and Irs2. Our results reveal that Igf-l receptors promote beta-cell development and survival through the Irs-2 signalling pathway. Thus, Irs-2 integrates the effects of insulin in peripheral target tissues with Igf-l in pancreatic beta-cells to maintain glucose homeostasis.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	White, ME (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	morris.white@joslin.harvard.edu	Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521	NIDDK NIH HHS [DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bernal D, 1998, DIABETES, V47, P976, DOI 10.2337/diabetes.47.6.976; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GUZ Y, 1995, DEVELOPMENT, V121, P11; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LeRoith D, 1997, ENDOCRINE, V7, P103, DOI 10.1007/BF02778074; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, J BIOL CHEM, V272, P16414, DOI 10.1074/jbc.272.26.16414; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Schuppin GT, 1998, DIABETES, V47, P1074, DOI 10.2337/diabetes.47.7.1074; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Vaisse C, 1997, DIABETES, V46, P1364, DOI 10.2337/diabetes.46.8.1364; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Velloso LA, 1995, FEBS LETT, V377, P353, DOI 10.1016/0014-5793(95)01370-9; WHITEHEAD M, 1994, I C S S, V8, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	36	443	465	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					32	40		10.1038/12631	http://dx.doi.org/10.1038/12631			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471495				2022-12-25	WOS:000082337300012
J	Branden, LJ; Mohamed, AJ; Smith, CIE				Branden, LJ; Mohamed, AJ; Smith, CIE			A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA	NATURE BIOTECHNOLOGY			English	Article						nuclear localization signal; peptide nucleic acid; transfection; translocation; plasmid; oligonucleotide	POLYETHYLENIMINE; PROTEIN; LIGANDS; VECTOR; IMPORT; GENE	We have combined a peptide nucleic acid (PNA) with the SV40 core nuclear localization signal (NLS), to create a bifunctional PNA-NLS peptide. The PNA-NLS peptide increased the nuclear uptake of oligonucleotides and enhanced the transfection efficacy of plasmids. Gene expression from an enhanced green fluorescent protein plasmid and a lacZ plasmid was preserved when hybridized to PNA-NLS. In combination with the transfection agent polyethyleneimine, we have improved both the nuclear translocation of fluorescence-marked oligonucleotides, and the efficacy of plasmid transfection, up to eightfold. The technique obviates the use of cumbersome coupling procedures of the vector due to DNA-PNA duplex formation or displacement of the antisense plasmid DNA strand by a PNA molecule.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, SE-14157 Huddinge, Sweden; Huddinge Hosp, Dept Clin Immunol Microbiol Pathol & Infect Dis, S-14186 Huddinge, Sweden; Univ Coll S Stockholm, SE-14104 Stockholm, Sweden; Karolinska Inst, Huddinge Hosp, Gene Therapy Res Ctr, Clin Res Ctr, SE-14186 Huddinge, Sweden	Karolinska Institutet; Sodertorn University; Karolinska Institutet	Branden, LJ (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, SE-14157 Huddinge, Sweden.			SMITH, C. I. Edvard/0000-0003-1907-3392; Branden, Lars/0000-0002-1904-0470				*AUSUBEL FM, 1992, MOBILITY SHIFT ASSAY; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bukrinsky MI, 1998, MOL MED, V4, P138, DOI 10.1007/BF03401911; Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; NIELSEN PE, 1991, BIOCONJUGATE CHEM, V2, P57, DOI 10.1021/bc00007a010; *PERS BIOS INC, PEPT NUCL AC PNA SYN; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; Zanta MA, 1999, P NATL ACAD SCI USA, V96, P91, DOI 10.1073/pnas.96.1.91	14	323	357	4	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					784	787		10.1038/11726	http://dx.doi.org/10.1038/11726			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429244				2022-12-25	WOS:000081751400028
J	Zheng, BH; Sage, M; Cai, WW; Thompson, DM; Tavsanli, BC; Cheah, YC; Bradley, A				Zheng, BH; Sage, M; Cai, WW; Thompson, DM; Tavsanli, BC; Cheah, YC; Bradley, A			Engineering a mouse balancer chromosome	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; GENE; RECOMBINATION; MUTAGENESIS; GENOME; MAP	Balancer chromosomes are genetic reagents that are used in Drosophila melanogaster for stock maintenance and mutagenesis screens(1). Despite their utility, balancer chromosomes are rarely used in mice because they are difficult to generate using conventional methods. Here we describe the engineering of a mouse balancer chromosome with the Cre-loxP recombination system. The chromosome features a 24-centiMorgan (cM) inversion between Trp53 (also known as p53) and Wnt3 on mouse chromosome 11 that is recessive lethal and dominantly marked with a K14-Agouti transgene(2). When allelic to a wild-type chromosome, the inversion suppresses crossing over in the inversion interval, accompanied by elevated recombination in the flanking regions. The inversion functions as a balancer chromosome because it can be used to maintain a lethal mutation in the inversion interval as a self-sustaining trans-heterozygous stock. This strategy can be used to generate similar genetic reagents throughout the mouse genome. Engineering of visibly marked inversions and deficiencies is an important step toward functional analyses of the mouse genome and will facilitate large-scale mutagenesis programs.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dev Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Bradley, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl, Houston, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839				Araki K, 1997, NUCLEIC ACIDS RES, V25, P868, DOI 10.1093/nar/25.4.868; Ashburner M., 1989, DROSOPHILA LAB HDB; BALDINI A, 1994, IN SITU HYBRIDIZATIO, P75; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Brown SDM, 1998, HUM MOL GENET, V7, P1627, DOI 10.1093/hmg/7.10.1627; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; de Angelis MH, 1998, MUTAT RES-FUND MOL M, V400, P25, DOI 10.1016/S0027-5107(98)00061-X; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; JUSTICE MJ, MOUSE GENETICS TRANS; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu PT, 1998, GENETICS, V150, P1155; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Muller HJ, 1918, GENETICS, V3, P422; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Rinchik E.M., 1990, GENOME ANAL, P121; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; SINGLETON JR, 1964, GENETICS, V49, P541; STRICKBERGER MW, 1985, GENETICS, P435; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354	31	109	116	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	1999	22	4					375	378		10.1038/11949	http://dx.doi.org/10.1038/11949			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	222FH	10431243				2022-12-25	WOS:000081772500021
J	Matsumura, I; Wallingford, JB; Surana, NK; Vize, PD; Ellington, AD				Matsumura, I; Wallingford, JB; Surana, NK; Vize, PD; Ellington, AD			Directed evolution of the surface chemistry of the reporter enzyme beta-glucuronidase	NATURE BIOTECHNOLOGY			English	Article						beta-glucuronidase; reporter gene; in vitro evolution; directed evolution; DNA shuffling; Xenopus laevis	ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; GENE; EXPRESSION; XENOPUS; PURIFICATION; ESTERASE; EMBRYOS; MARKER	The use of the Escherichia coli enzyme beta-glucuronidase (GUS) as a reporter in gene expression studies is limited due to loss of activity during tissue fixation by glutaraldehyde or formaldehyde. We have directed the evolution of a GUS variant that is significantly more resistant to both glutaraldehyde and formaldehyde than the wild-type enzyme. A variant with eight amino acid changes was isolated after three rounds of mutation, DNA shuffling, and screening. Surprisingly, although glutaraldehyde is known to modify and cross-link free amines, only one lysine residue was mutated. Instead, amino acid changes generally occurred near conserved lysines, implying that the surface chemistry of the enzyme was selected to either accept or avoid glutaraldehyde modifications that would normally have inhibited function. We have shown that the GUS variant can be used to trace cell lineages in Xenopus embryos under standard fixation conditions, allowing double staining when used in conjunction with other reporters.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Dept Zool, Ctr Dev Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), Univ Texas, Inst Mol & Cellular Biol, ICMB A4800-MBB 3-424,26th & Speedway, Austin, TX 78712 USA.	andy.ellington@mail.utexas.edu	Matsumura, Ichiro/E-1985-2011					BLANCO C, 1987, BIOCHIMIE, V69, P157, DOI 10.1016/0300-9084(87)90248-3; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Craig S., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P115; DAMORE MA, 1988, BIOCHEMISTRY-US, V27, P7131, DOI 10.1021/bi00418a070; FARRELL LB, 1990, PLANT MOL BIOL, V15, P821, DOI 10.1007/BF00039422; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GRIMM E, 1995, NUCLEIC ACIDS RES, V23, P4518, DOI 10.1093/nar/23.21.4518; HABEEB AFS, 1968, ARCH BIOCHEM BIOPHYS, V126, P16, DOI 10.1016/0003-9861(68)90554-7; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JEFFERSON RA, 1989, NATURE, V342, P837, DOI 10.1038/342837a0; KING PV, 1986, FOCUS, V8, P30; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Krieg Paul A., 1996, P141; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Naleway JJ, 1992, GUS PROTOCOLS USING, P61; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; PENG HB, 1991, METHOD CELL BIOL, V36, P657; Ray J, 1998, GENOMICS, V48, P248, DOI 10.1006/geno.1997.5189; Raz E, 1998, DEV BIOL, V203, P290, DOI 10.1006/dbio.1998.8999; SCHLAMAN HRM, 1994, GENE, V138, P259, DOI 10.1016/0378-1119(94)90820-6; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; VANDERLOOS CM, 1993, HISTOCHEM J, V25, P1; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; Wallingford JB, 1998, DEV BIOL, V202, P103, DOI 10.1006/dbio.1998.8989; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhang XJ, 1995, PROTEIN ENG, V8, P1017, DOI 10.1093/protein/8.10.1017	34	55	63	0	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1999	17	7					696	701		10.1038/10910	http://dx.doi.org/10.1038/10910			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	213WU	10404164				2022-12-25	WOS:000081296900031
J	Mizuta, T; Fujiwara, M; Hatta, T; Abe, T; Miyano-Kurosaki, N; Shigeta, S; Yokota, T; Takaku, H				Mizuta, T; Fujiwara, M; Hatta, T; Abe, T; Miyano-Kurosaki, N; Shigeta, S; Yokota, T; Takaku, H			Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A	NATURE BIOTECHNOLOGY			English	Article						antisense therapeutics; influenza A virus; animal model	HUMAN-IMMUNODEFICIENCY-VIRUS; PHOSPHOROTHIOATE ANALOGS; IN-VITRO; EXPRESSION; INHIBITION; OLIGODEOXYNUCLEOTIDES; CELL; REPLICATION; DNA; NUCLEOPROTEIN	We have investigated the ability of antisense phosphorothioate oligonucleotides to enhance the survival of mice infected with influenza A virus. The oligonucleotides were complementary to sequences surrounding the translation initiation codons of the viral PB2 or PA genes (PB2-as or PA-as, respectively) of the influenza A virus RNA polymerases. Intravenous administration of PB2-as in a complex with a cationic liposome, Tfx-10, significantly prolonged the mean survival time in days and increased overall survival rates of mice infected with the influenza A virus. Liposomally encapsulated PB2-as inhibited viral growth in lung tissues and reduced pulmonary consolidations. Liposomally encapsulated PB2-as could be an effective therapeutic agent against influenza A virus.	Chiba Inst Technol, Dept Ind Chem, Chiba 2750016, Japan; Rat Drug Design Labs, Matsukawa, Fukushima 9601242, Japan; Fukushima Univ, Sch Med, Dept Microbiol, Fukushima 9601295, Japan	Chiba Institute of Technology; Fukushima Medical University; Fukushima University	Takaku, H (corresponding author), Chiba Inst Technol, Dept Ind Chem, 2-17-1 Tsudanuma, Chiba 2750016, Japan.							Abe T, 1998, ANTIVIR CHEM CHEMOTH, V9, P253, DOI 10.1177/095632029800900306; Agatsuma T, 1997, ANTIVIR RES, V34, P121, DOI 10.1016/S0166-3542(97)01032-2; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Davis HL, 1998, J IMMUNOL, V160, P870; DETJEN BM, 1987, J VIROL, V61, P16, DOI 10.1128/JVI.61.1.16-22.1987; ERICKSON RP, 1992, GENE REGULATION BIOL; Hatta T, 1996, BIOCHEM BIOPH RES CO, V223, P341, DOI 10.1006/bbrc.1996.0896; Hatta T, 1997, BIOCHEM BIOPH RES CO, V232, P545, DOI 10.1006/bbrc.1997.6185; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Jambrina E, 1997, VIROLOGY, V235, P209, DOI 10.1006/viro.1997.8682; Keogh MC, 1997, GENE THER, V4, P162, DOI 10.1038/sj.gt.3300374; KIM SG, 1993, BIOORG MED CHEM LETT, V3, P1223, DOI 10.1016/S0960-894X(00)80320-0; KIM SG, 1995, BIOORGAN MED CHEM, V3, P49, DOI 10.1016/0968-0896(94)00142-P; LEITER JME, 1990, P NATL ACAD SCI USA, V87, P3430, DOI 10.1073/pnas.87.9.3430; LEONETTI JP, 1990, P NATL ACAD SCI USA, V87, P2448, DOI 10.1073/pnas.87.7.2448; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MILHAUD PG, 1991, J INTERFERON RES, V11, P261, DOI 10.1089/jir.1991.11.261; Millan CLB, 1998, P NATL ACAD SCI USA, V95, P15553, DOI 10.1073/pnas.95.26.15553; MILLER PS, 1985, BIOCHIMIE, V67, P769, DOI 10.1016/S0300-9084(85)80166-8; MILLER PS, 1981, BIOCHEMISTRY-US, V20, P1874, DOI 10.1021/bi00510a024; NAKAGAWA Y, 1995, J VIROL, V69, P728, DOI 10.1128/JVI.69.2.728-733.1995; ROTHENBERG M, 1989, J NATL CANCER I, V81, P1538; SANZEZQUERRO JJ, 1995, J VIROL, V69, P2420, DOI 10.1128/JVI.69.4.2420-2426.1995; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; THIERRY AR, 1992, NUCLEIC ACIDS RES, V20, P5691, DOI 10.1093/nar/20.21.5691; Tsan MF, 1997, HUM GENE THER, V8, P817, DOI 10.1089/hum.1997.8.7-817; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Whitesell L, 1991, Antisense Res Dev, V1, P343; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; YAMASHITA M, 1989, VIROLOGY, V171, P458, DOI 10.1016/0042-6822(89)90615-6; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143; ZERIAL A, 1987, NUCLEIC ACIDS RES, V15, P9909, DOI 10.1093/nar/15.23.9909; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	46	51	67	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					583	587		10.1038/9893	http://dx.doi.org/10.1038/9893			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385324				2022-12-25	WOS:000080716500031
J	Jimenez, B; Volpert, OV; Crawford, SE; Febbraio, M; Silverstein, RL; Bouck, N				Jimenez, B; Volpert, OV; Crawford, SE; Febbraio, M; Silverstein, RL; Bouck, N			Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1	NATURE MEDICINE			English	Article							PROTEIN-TYROSINE KINASES; FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; TUMOR-GROWTH; INDUCE APOPTOSIS; IN-VIVO; ANGIOGENESIS; ACTIVATION; ANGIOSTATIN; REQUIRES	Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that limits vessel density in normal tissues and curtails tumor growth. Here, we show that the inhibition of angiogenesis in vitro and in vivo and the induction of apoptosis by thrombospondin-1 all required the sequential activation of CD36, p59(fyn), caspase-3 like proteases and p38 mitogen-activated protein kinases. We also detected increased endothelial cell apoptosis in situ at the margins of tumors in mice treated with thrombospondin-1. These results indicate that thrombospondin-1, and possibly other broad-spectrum natural inhibitors of angiogenesis, act in vivo by inducing receptor-mediated apoptosis in activated microvascular endothelial cells.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Cornell University	Bouck, N (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.		Cuenca, Benilde Jimenez/K-9959-2014	Volpert, Olga/0000-0003-1381-5543; Jimenez Cuenca, Benilde/0000-0002-1806-6636	NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER; NCI NIH HHS [CA52750, CA64239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Castle VP, 1997, LAB INVEST, V77, P51; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DAWSON DW, 1998, ANTIANGIOGENIC AGENT, P185; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DIPIETRO LA, 1997, REGULATION ANGIOGENE, P295; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Guo NH, 1997, CANCER RES, V57, P1735; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lucas R, 1998, BLOOD, V92, P4730; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Salazar R, 1999, EXP CELL RES, V249, P22, DOI 10.1006/excr.1999.4460; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	48	786	826	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2000	6	1					41	48		10.1038/71517	http://dx.doi.org/10.1038/71517			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613822				2022-12-25	WOS:000084583300033
J	Zaccolo, M; De Giorgi, F; Cho, CY; Feng, LX; Knapp, T; Negulescu, PA; Taylor, SS; Tsien, RY; Pozzan, T				Zaccolo, M; De Giorgi, F; Cho, CY; Feng, LX; Knapp, T; Negulescu, PA; Taylor, SS; Tsien, RY; Pozzan, T			A genetically encoded, fluorescent indicator for cyclic AMP in living cells	NATURE CELL BIOLOGY			English	Article							DEPENDENT PROTEIN-KINASE; SUBUNIT	Cyclic AMP controls several signalling cascades within cells, and changes in the amounts of this second messenger have an essential role in many cellular events. Here we describe a new methodology for monitoring the fluctuations of cAMP in living cells, By tagging the cAMP effector protein kinase A with two suitable green fluorescent protein mutants, we have generated a probe in which the fluorescence resonance energy transfer between the two fluorescent moieties is dependent on the levels of cAMP, This new methodology opens the way to the elucidation of the biochemistry of cAMP in vivo.	Univ Padua, Dept Expt Biomed Sci, I-35121 Padua, Italy; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol 0647, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Aurora Biosci Corp, San Diego, CA 92121 USA	University of Padua; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zaccolo, M (corresponding author), Univ Padua, Dept Expt Biomed Sci, I-35121 Padua, Italy.	pozzant@civ.bio.unipd.it	Zaccolo, Manuela/B-3802-2011; Zaccolo, Manuela/AAP-6706-2020	Zaccolo, Manuela/0000-0002-0934-3662; De Giorgi, Francesca/0000-0003-4850-3582	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ADAMS SR, 1999, FLUORESCENCE LUMINES, P156; Biondi RM, 1998, NUCLEIC ACIDS RES, V26, P4946, DOI 10.1093/nar/26.21.4946; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; CLEGG RM, 1996, FLUORESCENCE IMAGING, P172; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	14	374	408	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2000	2	1					25	29		10.1038/71345	http://dx.doi.org/10.1038/71345			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	275WR	10620803				2022-12-25	WOS:000084843600015
J	Lane, M; Bavister, BD; Lyons, EA; Forest, KT				Lane, M; Bavister, BD; Lyons, EA; Forest, KT			Containerless vitrification of mammalian oocytes and embryos - Adapting a proven method for flash-cooling protein crystals to the cryopreservation of live cells.	NATURE BIOTECHNOLOGY			English	Article							MOUSE EMBRYOS; DEVELOPMENTAL COMPETENCE; BOVINE OOCYTES; SURVIVAL		Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lane, M (corresponding author), Colorado Ctr Reprod Med, 799 E Hampden Ave,Suite 300, Englewood, CO 80110 USA.	mlane@colocrm.com	Lane, Michelle/D-1512-2010		NICHD NIH HHS [HD22023] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD022023] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		FOREST KT, 1998, Patent No. 104266; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; Krisher RL, 1999, BIOL REPROD, V60, P1345, DOI 10.1095/biolreprod60.6.1345; Lane M, 1998, MOL REPROD DEV, V50, P443, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;443::AID-MRD8&gt;3.0.CO;2-I; LANE M, 1999, IN PRESS FERTIL STER; LEIBO SP, 1978, CRYOBIOLOGY, V15, P257, DOI 10.1016/0011-2240(78)90036-6; LEIBO SP, 1974, EXP CELL RES, V89, P79, DOI 10.1016/0014-4827(74)90189-X; Martino A, 1996, BIOL REPROD, V54, P1059, DOI 10.1095/biolreprod54.5.1059; Martino A, 1996, MOL REPROD DEV, V45, P503, DOI 10.1002/(SICI)1098-2795(199612)45:4&lt;503::AID-MRD13&gt;3.0.CO;2-X; Menezo Y, 1997, IN VITRO FERTILIZATION AND ASSISTED REPRODUCTION, P49; Parkin S, 1998, J APPL CRYSTALLOGR, V31, P945, DOI 10.1107/S0021889898005305; RALL WF, 1985, NATURE, V313, P573, DOI 10.1038/313573a0; RALL WF, 1987, CRYOBIOLOGY, V24, P387, DOI 10.1016/0011-2240(87)90042-3; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; Vajta G, 1998, MOL REPROD DEV, V51, P53, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;53::AID-MRD6&gt;3.0.CO;2-V; Vajta G, 1997, CRYO-LETT, V18, P191	17	164	180	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1999	17	12					1234	1236		10.1038/70795	http://dx.doi.org/10.1038/70795			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	264FV	10585728				2022-12-25	WOS:000084170700038
J	Hazan, J; Fonknechten, N; Mavel, D; Paternotte, C; Samson, D; Artiguenave, F; Davoine, CS; Cruaud, C; Durr, A; Wincker, P; Brottier, P; Cattolico, L; Barbe, V; Burgunder, JM; Prud'homme, JF; Brice, A; Fontaine, B; Heilig, R; Weissenbach, J				Hazan, J; Fonknechten, N; Mavel, D; Paternotte, C; Samson, D; Artiguenave, F; Davoine, CS; Cruaud, C; Durr, A; Wincker, P; Brottier, P; Cattolico, L; Barbe, V; Burgunder, JM; Prud'homme, JF; Brice, A; Fontaine, B; Heilig, R; Weissenbach, J			Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia	NATURE GENETICS			English	Article							CHROMOSOME 2P; BINDING-PROTEIN; LOCUS; YEAST; SEQUENCES; FAMILY; GENE; LINKAGE; DISEASE; CLASSIFICATION	Autosomal dominant hereditary spastic paraplegia (AD-HSP) is a genetically heterogeneous neurodegenerative disorder characterized by progressive spasticity of the lower limbs. Among the four loci causing AD-HSP identified so far, the SPG4 locus at chromosome 2p21-p22 has been shown to account for 40-50% of all AD-HSP families. Using a positional cloning strategy based on obtaining sequence of the entire SPG4 interval, we identified a candidate gene encoding a new member of the AAA protein family, which we named spastin. Sequence analysis of this gene in seven SPG4-linked pedigrees revealed several DNA modifications, including missense, nonsense and splice-site mutations. Both SPG4 and its mouse orthologue were shown to be expressed early and ubiquitously in fetal and adult tissues. The sequence homologies and putative subcellular localization of spastin suggest that this ATPase is involved in the assembly or function of nuclear protein complexes.	Genoscope, Evry, France; Fac Med Pitie Salpetriere, INSERM, Paris, France; Federat Neurol, Paris, France; INSERM, U289, Paris, France; Grp Hosp Pitie Salpetriere, F-75634 Paris, France; Univ Spital Bern, Neurol Klin & Poliklin, Bern, Switzerland; Genethon, Evry, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Bern; University Hospital of Bern	Hazan, J (corresponding author), Genoscope, Evry, France.		Brice, Alexis/A-2170-2009; brice, alexis/AAE-8275-2019	brice, alexis/0000-0002-0941-3990; Steinbach, Delphine/0000-0001-7144-7908; Hazan, Jamile/0000-0001-8119-0325; Cruaud, Corinne/0000-0002-4752-7278				ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; Beyer A, 1997, PROTEIN SCI, V6, P2043; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Durr A, 1996, BRAIN, V119, P1487, DOI 10.1093/brain/119.5.1487; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FINK JK, 1995, AM J HUM GENET, V56, P188; Fink JK, 1996, NEUROLOGY, V46, P1507, DOI 10.1212/WNL.46.6.1507; HARDING AE, 1983, LANCET, V1, P1151; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Harris NL, 1997, GENOME RES, V7, P754, DOI 10.1101/gr.7.7.754; HAZAN J, 1993, NAT GENET, V5, P163, DOI 10.1038/ng1093-163; HAZAN J, 1994, HUM MOL GENET, V3, P1569, DOI 10.1093/hmg/3.9.1569; HAZAN J, IN PRESS GENOMICS; Hedera P, 1999, AM J HUM GENET, V64, P563, DOI 10.1086/302258; Heinzlef O, 1998, J MED GENET, V35, P89, DOI 10.1136/jmg.35.2.89; HENTATI A, 1994, HUM MOL GENET, V3, P1867, DOI 10.1093/hmg/3.10.1867; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; ICHIDA K, 1993, GENE, V133, P279; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOSAK M, 1996, MAMM GENOME, V7, P563; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; KULP D, 1996, P 4 INT C INT SYST M, P134; Liberzon A, 1996, FEBS LETT, V388, P5, DOI 10.1016/0014-5793(96)00500-5; Neuwald AF, 1999, GENOME RES, V9, P27; Nielsen JE, 1997, HUM MOL GENET, V6, P1811, DOI 10.1093/hmg/6.11.1811; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; PERIER F, 1994, FEBS LETT, V351, P286, DOI 10.1016/0014-5793(94)00879-5; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Reid E, 1997, J MED GENET, V34, P499, DOI 10.1136/jmg.34.6.499; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SAUGIERVEBER P, 1994, NAT GENET, V6, P257, DOI 10.1038/ng0394-257; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; Scott WK, 1997, NEUROGENETICS, V1, P95, DOI 10.1007/s100480050014; SKRE H, 1974, CLIN GENET, V6, P165; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Swaffield JC, 1997, J MOL EVOL, V45, P549, DOI 10.1007/PL00006259; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WERDERLIN L, 1986, ACTA NEUROL SCA S106, V73, P124; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; Xu Y, 1994, Genet Eng (N Y), V16, P241; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	48	483	509	0	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					296	303		10.1038/15472	http://dx.doi.org/10.1038/15472			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10610178				2022-12-25	WOS:000083792200017
J	Morgan, R; Hooiveld, MHW; Pannese, M; Dati, G; Broders, F; Delarue, M; Thiery, JP; Boncinelli, E; Durston, AJ				Morgan, R; Hooiveld, MHW; Pannese, M; Dati, G; Broders, F; Delarue, M; Thiery, JP; Boncinelli, E; Durston, AJ			Calponin modulates the exclusion of Otx-expressing cells from convergence extension movements	NATURE CELL BIOLOGY			English	Article							ORTHODENTICLE-RELATED PROTEIN; STRONGYLOCENTROTUS-PURPURATUS; HEAD DEVELOPMENT; XENOPUS-LAEVIS; HOMEOBOX GENE; SEA-URCHIN; EMBRYOS; IDENTIFICATION; GASTRULATION; BRAIN	Otx2, a vertebrate homologue of the Drosophila orthodenticle gene, coordinates two processes in early embryonic development. Not only does it specify cell fate in the anterior regions of the embryo, it also prevents the cells that express it from participating in the convergence extension movements that shape the rest of the body axis. Here we show that, in Xenopus, this latter function is mediated by XclpH3, transcription of which is directly stimulated by Xotx2. XclpH3 is a Xenopus homologue of the mammalian calponin gene, the product of which binds both actin and myosin and prevents the generation of contractile force by actin filaments.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Ist Sci San Raffaele, DIBIT, I-20132 Milan, Italy; Inst Curie, CNRS, UMR 144, Lab Morphogenese Cellulaire & Progress Tumorale, F-75248 Paris 05, France; Univ Paris 06, Lab Biol Mol & Cellulaire Dev, UMR 7622,CNRS, Equipe Biol Expt, F-75230 Paris 05, France	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Vita-Salute San Raffaele University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite	Morgan, R (corresponding author), UCL, MRC LMCB, Gower St, London WC1E 6BT, England.	tony@niob.knaw.nl	PANNESE, MARIA/K-7214-2018; Thiery, Jean Paul/H-1550-2011	PANNESE, MARIA/0000-0001-8132-5138; Morgan, Richard/0000-0002-8721-4479; Thiery, Jean Paul/0000-0003-0478-5020				Andreazzoli M, 1997, DEVELOPMENT, V124, P1733; Ang SL, 1996, DEVELOPMENT, V122, P243; Bhatia-Dey N, 1998, MECH DEVELOP, V78, P33, DOI 10.1016/S0925-4773(98)00136-1; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; BUSSE U, 1993, DIFFERENTIATION, V53, P7, DOI 10.1111/j.1432-0436.1993.tb00640.x; DALE L, 1987, DEVELOPMENT, V99, P527; ElMezgueldi M, 1996, BIOCHEMISTRY-US, V35, P3654, DOI 10.1021/bi952027e; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; Gammill LS, 1997, DEVELOPMENT, V124, P471; GAN L, 1995, DEV BIOL, V167, P517, DOI 10.1006/dbio.1995.1046; HARDIN SH, 1985, J MOL BIOL, V186, P243, DOI 10.1016/0022-2836(85)90101-9; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KELLER R, 1991, METHOD CELL BIOL, V36, P61; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Mao CA, 1996, DEVELOPMENT, V122, P1489; PANNESE M, 1995, DEVELOPMENT, V121, P707; Rokolya A, 1996, AM J PHYSIOL-HEART C, V271, pH776, DOI 10.1152/ajpheart.1996.271.2.H776; SALISBURY JR, 1988, J ANAT, V157, P175; SHIRINSKY V, 1992, J BIOL CHEM, V306, P199; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; STRASSER P, 1993, FEBS LETT, V330, P13, DOI 10.1016/0014-5793(93)80909-E; Winder SJ, 1998, ACTA PHYSIOL SCAND, V164, P415, DOI 10.1111/j.1365-201X.1998.tb10697.x	25	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					404	408		10.1038/15635	http://dx.doi.org/10.1038/15635			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559983				2022-12-25	WOS:000083533100012
J	Dealy, MJ; Nguyen, KVT; Lo, J; Gstaiger, M; Krek, W; Elson, D; Arbeit, J; Kipreos, ET; Johnson, RS				Dealy, MJ; Nguyen, KVT; Lo, J; Gstaiger, M; Krek, W; Elson, D; Arbeit, J; Kipreos, ET; Johnson, RS			Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E	NATURE GENETICS			English	Article							F-BOX PROTEIN; UBIQUITIN LIGASE; COMPLEX; DEGRADATION; TRANSITION; PATHWAY; FAMILY; ASSOCIATION; TARGETS; CDC4P	The sequential timing of cell-cycle transitions is primarily governed by the availability and activity of key cell-cycle proteins(1). Recent studies in yeast have identified a class of ubiquitin ligases (E3 enzymes) called SCF complexes, which regulate the abundance of proteins that promote(2-4) and inhibit(4-6) cell-cycle progression at the G1-S phase transition. SCF complexes consist of three invariable components, Skp1, Cul-1 (Cdc53 in yeast) and Rbx1, and a variable F-box protein that recruits a specific cellular protein to the ubquitin pathway for degradation(2,3,5,7-13). To study the role of Cul-1 in mammalian development and cell-cycle regulation, we generated mice deficient for Cul1 and analysed null embryos and heterozygous cell lines. We show that Cul1 is required for early mouse development and that Cul1 mutants fail to regulate the abundance of the G1 cyclin, cyclin E (encoded by Gene), during embryogenesis.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Calif San Francisco, Dept Surg, Ctr Canc, San Francisco, CA 94143 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University of California System; University of California San Diego; Friedrich Miescher Institute for Biomedical Research; University of California System; University of California San Francisco; University System of Georgia; University of Georgia	Johnson, RS (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Arbeit, Jeffrey/K-6920-2019; Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639				Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HOGAN B, 1994, MANIPULATING MOUSE E, P61; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Papaioannou V., 1993, Gene targeting: a practical approach., P107; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, GENE DEV, V12, P3144; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Slingerland J, 1998, Results Probl Cell Differ, V22, P133; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, GENE DEV, V13, P1050; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	30	144	147	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					245	248		10.1038/13886	http://dx.doi.org/10.1038/13886			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508527				2022-12-25	WOS:000082827500030
J	Greenspan, NS; Di Cera, E				Greenspan, NS; Di Cera, E			Defining epitopes: It's not as easy as it seems	NATURE BIOTECHNOLOGY			English	Editorial Material							ALANINE-SCANNING MUTAGENESIS; ACID-BINDING PROTEIN; SPECIFICITY; RECEPTOR; RECOGNITION; THROMBIN; ENERGY		Case Western Reserve Univ, Cleveland, OH 44106 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	Case Western Reserve University; Washington University (WUSTL)	Greenspan, NS (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.		Greenspan, Neil/AAJ-4795-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline; NIAID NIH HHS [AI41657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 1998, ADV PROTEIN CHEM, V51, P59; Di Cera E, 1998, CHEM REV, V98, P1563, DOI 10.1021/cr960135g; GREENSPAN NS, 1997, CONCEPTS CHEM CONT C, P383; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; Richieri GV, 1997, J BIOL CHEM, V272, P16737, DOI 10.1074/jbc.272.27.16737; Rondard P, 1998, J BIOL CHEM, V273, P34753, DOI 10.1074/jbc.273.52.34753; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Van Regenmortel MHV, 1998, J IMMUNOL METHODS, V216, P37, DOI 10.1016/S0022-1759(98)00069-6	14	58	492	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1999	17	10					936	937		10.1038/13590	http://dx.doi.org/10.1038/13590			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	243UM	10504677				2022-12-25	WOS:000083015700005
J	Qiu, BS; Vallance, BA; Blennerhassett, PA; Collins, SM				Qiu, BS; Vallance, BA; Blennerhassett, PA; Collins, SM			The role of CD4(+) lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis	NATURE MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; SULFONIC-ACID; RAT MODEL; T-CELLS; EVENTS; COLON	Idiopathic inflammatory bowel disease is a chronic relapsing condition. The role of stress in causing relapses of inflammatory bowel disease remains controversial. We now show that colitis induced in mice by dinitrobenzenesulfonic acid (DNBS) resolves by 6 weeks, but can subsequently be reactivated by stress plus a sub-threshold dose of DNBS, but not by DNBS alone. Stress reduced colonic mucin and increased colon permeability. Susceptibility to reactivation by stress required CD4(+) lymphocytes and could be adoptively transferred. We conclude that stress reactivates experimental colitis by facilitating entry of luminal contents that activate previously sensitized CD4 cells in the colon.	McMaster Univ, Fac Hlth Sci, Dept Med, Div Gastroenterol,Intestinal Dis Res Unit, Hamilton, ON L8N 3Z5, Canada; Hamilton Hlth Sci Corp, Digest Dis Program, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Collins, SM (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Med, Div Gastroenterol,Intestinal Dis Res Unit, Room 4W8, Hamilton, ON L8N 3Z5, Canada.			Vallance, Bruce/0000-0003-1345-6747				BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; Brandwein SL, 1997, J IMMUNOL, V159, P44; Castagliuolo I, 1996, AM J PHYSIOL-GASTR L, V271, pG884, DOI 10.1152/ajpgi.1996.271.5.G884; CLARK DA, 1993, AM J REPROD IMMUNOL, V29, P141, DOI 10.1111/j.1600-0897.1993.tb00579.x; Collins SM, 1996, GASTROENTEROLOGY, V111, P1509, DOI 10.1016/S0016-5085(96)70012-4; Drossman DA, 1995, INFLAMM BOWEL DIS, P492; Duffy L C, 1991, Epidemiology, V2, P141, DOI 10.1097/00001648-199103000-00009; DUFFY LC, 1991, BEHAV MED, V17, P101, DOI 10.1080/08964289.1991.9937553; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; ENGEL GL, 1969, GASTROENTEROLOGY, V57, P362; Fava G A, 1976, Psychother Psychosom, V27, P93; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GARRETT VD, 1991, J BEHAV MED, V14, P87, DOI 10.1007/BF00844770; GONG H, 1990, AM J PHYSIOL, V259, pG681; GREENE BR, 1994, BEHAV RES THER, V32, P217, DOI 10.1016/0005-7967(94)90114-7; Gue M, 1997, AM J PHYSIOL-GASTR L, V272, pG84, DOI 10.1152/ajpgi.1997.272.1.G84; Kemler MA, 1999, GASTROENTEROLOGY, V117, P215, DOI 10.1016/S0016-5085(99)70570-6; LOPEZ Y, 1991, GASTROENTEROLOGY, V101, P1249, DOI 10.1016/0016-5085(91)90074-U; Million M, 1999, AM J PHYSIOL-GASTR L, V276, pG1027, DOI 10.1152/ajpgi.1999.276.4.G1027; MILNE B, 1986, J ADV NURS, V11, P561, DOI 10.1111/j.1365-2648.1986.tb01288.x; MONNIKES H, 1992, AM J PHYSIOL, V262, pG137, DOI 10.1152/ajpgi.1992.262.1.G137; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; NORTH CS, 1991, ANN INTERN MED, V114, P381, DOI 10.7326/0003-4819-114-5-381; NORTH CS, 1990, AM J PSYCHIAT, V147, P974; Palmen MJHJ, 1998, CLIN EXP IMMUNOL, V112, P216; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POTHOULAKIS C, 1993, GASTROENTEROLOGY, V105, P701, DOI 10.1016/0016-5085(93)90886-H; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Rubio C A, 1992, In Vivo, V6, P81; SALEM SN, 1967, LANCET, V1, P473; Saunders PR, 1997, AM J PHYSIOL-GASTR L, V273, pG486, DOI 10.1152/ajpgi.1997.273.2.G486; SCHWARZ TL, 1990, NEURON, V2, P119; Sternberg EM, 1995, ANN NY ACAD SCI, V771, P364, DOI 10.1111/j.1749-6632.1995.tb44695.x; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; STOUT C, 1969, GASTROENTEROLOGY, V57, P256; STURIALE S, IN PRESS P NATL ACAD; Vallance BA, 1998, GASTROENTEROLOGY, V115, P978, DOI 10.1016/S0016-5085(98)70270-7; WALLACE JL, 1990, AM J PHYSIOL, V258, pG527, DOI 10.1152/ajpgi.1990.258.4.G527; WALLACE JL, 1995, J PHARMACOL TOXICOL, V33, P237, DOI 10.1016/1056-8719(95)00001-X; WILKINSON CW, 1981, ENDOCRINOLOGY, V109, P162, DOI 10.1210/endo-109-1-162; ZHOU DH, 1993, ENDOCRINOLOGY, V133, P2523, DOI 10.1210/en.133.6.2523	43	196	199	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1178	1182		10.1038/13503	http://dx.doi.org/10.1038/13503			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502822				2022-12-25	WOS:000082933200045
J	Schiaffino, MV; d'Addio, M; Alloni, A; Baschirotto, C; Valetti, C; Cortese, K; Puri, C; Bassi, MT; Colla, C; De Luca, M; Tacchetti, C; Ballabio, A				Schiaffino, MV; d'Addio, M; Alloni, A; Baschirotto, C; Valetti, C; Cortese, K; Puri, C; Bassi, MT; Colla, C; De Luca, M; Tacchetti, C; Ballabio, A			Ocular albinism: evidence for a defect in an intracellular signal transduction system	NATURE GENETICS			English	Article							PROTEIN-COUPLED RECEPTORS; MUTATIONS; ANTIGENS	G protein-coupled receptors (GPCRs) participate in the most common signal transduction system at the plasma membrane(1). The wide distribution of heterotrimeric C proteins in the internal membranes suggests that a similar signalling mechanism might also be used at intracellular locations(2). We provide here structural evidence that the protein product of the ocular albinism type 1 gene (OA1). a pigment cell-specific integral membrane glycopratein(3). represents a novel member of the GPCR superfamily and demonstrate that it binds heterotrimeric G proteins. Moreover, we show that OA1 is not found at the plasma membrane, being instead targeted to specialized intracellular organelles, the melanosomes. Our data suggest that OA1 represents the first example of an exclusively intracellular GPCR and support the hypothesis that GPCR-mediated signal transduction systems also operate at the internal membranes in mamalian cells.	Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Genoa, Dept Expt Med, Anat Sect, I-16132 Genoa, Italy; Ist Dermopat Immacolata, IRCCS, I-00167 Rome, Italy; Univ Vita Salute San Raffaele, I-20132 Milan, Italy	Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Genoa; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Vita-Salute San Raffaele University	Schiaffino, MV (corresponding author), Telethon Inst Genet & Med, I-20132 Milan, Italy.	schiaffi@tigem.it	BALLABIO, Andrea/AAL-2672-2020; Bassi, Maria Teresa T/A-3517-2014; Cortese, Katia/AAC-2990-2021; Schiaffino, Maria Vittoria/AAN-3313-2020; De Luca, Michele/N-5883-2014	BALLABIO, Andrea/0000-0003-1381-4604; Bassi, Maria Teresa T/0000-0002-8236-1197; Schiaffino, Maria Vittoria/0000-0001-9744-7025; De Luca, Michele/0000-0002-0850-8445; Cortese, Katia/0000-0001-9218-8933; TACCHETTI, CARLO/0000-0003-4602-000X	Telethon [TGM06S01, TGM97000, A.041, E.0583] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Mironov A. A.  Jr., 1996, Journal of Computer-Assisted Microscopy, V8, P231; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; ODONNELL FE, 1976, ARCH OPHTHALMOL-CHIC, V94, P1883, DOI 10.1001/archopht.1976.03910040593001; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROST B, 1995, PROTEIN SCI, V4, P521; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P2319, DOI 10.1093/hmg/4.12.2319; Schiaffino MV, 1996, P NATL ACAD SCI USA, V93, P9055, DOI 10.1073/pnas.93.17.9055; Schnur RE, 1998, AM J HUM GENET, V62, P800, DOI 10.1086/301776; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WINDER AJ, 1993, J CELL SCI, V106, P153	21	101	107	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	1999	23	1					108	112		10.1038/12715	http://dx.doi.org/10.1038/12715			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471510				2022-12-25	WOS:000082337300027
J	Tronche, F; Kellendonk, C; Kretz, O; Gass, P; Anlag, K; Orban, PC; Bock, R; Klein, R; Schutz, G				Tronche, F; Kellendonk, C; Kretz, O; Gass, P; Anlag, K; Orban, PC; Bock, R; Klein, R; Schutz, G			Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety	NATURE GENETICS			English	Article							CORTICOTROPIN-RELEASING-FACTOR; IMPAIRED STRESS-RESPONSE; ELEVATED PLUS-MAZE; ADRENOCORTICAL REGULATION; TRANSGENIC MICE; BEHAVIOR; BRAIN; TRANSCRIPTION; EXPRESSION; SECRETION	The glucocorticoid receptor (Gr, encoded by the gene Grl1) controls transcription of target genes both directly by interaction with DNA regulatory elements and indirectly by cross-talk with other transcription factors(1, 2). In response to various stimuli, including stress, glucocorticoids coordinate metabolic, endocrine, immune and nervous system responses and ensure an adequate profile of transcription. In the brain, Gr has been proposed to modulate emotional behaviour, cognitive functions and addictive states(3-5). Previously, these aspects were not studied in the absence of functional Gr because inactivation of Grl1 in mice causes lethality at birth(6) (F.T., C.K, and G.S., unpublished data), Therefore, we generated tissue-specific mutations of this gene using the Cre/loxP-recombination system(7). This allowed us to generate viable adult mice with loss of Gr function in selected tissues. Loss of Gr function in the nervous system impairs hypothalamus-pituitary-adrenal (HPA)-axis regulation, resulting in increased glucocorticoid (GC) levels that lead to symptoms reminiscent of those observed in Cushing syndrome, Conditional mutagenesis of Gr in the nervous system provides genetic evidence for the importance of Gr signalling in emotional behaviour because mutant animals show an impaired behavioural response to stress and display reduced anxiety.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Saarland, Inst Anat, Homburg, Germany; EMBL, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Saarland University; European Molecular Biology Laboratory (EMBL)	Schutz, G (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		TRONCHE, François/F-3895-2011; Kellendonk, Christoph/O-7229-2018; Klein, Ruediger/C-6147-2008	Kellendonk, Christoph/0000-0003-3302-2188; Klein, Ruediger/0000-0002-3109-0163; Kretz, Oliver/0000-0003-1152-5956				ANDREATINI R, 1994, PROG NEURO-PSYCHOPH, V18, P1333, DOI 10.1016/0278-5846(94)90097-3; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; BRITTON KT, 1986, LIFE SCI, V39, P1281, DOI 10.1016/0024-3205(86)90189-X; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; FINK G, 1997, MECHANISM NEGATIVE P, P30; GAGNER JP, 1987, MOL ENDOCRINOL, V1, P677, DOI 10.1210/mend-1-10-677; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Heym C, 1997, HISTOL HISTOPATHOL, V12, P567; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; JEFFERYS D, 1987, ENDOCRINOLOGY, V121, P1006, DOI 10.1210/endo-121-3-1006; KORTE SM, 1995, PSYCHONEUROENDOCRINO, V20, P385, DOI 10.1016/0306-4530(94)00069-7; Korte SM, 1996, EUR J PHARMACOL, V301, P19, DOI 10.1016/0014-2999(96)00064-7; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; Miller W.L., 1995, ADRENAL CORTEX, P555; MONTKOWSKI A, 1995, J NEUROENDOCRINOL, V7, P841, DOI 10.1111/j.1365-2826.1995.tb00724.x; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sapolsky RM, 1996, SCIENCE, V273, P749, DOI 10.1126/science.273.5276.749; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; SHIPSTON MJ, 1995, TRENDS ENDOCRIN MET, V6, P261, DOI 10.1016/1043-2760(95)00149-2; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Smythe JW, 1997, PHARMACOL BIOCHEM BE, V56, P507, DOI 10.1016/S0091-3057(96)00244-4; STENZELPOORE MP, 1994, J NEUROSCI, V14, P2579; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; vanHaarst AD, 1996, ENDOCRINOLOGY, V137, P4935, DOI 10.1210/en.137.11.4935; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	30	1387	1418	2	92	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	1999	23	1					99	103		10.1038/12703	http://dx.doi.org/10.1038/12703			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	231XU	10471508				2022-12-25	WOS:000082337300025
J	May, AP; Misura, KMS; Whiteheart, SW; Weis, WI				May, AP; Misura, KMS; Whiteheart, SW; Weis, WI			Crystal structure of the amino-terminal domain of N-ethylmaleimide-sensitive fusion protein	NATURE CELL BIOLOGY			English	Article							MEMBRANE-FUSION; ATPASE ACTIVITY; YEAST VACUOLES; SNARE COMPLEX; ALPHA-SNAP; T-SNARE; NSF; EXOCYTOSIS; TRANSPORT; DOCKING	The cytosolic ATPase N-ethylmaleimide-sensitive fusion protein (NSF) disassembles complexes of membrane-bound proteins known as SNAREs, an activity essential for vesicular trafficking. The aminoterminal domain of NSF (NSF-N) is required for the interaction of NSF with the SNARE complex through the adaptor protein alpha-SNAP. The crystal structure of NSF-N reveals two subdomains linked by a single stretch of polypeptide. A polar interface between the two subdomains indicates that they can move with respect to one another during the catalytic cycle of NSF. Structure-based sequence alignments indicate that in addition to NSF orthologues, the p97 family of ATPases contain an amino-terminal domain of similar structure.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Stanford University; University of Kentucky	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.		Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Whiteheart, Sidney/0000-0001-5577-0473	NHLBI NIH HHS [HL56652] Funding Source: Medline; NIGMS NIH HHS [GM08294] Funding Source: Medline; NIMH NIH HHS [MH58570] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056652] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; Castillo RM, 1999, STRUCTURE, V7, P227, DOI 10.1016/S0969-2126(99)80028-8; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Matveeva E, 1998, FEBS LETT, V435, P211, DOI 10.1016/S0014-5793(98)01071-0; Matveeva EA, 1997, J BIOL CHEM, V272, P26413, DOI 10.1074/jbc.272.42.26413; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; MORGAN A, 1994, J BIOL CHEM, V269, P29347; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Neuwald AF, 1999, GENOME RES, V9, P27; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALLANCK L, 1995, J BIOL CHEM, V270, P18742, DOI 10.1074/jbc.270.32.18742; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Woodman PG, 1997, BBA-MOL CELL RES, V1357, P155, DOI 10.1016/S0167-4889(97)00039-6; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; YU RC, IN PRESS MOL CELL	50	86	87	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	1999	1	3					175	182		10.1038/11097	http://dx.doi.org/10.1038/11097			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HY	10559905				2022-12-25	WOS:000083102500017
J	Pierce, EA; Quinn, T; Meehan, T; McGee, TL; Berson, EL; Dryja, TP				Pierce, EA; Quinn, T; Meehan, T; McGee, TL; Berson, EL; Dryja, TP			Mutations in a gene encoding a new oxygen-regulated photoreceptor protein cause dominant retinitis pigmentosa	NATURE GENETICS			English	Article							MESSENGER-RNA; DIFFERENTIAL DISPLAY; RHODOPSIN GENE; ONE FORM; DNA; LINKAGE; REGION; RP1	The autosomal dominant retinitis pigmentosa (RP) locus, designated RP1, has been mapped through linkage studies to a 4-cM interval at 8q11-13. Here we describe a new photoreceptor-specific gene that maps in this interval and whose expression is modulated by retinal oxygen levels in vivo. This gene consists of at least 4 exons that encode a predicted protein of 2,156 amino acids. A nonsense mutation at codon 677 of this gene is present in approximately 3% of cases of dominant RP in North America. We also detected two deletion mutations that cause frameshifts and introduce premature termination codons in three other families with dominant RP. Our data suggest that mutations in this gene cause dominant RP, and that the encoded protein has an important but unknown role in photoreceptor biology.	Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Stellar Chance Labs 311, Philadelphia, PA 19104 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA	University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Pierce, EA (corresponding author), Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Stellar Chance Labs 311, 422 Curie Blvd, Philadelphia, PA 19104 USA.			Pierce, Eric/0000-0002-2354-4102; Meehan, Terrence/0000-0003-1980-3228	NEI NIH HHS [EY00169, EY08689, EY12910] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY000169, R01EY012910, R01EY000169] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIELLO LP, 1996, P NATL ACAD SCI USA, P6231; ARCELLANAPANLILIO MY, 1993, METHOD ENZYMOL, V225, P303; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bahri SM, 1997, MOL CELL BIOL, V17, P5521, DOI 10.1128/MCB.17.9.5521; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRYJA TP, 1992, EYE, V6, P1; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; DRYJA TP, 1998, SEM OPT ISPEN, V10, P25; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; GRUN G, 1982, DEV VERTEBRATE RETIN; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Parminder AH, 1997, INVEST OPHTH VIS SCI, V38, P704; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; SPENCE MA, 1977, AM J HUM GENET, V29, P397; SPENCE MA, 1977, AM J HUM GENET, V29, P592; Su MT, 1998, BIOTECHNIQUES, V25, P44, DOI 10.2144/98251bm08; VAITHINATHAN R, 1994, GENOMICS, V21, P461, DOI 10.1006/geno.1994.1301; Xu SY, 1996, HUM GENET, V98, P741, DOI 10.1007/s004390050296	36	152	168	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	1999	22	3					248	254		10.1038/10305	http://dx.doi.org/10.1038/10305			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	210VT	10391211				2022-12-25	WOS:000081125900016
J	Sebolt-Leopold, JS; Dudley, DT; Herrera, R; Van Becelaere, K; Wiland, A; Gowan, RC; Tecle, H; Barrett, SD; Bridges, A; Przybranowski, S; Leopold, WR; Saltiel, AR				Sebolt-Leopold, JS; Dudley, DT; Herrera, R; Van Becelaere, K; Wiland, A; Gowan, RC; Tecle, H; Barrett, SD; Bridges, A; Przybranowski, S; Leopold, WR; Saltiel, AR			Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo	NATURE MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN BREAST-CANCER; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; IN-VITRO; RAS; TRANSFORMATION; SCATTERING; PHOSPHORYLATION; DIFFERENTIATION	The mitogen-activated protein kinase pathway is thought to be essential in cellular growth and differentiation. Here we report the discovery of a highly potent and selective inhibitor of the upstream kinase MEK that is orally active. Tumor growth was inhibited as much as 80% in mice with colon carcinomas of both mouse and human origin after treatment with this inhibitor. Efficacy was achieved with a wide range of doses with no signs of toxicity, and correlated with a reduction in the levels of activated mitogen-activated protein kinase in excised tumors. These data indicate that MEK inhibitors represent a promising, noncytotoxic approach to the clinical management of colon cancer.	Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Cell Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Chem, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Canc Res, Ann Arbor, MI 48105 USA	Pfizer; Pfizer; Pfizer	Sebolt-Leopold, JS (corresponding author), Parke Davis Pharmaceut Res, Div Warner Lambert, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORBETT TH, 1975, CANCER RES, V35, P2434; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUDLEY DT, SIGNAL TRANSDUCTION; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Herrera R, 1998, J CELL SCI, V111, P1039; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Licato LL, 1998, DIGEST DIS SCI, V43, P1454, DOI 10.1023/A:1018894227169; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Petit AMV, 1997, AM J PATHOL, V151, P1523; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Streit M, 1996, J MOL MED-JMM, V74, P253, DOI 10.1007/s001090050027; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	37	833	885	0	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	1999	5	7					810	816		10.1038/10533	http://dx.doi.org/10.1038/10533			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	224YB	10395327				2022-12-25	WOS:000081926600037
J	French, CE; Rosser, SJ; Davies, GJ; Nicklin, S; Bruce, NC				French, CE; Rosser, SJ; Davies, GJ; Nicklin, S; Bruce, NC			Biodegradation of explosives by transgenic plants expressing pentaerythritol tetranitrate reductase	NATURE BIOTECHNOLOGY			English	Article						phytoremediation; explosives; transgenic plants; PETN reductase	ENTEROBACTER-CLOACAE PB2; PHYTOREMEDIATION; DEGRADATION	Plants offer many advantages over bacteria as agents for bioremediation; however, they typically lack the degradative capabilities of specially selected bacterial strains. Transgenic plants expressing microbial degradative enzymes could combine the advantages of both systems. To investigate this possibility in the context of bioremediation of explosive residues, we generated transgenic tobacco plants expressing pentaerythritol tetranitrate reductase, an enzyme derived from an explosive-degrading bacterium that enables degradation of nitrate ester and nitroaromatic explosives. Seeds from transgenic plants were able to germinate and grow in the presence of 1 mM glycerol trinitrate (GTN) or 0.05 mM trinitrotoluene, at concentrations that inhibited germination and growth of wild-type seeds. Transgenic seedlings grown in liquid medium with 1 mM GTN showed more rapid and complete denitration of GTN than wild-type seedlings. This example suggests that transgenic plants expressing microbial degradative genes may provide a generally applicable strategy for bioremediation of organic pollutants in soil.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England	University of Cambridge	Bruce, NC (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.			Rosser, Susan/0000-0002-2560-6485				Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Cunningham SD, 1996, PLANT PHYSIOL, V110, P715, DOI 10.1104/pp.110.3.715; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Goel A, 1997, NAT BIOTECHNOL, V15, P174, DOI 10.1038/nbt0297-174; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; Hoeppel R. E., 1994, Hazardous waste site soil remediation: theory and application of innovative technologies., P311; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hughes JB, 1997, ENVIRON SCI TECHNOL, V31, P266, DOI 10.1021/es960409h; OGAWA N, 1995, BIOL PHARM BULL, V18, P1352; Raskin I, 1996, P NATL ACAD SCI USA, V93, P3164, DOI 10.1073/pnas.93.8.3164; Rugh CL, 1998, NAT BIOTECHNOL, V16, P925, DOI 10.1038/nbt1098-925; Sambrook J., 2002, MOL CLONING LAB MANU; Schnoor J.L., 1995, ENV SCI TECH, V29, P318; SHANNON MJR, 1993, ANNU REV MICROBIOL, V47, P715, DOI [10.1146/annurev.micro.47.1.715, 10.1146/annurev.mi.47.100193.003435]; TAYLOR IW, 1989, INT J BIOCHEM, V21, P67, DOI 10.1016/0020-711X(89)90028-1	17	160	170	3	47	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1999	17	5					491	494		10.1038/8673	http://dx.doi.org/10.1038/8673			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	192JE	10331811				2022-12-25	WOS:000080074500036
J	Zhang, QG; Siebert, R; Yan, MH; Hinzmann, B; Cui, XL; Xue, LQ; Rakestraw, KM; Naeve, CW; Beckmann, G; Weisenburger, DD; Sanger, WG; Nowotny, H; Vesely, M; Callet-Bauchu, E; Salles, G; Dixit, VM; Rosenthal, A; Schlegelberger, B; Morris, SW				Zhang, QG; Siebert, R; Yan, MH; Hinzmann, B; Cui, XL; Xue, LQ; Rakestraw, KM; Naeve, CW; Beckmann, G; Weisenburger, DD; Sanger, WG; Nowotny, H; Vesely, M; Callet-Bauchu, E; Salles, G; Dixit, VM; Rosenthal, A; Schlegelberger, B; Morris, SW			Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32)	NATURE GENETICS			English	Article							NF-KAPPA-B; SOMATIC HYPERMUTATION; TRANSCRIPTION FACTORS; CELL LYMPHOMA; ACTIVATION; TRANSFORMATION; REQUIREMENT; APOPTOSIS; DISEASE; CARD	Mucosa-associated lymphoid tissue (MALT) lymphomas most frequently involve the gastrointestinal tract and are the most common subset of extranodal non-Hodgkin lymphoma(1) (NHL). Here we describe overexpression of BCL10, a novel apoptotic signalling gene that encodes an amino-terminal caspase recruitment domain (CARD; ref. 2), in MALT lymphomas due to the recurrent t(1;14)(p22;q32) (ref. 3). BCL10 cDNAs from t(1;14)-positive MALT tumours contained a variety of mutations, most resulting in truncations either in or carboxy terminal to the CARD. Wild-type BCL10 activated NF-kappa B but induced apoptosis of MCF7 and 293 cells. CARD-truncation mutants were unable to induce cell death or activate NF-kappa B, whereas mutants with C-terminal truncations retained NF-kappa B activation but did not induce apoptosis, Mutant BCL10 overexpression might have a twofold lymphomagenic effect: loss of BCL10 pro-apoptosis may confer a survival advantage to MALT B-cells, and constitutive NF-kappa B activation may provide both anti-apoptotic and proliferative signals mediated via its transcriptional targets.	St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Ctr Biotechnol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38163 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; MetaGen Gesell Genomforsch mbH, D-14195 Berlin, Germany; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Ctr Human Genet, Omaha, NE 68198 USA; Hanusch Hosp, Ludwig Boltzmann Inst Leukemia Res & Hematol, A-1140 Vienna, Austria; Lainz Hosp, Jakob Erdheim Inst Pathol, A-1130 Vienna, Austria; Univ Lyon 1, Ctr Hosp Lyon Sud, Hematol Lab, F-69495 Pierre Benite, France; Univ Lyon 1, Ctr Hosp Lyon Sud, Serv Hematol, F-69495 Pierre Benite, France; Univ Kiel, Dept Human Genet, D-24105 Kiel, Germany	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Roche Holding; Genentech; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Ludwig Boltzmann Institute; WGKK - Hanusch Hospital; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Kiel	Morris, SW (corresponding author), St Jude Childrens Res Hosp, Dept Pathol & Lab Med, 332 N Lauderdale St, Memphis, TN 38105 USA.		Siebert, Reiner/A-8049-2010; Salles, Gilles/Z-2336-2019; dixit, vishva m/A-4496-2012	Salles, Gilles/0000-0002-9541-8666; dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA-27165] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Lee H, 1995, Curr Top Microbiol Immunol, V194, P247; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SCHLEGELBERGER B, 1994, LEUKEMIA, V8, P72; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Siebert R, 1998, BLOOD, V91, P984, DOI 10.1182/blood.V91.3.984.984_984_990; Snow EC, 1997, CURR TOP MICROBIOL, V224, P211; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Storb U, 1998, IMMUNOL REV, V162, P5, DOI 10.1111/j.1600-065X.1998.tb01424.x; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; TILLY H, 1994, BLOOD, V84, P1043; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Willis TG, 1997, BLOOD, V90, P2456; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; WOTHERSPOON AC, 1992, CANCER GENET CYTOGEN, V58, P35, DOI 10.1016/0165-4608(92)90130-Z; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zucca E, 1998, BRIT J HAEMATOL, V100, P3, DOI 10.1046/j.1365-2141.1998.00513.x	27	312	326	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	1999	22	1					63	68		10.1038/8767	http://dx.doi.org/10.1038/8767			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319863				2022-12-25	WOS:000080096300024
J	Beeson, JG; Rogerson, SJ; Cooke, BM; Reeder, JC; Chai, WG; Lawson, AM; Molyneux, ME; Brown, GV				Beeson, JG; Rogerson, SJ; Cooke, BM; Reeder, JC; Chai, WG; Lawson, AM; Molyneux, ME; Brown, GV			Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria	NATURE MEDICINE			English	Article							CHONDROITIN SULFATE-A; ADHERENCE; PREGNANCY; RECEPTOR; CELLS; FLOW; CD36	Infection with Plasmodium falciparum during pregnancy leads to the accumulation of parasite-infected erythrocytes in the placenta(1), and is associated with excess perinatal mortality, premature delivery and intrauterine growth retardation in the infant, as well as increased maternal mortality and morbidity(2,3). P. falciparum can adhere to specific receptors on host cells, an important virulence factor enabling parasites to accumulate in various organs(4). We report here that most P. falciparum isolates from infected placentae can bind to hyaluronic acid, a newly discovered receptor for parasite adhesion that is present on the placental lining. In laboratory isolates selected for specific high-level adhesion, binding to hyaluronic acid could be inhibited by dodecamer or larger oligosaccharide fragments or polysaccharides, treatment of immobilized receptor with hyaluronidase, or treatment of infected erythrocytes with trypsin. In vitro flow-based assays demonstrated that high levels of adhesion occurred at low wall shear stress, conditions thought to prevail in the placenta. Our findings indicate that adhesion to hyaluronic acid is involved in mediating placental parasite accumulation, thus changing the present understanding of the mechanisms of placental infection, with implications for the development of therapeutic and preventative interventions.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Malawi, Coll Med, Wellcome Trust Res Labs, Blantyre, Malawi; Univ Malawi, Coll Med, Malaria Project, Blantyre, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Northwick Pk Hosp, Imperial Coll, Sch Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England	Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Malawi; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; Monash University; Imperial College London	Beeson, JG (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.			Reeder, John/0000-0003-1395-1289; Rogerson, Stephen/0000-0003-4287-1982	Wellcome Trust [063215] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Chai WG, 1998, EUR J BIOCHEM, V251, P114, DOI 10.1046/j.1432-1327.1998.2510114.x; Chien S., 1972, HEMODILUTION THEORET, P1; COOKE BM, 1995, PARASITOL TODAY, V11, P282, DOI 10.1016/0169-4758(95)80040-9; Cooke BM, 1998, MOL MICROBIOL, V30, P83, DOI 10.1046/j.1365-2958.1998.01040.x; COWMAN MK, 1981, BIOCHEMISTRY-US, V20, P1379, DOI 10.1021/bi00508a053; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; KIRBY DRS, 1964, NATURE, V204, P548, DOI 10.1038/204548a0; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lea RG, 1997, CURR OPIN INFECT DIS, V10, P171, DOI 10.1097/00001432-199706000-00003; MARTIN BJ, 1974, ANAT REC, V178, P769, DOI 10.1002/ar.1091780408; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; MCGREGOR IA, 1984, AM J TROP MED HYG, V33, P517, DOI 10.4269/ajtmh.1984.33.517; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; Ramsey EM, 1980, ANATOMY PHYSL RADIOL; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SUNDERLAND CA, 1985, J REPROD IMMUNOL, V8, P197, DOI 10.1016/0165-0378(85)90041-5; WALTER PR, 1982, AM J PATHOL, V109, P330	24	245	250	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2000	6	1					86	90		10.1038/71582	http://dx.doi.org/10.1038/71582			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	271FJ	10613830	Green Accepted			2022-12-25	WOS:000084583300041
J	Furukawa, T; Morrow, EM; Li, TS; Davis, FC; Cepko, CL				Furukawa, T; Morrow, EM; Li, TS; Davis, FC; Cepko, CL			Retinopathy and attenuated circadian entrainment in Crx-deficient mice	NATURE GENETICS			English	Article							CONE-ROD DYSTROPHY; RDS MUTANT MICE; HOMEOBOX GENE; RETINITIS-PIGMENTOSA; TRANSGENIC MICE; OUTER SEGMENTS; MUTATIONS; PHOTORECEPTOR; EXPRESSION; DIFFERENTIATION	Crx, an Otx-like homeobox gene, is expressed specifically in the photoreceptors of the retina and the pinealocytes of the pineal gland(1,2). Crx has been proposed to have a role in the regulation of photoreceptor-specific genes in the eye and of pineal-specific genes in the pineal gland. Mutations in human CRX are associated with the retinal diseases, cone-rod dystrophy-2 (adCRD2; refs 3-5), retinitis pigmentosa(5) (RP) and Leber congenital amaurosis(5,6) (LCA), which all lead to loss of vision. We generated mice carrying a targeted disruption of Crx. Crx(-/-) mice do not elaborate photoreceptor outer segments and lacked rod and cone activity as assayed by electroretinogram (ERG). Expression of several photoreceptor- and pineal-specific genes was reduced in Crx mutants. Circadian entrainment was also affected in Crx(-/-) mice.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Northeastern University; Harvard University; Harvard Medical School	Furukawa, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX USA.	furukawa@utsw.swmed.edu; cepko@rascal.med.harvard.edu	Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520				Blackshaw S, 1997, J NEUROSCI, V17, P8074; Boatright J H, 1997, Mol Vis, V3, P15; Bovolenta P, 1997, J NEUROSCI, V17, P4243; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOXMAN SG, 1985, ARCH OPHTHALMOL-CHIC, V103, P1502; Freedman MS, 1999, SCIENCE, V284, P502, DOI 10.1126/science.284.5413.502; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; Grosse D, 1998, J NEUROSCI, V18, P8032; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Li XD, 1998, P NATL ACAD SCI USA, V95, P1876, DOI 10.1073/pnas.95.4.1876; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; Lucas RJ, 1999, SCIENCE, V284, P505, DOI 10.1126/science.284.5413.505; Morrow EM, 1999, DEVELOPMENT, V126, P23; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; REUTER JH, 1984, NEUROSCI LETT, V48, P231, DOI 10.1016/0304-3940(84)90024-7; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Soni BG, 1998, NATURE, V394, P27, DOI 10.1038/27794; Sun H, 1997, P NATL ACAD SCI USA, V94, P9893, DOI 10.1073/pnas.94.18.9893; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7	27	414	422	2	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	1999	23	4					466	470		10.1038/70591	http://dx.doi.org/10.1038/70591			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	261RZ	10581037				2022-12-25	WOS:000084023900026
J	Lo, RS; Massague, J				Lo, RS; Massague, J			Ubiquitin-dependent degradation of TGF-beta-activated Smad2	NATURE CELL BIOLOGY			English	Article							ACTIVIN	SMAD proteins are phosphorylated by transforming growth factor-beta (TGF-beta) receptors and translocate to the nucleus, where they control transcription. Here we investigate the fate of activated Smad2. We show that receptor-mediated activation leads to multi-ubiquitination and subsequent degradation of Smad2 by the proteasome. Ubiquitination of Smad2 is a consequence of its accumulation in the nucleus. If degradation is averted, the phosphorylated Smad2 remains in the nucleus in an active state. By targeting Smad2 for destruction, TGF-beta ensures the irreversible termination of its own signalling function.	Howard Hughes Med Inst, Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Howard Hughes Med Inst, Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6	6	285	297	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	1999	1	8					472	478		10.1038/70258	http://dx.doi.org/10.1038/70258			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	263QE	10587642				2022-12-25	WOS:000084136100014
J	Chang, SH; Svitkina, TM; Borisy, GG; Popov, SV				Chang, SH; Svitkina, TM; Borisy, GG; Popov, SV			Speckle microscopic evaluation of microtubule transport in growing nerve processes	NATURE CELL BIOLOGY			English	Article							AXONAL GROWTH; CULTURED-CELLS; DYNAMIC INSTABILITY; FROG NEURONS; MEMBRANE; TUBULIN; ELONGATION; TURNOVER; CYTOSKELETON; CENTROSOME	Assembly of microtubules is fundamental to neuronal morphogenesis. Microtubules typically form crosslinked bundles in nerve processes, precluding resolution of single microtubules at the light microscopic level. Therefore, previous studies of microtubule transport in neurites have had to rely on indirect approaches. Here we show that individual microtubules can be visualized directly in the axonal shafts of Xenopus embryo neurons by using digital fluorescence microscopy. We find that, although the array of axonal microtubules is dynamic, microtubules are stationary relative to the substrate. These results argue against a model in which newly synthesized tubulin is transported down the axon in the form of microtubules.	Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison	Popov, SV (corresponding author), Univ Illinois, Dept Physiol & Biophys, M-C 901,835 S Wolcott Ave, Chicago, IL 60612 USA.	spopov@uic.edu	Chang, Sunghoe/J-2784-2012	Borisy, Gary/0000-0002-0266-8018; chang, sunghoe/0000-0002-3446-7288				Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; AHMAD FJ, 1995, J CELL SCI, V108, P2761; Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; Baas PW, 1997, CURR OPIN CELL BIOL, V9, P29, DOI 10.1016/S0955-0674(97)80148-2; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Bray D, 1997, TRENDS CELL BIOL, V7, P379, DOI 10.1016/S0962-8924(97)01134-3; BRAY D, 1981, J NEUROCYTOL, V10, P589, DOI 10.1007/BF01262592; Chang SH, 1998, J NEUROSCI, V18, P821; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; deMiguel FF, 1997, NEUROREPORT, V8, P761, DOI 10.1097/00001756-199702100-00036; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; HEIDEMANN SR, 1981, J CELL BIOL, V91, P661, DOI 10.1083/jcb.91.3.661; Hirokawa N, 1997, TRENDS CELL BIOL, V7, P384, DOI 10.1016/S0962-8924(97)01133-1; HOLLENBECK PJ, 1987, J CELL BIOL, V105, P2827, DOI 10.1083/jcb.105.6.2827; HOLLENBECK PJ, 1993, J CELL BIOL, V121, P305, DOI 10.1083/jcb.121.2.305; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; LASEK RJ, 1976, CELL MOTILITY, V3, P1021; LIM SS, 1990, J CELL BIOL, V111, P123, DOI 10.1083/jcb.111.1.123; Miller KE, 1996, J CELL BIOL, V133, P1355, DOI 10.1083/jcb.133.6.1355; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; OKABE S, 1993, J CELL BIOL, V120, P1177, DOI 10.1083/jcb.120.5.1177; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; POPOV S, 1993, SCIENCE, V259, P244, DOI 10.1126/science.7678471; POPOV S, 1992, J NEUROSCI, V12, P77; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; RODIONOV VI, 1994, J CELL BIOL, V126, P1455, DOI 10.1083/jcb.126.6.1455; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; SABRY J, 1995, NEURON, V14, P1247, DOI 10.1016/0896-6273(95)90271-6; SCHNAPP BJ, 1982, J CELL BIOL, V94, P667, DOI 10.1083/jcb.94.3.667; Slaughter T, 1997, J NEUROSCI, V17, P5807; Stewart R, 1996, J NEUROBIOL, V30, P425, DOI 10.1002/(SICI)1097-4695(199607)30:3<425::AID-NEU10>3.0.CO;2-G; Svitkina TM, 1998, METHOD ENZYMOL, V298, P570, DOI 10.1016/S0076-6879(98)98045-4; Svitkina TM, 1995, J STRUCT BIOL, V115, P290, DOI 10.1006/jsbi.1995.1054; TAKEDA S, 1995, NEURON, V14, P1257, DOI 10.1016/0896-6273(95)90272-4; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; Vorobjev IA, 1997, J CELL SCI, V110, P2635; Wade RH, 1997, CURR OPIN CELL BIOL, V9, P12, DOI 10.1016/S0955-0674(97)80146-9; Waterman-Storer CM, 1998, BIOPHYS J, V75, P2059, DOI 10.1016/S0006-3495(98)77648-9; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Zakharenko S, 1998, J CELL BIOL, V143, P1077, DOI 10.1083/jcb.143.4.1077	42	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	1999	1	7					399	403		10.1038/15629	http://dx.doi.org/10.1038/15629			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	252ZX	10559982				2022-12-25	WOS:000083533100011
J	de Wind, N; Dekker, M; Claij, N; Jansen, L; van Klink, Y; Radman, M; Riggins, G; van der Valk, M; van 't Wout, K; Riele, HT				de Wind, N; Dekker, M; Claij, N; Jansen, L; van Klink, Y; Radman, M; Riggins, G; van der Valk, M; van 't Wout, K; Riele, HT			HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and MSh6 mismatch-repair protein functions	NATURE GENETICS			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE; TUMOR-CELLS; GENE; MUTATION; RECOMBINATION; DEFICIENCY; HYPERMUTABILITY; HETERODIMER; HOMOLOG		Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; Univ Paris 05, Fac Med Necker, INSERM, E9916, Paris, France; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Netherlands Cancer Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Duke University	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.		jansen, leon/W-9159-2019	Radman, Miroslav/0000-0002-7034-4365				Akiyama Y, 1997, CANCER RES, V57, P3920; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Reitmair AH, 1996, CANCER RES, V56, P3842; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SELVA EM, 1995, GENETICS, V139, P1175; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; Umar A, 1998, GENETICS, V148, P1637; Umar A, 1997, CANCER RES, V57, P3949	28	174	175	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	NOV	1999	23	3					359	362		10.1038/15544	http://dx.doi.org/10.1038/15544			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	257QC	10545954				2022-12-25	WOS:000083792200029
J	Chan, SY; Li, KW; Piccotti, JR; Louie, MC; Judge, TA; Turka, LA; Eichwald, EJ; Bishop, DK				Chan, SY; Li, KW; Piccotti, JR; Louie, MC; Judge, TA; Turka, LA; Eichwald, EJ; Bishop, DK			Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants	NATURE MEDICINE			English	Article							MEDIATED GENE-TRANSFER; VIRAL-ANTIGENS; IN-VIVO; RECOMBINANT ADENOVIRUS; TRANSGENE EXPRESSION; INFECTED HEPATOCYTES; LIVER ALLOGRAFTS; MOUSE-LIVER; THERAPY; VECTORS	The immune response to adenoviral vectors can induce inflammation and loss of transgene expression in transfected tissues. This would limit the use of adenovirus-mediated gene transfer in disease states in which long-term gene expression is required. While studying the effect of the anti-adenoviral immune response in transplantation, we found that transgene expression persisted in cardiac isografts transfected with an adenovirus encoding beta-galactosidase. Transfected grafts remained free of inflammation, despite the presence of an immune response to the vector. Thus, adenovirus-mediated gene transfer may have therapeutic value in cardiac transplantation and heart diseases. Furthermore, immunological limitations of adenoviral vectors for gene therapy are not universal for all tissue types.	Univ Michigan, Sch Med, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA	University of Michigan System; University of Michigan; University of Pennsylvania; Utah System of Higher Education; University of Utah	Bishop, DK (corresponding author), Univ Michigan, Sch Med, Dept Surg, Sect Gen Surg, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031946] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI HL 31946] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTYN JM, 1994, J IMMUNOL, V152, P2401; BISHOP DK, 1992, TRANSPLANTATION, V53, P849, DOI 10.1097/00007890-199204000-00027; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; CRYSTAL RG, 1995, NAT MED, V1, P15, DOI 10.1038/nm0195-15; Dematteo RP, 1996, GENE THER, V3, P4; DeMatteo RP, 1997, TRANSPLANTATION, V63, P315, DOI 10.1097/00007890-199701270-00024; Drazan KE, 1996, TRANSPLANTATION, V62, P1080, DOI 10.1097/00007890-199610270-00010; DRAZAN KE, 1995, J SURG RES, V59, P299, DOI 10.1006/jsre.1995.1168; Gao X, 1995, GENE THER, V2, P710; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Gunzburg WH, 1996, J MOL MED, V74, P171; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lee K, 1996, INT J HEALTH PLAN M, V11, P1, DOI 10.1002/(SICI)1099-1751(199601)11:1<1::AID-HPM420>3.0.CO;2-V; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MCCOY RD, 1995, GENE THER, V2, P437; Merrick AF, 1996, TRANSPLANTATION, V62, P1085, DOI 10.1097/00007890-199610270-00011; Olthoff KM, 1998, NAT MED, V4, P194, DOI 10.1038/nm0298-194; Qin LH, 1997, HUM GENE THER, V8, P1365, DOI 10.1089/hum.1997.8.11-1365; SHAKED A, 1994, TRANSPLANTATION, V57, P1508; Shiraishi M, 1996, SURG TODAY, V26, P624, DOI 10.1007/BF00311668; Trapnell Bruce C., 1994, Current Opinion in Biotechnology, V5, P617, DOI 10.1016/0958-1669(94)90084-1; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; VILQUIN JT, 1995, HUM GENE THER, V6, P1391, DOI 10.1089/hum.1995.6.11-1391; Wang J, 1996, TRANSPLANTATION, V61, P1726, DOI 10.1097/00007890-199606270-00011; Wilson JM, 1996, NEW ENGL J MED, V334, P1185, DOI 10.1056/NEJM199605023341809; Yang Y, 1996, GENE THER, V3, P137; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Ye XH, 1996, J BIOL CHEM, V271, P3639	31	45	47	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	1999	5	10					1143	1149		10.1038/13467	http://dx.doi.org/10.1038/13467			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	242GY	10502817				2022-12-25	WOS:000082933200040
J	Cismowski, MJ; Takesono, A; Ma, CL; Lizano, JS; Xie, XB; Fuernkranz, H; Lanier, SM; Duzic, E				Cismowski, MJ; Takesono, A; Ma, CL; Lizano, JS; Xie, XB; Fuernkranz, H; Lanier, SM; Duzic, E			Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling	NATURE BIOTECHNOLOGY			English	Article						functional screens; Saccharomyces cerevisiae; G alpha regulation; nonreceptor modulators; Ras-like GTPase	PHEROMONE-RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL GENOMICS; SHUTTLE VECTORS; A-FACTOR; CELLS; TRANSDUCTION; EXPRESSION; RECEPTOR; ENCODES	We describe genetic screens in Saccharomyces cerevisiae designed to identify mammalian nonreceptor modulators of G-protein signaling pathways. Strains lacking a pheromone-responsive G-protein coupled receptor and expressing a mammalian-yeast G alpha hybrid protein were made conditional for growth upon either pheromone pathway activation (activator screen) or pheromone pathway inactivation (inhibitor screen). Mammalian cDNAs that conferred plasmid-dependent growth under restrictive conditions were identified. One of the cDNAs identified from the activator screen, a human Ras-related G protein that we term AGS1 (for activator of G-protein signaling), appears to function by facilitating guanosine triphosphate (GTP) exchange on the heterotrimeric G alpha. A cDNA product identified from the inhibitor screen encodes a previously identified regulator of G-protein signaling, human RGS5.	Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Medical University of South Carolina	Duzic, E (corresponding author), Cadus Pharmaceut Corp, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	eduzic@cadus.com	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NINDS NIH HHS [R01-NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROACH JR, 1983, EXPT MANIPULATION GE; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Evans MJ, 1997, TRENDS GENET, V13, P370, DOI 10.1016/S0168-9525(97)01240-7; FOWLKES DM, 1998, Patent No. 5789184; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; KURJAN J, 1993, ANNU REV GENET, V27, P147; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEE E, 1992, J BIOL CHEM, V267, P1212; Manfredi JP, 1996, MOL CELL BIOL, V16, P4700; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SIMONSEN H, 1994, TRENDS PHARMACOL SCI, V15, P437, DOI 10.1016/0165-6147(94)90052-3; Spence P, 1998, DRUG DISCOV TODAY, V3, P179, DOI 10.1016/S1359-6446(97)01162-8; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Whitney M, 1998, NAT BIOTECHNOL, V16, P1329, DOI 10.1038/4302	38	152	160	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					878	883		10.1038/12867	http://dx.doi.org/10.1038/12867			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471929				2022-12-25	WOS:000082365800029
J	Persidis, A				Persidis, A			Cardiovascular disease drug discovery	NATURE BIOTECHNOLOGY			English	Article									Argonex Inc, Business Dev, Charlottesville, VA 22903 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 706 Forest St, Charlottesville, VA 22903 USA.							Fox KAA, 1999, CARDIOVASC DRUG THER, V13, P211, DOI 10.1023/A:1007792024993; Hwang DM, 1997, CIRCULATION, V96, P4146; Li A, 1999, AM J MED GENET, V86, P57, DOI 10.1002/(SICI)1096-8628(19990903)86:1<57::AID-AJMG11>3.0.CO;2-R; Meyer BJ, 1996, EUR HEART J, V17, P1318; Persidis A, 1998, NAT BIOTECHNOL, V16, P209, DOI 10.1038/nbt0298-209; Plebani M, 1999, INT J CLIN LAB RES, V29, P56, DOI 10.1007/s005990050064; *WHO, 1995, WORLD HLTH STAT Q, V48; *WHO, 1993, WORLD HLTH STAT Q, V46	8	5	5	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1999	17	9					930	931		10.1038/12935	http://dx.doi.org/10.1038/12935			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	232HU	10471943				2022-12-25	WOS:000082365800039
J	Christoforidis, S; Miaczynska, M; Ashman, K; Wilm, M; Zhao, LY; Yip, SC; Waterfield, MD; Backer, JM; Zerial, M				Christoforidis, S; Miaczynska, M; Ashman, K; Wilm, M; Zhao, LY; Yip, SC; Waterfield, MD; Backer, JM; Zerial, M			Phosphatidylinositol-3-OH kinases are Rab5 effectors	NATURE CELL BIOLOGY			English	Article							ENDOSOME FUSION; 3-KINASE; BINDING; PROTEIN; FINGERS; EEA1		Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; UCL, Ludwig Inst Canc Res, London W1P 8BT, England	Max Planck Society; European Molecular Biology Laboratory (EMBL); Yeshiva University; Albert Einstein College of Medicine; Ludwig Institute for Cancer Research; University of London; University College London	Zerial, M (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr, D-01307 Dresden, Germany.	zerial@embl-heidelberg.de	Ashman, Keith/G-2328-2011	Wilm, Matthias/0000-0002-5461-6834; Christoforidis, Savvas/0000-0002-0210-0713; Miaczynska, Marta/0000-0003-0031-5267				BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jones AT, 1998, MOL BIOL CELL, V9, P323, DOI 10.1091/mbc.9.2.323; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752	18	419	431	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	1999	1	4					249	252		10.1038/12075	http://dx.doi.org/10.1038/12075			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	245HZ	10559924				2022-12-25	WOS:000083102700021
J	Lee, CL; Linton, J; Soughayer, JS; Sims, CE; Allbritton, NL				Lee, CL; Linton, J; Soughayer, JS; Sims, CE; Allbritton, NL			Localized measurement of kinase activation in oocytes of Xenopus laevis	NATURE BIOTECHNOLOGY			English	Article						kinase; Xenopus laevis; oocyte; capillary electrophoresis; peptide; protein kinase C; protein kinase A; cdc2 kinase	INDUCED NEURITE RETRACTION; PROTEIN-KINASE; LYSOPHOSPHATIDIC ACID; MESSENGER-RNA; PC12 CELLS; RECEPTORS; PEPTIDES; DOMAIN	We have combined a rapid cytoplasmic sampling technique with capillary electrophoresis to measure the activation of protein kinase C (PKC) in a small region (approximately 60 mu m) of a Xenopus oocyte, The phosphorylation of a fluorescent PKC substrate was measured following addition of a pharmacological or physiological stimulus to an oocyte. When substrates for cdc2 kinase (cdc2K), PKC, and protein kinase A (PKA) were comicroinjected into an oocyte, all three substrates could be identified on the electropherogram after cytoplasmic sampling. With this new method, it should be possible to measure simultaneously the activation of multiple different kinases in a single cell, enabling the quantitative dissection of signal transduction pathways.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Natl Def Med Ctr, Inst Aerosp Med, Taipei, Taiwan	University of California System; University of California Irvine; National Defense Medical Center	Allbritton, NL (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	nlallbri@uci.edu			NCRR NIH HHS [RR13314] Funding Source: Medline; NIAID NIH HHS [K08AI01513] Funding Source: Medline; NIGMS NIH HHS [GM57015] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R55RR013314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057015] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; ERIM FB, 1995, J CHROMATOGR A, V708, P356; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hausen P., 1991, EARLY DEV XENOPUS LA; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KLINE D, 1988, SCIENCE, V241, P464, DOI 10.1126/science.3134693; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; Luzzi V, 1997, ANAL CHEM, V69, P4761, DOI 10.1021/ac970550o; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Weinberger R., 1993, PRACTICAL CAPILLARY; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	19	39	46	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1999	17	8					759	762		10.1038/11691	http://dx.doi.org/10.1038/11691			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	221WX	10429239				2022-12-25	WOS:000081751400023
J	Tassignon, J; Ismaili, J; Le Moine, A; Van Laethem, F; Leo, O; Vandevelde, M; Goldman, M				Tassignon, J; Ismaili, J; Le Moine, A; Van Laethem, F; Leo, O; Vandevelde, M; Goldman, M			Azodicarbonamide inhibits T-cell responses in vitro and in vivo	NATURE MEDICINE			English	Article							NUCLEOCAPSID PROTEIN; LYMPHOCYTES; REPLICATION	Azodicarbonamide was recently identified as a new anti-HIV agent that targets the zinc finger domains of the HIV-1 NCp7 nucleocapsid protein(1-3). Here, we demonstrate that azodicarbonamide inhibits in a dose-dependent manner the responses of purified human CD4(+) T lymphocytes stimulated either by monoclonal antibodies against CD3 and CD28 or by allogeneic dendritic cells. These suppressive effects involve a direct action on the calcium mobilization machinery, as azodicarbonamide strongly inhibited the calcium influx induced either by antibodies against CD3 and CD28 or the chemokine RANTES, as well as by thapsigargin, an activator of depletion-activated calcium channels. In vivo, administration of azodicarbonamide into mice blunted their response to polyclonal T-cell activation induced by the injection of monoclonal antibody against CD3 and resulted in delayed rejection of skin allografts. In addition to its anti-HIV properties, azodicarbonamide is a new immunosuppressive agent that might have therapeutic applications in T cell-mediated inflammatory disorders.	Free Univ Brussels, Expt Immunol Lab, B-1070 Brussels, Belgium; Free Univ Brussels, Dept Biol Mol, B-1640 Rhode St Genese, Belgium; Hubriphar SA, Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Goldman, M (corresponding author), Free Univ Brussels, Expt Immunol Lab, 808 Route Lennik, B-1070 Brussels, Belgium.							ALEGRE ML, 1991, J IMMUNOL, V146, P1184; BACON KB, 1995, METHOD ENZYMOL, V288, P362; BAUS E, 1994, J IMMUNOL METHODS, V173, P41, DOI 10.1016/0022-1759(94)90281-X; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543; ICHIMURA H, 1995, VIROLOGY, V211, P554, DOI 10.1006/viro.1995.1437; Jaworowski A, 1999, IMMUNOL CELL BIOL, V77, P90, DOI 10.1046/j.1440-1711.1999.00798.x; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; ROSENBERG AS, 1992, ANNU REV IMMUNOL, V10, P333, DOI 10.1146/annurev.immunol.10.1.333; THALI M, 1995, MOL MED TODAY, V1, P287, DOI 10.1016/S1357-4310(95)91208-8; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567	13	25	27	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	1999	5	8					947	950		10.1038/11392	http://dx.doi.org/10.1038/11392			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	220TR	10426321				2022-12-25	WOS:000081684000041
J	Facciotti, MT; Bertain, PB; Yuan, L				Facciotti, MT; Bertain, PB; Yuan, L			Improved stearate phenotype in transgenic canola expressing a modified acyl-acyl carrier protein thioesterase	NATURE BIOTECHNOLOGY			English	Article						alanine scanning; site-directed mutagenesis; stearate; transgenic plants; protein engineering	SUBSTRATE-SPECIFICITY; SCANNING MUTAGENESIS; ACP THIOESTERASES; FATTY-ACIDS; TRANSFORMATION	The engineering of crops for selected fatty acid production is one of the major goals of plant biotechnology. The Garm FatA1, an acyl-acyl carrier protein (ACP) thioesterase isolated from Garcinia mangostana, generates an elevated stearate (18:0) phenotype in transgenic Brassica plants. By site-directed mutagenesis, we generated seven mutants that showed up to a 13-fold increase in specific enzyme activity toward 18:0-ACP in vitro. The seed-specific expression of mutant S111A/V193A in Brassica plants results in transgenic plants that accumulate 55-68% more stearate than plants expressing the wild-type enzyme. Our results demonstrate that a thioesterase can be engineered to increase specific activity and that its improved function demonstrated in vitro is retained in vivo.	Calgene Inc, LLC, Davis, CA 95616 USA		Yuan, L (corresponding author), Maxygen, Redwood City, CA 94063 USA.		Facciotti, Marc/AAF-9227-2020	Facciotti, Marc/0000-0003-4453-3274				BERNATZKY R, 1986, THEOR APPL GENET, V72, P314, DOI 10.1007/BF00288567; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; DELVECCHIO AJ, 1996, INFORM, V7, P230; Facciotti MT, 1998, FETT-LIPID, V100, P167; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Hawkins DJ, 1998, PLANT J, V13, P743, DOI 10.1046/j.1365-313X.1998.00073.x; JONES A, 1995, PLANT CELL, V7, P359, DOI 10.1105/tpc.7.3.359; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; KNUDSON DS, 1992, P NATL ACAD SCI USA, V89, P2624; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Maniatis T., 1982, MOL CLONING LAB MANU; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Nelson GJ, 1998, NUTR REV, V56, P250, DOI 10.1111/j.1753-4887.1998.tb01758.x; Nickerson DP, 1997, FEBS LETT, V405, P153, DOI 10.1016/S0014-5793(97)00174-9; RADKE SE, 1992, PLANT CELL REP, V11, P499, DOI 10.1007/BF00236265; VOLKER T, 1996, GENETIC ENG, P111; YUAN L, 1995, P NATL ACAD SCI USA, V92, P10639, DOI 10.1073/pnas.92.23.10639; Yuan L, 1996, J BIOL CHEM, V271, P3417; Yuan L, 1997, CURR OPIN BIOTECH, V8, P227, DOI 10.1016/S0958-1669(97)80107-3	21	51	82	2	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					593	597		10.1038/9909	http://dx.doi.org/10.1038/9909			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385326				2022-12-25	WOS:000080716500033
J	Persidis, A				Persidis, A			Agricultural biotechnology	NATURE BIOTECHNOLOGY			English	Article							TOBACCO MOSAIC-VIRUS; TRANSGENIC PLANTS; EXPRESSION; GENE		Argonex Inc, Business Dev, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, Business Dev, 2044 India Rd, Charlottesville, VA 22901 USA.							ABEL PP, 1986, SCIENCE, V232, P738, DOI 10.1126/science.3457472; Abelson PH, 1998, SCIENCE, V279, P2019; Bos L, 1999, PHILOS T ROY SOC B, V354, P675, DOI 10.1098/rstb.1999.0420; Briggs SP, 1998, CURR OPIN BIOTECH, V9, P233, DOI 10.1016/S0958-1669(98)80121-3; Chaney RL, 1997, CURR OPIN BIOTECH, V8, P279, DOI 10.1016/S0958-1669(97)80004-3; Gelvin SB, 1998, CURR OPIN BIOTECH, V9, P227, DOI 10.1016/S0958-1669(98)80120-1; HIATT A, 1990, NATURE, V344, P469, DOI 10.1038/344469a0; Ma JKC, 1996, ANN NY ACAD SCI, V792, P72, DOI 10.1111/j.1749-6632.1996.tb32493.x; POWELL PA, 1989, P NATL ACAD SCI USA, V86, P6949, DOI 10.1073/pnas.86.18.6949; Scholthof HB, 1996, ANNU REV PHYTOPATHOL, V34, P299, DOI 10.1146/annurev.phyto.34.1.299; Smith G, 1997, REPROD FERT DEVELOP, V9, P85, DOI 10.1071/R96051; WARNER DT, 1964, J THEOR BIOL, V6, P118, DOI 10.1016/0022-5193(64)90068-2; Yu KF, 1999, GENOME, V42, P27, DOI 10.1139/gen-42-1-27	13	7	7	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1999	17	6					612	614		10.1038/9940	http://dx.doi.org/10.1038/9940			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	203PR	10385330				2022-12-25	WOS:000080716500037
J	Bi, WM; Deng, JM; Zhang, ZP; Behringer, RR; de Crombrugghe, B				Bi, WM; Deng, JM; Zhang, ZP; Behringer, RR; de Crombrugghe, B			Sox9 is required for cartilage formation	NATURE GENETICS			English	Article							AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CHONDROCYTE-SPECIFIC ENHANCER; COLLAGEN MESSENGER-RNAS; IN-SITU HYBRIDIZATION; CAMPOMELIC DYSPLASIA; SKELETAL DEVELOPMENT; HERITABLE DISEASES; MOLECULAR INSIGHTS; II COLLAGEN	Chondrogenesis results in the formation of cartilages, initial skeletal elements that can serve as templates for endochondral hone formation. Cartilage formation begins with the condensation of mesenchyme cells followed by their differentiation into chondrocytes, Although much is known about the terminal differentiation products that are expressed by chondrocytes(1-3), little is known about the factors that specify the chondrocyte lineage(4-6). SOX9 is a high-mobility-group (HMG) domain transcription factor that is expressed in chondrocytes and other tissues(7-12). In humans, SOX9 haploinsufficiency results in sues campomelic dysplasia, a lethal skeletal malformation syndrome, and XY sex reversal(7,13-16). During embryogenesis, Sox9 is expressed in all cartilage primordia and cartilages, coincident with the expression of the collagen alpha 1(II) gene (Col2a1; refs 8,11,12), Sox9 is also expressed in other tissues, including the central nervous and urogenital systems(8-12). Sox9 binds to essential sequences in the Col2a1 and collagen alpha 2(XI) gene (Col11a2) chondrocyte-specific enhancers and can activate these enhancers in non-chondrocytic cells(17-19). Here, Sox9 is identified as a regulator of the chondrocyte lineage. In mouse chimaeras, Sox9(-/-) cells are excluded from all cartilages but are present as a juxtaposed mesenchyme that does not express the chondrocyte-specific markers Col2a1, Col9a2, Col11a2 and Age. This exclusion occurred cell autonomously at the condensing mesenchyme stage of chondrogenesis, Moreover, no cartilage developed in teratomas derived from Sox9(-/-) embryonic stem (ES) cells. Our results identify Sox9 as the first transcription factor that is essential for chondrocyte differentiation and cartilage formation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	de Crombrugghe, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	bhr@molgen.mdacc.tmc.edu; benoit_decrombrugghe@molgen.mdacc.tmc.edu			NIAMS NIH HHS [AR42919] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abuin A, 1996, MOL CELL BIOL, V16, P1851; [Anonymous], 1991, CARTILAGE MOL ASPECT; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GLUMOFF V, 1994, BBA-GENE STRUCT EXPR, V1219, P613, DOI 10.1016/0167-4781(94)90220-8; Hogan B, 1994, MANIPULATING MOUSE E; HOVMOLLER ML, 1977, HEREDITAS, V86, P51; Kent J, 1996, DEVELOPMENT, V122, P2813; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; METSARANTA M, 1991, BIOCHIM BIOPHYS ACTA, V1089, P241, DOI 10.1016/0167-4781(91)90014-D; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; Robertson E. J., 1987, TERATOCARCINOMAS EMB; STOCKWELL RA, 1979, BIOL CARTILAGE CELLS; TAKAHASHI H, 1992, J LARYNGOL OTOL, V106, P361, DOI 10.1017/S0022215100119504; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	30	1300	1350	1	115	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	1999	22	1					85	89		10.1038/8792	http://dx.doi.org/10.1038/8792			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	192TU	10319868				2022-12-25	WOS:000080096300029
J	Hahm, KB; Cho, KN; Lee, C; Im, YH; Chang, J; Choi, SG; Sorensen, PHB; Thiele, CJ; Kim, SJ				Hahm, KB; Cho, KN; Lee, C; Im, YH; Chang, J; Choi, SG; Sorensen, PHB; Thiele, CJ; Kim, SJ			Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein	NATURE GENETICS			English	Article							EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; DNA-BINDING; FUSION PROTEIN; ETS-FAMILY; EWS GENE; EXPRESSION; SEQUENCE; CANCER; CELLS	Chromosomal translocations resulting in the expression of chimaeric transcription factors are frequently observed in tumour cells(1), and have been suggested to be a common mechanism in human carcinogenesis. Ewing sarcoma and related peripheral primitive neuroectodermal tumours share recurrent translocations that fuse the gene EWSR1 (formerly EWS) from 22q-12 to FLI1 and genes encoding other ETS transcription factors(2-4) (which bind DNA through the conserved ETS domain(5,6)). It has been shown that transduction of the gene EWSR1-FLI1 (encoding EWS-FLI1 protein) can transform NIH3T3 cells, and that mutants containing a deletion in either the EWS domain or the DNA-binding domain in FLI1 lose this ability(5-8). This indicates that the EWS-FLI1 fusion protein may act as an aberrant transcription factor, but the exact mechanism of oncogenesis remains unknown. Because ETS transcription factors regulate expression of TGFBR2 (encoding the TGF-beta type II receptor, TGF-beta RII; refs 9,14), a putative tumour suppressor gene, we hypothesized that TGFBR2 may be a target of the EWS-FLI1 fusion protein. We show here that embryonic stem (ES) cell lines with the EWSR1-FLI1 fusion have reduced TGF-beta sensitivity, and that fusion-positive ES cells and primary tumours both express low or undetectable levels of TGFBR2 mRNA and protein product. Co-transfection of FLI1 and the TGFBR2 promoter induces promoter activity, whereas EWSR1-FLI1 leads to suppression of TGFBR2 promoter activity and FLI1-induced promoter activity. Introduction of EWSR1-FLI1 into cells lacking the EWSR1-FLI1 fusion suppresses TGF-beta RII expression, whereas antisense to EWSR1-FLI1 in ES cell lines positive for this gene fusion restores TGF-beta RII expression. Furthermore, introduction of normal TGF-beta RII into ES cell lines restores TGF-beta sensitivity and blocks tumorigenicity. Our results implicate TGF-beta RII as a direct target of EWS-FLI1.	NCI, Lab Cell Regulat & Carcinogenesis, DBS, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, DCS, Bethesda, MD 20892 USA; British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); BC Childrens Hospital; University of British Columbia	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, DBS, Bethesda, MD 20892 USA.							Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; CHANG J, 1998, CANCER RES, V57, P1; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; JEON IS, 1995, ONCOGENE, V10, P1229; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOME JR, 1996, P 2 EUR THERM SCI 14, V1, P15; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	20	194	201	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	1999	23	2					222	227		10.1038/13854	http://dx.doi.org/10.1038/13854			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	240LM	10508522				2022-12-25	WOS:000082827500025
J	Santiago, FS; Lowe, HC; Kavurma, MM; Chesterman, CN; Baker, A; Atkins, DG; Khachigian, LM				Santiago, FS; Lowe, HC; Kavurma, MM; Chesterman, CN; Baker, A; Atkins, DG; Khachigian, LM			New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury	NATURE MEDICINE			English	Article							FACTOR-A-CHAIN; ENDOTHELIAL-CELLS; GENE-EXPRESSION; ANTISENSE OLIGONUCLEOTIDE; TRANSCRIPTION FACTORS; ARTERIAL INJURY; MESSENGER-RNA; GROWTH; RIBOZYME; ATHEROSCLEROSIS	Early growth response factor-1 (Egr-1) binds to the promoters of many genes whose products influence cell movement and replication in the artery wall. Here we targeted Egr-1 using a new class of DNA-based enzyme that specifically cleaved Egr-1 mRNA, blocked induction of Egr-1 protein, and inhibited cell proliferation and wound repair in culture. The DNA enzyme also inhibited Egr-1 induction and neointima formation after balloon injury to the rat carotid artery wall. These findings demonstrate the utility of DNA enzymes as biological tools to delineate the specific functions of a given gene, and implicate catalytic nucleic acid molecules composed entirely of DNA as potential therapeutic agents.	Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW, Australia; Prince Wales Hosp, Sydney, NSW, Australia; Johnson & Johnson Res Pty Ltd, Sydney, NSW, Australia	University of New South Wales Sydney; Johnson & Johnson	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW, Australia.	L.Khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Kavurma, Mary/0000-0001-7353-0932; Khachigian, Levon/0000-0003-3446-0323; Baker, Andrew/0000-0003-1441-5576				Bauer G, 1997, BLOOD, V89, P2259, DOI 10.1182/blood.V89.7.2259; BUCK RC, 1961, CIRC RES, V9, P418, DOI 10.1161/01.RES.9.2.418; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CLOWES AW, 1983, LAB INVEST, V49, P327; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; Delbridge GJ, 1997, CIRC RES, V81, P282, DOI 10.1161/01.RES.81.2.282; Dryden S, 1998, J ENDOCRINOL, V157, P169, DOI 10.1677/joe.0.1570169; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; HALASZ P, 1984, P R MICROSCOP SOC, V19, P312; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; Horodyski J, 1996, J SURG RES, V66, P115, DOI 10.1006/jsre.1996.0381; Houston P, 1999, ARTERIOSCL THROM VAS, V19, P281, DOI 10.1161/01.ATV.19.2.281; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; KOBAYASHI H, 1994, CANCER RES, V54, P1271; Kuwabara T, 1997, NUCLEIC ACIDS RES, V25, P3074, DOI 10.1093/nar/25.15.3074; LEMIRE JM, 1994, AM J PATHOL, V144, P1068; LIBBY P, 1995, CIRC RES S3, V86, P47; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; Pitsch RJ, 1996, J VASC SURG, V23, P783, DOI 10.1016/S0741-5214(96)70240-9; Rafty LA, 1998, J BIOL CHEM, V273, P5758, DOI 10.1074/jbc.273.10.5758; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	45	216	247	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	1999	5	11					1264	1269		10.1038/15215	http://dx.doi.org/10.1038/15215			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	305PZ	10545992				2022-12-25	WOS:000086550600036
J	Girod, A; Ried, M; Wobus, C; Lahm, H; Leike, K; Kleinschmidt, J; Deleage, G; Hallek, M				Girod, A; Ried, M; Wobus, C; Lahm, H; Leike, K; Kleinschmidt, J; Deleage, G; Hallek, M			Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2	NATURE MEDICINE			English	Article							PROTEIN SECONDARY STRUCTURE; ADENOASSOCIATED VIRUS; IDENTIFICATION; REPLICATION; SEQUENCE; VECTORS; MUTANTS; THERAPY; INVITRO	The human parvovirus adeno-associated virus type 2 (AAV2) has many features that make it attractive as a vector for gene therapy(1,2). However, the broad host range of AAV2 might represent a limitation for some applications in vivo, because recombinant AAV vector (rAAV)-mediated gene transfer would not be specific for the tissue of interest. This host range is determined by the binding of the AAV2 capsid to specific cellular receptors and/or co-receptors(3,6). The tropism of AAV2 might be changed by genetically introducing a ligand peptide into the viral capsid, thereby redirecting the binding of AAV2 to other cellular receptors. We generated six AAV2 capsid mutants by inserting a 14-amino-acid targeting peptide, L14, into six different putative loops of the AAV2 capsid protein identified by comparison with the known three-dimensional structure of canine parvovirus. All mutants were efficiently packaged. Three mutants expressed L14 on the capsid surface, and one efficiently infected wild-type AAV2-resistant cell lines that expressed the integrin receptor recognized by L14. The results demonstrate that the AAV2 capsid tolerates the insertion of a nonviral ligand sequence. This might open new perspectives for the design of targeted AAV2 vectors for human somatic gene therapy.	Univ Munich, Mol Biol Lab, Genzentrum, Klinikum Grosshadern, D-81377 Munich, Germany; Univ Munich, Med Klin 3, Klinikum Grosshadern, D-81377 Munich, Germany; Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Inst Biol & Chim Prot, UPR412, CNRS, Lab Conformat Prot, F-69367 Lyon 07, France	University of Munich; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS)	Hallek, M (corresponding author), Univ Munich, Mol Biol Lab, Genzentrum, Klinikum Grosshadern, Feodor Lynen Str 25, D-81377 Munich, Germany.		Deléage, Gilbert/F-7163-2010; Hallek, Michael/Y-3191-2019	Deléage, Gilbert/0000-0003-1939-1614; Hallek, Michael/0000-0002-7425-4455; Wobus, Christiane/0000-0001-5286-0924				AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; Bartlett JS, 1999, NAT BIOTECHNOL, V17, P181, DOI 10.1038/6185; CARREL S, 1976, CANCER RES, V36, P3978; Chiorini JA, 1995, HUM GENE THER, V6, P1531, DOI 10.1089/hum.1995.6.12-1531; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; HALLEK M, 1998, DRUGS, V1, P561; HERMONAT PL, 1984, J VIROL, V51, P329, DOI 10.1128/JVI.51.2.329-339.1984; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOTIN RM, 1994, HUM GENE THER, V5, P793, DOI 10.1089/hum.1994.5.7-793; Mizukami H, 1996, VIROLOGY, V217, P124, DOI 10.1006/viro.1996.0099; Qing K, 1999, NAT MED, V5, P71, DOI 10.1038/4758; RUFFING M, 1994, J GEN VIROL, V75, P3385, DOI 10.1099/0022-1317-75-12-3385; SAMULSKI RJ, 1987, J VIROL, V61, P3096, DOI 10.1128/JVI.61.10.3096-3101.1987; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stewart PL, 1997, EMBO J, V16, P1189, DOI 10.1093/emboj/16.6.1189; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRATSCHIN JD, 1984, J VIROL, V51, P611, DOI 10.1128/JVI.51.3.611-619.1984; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VAISESLAWITTMAN.S, 1994, J VIROL, V68, P4609; WHITE JM, 1993, CURR BIOL, V3, P596, DOI 10.1016/0960-9822(93)90007-B; Wistuba A, 1997, J VIROL, V71, P1341, DOI 10.1128/JVI.71.2.1341-1352.1997; Yang QC, 1998, HUM GENE THER, V9, P1929, DOI 10.1089/hum.1998.9.13-1929	24	274	341	0	18	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	1999	5	9					1052	1056		10.1038/12491	http://dx.doi.org/10.1038/12491			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	231XT	10470084				2022-12-25	WOS:000082337200041
